<SEC-DOCUMENT>0001559053-20-000026.txt : 20200806
<SEC-HEADER>0001559053-20-000026.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806163154
ACCESSION NUMBER:		0001559053-20-000026
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PROTHENA CORP PUBLIC LTD CO
		CENTRAL INDEX KEY:			0001559053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35676
		FILM NUMBER:		201082217

	BUSINESS ADDRESS:	
		STREET 1:		77 SIR JOHN ROGERSON'S QUAY, BLOCK C
		STREET 2:		GRAND CANAL DOCKLANDS
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 T804
		BUSINESS PHONE:		011-353-1-236-2500

	MAIL ADDRESS:	
		STREET 1:		77 SIR JOHN ROGERSON'S QUAY, BLOCK C
		STREET 2:		GRAND CANAL DOCKLANDS
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 T804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prothena Corp plc
		DATE OF NAME CHANGE:	20121102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Neotope Corp Ltd
		DATE OF NAME CHANGE:	20120926
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>prta-20200630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:38da442c-e5f6-4ed8-bb27-93106113c3da,g:af883291-30ed-4afd-a355-adc261f9a88c,d:d78a5ecf693745eb81aedf6e125c6b7c--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:prta="http://www.prothena.com/20200630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>prta-20200630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180L2ZyYWc6NDRhNjMzNWU5NjAyNDY0Njk4NmU0ZmQwMzEyZDEzMmYvdGFibGU6NTM4ODc1OTczZTI4NGIxMjg0N2RjYjU2OTcyNzRlY2MvdGFibGVyYW5nZTo1Mzg4NzU5NzNlMjg0YjEyODQ3ZGNiNTY5NzI3NGVjY181LTEtMS0xLTA_af77d210-f787-4a46-b256-0647c7fb3a06">false</ix:nonNumeric><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180L2ZyYWc6NDRhNjMzNWU5NjAyNDY0Njk4NmU0ZmQwMzEyZDEzMmYvdGFibGU6NTM4ODc1OTczZTI4NGIxMjg0N2RjYjU2OTcyNzRlY2MvdGFibGVyYW5nZTo1Mzg4NzU5NzNlMjg0YjEyODQ3ZGNiNTY5NzI3NGVjY184LTEtMS0xLTA_2f3e0d60-11fb-4d16-a94f-b3a0c19d0568">2020</ix:nonNumeric><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180L2ZyYWc6NDRhNjMzNWU5NjAyNDY0Njk4NmU0ZmQwMzEyZDEzMmYvdGFibGU6NTM4ODc1OTczZTI4NGIxMjg0N2RjYjU2OTcyNzRlY2MvdGFibGVyYW5nZTo1Mzg4NzU5NzNlMjg0YjEyODQ3ZGNiNTY5NzI3NGVjY185LTEtMS0xLTA_de1d0801-a5f6-40c9-9ec4-4800508e5c83">Q2</ix:nonNumeric><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180L2ZyYWc6NDRhNjMzNWU5NjAyNDY0Njk4NmU0ZmQwMzEyZDEzMmYvdGFibGU6NTM4ODc1OTczZTI4NGIxMjg0N2RjYjU2OTcyNzRlY2MvdGFibGVyYW5nZTo1Mzg4NzU5NzNlMjg0YjEyODQ3ZGNiNTY5NzI3NGVjY18xMS0xLTEtMS0w_0c9de5fb-2f6f-4b13-a752-5337bac5c62a">0001559053</ix:nonNumeric><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180L2ZyYWc6NDRhNjMzNWU5NjAyNDY0Njk4NmU0ZmQwMzEyZDEzMmYvdGFibGU6NTM4ODc1OTczZTI4NGIxMjg0N2RjYjU2OTcyNzRlY2MvdGFibGVyYW5nZTo1Mzg4NzU5NzNlMjg0YjEyODQ3ZGNiNTY5NzI3NGVjY18xMi0xLTEtMS0w_be9f9cfe-fb18-4bb8-bc4d-d679601e3eba">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i8154f8e4fb0a43068ce1feebb738c177_D20160301-20160331" format="ixt-sec:durwordsen" name="prta:BuildtosuitLeaseTermofContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181Mi9mcmFnOmIwZmIwM2FmNTQ4ZTRhZjk4ZTUzMmM4NDc5ZDM4NzU3L3RhYmxlOmQ4NDA1YjExYmE3NzQzNmE4MWRjNGU1N2MwODRiYzQxL3RhYmxlcmFuZ2U6ZDg0MDViMTFiYTc3NDM2YTgxZGM0ZTU3YzA4NGJjNDFfMi0yLTEtMS0w_4843c4a9-6bd8-4d92-9791-887fd13e865e">7 years, 9 months, 30 days</ix:nonNumeric><ix:nonNumeric contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320" name="prta:CollaborationAgreementUpfrontPaymentPaymentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzk0Njc_0bf4cdb7-932a-472a-9ad8-2ce5f72c6492">P10D</ix:nonNumeric><ix:nonNumeric contextRef="i84637f79b65c470f84d8f4b8fb8e16cf_D20200101-20200630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTcwNDI0MzAyMzk3NDM_37e1f852-c414-4fe4-86e8-7b6225eb6fa8">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="ifc344697e4b14499a86b91af81b71dcf_D20200101-20200630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTQ0Mw_743a930b-b10b-459b-82c5-ed0937653214">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="i6f0f422fe8fd406e815795229f9d4c4a_D20200225-20200225" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTkzNw_cef9d024-7d91-407e-8091-cfdb99879f97">P10Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="prta-20200630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2076d6dfdfd942b4a9a3009e044262c6_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6ecda07bc4ba4408a09994ddf7154fb8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a01076460454a2eac50eac78fcb4c4e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3d1c0ac6b42476b8901a5b86894d8a8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if407b818af644e46b2c8fd3f4ef0916b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37e74aa909674a31a31bf76e13ce1a5f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i699a71835ede41ffb63bc12dc5058195_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5d2e09455d741d0af7adef0326a9464_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735a4a62bab9471a84edda62005153d0_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc1dc4b8e3a409780b630469f43a9e2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1f6a961f634e87b2d33d5dc95c15fa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0a37738944a4b5da8bacd6100c18c37_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i033a9b5c0519456bbe6ff44d9d446f2e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a8e6071ca4d4f418bf2650962cca842_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbd0a1f2b3f648e0bcca646f1febd857_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59896a4eae7b4d1cadd70ccca76ef293_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief7a957fd4e343de80e8f3dd3bd7c665_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b53209923b24243a79113052e4c7869_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244c64bf960045f0800d51e075bbe10e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i033cbd2485614a1a80c8930dd799a610_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a18c2130f0248389ca0f5818a9bea98_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if139ce926c9c4e47b596fdf915376cf8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11412c4befdf4ea0807e0b06f12cfe03_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b323be88ba54d09b5f05f59648156ba_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bb18a09ab4f41a08e2c1022903f9906_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654c8eaba7c84a3ba5bb798a14bf89b4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3911131dcd2547b8b1b797508b9ffa15_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb9f2b53bed498ca4df974ff5e0eb3f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f9f83b1ec94f83ba9e88d181f91f31_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia217e25a3bae43ae8dce414a766f8967_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7447e849c70240ebb46c71019b182af5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i529cd4e894eb4d85b99f95e755920f22_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f79eb93966141d7a3a13adc3ac38d49_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1514bd0122184324869e45816a840dff_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i359327a4643e466ca3a685787fdbf791_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3888cc09d684fd7b2c05fab7e9b2a3a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d6464030811498ea45278866f1f669b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8799a9e7d9a5439bbef0dd2887838f26_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b149813b9fd4ba6a6381399eba9055f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06f9dd74ab7b4824a2d89b866088ebdf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3b99b92bd8c4e959e5259476524c341_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie594e8889b9b4963ae70ebdb928a145b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec113c33f31b44c790f21ee119a59cfc_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f59203e494b4d0aa54e4354c6b66ab5_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b64af079f774a46a8be8b6571368300_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d3275580fa4bd1961ee805e56db0d0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf82b12dcb0a4510a9e8d227e7f54b0f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35e6e65a4d584b26a679bc03ea55c9d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2330f117cb341549ed1cb65fe74eff0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7e67ec9f2a141d3afb5af2d44c43cf4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b797a322b643859e1d254057908a54_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdeb4d65f9b2469ca2008e311f8a3473_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iededd3a706834ae081db1b4deff0a8bb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3fa83c08da0419a82890f9cdd288a03_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i03363be070604a69a801733692c0eb01_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i8154f8e4fb0a43068ce1feebb738c177_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa84acb8305c4045b894b70949b443e0_I20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5ee13ac88c14078b954248c161c0e37_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf705e3bc94419cad46238812fd99d7_I20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d1009cc88444495b1b71ed313bd65be_D20160401-20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbc0b76aa18c4b81ab20c7e33334019e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c8f6072f864cafae096d1bc47eb2f8_D20180718-20180718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-18</xbrli:startDate><xbrli:endDate>2018-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218bb3aa60ae4e83aa3e4a7e671866cf_I20180718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-07-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fcd1972dc354290ba6864c10a7dfd26_D20180924-20180924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-24</xbrli:startDate><xbrli:endDate>2018-09-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a5e914e22c04ed09c890f4bac3875ee_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prta:DublinIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ec87774e684456b390ddadf981db10_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prta:DublinIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d734226c866410c9fa6e63cc16602c0_I20180927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prta:DublinIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i9ee0a5361cff4ddb8357d8b71f892efb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec44022c93d44923a6ba45741b5572ca_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">prta:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b8cf0763bb4f5397b004275677c01b_D20140201-20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-02-01</xbrli:startDate><xbrli:endDate>2014-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaed79f2beb64ec6a2029bcf63a64073_D20140501-20140531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-05-01</xbrli:startDate><xbrli:endDate>2014-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib00e147a1cff4155afb7ec6051700710_D20170601-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74335244f76841eb87c826533b83cc37_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if675ef5553934becb22c4267dbb63ed6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prta:DevelopmentCostsReimbursementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic854f60120d74aedb489b48755f518b9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibca1ba5c855446de877d16de250feabe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i073a0b78fb35421ba6e8592c0a197dfe_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb959663c6fb41d287b63b8363fda883_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:RoyaltyBearingLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba8be9d9c3a400b803bd9eaae95a8ee_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:INDandDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd6584a0477e41a785e2b634ec00c3ec_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:SupplyServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0175d817a5f44f01ac9efd8385decd07_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:RoyaltyBearingLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia759813a15794ad4bdcf62a8a938c100_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:INDandDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7b2c3d5be4540b6921b9e212efe9451_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:ClinicalProductSupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic84e2a6f4eb048d58a8ce416274ea456_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:SupplyServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c607e622d1f49aa8ceca2e000427c5e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia09f6d9b318949658f4b5edbbc1060d4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prta:ResearchReimbursementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec0766c4dcbb452d92267a1537fc4521_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da9211e8d7c43f6be07d56a02195be6_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic027828db76f4a93885ac0251d9ed379_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10bc3926f14143428f8b45360781a239_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf958f5bfd554f5db359067fc2e7e217_I20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-20</xbrli:startDate><xbrli:endDate>2018-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823dfe17698f4577941dc181be64c092_I20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb2d17fa473c4e86a3e307306a386a61_D20180320-20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramUSRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-20</xbrli:startDate><xbrli:endDate>2018-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781ce1f9fb114a1288a2399d11b4d4a5_D20180320-20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramGlobalRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-20</xbrli:startDate><xbrli:endDate>2018-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-20</xbrli:startDate><xbrli:endDate>2018-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement_term"><xbrli:measure>prta:agreement_term</xbrli:measure></xbrli:unit><xbrli:context id="i1a7adf1102ac42aa80af37c1765abece_I20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa4c2edd44bb4660bab9e79530b6b7fe_I20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramUSRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08072583f71487086cd63ba104febe6_I20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramUSRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i754447b94e7e46e1832a0a572e8edf4d_I20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramGlobalRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a50341614dd4cabbccefeba93a88fd1_I20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramGlobalRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f99a1d0727d46a9adc11dcafd022744_I20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramUSRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d8e1da3a7d44d8a442dd98f2a66211_I20180320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramGlobalRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>prta:vote</xbrli:measure></xbrli:unit><xbrli:context id="if308d0f707774e83b68197d8cba203b0_D20180515-20180515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-15</xbrli:startDate><xbrli:endDate>2018-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i044cf0c67aab4755b4c3d1811b2ed835_D20200519-20200519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:AmendedAndRestated2018LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-19</xbrli:startDate><xbrli:endDate>2020-05-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i963269705b7b4e5f9ae3a71c1c9ff5bd_I20180515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:AmendedAndRestated2018LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c7ac19e5f714d5c9b45c2f8f4858855_D20180515-20180515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:AmendedAndRestated2018LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-15</xbrli:startDate><xbrli:endDate>2018-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f801f178cb46208ea96162e7973433_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:AmendedAndRestated2018LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84637f79b65c470f84d8f4b8fb8e16cf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:AmendedAndRestated2018LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc344697e4b14499a86b91af81b71dcf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:A2012LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13cded138cc145cf8025f23802654b94_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:A2020EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0f422fe8fd406e815795229f9d4c4a_D20200225-20200225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:A2020EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-25</xbrli:startDate><xbrli:endDate>2020-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e195fad49074becb102c91d64d9ebb5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:A2020EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3afaf46701c249838b3b57dcd7cd2fd1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i619b94a5d1c748048b980c4beb1d3f80_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5770524a4fb64c908398d01f9b105d07_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6af301e0d5464d0f8688b96cc7ecbcc2_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia19f4446d12d455d8ed873aacb41c471_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d8293363e094a25a626f7be205cd571_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c7537c8b63e44b2b5a02d22312caaac_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida53c60bb2f6447e8d6a93e583eb07f7_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44af5ba0fe6a40a0b2d7a1b155ed8d12_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea1807fc55f1435bb318a4fb39dde186_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied6043afc98548c7ae9c22d39f61cb44_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacb3936c27de4e4c87eba688149d459e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3729d833e9b64a35af79dd7d137d50e1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dbe480e059f408dbac0ebcadbd9f854_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib78a576b8afe40d2aaeedaae8a663a59_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i051466dca10b47ce8e0373f83d6dd3c4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001559053</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0yLTEtMS0w_5f3108b4-003e-4217-97a9-918ad4eff694 id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTA4Ng_b90c43e7-5b76-4c95-a964-a50a1b7740f8 id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS04LTEtMS0w_3ec32750-c162-4cbe-a782-73b16508ce2a id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMC0xLTEtMA_ed5c89f7-7a2d-4b6f-b487-7eca19bf639f id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS00LTEtMS0w_0d6a5349-1f1d-4ee2-bf18-2da78d46b732 id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS02LTEtMS0w_968e18ff-f704-40e1-af8e-ade8d713a7d5 id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMi0xLTEtMA_0b3aeffe-6172-4012-aac6-b156ff07d4e6 id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xNC0xLTEtMA_e2091f3a-244a-47c5-a346-3a51b3732344" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi00LTEtMS0w_1fa28666-44ab-4ba3-a3f7-564d7a236b83 id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0yLTEtMS0w_27166e2e-f2bf-45c2-889c-3e5de0a062f3 id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi02LTEtMS0w_216f6b01-ebe6-41d8-8814-5b4e6a8c3b1d id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMC0xLTEtMA_cb5c692b-52a0-4e68-8193-10c979c52cb3 id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xNC0xLTEtMA_c91b8d3a-9589-4833-8207-44eef2597f50 id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMi0xLTEtMA_350d758a-8b8b-4f0f-9fec-3804b88e6df1 id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi04LTEtMS0w_298f6cfa-762b-416b-9a52-e0f6c5e01f00" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5MQ_d26b4a34-2365-4ad3-86c2-aef2e41ba8e2" order="1"></ix:relationship></ix:resources></ix:header></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_1"></div><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________________________________&#160;</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18yNzQ4Nzc5MDcxMjU4_ca2dca6b-209b-4fce-86fb-830300ddd0a9">10-Q</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;_____________________________________</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.856%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.144%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6N2FhMWQyMTM2OWUxNGVhYjk4NjZlOWNjNDdkYWJkZTcvdGFibGVyYW5nZTo3YWExZDIxMzY5ZTE0ZWFiOTg2NmU5Y2M0N2RhYmRlN18wLTAtMS0xLTE0OQ_2c47b713-3083-4eb9-bcfb-cec780752c82">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18zMjk4NTM0ODg1Mjcz_1fa34c8f-5727-4162-9f99-898af6a464e3">June 30, 2020</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Or</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.856%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.144%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6ZTM5NzBkOTc1ODgzNDhkZDgwZGY1MGQyZGQ2NzZmNmQvdGFibGVyYW5nZTplMzk3MGQ5NzU4ODM0OGRkODBkZjUwZDJkZDY3NmY2ZF8wLTAtMS0xLTE1MQ_5f2df131-a9fd-4b09-8d08-2a08d5b84467">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission file number: <ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18zMjk4NTM0ODg1MTkw_810ab8e8-9bdb-4be2-9a7d-a311f050f5e3">001-35676</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________________________________&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18yNzQ4Nzc5MDcxMjc3_7cf95eea-1305-4411-be57-f8610ffa04f3">PROTHENA CORPORATION PUBLIC LIMITED COMPANY</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________________________________&#160;</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:46.609%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.610%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6N2Q5OGI2MDA0MGUzNDdhMjg2NzkyMGM3YjVhM2NhYWQvdGFibGVyYW5nZTo3ZDk4YjYwMDQwZTM0N2EyODY3OTIwYzdiNWEzY2FhZF8wLTAtMS0xLTE2MA_44d5584b-29e1-4d6a-a8c2-f2ba7ea956e0">Ireland</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6N2Q5OGI2MDA0MGUzNDdhMjg2NzkyMGM3YjVhM2NhYWQvdGFibGVyYW5nZTo3ZDk4YjYwMDQwZTM0N2EyODY3OTIwYzdiNWEzY2FhZF8wLTItMS0xLTE2Mg_29c508a3-1d48-40a4-b816-f4de7a1ef611">98-1111119</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:225.75pt;"><tr><td style="width:1.0pt;"></td><td style="width:79.00pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:64.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:76.00pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6YjQ5NzhjZGNmNTQzNDJiZWFjMGQ4ZjIyZmUxNDAyZWUvdGFibGVyYW5nZTpiNDk3OGNkY2Y1NDM0MmJlYWMwZDhmMjJmZTE0MDJlZV8wLTAtMS0xLTE5NQ_e06dc253-c97c-4c0c-a855-d65b14f64b49">77 Sir John Rogerson&#8217;s Quay, Block C</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6YjQ5NzhjZGNmNTQzNDJiZWFjMGQ4ZjIyZmUxNDAyZWUvdGFibGVyYW5nZTpiNDk3OGNkY2Y1NDM0MmJlYWMwZDhmMjJmZTE0MDJlZV8xLTAtMS0xLTE5NQ_d32c7225-216a-459b-988e-dfdeeeb7b52a">Grand Canal Docklands</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6YjQ5NzhjZGNmNTQzNDJiZWFjMGQ4ZjIyZmUxNDAyZWUvdGFibGVyYW5nZTpiNDk3OGNkY2Y1NDM0MmJlYWMwZDhmMjJmZTE0MDJlZV8yLTAtMS0xLTE5NQ_05368501-39ce-4888-893a-b4a446aee5c7">Dublin 2,</ix:nonNumeric> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6YjQ5NzhjZGNmNTQzNDJiZWFjMGQ4ZjIyZmUxNDAyZWUvdGFibGVyYW5nZTpiNDk3OGNkY2Y1NDM0MmJlYWMwZDhmMjJmZTE0MDJlZV8yLTEtMS0xLTE5NQ_41d8e404-a781-4cbb-b2c0-80b26e380068">D02 T804,</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6YjQ5NzhjZGNmNTQzNDJiZWFjMGQ4ZjIyZmUxNDAyZWUvdGFibGVyYW5nZTpiNDk3OGNkY2Y1NDM0MmJlYWMwZDhmMjJmZTE0MDJlZV8yLTItMS0xLTE5NQ_36a1b40d-b1e6-40f4-ad30-6218a5d46f95">Ireland</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of principal executive offices including Zip Code)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Registrant&#8217;s telephone number, including area code: </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">011-<ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:CountryRegion" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18yNzQ4Nzc5MDcxMzM3_ca05930e-05f0-4aa4-ab45-e0ded8b5bf53">353</ix:nonNumeric>-<ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18yNzQ4Nzc5MDcxMzQy_43ed435d-f09f-4b8d-b473-0e3da641e3b3">1</ix:nonNumeric>-<ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18yNzQ4Nzc5MDcxMzQ0_21735a9d-5252-416b-bc1b-5680e071caed">236-2500</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;______________________________________</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:40.313%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.251%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.436%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Title of Each Class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Trading Symbol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6MWI1ZmQ4MWJhODM0NGFmMzkyYjViNWE2MGJmY2JkYzcvdGFibGVyYW5nZToxYjVmZDgxYmE4MzQ0YWYzOTJiNWI1YTYwYmZjYmRjN18xLTAtMS0xLTE5Nw_36df0320-b65a-405a-8359-9587a4596bf1">Ordinary Shares, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6MWI1ZmQ4MWJhODM0NGFmMzkyYjViNWE2MGJmY2JkYzcvdGFibGVyYW5nZToxYjVmZDgxYmE4MzQ0YWYzOTJiNWI1YTYwYmZjYmRjN18xLTEtMS0xLTE5Nw_6d304e33-3e4d-4925-99b4-bbf7d04f3f71">PRTA</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6MWI1ZmQ4MWJhODM0NGFmMzkyYjViNWE2MGJmY2JkYzcvdGFibGVyYW5nZToxYjVmZDgxYmE4MzQ0YWYzOTJiNWI1YTYwYmZjYmRjN18xLTItMS0xLTE5Nw_d15d28db-9469-44df-8e34-2ee3f414b47c">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18zMjk4NTM0ODg1MTg3_752584ab-bcd8-435b-82a7-c4aa96d697ae">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18zMjk4NTM0ODg1MTg4_95aa5640-b1be-44dc-935d-96cc24b6d6e1">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%;"><tr><td style="width:1.0%;"></td><td style="width:17.082%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:50.071%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.928%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.919%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6ZTg4YzFmMGQ4ODY0NGEyZTllN2U5MTllMGUwYjU0MDAvdGFibGVyYW5nZTplODhjMWYwZDg4NjQ0YTJlOWU3ZTkxOWUwZTBiNTQwMF8wLTItMS0xLTIwOQ_c2f1d925-c0c6-4ecd-8121-ca6c6194a1ae">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9746;</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6ZTg4YzFmMGQ4ODY0NGEyZTllN2U5MTllMGUwYjU0MDAvdGFibGVyYW5nZTplODhjMWYwZDg4NjQ0YTJlOWU3ZTkxOWUwZTBiNTQwMF8yLTMtMS0xLTIxMQ_b440bfb9-e648-41a9-8125-2ee1ad237755">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6ZTg4YzFmMGQ4ODY0NGEyZTllN2U5MTllMGUwYjU0MDAvdGFibGVyYW5nZTplODhjMWYwZDg4NjQ0YTJlOWU3ZTkxOWUwZTBiNTQwMF8zLTMtMS0xLTIxMw_c1ec703b-55fe-4e44-bc07-afcd680001ce">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18zMjk4NTM0ODg1MTg5_4f828d5f-c945-40b6-93ce-5f3cbbf52bf7">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of ordinary shares outstanding  was <ix:nonFraction unitRef="shares" contextRef="i2076d6dfdfd942b4a9a3009e044262c6_I20200731" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18xODA0_c90ad8af-8be1-4657-a075-f68860bd6c1c">39,911,413</ix:nonFraction> as of July&#160;31, 2020.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PROTHENA CORPORATION PLC</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Form 10-Q &#8211; QUARTERLY REPORT</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the Quarter Ended June&#160;30, 2020 </span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:89.215%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.785%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">PART I. FINANCIAL INFORMATION</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Item&#160;1. Financial Statements (unaudited)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2020 and 2019</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_22">2</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2020 and 2019</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:49.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Condensed Consolidated Statements of Shareholders' Equity for the three and six months ended June 30, 2020 and 2019</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Notes to Condensed Consolidated Financial Statements</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_31">6</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_73">23</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_82">30</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Item&#160;4. Controls and Procedures</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_85">30</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">PART II. OTHER INFORMATION</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_88">32</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Item&#160;1. Legal Proceedings</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_91">32</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Item&#160;1A. Risk Factors</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_94">32</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_97">56</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Item&#160;3. Defaults Upon Senior Securities</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_100">56</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Item&#160;4. Mine Safety Disclosures</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_100">56</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Item&#160;5. Other Information</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_106">56</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Item&#160;6. Exhibits</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_109">57</a></span></div></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">SIGNATURES</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_115">58</a></span></div></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">EXHIBIT INDEX</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#id78a5ecf693745eb81aedf6e125c6b7c_112">57</a></span></div></td></tr></table></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I. FINANCIAL INFORMATION</span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_13"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;1. FINANCIAL STATEMENTS</span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_16"></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Prothena Corporation plc and Subsidiaries</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets (unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%;"><tr><td style="width:1.0%;"></td><td style="width:72.547%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.378%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.495%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.380%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNC0xLTEtMS0w_6e6b4a91-8880-4a03-95c2-167432c79c22">333,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNC0zLTEtMS0w_1fa4490d-e5c1-42c7-b725-5e33ec0ac74b">375,723</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNS0xLTEtMS0w_2bcbf77f-6854-4b34-b282-7f684230b533">56</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNS0zLTEtMS0w_72422637-094e-4dab-956b-d7c08b8cfad0">68</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNi0xLTEtMS0w_fcc3f624-bd53-4528-b51b-5c7c2a829194">7,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNi0zLTEtMS0w_cbe63728-6bcc-4032-a765-b89b156d2a70">2,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNy0xLTEtMS0w_80c99b4e-e974-4e7b-8c58-4daff9aadbcc">341,123</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNy0zLTEtMS0w_f2bef614-6020-40ea-8fff-705bc3149503">378,375</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfOS0xLTEtMS0w_28493b27-09df-4c9e-8976-5fa0a95bfe72">3,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfOS0zLTEtMS0w_13a5b45b-78df-4d91-aba6-e3c8253543b0">3,874</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTAtMS0xLTEtMA_2cac4af0-960e-4d7e-809a-65315c6254cc">20,570</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTAtMy0xLTEtMA_47b96b2b-b22a-4b00-a244-f101ec17f789">23,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTEtMS0xLTEtMA_858543bf-1aee-4436-a0c7-611649f5b764">11,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTEtMy0xLTEtMA_f8f65f8b-f30d-496b-a85c-a5d27a4d068b">9,956</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash, non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTItMS0xLTEtMA_c5d90d58-bca0-441d-9182-3654e4ff64cc">2,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTItMy0xLTEtMA_14b379fd-3576-48fa-a04a-d8584c686110">2,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTMtMS0xLTEtMA_e4166aff-4264-454c-a2dc-6dcc07f14f3f">304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTMtMy0xLTEtMA_dfd9cc55-b79d-477f-bba6-4e9631680604">1,085</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total non-current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTQtMS0xLTEtMA_d8e1201e-25cc-4bff-bd78-d097352d614c">37,810</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTQtMy0xLTEtMA_f601ed26-317b-49d7-8ba8-d4bad5fbec56">40,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTUtMS0xLTEtMA_5e6a9468-961f-4b95-92b8-364a376692c3">378,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTUtMy0xLTEtMA_20c52362-57cb-409e-a89e-aa345dabc649">419,268</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTgtMS0xLTEtMA_88bdac67-74f6-4989-bdec-f3da10a8c491">2,124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTgtMy0xLTEtMA_771d0f67-5997-41be-bdde-ef0092c8c85a">1,242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="prta:AccruedResearchAndDevelopmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTktMS0xLTEtMA_ad9ad8af-f5de-4264-8d49-8e06b94a7a9d">6,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="prta:AccruedResearchAndDevelopmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTktMy0xLTEtMA_ef4f0718-93cc-450b-aba9-5d811e3f3048">5,826</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income taxes payable, current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjAtMS0xLTEtMA_e63a1c3c-9a60-47c8-a0f1-1a295a2c3a7b">221</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjAtMy0xLTEtMA_85e55a20-47c3-4f33-b712-efd202ee7255">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability, current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjEtMS0xLTEtMA_17245c1e-f202-4708-ae47-58c1621d5894">5,304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjEtMy0xLTEtMA_b2ef9ed7-6640-4cbb-87cd-308240a072ba">5,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjItMS0xLTEtMA_ddf4e9ab-cc61-4e96-919c-043746423ab0">4,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjItMy0xLTEtMA_4aba84a9-633c-41fc-9cdc-c5659a7c267d">5,540</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjMtMS0xLTEtMA_14592055-e109-4669-97b4-041807969209">18,544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjMtMy0xLTEtMA_94811d63-cbeb-4560-a3d0-c1404b57aa29">17,714</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjUtMS0xLTEtMA_ecf0a295-04eb-4f34-bfe6-7a913f51f828">110,242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjUtMy0xLTEtMA_b22534c4-25e7-44c2-9eb7-196e79d84099">110,242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability, non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjYtMS0xLTEtMA_faab32e7-d4df-4a32-8695-7b3f0a5caf27">15,150</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjYtMy0xLTEtMA_e173bf12-6d20-4132-8c49-5834d91b1bd0">17,838</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjctMS0xLTEtMA_70837eac-42fb-4bff-add6-75c403f1fdea">553</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjctMy0xLTEtMA_688eb972-3798-4818-9dca-7bf27a2b0434">553</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total non-current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjgtMS0xLTEtMA_b8e1962d-663f-4928-9938-b334a57b4f8b">125,945</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjgtMy0xLTEtMA_15929cb2-140c-4014-b820-80ecaabf8dea">128,633</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjktMS0xLTEtMA_af7149cf-1a82-4b28-a8c7-f3c55765324f">144,489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjktMy0xLTEtMA_83bc526f-6fde-4904-b142-0b5eaabb5dbe">146,347</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzAtMS0xLTEtMA_e5a60894-298a-47c2-9ff3-30abb7b534a0"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzAtMy0xLTEtMA_d2f8473e-11a8-480b-b6a6-35b241423e4f"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Euro deferred shares, &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="0" name="prta:DeferredSharesParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzItMC0xLTEtMzQzL3RleHRyZWdpb246MjEyODg5ZTAxNjJhNDhjYWFmZDY3YmM2MGM2ODA5ZDRfMzI5ODUzNDg4MzM3NQ_5a3fb322-2af3-4858-9537-1140a1fe28fc"><ix:nonFraction unitRef="eurPerShare" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="0" name="prta:DeferredSharesParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzItMC0xLTEtMzQzL3RleHRyZWdpb246MjEyODg5ZTAxNjJhNDhjYWFmZDY3YmM2MGM2ODA5ZDRfMzI5ODUzNDg4MzM3NQ_dc7ac8a7-8886-43a2-a6f0-338b7352d881">22</ix:nonFraction></ix:nonFraction> nominal value:</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:zerodash" name="prta:DeferredSharesValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzItMS0xLTEtMA_7be428fd-bd72-4dd4-be6f-1832170a1fd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:zerodash" name="prta:DeferredSharesValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzItMy0xLTEtMA_ad3c3182-182a-439c-98ab-439249dd17aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Authorized shares &#8212; <ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt:numdotdecimal" name="prta:DeferredSharesSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzMtMC0xLTEtMjU1Ni90ZXh0cmVnaW9uOmVhNTg0NmNiNjcyODRlMWQ5ODRmYWZmZWY4ODZlZTUzXzE2NDkyNjc0NDE3Mzk_48e27ede-ef43-4b7f-b44c-4330864a0229"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt:numdotdecimal" name="prta:DeferredSharesSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzMtMC0xLTEtMjU1Ni90ZXh0cmVnaW9uOmVhNTg0NmNiNjcyODRlMWQ5ODRmYWZmZWY4ODZlZTUzXzE2NDkyNjc0NDE3Mzk_7492f75e-bf31-497b-b1b6-62b742d6a3b5"><ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="INF" format="ixt:numdotdecimal" name="prta:DeferredSharesSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzMtMC0xLTEtMjU1Ni90ZXh0cmVnaW9uOmVhNTg0NmNiNjcyODRlMWQ5ODRmYWZmZWY4ODZlZTUzXzE2NDkyNjc0NDE3Mzk_9419a155-f094-45b1-859d-5b7d91aec99b"><ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="INF" format="ixt:numdotdecimal" name="prta:DeferredSharesSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzMtMC0xLTEtMjU1Ni90ZXh0cmVnaW9uOmVhNTg0NmNiNjcyODRlMWQ5ODRmYWZmZWY4ODZlZTUzXzE2NDkyNjc0NDE3Mzk_d34f3e91-2b48-410a-9ce1-9ab7141ca16a">10,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> at June 30, 2020 and December 31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Issued and outstanding shares &#8212; <ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="prta:DeferredSharesShareOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_07c2a6bf-d591-4414-9ad1-30d6662e56ce"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="prta:DeferredSharesShareIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_22eac314-f0c0-4c7b-a012-000ec44648f3"><ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="prta:DeferredSharesShareOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_53e3bd1a-4b27-4261-bea8-2d9d8acc971b"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="prta:DeferredSharesShareOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_5c674dcf-67a8-4634-9452-19d23ea6cb08"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="prta:DeferredSharesShareOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_67db6464-ccec-4fb8-a2f8-fa85fd0d5145"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="prta:DeferredSharesShareIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_a92ab6f0-b2df-4ded-bf74-19144365d946"><ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="prta:DeferredSharesShareIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_b041e136-244d-4340-852c-383ba4c76069"><ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="prta:DeferredSharesShareIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_befc2b65-9e13-43a4-948d-7a2ed3121eb6">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> at June 30, 2020 and December 31, 2019</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzUtMC0xLTEtNDkzNy90ZXh0cmVnaW9uOjI5NmJmZDIwNjNhNjQ0N2U5ZWUxOTNjOTFjNzc1OTk0XzEwOTk1MTE2Mjc4MTg_11550f18-8dc4-403b-a565-3fb370d18893"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzUtMC0xLTEtNDkzNy90ZXh0cmVnaW9uOjI5NmJmZDIwNjNhNjQ0N2U5ZWUxOTNjOTFjNzc1OTk0XzEwOTk1MTE2Mjc4MTg_d303e466-58fd-44f6-9ebe-b29407254a58">0.01</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzUtMS0xLTEtMA_2d7b725e-87a4-4fad-ab29-80d66b7556a8">399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzUtMy0xLTEtMA_e134b993-0d9a-474c-af34-1224f31df3ec">399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Authorized shares &#8212; <ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzYtMC0xLTEtMjU2MC90ZXh0cmVnaW9uOmRkMjI3OTg5ZmRiZTQxZTM5ZmI4MWI1ZmU5NjZhZmNkXzEwOTk1MTE2Mjc4NjE_004c3949-ea3a-44c1-8014-c73d16b68bf9"><ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzYtMC0xLTEtMjU2MC90ZXh0cmVnaW9uOmRkMjI3OTg5ZmRiZTQxZTM5ZmI4MWI1ZmU5NjZhZmNkXzEwOTk1MTE2Mjc4NjE_a0ad84a7-cbb3-45bd-8c5f-98c86d20d959"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzYtMC0xLTEtMjU2MC90ZXh0cmVnaW9uOmRkMjI3OTg5ZmRiZTQxZTM5ZmI4MWI1ZmU5NjZhZmNkXzEwOTk1MTE2Mjc4NjE_ef294dc4-5aa9-417c-b17f-58a3e32f0e12"><ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzYtMC0xLTEtMjU2MC90ZXh0cmVnaW9uOmRkMjI3OTg5ZmRiZTQxZTM5ZmI4MWI1ZmU5NjZhZmNkXzEwOTk1MTE2Mjc4NjE_fd82d6c5-a1f6-423c-be46-fff78888c424">100,000,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> at June 30, 2020 and December 31, 2019</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Issued and outstanding shares &#8212; <ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ1NA_51c3f548-bf2b-4a6a-adaa-313353774b6f"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ1NA_7e7b8192-2702-4a86-9d0c-7d2208ff76f5"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ1NA_b961d89f-d316-43d2-9752-00cf295aa8f2"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ1NA_ec03dd18-17d6-4d4e-8e33-6e0105934b0b">39,911,413</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">and <ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ2Nw_38ba33b4-bdbf-48c4-ba3c-6f54d885ae3a"><ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ2Nw_74c40d48-9d28-489d-80e8-b290f165f9f1"><ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ2Nw_bbefe083-a8c1-434a-9288-0370881aba1f"><ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ2Nw_f2e54b3e-4c1d-429a-88b2-c3c8e128a3fe">39,898,561</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> at June 30, 2020 and December 31, 2019, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzgtMS0xLTEtMA_10207a17-2947-4709-95a6-e7f9f29e1f36">955,781</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzgtMy0xLTEtMA_0d1a9187-b55b-4a4d-88be-5d8d3fa58ccc">944,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzktMS0xLTEtMA_743d7069-1cab-405a-82dc-f975a1f78453">721,736</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzktMy0xLTEtMA_a72c099e-c58d-493a-a688-aeb475f2c262">671,885</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total shareholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNDAtMS0xLTEtMA_b5695730-4510-4f21-b479-a8d72a193611">234,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNDAtMy0xLTEtMA_5a338a83-cf94-4705-b4c2-d10ad76bfc89">272,921</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and shareholders&#8217; equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNDEtMS0xLTEtMA_f5212125-7615-4cab-ba63-8e8c5676abd3">378,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNDEtMy0xLTEtMA_8c1c1bed-a91e-433b-8246-39a61bce3a62">419,268</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_22"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Prothena Corporation plc and Subsidiaries</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except per share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited) </span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.722%;"><tr><td style="width:1.0%;"></td><td style="width:49.949%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.357%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.559%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.496%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.559%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.496%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.142%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.496%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.146%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ecda07bc4ba4408a09994ddf7154fb8_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMi0yLTEtMS00MzY_4b1f5624-c968-40a1-965d-9331a6ec2c14">145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a01076460454a2eac50eac78fcb4c4e_D20190401-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMi00LTEtMS00MzY_06f2ed4b-f4b8-405d-b17d-4e8f9053a4de">167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if3d1c0ac6b42476b8901a5b86894d8a8_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMi0yLTEtMS0w_946f647a-a5f6-4bb8-8563-4b8b08c8574b">286</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if407b818af644e46b2c8fd3f4ef0916b_D20190101-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMi00LTEtMS0w_7ba2a6ff-6f7e-40fb-8d6e-070e2fd7ce6e">353</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License revenue</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37e74aa909674a31a31bf76e13ce1a5f_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy0yLTEtMS0xODQy_a1e0e7e3-43dd-4915-8be1-1f0ed4d13bcb">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i699a71835ede41ffb63bc12dc5058195_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy00LTEtMS0xODQy_86a36854-60d6-4152-9859-cb31edf61422">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d2e09455d741d0af7adef0326a9464_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy02LTEtMS0xODQy_8b2d51c5-1d87-48d2-b9ed-bc59995dc538">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i735a4a62bab9471a84edda62005153d0_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy04LTEtMS0xODQy_65d490f2-4afd-4061-a0ee-070df513e6b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy0yLTEtMS00Mzk_34595b08-ac58-40d5-97b7-162ed8d7272f">195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy00LTEtMS00Mzk_d6c2d3fb-342a-4a4b-82e7-bb049a02f9bb">167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy0yLTEtMS0w_f9b771e1-955e-48c8-9b90-63f46aeffb08">336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy00LTEtMS0w_def65d5e-5939-4660-a8dd-32b43e3fdf5e">353</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNS0yLTEtMS00NDE_7c222edf-d5ef-4145-964e-6457acf46124">17,271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNS00LTEtMS00NDE_d3328ccd-385e-4827-8867-cbf722def7ef">9,583</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNS0yLTEtMS0w_578f49b1-664d-4338-bc99-deb6807305b8">32,519</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNS00LTEtMS0w_4f1af8d6-1ad4-40de-b260-5eca9c384555">22,879</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNi0yLTEtMS00NDE_3d3c2b3e-70dc-41a4-b95c-eeeeaaf1b710">9,656</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNi00LTEtMS00NDE_c1903ae8-2170-42d6-aabf-5908c2dadf5a">9,081</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNi0yLTEtMS0w_9f798808-03df-4863-8c58-8b300c964b30">19,397</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNi00LTEtMS0w_d4d909c7-31d3-4ee3-878f-0aa1a9b22231">18,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring credits</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:RestructuringCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNy0yLTEtMS00NDE_c7564e3e-c443-4b96-9b2a-725d896ce568">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:RestructuringCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNy00LTEtMS00NDE_bbc956ca-77ed-4a38-89ba-564e661ab576">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:RestructuringCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNy0yLTEtMS0w_43a44b36-3ea2-4191-8c51-ac1a3ed2d07e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:RestructuringCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNy00LTEtMS0w_cd83d1ed-8b06-4014-b993-cd1770f46463">61</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOC0yLTEtMS00NDE_79bcd56c-dd23-49c5-ac2b-e9e4938a2b1d">26,927</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOC00LTEtMS00NDE_1ab2e0f2-0019-4d41-a4c5-17c7e005c3fa">18,664</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOC0yLTEtMS0w_7c37aa97-baa2-46e0-ba3e-630abd21aed1">51,916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOC00LTEtMS0w_3ea20456-01aa-43b6-a570-0b44ac5508e1">41,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOS0yLTEtMS00NDM_344e8e85-b5e7-44f4-931b-d4fe099e0ec1">26,732</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOS00LTEtMS00NDM_0ea5d8a5-a4fb-43b8-af62-b34ade783ca0">18,497</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOS0yLTEtMS0w_cb51cddf-f44d-4369-a0eb-ff61252d7a64">51,580</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOS00LTEtMS0w_5b984e29-5d83-4f49-b630-2646dc098b63">41,451</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTEtMi0xLTEtNDQ1_6137a804-6d98-4fb5-b7c4-a446ec215c82">179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTEtNC0xLTEtNDQ1_d9f2187f-822a-4555-9d2b-a57d71ccef5b">2,296</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTEtMi0xLTEtMA_16e117b9-8fe5-4685-b1ff-01ac0451485e">1,316</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTEtNC0xLTEtMA_c95899bf-169b-45fa-a217-59f5434e5049">4,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTItMi0xLTEtNDQ1_587e6413-9beb-4496-93c0-f9851a4692a8">16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTItNC0xLTEtNDQ1_92e2a463-fcb9-44e8-a9ba-9851bfa72f4e">235</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTItMi0xLTEtMA_1138d53c-879d-425e-926c-a758710019e5">8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTItNC0xLTEtMA_dbfc284a-fb22-49b0-b1aa-26bd0f23a116">218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income, net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTMtMi0xLTEtNDQ1_0f75dc76-ec07-43f5-986f-9c44fdb36b42">195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTMtNC0xLTEtNDQ1_2b0a525d-453b-4d90-a209-c34a1b5fc5ad">2,531</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTMtMi0xLTEtMA_675a4d60-a414-481a-94f6-756f9764df5b">1,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTMtNC0xLTEtMA_a83d0a38-b14b-49ce-a4eb-59c9a57943f3">4,818</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTQtMi0xLTEtNDQ4_1e4278a3-43e7-4215-b09e-814df5197886">26,537</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTQtNC0xLTEtNDQ4_0d54ec33-af90-4754-a00d-af17b707be1c">15,966</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTQtMi0xLTEtMA_96a9773b-711c-4e88-9eff-b7ba1ffd288c">50,272</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTQtNC0xLTEtMA_1f43cae0-681c-44cd-8416-8a4cb3cbf0f3">36,633</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for (benefit from) income taxes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="0" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTUtMi0xLTEtNDQ4_e847b91e-eb93-4e24-9936-56df8ca107a1">255</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="0" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTUtNC0xLTEtNDQ4_6abb0bff-bf69-4ca7-8c51-25da907bc4f9">156</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="0" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTUtMi0xLTEtMA_506cec37-4f3e-4ae1-a086-0d3abe20a258">421</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTUtNC0xLTEtMA_307012c1-8a42-44bc-9072-b9e3469c3412">42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iecc1dc4b8e3a409780b630469f43a9e2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTYtMi0xLTEtNDQ4_2597014a-4ae1-4274-93a4-941fd76b0bab">26,282</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTYtNC0xLTEtNDQ4_96e8b75b-014f-44a5-86fd-3500be3c9bce">15,810</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTYtMi0xLTEtMA_02e31282-9fae-458d-94f2-411267ec2ea5">49,851</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTYtNC0xLTEtMA_338c52b4-6bcb-455d-acc0-ccb4e45210e6">36,675</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTctMi0xLTEtNDQ4_d266d575-5030-4477-ba4d-2835a40e2f1c">0.66</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTctNC0xLTEtNDQ4_7850d1a1-b770-401d-879b-9bc95e8f7284">0.40</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTctMi0xLTEtMA_9f407341-5848-4bee-a7cb-3be7d80f0121">1.25</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTctNC0xLTEtMA_d2a2a5d6-9ba1-4022-9d28-1958de5c13ed">0.92</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Shares used to compute basic and diluted net loss per share </span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTgtMi0xLTEtNDUw_f32170c6-b4c0-44ae-a8cf-5bf073c6c98c">39,911</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTgtNC0xLTEtNDUw_5423f330-4689-41ec-af98-96d47d690d98">39,872</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTgtMi0xLTEtMA_ff38ab72-3972-4d1d-89ae-324c92ec853e">39,910</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTgtNC0xLTEtMA_b13373d7-0186-4e4c-b943-66260302308d">39,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Prothena Corporation plc and Subsidiaries</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.684%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.865%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.721%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMy0xLTEtMS0w_02e31282-9fae-458d-94f2-411267ec2ea5">49,851</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMy0zLTEtMS0w_6cb584d4-7786-449e-9eac-22545db8896e">36,675</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Adjustments to reconcile net loss to cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNS0xLTEtMS0w_a463ec3b-7bec-4bc9-b191-f2382f458951">765</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNS0zLTEtMS0w_42fce8dc-dd44-49c0-a1b3-8db9a38b4671">772</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNi0xLTEtMS0w_4cd12d01-6069-4edb-ad95-0f0c7a9d82b1">11,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNi0zLTEtMS0w_44d6e6f7-0e41-4c63-a8dd-84a78fb4b190">12,482</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNy0xLTEtMS0w_942715d2-5398-42c0-95c2-8b8f20d80440">1,061</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNy0zLTEtMS0w_9e25c1e9-e4cb-4dcf-a727-57ceb70b5af3">784</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="prta:Amortizationofrightofuseasset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfOC0xLTEtMS0w_2fe4c2fb-961e-4f6a-aec0-2c7ba0926660">2,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="prta:Amortizationofrightofuseasset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfOC0zLTEtMS0w_824074f2-7a0b-4257-abe4-4dd80ecdc717">2,603</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTAtMS0xLTEtMA_cc0e22f3-a91c-4676-a321-f2ab1433c34c">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTAtMy0xLTEtMA_fea7c69c-f452-4c7c-94ff-98539b0c6d53">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTEtMS0xLTEtMA_84e64cff-7b1f-4dd8-ac43-46e240377b25">3,760</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTEtMy0xLTEtMA_823081d8-765d-4d66-b09c-1bf64d04bcc2">15,593</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable, accruals and other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTItMS0xLTEtMA_e00d72df-8955-4bfe-8f59-d2419622bb5d">589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTItMy0xLTEtMA_08047018-df8a-493a-bbf1-296cf681e8de">10,414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInRestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTMtMS0xLTEtMA_04b70d8b-d34f-4964-9056-b4734230521b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInRestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTMtMy0xLTEtMA_47ad5791-d528-47ee-b6bc-5d80ad21f1ab">461</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="prta:IncreaseDecreaseinOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTQtMS0xLTEtMA_9b79a450-a920-4cf5-a601-e384278b6be0">2,485</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="prta:IncreaseDecreaseinOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTQtMy0xLTEtMA_a4dc0d8d-2cfc-4e28-ba05-40f1616fc509">2,298</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTUtMS0xLTEtMA_4a966ca7-cfa5-49e2-a774-3c875a9795c3">41,864</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTUtMy0xLTEtMA_44eded05-7b89-4d38-86dd-1c6743ffd4ea">29,538</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTctMS0xLTEtMA_0166c0f6-6915-4698-8ba1-1b60ead8dca3">68</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTctMy0xLTEtMA_5820fb4f-83b9-48b5-84e1-6f30ce8eb89a">200</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from disposal of fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTgtMS0xLTEtMA_732becaf-e046-4d46-9db7-7db5d14c08d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTgtMy0xLTEtMA_3c5b31f3-e1f3-4fb5-a4b4-fec2baf7c391">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTktMS0xLTEtMA_0d74c949-ac80-4bb0-a158-8aad2acff07e">68</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTktMy0xLTEtMA_0b4472e7-cdd2-41c5-a4ec-f40b745c239e">192</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of ordinary shares upon exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjEtMS0xLTEtMA_c8e03e73-8c1e-4477-9269-26f390e02b08">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjEtMy0xLTEtMA_501489e2-bc90-4621-b7c0-10a9a0891c80">215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjItMS0xLTEtMA_2627bf16-7555-4a4a-b49b-4b7669dfecdf">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjItMy0xLTEtMA_1f20856d-f7a9-4177-bf27-caac0533fc6f">215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjMtMS0xLTEtMA_cff6be96-c1ee-42ed-ba17-608d2df41722">41,781</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjMtMy0xLTEtMA_2d91e8d4-ccbe-4785-8e66-2ef0106b89bd">29,515</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash, beginning of the year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjQtMS0xLTEtMA_dddc7605-6b8e-40e4-a749-6e7b736c1b64">378,427</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb1f6a961f634e87b2d33d5dc95c15fa_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjQtMy0xLTEtMA_89cbee8e-0082-4791-be32-336a35bba9d8">431,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash, end of the period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjUtMS0xLTEtMA_986335a5-65cb-4f72-8a2d-30c3dd521cf1">336,646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjUtMy0xLTEtMA_685fe036-a1bb-4b14-a881-92fdf7310783">402,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosures of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for income taxes, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjgtMS0xLTEtMA_d8161a8d-d0c6-4c1e-a321-53dc426ee536">417</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjgtMy0xLTEtMA_3d4c803e-8e0b-477f-aa23-8804f090ad98">755</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosures of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Acquisition of property and equipment included in accounts payable and accrued liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzEtMS0xLTEtMA_7a408055-8e0f-42cf-bdee-05a34051c3c4">43</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzEtMy0xLTEtMA_0c605c29-202f-4a50-987d-85eabebb971e">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets recorded upon adoption of ASC 842</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzItMS0xLTEtMA_cb78321d-130a-4ad4-92c3-fbfb7c3b69ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzItMy0xLTEtMA_a687a6be-56c4-4e62-8985-1db828ca93f2">28,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reduction of build-to-suit lease obligation upon adoption of ASC 842</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="prta:ReductionofBuildtosuitLeaseObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzMtMS0xLTEtMA_89d22974-8faf-4eec-ac8f-bb752ed168a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="prta:ReductionofBuildtosuitLeaseObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzMtMy0xLTEtMA_afdd0608-ef30-49df-9d66-7194b051718d">51,546</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Reduction of amounts capitalized under build-to-suit lease upon adoption of ASC 842</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="prta:ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzQtMS0xLTEtMA_683b3b73-cb7e-43ae-9a81-7c19eb9449b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="prta:ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzQtMy0xLTEtMA_84cec338-a924-4596-965b-9965011ad1c5">46,760</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:31.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Reduction of capitalized interest under build-to-suit lease upon adoption of ASC 842</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="prta:ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzUtMS0xLTEtMA_ca0f5124-99b7-4cda-826a-776edcfc6d34">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="prta:ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzUtMy0xLTEtMA_0faab2e8-9a9b-449c-b769-fa51ea1d39c3">1,099</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the Condensed Consolidated Statements of Cash Flows. </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:72.377%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.445%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.446%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfMi0xLTEtMS0w_6e6b4a91-8880-4a03-95c2-167432c79c22">333,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfMi0zLTEtMS0w_9e22031a-3a11-49f8-a1a3-13159488f507">398,144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash, current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfMy0xLTEtMS0w_0aeeb086-72f1-4adc-a9a3-acf2e26f5ee7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfMy0zLTEtMS0w_0a8c46b5-5ad4-492f-9e69-bd4c3eb9437d">1,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash, non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfNC0xLTEtMS0w_c5d90d58-bca0-441d-9182-3654e4ff64cc">2,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfNC0zLTEtMS0w_20ac8952-d827-4e89-ba6b-e3f869f8c4c3">2,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and restricted cash, end of the period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfNS0xLTEtMS0w_82120af3-f431-434e-94a3-16010336f213">336,646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfNS0zLTEtMS0w_32fea267-6271-4234-b7f9-1975163e0ef0">402,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Prothena Corporation plc and Subsidiaries</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Shareholders' Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.812%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.111%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.941%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.111%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.433%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ordinary Shares</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-in Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Shareholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i033a9b5c0519456bbe6ff44d9d446f2e_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfMy0xLTEtMS00OTE_b9b752e1-5f70-4941-bd05-153b304d4782">39,911,413</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i033a9b5c0519456bbe6ff44d9d446f2e_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfMy0zLTEtMS00OTE_cad71660-e073-4aa6-a419-198ef8bed8b9">399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a8e6071ca4d4f418bf2650962cca842_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfMy01LTEtMS00OTE_5f6d6718-ea92-4ed3-8f86-162994ef772a">950,094</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idbd0a1f2b3f648e0bcca646f1febd857_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfMy03LTEtMS00OTE_74f3d549-853e-444a-bdc9-fe02c465de3d">695,454</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i59896a4eae7b4d1cadd70ccca76ef293_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfMy05LTEtMS00OTM_1f6eee21-b2eb-4c97-90c0-243f354578e4">255,039</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief7a957fd4e343de80e8f3dd3bd7c665_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNC01LTEtMS01MDE_617df660-5064-47da-81d4-7edf1cd0aa4d">5,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNC05LTEtMS01MDQ_e3c5f02f-b74a-4bda-ada0-4e7501db658a">5,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of ordinary shares upon exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iecc1dc4b8e3a409780b630469f43a9e2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNi03LTEtMS00OTU_fdcc34a0-24a0-4e06-bab1-2f34bcef7ed3">26,282</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNi05LTEtMS00OTg_0e2e708a-83e1-45cb-a094-0bf357499891">26,282</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2b53209923b24243a79113052e4c7869_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNy0xLTEtMS01MTY_d69d1384-16c6-4333-b959-cd12d1de504f">39,911,413</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b53209923b24243a79113052e4c7869_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNy0zLTEtMS01MTY_ebd083bf-5ba9-43c7-891f-bfd3f4a13711">399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i244c64bf960045f0800d51e075bbe10e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNy01LTEtMS01MTY_f08dd6c8-6800-4417-b31a-e3e093a183c4">955,781</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i033cbd2485614a1a80c8930dd799a610_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNy03LTEtMS01MTY_16ebb939-6ae3-414e-9983-a86f9709b599">721,736</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNy05LTEtMS01MTk_530ad475-3bf0-4ef8-8861-8f289885093c">234,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:40.313%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.127%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.370%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.688%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.385%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.273%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.448%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ordinary Shares</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Shareholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Balances at March 31, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2a18c2130f0248389ca0f5818a9bea98_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfMy0xLTEtMS00NjI1_881cada9-7a4c-461b-9add-3ad544e054e5">39,864,561</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a18c2130f0248389ca0f5818a9bea98_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfMy0zLTEtMS00NjI1_0815d9a5-7c5f-4743-ba5d-59b8c2ce0673">399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if139ce926c9c4e47b596fdf915376cf8_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfMy01LTEtMS00NjI1_f5d3c824-3d8a-45b5-8dc6-f54f37af9ee1">926,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11412c4befdf4ea0807e0b06f12cfe03_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfMy03LTEtMS00NjI1_9301cf0b-8bc5-407b-82f2-e920e72e7cf0">615,073</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b323be88ba54d09b5f05f59648156ba_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfMy05LTEtMS00NjI1_91864bd3-3f3d-465d-a39b-4c2cd6a324cc">312,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Share-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bb18a09ab4f41a08e2c1022903f9906_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNC01LTEtMS00NjI1_c74bd77c-87e7-4d53-8cf3-77ccb6b0ffb5">6,277</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNC05LTEtMS00NjI1_865301f3-3f5a-4649-9ccf-8f1ac5a7b1ca">6,277</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Issuance of ordinary shares upon exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i654c8eaba7c84a3ba5bb798a14bf89b4_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNS0xLTEtMS00NjI1_38781607-5447-415e-bc17-1d0c4e5f3be4">32,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bb18a09ab4f41a08e2c1022903f9906_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNS01LTEtMS00NjI1_1778df3b-8acb-413c-be40-75299eff5a71">210</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNS05LTEtMS00NjI1_a2a198a0-7fc6-4b46-90ee-3b357e31aced">210</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3911131dcd2547b8b1b797508b9ffa15_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNi03LTEtMS00NjI1_5b899edb-acaf-4549-a89c-24fefe0b54a4">15,810</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNi05LTEtMS00NjI1_fbdeb1f3-0c71-4261-a073-b675ec9e0bc7">15,810</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Balances at June 30, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaeb9f2b53bed498ca4df974ff5e0eb3f_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNy0xLTEtMS00NjI1_73e71ea7-6b64-4740-97b2-b1f4e5e5732f">39,896,561</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaeb9f2b53bed498ca4df974ff5e0eb3f_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNy0zLTEtMS00NjI1_048f7af8-63ad-407d-bf1d-aa82924a1ec3">399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58f9f83b1ec94f83ba9e88d181f91f31_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNy01LTEtMS00NjI1_f37513b4-7489-4c9b-a9ae-2a02d2aefd9f">933,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia217e25a3bae43ae8dce414a766f8967_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNy03LTEtMS00NjI1_7e3174f7-d0d9-4d24-8ef1-be042a14e0e5">630,883</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNy05LTEtMS00NjI1_48e92209-f872-45d5-8710-c124db07a308">302,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:40.143%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.397%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.485%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ordinary Shares</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Shareholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Balances at December 31, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7447e849c70240ebb46c71019b182af5_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfMy0xLTEtMS0w_ebb7e6f6-5ebd-4650-ab4a-8e6acebd591f">39,898,561</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7447e849c70240ebb46c71019b182af5_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfMy0zLTEtMS0w_01e48847-7b23-4e72-8229-e7399e1e7086">399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i529cd4e894eb4d85b99f95e755920f22_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfMy01LTEtMS0w_a57a18dc-482f-43c0-aa3e-087234986e9a">944,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2f79eb93966141d7a3a13adc3ac38d49_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfMy03LTEtMS0w_2050cd0b-a669-46ef-bd92-531acc1ad7bb">671,885</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfMy05LTEtMS0w_95e6e9cb-9da6-4801-964c-356688c7926c">272,921</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Share-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1514bd0122184324869e45816a840dff_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNC01LTEtMS0w_aa2c8a14-aaf7-4809-b137-31e9a8e04b20">11,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNC05LTEtMS0w_7212bfd2-c2c5-4a0b-a844-5d94800b28fb">11,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Issuance of ordinary shares upon exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i359327a4643e466ca3a685787fdbf791_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNS0xLTEtMS0w_ea8553ae-d6f0-4dbf-bf2f-d30920249123">12,852</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1514bd0122184324869e45816a840dff_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNS01LTEtMS0w_d30e1964-090b-4f60-8569-f4ba4c34e962">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNS05LTEtMS0w_e6aa163d-e406-4adc-aca4-a87cd885b32d">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id3888cc09d684fd7b2c05fab7e9b2a3a_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNi03LTEtMS0w_a5a1481b-9348-4b42-9401-eb4f09f72a10">49,851</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNi05LTEtMS0w_1f251553-cab7-48e3-8efd-60544cf16411">49,851</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2b53209923b24243a79113052e4c7869_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNy0xLTEtMS0w_d69d1384-16c6-4333-b959-cd12d1de504f">39,911,413</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b53209923b24243a79113052e4c7869_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNy0zLTEtMS0w_ebd083bf-5ba9-43c7-891f-bfd3f4a13711">399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i244c64bf960045f0800d51e075bbe10e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNy01LTEtMS0w_f08dd6c8-6800-4417-b31a-e3e093a183c4">955,781</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i033cbd2485614a1a80c8930dd799a610_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNy03LTEtMS0w_16ebb939-6ae3-414e-9983-a86f9709b599">721,736</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNy05LTEtMS0w_530ad475-3bf0-4ef8-8861-8f289885093c">234,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:39.911%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.176%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.411%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.323%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.504%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ordinary Shares</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Shareholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Balances at December 31, 2018</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0d6464030811498ea45278866f1f669b_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfMy0xLTEtMS0w_2764468f-42cc-485e-a0f1-ffe305a639da">39,863,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d6464030811498ea45278866f1f669b_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfMy0zLTEtMS0w_bcd7ac17-6f47-419f-901a-120f29775def">399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8799a9e7d9a5439bbef0dd2887838f26_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfMy01LTEtMS0w_0ccc1d83-36aa-43a6-b224-80d9d34275f5">920,594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8b149813b9fd4ba6a6381399eba9055f_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfMy03LTEtMS0w_4e1cf69c-1f64-44f0-8471-f0b54965d2af">597,995</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb1f6a961f634e87b2d33d5dc95c15fa_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfMy05LTEtMS0w_7e6efb0d-1a71-4eeb-b14a-40eda9777d4a">322,998</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Cumulative adjustment to accumulated deficit upon adoption of ASC 842</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i06f9dd74ab7b4824a2d89b866088ebdf_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNC03LTEtMS0w_ca72f6eb-43fd-44a9-9702-1864edf6118f">3,787</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia3b99b92bd8c4e959e5259476524c341_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNC05LTEtMS0w_ad3cdece-7f4a-417d-b028-f28670c51ae1">3,787</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Share-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie594e8889b9b4963ae70ebdb928a145b_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNS01LTEtMS0w_abd80694-1e07-4d06-ae5b-36a783ad4816">12,482</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNS05LTEtMS0w_a6f636cc-75b8-4ae5-a9ed-ff31e3c698d3">12,482</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Issuance of ordinary shares upon exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iec113c33f31b44c790f21ee119a59cfc_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNi0xLTEtMS0w_39e814b9-4be5-4621-be3c-6c79815d0b5d">32,850</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie594e8889b9b4963ae70ebdb928a145b_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNi01LTEtMS0w_a80725e8-4008-4fca-8f7e-28b0c5fb26b6">215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNi05LTEtMS0w_ad9de5d5-0df2-49a8-8922-0849ed29ade5">215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3f59203e494b4d0aa54e4354c6b66ab5_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNy03LTEtMS0w_b083ccea-7a09-49ae-971c-99e0e398b49c">36,675</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNy05LTEtMS0w_e27930ec-d133-40d1-a63e-5b58457c8889">36,675</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaeb9f2b53bed498ca4df974ff5e0eb3f_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfOC0xLTEtMS0w_4107287b-cc9c-403d-b57c-a1909551dbe8">39,896,561</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaeb9f2b53bed498ca4df974ff5e0eb3f_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfOC0zLTEtMS0w_bb5f4e44-c2da-454c-ae8d-89f4094eca14">399</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58f9f83b1ec94f83ba9e88d181f91f31_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfOC01LTEtMS0w_ff3e99ec-a687-4de2-b7af-33d2b56f1e31">933,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia217e25a3bae43ae8dce414a766f8967_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfOC03LTEtMS0w_79f1a6af-69df-4b7c-8154-7efd9d003676">630,883</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfOC05LTEtMS0w_70bf18e4-ab38-4945-b26d-ebb4b1a8ed6d">302,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Consolidated Financial Statements. </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to the Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_34"></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:-9pt;padding-left:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:1.5pt;"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNC9mcmFnOmI5ZDk0MmEzYjUxOTQ1NTM4MzU0MDg5YzU2MjM3ZTFiL3RleHRyZWdpb246YjlkOTQyYTNiNTE5NDU1MzgzNTQwODljNTYyMzdlMWJfMzQwMQ_a0e4d1e6-30c3-40a9-a136-4ecdc28d902a" continuedAt="i565bda8d6f114c60b998451c39ab0ef1" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i565bda8d6f114c60b998451c39ab0ef1"><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Prothena Corporation plc (&#8220;Prothena&#8221; or the &#8220;Company&#8221;) is a clinical-stage neuroscience company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases. Fueled by our deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which our ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena's partnered programs include prasinezumab (PRX002/RG7935), in collaboration with Roche for the potential treatment of Parkinson&#8217;s disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer&#8217;s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) or other neurodegenerative diseases. The Company's proprietary programs include PRX004 for the potential treatment of ATTR amyloidosis, and programs that target A&#946; (Amyloid beta) for the potential treatment of Alzheimer&#8217;s disease.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company was formed on September 26, 2012, under the laws of Ireland and re-registered as an Irish public limited company on October 25, 2012. The Company's ordinary shares began trading on The Nasdaq Global Market under the symbol &#8220;PRTA&#8221; on December 21, 2012, and currently trade on The Nasdaq Global Select Market.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity and Business Risks</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNC9mcmFnOmI5ZDk0MmEzYjUxOTQ1NTM4MzU0MDg5YzU2MjM3ZTFiL3RleHRyZWdpb246YjlkOTQyYTNiNTE5NDU1MzgzNTQwODljNTYyMzdlMWJfMTA5OTUxMTYzMTE5MA_331afb90-634b-44d3-91dd-200cd7ec74b5">721.7</ix:nonFraction> million and cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNC9mcmFnOmI5ZDk0MmEzYjUxOTQ1NTM4MzU0MDg5YzU2MjM3ZTFiL3RleHRyZWdpb246YjlkOTQyYTNiNTE5NDU1MzgzNTQwODljNTYyMzdlMWJfMTA5OTUxMTYzMTE5NQ_1cf49ee5-e3cf-49a7-ad42-27c69e9edb10">333.9</ix:nonFraction> million. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on the Company's business plans, management believes that the Company&#8217;s cash and cash equivalents at June&#160;30, 2020, are sufficient to meet its obligations for at least the next twelve months. To operate beyond such period, or if the Company elects to increase its spending on research and development programs significantly above current long-term plans or enters into potential licenses and or other acquisitions of complementary technologies, products or companies, the Company may need additional capital. The Company expects to continue to finance future cash needs that exceed its cash from operating activities primarily through its current cash and cash equivalents, its collaborations with Roche and Bristol-Myers Squibb, and, to the extent necessary, through proceeds from public or private equity or debt financings, loans and other collaborative agreements with corporate partners or other arrangements.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company is subject to a number of risks, including but not limited to: the uncertainty of the Company&#8217;s research and development (&#8220;R&amp;D&#8221;) efforts resulting in future successful commercial products; obtaining regulatory approval for its product candidates; its ability to successfully commercialize its product candidates, if approved; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; the outbreak of the novel strain of coronavirus SARS-CoV-2; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the healthcare industry.</span></div></ix:continuation><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_37"></div><div style="text-indent:-9pt;padding-left:9pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:1.5pt;"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNjY0Nw_a4c9c326-8356-4eef-93f9-e50440230c82" continuedAt="ie0cfa003cd724077b7ff40453cc747c3" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ie0cfa003cd724077b7ff40453cc747c3" continuedAt="id3120ed00d5446e69932bf2130e59651"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNjY0OA_5fe872ac-ef75-4ff1-b1b9-0d8853808e2d" continuedAt="i43706d20e4dd4cfa9b3e7c8e92ad73ed" escape="true"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Preparation and Presentation of Financial Information</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These accompanying Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with the accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the instructions for Form 10-Q and Regulation S-X statements. Accordingly, they do not include all of the information and notes required for complete financial statements. These interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto contained in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;3, 2020 (the &#8220;2019 Form 10-K&#8221;). These Unaudited Interim Condensed Consolidated Financial Statements are presented in U.S. dollars, which is the functional currency of the Company and its consolidated subsidiaries. These Unaudited Interim Condensed Consolidated Financial Statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current year presentation.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="id3120ed00d5446e69932bf2130e59651" continuedAt="i243b1f1581de4b46a26c4bd105662f17"><ix:continuation id="i43706d20e4dd4cfa9b3e7c8e92ad73ed"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Financial Information</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Unaudited Interim Condensed Consolidated Financial Statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements, however certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.</span></div></ix:continuation><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNjYzNQ_4ece2fe4-e494-4d71-b8e3-4ef7c9364362" escape="true"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures.  On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div></ix:nonNumeric><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Accounting Policies</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no significant changes to the accounting policies during the six months ended June 30, 2020, from the significant accounting policies described in Note 2 of the Notes to Consolidated Financial Statements in the 2019 Form 10-K.</span></div><div style="text-indent:9pt;"><span><br/></span></div><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNjYyMw_543934f1-4e37-4815-8c0e-2fcebd0bf752" escape="true"><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segment and Concentration of Risks</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company operates in one segment. The Company&#8217;s chief operating decision maker (the &#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM reviews all financial information on a consolidated basis.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits.  The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The receivables recorded in the Condensed Consolidated Balance Sheet include amounts due from a Roche entity located in Switzerland. Revenue recorded in the Condensed Consolidated Statements of Operations consists of reimbursement from Roche for research and development services. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  As of June&#160;30, 2020, $<ix:nonFraction unitRef="usd" contextRef="i7b64af079f774a46a8be8b6571368300_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNDgxOA_cf7e11c0-8f45-4901-bf89-11f29eb8c22c">3.2</ix:nonFraction> million of the Company&#8217;s property and equipment, net were held in the U.S. and <ix:nonFraction unitRef="usd" contextRef="i11d3275580fa4bd1961ee805e56db0d0_I20200630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNDg5Mg_ca60df0d-474d-4032-a534-f24221279097">none</ix:nonFraction> were in Ireland.  As of December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="idf82b12dcb0a4510a9e8d227e7f54b0f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNDkyMw_bcca38d3-f96f-403c-a469-876bdc4bed1e">3.9</ix:nonFraction> million of the Company's property and equipment, net were held in the U.S. and <ix:nonFraction unitRef="usd" contextRef="i35e6e65a4d584b26a679bc03ea55c9d0_I20191231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNDk5Nw_30e4f423-7d04-4b7d-95b3-b52489d80fc5">none</ix:nonFraction> were in Ireland. </span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNjY1MQ_99e68dc5-15aa-4bb4-b18e-5ec066b0ae71" continuedAt="ib01404f57507422f8a030a39ad9e01e7" escape="true"><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 18, 2019, the Finance Accounting Standards Board ("FASB") issued Accounting Standards Update 2019-12 ("ASU 2019-12"), Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes as part of the FASB&#8217;s overall initiative to reduce complexity in accounting standards.  Amendments include removal of certain exceptions to the general principles of ASC 740, Income Taxes, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. While not required to be adopted until 2021 for most calendar year public business entities (and 2022 for other entities), early adoption is permitted for any financial statements. The Company does not expect the adoption of ASU 2019-12 to have a significant impact on its </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i243b1f1581de4b46a26c4bd105662f17"><ix:continuation id="ib01404f57507422f8a030a39ad9e01e7">consolidated financial statements. The Company will continue to evaluate the impact of ASU 2019-12 on its consolidated financial statements.</ix:continuation></ix:continuation></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_40"></div><div style="text-indent:-9pt;padding-left:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:1.5pt;"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180MC9mcmFnOmYxN2YyMTM5NzQ4YjQxZGRhYmU0MDMwNzk4MTdkNWY3L3RleHRyZWdpb246ZjE3ZjIxMzk3NDhiNDFkZGFiZTQwMzA3OTgxN2Q1ZjdfMjI0MA_df1f999c-d5b4-468a-ad9f-5bcbc42c0645" continuedAt="i04c09d14a23a4aaa8323d2745b52899a" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i04c09d14a23a4aaa8323d2745b52899a"><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents.&#160;Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></div><div style="text-indent:-49.5pt;padding-left:72pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;1&#160;&#8212;&#160;Observable inputs such as quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="text-indent:-49.5pt;padding-left:72pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;2&#160; &#8212;&#160;Include other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and credit ratings.</span></div><div style="text-indent:-49.5pt;padding-left:72pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities, and low market interest rates, if applicable. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on the fair value hierarchy, the Company classifies its cash equivalents within Level 1. This is because the Company values its cash equivalents using quoted market prices. The Company&#8217;s Level 1 securities consisted of $<ix:nonFraction unitRef="usd" contextRef="ib2330f117cb341549ed1cb65fe74eff0_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180MC9mcmFnOmYxN2YyMTM5NzQ4YjQxZGRhYmU0MDMwNzk4MTdkNWY3L3RleHRyZWdpb246ZjE3ZjIxMzk3NDhiNDFkZGFiZTQwMzA3OTgxN2Q1ZjdfMjEzOQ_deb67441-8569-4aee-b556-afbc85729e9d">287.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id7e67ec9f2a141d3afb5af2d44c43cf4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180MC9mcmFnOmYxN2YyMTM5NzQ4YjQxZGRhYmU0MDMwNzk4MTdkNWY3L3RleHRyZWdpb246ZjE3ZjIxMzk3NDhiNDFkZGFiZTQwMzA3OTgxN2Q1ZjdfMjE0Ng_2a89d208-5505-4a0d-8d3e-225b422921dc">338.2</ix:nonFraction> million in money market funds included in cash and cash equivalents at June&#160;30, 2020, and December&#160;31, 2019, respectively.</span></div></ix:continuation><div id="id78a5ecf693745eb81aedf6e125c6b7c_43"></div><div style="text-indent:-9pt;padding-left:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:1.5pt;"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfMzI5_96d99ad9-6ab0-4c73-8a62-7a068ae7bda9" continuedAt="i2d959a8e6d744fd89e175e7e2b5f0200" escape="true">Composition of Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:continuation id="i2d959a8e6d744fd89e175e7e2b5f0200" continuedAt="i5511c40ce0704825a2d6239f42cc5177"><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, net</span></div><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfMzIz_5183ee71-c737-4b2c-85e4-fa51c2be85e3" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consisted of the following (in thousands):</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:73.659%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.876%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.732%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Machinery and equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfMi0xLTEtMS0w_a26fdbfc-079d-41b9-b8bd-2c1f1711d76c">9,334</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfMi0zLTEtMS0w_cbdaa25f-3e7c-43c3-addd-22805a7734af">9,312</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseholdImprovementsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfMy0xLTEtMS0w_52668dc2-6984-4944-bad4-f9dacb1102dc">1,261</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseholdImprovementsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfMy0zLTEtMS0w_ba8beb48-7641-4477-8723-6023b2f0ea55">1,261</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchased computer software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNC0xLTEtMS0w_90e7574a-3654-4ac4-bee1-f5c13f3d6c31">1,392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNC0zLTEtMS0w_c41a5f47-b2a2-4c76-bfa1-823f51fec414">1,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNS0xLTEtMS0w_b955d4f4-2f45-49ca-9f19-51fd68010199">11,987</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNS0zLTEtMS0w_49c9aba1-3a06-42b2-9349-5ff97659a5a1">11,881</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNi0xLTEtMS0w_a6ff944a-6c56-4382-93d3-1f58d618f862">8,772</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNi0zLTEtMS0w_65519dda-d769-442a-872a-98d3b40d1d71">8,007</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNy0xLTEtMS0w_c6efacf6-f1be-4f30-86c3-6b7550920c44">3,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNy0zLTEtMS0w_4708e4d2-15b5-449c-b3b1-3560755a9584">3,874</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfMTc2_b5418a42-d83c-43c8-93ed-343a7034b5df">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfNjA0NzMxMzk1MzE3MA_de709b21-e61e-4b35-937b-c9589a13ffa3">0.8</ix:nonFraction> million for the three and six months ended June&#160;30, 2020, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfNjA0NzMxMzk1MzE3NQ_aebb808c-b763-4228-9e11-ef72de8e9a2e">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfNjA0NzMxMzk1MzE3OQ_aeb7e555-2031-4062-b071-c42afdc12faa">0.8</ix:nonFraction> million for the three and six months ended June&#160;30, 2019, respectively.</span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><ix:continuation id="i5511c40ce0704825a2d6239f42cc5177"><div style="text-indent:9pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Current Liabilities</span></div><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfMzE4_363518f9-46fa-487c-8470-e8b4e699bd85" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current liabilities consisted of the following (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payroll and related expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfMi0xLTEtMS0w_0e329ddf-4296-4cb7-9d97-511f074cc6ce">3,355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfMi0zLTEtMS0w_746415a4-761e-4f2f-be32-bc1bee36da48">4,818</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfMy0xLTEtMS0w_527597b8-93ae-44af-8c65-35450712a987">715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfMy0zLTEtMS0w_d5ac0efe-3414-4b8e-9b5b-14c5393b52dc">400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfNC0xLTEtMS0w_75c3573e-7251-4d55-842a-75cbb85447c4">673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfNC0zLTEtMS0w_0b8b44bc-15a1-4501-952b-71556dec2133">322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfNS0xLTEtMS0w_b065483a-933e-44ea-8112-58a2f7ee9506">4,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfNS0zLTEtMS0w_a4dd31f4-7144-49d3-bf49-eecba18d7cac">5,540</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_46"></div><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:1.5pt;"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RleHRyZWdpb246Mjc3OGExNDI3YTg4NDZjOGE3YzczZjIxNDEwYTgzOGFfOTAx_07dd3598-7046-4f0d-996b-80989a82bab9" continuedAt="i8cd40ba6b0654ff58410051c585aecbf" escape="true">Net Loss Per Ordinary Share</ix:nonNumeric></span></div><ix:continuation id="i8cd40ba6b0654ff58410051c585aecbf"><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net income (loss) per ordinary share is calculated by dividing net income (loss) by the weighted-average number of ordinary shares outstanding during the period. Shares used in diluted net income per ordinary share would include the dilutive effect of ordinary shares potentially issuable upon the exercise of stock options outstanding. However, potentially issuable ordinary shares are not used in computing diluted net loss per ordinary share as their effect would be anti-dilutive due to the loss recorded during the three and six months ended June&#160;30, 2020, and 2019, and therefore diluted net loss per share is equal to basic net loss per share.</span></div><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RleHRyZWdpb246Mjc3OGExNDI3YTg4NDZjOGE3YzczZjIxNDEwYTgzOGFfOTAy_3651fcb5-8f78-4d7e-86ff-5bb7ae848670" escape="true"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per ordinary share was determined as follows (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:42.040%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.517%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.381%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.517%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.381%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.517%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.521%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iecc1dc4b8e3a409780b630469f43a9e2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfMy0xLTEtMS0yMjM4_2597014a-4ae1-4274-93a4-941fd76b0bab">26,282</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfMy0zLTEtMS0yMjM4_96e8b75b-014f-44a5-86fd-3500be3c9bce">15,810</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfMy0xLTEtMS0w_02e31282-9fae-458d-94f2-411267ec2ea5">49,851</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfMy0zLTEtMS0w_338c52b4-6bcb-455d-acc0-ccb4e45210e6">36,675</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average ordinary shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNS0xLTEtMS0yMjQ1_f32170c6-b4c0-44ae-a8cf-5bf073c6c98c">39,911</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNS0zLTEtMS0yMjQ1_5423f330-4689-41ec-af98-96d47d690d98">39,872</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNS0xLTEtMS0w_ff38ab72-3972-4d1d-89ae-324c92ec853e">39,910</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNS0zLTEtMS0w_b13373d7-0186-4e4c-b943-66260302308d">39,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNy0xLTEtMS0yMjUw_d266d575-5030-4477-ba4d-2835a40e2f1c">0.66</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNy0zLTEtMS0yMjUw_7850d1a1-b770-401d-879b-9bc95e8f7284">0.40</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNy0xLTEtMS0w_9f407341-5848-4bee-a7cb-3be7d80f0121">1.25</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNy0zLTEtMS0w_d2a2a5d6-9ba1-4022-9d28-1958de5c13ed">0.92</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RleHRyZWdpb246Mjc3OGExNDI3YTg4NDZjOGE3YzczZjIxNDEwYTgzOGFfOTA0_136c1965-8598-491d-82e3-049f995d822f" escape="true"><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The equivalent ordinary shares not included in diluted net loss per share because their effect would be anti-dilutive are as&#160;follows&#160;(in&#160;thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:45.222%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.723%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase ordinary shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i54b797a322b643859e1d254057908a54_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjVmNTRmOTBkNTIxNTQ3ZTdhOTVjOWIxYTY5ZWE5Yzg3L3RhYmxlcmFuZ2U6NWY1NGY5MGQ1MjE1NDdlN2E5NWM5YjFhNjllYTljODdfMi0xLTEtMS0yMjcy_77e65605-95fc-4a54-964c-a004c9947b90">8,672</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ifdeb4d65f9b2469ca2008e311f8a3473_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjVmNTRmOTBkNTIxNTQ3ZTdhOTVjOWIxYTY5ZWE5Yzg3L3RhYmxlcmFuZ2U6NWY1NGY5MGQ1MjE1NDdlN2E5NWM5YjFhNjllYTljODdfMi0zLTEtMS0yMjcy_0d942d2a-fff0-423a-82da-e04a7f5911e9">7,168</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iededd3a706834ae081db1b4deff0a8bb_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjVmNTRmOTBkNTIxNTQ3ZTdhOTVjOWIxYTY5ZWE5Yzg3L3RhYmxlcmFuZ2U6NWY1NGY5MGQ1MjE1NDdlN2E5NWM5YjFhNjllYTljODdfMi0xLTEtMS0w_6addf28d-ca3e-4c94-aefc-3cd9f0615e08">8,672</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic3fa83c08da0419a82890f9cdd288a03_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjVmNTRmOTBkNTIxNTQ3ZTdhOTVjOWIxYTY5ZWE5Yzg3L3RhYmxlcmFuZ2U6NWY1NGY5MGQ1MjE1NDdlN2E5NWM5YjFhNjllYTljODdfMi0zLTEtMS0w_bd5a820e-8f71-4dae-b449-36a1f437f468">7,168</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_49"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2Mjc3MA_208ebc77-1b5e-490f-8b61-3e0dbaaf2000" continuedAt="i24dbc87a045d4132a62a050f581374d8" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i24dbc87a045d4132a62a050f581374d8" continuedAt="i7b4c202cf5f34fb496c5acf2c123ad51"><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Lease Commitments</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted ASC 842, Leases effective January 1, 2019. Prior period amounts have not been adjusted and continued to be reported in accordance with the Company&#8217;s historical accounting under ASC 840. For lease arrangements entered prior to the adoption of ASC 842, right-of-use asset and lease liability are determined based on the present value of minimum lease payments over the remaining lease term and the Company&#8217;s incremental borrowing rate based on information available as of January 1, 2019. The right-of-use asset also includes any lease prepayments made and excludes unamortized lease incentives including rent abatements and/or concessions and rent holidays. Tenant improvements made by the Company as a lessee, in which such improvements are deemed to be owned by the lessor, are viewed as lease prepayments by the Company and are included in the right-of-use asset. Lease expense is recognized on a straight-line basis over the expected lease term. Total operating lease cost was $<ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjU3MQ_fc4f17ac-18b1-4e5f-9fe4-73092ef4b44f">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMTA1Nw_e2453a69-5322-4d6b-9a70-5f605fb6a3a1">3.2</ix:nonFraction> million for the three and six months ended June&#160;30, 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjYwNQ_4f01b497-e36d-4c06-8832-72f631045ed3">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjYxMg_15820c95-4727-4221-8890-8d1b8ad349f9">3.2</ix:nonFraction> million three and six months ended June&#160;30, 2019, respectively. Total cash paid against the operating lease liability was $<ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjY5Mg_031a37fe-83a9-4b4b-8a49-3f88aa095e71">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMTE1OA_0285857b-bf2d-4744-9b24-ea9bfdf21ee8">3.0</ix:nonFraction> million for the three and six months ended June&#160;30, 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjcxOQ_67748a58-de2b-4257-8657-3c6a47644eae">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjcyNg_7576d683-d243-4250-847d-09ac0db7ae02">2.9</ix:nonFraction> million three and six months ended June&#160;30, 2019, respectively. </span></div></ix:continuation><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i7b4c202cf5f34fb496c5acf2c123ad51" continuedAt="i5022523d713149abb74b83f32b37a33d"><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the purpose of estimating the incremental borrowing rate in the adoption of ASC 842, the Company inquired with banks that had a business relationship with the Company to determine the Company's collateralized incremental borrowing rate. The discount rate used to determine the lease liability was <ix:nonFraction unitRef="number" contextRef="i03363be070604a69a801733692c0eb01_I20200630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMTUwNA_99b99972-53db-49a3-8d44-9515b76ebc5e">4.25</ix:nonFraction>%. There was no change in the accounting of the Sub-Sublease (as defined below) of the Current SSF Facility (as defined below) upon adoption of ASC 842. Furthermore, the Company's operating lease in Dublin is not included in the lease liability and right-of-use asset recorded due to its nominal amount.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company performed an evaluation of its other contracts with customers and suppliers in accordance with ASC 842 and have determined that, except for the leases described below, a nominal operating lease for medical monitoring equipment and a nominal operating lease for office equipment, none of the Company&#8217;s contracts contain a lease.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="padding-left:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Current SSF Facility</span></div><div style="padding-left:22.5pt;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2016, the Company entered into a noncancelable operating sublease (the &#8220;Lease&#8221;) to lease <ix:nonFraction unitRef="sqft" contextRef="i8154f8e4fb0a43068ce1feebb738c177_D20160301-20160331" decimals="0" format="ixt:numdotdecimal" name="prta:OperatingLeaseArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMjI3Mg_850915dd-c7cf-4056-af1e-1f42446afb77">128,751</ix:nonFraction> square feet of office and laboratory space in South San Francisco, California, U.S. (the &#8220;Current SSF Facility&#8221;). Subsequently, in April 2016, the Company took possession of the Current SSF Facility. The Lease includes a free rent period and escalating rent payments and has a remaining lease term of <ix:nonNumeric contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMjU3Ng_e0f1df37-ec67-482b-8297-383defede416">3.50</ix:nonNumeric> years that expires on <ix:nonNumeric contextRef="i8154f8e4fb0a43068ce1feebb738c177_D20160301-20160331" format="ixt:datemonthdayyearen" name="us-gaap:LeaseExpirationDate1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMjU5NQ_fc9366db-7247-4983-b6b1-3bd7b0a42b9d">December&#160;31, 2023</ix:nonNumeric>, unless terminated earlier.  The Company's obligation to pay rent commenced on August 1, 2016. The Company is obligated to make lease payments totaling approximately $<ix:nonFraction unitRef="usd" contextRef="iaa84acb8305c4045b894b70949b443e0_I20160430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalLeasesFutureMinimumPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMjc2NA_06bff288-0181-4bd6-b8da-d8cad28a4867">39.2</ix:nonFraction> million over the lease term. The Lease further provides that the Company is obligated to pay to the sublandlord and master landlord certain costs, including taxes and operating expenses. The Lease is considered an operating lease under ASC 842. Prior to the Company's adoption of ASC 842, this Lease was considered a build-to-suit lease. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In connection with this Lease, the Company received a tenant improvement allowance of $<ix:nonFraction unitRef="usd" contextRef="ie5ee13ac88c14078b954248c161c0e37_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="prta:OperatingLeasesImprovementAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMzE4Ng_13aed1b1-c238-453c-a63e-3d34136f46c0">14.2</ix:nonFraction> million from the sublandlord and the master landlord, for the costs associated with the design, development and construction of tenant improvements for the Current SSF Facility. The Company is obligated to fund all costs incurred in excess of the tenant improvement allowance. The initial measurement of right-of-use asset for the Lease includes the tenant improvement added by the Company wherein the lessor was deemed the accounting owner, net of the tenant improvement allowance received from the sublandlord and the master landlord. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company obtained a standby letter of credit in April 2016 in the initial amount of $<ix:nonFraction unitRef="usd" contextRef="ibaf705e3bc94419cad46238812fd99d7_I20160430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMzgwNw_5a7c1479-bc41-4d73-a56b-18732b62ccc9">4.1</ix:nonFraction> million, which may be drawn down by the sublandlord in the event the Company fails to fully and faithfully perform all of its obligations under the Lease and to compensate the sublandlord for all losses and damages the sublandlord may suffer as a result of the occurrence of any default on the part of Company not cured within the applicable cure period. This standby letter of credit is collateralized by a certificate of deposit of the same amount which is classified as restricted cash. The Company was entitled to a $<ix:nonFraction unitRef="usd" contextRef="i2d1009cc88444495b1b71ed313bd65be_D20160401-20160430" decimals="-5" format="ixt:numdotdecimal" name="prta:LineofCreditFacilityFaceAmountReductiononThirdAnniversary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNDMyMg_ad4c736d-b2af-47dc-980a-bfff5e9a9887">1.4</ix:nonFraction> million reduction in the face amount of the standby letter of credit on the third anniversary of the contractual rent commencement, which was received in 2019, and another $<ix:nonFraction unitRef="usd" contextRef="i2d1009cc88444495b1b71ed313bd65be_D20160401-20160430" decimals="-5" format="ixt:numdotdecimal" name="prta:LineofCreditFacilityFaceAmountReductiononFifthAnniversary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNDQ4OQ_a8f1f1a9-6367-4c9b-beee-4f1fb65d9199">1.4</ix:nonFraction> million on the fifth anniversary of the contractual rent commencement. As a condition to the reduction of the standby letter of credit amount, no uncured default by the Company shall then exist under the Lease.  As of June&#160;30, 2020, <ix:nonFraction unitRef="usd" contextRef="ibbc0b76aa18c4b81ab20c7e33334019e_I20200630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNDcwNg_05ed9c27-4c11-4fbf-a6e2-7b5fe12d1263">none</ix:nonFraction> of the remaining standby letter of credit amount of $<ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMTA5OTUxMTYzNzUxMA_f6c4d18c-e000-4748-9a11-a6866517fa8f">2.7</ix:nonFraction> million has been used.</span></div><div style="padding-left:22.5pt;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sub-Sublease of Current SSF Facility </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July&#160;18, 2018, the Company entered into a Sub-Sublease Agreement (the &#8220;Sub-Sublease&#8221;) with Assembly Biosciences, Inc. (the &#8220;Sub-Subtenant&#8221;) to sub-sublease approximately <ix:nonFraction unitRef="sqft" contextRef="id8c8f6072f864cafae096d1bc47eb2f8_D20180718-20180718" decimals="0" format="ixt:numdotdecimal" name="prta:OperatingLeasesSubleaseRentalsAreaofSubleaseRental" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNDk4MQ_2ec71f1a-bffe-480c-b845-956ddf7b5e51">46,641</ix:nonFraction> square feet of office and laboratory space of the Current SSF Facility to the Sub-Subtenant. The Sub-Sublease is considered an operating lease under ASC 842. There was no change in the accounting of the Sub-Sublease of the Current SSF Facility upon the Company's adoption of ASC 842. For the three and six months ended June 30, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2Mjc4OA_ae2b0156-53a6-4bc0-abf7-eb08e89a2dae">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNTMwOA_a4d9a51a-4e21-4e56-9e0b-63e21d76c438">1.5</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjgwMQ_40a0b584-0694-4e7c-8828-1b96adc2c14a">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjgwOA_5dd1f444-3293-4231-ac0e-7589ce2bc59d">1.5</ix:nonFraction> million three and six months ended June&#160;30, 2019, respectively, of sub-lease rental income as an offset to its operating expenses. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Sub-Sublease provides for initial annual base rent for the complete Sub-Subleased Premises of approximately $<ix:nonFraction unitRef="usd" contextRef="i218bb3aa60ae4e83aa3e4a7e671866cf_I20180718" decimals="-5" format="ixt:numdotdecimal" name="prta:SubleaserentalsAnnualBaseRentInitialAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNTUxNQ_dc91be89-8aec-4910-9c7b-3888e30b2845">2.7</ix:nonFraction> million, with increases of approximately <ix:nonFraction unitRef="number" contextRef="id8c8f6072f864cafae096d1bc47eb2f8_D20180718-20180718" decimals="3" name="prta:OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNTU1MQ_1b12b3ed-110a-4be6-9be7-554ae10717c1">3.5</ix:nonFraction>% in annual base rent on September 1, 2019 and each anniversary thereof. The Sub-Sublease rental income excludes reimbursements for executory costs received from the Sub-Subtenant. The Sub-Sublease became effective on September&#160;24, 2018, and has a term of <ix:nonNumeric contextRef="i7fcd1972dc354290ba6864c10a7dfd26_D20180924-20180924" format="ixt-sec:duryear" name="prta:OperatingLeasesSubleaseRentalsTermofContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNTc5Mg_a26ad5d4-c4be-4691-b254-e71eed5ee291">5.2</ix:nonNumeric> years which terminates on December&#160;15, 2023. The Sub-Sublease will terminate if the Lease or the corresponding master lease terminates. The Company or the Sub-Subtenant may elect, subject to limitations set forth in the Sub-Sublease, to terminate the Sub-Sublease following a material casualty or condemnation affecting the Subleased Premises. The Company may terminate the Sub-Sublease following an event of default, which is defined in the Sub-Sublease to include, among other things, non-payment of amounts owing by the Sub-Subtenant under the Sub-Sublease.</span></div></ix:continuation><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i5022523d713149abb74b83f32b37a33d" continuedAt="i51737225160240b28b550ac097cc4856"><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required under the Lease to pay to the sublandlord <ix:nonFraction unitRef="number" contextRef="id8c8f6072f864cafae096d1bc47eb2f8_D20180718-20180718" decimals="2" name="prta:OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjQwMg_e6ae4ec3-9b28-4df7-82d7-1778c41730be">50</ix:nonFraction>% of that portion of the cash sums and other economic consideration received from the Sub-Subtenant that exceeds the base rent paid by the Company to the sublandlord after deducting certain of the Company&#8217;s costs.</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="padding-left:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dublin</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company entered into an agreement to lease <ix:nonFraction unitRef="sqft" contextRef="i9a5e914e22c04ed09c890f4bac3875ee_D20180901-20180930" decimals="0" name="prta:LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjY3Mw_c3bc0dec-2226-463f-8f0e-1587b7851ca5">133</ix:nonFraction> square feet of office space in Dublin, Ireland (the "Dublin Lease"). The current <ix:nonNumeric contextRef="i71ec87774e684456b390ddadf981db10_I20200630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjc1Nw_3386278a-daec-40cf-8906-f664d77927da">one year</ix:nonNumeric> lease term expires on November&#160;30, 2020. The Dublin Lease also has an automatic renewal clause, pursuant to which the agreement will be extended automatically for successive periods equal to the current term but no less than <ix:nonNumeric contextRef="i4d734226c866410c9fa6e63cc16602c0_I20180927" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjk3NQ_47801157-ddad-4b84-918f-370f833dfdf2">three months</ix:nonNumeric>, unless the agreement is cancelled by the Company. This operating lease is not included in the lease liability and operating lease right-of-use asset recorded due to its nominal amount. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of  June&#160;30, 2020, the Company is obligated to make lease payments over the remaining term of the Dublin Lease of approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="i71ec87774e684456b390ddadf981db10_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNzI4NQ_93118d02-ebec-4b72-a703-71f29f09c528">10,000</ix:nonFraction>, or $<ix:nonFraction unitRef="usd" contextRef="i71ec87774e684456b390ddadf981db10_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNzI5Mg_beb930b4-d239-4151-bf77-077b5bf19650">11,000</ix:nonFraction> as converted using an exchange rate as of June&#160;30, 2020.</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5NA_56255ecd-8194-476e-ab51-c2df7937e8ec" escape="true"><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum payments under the above-described noncancelable operating leases, including a reconciliation to the lease liabilities recognized in the Condensed Consolidated Balance Sheets, and future minimum rentals to be received under the Sub-Sublease as of June&#160;30, 2020, are as follows (in thousands):</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:72.269%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.134%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.137%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sub-Sublease Rental</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (6 months)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMS0yLTEtMS0w_c1e053fb-5164-4c59-a80f-ef5511ec4ea9">3,040</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMS00LTEtMS0w_2be51eeb-9ee2-4ff2-bb5e-745f7d5247c9">1,438</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMi0yLTEtMS0w_eaf6bea8-e658-4931-a6c7-2cd2b3890a99">6,165</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMi00LTEtMS0w_06229de4-2350-47fb-b945-ba666605bfa8">2,944</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMy0yLTEtMS0w_6692f125-dce1-44e7-b036-f6b07ac39326">6,350</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMy00LTEtMS0w_8903aba6-5752-4bf7-84f6-f2abe07ed206">3,047</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNC0yLTEtMS0w_00052881-e848-4583-83d6-83566d6e612a">6,535</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNC00LTEtMS0w_4eb15821-f2ce-4fa5-88cb-4d0286b31ca0">3,019</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNS0yLTEtMS0w_789d6b44-cf58-4893-906c-b718e23ebe3e">22,090</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNS00LTEtMS0w_12839347-1886-4255-a528-eec578aba8a9">10,448</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less:  Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNi0yLTEtMS0w_ba29dfa2-7741-49f7-9f3a-103498796122">1,625</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nominal lease payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="prta:LesseeOperatingLeaseLiabilityNominalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNy0yLTEtMS0w_bd20be4d-6ae8-4657-983f-ab14190272c7">11</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfOC0yLTEtMS0w_d6050698-e9c3-4028-b662-918c452ec18f">20,454</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:9pt;"><span><br/></span></div><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indemnity Obligations</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has entered into indemnification agreements with its current and former directors and officers and certain key employees. These agreements contain provisions that may require the Company, among other things, to indemnify such persons against certain liabilities that may arise because of their status or service and advance their expenses incurred as a result of any indemnifiable proceedings brought against them. The obligations of the Company pursuant to the indemnification agreements continue during such time as the indemnified person serves the Company and continues thereafter until such time as a claim can be brought. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer liability insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts paid. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of June&#160;30, 2020 and 2019.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Commitments</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into various firm purchase commitments primarily related to research and development activities. As of June&#160;30, 2020, the Company had non-cancelable purchase commitments to suppliers for $<ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTA4Ng_b90c43e7-5b76-4c95-a964-a50a1b7740f8">4.0</ix:nonFraction> million of which $<ix:nonFraction unitRef="usd" contextRef="i9ee0a5361cff4ddb8357d8b71f892efb_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTA5OA_62c2c82a-7d43-455c-943a-48a57da6fda2">0.4</ix:nonFraction> million is included in accrued current liabilities, and contractual obligations under license agreements of $<ix:nonFraction unitRef="usd" contextRef="iec44022c93d44923a6ba45741b5572ca_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTIwMQ_fde6ccd4-16ea-45d6-bf85-b96393ef489a">1.1</ix:nonFraction> million of which $<ix:nonFraction unitRef="usd" contextRef="i9ee0a5361cff4ddb8357d8b71f892efb_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTIxMw_9e695609-56d0-49c8-8eb4-bfdc8f435f87">0.1</ix:nonFraction> million is included in accrued current liabilities. <ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5Ng_a530d4f4-292c-4b57-a881-44d3b6c91ca7" continuedAt="i40fd2ea921674d6391a816f780997800" escape="true">The following is a summary of the Company's non-cancelable purchase commitments and contractual obligations as of June&#160;30, 2020 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i40fd2ea921674d6391a816f780997800" continuedAt="iec8e99c68d9b49ddb80b288ca28ebde6"><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:34.082%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.394%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.394%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.394%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.394%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.394%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.394%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.402%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Purchase Obligations</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0yLTEtMS0w_5f3108b4-003e-4217-97a9-918ad4eff694">3,959</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS00LTEtMS0w_0d6a5349-1f1d-4ee2-bf18-2da78d46b732">3,959</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PurchaseObligationDueInSecondYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS02LTEtMS0w_968e18ff-f704-40e1-af8e-ade8d713a7d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PurchaseObligationDueInThirdYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS04LTEtMS0w_3ec32750-c162-4cbe-a782-73b16508ce2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PurchaseObligationDueInFourthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMC0xLTEtMA_ed5c89f7-7a2d-4b6f-b487-7eca19bf639f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PurchaseObligationDueInFifthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMi0xLTEtMA_0b3aeffe-6172-4012-aac6-b156ff07d4e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PurchaseObligationDueAfterFifthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xNC0xLTEtMA_e2091f3a-244a-47c5-a346-3a51b3732344">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contractual obligations under license agreements</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (2)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0yLTEtMS0w_27166e2e-f2bf-45c2-889c-3e5de0a062f3">1,075</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630" decimals="-3" name="us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi00LTEtMS0w_1fa28666-44ab-4ba3-a3f7-564d7a236b83">285</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630" decimals="-3" name="us-gaap:ContractualObligationDueInSecondYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi02LTEtMS0w_216f6b01-ebe6-41d8-8814-5b4e6a8c3b1d">95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630" decimals="-3" name="us-gaap:ContractualObligationDueInThirdYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi04LTEtMS0w_298f6cfa-762b-416b-9a52-e0f6c5e01f00">80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630" decimals="-3" name="us-gaap:ContractualObligationDueInFourthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMC0xLTEtMA_cb5c692b-52a0-4e68-8193-10c979c52cb3">80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630" decimals="-3" name="us-gaap:ContractualObligationDueInFifthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMi0xLTEtMA_350d758a-8b8b-4f0f-9fec-3804b88e6df1">70</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630" decimals="-3" name="us-gaap:ContractualObligationDueAfterFifthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xNC0xLTEtMA_c91b8d3a-9589-4833-8207-44eef2597f50">465</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:13.5pt;padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="prta:PurchaseandContractualObligationTotal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy0yLTEtMS0w_0d787b55-c98f-41b6-8b78-709719eb94a7">5,034</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="prta:PurchaseandContractualObligationRemainderofFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy00LTEtMS0w_128ce0d5-e131-45ba-8443-40ec8a97b1d1">4,244</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="prta:PurchaseandContractualObligationDueinSecondYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy02LTEtMS0w_86733ff6-5190-4b53-bac6-c82a922a6e4d">95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="prta:PurchaseandContractualObligationDueinThirdYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy04LTEtMS0w_1230ff70-e034-45b0-9cca-fe515eb81b7c">80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="prta:PurchaseandContractualObligationDueinFourthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy0xMC0xLTEtMA_7bfc8525-3185-476b-a957-749b48cf5474">80</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="prta:PurchaseandContractualObligationDueinFifthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy0xMi0xLTEtMA_5d502055-cf69-410a-9afa-b337f335113a">70</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" name="prta:PurchaseandContractualObligationDueAfterFifthYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy0xNC0xLTEtMA_266f782b-520b-4269-8e7b-9d87bb2885d3">465</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">________________</span></div><div style="text-indent:27pt;text-align:justify;margin-top:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b" footnoteRole="http://www.xbrl.org/2003/role/footnote">Purchase obligations consist of non-cancelable purchase commitments to suppliers.</ix:footnote></span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><ix:continuation id="i51737225160240b28b550ac097cc4856"><ix:continuation id="iec8e99c68d9b49ddb80b288ca28ebde6"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5MQ_d26b4a34-2365-4ad3-86c2-aef2e41ba8e2" footnoteRole="http://www.xbrl.org/2003/role/footnote">Excludes future obligations pursuant to the cost-sharing arrangement under the Company's License Agreement with Roche. Amounts of such obligations, if any, cannot be determined at this time.</ix:footnote></span></ix:continuation></ix:continuation></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_55"></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7. <ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="prta:SignificantAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTA5OTUxMTY2OTkyNw_db30af57-dddb-4afd-b6dc-adcedc69225d" continuedAt="ie9db3e725b774bff8e760e80ba5b1ab1" escape="true">Significant Agreements</ix:nonNumeric></span></div><ix:continuation id="ie9db3e725b774bff8e760e80ba5b1ab1" continuedAt="iecc2b7f864994d3ebd468f342b55f44e"><div style="text-indent:9pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Roche License Agreement</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2013, the Company through its wholly owned subsidiary Prothena Biosciences Limited and Prothena Biosciences Inc entered into a License, Development, and Commercialization Agreement (the &#8220;License Agreement&#8221;) with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together, &#8220;Roche&#8221;) to develop and commercialize certain antibodies that target &#945;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">synuclein, including prasinezumab, which are referred to collectively as &#8220;Licensed Products.&#8221; Upon the effectiveness of the License Agreement in January 2014, the Company granted to Roche an exclusive, worldwide license to develop, make, have made, use, sell, offer to sell, import and export the Licensed Products. The Company retained certain rights to conduct development of the Licensed Products and an option to co-promote prasinezumab in the U.S. During the term of the License Agreement, the Company and Roche will work exclusively with each other to research and develop antibody products targeting alpha-synuclein (or &#945;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">synuclein) potentially including incorporation of Roche&#8217;s proprietary Brain Shuttle&#8482; technology to potentially increase delivery of therapeutic antibodies to the brain. The License Agreement provided for Roche making an upfront payment to the Company of $<ix:nonFraction unitRef="usd" contextRef="if3b8cf0763bb4f5397b004275677c01b_D20140201-20140228" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationRevenueLicenseUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI4Ng_f3eb06db-8454-46c0-a887-d116564fe323">30.0</ix:nonFraction> million, which was received in February 2014; making a clinical milestone payment of $<ix:nonFraction unitRef="usd" contextRef="iaaed79f2beb64ec6a2029bcf63a64073_D20140501-20140531" decimals="-5" format="ixt:numdotdecimal" name="prta:MilestonePaymentReceivedClinicalMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM2Ng_ee8229ac-bac6-4e4c-a2a7-d6ee5f20b590">15.0</ix:nonFraction> million upon initiation of the Phase 1 study for prasinezumab, which was received in May 2014; and making a clinical milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ib00e147a1cff4155afb7ec6051700710_D20170601-20170630" decimals="-5" format="ixt:numdotdecimal" name="prta:MilestoneAchievementClinicalMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTQ5OQ_042e6620-baae-4bb2-a777-02efdd3d636e">30.0</ix:nonFraction> million upon dosing of the first patient in the Phase 2 study for prasinezumab, which was achieved in June 2017.</span></div><div style="padding-left:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For prasinezumab, Roche is also obligated to pay:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"> up to $<ix:nonFraction unitRef="usd" contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTY2NQ_f677a8a5-6b68-4018-9543-9450aad68410">350.0</ix:nonFraction> million upon the achievement of development, regulatory and various first commercial sales milestones;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"> up to an additional $<ix:nonFraction unitRef="usd" contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTc4NA_3e1258af-28ed-4ddc-9d91-9137d0c5b5b2">175.0</ix:nonFraction> million upon achievement of ex-U.S. commercial sales milestones; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"> tiered, high single-digit to high double-digit royalties in the teens on ex-U.S. annual net sales, subject to certain adjustments.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Roche bore <ix:nonFraction unitRef="number" contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630" decimals="2" name="prta:LicensingAgreementCostAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTk5MQ_c929b567-2a43-4c32-965a-7285cab4724f">100</ix:nonFraction>% of the cost of conducting the research collaboration under the License Agreement during the research term, which expired December 31, 2017. In the U.S., the parties share all development and commercialization costs, as well as profits, all of which will be allocated <ix:nonFraction unitRef="number" contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630" decimals="2" name="prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjI2MQ_078e2451-06bc-4d0f-a95a-c562af657a72">70</ix:nonFraction>% to Roche and <ix:nonFraction unitRef="number" contextRef="i74335244f76841eb87c826533b83cc37_D20200101-20200630" decimals="2" name="prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjI3Nw_c5755f38-8cad-4d72-909f-961dcf8475e1">30</ix:nonFraction>% to the Company, for prasinezumab in the Parkinson&#8217;s disease indication, as well as any other Licensed Products and/or indications for which the Company opts in to participate in co-development and co-funding. After the completion of specific clinical trial activities, the Company may opt out of the co-development and cost and profit sharing on any co-developed Licensed Products and instead receive U.S. commercial sales milestones totaling up to $<ix:nonFraction unitRef="usd" contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:LicenseAgreementPotentialAlternativeCommercialSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjcyOQ_5ab4ea6c-91ef-4928-8c7e-08a1539178bf">155.0</ix:nonFraction> million and tiered, single-digit to high double-digit royalties in the teens based on U.S. annual net sales, subject to certain adjustments, with respect to the applicable Licensed Product.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company filed an Investigational New Drug Application (&#8220;IND&#8221;) with the FDA for prasinezumab and subsequently initiated a Phase 1 study in 2014. Following the Phase 1 studies, Roche became primarily responsible for developing, obtaining and maintaining regulatory approval for and commercializing Licensed Products. Roche also became responsible for the clinical and commercial manufacture and supply of Licensed Products.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the Company has an option under the License Agreement to co-promote prasinezumab in the U.S. in the Parkinson&#8217;s disease indication. If the Company exercises such option, it may also elect to co-promote additional Licensed Products in the U.S. approved for Parkinson&#8217;s disease. Outside the U.S., Roche will have responsibility for developing and commercializing the Licensed Products. Roche bears all costs that are specifically related to obtaining or maintaining regulatory approval outside the U.S. and will pay the Company a variable royalty based on annual net sales of the Licensed Products outside the U.S.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While Roche will record product revenue from sales of the Licensed Products, the Company and Roche will share in the net profits and losses of sales of the prasinezumab for the Parkinson's disease indication in the U.S. on a <ix:nonFraction unitRef="number" contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630" decimals="2" name="prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDE5MQ_078e2451-06bc-4d0f-a95a-c562af657a72">70</ix:nonFraction>%/<ix:nonFraction unitRef="number" contextRef="i74335244f76841eb87c826533b83cc37_D20200101-20200630" decimals="2" name="prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDE5NA_c5755f38-8cad-4d72-909f-961dcf8475e1">30</ix:nonFraction>% basis with the Company receiving <ix:nonFraction unitRef="number" contextRef="i74335244f76841eb87c826533b83cc37_D20200101-20200630" decimals="2" name="prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDIzMA_c5755f38-8cad-4d72-909f-961dcf8475e1">30</ix:nonFraction>% of the profit and losses provided that the Company has not exercised its opt-out right.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The License Agreement continues on a country-by-country basis until the expiration of all payment obligations under the License Agreement. The License Agreement may also be terminated (i) by Roche at will after the first anniversary of the effective date of the License Agreement, either in its entirety or on a Licensed Product-by-Licensed Product basis, upon 90 days&#8217; prior written notice to the Company prior to first commercial sale and 180 days&#8217; prior written notice to Prothena after first commercial sale, (ii) by either party, either in its entirety or on a Licensed Product-by-Licensed Product or region-by-region </span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="iecc2b7f864994d3ebd468f342b55f44e" continuedAt="iaa4cf9f83f3146908cedb2215839f2b9"><div style="text-align:justify;margin-top:9pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">basis, upon written notice in connection with a material breach uncured 90 days after initial written notice, and (iii) by either party, in its entirety, upon insolvency of the other party. The License Agreement may be terminated by either party on a patent-by-patent and country-by-country basis if the other party challenges a given patent in a given country. The Company&#8217;s rights to co-develop Licensed Products under the License Agreement will terminate if the Company commences certain studies for certain types of competitive products. The Company&#8217;s rights to co-promote Licensed Products under the License Agreement will terminate if the Company commences a Phase 3 study for such competitive products.</span></div><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The License Agreement cannot be assigned by either party without the prior written consent of the other party, except to an affiliate of such party or in the event of a merger or acquisition of such party, subject to certain conditions. The License Agreement also includes customary provisions regarding, among other things, confidentiality, intellectual property ownership, patent prosecution, enforcement and defense, representations and warranties, indemnification, insurance, and arbitration and dispute resolution.</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration Accounting</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The License Agreement was evaluated under ASC 808, Collaborative Agreements.  At the outset of the License Agreement, the Company concluded that it did not qualify as collaboration under ASC 808 because the Company does not share significant risks due to the net profit and loss split (under which Roche incurs substantially more of the costs of the collaboration) and because of the Company&#8217;s opt-out provision. The Company believes that Roche will be the principal in future sales transactions with third parties as Roche will be the primary obligor bearing inventory and credit risk. The Company will record its share of pre-tax commercial profit generated from the collaboration as collaboration revenue once the Company can conclude it is probable that a significant revenue reversal will not occur in future periods. Prior to commercialization of a Licensed Product, the Company&#8217;s portion of the expenses related to the License Agreement reflected on its income statement will be limited to R&amp;D expenses. After commercialization, if the Company opts-in to co-detail commercialization, expenses related to commercial capabilities, including expenses related to the establishment of a field sales force and other activities to support the Company&#8217;s commercialization efforts, will be recorded as sales, general and administrative (&#8220;SG&amp;A&#8221;) expense and will be factored into the computation of the profit and loss share. The Company will record the receivable related to commercialization activities as collaboration revenue once the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Adoption of ASC 606, Revenue from Contracts with Customers </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted ASC 606, Revenue from Contracts with Customers, as of January 1, 2018, using the modified retrospective transition method. The Company recognized the cumulative effect of applying the new revenue standard as an adjustment to the opening balance of the accumulated deficit as of January 1, 2018. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of January 1, 2018, the Company did not record any changes to the opening balance of the accumulated deficit since the cumulative effect of applying the new revenue standard was the same as applying ASC 605. The impact of the adoption of ASC 606 to revenues for the year ended December&#160;31, 2018, was an increase of $<ix:nonFraction unitRef="usd" contextRef="if675ef5553934becb22c4267dbb63ed6_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="prta:DevelopmentServicesAdditional" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfODU0MA_728e67e8-a25f-46b3-b542-52467a026a15">1.0</ix:nonFraction> million, which represents the revenue recognized for the development services provided by the Company during the period that is reimbursable by Roche. Historically, the Company recorded such reimbursement as an offset against its R&amp;D expenses under ASC 605. Upon the adoption of ASC 606, the reimbursement for development services is now included as part of the Company&#8217;s collaboration revenue.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Performance Obligations</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The License Agreement was evaluated under ASC 606. The License Agreement includes the following distinct performance obligations: (1) the Company&#8217;s grant of an exclusive royalty bearing license, with the right to sublicense to develop and commercialize certain antibodies that target &#945;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">synuclein, including prasinezumab, and the initial know how transfer which was delivered at the effective date (the &#8220;Royalty Bearing License&#8221;); (2) the Company&#8217;s obligation to supply clinical material as requested by Roche for a period up to twelve months (the &#8220;Clinical Product Supply Obligation&#8221;); (3) the Company&#8217;s obligation to provide manufacturing related services to Roche for a period up to twelve months (the &#8220;Supply Services Obligation&#8221;); (4) the Company&#8217;s obligation to prepare and file the IND (the &#8220;IND Obligation&#8221;); and (5) the Company&#8217;s obligation to provide development activities under the development plan during Phase 1 clinical trials (the &#8220;Development Services Obligation&#8221;). Revenue allocated to the above performance obligations under the License Agreement are recognized when the Company has satisfied its obligations either at a point in time or over a period of time.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that the Royalty Bearing License and the Clinical Product Supply Obligation were satisfied at a point in time. The Royalty Bearing License is considered to be a functional intellectual property, in which the revenue would be recognized at the point in time since (a) the Company concluded that the license to Roche has a significant stand-alone </span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="iaa4cf9f83f3146908cedb2215839f2b9" continuedAt="idaf27503c1e4450895c01716f209d4f1"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">functionality, (b) the Company does not expect the functionality of the intellectual property to be substantially changed during the license period as a result of activities of Prothena, and (c) Prothena&#8217;s activities transfer a good or service to Roche. The Clinical Product Supply Obligation does not meet criteria for over time recognition; as such, the revenue related to such performance obligation was recognized the point in time at which Roche obtained control of manufactured supplies, which occurred during the first quarter of 2014. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that the Supply Services Obligation, the IND Obligation and the Development Services Obligation were satisfied over time. The Company utilized an input method measure of progress by basing the recognition period on the efforts or inputs towards satisfying the performance obligation (i.e. costs incurred and the time elapsed to complete the related performance obligations). The Company determined that such input method provides an appropriate measure of progress toward complete satisfaction of such performance obligations.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, and December&#160;31, 2019, there were <ix:nonFraction unitRef="usd" contextRef="ic854f60120d74aedb489b48755f518b9_I20200630" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTE2Mjc_17f6aa0e-c585-4fb8-b993-a752851b5059"><ix:nonFraction unitRef="usd" contextRef="ibca1ba5c855446de877d16de250feabe_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTE2Mjc_46419f89-d60c-4de9-925d-152e5faca9d7">no</ix:nonFraction></ix:nonFraction> remaining performance obligations under License Agreement since the obligations related to research and development activities were only for the Phase 1 clinical trial and the remaining obligations were delivered or performed.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Transaction Price</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">According to ASC 606-10-32-2, the transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Factors considered in the determination of the transaction price include, among other things, estimated selling price of the license and costs for clinical supply and development costs. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial transaction price under the License Agreement, pursuant to ASC 606, was $<ix:nonFraction unitRef="usd" contextRef="i073a0b78fb35421ba6e8592c0a197dfe_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:InitialTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI1NDQ_c802221b-4636-4f62-befc-eafc15174c11">55.1</ix:nonFraction> million, including $<ix:nonFraction unitRef="usd" contextRef="icb959663c6fb41d287b63b8363fda883_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:InitialTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI1NTg_2880fe80-b8d4-414f-958c-11b673702295">45.0</ix:nonFraction> million for the Royalty Bearing License, $<ix:nonFraction unitRef="usd" contextRef="i5ba8be9d9c3a400b803bd9eaae95a8ee_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:InitialTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI1OTQ_a24c9560-4027-4575-9554-704e8729ac5a">9.1</ix:nonFraction> million for the IND and Development Services Obligations, and $<ix:nonFraction unitRef="usd" contextRef="icd6584a0477e41a785e2b634ec00c3ec_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:InitialTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI2NTE_15fae11f-7282-434c-ad7d-42f4c15cd8f0">1.1</ix:nonFraction> million for the Supply Services Obligation. The $<ix:nonFraction unitRef="usd" contextRef="icb959663c6fb41d287b63b8363fda883_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:InitialTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI2OTQ_2880fe80-b8d4-414f-958c-11b673702295">45.0</ix:nonFraction> million for the Royalty Bearing License included the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="if3b8cf0763bb4f5397b004275677c01b_D20140201-20140228" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationRevenueLicenseUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI3NjE_f3eb06db-8454-46c0-a887-d116564fe323">30.0</ix:nonFraction> million and the clinical milestone payment of $<ix:nonFraction unitRef="usd" contextRef="iaaed79f2beb64ec6a2029bcf63a64073_D20140501-20140531" decimals="-5" format="ixt:numdotdecimal" name="prta:MilestonePaymentReceivedClinicalMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI4MDI_ee8229ac-bac6-4e4c-a2a7-d6ee5f20b590">15.0</ix:nonFraction> million upon initiation of the Phase 1 clinical trial of prasinezumab, both of which were made in 2014. The remaining transaction price amounts the Company expected to receive as reimbursements were based on costs expected to be paid to third parties and other costs to be incurred by the Company in order to satisfy its performance obligations. They are considered to be variable considerations not subject to constraint. The Company did not incur any incremental costs, such as commissions, to obtain or fulfill the License Agreement.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under ASC 606, the transaction price was allocated to the performance obligations as follows: $<ix:nonFraction unitRef="usd" contextRef="i0175d817a5f44f01ac9efd8385decd07_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:AllocatedConsiderationtoPerformanceObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM0Mjg_d7ff3dd8-fd82-4fd5-bba4-994684d4092d">48.9</ix:nonFraction> million to the Royalty Bearing License; $<ix:nonFraction unitRef="usd" contextRef="ia759813a15794ad4bdcf62a8a938c100_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:AllocatedConsiderationtoPerformanceObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM0NjM_a52630f2-7ede-470d-bfe1-14a79c9f3a63">4.6</ix:nonFraction> million to the IND and Development Services Obligations; $<ix:nonFraction unitRef="usd" contextRef="ic7b2c3d5be4540b6921b9e212efe9451_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:AllocatedConsiderationtoPerformanceObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM1MTU_40fe55a3-3810-4e71-94fa-0be344c0dc44">1.1</ix:nonFraction> million to the Clinical Product Supply Obligation; and $<ix:nonFraction unitRef="usd" contextRef="ic84e2a6f4eb048d58a8ce416274ea456_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:AllocatedConsiderationtoPerformanceObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM1NjU_b7f05eb2-d54c-417c-a5d7-dfa015c9f2e3">0.6</ix:nonFraction> million to the Supply Services Obligation. As of June&#160;30, 2020, the aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied is $<ix:nonFraction unitRef="usd" contextRef="ic854f60120d74aedb489b48755f518b9_I20200630" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM3MjQ_17f6aa0e-c585-4fb8-b993-a752851b5059"><ix:nonFraction unitRef="usd" contextRef="ibca1ba5c855446de877d16de250feabe_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM3MjQ_46419f89-d60c-4de9-925d-152e5faca9d7">nil</ix:nonFraction></ix:nonFraction>. Prior to the adoption of ASC 606, the transaction price was allocated to the deliverables as follows: $<ix:nonFraction unitRef="usd" contextRef="i0175d817a5f44f01ac9efd8385decd07_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:ASC605AllocatedConsiderationtoDeliverables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM4MzA_56259151-c81a-4469-b2af-71952cd2cc4b">35.6</ix:nonFraction> million to the Royalty Bearing License; $<ix:nonFraction unitRef="usd" contextRef="ia759813a15794ad4bdcf62a8a938c100_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:ASC605AllocatedConsiderationtoDeliverables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM4NjU_7ba8a7a6-b7cd-46a9-a434-00c030b4eb95">3.3</ix:nonFraction> million to the IND and Development Services Obligations; $<ix:nonFraction unitRef="usd" contextRef="ic7b2c3d5be4540b6921b9e212efe9451_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:ASC605AllocatedConsiderationtoDeliverables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM5MTc_7d29a8bf-5187-4655-99ea-1579e074aa5e">0.8</ix:nonFraction> million to the Clinical Product Supply Obligation; and $<ix:nonFraction unitRef="usd" contextRef="ic84e2a6f4eb048d58a8ce416274ea456_I20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:ASC605AllocatedConsiderationtoDeliverables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM5Njc_7acd0159-71e6-4174-a238-4e8ba9e3be44">0.4</ix:nonFraction> million to the Supply Services Obligation.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allocated the initial transaction price to the Royalty Bearing License and other performance obligations using the relative selling price method based on its best estimate of selling price for the Royalty Bearing License and third party evidence for the remaining performance obligations. The best estimate of selling price for the Royalty Bearing License was based on a discounted cash flow model. The key assumptions used in the discounted cash flow model used to determine the best estimate of selling price for the Royalty Bearing License included the market opportunity for commercialization of prasinezumab in the U.S. and the royalty territory (for licensed products that are jointly funded the royalty territory is worldwide except for the U.S., and for all licensed products that are not jointly funded the Royalty Territory is worldwide), the probability of successfully developing and commercializing prasinezumab, the estimated remaining development costs for prasinezumab, and the estimated time to commercialization of prasinezumab. The Company concluded that a change in the assumptions used to determine the best estimate of selling price (&#8220;BESP&#8221;) of the license deliverable would not have a significant effect on the allocation of arrangement consideration.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s discounted cash flow model included several market conditions and entity-specific inputs, including the likelihood that clinical trials for prasinezumab will be successful, the likelihood that regulatory approval will be obtained and the product commercialized, the appropriate discount rate, the market locations, size and potential market share of the product, the expected life of the product, and the competitive environment for the product. The market assumptions were generated using a patient-based forecasting approach, with key epidemiological, market penetration, dosing, compliance, length of treatment and pricing assumptions derived from primary and secondary market research, referenced from third-party sources.</span></div></ix:continuation><div style="text-indent:22.5pt;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:22.5pt;"><span><br/></span></div><ix:continuation id="idaf27503c1e4450895c01716f209d4f1" continuedAt="i0a68d94fc3644312a5afe664c897556d"><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Significant Payment Terms</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payments for development services are due within <ix:nonNumeric contextRef="i0c607e622d1f49aa8ceca2e000427c5e_D20200101-20200630" format="ixt-sec:durday" name="prta:LicenseAgreementDevelopmentServicesPaymentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTYxMTA_f4b73d80-8353-4132-9342-b53abdc326d4">45</ix:nonNumeric> days after receiving an invoice from the Company. Variable considerations related to clinical and regulatory milestone payments are constrained due to high likelihood of a revenue reversal. The payment term for all milestone payments are due within <ix:nonNumeric contextRef="i0c607e622d1f49aa8ceca2e000427c5e_D20200101-20200630" format="ixt-sec:durday" name="prta:LicenseAgreementMilestonePaymentsPaymentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTYzNjI_abcd7e95-5602-4177-a8cc-1b88186ffebc">45</ix:nonNumeric> days after the achievement of the relevant milestone and receipt by Roche of an invoice for such an amount from the Company.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">According to ASC 606-10-32-17, a significant financing component does not exist if a substantial amount of the consideration promised by the customer is variable, and the amount or timing of that consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the customer or the entity. Since a &#8220;substantial amount of the consideration&#8221; promised by Roche to the Company is variable (i.e., is in the form of either milestone payments or sales-based royalties) and the amount of such variable consideration varies based upon the occurrence or nonoccurrence of future events that are not within the control of either Roche or the Company (i.e., are largely subject to regulatory approval), the License Agreement does not have a significant financing component.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Optional Goods and Services</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An option for additional goods or services exists when a customer has a present contractual right that allows it to choose the amount of additional distinct goods or services that are purchased. Prior to the customer&#8217;s exercise of that right, the vendor is not presently obligated to provide those goods or services. ASC 606-10-25-18(j) requires recognition of an option as a distinct performance obligation when the option provides a customer with a material right.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the distinct performance obligations noted above, the Company was obligated to provide indeterminate research services for up to three years ending in 2017 at rates that were not significantly discounted and fully reimbursable by Roche (the &#8220;Research Services&#8221;). The amount for any such Research Services was not fixed and determinable and was not at a significant incremental discount. There were no refund rights, concessions or performance bonuses to consider. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the obligation to perform Research Services under ASC 606-10-55-42 and 55-43 to determine whether it gave Roche a &#8220;material right&#8221;. According to ASC 606-10-55-43, if a customer has the option to acquire an additional good or services at a price that would reflect the standalone selling price for that good or service, that option does not provide the customer with a material right even if the option can be exercised only by entering into a previous contract.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that Roche&#8217;s option to have the Company perform Research Services did not represent a &#8220;material right&#8221; to Roche that it would not have received without entering into the License Agreement. As a result, Roche&#8217;s option to acquire additional Research Services was not considered a performance obligation at the outset of the License Agreement under ASC 606. Accordingly, this deliverable will become new performance obligation for Prothena when Roche asks Prothena to conduct such Research Services. As of June&#160;30, 2020, there were <ix:nonFraction unitRef="usd" contextRef="ia09f6d9b318949658f4b5edbbc1060d4_I20200630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTkzMjA_9a412c9b-07a6-483f-ac40-87ba1a0fb96e">no</ix:nonFraction> remaining Research Services performance obligations. </span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Post Contract Deliverables</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any development services provided by the Company after performance of the Development Service Obligation are not considered a contractual performance obligation under the License Agreement, since the License Agreement does not require the Company to provide any development services after completion of the Development Service Obligation. However, the collaboration&#8217;s Joint Steering Committee approved continued funding for additional development services to be provided by the Company (the &#8220;Additional Development Services&#8221;).  Under the License Agreement and upon the adoption of ASC 606, the Company recognizes the reimbursements for Additional Development Services as collaboration revenue as earned. </span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue and Expense Recognition</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTA5OTUxMTY2OTkzMQ_cf5d1ba9-7dfe-447a-b043-66108a441179">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjA0NzMxMzk5NDk3OQ_7065e8af-ff8f-477f-a770-a16bbaa93e6c">0.3</ix:nonFraction>&#160;million as collaboration revenue from Roche for the three and six months ended June&#160;30, 2020, respectively, as compared to $<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjU5NzA2OTgwOTQxNg_655134f0-a2a9-47d4-ad66-59be01d80d39">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjA0NzMxMzk5NTAwNg_a18a2803-c6e0-4456-88d7-854924bf6037">0.4</ix:nonFraction>&#160;million for the three and six months ended June&#160;30, 2019, respectively. Cost sharing payments to Roche are recorded as R&amp;D expenses. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="iec0766c4dcbb452d92267a1537fc4521_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjA0NzMxMzk5NTEyMg_f0fca562-eb7b-4828-8617-6d53d7b88fb7">4.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjAzMjk_f28a0593-2520-4eea-80fb-59ed6cca9ba8">8.5</ix:nonFraction> million in R&amp;D expenses for payments made to Roche during the three and six months ended June&#160;30, 2020, respectively, as compared to $<ix:nonFraction unitRef="usd" contextRef="i5da9211e8d7c43f6be07d56a02195be6_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjA0NzMxMzk5NTIzMw_62faf824-80d5-4b13-958a-865975f12185">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic027828db76f4a93885ac0251d9ed379_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjA0NzMxMzk5NTI0NQ_59257c22-8a60-4410-9f21-e330f3018836">4.0</ix:nonFraction> million for the three and six months ended June&#160;30, 2019, respectively. The Company had accounts receivable from Roche of $<ix:nonFraction unitRef="usd" contextRef="i073a0b78fb35421ba6e8592c0a197dfe_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjA0Njg_e7b08d51-d54f-45cf-9926-8328f6675e44">4,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i10bc3926f14143428f8b45360781a239_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjA0NzU_507f4d6c-5428-4470-b0b7-5babf3228c2f">2,000</ix:nonFraction> at June&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span><br/></span></div><ix:continuation id="i0a68d94fc3644312a5afe664c897556d" continuedAt="i33c0ab8890254344acf14e9b3f7de6c5"><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone Accounting</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the License Agreement, only if the U.S. and or global options are exercised, the Company is eligible to receive milestone payments upon the achievement of development, regulatory and various first commercial sales milestones. Milestone payments are evaluated under ASC Topic 606. Factors considered in this determination included scientific and regulatory risk that must be overcome to achieve each milestone, the level of effort and investment required to achieve the milestone, and the monetary value attributed to the milestone. Accordingly, the Company estimates payments in the transaction price based on the most likely approach, which considers the single most likely amount in a range of possible amounts related to the achievement of these milestones. Additionally, milestone payments are included in the transaction price only when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods when the milestone is achieved.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company excludes the milestone payments and royalties in the initial transaction price calculation because such payments are considered to be variable considerations with constraint. Such milestone payments and royalties will be recognized as revenue once the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The clinical and regulatory milestones under the License Agreement after the point at which the Company could opt-out are considered to be variable considerations with constraint due to the fact that active participation in the development activities that generate the milestones is not required under the License Agreement, and the Company can opt-out of these activities. There are no refunds or claw-back provisions and the milestones are uncertain of occurrence even after the Company has opted out. Based on this determination, these milestones will be recognized when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration Agreement with Bristol-Myers Squibb</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Overview</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March&#160;20, 2018, the Company, through its wholly owned subsidiary Prothena Biosciences Limited, entered into a Master Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;) with Celgene Switzerland LLC (&#8220;Celgene&#8221;), a subsidiary of Celgene Corporation (which was acquired by Bristol-Myers Squibb ("BMS") in November 2019), pursuant to which Prothena granted to Celgene a right to elect in its sole discretion to exclusively license rights both in the U.S. (the &#8220;US Rights&#8221;) and on a global basis (the &#8220;Global Rights&#8221;), with respect to the Company&#8217;s programs to develop and commercialize antibodies targeting Tau, TDP-43 and an undisclosed target (the &#8220;Collaboration Targets&#8221;). For each such program, BMS may exercise its US Rights at the IND filing, and if it so exercises such US Rights would also have a right to expand the license to Global Rights. If BMS exercises its US Rights for a program, then following the first to occur of (a) completion by the Company, in its discretion and at its cost, of Phase 1 clinical trials for such program or (b) the date on which BMS elects to assume responsibility for completing such Phase 1 clinical trials (at its cost), BMS would have decision making authority over development activities and all regulatory, manufacturing and commercialization activities in the U.S. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Collaboration Agreement provided for Celgene making an upfront payment to the Company of $<ix:nonFraction unitRef="usd" contextRef="idf958f5bfd554f5db359067fc2e7e217_I20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationAgreementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjQwMjg_70c4380c-17ac-4d3e-a9d6-362def5e1833">100.0</ix:nonFraction> million, which was received in April 2018, plus future potential license exercise payments and regulatory and commercial milestones for each program under the Collaboration Agreement, as well as royalties on net sales of any resulting marketed products. In connection with the Collaboration Agreement, the Company and Celgene entered into a Share Subscription Agreement on March&#160;20, 2018, under which Celgene subscribed to <ix:nonFraction unitRef="shares" contextRef="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjQ0MzQ_d6e98a2f-5c44-40f0-a029-40461563e3a5">1,174,536</ix:nonFraction> of the Company&#8217;s ordinary shares for a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i823dfe17698f4577941dc181be64c092_I20180320" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjQ0ODU_84ee0fe7-aef9-4b43-acff-081769bdc82e">42.57</ix:nonFraction> per share, for a total of approximately $<ix:nonFraction unitRef="usd" contextRef="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjQ1Mjg_9fb7824d-0732-4df6-90c0-ab25cf6ceef1">50.0</ix:nonFraction> million.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BMS US and Global Rights and Licenses</span></div><div><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On a program-by-program basis, beginning on the effective date of the Collaboration Agreement and ending on the date that the IND Option term expires for such program (which generally occurs sixty days after the date on which Prothena delivers to BMS the first complete data package for an IND that was filed for a lead candidate from the relevant program), BMS may elect in its sole discretion to exercise its US Rights to receive an exclusive license to develop, manufacture and commercialize antibodies targeting the applicable Collaboration Target in the U.S. (the &#8220;US License&#8221;). If BMS exercises its US Rights for a collaboration program, it is obligated to pay the Company an exercise fee of approximately $<ix:nonFraction unitRef="usd" contextRef="ibb2d17fa473c4e86a3e307306a386a61_D20180320-20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationAgreementExerciseFeeperProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjUyODM_677a456b-724b-4603-94d7-6988ce42f866">80.0</ix:nonFraction> million per program. Thereafter, following the first to occur of (a) completion by the Company, in its discretion and at its cost, of Phase 1 clinical trials for such program or (b) BMS&#8217;s election to assume responsibility to complete such Phase 1 clinical trials (at its cost), BMS would have the sole right to  develop, manufacture and commercialize antibody products targeting the relevant Collaboration Target for such program (the &#8220;Collaboration Products&#8221;) in the U.S.</span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i33c0ab8890254344acf14e9b3f7de6c5" continuedAt="ic7942e44ec66415b9e697263f7e94cd7"><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On a program-by-program basis, following completion of a Phase 1 clinical trial for a collaboration program for which BMS has previously exercised its US Rights, BMS may elect in its sole discretion to exercise its Global Rights with respect to such collaboration program to receive a worldwide, exclusive license to develop, manufacture and commercialize antibodies targeting the applicable Collaboration Target (the &#8220;Global License&#8221;). If BMS exercises its Global Rights, BMS would be obligated to pay the Company an additional exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i781ce1f9fb114a1288a2399d11b4d4a5_D20180320-20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationAgreementExerciseFeeperProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjYyOTY_018ef881-0e3c-4c2a-bcfd-e75447166247">55.0</ix:nonFraction> million for such collaboration program. The Global Rights would then replace the US Rights for that collaboration program, and BMS would have decision making authority over developing, obtaining and maintaining regulatory approval for, manufacturing and commercializing the Collaboration Products worldwide.    </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After BMS&#8217;s exercise of Global Rights for a collaboration program, the Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjY3MTE_3663cc2f-b060-48ff-9bf1-1e6c09823026">562.5</ix:nonFraction> million in regulatory and commercial milestones per program. Following an exercise by BMS of either US Rights or Global Rights for such collaboration program, the Company will also be eligible to receive tiered royalties on net sales of Collaboration Products ranging from high single digit to high teen percentages, on a weighted average basis depending on the achievement of certain net sales thresholds. Such exercise fees, milestones and royalty payments are subject to certain reductions as specified in the Collaboration Agreement, the agreement for US Rights and the agreement for Global Rights.  </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">BMS will continue to pay royalties on a Collaboration Product-by-Collaboration Product and country-by-country basis, until the latest of (i) expiration of certain patents covering the Collaboration Product, (ii) expiration of all regulatory exclusivity for the Collaboration Product, and (iii) an agreed period of time after the first commercial sale of the Collaboration Product in the applicable country (the &#8220;Royalty Term&#8221;).</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Term and Termination</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The research term under the Collaboration Agreement continues for a period of <ix:nonNumeric contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320" format="ixt-sec:durwordsen" name="prta:CollaborationAgreementTermofAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjc4NDA_2035f8bb-a8a0-4ab6-9526-c6dee32f433a">six years</ix:nonNumeric>, which BMS may extend for up to <ix:nonFraction unitRef="agreement_term" contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320" decimals="0" format="ixt-sec:numwordsen" name="prta:CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjc4NzU_8df49550-bd73-4e02-86ac-a7fdd8d57c93">two</ix:nonFraction> additional 12-month periods by paying an extension fee of $<ix:nonFraction unitRef="usd" contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationAgreementExtensionFeeperExtensionPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjc5MzY_1fa42f23-1a63-4a25-89a3-ffb816151df0">10.0</ix:nonFraction> million per extension period.  The term of the Collaboration Agreement continues until the last to occur of the following: (i) expiration of the research term; (ii) expiration of all US Rights terms; and (iii) expiration of all Global Rights terms. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The term of any US License or Global License would continue on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of all Royalty Terms under such agreement. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Collaboration Agreement may be terminated (i) by either party on a program-by-program basis if the other party remains in material breach of the Collaboration Agreement following a cure period to remedy the material breach, (ii) by BMS at will on a program-by-program basis or in its entirety, (iii) by either party, in its entirety, upon insolvency of the other party, or (iv) by Prothena, in its entirety, if BMS challenges a patent licensed by Prothena to BMS under the Collaboration Agreement.  </span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share Subscription Agreement</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">  </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the Collaboration Agreement, the Company entered into a Share Subscription Agreement (the &#8220;SSA&#8221;) with Celgene, pursuant to which the Company issued, and Celgene subscribed for, <ix:nonFraction unitRef="shares" contextRef="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjkxMTU_d6e98a2f-5c44-40f0-a029-40461563e3a5">1,174,536</ix:nonFraction> of the Company&#8217;s ordinary shares (the &#8220;Shares&#8221;) for an aggregate subscription price of approximately $<ix:nonFraction unitRef="usd" contextRef="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjkyMTk_9fb7824d-0732-4df6-90c0-ab25cf6ceef1">50.0</ix:nonFraction> million, pursuant to the terms and conditions thereof.  </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the SSA, BMS (formerly Celgene) is subject to certain transfer restrictions. In addition, BMS will be entitled to request the registration of the Shares with the U.S. Securities and Exchange Commission on Form S-3ASR or Form S-3 following termination of the transfer restrictions if the Shares cannot be resold without restriction pursuant to Rule 144 promulgated under the U.S. Securities Act of 1933, as amended.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration Accounting</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Collaboration Agreement was evaluated under ASC 808, Collaborative Agreements. At the outset of the Collaboration Agreement, the Company concluded that it does not qualify as collaboration under ASC 808 because the Company does not share significant risks due to economics of the collaboration.</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Performance Obligations</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the Collaboration Agreement and concluded that it represented a contract with a customer within the scope of ASC 606. Per ASC 606, a performance obligation is defined as a promise to transfer a good or service or a series of distinct goods or services. At inception of the Collaboration Agreement, the Company is not obligated to transfer the US License or Global License to BMS unless BMS exercises its US Rights or Global Rights, respectively, and the Company is not </span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ic7942e44ec66415b9e697263f7e94cd7" continuedAt="i6ced901da26144a4be61cb0a1b188a37"><div style="text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">obligated to perform development activities under the development plan during preclinical and Phase 1 clinical trials including the regulatory filing of the IND. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The discovery, preclinical and clinical development activities performed by the Company are to be performed at the Company&#8217;s discretion and are not promised goods or services and therefore are not considered performance obligations under ASC 606, unless and until the Company agrees to perform the Phase 1 clinical studies (after the IND option exercise) that are determined to be performance obligations at the time the option is exercised. Per the terms of the Collaboration Agreement, the Company may conduct discovery activities to characterize, identify and generate antibodies to become collaboration candidates that target such Collaboration Target, and thereafter may pre-clinically develop collaboration candidates to identify lead candidates that target such Collaboration Target and file an IND with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for a Phase 1 clinical trial for such lead candidates. In the event the Company agrees to be involved in a Phase 1 clinical study, the Company will further evaluate whether any such promise represents a performance obligation at the time the option is exercised. If it is concluded that the Company has obligated itself to an additional performance obligation besides the license granted at IND option exercise, then the effects of the changes in the arrangement will be evaluated under the modification guidance of ASC 606.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is not obligated to perform manufacturing activities. Per the terms of the Collaboration Agreement, to the extent that the Company, at its discretion, conducts a program, the Company shall be responsible for the manufacture of collaboration candidates and collaboration products for use in such program, as well as the associated costs. Delivery of manufactured compound (clinical product supply) is not deemed a performance obligation under ASC 606 as the Company is not obligated to transfer supply of collaboration product to BMS unless BMS exercises its right to participate in the Phase 1 development.  </span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Compensation for the Company&#8217;s provision of inventory supply, to the extent requested by BMS would be paid to Prothena by BMS at a reasonable stand-alone selling price for such supply. Given that (i) there is substantial uncertainty about the development of the programs, (ii) the pricing for the inventory is at its standalone selling price and (iii) the manufacturing services require the entity to transfer additional goods or services that are incremental to the goods and services provided prior to the resolution of the contingency, the Company&#8217;s supply of product is not a material right. Therefore, the inventory supply is not considered a performance obligation unless and until, requested by BMS.</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the grant of the US License after BMS exercises its US Rights for a program, BMS is entitled to receive certain ancillary development services from the Company, such as technology transfer assistance, regulatory support, safety data reporting activities and transition supply, if requested by BMS. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the grant of the Global License after BMS exercises the Global Rights for a program, BMS is entitled to receive certain ancillary development services from Prothena, such as ongoing clinical trial support upon request by BMS, transition supply, if requested by BMS, and regulatory support for coordination of pharmacovigilance matters.</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the potential obligations to transfer the US Licenses and Global Licenses and performance of the ancillary development services subsequent to exercise of the US Rights and Global Rights, if the options are exercised by BMS, under ASC 606-10-55-42 and 55-43 to determine whether the US Rights or the Global Rights provided BMS a &#8220;material right&#8221; and concluded that BMS&#8217;s options to exercise its US Rights and Global Rights represented &#8220;material rights&#8221; to BMS that it would not have received without entering into the Agreement. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are a total of six options including US Rights and Global Rights to acquire a US License and a Global License, respectively, and rights to request certain development services (following exercise of the US Rights and Global Rights, respectively) for each of the three programs. Per ASC 606, the US Rights and Global Rights are material rights and therefore are performance obligations. The goods and services underlying the options are not accounted for as separate performance obligations, but rather become performance obligations, if and when, an option is exercised. </span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Transaction Price</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">According to ASC 606-10-32-2, the transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Factors considered in the determination of the transaction price included, among other things, estimated selling price of the license and costs for clinical supply and development costs. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial transaction price under the Collaboration Agreement, pursuant to ASC 606, was $<ix:nonFraction unitRef="usd" contextRef="i1a7adf1102ac42aa80af37c1765abece_I20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:InitialTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzU5MDE_1b6ba73e-58d8-49be-813c-2d0e7cb80954">110.2</ix:nonFraction> million, including the $<ix:nonFraction unitRef="usd" contextRef="idf958f5bfd554f5db359067fc2e7e217_I20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationAgreementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzU5MTk_70c4380c-17ac-4d3e-a9d6-362def5e1833">100.0</ix:nonFraction> million upfront payment and $<ix:nonFraction unitRef="usd" contextRef="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:SaleofStockPremiumReceivedonTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzU5NDI_d112fc57-2a81-43d4-9bef-8f5b144d5820">10.2</ix:nonFraction> million premium on the ordinary shares purchased under the SSA. The Company </span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i6ced901da26144a4be61cb0a1b188a37" continuedAt="icb96d0ccceaf44e487f4681cf1c1cf76"><div style="text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">expects that the initial transaction price will be allocated across the US Rights and Global Rights for each program in a range of approximately $<ix:nonFraction unitRef="usd" contextRef="ifa4c2edd44bb4660bab9e79530b6b7fe_I20180320" decimals="-6" name="prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzYxNTg_2e0f3d99-9ef9-40eb-8060-57ced64d23a9">15</ix:nonFraction>-$<ix:nonFraction unitRef="usd" contextRef="ie08072583f71487086cd63ba104febe6_I20180320" decimals="-6" format="ixt:numdotdecimal" name="prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzYxNjE_22dcda5a-d685-4edd-bb92-c54d3a5813a3">25</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i754447b94e7e46e1832a0a572e8edf4d_I20180320" decimals="-6" name="prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzYxNjg_398d1943-77db-48a6-9079-4158332a6319">10</ix:nonFraction>-$<ix:nonFraction unitRef="usd" contextRef="i9a50341614dd4cabbccefeba93a88fd1_I20180320" decimals="-6" format="ixt:numdotdecimal" name="prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzYxNzE_eebc7db9-f658-46d1-a875-968d8ed5480b">18</ix:nonFraction> million, respectively.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not include the option fees in the initial transaction price because such fees are contingent on the options to the US Rights and the Global Rights being exercised. Upon the exercise of the US Rights and the Global Rights for a program, the Company will have the obligation to deliver the US License and Global License and provide certain ancillary development services if requested by BMS, subsequent to its exercise of the US Rights and Global Rights, respectively, for such program. The Company will include the option fees in the transaction price at the point in time a material right is exercised. In addition, the Company did not include in the initial transaction price certain clinical and regulatory milestone payments since they relate to licenses for which BMS has not yet exercised its option to obtain and these variable considerations are constrained due to the likelihood of a significant revenue reversal.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the inception of the Collaboration Agreement, the Company did not transfer any goods or services to BMS (formerly Celgene) that are material. Accordingly, the Company has concluded that the initial transaction price will be recognized as contract liability and will be deferred until the Company transfers control of goods or services to BMS (which would be when BMS exercises the US Right or Global Right and receives control of the US License or Global License for at least one of the programs),&#160;or when the IND Option term expires if BMS does not exercise the US Right (which is generally sixty days after the date on which Prothena delivers to BMS the first complete data package for an IND that was filed for a lead candidate from the relevant program), or when the Phase 1 Option term expires if BMS does not exercise the Global Right (which is generally ninety days after the date on which Prothena delivers to BMS the first complete data package for a Phase 1 clinical trial for a lead candidate from the relevant program)&#160;or at the termination of the Collaboration Agreement, whichever occurs first. At such point that the Company transfers control of goods or services to BMS, or when the option expires, the Company will recognize revenue as a continuation of the original contract. Under this approach, the Company will treat the consideration allocated to the material right as an addition to the consideration for the goods or services underlying the contract option. </span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At inception of the Collaboration Agreement, the Company estimated the standalone selling price for each performance obligation (i.e., the US Rights and Global Rights by program). The estimate of standalone selling price for the US Rights and Global Rights by program was based on the adjusted market assessment approach using a discounted cash flow model. The key assumptions used in the discounted cash flow model included the market opportunity for commercialization of each program in the U.S. or globally depending on the license, the probability of successfully developing and commercializing a given program target, the estimated remaining development costs for the respective program, the estimated time to commercialization of the drug for that program and a discount rate. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Significant Payment Terms</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The upfront payment of $<ix:nonFraction unitRef="usd" contextRef="idf958f5bfd554f5db359067fc2e7e217_I20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationAgreementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzk0NDk_70c4380c-17ac-4d3e-a9d6-362def5e1833">100.0</ix:nonFraction> million was due within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzk0Njc_0bf4cdb7-932a-472a-9ad8-2ce5f72c6492">ten</span> business days after the effective date of the Collaboration Agreement and was received in April 2018, while all option fees and milestone payments are due within <ix:nonNumeric contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320" format="ixt-sec:durday" name="prta:CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzk2MzI_33e0a263-923f-45ec-838e-3cd6243f6761">30</ix:nonNumeric> days after the achievement of the relevant milestone by BMS or receipt by BMS of an invoice for such an amount from the Company.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Collaboration Agreement does not have a significant financing component since a substantial amount of consideration promised by BMS to the Company is variable and the amount of such variable consideration varies based upon the occurrence or non-occurrence of future events that are not within the control of either BMS or the Company. Variable considerations related to clinical and regulatory milestone payments and option fees are constrained due to the likelihood of a significant revenue reversal.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone and Royalties Accounting</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is eligible to receive milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i2f99a1d0727d46a9adc11dcafd022744_I20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDAzNzE_c513d87d-49db-4a1c-b0ea-27b019873cc9">90.0</ix:nonFraction> million per program upon the achievement of certain specified regulatory milestones and milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i2f99a1d0727d46a9adc11dcafd022744_I20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDA0ODI_ab4438aa-7362-47ed-9861-5486bfd044ad">375.0</ix:nonFraction> million per program upon the achievement of certain specified commercial sales milestones under the US License for such program. The Company is also eligible to receive milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ib5d8e1da3a7d44d8a442dd98f2a66211_I20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDA2NzQ_b3225e2e-35a8-4b6d-8e0b-621e55680651">187.5</ix:nonFraction> million per program upon the achievement of certain specified regulatory milestones and milestone payments of up $<ix:nonFraction unitRef="usd" contextRef="ib5d8e1da3a7d44d8a442dd98f2a66211_I20180320" decimals="-5" format="ixt:numdotdecimal" name="prta:CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDA3ODI_c63aa5d6-1d71-41dc-9ac0-0becb30e41d6">375.0</ix:nonFraction> million per program upon the achievement of certain specified commercial sale milestones under the Global License for such program. Milestone payments are evaluated under ASC Topic 606. Factors considered in this determination included scientific and regulatory risk that must be overcome to achieve each milestone, the level of effort and investment required to achieve the milestone, and the monetary value attributed to the milestone. Accordingly, the Company estimates payments in the transaction price based on the most likely approach, which considers the single most likely amount in a range of possible amounts related to the achievement of these milestones. Additionally, milestone payments are included in the transaction price only when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.</span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="icb96d0ccceaf44e487f4681cf1c1cf76"><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company excluded the milestone payments and royalties in the initial transaction price because such payments are considered to be variable considerations with constraint. Such milestone payments and royalties will be recognized as revenue at a point in time when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not achieve any clinical and regulatory milestones under the Collaboration Agreement during the three and six months ended June&#160;30, 2020, and 2019.</span></div></ix:continuation><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_61"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfNzA4_866cb1d8-d69e-44f6-b1bf-2447a7eaadc7" continuedAt="iaafd94e41f964a349b77fcd54f8df236" escape="true">Shareholders' Equity</ix:nonNumeric></span></div><ix:continuation id="iaafd94e41f964a349b77fcd54f8df236"><div style="text-indent:9pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ordinary Shares</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfNzE_97a55bdd-496d-45d2-bbc4-d336bc6c25d1">100,000,000</ix:nonFraction> ordinary shares authorized for issuance with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfMTM0_ac37072b-697c-4eaf-8817-047c8e63fae2">0.01</ix:nonFraction> per ordinary share and <ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfMTYw_7f7e2eed-eb3e-4414-9b13-4737894487be"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfMTYw_e3c70a11-79d1-4ced-bfef-654219e57795">39,911,413</ix:nonFraction></ix:nonFraction> ordinary shares issued and outstanding. Each ordinary share is entitled to <ix:nonFraction unitRef="vote" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="prta:NumberofVotes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfMjM4_8d1d7315-4867-4044-b7ea-94d7ab9b3160">one</ix:nonFraction> vote and, on a pro rata basis, to dividends when declared and the remaining assets of the Company in the event of a winding up.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Euro Deferred Shares</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt:numdotdecimal" name="prta:DeferredSharesSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfNDE2_a79f75a7-4f9c-4362-b1aa-488620182e4a">10,000</ix:nonFraction> Euro Deferred Shares authorized for issuance with a nominal value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" name="prta:DeferredSharesParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfNDg4_18801aec-9d9b-434b-b18e-cfe199120e06">22</ix:nonFraction>&#160;per share. <ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="prta:DeferredSharesShareOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfNTAy_93c7935f-45b7-49b3-92cf-09107c87643d">No</ix:nonFraction> Euro Deferred Shares are outstanding at June&#160;30, 2020. The rights and restrictions attaching to the Euro Deferred Shares rank </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">pari passu</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with the ordinary shares and are treated as a single class in all respects.</span></div></ix:continuation><div style="text-indent:24.75pt;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_67"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9. <ix:nonNumeric contextRef="if308d0f707774e83b68197d8cba203b0_D20180515-20180515" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjQ1Nw_d9661960-c106-4a63-976a-f8accc2a6ba7" continuedAt="idb37fd9365ee4a228731f3702145ff0f" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="idb37fd9365ee4a228731f3702145ff0f" continuedAt="i3820a8d7bff848959c41d718237dff79"><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2018 Long Term Incentive Plan</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the Company&#8217;s shareholders approved the 2018 Long Term Incentive Plan. In May 2020, the Company's shareholders approved an amendment to the 2018 Long Term Incentive Plan (as amended, the &#8220;2018 LTIP&#8221;) to increase the number of ordinary shares available for issuance under that Plan by <ix:nonFraction unitRef="shares" contextRef="i044cf0c67aab4755b4c3d1811b2ed835_D20200519-20200519" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTY0OTI2NzQ0OTQ0MA_a6e66a8d-a853-43cb-8c0b-11a3c6e0dff5">1,500,000</ix:nonFraction> ordinary shares. Under the 2018 LTIP, the number of ordinary shares authorized for issuance under the 2018 LTIP is equal to the sum of (a) <ix:nonFraction unitRef="shares" contextRef="i963269705b7b4e5f9ae3a71c1c9ff5bd_I20180515" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTY0OTI2NzQ0OTUxNw_e8a6677b-8c3b-4fe5-abb9-8a972829fab2">3,300,000</ix:nonFraction> ordinary shares, (b) <ix:nonFraction unitRef="shares" contextRef="i8c7ac19e5f714d5c9b45c2f8f4858855_D20180515-20180515" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjQz_3547e2bc-56cd-4f90-8acc-182a16995c11">1,177,933</ix:nonFraction> ordinary shares that were available for issuance under the 2012 LTIP as of the May 15, 2018, effective date of the 2018 LTIP, and (c) any ordinary shares subject to issued and outstanding awards under the 2012 Long Term Incentive Plan (the &#8220;2012 LTIP&#8221;) that expire, are cancelled or otherwise terminate following the effective date of the 2018 LTIP; provided, that no more than <ix:nonFraction unitRef="shares" contextRef="i21f801f178cb46208ea96162e7973433_I20200630" decimals="INF" format="ixt:numdotdecimal" name="prta:MaximumNumberofSharestobeIssuedISOExercise" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTAwNg_b6a5147e-54a8-4fc1-9351-7e1965d3fce8">2,500,000</ix:nonFraction> ordinary shares may be issued pursuant to the exercise of ISOs. The 2018 LTIP provides for the grant of ISOs, NQSOs, SARs, restricted shares, RSUs, performance bonus awards, performance share units awards, dividend equivalents and other share or cash-based awards to eligible individuals. Options under the 2018 LTIP may be granted for periods up to <ix:nonNumeric contextRef="i8c7ac19e5f714d5c9b45c2f8f4858855_D20180515-20180515" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMzI5ODUzNDg5NDIwMA_3d59bfb6-89c2-40fe-8365-ab581dabe1cd">ten years</ix:nonNumeric>. All options issued to date have had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTcwNDI0MzAyMzk3NDM_37e1f852-c414-4fe4-86e8-7b6225eb6fa8">ten</span> year life. </span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amended and Restated 2012 Long Term Incentive Plan</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the effective date of the 2018 LTIP, employees and consultants of the Company, its subsidiaries and affiliates, as well as members of the Company&#8217;s Board of Directors, received equity awards under the 2012 LTIP. Options under the 2012 LTIP were granted for periods up to <ix:nonNumeric contextRef="ifc344697e4b14499a86b91af81b71dcf_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTM5NQ_743a930b-b10b-459b-82c5-ed0937653214">ten years</ix:nonNumeric>. All options issued to date have had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTQ0Mw_743a930b-b10b-459b-82c5-ed0937653214">ten</span> year life.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2020 Employment Inducement Incentive Plan</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2020, the Company's Board of Directors approved the 2020 Employment Inducement Incentive Plan. On April 1, 2020, the Company's Board of Directors approved an amendment to the 2020 Employment Inducement Incentive Plan (as amended, the "2020 EIIP") to increase the ordinary shares available for issuance under that Plan by <ix:nonFraction unitRef="shares" contextRef="i13cded138cc145cf8025f23802654b94_D20200401-20200401" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTY0OTI2NzQ0OTI0MQ_41058eec-0c09-48db-ae6f-4588fa6dd2ef">120,000</ix:nonFraction> ordinary shares. The 2020 EIIP provides for the grant of NQSOs, SARs, restricted shares, RSUs, performance bonus awards, performance share units awards, or other share or cash-based awards to eligible individuals. Options under the 2020 EIIP may be granted for periods up to <ix:nonNumeric contextRef="i6f0f422fe8fd406e815795229f9d4c4a_D20200225-20200225" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMzI5ODUzNDg5NDIxOA_fc749ea5-4320-41d8-b7cd-2336908d9ea3">ten years</ix:nonNumeric>. All options issued to date have had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTkzNw_cef9d024-7d91-407e-8091-cfdb99879f97">ten</span> year life. As of June&#160;30, 2020, the number of ordinary shares authorized for issuance under the 2020 EIIP was <ix:nonFraction unitRef="shares" contextRef="i5e195fad49074becb102c91d64d9ebb5_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjAzOQ_dd607cf6-36f3-40db-aafa-90546c4b689b">360,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5e195fad49074becb102c91d64d9ebb5_I20200630" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjA0Ng_80bca8a3-7b00-43a4-b680-4a606846bb69">no</ix:nonFraction> ordinary shares remained available for future awards under the 2020 EIIP, although the Company's Board of Directors reserves the right to amend the 2020 EIIP to increase the number of ordinary shares available and to make additional awards to key new hires.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Shares Available for Grant</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company granted <ix:nonFraction unitRef="shares" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTI2Mw_8c33ef02-2b91-49eb-92cc-3de80cb1f00c">263,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTI3MA_938a11f8-cfd6-437c-b063-60a865a818dd">145,000</ix:nonFraction> options during the three months ended June 30, 2020, and 2019, respectively, and <ix:nonFraction unitRef="shares" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTI4OA_1fa491fe-186e-45c5-abe1-5548060f00d9">1,718,950</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTM1Mw_e314cd13-93ba-4751-8397-305221d163b1">997,975</ix:nonFraction> options during the six months ended June 30, 2020 and 2019, respectively, in </span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i3820a8d7bff848959c41d718237dff79" continuedAt="i31dd1a3b8f2e41c090149296ab501f6f"><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">aggregate under its equity plans. The Company&#8217;s option awards generally vest over <ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjQ5NA_2039f285-0e55-4e9f-b4e8-07a0db8273ad">four years</ix:nonNumeric>. As of June&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="i21f801f178cb46208ea96162e7973433_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjUxNA_d5f9d96a-d85e-4d0f-aec1-3979b57fa90c">1,402,179</ix:nonFraction> ordinary shares remained available for grant under the 2018 LTIP, and options to purchase <ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjYwNw_e65dbe05-e1b6-41ee-9270-046ffbc2012c">8,672,205</ix:nonFraction> ordinary shares in aggregate under the Company's equity plans were outstanding with a weighted-average exercise price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjc0NQ_22bb2221-c57e-46c7-ab3f-96f400558297">21.09</ix:nonFraction> per share.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-based Compensation Expense</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company estimates the fair value of share-based compensation on the date of grant using an option-pricing model. The Company uses the Black-Scholes model to value share-based compensation, excluding RSUs, which the Company values using the fair market value of its ordinary shares on the date of grant. The Black-Scholes option-pricing model determines the fair value of share-based payment awards based on the share price on the date of grant and is affected by assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, the Company&#8217;s share price, volatility over the expected life of the awards and actual and projected employee stock option exercise behaviors.  Since the Company does not have sufficient historical employee share option exercise data, the simplified method has been used to estimate the expected life of all options. The Company uses its historical volatility for the Company&#8217;s stock to estimate expected volatility starting January 1, 2018. Although the fair value of share options granted by the Company is estimated by the Black-Scholes model, the estimated fair value may not be indicative of the fair value observed in a willing buyer and seller market transaction.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As share-based compensation expense recognized in the Condensed Consolidated Financial Statements is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. Forfeitures were estimated based on estimated future turnover and historical experience.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Share-based compensation expense will continue to have an adverse impact on the Company&#8217;s results of operations, although it will have no impact on its overall financial position. The amount of unearned share-based compensation currently estimated to be expensed from now through the year 2024 related to unvested share-based payment awards at June&#160;30, 2020, is $<ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNDgxOA_229f5551-9341-4c18-a194-df5b370b739f">41.8</ix:nonFraction> million. The weighted-average period over which the unearned share-based compensation is expected to be recognized is <ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNDkzMQ_97a431c2-92b2-4cc9-8ea6-d06cee733ad7">2.63</ix:nonNumeric> years. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate and/or increase any remaining unearned share-based compensation expense. Future share-based compensation expense and unearned share-based compensation will increase to the extent that the Company grants additional equity awards.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Share-based compensation expense recorded in these Condensed Consolidated Financial Statements for the three and six months ended June&#160;30, 2020, and 2019 was based on awards granted under the 2012 LTIP, the 2018 LTIP, and the 2020 EIIP. <ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjQ2Mg_85353c26-c90c-4a7d-8104-6d58c2af9650" continuedAt="ib5a65e09695c42c7a11af036c7354718" escape="true">The following table summarizes share-based compensation expense for the periods presented (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;"><ix:continuation id="ib5a65e09695c42c7a11af036c7354718"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:40.543%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.602%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3afaf46701c249838b3b57dcd7cd2fd1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMi0yLTEtMS0w_51a65944-2387-4489-87b0-8d89b3338237">2,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i619b94a5d1c748048b980c4beb1d3f80_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMi00LTEtMS0w_e6b22d09-0361-4ed0-90f9-fc1fb955e621">2,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5770524a4fb64c908398d01f9b105d07_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMi02LTEtMS0xMDEx_038ff162-af03-45c5-8c0f-0e5c4472a516">4,075</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6af301e0d5464d0f8688b96cc7ecbcc2_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMi04LTEtMS0xMDEx_58d41ffd-1d44-4209-a96b-3a63e84882db">4,199</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia19f4446d12d455d8ed873aacb41c471_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMy0yLTEtMS0w_7c888ec9-4f74-462e-a723-7ddb4c9ec137">3,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d8293363e094a25a626f7be205cd571_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMy00LTEtMS0w_39f8d378-1a37-4169-8c69-dafc6cfe0ff2">4,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c7537c8b63e44b2b5a02d22312caaac_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMy02LTEtMS0xMDEx_824388fb-7770-44c0-a51a-e58a487306d4">7,148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida53c60bb2f6447e8d6a93e583eb07f7_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMy04LTEtMS0xMDEx_6f42733e-5cde-4033-b9d5-8fe93f491bae">8,283</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfNC0yLTEtMS0w_b0bf9824-bc0b-48e6-9f53-6065a1b7f7ff">5,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfNC00LTEtMS0w_95434ce9-91ab-4695-9256-99ad86cd016c">6,277</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfNC02LTEtMS0xMDE0_384585cf-936d-4500-8644-b3a90886477d">11,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfNC04LTEtMS0xMDE0_1ccced97-3f9c-4780-b5a1-d15729325373">12,482</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognized tax benefits from share-based awards of $<ix:nonFraction unitRef="usd" contextRef="i44af5ba0fe6a40a0b2d7a1b155ed8d12_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQ0Mw_2c1e9166-a9e8-44f1-bb31-90ba66918bdf">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iea1807fc55f1435bb318a4fb39dde186_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQ0NQ_9e5461ba-f44f-4beb-b262-16a3e45dae79">1.2</ix:nonFraction> million for the three months ended June 30, 2020, and 2019, and $<ix:nonFraction unitRef="usd" contextRef="ied6043afc98548c7ae9c22d39f61cb44_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQzNA_306c6ca4-0c95-45bc-84f8-e8f76fb17c84">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iacb3936c27de4e4c87eba688149d459e_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQ0MQ_d9fffcba-d442-4d2c-9327-379c77b4a723">2.5</ix:nonFraction> million for the six months ended June 30, 2020 and 2019, respectively.</span></div><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjQ1Mw_62d0b64d-0da6-48a0-aa7f-2f113a0a2c52" escape="true"><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the options granted to employees and non-employee directors during the three and six months ended June&#160;30, 2020, and 2019 was estimated as of the grant date using the Black-Scholes option-pricing model assuming the weighted-average assumptions listed in the following table:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.274%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.601%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMi0xLTEtMS0xMDgz_fda49c42-62c6-44b7-8371-f9746b54fcd9">79.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMi0zLTEtMS0xMDg3_c73508ce-400f-452b-922c-f76291ca5319">81.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMi0xLTEtMS0w_aecefa09-af41-4434-9f2a-8effdf8fe278">81.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMi0zLTEtMS0w_7cab9803-282a-4aff-8c31-3e7106515be0">81.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMy0xLTEtMS0xMDgz_43275bb3-f24b-4d8d-927a-ab3de978d1c5">0.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMy0zLTEtMS0xMDg3_e3730202-b83d-4dea-8d21-af80abf60a95">2.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMy0xLTEtMS0w_9345c6c1-22d9-4b8e-b63a-9310318fff1c">1.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMy0zLTEtMS0w_86059dae-644b-46bf-b8d2-a110a6a71877">2.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNC0xLTEtMS0xMDgz_8133bc54-4d82-44b6-bc47-9d8dbdb81acc">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNC0zLTEtMS0xMDg3_3cf3f1e9-8839-40dc-b31b-530a80ba4a34">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNC0xLTEtMS0w_5c6e0d90-ae59-4abf-9159-b625ad680b20">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNC0zLTEtMS0w_027230cb-2f0c-404f-b268-e74188a0505a">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNS0xLTEtMS0xMDgz_78ba580e-1d02-4cc5-84aa-67c7fc5fe8a7">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNS0zLTEtMS0xMDg3_2ea0f94d-2e8a-4ccc-b226-df70357389e6">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNS0xLTEtMS0w_8981855a-cefc-4ea0-b4ba-ce702c718470">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNS0zLTEtMS0w_2d11b63a-648b-41ea-ab95-fa673215ccd1">6.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average grant date fair value</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNi0xLTEtMS0xMDgz_31c7f8f4-f18b-49a2-b43f-f581e0d689e6">7.52</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNi0zLTEtMS0xMDg3_777c3e6d-ccc4-4112-b4f1-67738cceacf5">6.58</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNi0xLTEtMS0w_5c2f8b30-271c-4abf-b1dc-f239cc7747ad">8.19</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNi0zLTEtMS0w_fc251590-249c-484f-95ba-9cbc8fc11842">9.06</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i31dd1a3b8f2e41c090149296ab501f6f"><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period for each award. Each of the inputs discussed above is subjective and generally requires significant management judgment to determine.</span></div><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjQ4OQ_e8235c8c-fa6a-491f-a99d-31413a447f54" escape="true"><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s stock option activity during the six months ended June 30, 2020:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:47.853%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.257%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.549%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.555%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMS0xLTEtMS0w_7ffb9a0a-497c-4acb-9afb-9605e89f834e">7,008,403</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMS0zLTEtMS0w_25758e18-1594-4832-ae3f-32149c4d3583">23.34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i3729d833e9b64a35af79dd7d137d50e1_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMS01LTEtMS0w_504e18a8-4f92-41fa-875f-ceedb723666b">7.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMS03LTEtMS0w_338f8ec7-11ca-4fbb-92e0-53312fce1c75">11,901</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMi0xLTEtMS0w_25b06a7b-d2f6-4e6f-90d7-35407d8fda8d">1,718,950</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMi0zLTEtMS0w_94d82a2a-604f-4028-aae4-e09cc6e3695d">11.87</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMy0xLTEtMS0w_3e628c76-16d2-45fe-bb52-5a1cd8b24e18">12,852</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMy0zLTEtMS0w_10bdc9aa-3e84-41ea-8ea8-eec7f0ed7c2f">11.76</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNC0xLTEtMS0w_262c52e4-0941-4d6f-98a1-9165481fde0d">20,960</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNC0zLTEtMS0w_e443a9bc-1415-4a47-a624-678f155ead41">11.44</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNS0xLTEtMS0w_df7e9d08-6258-47da-975a-19cc11372da7">21,336</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNS0zLTEtMS0w_205df9b6-b457-4cc4-bc74-9ec2cb9009eb">33.61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNi0xLTEtMS0w_e65dbe05-e1b6-41ee-9270-046ffbc2012c">8,672,205</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNi0zLTEtMS0w_22bb2221-c57e-46c7-ab3f-96f400558297">21.09</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNi01LTEtMS0w_e4dfc852-df5e-4af1-b7fc-648a87ce6ab6">7.37</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNi03LTEtMS0w_31cac94b-cc19-49f5-8d69-109473ee8eac">2,426</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNy0xLTEtMS0w_9f8472e4-6a19-4674-8ddd-8d53315a0855">8,194,918</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNy0zLTEtMS0w_a72a0113-24da-4e8f-9839-be85645cb295">21.50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNy01LTEtMS0w_424fe0f5-1398-4fee-b504-e4a0d6ae66dc">7.27</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNy03LTEtMS0w_b1fa478a-02be-4240-88b3-94d9e43f1fb5">2,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfOC0xLTEtMS0w_e3427fef-d1e4-4411-8040-5f780e2f9012">4,500,202</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfOC0zLTEtMS0w_e6962e2c-5b75-44c4-8f4d-ddfe4e2c388a">26.35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfOC01LTEtMS0w_2d5b88a7-271b-48b0-92b2-de0b0c13a7f6">6.04</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="prta:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfOC03LTEtMS0w_0e0fbb02-3986-470a-8f9a-ec7b791c252a">2,254</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total intrinsic value of options exercised was approximately <ix:nonFraction unitRef="usd" contextRef="i44af5ba0fe6a40a0b2d7a1b155ed8d12_D20200401-20200630" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTUyMw_bc38788a-db1b-4e61-a5e2-9951aa7d217f">none</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iea1807fc55f1435bb318a4fb39dde186_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTUyOA_776fa5e6-6ce2-444e-98ee-8b046e353522">103,000</ix:nonFraction> during the three months ended June 30, 2020, and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ied6043afc98548c7ae9c22d39f61cb44_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQ3Ng_1f3cad2e-0005-4e6b-866a-f1e92c0ad552">35,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iacb3936c27de4e4c87eba688149d459e_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQ4NA_fdf36621-aef7-4c55-bc15-245c089c099c">109,000</ix:nonFraction> during the six months ended June 30, 2020 and 2019, respectively, determined as of the date of exercise.</span></div></ix:continuation><div id="id78a5ecf693745eb81aedf6e125c6b7c_70"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">10. <ix:nonNumeric contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMzE0Nw_a4bb4445-6954-4bcc-b4c9-cfb6b8e59323" continuedAt="i8570adf937b548abb0ba27b4579f0389" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i8570adf937b548abb0ba27b4579f0389"><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The major taxing jurisdictions for the Company are Ireland and the U.S. The Company recorded an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfNjA0NzMxMzk1NjAxMA_5d7b26b7-2af5-4fbb-89c0-63e553b582ab">255,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfNjA0NzMxMzk1NjAwMw_90d9c9e2-c559-449a-b0a3-1b45ec13b2bf">421,000</ix:nonFraction> for the three and six months ended June&#160;30, 2020, respectively, as compared to an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfNjA0NzMxMzk1NjAwOA_fd7dab2a-d811-4a2f-b415-15b79d233d13">156,000</ix:nonFraction> and an income tax provision of $<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfNjA0NzMxMzk1NjAyOA_816038d9-e97d-4eb8-9647-1b03d4b771f3">42,000</ix:nonFraction> for the three and six months ended June&#160;30, 2019, respectively.&#160;The provision for income taxes differs from the statutory tax rate of <ix:nonFraction unitRef="number" contextRef="i3dbe480e059f408dbac0ebcadbd9f854_D20200101-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMjgx_6dc95edd-7ad4-4f42-9813-8cb8cc44eef3">12.5</ix:nonFraction>% applicable to Ireland primarily due to Irish net operating losses for which a tax provision benefit is not recognized, U.S. income taxed at different rates, and net tax shortfall from cancellations of stock options. The income tax provision reflects the estimate of the effective tax rate expected to be applicable for the full year and the Company re-evaluates this estimate each quarter based on its forecasted tax expense for the full year. Jurisdictions with a projected loss for the year where no tax benefit can be recognized are excluded from the estimated annual effective tax rate.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to ASU 2016-09, the Company recorded a net tax shortfall of a <ix:nonFraction unitRef="usd" contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMTE1NDQ4NzIwOTUxODY_6baf63dc-e8e9-4155-a7ab-ba72c97d1dd3">no</ix:nonFraction>minal amount and $<ix:nonFraction unitRef="usd" contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfOTQ0_f9a4252b-b114-4899-8670-514d9bf59c14">0.1</ix:nonFraction>&#160;million for the three and six months ended June&#160;30, 2020, respectively, and a net tax shortfall of $<ix:nonFraction unitRef="usd" contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMTE1NDQ4NzIwOTUyMTY_c1e2158b-8e3a-4ebf-ba33-f3afdc034d27">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMTE1NDQ4NzIwOTUyMDI_d8d07b05-4659-49d0-a56b-0d4cbb56d9ac">1.0</ix:nonFraction>&#160;million for the three and six months ended June&#160;30, 2019, respectively, all of which were recorded as part of its income tax provision in the Condensed Consolidated Statements of Operations. The Company&#8217;s income tax expense will continue to be impacted by fluctuations in stock price between the grant dates and the exercise dates of its option awards.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2019, the Company adopted ASC 842, and it recorded a reduction in deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="ib78a576b8afe40d2aaeedaae8a663a59_I20190101" decimals="-3" format="ixt:numdotdecimal" name="prta:NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMTM3Mg_353c6631-981f-4abd-aad1-69bd2c4a04cd">1.0</ix:nonFraction> million as part of the $<ix:nonFraction unitRef="usd" contextRef="ib78a576b8afe40d2aaeedaae8a663a59_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMTM5MA_f0c29f68-e974-42ac-91f4-ce3fb3689785">3.8</ix:nonFraction> million change in the opening balance of the accumulated deficit for the cumulative effect of applying ASC 842.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company's deferred tax assets are composed primarily of its Irish subsidiaries' net operating loss carryovers, state net operating loss carryforwards available to reduce future taxable income of the Company's U.S. subsidiaries, federal and California tax credit carryforwards, share-based compensation and other temporary differences. The Company maintains a valuation allowance against certain U.S. federal and state and Irish deferred tax assets. Each reporting period, the Company evaluates the need for a valuation allowance on its deferred tax assets by jurisdiction.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No provision for income tax in Ireland has been recognized on undistributed earnings of the Company&#8217;s U.S. subsidiaries. The Company considers the U.S. earnings to be indefinitely reinvested. The Company's Swiss subsidiary, Prothena Switzerland GmbH ("PSG") has ceased operations and the Company finalized the liquidation of PSG in May 2020. Unremitted earnings may be subject to withholding taxes (potentially at <ix:nonFraction unitRef="number" contextRef="i051466dca10b47ce8e0373f83d6dd3c4_D20200101-20200630" decimals="2" name="prta:PotentialWithholdingTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMjc4OA_63a53263-e447-4652-a85d-050602cf32dd">5</ix:nonFraction>% in the U.S.) and Irish taxes (potentially at a rate of <ix:nonFraction unitRef="number" contextRef="i3dbe480e059f408dbac0ebcadbd9f854_D20200101-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMjg0Ng_a251c023-931c-4229-8b77-c89e3b712b5f">12.5</ix:nonFraction>%) if they were to be distributed as dividends. However, Ireland allows a credit against Irish taxes for U.S. taxes withheld, and as of June&#160;30, 2020, the Company's current year net operating losses in Ireland are sufficient to offset any potential dividend income received from its overseas subsidiaries.</span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_73"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-40.5pt;padding-left:40.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-indent:22.5pt;padding-right:4.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to historical information, this Quarterly Report on Form 10-Q, including this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements within the meaning of Section&#160;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances are forward-looking statements.</span></div><div style="text-indent:22.5pt;padding-right:4.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These forward-looking statements, which reflect our beliefs, objectives, and expectations as of the date hereof, are estimates based on our best judgment. These statements relate to, among other things, our expected increase in research and development (&#8220;R&amp;D&#8221;) and general and administrative (&#8220;G&amp;A&#8221;) expenses in 2020; the sufficiency of our cash and cash equivalents to meet our obligations; our anticipated need for additional capital; our current intention not to repatriate funds to Ireland; and our estimates of certain future contractual obligations.  </span></div><div style="text-indent:22.5pt;padding-right:4.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Forward-looking statements are subject to risks and uncertainties, and actual events or results may differ materially. You should bear this in mind as you consider forward-looking statements, and you are cautioned not to place undue reliance on forward-looking statements. Factors that could cause our actual results to differ materially include, but are not limited to, the risks and uncertainties listed below as well as those discussed under Part II Item 1A - Risk Factors of this Form 10-Q:</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to obtain additional financing in future offerings and/or obtain funding from future collaborations;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our operating losses;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to successfully complete research and development of our drug candidates;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to develop, manufacture and commercialize products;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our collaborations with third parties, including Roche and Bristol-Myers Squibb;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to protect our patents and other intellectual property;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to hire and retain key employees;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">tax treatment of our separation from Elan and subsequent distribution of our ordinary shares;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to maintain financial flexibility and sufficient cash, cash equivalents and investments and other assets capable of being monetized to meet our liquidity requirements;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">potential disruptions in the U.S. and global capital and credit markets;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">government regulation of our industry;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the volatility of the market price of our ordinary shares; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the outbreak of the novel strain of coronavirus SARS-CoV-2; and</span></div><div style="text-indent:-13.5pt;padding-left:36pt;padding-right:4.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">business disruptions.</span></div><div style="text-indent:22.5pt;padding-right:4.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except as required by law or by the rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that arises after the date of this Quarterly Report on Form 10-Q.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This discussion should be read in conjunction with the Condensed Consolidated Financial Statements and Notes presented in this Quarterly Report on Form 10-Q and the Consolidated Financial Statements and Notes contained in our Annual Report on Form 10-K filed with the SEC on March&#160;3, 2020 (the &#8220;2019 Form 10-K&#8221;).</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Prothena Corporation plc (&#8220;Prothena&#8221; or the &#8220;Company&#8221;) is a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by our deep scientific expertise built over decades of research, we are advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which our ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Our partnered programs include prasinezumab (PRX002/RG7935), in collaboration with Roche for the potential treatment of </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Parkinson&#8217;s disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer&#8217;s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) or other neurodegenerative diseases. Our proprietary programs include PRX004 for the potential treatment of ATTR amyloidosis, and programs that target A&#946; (Amyloid beta) for the potential treatment of Alzheimer&#8217;s disease.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were formed on September 26, 2012, under the laws of Ireland and re-registered as an Irish public limited company on October 25, 2012. Our ordinary shares began trading on The Nasdaq Global Market under the symbol &#8220;PRTA&#8221; on December 21, 2012, and currently trade on The Nasdaq Global Select Market.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Developments</span></div><div><span><br/></span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prasinezumab (PRX002/RG7935) for the Potential Treatment of Parkinson&#8217;s Disease and other synucleinopathies</span></div><div><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prasinezumab is an investigational monoclonal antibody targeting alpha-synuclein designed to slow the progressive neurodegeneration associated with synuclein misfolding and/or the cell-to-cell transmission of the pathogenic, aggregated forms of synuclein in Parkinson&#8217;s disease and other synucleinopathies. Prasinezumab is the focus of a worldwide collaboration between Prothena and Roche, and Roche is conducting the ongoing Phase 2 PASADENA study in patients with early Parkinson&#8217;s disease.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April, Roche provided an update on Part 1 of the Phase 2 PASADENA study. As announced by Roche, the study did not meet the primary objective, but showed signals of efficacy. These signals were observed on multiple prespecified secondary and exploratory clinical endpoints.  Roche has begun further clinical development planning activities and is evaluating the data from Part 1 of the PASADENA study to determine next steps. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The study was designed with 80% power and a one-sided alpha of 0.10 to detect a 37.5% relative between group reduction from baseline to week 52 on the primary endpoint (i.e., the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score (parts I, II and III) vs placebo in Part 1 of the study). Part 2 of the study is ongoing. Prasinezumab was generally well tolerated with a favorable safety profile.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Baseline data from Part 1 of the PASADENA study was presented in a virtual oral presentation at the Advances in Alzheimer&#8217;s and Parkinson&#8217;s Therapies AAT-AD/PD Focus Meeting (AAT-AD/PD) in April. The presentation noted that the PASADENA study population can be considered representative of a wider Parkinson&#8217;s disease population, such as the one studied in the Parkinson's Progression Markers Initiative (PPMI) and is therefore suitable for testing the potential beneficial effect of drugs acting on disease progression, such as prasinezumab.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Estimates</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with the accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenues, expenses and related disclosures. </span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no significant changes to our critical accounting policies and estimates during the six months ended June 30, 2020, from the critical accounting policies and estimates disclosed in Management's Discussion and Analysis of Financial Condition and Results of Operations in our 2019 Form 10-K.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no new accounting pronouncements or changes to accounting pronouncements during the six months ended June 30, 2020, as compared to the recent accounting pronouncements described in our 2019 Form 10-K, that are of significance or potential significance to us.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_76"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of Three and Six Months Ended June&#160;30, 2020 and 2019</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:61.343%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.731%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Change</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">n/m</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="padding-left:22.5pt;"><span><br/></span></div><div style="text-align:center;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:61.157%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.700%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Change</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">353&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">n/m</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">353&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_____________</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">n/m = not meaningful</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue was $0.2 million and $0.2 million  for the three months ended June 30, 2020 and 2019, respectively, and $0.3 million and $0.4 million for the six months ended June 30, 2020 and 2019, respectively. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Collaboration revenue includes reimbursements under our License Agreement with Roche. See Note 7, &#8220;Significant Agreements&#8221; to the Condensed Consolidated Financial Statements regarding the Roche License Agreement for more information.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">License revenue includes revenue from the transfer of license technology to a third party.</span></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Expenses</span></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-align:center;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:61.157%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.700%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Change</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,583&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,656&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,081&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,927&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,664&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:61.450%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.700%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Change</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,519&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,879&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,397&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(61)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,916&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,804&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total operating expenses consist of R&amp;D expenses, G&amp;A expenses and restructuring credits. Our operating expenses were $26.9 million and $51.9 million for the three and six months ended June&#160;30, 2020, respectively, and $18.7 million and $41.8 million for the three and six months ended June&#160;30, 2019, respectively.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our R&amp;D expenses primarily consist of personnel costs and related expenses, including share-based compensation and external costs associated with nonclinical activities and drug development related to our drug programs, including NEOD001, prasinezumab, PRX004 and our discovery programs. Pursuant to our License Agreement with Roche, we make payments to Roche for our share of the development expenses incurred by Roche related to the prasinezumab program, which is included in our R&amp;D expense.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our G&amp;A expenses primarily consist of professional service expenses and personnel costs and related expenses, including share-based compensation.</span></div><div style="text-indent:24.75pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our R&amp;D expense increased by $7.7 million or 80%, for the three months ended June 30, 2020, and increased by $9.6 million, or 42%, for the six months ended June 30, 2020, compared to the same periods in the prior year. The increase for the three and six months ended June 30, 2020 was primarily due to higher collaboration expense with Roche related to the prasinezumab program and higher manufacturing costs (primarily related to the tau, A&#946; and PRX004 programs).</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research activities are aimed at developing new drug products. Our development activities involve the translation of our research into potential new drugs. R&amp;D expenses include personnel costs and related expenses, external expenses associated with nonclinical and drug development and materials, equipment and facilities costs that are allocated to clearly related R&amp;D activities.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the R&amp;D expenses for our major programs (specifically, any program with successful first dosing in a Phase 1 clinical trial, which were NEOD001, prasinezumab, PRX003 and PRX004) and other R&amp;D expenses for the three and six months ended June&#160;30, 2020 and 2019 and the cumulative amounts to date (in thousands):</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:37.035%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.403%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.703%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative to Date</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">NEOD001 </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,825&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,885&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">313,161&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Prasinezumab (PRX002/RG7935)</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,649&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88,754&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">PRX003 </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(264)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,903&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">PRX004 </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,778&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other R&amp;D </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(5)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,977&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,583&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,519&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,879&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration: underline;">                                  </span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.43pt;">Cumulative R&amp;D costs to date for NEOD001 include the costs incurred from the date when the program was separately tracked in preclinical development. Expenditures in the early discovery stage are not tracked by program and accordingly have been excluded from this cumulative amount. In April 2018, we announced that we were discontinuing development of NEOD001. Since that date we have incurred costs associated with the close out of NEOD001 studies and ongoing evaluation of NEOD001.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:5pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.43pt;">Cumulative R&amp;D costs to date for prasinezumab and related antibodies include the costs incurred from the date when the program was separately tracked in nonclinical development. Expenditures in the early discovery stage are not tracked by program and accordingly have been excluded from this cumulative amount. Prasinezumab costs include payments to Roche for our share of the development expenses incurred by Roche related to prasinezumab programs and</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">through December 31, 2017, is net of reimbursements from Roche for development and supply services recorded as an offset to R&amp;D expense. For the three and six months ended</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">June&#160;30, 2020,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">$0.1 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> $0.3 million, respectively, and for the three and six months ended June&#160;30, 2019, $0.2 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">and $0.4 million, respectively, of reimbursements from Roche for development services were recorded as part of collaboration revenue. </span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:5pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">(3)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.43pt;">Cumulative R&amp;D costs to date for PRX003 include the costs incurred from the date when the program was separately tracked in nonclinical development. Expenditures in the early discovery stage are not tracked by program and accordingly have been excluded from this cumulative amount. Based on the Phase 1b multiple ascending dose study results announced in September 2017, we announced that we will not advance PRX003 into mid-stage clinical development for psoriasis or psoriatic arthritis as previously planned.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:5pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">(4)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.43pt;">Cumulative R&amp;D costs to date for PRX004 include the costs incurred from the date when the program was separately tracked in nonclinical development. Expenditures in the early discovery stage are not tracked by program and accordingly have been excluded from this cumulative amount. </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:5pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;">(5)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.43pt;">Other R&amp;D is comprised of preclinical development and discovery programs that have not progressed to first patient dosing in a Phase 1 clinical trial.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our R&amp;D expenses to increase in 2020 over the prior year, primarily due to investments in our neuroscience programs.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our G&amp;A expenses increased by $0.6 million, or, 6%, for the three months ended June 30, 2020, and increased by $0.4 million, or 2%, for the six months ended June 30, 2020, compared to the same periods in the prior year. The increase for the three and six months ended June 30, 2020, compared to the prior year, was primarily due to higher costs for our director and officer insurance premiums and higher legal and accounting fees offset in part by lower personnel costs (including share-based compensation expense). </span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our G&amp;A expenses to increase in 2020 compared to the prior year, primarily related to increases in our director and officer insurance premiums.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restructuring Credits</span></div><div style="text-indent:27pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;padding-right:4.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, we commenced a reorganization plan to reduce our operating costs and better align our workforce with the needs of our business following our decision in April 2018 to discontinue further development of NEOD001. For the six months ended June 30, 2019, we recorded a restructuring credit of approximately $61,000 primarily due to an adjustment in previously recorded employee termination benefits. </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income (Expense)</span></div><div style="text-align:center;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:61.596%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.554%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Change</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,296&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(92)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(93)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,531&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(92)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:61.450%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.700%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Change</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,316&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(71)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(104)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,818&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(73)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income decreased by $2.1 million, or 92%, for the three months ended June 30, 2020, and decreased by $3.3 million, or 71%, for the six months ended June 30, 2020, compared to the same periods in the prior year, primarily due to lower interest income from our cash and money market accounts resulting from lower interest rates and lower cash and money market balances. Other income (expense), net for the three and six months ended June&#160;30, 2020 and 2019, was primarily foreign exchange gains (losses) from transactions with vendors denominated in Euros.</span></div><div style="text-indent:24.75pt;"><span><br/></span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provision for (benefit from) Income Taxes</span></div><div style="text-align:center;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:61.157%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.695%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.700%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Change</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for (benefit from) income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(255)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(156)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:61.543%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.566%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.714%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Change</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Dollars in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for (benefit from) income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(421)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,102)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The benefit from income taxes for the three months ended June 30, 2020 and 2019 was $255,000 and $156,000, respectively. The benefit from income taxes for the six months ended June 30, 2020 was $421,000 and the provision for income taxes for six months ended June 30, 2019 was $42,000. The benefit from income taxes increased by $99,000 for the three months ended June 30, 2020, and the provision for income tax decreased by $463,000 for the six months ended June 30, 2020, compared to the same periods in the prior year. The change in provision for (benefit from) income taxes for the three and six months ended June 30, 2020, as compared to the same period in the prior year, was primarily due to a decrease in tax shortfall related to higher stock option cancellations in the prior year, offset in part by a higher projected effective tax rate largely driven by an increase in the amount disallowed as tax deductions related to compensation of certain executives during the year. Our income tax expense will continue to be impacted by fluctuations in stock price between the grant dates and the exercise or cancellation dates of stock options.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The tax provisions for all periods presented reflect U.S. federal taxes associated with recurring profits attributable to intercompany services that our U.S. subsidiary performs for the Company. No tax benefit has been recorded related to tax losses recognized in Ireland and any deferred tax assets for those losses are offset by a valuation allowance.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_79"></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="padding-left:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.720%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Working capital</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">322,579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333,942&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">375,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">378,933&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">419,268&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144,489&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146,347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total shareholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">234,444&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">272,921&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Working capital was $322.6 million as of June&#160;30, 2020, a decrease of $38.1 million from working capital of $360.7 million as of December&#160;31, 2019. This decrease in working capital during the six months ended June 30, 2020, was primarily due to cash use of $51.9 million for operating expenses (adjusted to exclude non-cash charges).</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we had $333.9 million in cash and cash equivalents. Although we believe, based on our current business plans, that our existing cash and cash equivalents will be sufficient to meet our obligations for at least the next twelve months, we anticipate that we will require additional capital in the future in order to continue the research and development of our drug candidates. As of June&#160;30, 2020, $132.3 million of our outstanding cash and cash equivalents related to U.S. operations are considered permanently reinvested. We do not intend to repatriate these funds. However, if these funds were repatriated back to Ireland, we would incur a withholding tax from the dividend distribution.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of our product candidates. Our future capital requirements will depend on numerous factors, including, without limitation, the timing of initiation, progress, results and costs of our clinical trials; the results of our research and nonclinical studies; the costs of clinical manufacturing and of establishing commercial manufacturing arrangements; the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; the costs and timing of capital asset purchases; our ability to establish research collaborations, strategic collaborations, licensing or other arrangements; the costs to satisfy our obligations under current and potential future collaborations; the costs of any in-licensing transactions; and the timing, receipt, and amount of revenues or royalties, if any, from any approved drug candidates. Pursuant to the License Agreement with Roche, in the U.S., we and Roche share all development and commercialization costs, as well as profits, all of which will be allocated 70% to Roche and 30% to us, for prasinezumab, as well as any other Licensed Products and/or indications for which we opt in to co-develop and co-fund. Pursuant to the Collaboration Agreement with BMS (formerly Celgene), the Company is eligible to receive payments for </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">commercial and regulatory milestones and royalties on net sales of Collaboration Products. In order to develop and obtain regulatory approval for our potential products we will need to raise substantial additional funds. We expect to raise any such additional funds through public or private equity or debt financings, collaborative agreements with corporate partners or other arrangements. We cannot assume that such additional financings will be available on acceptable terms, if at all, and such financings may only be available on terms dilutive to our shareholders.</span></div><div style="padding-left:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows for the Six Months Ended June 30, 2020 and 2019 </span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes, for the periods indicated, selected items in our Condensed Consolidated Statements of Cash Flows (in thousands):</span></div><div style="margin-top:5pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:75.923%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.675%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,864)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29,538)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(68)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(192)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,781)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29,515)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash Used in Operating Activities</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities was $41.9 million for the six months ended June 30, 2020, primarily due to use of $51.9 million for operating expenses (adjusted to exclude non-cash charges), cash paid for prepaid expenses and other current assets and operating lease payments.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities was $29.5 million for the six months ended June 30, 2019, was primarily due to  $41.8 million for operating expenses (adjusted to exclude non-cash charges) and a decrease in accounts payable, accruals and other liabilities and operating lease liabilities.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash Used in Investing Activities</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities was $68,000 and $192,000 for the six months ended June 30, 2020 and 2019, respectively. Net cash used in investing activities for the six months ended June 30, 2020 and 2019 was primarily related to purchases of property and equipment.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash Provided by Financing Activities</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by financing activities was $151,000 and $215,000 for the six months ended June 30, 2020 and 2019, respectively, which were proceeds from issuances of ordinary shares upon exercises of stock options.</span></div><div style="text-align:justify;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June&#160;30, 2020, we were not a party to any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.</span></div><div style="text-align:justify;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our contractual obligations as of June&#160;30, 2020, consisted of minimum cash payments under operating leases of $22.1 million, purchase obligations of $4.0 million (of which $0.4 million is included in accrued current liabilities), and contractual obligations under license agreements of $1.1 million (of which $0.1 million is included in accrued current liabilities). Purchase obligations consist of non-cancelable purchase commitments to suppliers. Operating leases represent our future minimum rental commitments under our non-cancelable operating leases. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2016, we entered into a noncancelable operating sublease to lease 128,751 square feet of office and laboratory space in South San Francisco, California. We are obligated to make lease payments totaling approximately $39.2 million over the lease term. Of this obligation, approximately $22.1 million remains outstanding as of June&#160;30, 2020.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018, we entered into an agreement to lease an office space in Dublin, Ireland. The initial lease term expired in November 2019. We renewed such lease in August 2019 for one year and the current term expires on November&#160;30, 2020. As of June&#160;30, 2020, we are obligated to make lease payments over the remaining term of the lease of approximately &#8364;10,000, or $11,000 as converted using an exchange rate as of June&#160;30, 2020.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of our contractual obligations as of June&#160;30, 2020 (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:30.602%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.918%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.771%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.918%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.918%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.918%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.918%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.927%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Operating leases </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,090&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,165&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase obligations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contractual obligations under license agreements </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,075&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">285&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">465&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,124&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,284&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,260&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,430&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,615&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">465&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration: underline;">                                  </span></div><div style="text-indent:-13.5pt;padding-left:40.5pt;margin-top:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">See Note 6, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">Commitments and Contingencies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;"> to our Condensed Consolidated Financial Statements.</span></div><div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">Excludes future obligations pursuant to the cost-sharing arrangement under our License Agreement with Roche. Amounts of such obligations, if any, cannot be determined at this time.</span></div><div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"><span><br/></span></div><div style="text-indent:-9pt;padding-left:36pt;margin-top:6pt;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_82"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Foreign Currency Risk</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business is primarily conducted in U.S. dollars except for our agreements with contract manufacturers for drug supplies which are denominated in Euros. We recorded a loss on foreign currency exchange rate differences of approximately $8,000 and a gain on foreign currency exchange rate differences of $218,000 during the six months ended June 30, 2020, and 2019, respectively. If we increase our business activities that require the use of foreign currencies, we may be exposed to losses if the Euro and other such currencies continue to strengthen against the U.S. dollar.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest Rate Risk</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our exposure to interest rate risk is limited to our cash equivalents, which consist of accounts maintained in money market funds. We have assessed that there is no material exposure to interest rate risk given the nature of money market funds. In general, money market funds are not subject to interest rate risk because the interest paid on such funds fluctuates with the prevailing interest rate. Accordingly, our interest income fluctuates with short-term market conditions.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the future, we anticipate that our exposure to interest rate risk will primarily be related to our investment portfolio. We intend to invest any surplus funds in accordance with a policy approved by our board of directors which will specify the categories, allocations, and ratings of securities we may consider for investment. The primary objectives of our investment policy are to preserve principal and maintain proper liquidity to meet our operating requirements. Our investment policy also specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Credit Risk</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject us to concentration of credit risk consist of cash and cash equivalents and accounts receivable. We place our cash and cash equivalents with high credit quality financial institutions and pursuant to our investment policy, we limit the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits.  We have not experienced any losses on our deposits of cash and cash equivalents. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_85"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;4. CONTROLS AND PROCEDURES</span></div><div style="text-indent:24.75pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, with the participation of our chief executive officer (&#8220;CEO&#8221;) and chief financial officer (&#8220;CFO&#8221;) evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as of the end of the period covered by this Form 10-Q. Based on this evaluation, our CEO and CFO concluded that, as of June&#160;30, 2020, our disclosure controls and procedures are designed and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Changes in Internal Control over Financial Reporting</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no changes in our internal control over financial reporting during the quarter ended June&#160;30, 2020, which were identified in connection with management&#8217;s evaluation required by paragraph (d) of Rules 13a-15 or 15d-15 of the Exchange Act that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:24.75pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Limitations on Effectiveness of Controls and Procedures</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_88"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II. OTHER INFORMATION</span></div><div style="text-align:center;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_91"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;1. LEGAL PROCEEDINGS </span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not currently a party to any material legal proceedings.&#160;We may at times be party to ordinary routine litigation incidental to our business. When appropriate in management&#8217;s estimation, we may record reserves in our financial statements for pending legal proceedings.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_94"></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;1A. RISK FACTORS</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investing in our ordinary shares involves a high degree of risk.&#160;Our Annual Report on Form 10-K for 2019 (filed with the SEC on March&#160;3, 2020) includes a detailed discussion of our business and the risks to our business. You should carefully read that Form 10-K.&#160;You should also read and carefully consider the risks described below and the other information in this Quarterly Report on Form 10-Q.&#160;The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and/or growth prospects. In such an event, the market price of our ordinary shares could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. </span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to Our Financial Position, Our Need for Additional Capital and Our Business</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We anticipate that we will incur losses for the foreseeable future and we may never sustain profitability. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not generate the cash that is necessary to finance our operations in the foreseeable future. We incurred net losses of $77.7 million, $155.6 million, and $153.2 million for the years ended December&#160;31, 2019, 2018, and 2017, respectively. We expect to continue to incur substantial losses for the foreseeable future as we: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">support the Phase 2 PASADENA clinical trial for prasinezumab (PRX002/RG7935) being conducted by Roche and our Phase 1 clinical trial for PRX004, and possibly initiate additional clinical trials for these and other programs; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">develop and possibly commercialize our product candidates, including prasinezumab and PRX004; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">undertake nonclinical development of other product candidates and initiate clinical trials, if supported by nonclinical data; and </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">pursue our early stage research and seek to identify additional drug candidates; and </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">potentially acquire rights from third parties to drug candidates or technologies through licenses, acquisitions or other means. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We must generate significant revenue to achieve and maintain profitability. Even if we succeed in discovering, developing and commercializing one or more drug candidates, we may not be able to generate sufficient revenue and we may never be able to achieve or sustain profitability.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will require additional capital to fund our operations, and if we are unable to obtain such capital, we will be unable to successfully develop and commercialize drug candidates. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we had cash and cash equivalents of $333.9 million. Although we believe, based on our current business plans, that our existing cash and cash equivalents will be sufficient to meet our obligations for at least the next twelve months, we anticipate that we will require additional capital in the future in order to continue the research and development, and eventual commercialization, of our drug candidates. Our future capital requirements will depend on many factors that are currently unknown to us, including, without limitation: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the timing of progress, results and costs of our clinical trials, including the Phase 2 clinical trial for prasinezumab and our Phase 1 clinical trial for PRX004;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the timing, initiation, progress, results and costs of these and our other research, development and possible commercialization activities; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the results of our research, nonclinical and clinical studies; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the costs of manufacturing our drug candidates for clinical development as well as for future commercialization needs; </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">if and when appropriate, the costs of preparing for commercialization of our drug candidates;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the costs of preparing, filing, and prosecuting patent applications, and maintaining, enforcing, and defending intellectual property-related claims; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to establish research, development, commercialization and/or strategic collaborations, licensing or other arrangements; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the timing, receipt and amount of any capital investments, cost-sharing contributions or reimbursements, milestone payments or royalties that we might receive under current or potential future collaborations;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the costs to satisfy our obligations under current and potential future collaborations; and </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the timing, receipt and amount of revenues or royalties, if any, from any approved drug candidates. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have based our expectations relating to liquidity and capital resources on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development and commercialization of our current product candidates. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the pharmaceutical industry, the research and development process is lengthy and involves a high degree of risk and uncertainty. This process is conducted in various stages and, during each stage, there is substantial risk that product candidates in our research and development pipeline will experience difficulties, delays or failures. This makes it difficult to estimate the total costs to complete our clinical trials and to estimate anticipated completion dates with any degree of accuracy, which raises concerns that attempts to quantify costs and provide estimates of timing may be misleading by implying a greater degree of certainty than actually exists. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to develop and obtain regulatory approval for our product candidates we will need to raise substantial additional funds. We expect to raise any such additional funds through public or private equity or debt financings, collaborative agreements with corporate partners or other arrangements. We cannot assure that additional funds will be available when we need them on terms that are acceptable to us, or at all. General market conditions may make it very difficult for us to seek or obtain financing from the capital markets. If we raise additional funds by issuing equity securities, substantial dilution to existing shareholders would result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. We may be required to relinquish rights to our technologies or drug candidates or grant licenses on terms that are not favorable to us in order to raise additional funds through strategic alliances, joint ventures or licensing arrangements. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If adequate funds are not available on a timely basis, we may be required to: </span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">terminate or delay clinical trials or other development activities for one or more of our drug candidates; </span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delay arrangements for activities that may be necessary to commercialize our drug candidates; </span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">curtail or eliminate our drug research and development programs that are designed to identify new drug candidates; or </span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">cease operations. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, if we do not meet our payment obligations to third parties as they come due, we may be subject to litigation claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and distract management, and may have unfavorable results that could further adversely impact our financial condition. </span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The COVID-19 pandemic could have a material adverse effect on our liquidity, results of operations, financial condition or business, including our nonclinical and clinical development programs.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The outbreak of the novel strain of coronavirus SARS-CoV-2, which causes coronavirus disease (&#8220;COVID-19&#8221;), has evolved into a global pandemic. While it is not possible at this time to estimate the overall impact that COVID-19 could have on our business, the continued rapid spread of COVID-19 and the measures taken by the governments of countries and local authorities affected could disrupt and delay our ongoing or planned clinical studies, our preclinical activities, the manufacture or shipment of both drug substance and finished drug product for our product candidates for preclinical testing and clinical trials </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and materially adversely impact our liquidity, results of operations, financial condition or business, including in the event of the following:</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we experience delays or interruptions in our business operations due to our key personnel, or a significant number of our personnel, becoming infected with COVID-19 and therefore being unable to work, even remotely, for an extended period of time;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the clinical development programs pursued by us and our collaboration partners (including the development of PRX004 and prasinezumab) are delayed or interrupted, including as a result of (1) interruptions of supply to clinical study sites of drug candidate or other equipment or materials, (2) inability or unwillingness of site investigators or other study personnel to travel to study sites, dispense drug candidate, or otherwise treat or monitor study participants or follow study protocols, or conduct necessary data collection or verification, (3) inability or unwillingness of study participants to travel to clinical study sites, receive infusions, or otherwise continue to participate in the study or (4) diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we, or our collaboration partners, are delayed in or prevented from initiating new clinical studies of current or prospective  drug candidates because of (1) delays or difficulties contracting with essential third-party vendors (such as contract research organizations), (2) delays or difficulties enlisting site investigators or initiating clinical study sites, (3) delays or difficulties recruiting or enrolling study participants, or (4) delays or difficulties supplying drug candidate to clinical study sites;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">interruption or delays in the operations of the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and comparable foreign regulatory agencies which impact review, inspection, and approval timelines for any of our development programs;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the pandemic adversely affects our collaboration partners, Roche and/or Celgene (now part of Bristol-Myers Squibb (&#8220;BMS&#8221;)), in way that adversely impacts our collaborations with them;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">business development opportunities become more limited or difficult to undertake;</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our costs significantly increase to manage impacts to our business to complete our planned operations within our projected timelines; </span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in local regulations as part of a response to COVID-19 which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or discontinuation of the clinical trials altogether; </span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we experience delays in necessary interactions with local regulators, ethics committees, and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; or</span></div><div style="text-indent:-18pt;padding-left:45pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our liquidity needs are adversely impacted by the economic effects of the pandemic on financial markets. </span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any one or more of these risks, if realized, could have a material adverse effect on our liquidity, results of operations, financial condition or business, including the progress of, and timelines for, our nonclinical and clinical development programs.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the spread of COVID-19 has caused a broad impact globally, and may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the market price of our ordinary shares.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The United Kingdom&#8217;s withdrawal from the European Union could have a negative effect on global economic conditions and financial markets, European Union regulatory procedures and our business.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following a national referendum and enactment of legislation by the government of the United Kingdom, the United Kingdom formally withdrew from the European Union on January 31, 2020, and entered into a transition period during which it will continue its ongoing and complex negotiations with the European Union relating to the future trading relationship between the parties.&#160; Significant political and economic uncertainty remains about whether the terms of the relationship will differ materially from the terms before withdrawal, as well as about the possibility that a so-called &#8220;no deal&#8221; separation will occur if negotiations are not completed by the end of the transition period. These developments, or the perception that any of them could </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">occur, have had and may continue to have a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Any of these factors could depress economic activity and restrict access to capital, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our future success depends on our ability to retain key personnel and to attract, retain and motivate qualified personnel. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are highly dependent on key personnel, including Dr.&#160;Gene G. Kinney, our President and Chief Executive Officer. There can be no assurance that we will be able to retain Dr.&#160;Kinney or any of our key personnel. The loss of the services of Dr.&#160;Kinney or any other person on whom we are highly dependent might impede the achievement of our research, development and commercial objectives. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recruiting and retaining qualified scientific and other personnel are critical to our growth and future success. Competition for qualified personnel in our industry is intense. We may not be able to attract and retain these personnel on acceptable terms given that competition. Failure to recruit and retain qualified personnel could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our collaborators, prospective collaborators and suppliers may need assurances that our financial resources and stability on a stand-alone basis are sufficient to satisfy their requirements for doing or continuing to do business with us. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some of our collaborators, prospective collaborators and suppliers may need assurances that our financial resources and stability on a stand-alone basis are sufficient to satisfy their requirements for doing or continuing to do business with us. If our collaborators, prospective collaborators or suppliers are not satisfied with our financial resources and stability, it could have a material adverse effect on our ability to develop our drug candidates, enter into licenses or other agreements and on our business, financial condition or results of operations. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The agreements we entered into with Elan involve conflicts of interest and therefore may have materially disadvantageous terms to us. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We entered into certain agreements with Elan in connection with our separation from Elan, which set forth the main terms of the separation and provided a framework for our initial relationship with Elan. These agreements may have terms that are materially disadvantageous to us or are otherwise not as favorable as those that might be negotiated between unaffiliated third parties. In December 2013, Elan was acquired by Perrigo Company plc (&#8220;Perrigo&#8221;), and in February 2014 Perrigo caused Elan to sell all of its shares of Prothena in an underwritten offering. As a result of the acquisition of Elan by Perrigo and the subsequent sale of all of its shares of Prothena, Perrigo may be less willing to collaborate with us in connection with the agreements to which we and Elan are a party and other matters.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be adversely affected by earthquakes or other natural disasters.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our key facility and almost all of our operations are in the San Francisco Bay Area of Northern California, which in the past has experienced severe earthquakes. If an earthquake, other natural disaster or similar event were to occur and prevent us from using all or a significant portion of those operations or local critical infrastructure, or that otherwise disrupts our operations, it could be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We have disaster recovery and business continuity plans, but they may prove to be inadequate in the event of a natural disaster or similar event. We may incur substantial expenses if our disaster recovery and business continuity plans prove to be inadequate. We do not carry earthquake insurance. Furthermore, third parties upon which we are materially dependent upon may be vulnerable to natural disasters or similar events. &#160;Accordingly, such a natural disaster or similar event could have an adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may experience breaches or similar disruptions of our information technology systems or data.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business is increasingly dependent on critical, complex and interdependent information technology systems to support business processes as well as internal and external communications. The size and complexity of those systems make them vulnerable to breakdown, malicious intrusion and computer viruses. We have developed systems and processes that are designed to protect our information technology systems and prevent data loss and other security breaches, including systems and processes designed to reduce the impact of a security breach. However, such measures cannot provide absolute security. Any breakdown, malicious intrusion or computer virus could result in the impairment of key business processes or breach of data security, which could cause us to lose trade secrets or other intellectual property or lead to unauthorized disclosure of personal data of our employees, third parties with which we do business, clinical trial participants or others. Such an event could have an adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are subject to increasingly complex data protection laws and regulations.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to various data protection laws and regulations, which are expanding and becoming more complex. In May 2018, the EU General Data Protection Regulation (the &#8220;GDPR&#8221;) was adopted in the EU and superseded the previous EU data protection legislation.&#160;Under the GDPR, enhanced data protection requirements as well as substantial fines for breaches of personal data apply and increase our obligations and potential liabilities for the personal data that we process or control.&#160;We may be required to implement additional controls to facilitate compliance with the GDPR and other new or evolving data protection laws and regulations. Ensuring our compliance with these laws and regulations involves substantial costs, and it is possible that governmental authorities or third parties will assert that our business practices fail to comply with these laws and regulations. If our operations are found to be in violation of any of such laws and regulations, we may be subject to significant civil, criminal and administrative damages, penalties and fines, as well as reputational harm, which could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to the Discovery, Development and Regulatory Approval of Drug Candidates </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our success is largely dependent on the success of our research and development programs. Our drug candidates are in various stages of development and we may not be able to successfully discover, develop, obtain regulatory approval for or commercialize any drug candidates. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The success of our business depends substantially upon our ability to discover, develop, obtain regulatory approval for and commercialize our drug candidates successfully. Our research and development programs are prone to the significant and likely risks of failure inherent in drug development, which can result from the failure of the drug candidate to be sufficiently effective, the safety profile of the drug candidate, a clinical trial that is not sufficiently enrolled or powered or adequately designed to detect a drug effect, or other reasons. We intend to continue to invest most of our time and financial resources in our research and development programs. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is no assurance that the results of the current Phase 2 clinical trial for prasinezumab and Phase 1 clinical trial for PRX004 will support further development of these drug candidates. In addition, we currently do not, and may never, have any other drug candidates in clinical trials, and we have not identified drug candidates for many of our research programs. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Before obtaining regulatory approvals for the commercial sale of any drug candidate for a target indication, we must demonstrate with substantial evidence gathered in adequate and well-controlled clinical trials that the drug candidate is safe and effective for use for that target indication. In the U.S., this must be done to the satisfaction of the FDA; in the EU this must be done to the satisfaction of the European Medicines Agency (the &#8220;EMA&#8221;); and in other countries this must be done to the satisfaction of comparable regulatory authorities. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain, and subject to unanticipated delays. Despite our efforts, our drug candidates may not: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">offer improvement over existing treatment options; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">be proven safe and effective in clinical trials; or </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">meet applicable regulatory standards. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Positive results in nonclinical studies of a drug candidate may not be predictive of similar results in humans during clinical trials, and promising results from early clinical trials of a drug candidate may not be replicated in later clinical trials. Interim results of a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early-stage development. Accordingly, the results from completed nonclinical studies and early clinical trials for our drug candidates may not be predictive of the results we may obtain in later stage studies or trials. Our nonclinical studies or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical studies or clinical trials, or to discontinue clinical trials altogether. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, we have not marketed, distributed or sold any products. Our success will, in addition to the factors discussed above, depend on the successful commercialization of our drug candidates, which may require: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">obtaining and maintaining commercial manufacturing arrangements with third-party manufacturers; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">developing the marketing and sales capabilities, internal and/or in collaboration with pharmaceutical companies or contract sales organizations, to market and sell any approved drug; and </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">acceptance of any approved drug in the medical community and by patients and third-party payers. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of these factors are beyond our control. We do not expect any of our drug candidates to be commercially available for several years and some or all may never become commercially available. Accordingly, we may never generate revenues through the sale of products. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have entered into collaborations and may enter into additional collaborations in the future, and we might not realize the anticipated benefits of such collaborations.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research, development, commercialization and/or strategic collaborations, including those that we have with Roche and BMS, are subject to numerous risks, which include the following:</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators may have significant control or discretion in determining the efforts and resources that they will apply to a collaboration, and might not commit sufficient efforts and resources or might misapply those efforts and resources;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may have limited influence or control over the approaches to research, development and/or commercialization of products candidates in the territories in which our collaboration partners lead research, development and/or commercialization; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators might not pursue research, development and/or commercialization of collaboration product candidates or might elect not to continue or renew research, development and/or commercialization programs based on nonclinical and/or clinical trial results, changes in their strategic focus due to the acquisition of competing products, availability of funding or other factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators might delay, provide insufficient resources to, or modify or stop research or clinical development for collaboration product candidates or require a new formulation of a product candidate for clinical testing;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators could develop or acquire products outside of the collaboration that compete directly or indirectly with our product candidates or require a new formulation of a product candidate for nonclinical and/or clinical testing;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators with sales, marketing and distribution rights to one or more product candidates might not commit sufficient resources to sales, marketing and distribution or might otherwise fail to successfully commercialize those product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators might not properly maintain or defend our intellectual property rights or might use our intellectual property improperly or in a way that jeopardizes our intellectual property or exposes us to potential liability; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaboration activities might result in the collaborator having intellectual property covering our activities or product candidates, which could limit our rights or ability to research, develop and/or commercialize our product candidates;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborators might not be in compliance with laws applicable to their activities under the collaboration, which could impact the collaboration or us;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">disputes might arise between us and a collaborator that could cause a delay or termination of the collaboration or result in costly litigation that diverts management attention and resources; and</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborations might be terminated, which could result in a need for additional capital to pursue further research, development and/or commercialization of our product candidates.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, funding provided by a collaborator might not be sufficient to advance product candidates under the collaboration.  For example, although BMS (formerly Celgene) made a $100 million upfront payment to us and made a $50 million equity investment in us upon entering into the Collaboration Agreement, we might need additional funding to advance product candidates prior to when BMS decides whether to exercise its license rights to those product candidates. We also note that, on November 20, 2019, BMS acquired Celgene. BMS might take a different approach to our collaboration or determine not to continue that collaboration. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If a collaborator terminates a collaboration or a program under a collaboration, including by failing to exercise a license or other option under the collaboration, whether because we fail to meet a milestone or otherwise, any potential revenue from the collaboration would be significantly reduced or eliminated. In addition, we will likely need to either secure other funding to advance research, development and/or commercialization of the relevant product candidate or abandon that program, the development of the relevant product candidate could be significantly delayed, and our cash expenditures could increase significantly if we are to continue research, development and/or commercialization of the relevant product candidates.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any one or more of these risks, if realized, could reduce or eliminate future revenue from product candidates under our collaborations, and could have a material adverse effect on our business, financial condition, results of operations and/or growth prospects.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If clinical trials of our drug candidates are prolonged, delayed, suspended or terminated, we may be unable to commercialize our drug candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any revenue from potential product sales. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot predict whether we will encounter problems with the Phase 2 clinical trial for prasinezumab, our Phase 1 clinical trial for PRX004 or any other future clinical trials that will cause us or any regulatory authority to delay or suspend those clinical trials or delay the analysis of data derived from them. A number of events, including any of the following, could delay the completion of our ongoing or planned clinical trials and negatively impact our ability to obtain regulatory approval for, and to market and sell, a particular drug candidate: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">conditions imposed on us by the FDA, the EMA or other comparable regulatory authorities regarding the scope or design of our clinical trials; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">delays in obtaining, or our inability to obtain, required approvals from institutional review boards (&#8220;IRBs&#8221;) or other reviewing entities at clinical sites selected for participation in our clinical trials; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">insufficient supply or deficient quality of our drug candidates or other materials necessary to conduct our clinical trials; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">delays in obtaining regulatory authority agreement for the conduct of our clinical trials; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">lower than anticipated enrollment and/or retention rate of subjects in our clinical trials, which can be impacted by a number of factors, including size of patient population, design of trial protocol, trial length, eligibility criteria, perceived risks and benefits of the drug candidate, patient proximity to trial sites, patient referral practices of physicians, availability of other treatments for the relevant disease and competition from other clinical trials; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">slower than expected rates of events in trials with a composite primary endpoint that is event-based;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">serious and unexpected drug-related side effects experienced by subjects in clinical trials; or </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">failure of our third-party contractors and collaborators to meet their contractual obligations to us or otherwise meet their development or other objectives in a timely manner.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are dependent upon Roche with respect to further development of prasinezumab. Under the terms of our collaboration with Roche, Roche is responsible for that further development, including the conduct of the ongoing Phase 2 clinical trial and any future clinical trial of that drug candidate. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clinical trials may also be delayed or terminated as a result of ambiguous or negative data or results. In addition, a clinical trial may be delayed, suspended or terminated by us, the FDA, the EMA or other comparable regulatory authorities, the IRBs at the sites where the IRBs are overseeing a trial, or the safety oversight committee overseeing the clinical trial at issue due to a number of factors, including: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">inspection of the clinical trial operations or trial sites by the FDA, the EMA or other regulatory authorities resulting in the imposition of a clinical hold on or imposition of additional conditions for the conduct of the trial; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">interpretation of data by the FDA, the EMA or other regulatory authorities; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">requirement by the FDA, the EMA or other regulatory authorities to perform additional studies; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">failure to achieve primary or secondary endpoints or other failure to demonstrate efficacy or adequate safety; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">unforeseen safety issues; or </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">lack of adequate funding to continue the clinical trial. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to regulatory authorities and IRBs for reexamination, which may impact the cost, timing or successful completion of a clinical trial. </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not know whether our clinical trials will be conducted as planned, will need to be restructured or will be completed on schedule, if at all. Delays in our clinical trials will result in increased development costs for our drug candidates. In addition, if we experience delays in the completion of, or if we terminate, any of our clinical trials, the commercial prospects for our drug candidates may be delayed or harmed and our ability to generate product revenues will be delayed or jeopardized. Furthermore, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a drug candidate.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The regulatory approval processes of the FDA, the EMA and other comparable regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The time required to obtain approval by the FDA, the EMA and other comparable regulatory authorities is inherently unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a drug candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any drug candidate and it is possible that none of our existing drug candidates or any drug candidates we may seek to develop in the future will ever obtain regulatory approval. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our drug candidates could fail to receive regulatory approval for many reasons, including the following: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the FDA, the EMA or comparable regulatory authorities may disagree with the design, implementation or conduct of our clinical trials; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable regulatory authorities that a drug candidate is safe and effective for its proposed indication; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA or comparable regulatory authorities for approval; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may be unable to demonstrate that a drug candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the FDA, the EMA or comparable regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the data collected from clinical trials of our drug candidates may not be sufficient to support the submission of a Biologic License Application (&#8220;BLA&#8221;) to the FDA, a Marketing Authorization Application (&#8220;MAA&#8221;) to the EMA or similar applications to comparable regulatory authorities; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the FDA, the EMA or comparable regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; or </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the approval policies or regulations of the FDA, the EMA or comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our drug candidates, which would significantly harm our business, results of operations and prospects. In addition, even if we were to obtain approval, regulatory authorities may approve any of our drug candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a drug candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that drug candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our drug candidates.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if our drug candidates receive regulatory approval in one country or jurisdiction, we may never receive approval or commercialize our products in other countries or jurisdictions. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to market drug candidates in a particular country or jurisdiction, we must establish and comply with numerous and varying regulatory requirements of that country or jurisdiction, including with respect to safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain, for example, FDA approval in the U.S. or EMA approval in the EU. The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the U.S. and EMA approval in the EU as well as other risks. Regulatory approval in one country or </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">jurisdiction does not ensure regulatory approval in another country or jurisdiction, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in one country or jurisdiction or any delay or setback in obtaining such approval would impair our ability to develop other markets for that drug candidate. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Both before and after marketing approval, our drug candidates are subject to ongoing regulatory requirements and continued regulatory review, and if we fail to comply with these continuing requirements, we could be subject to a variety of sanctions and the sale of any approved products could be suspended. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Both before and after regulatory approval to market a particular drug candidate, adverse event reporting, manufacturing, labeling, packaging, storage, distribution, advertising, promotion, record keeping and reporting related to the product are subject to extensive, ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, as well as continued compliance with current good manufacturing practice (&#8220;cGMP&#8221;) requirements and current good clinical practice (&#8220;cGCP&#8221;) requirements for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our drug candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the drug candidate. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or not previously observed in clinical trials, or with our third-party manufacturers or manufacturing processes, or failure to comply with the regulatory requirements of the FDA, the EMA and other comparable regulatory authorities could subject us to administrative or judicially imposed sanctions, including: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">restrictions on the marketing of our products or their manufacturing processes; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">warning letters; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">civil or criminal penalties; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">fines; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">injunctions; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">product seizures or detentions; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">import or export bans; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">voluntary or mandatory product recalls and related publicity requirements; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">suspension or withdrawal of regulatory approvals; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">total or partial suspension of production; and </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">refusal to approve pending applications for marketing approval of new products or supplements to approved applications. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA&#8217;s, the EMA&#8217;s or other comparable regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If side effects are identified during the time our drug candidates are in development or after they are approved and on the market, we may choose to or be required to perform lengthy additional clinical trials, discontinue development of the affected drug candidate, change the labeling of any such products, or withdraw any such products from the market, any of which would hinder or preclude our ability to generate revenues. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or other comparable regulatory authorities. Drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Even if any of our drug candidates receives marketing approval, as greater numbers of patients use a drug following its approval, an increase in the incidence or severity of side effects or the incidence of </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">other post-approval problems that were not seen or anticipated during pre-approval clinical trials could result in a number of potentially significant negative consequences, including: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">regulatory authorities may withdraw their approval of the product; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">regulatory authorities may require the addition of labeling statements, such as contraindications, warnings or precautions, or impose additional safety monitoring or reporting requirements; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we may be required to change the way the product is administered, conduct additional clinical trials; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">we could be sued and held liable for harm caused to patients; and </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our reputation may suffer. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of these events could substantially increase the costs and expenses of developing, commercializing and marketing any such drug candidates or could harm or prevent sales of any approved products.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We deal with hazardous materials and must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some of our research and development activities involve the controlled storage, use, and disposal of hazardous materials. We are subject to U.S. federal, state, local and other countries&#8217; and jurisdictions&#8217; laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. Although we believe that our safety procedures for the handling and disposing of these materials comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In the event of an accident, state or federal authorities may curtail our use of these materials, and we could be liable for any civil damages that result, which may exceed our financial resources and may seriously harm our business. Because we believe that our laboratory and materials handling policies and practices sufficiently mitigate the likelihood of materials liability or third-party claims, we currently carry no insurance covering such claims. An accident could damage, or force us to shut down, our operations.</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to the Commercialization of Our Drug Candidates </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if any of our drug candidates receives regulatory approval, if such approved product does not achieve broad market acceptance, the revenues that we generate from sales of the product will be limited. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if any drug candidates we may develop or acquire in the future obtain regulatory approval, they may not gain broad market acceptance among physicians, healthcare payers, patients and the medical community. The degree of market acceptance for any approved drug candidate will depend on a number of factors, including: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the indication and label for the product and the timing of introduction of competitive products; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">demonstration of clinical safety and efficacy compared to other products; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">prevalence, frequency and severity of adverse side effects; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">availability of coverage and adequate reimbursement from managed care plans and other third-party payers; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">convenience and ease of administration;&#160;</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">cost-effectiveness; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">other potential advantages of alternative treatment methods; and </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the effectiveness of marketing and distribution support of the product. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consequently, even if we discover, develop and commercialize a product, the product may fail to achieve broad market acceptance and we may not be able to generate significant revenue from the product.</span></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The success of prasinezumab in the United States is dependent upon the strength and performance of our collaboration with Roche. If we fail to maintain our existing collaboration with Roche, such termination would likely have a material adverse effect on our ability to develop and commercialize prasinezumab and our business. Furthermore, if we opt out of profit and loss sharing with Roche, our revenues from prasinezumab will be reduced. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The success of sales of prasinezumab in the U.S. will be dependent on the ability of Roche to successfully develop in collaboration with us, and launch and commercialize prasinezumab, if approved by the FDA, pursuant to the License Agreement we entered into in December 2013. Our collaboration with Roche is complex, particularly with respect to future U.S. commercialization of prasinezumab, with respect to financial provisions, allocations of responsibilities, cost estimates and the respective rights of the parties in decision making. Accordingly, significant aspects of the development and commercialization of prasinezumab require Roche to execute its responsibilities under the arrangement, or require Roche&#8217;s agreement or approval, prior to implementation, which could cause significant delays that may materially impact the potential success of prasinezumab in the U.S.&#160;In addition, Roche may under some circumstances independently develop products that compete with prasinezumab, or Roche may decide to not commit sufficient resources to the development, commercialization, marketing and distribution of prasinezumab. If we are not able to collaborate effectively with Roche on plans and efforts to develop and commercialize prasinezumab, our business could be materially adversely affected. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, the terms of the License Agreement provide that Roche has the ability to terminate such arrangement for any reason after the first anniversary of the License Agreement at any time upon 90 days&#8217; notice (if prior to first commercial sale) or 180 days&#8217; notice (if after first commercial sale). For example, Roche may determine that the outcomes of clinical trials have made prasinezumab a less attractive commercial product and terminate our collaboration. If the License Agreement is terminated, our business and our ability to generate revenue from sales of prasinezumab could be substantially harmed as we will be required to develop, commercialize and build our own sales and marketing organization or enter into another strategic collaboration in order to develop and commercialize prasinezumab in the U.S. Such efforts may not be successful and, even if successful, would require substantial time and resources to carry out. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The manner in which Roche launches prasinezumab, including the timing of launch and potential pricing, will have a significant impact on the ultimate success of prasinezumab in the U.S, and the success of the overall commercial arrangement with Roche. If launch of commercial sales of prasinezumab in the U.S. by Roche is delayed or prevented, our revenue will suffer and our stock price may decline. Further, if launch and resulting sales by Roche are not deemed successful, our business would be harmed and our stock price may decline. Any lesser effort by Roche in its prasinezumab sales and marketing efforts may result in lower revenue and thus lower profits with respect to the U.S. The outcome of Roche&#8217;s commercialization efforts in the U.S. could also have a negative effect on investors&#8217; perception of potential sales of prasinezumab outside of the U.S., which could also cause a decline in our stock price. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, pursuant to the License Agreement, we are responsible for 30% of all development and commercialization costs for prasinezumab for the treatment of Parkinson&#8217;s disease in the U.S., and for any future Licensed Products and/or indications that we opt to co-develop, in each case unless we elect to opt out of profit and loss sharing. If we elect to opt out of profit and loss sharing, we will instead receive sales milestones and royalties, and our revenue, if any, from prasinezumab will be reduced.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our right to co-develop prasinezumab and other Licensed Products under the License Agreement will terminate if we commence certain studies for a competitive product that treats Parkinson&#8217;s disease or other indications that we opted to co-develop. In addition, our right to co-promote prasinezumab and other Licensed Products will terminate if we commence a Phase 3 study for a competitive product that treats Parkinson&#8217;s disease.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;Moreover, under the terms of the License Agreement, we rely on Roche to provide us estimates of their costs, revenue and revenue adjustments and royalties, which estimates we use in preparing our quarterly and annual financial reports.&#160;If the underlying assumptions on which Roche&#8217;s estimates were based prove to be incorrect, actual results or revised estimates supplied by Roche that are materially different from the original estimates could require us to adjust the estimates included in our reported financial results.&#160;If material, these adjustments could require us to restate previously reported financial results, which could have a negative effect on our stock price.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to receive any significant revenue from prasinezumab will be dependent on Roche&#8217;s efforts and our participation in profit and loss sharing, and may result in lower levels of income than if we marketed or developed our product candidates entirely on our own. Roche may not fulfill its obligations or carry out marketing activities for prasinezumab as diligently as we would like. We could also become involved in disputes with Roche, which could lead to delays in or termination of development or commercialization activities and time-consuming and expensive litigation or arbitration. If Roche terminates or breaches the License Agreement, or otherwise decides not to complete its obligations in a timely manner, the chances of successfully developing, commercializing or marketing prasinezumab would be materially and adversely affected. </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Outside of the United States, we are solely dependent on the efforts and commitments of Roche, either directly or through third parties, to further develop and commercialize prasinezumab. If Roche&#8217;s efforts are unsuccessful, our ability to generate future product sales from prasinezumab outside the United States would be significantly reduced. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under our License Agreement, outside of the U.S., Roche has responsibility for developing and commercializing prasinezumab and any future Licensed Products targeting </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#945;-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">synuclein. As a consequence, any progress and commercial success outside of the U.S. is dependent solely on Roche&#8217;s efforts and commitment to the program. For example, Roche may delay, reduce or terminate development efforts relating to prasinezumab outside of the U.S., or under some circumstances independently develop products that compete with prasinezumab, or decide not to commit sufficient resources to the commercialization, marketing and distribution of prasinezumab. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event that Roche does not diligently develop and commercialize prasinezumab, the License Agreement provides us the right to terminate the License Agreement in connection with a material breach uncured for 90 days after notice thereof. However, our ability to enforce the provisions of the License Agreement so as to obtain meaningful recourse within a reasonable timeframe is uncertain. Further, any decision to pursue available remedies including termination would impact the potential success of prasinezumab, including inside the U.S., and we may choose not to terminate as we may not be able to find another partner and any new collaboration likely will not provide comparable financial terms to those in our arrangement with Roche. In the event of our termination, this may require us to develop and commercialize prasinezumab on our own, which is likely to result in significant additional expense and delay. Significant changes in Roche&#8217;s business strategy, resource commitment and the willingness or ability of Roche to complete its obligations under our arrangement could materially affect the potential success of the product. Furthermore, if Roche does not successfully develop and commercialize prasinezumab outside of the U.S., our potential to generate future revenue outside of the U.S. would be significantly reduced. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell approved products, we may be unable to generate product revenue. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not currently have a fully-scaled organization for the sales, marketing and distribution of pharmaceutical products. In order to market any products that may be approved by the FDA, the EMA or other comparable regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into the License Agreement with Roche for the development of prasinezumab and may develop our own sales force and marketing infrastructure to co-promote prasinezumab in the U.S. for the treatment of Parkinson&#8217;s disease and any future Licensed Products approved for Parkinson&#8217;s disease in the U.S. If we exercise our co-promotion option and are unable to develop our own sales force and marketing infrastructure to effectively commercialize prasinezumab or other Licensed Products, our ability to generate additional revenue from potential sales of prasinezumab or such products in the U.S. may be harmed. In addition, our right to co-promote prasinezumab and other Licensed Products will terminate if we commence a Phase 3 study for a competitive product that treats Parkinson&#8217;s disease. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For any other products that may be approved, if we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If government and third-party payers fail to provide coverage and adequate reimbursement rates for any of our drug candidates that receive regulatory approval, our revenue and prospects for profitability will be harmed. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In both U.S. and non-U.S. markets, our sales of any future products will depend in part upon the availability of reimbursement from third-party payers. Such third-party payers include government health programs such as Medicare, managed care providers, private health insurers, and other organizations. There is significant uncertainty related to the third-party coverage and reimbursement of newly approved drugs. Coverage and reimbursement may not be available for any drug that we or our collaborators commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Third-party payers often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Third-party payers are also increasingly attempting to contain healthcare costs by demanding price discounts or rebates limiting both coverage and the amounts that they will pay for new drugs, and, as a result, they may not cover or provide adequate payment for our drug candidates. We might need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future products to such payers&#8217; satisfaction. Such studies might require us to commit a significant amount of management time and financial and other resources. Our future products might not ultimately be considered cost-effective. Adequate third-party reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we or our collaborators may not be able to successfully commercialize any product candidates for which marketing approval is obtained. </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some countries, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we or our collaborators might obtain marketing approval for a drug in a particular country, but then be subject to price regulations that delay commercial launch of the drug, possibly for lengthy time periods, and negatively impact our ability to generate revenue from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain marketing approval. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">U.S. and other governments continue to propose and pass legislation designed to reduce the cost of healthcare. In the U.S., we expect that there will continue to be federal and state proposals to implement similar governmental controls. In addition, recent changes in the Medicare program and increasing emphasis on managed care in the U.S. will continue to put pressure on pharmaceutical product pricing. For example, in 2010, the U.S. Patient Protection and Affordable Care Act, as amended by the U.S. Health Care and Education Reconciliation Act (collectively, the &#8220;Healthcare Reform Law&#8221;), was enacted. The Healthcare Reform Law substantially changed the way healthcare is financed by both governmental and private insurers and significantly affects the pharmaceutical industry. Among the provisions of the Healthcare Reform Law of importance to the pharmaceutical industry are the following: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">an increase in the minimum rebates a manufacturer must pay under the U.S. Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">expansion of healthcare fraud and abuse laws, including the U.S. False Claims Act and the U.S. Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">a new Medicare Part D coverage gap discount program, under which manufacturers must agree to offer 50 percent point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">a licensure framework for follow-on biologic products; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">new requirements under the federal Open Payments program and its implementing regulations; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, other legislative changes have been proposed and adopted since the Healthcare Reform Law was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year, which went into effect in 2013 and will stay in effect through 2024 unless additional congressional action is taken. In 2013, the U.S. American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and, accordingly, our financial operations. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that the Healthcare Reform Law, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">approved drug. Legislation and regulations affecting the pricing of pharmaceuticals might change before our drug candidates are approved for marketing. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;There can be no assurance that our drug candidates, if they are approved for sale in the U.S. or in other countries, will be considered medically reasonable and necessary for a specific indication, that they will be considered cost-effective by third-party payers, that coverage or an adequate level of reimbursement will be available, or that third-party payers&#8217; reimbursement policies will not adversely affect our ability to sell our drug candidates profitably if they are approved for sale. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The markets for our drug candidates are subject to intense competition. If we are unable to compete effectively, our drug candidates may be rendered noncompetitive or obsolete. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The research, development and commercialization of new drugs is highly competitive. We will face competition with respect to all drug candidates we may develop or commercialize in the future from pharmaceutical and biotechnology companies worldwide. The key factors affecting the success of any approved product will be its indication, label, efficacy, safety profile, drug interactions, method of administration, pricing, coverage, reimbursement and level of promotional activity relative to those of competing drugs. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are pursuing the development of novel drugs that target the same indications we are targeting with our research and development program. We face, and expect to continue to face, intense and increasing competition as new products enter the market and advanced technologies become available. Many of our competitors have: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">significantly greater financial, technical and human resources than we have and may be better equipped to discover, develop, manufacture and commercialize drug candidates; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">more extensive experience in nonclinical testing and clinical trials, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">drug candidates that have been approved or are in late-stage clinical development; and/or </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">collaborative arrangements in our target markets with leading companies and research institutions. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Competitive products may render our research and development program obsolete or noncompetitive before we can recover the expenses of developing and commercializing our drug candidates. Furthermore, the development of new treatment methods and/or the widespread adoption or increased utilization of any vaccine or development of other products or treatments for the diseases we are targeting could render any of our drug candidates noncompetitive, obsolete or uneconomical. If we successfully develop and obtain approval for a drug candidate, we will face competition based on the safety and effectiveness of the approved product, the timing of its entry into the market in relation to competitive products in development, the availability and cost of supply, marketing and sales capabilities, coverage, reimbursement, price, patent position and other factors. Even if we successfully develop drug candidates but those drug candidates do not achieve and maintain market acceptance, our business will not be successful. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our drug candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our current drug candidates are regulated by the FDA as biologic products and we intend to seek approval for these products pursuant to the BLA pathway. The U.S. Biologics Price Competition and Innovation Act of 2009 (the &#8220;BPCIA&#8221;) created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biologic products. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that any of our drug candidates approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our drug candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are subject to healthcare and other laws and regulations, including anti-bribery, anti-kickback, fraud and abuse, false claims, physician payment transparency and health information privacy and security laws and regulations, which could expose us to criminal, civil and/or administrative sanctions and penalties, exclusion from governmental healthcare programs or reimbursements, contractual damages and reputational harm. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operations and activities are directly, or indirectly through our service providers and collaborators, subject to numerous healthcare and other laws and regulations, including, without limitation, those relating to anti-bribery, anti-kickback, fraud and abuse, false claims, physician payment transparency and health information privacy and security, in the U.S., the EU and other countries and jurisdictions in which we conduct our business. These laws include: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the U.S. Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">U.S. federal and state false claims laws, including the False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the U.S. Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which  imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and making false statements in connection with the delivery of or payment for healthcare benefits, items or services, and under the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) imposes obligations, including mandatory contractual terms, on certain types of individuals and entities with respect to safeguarding the privacy, security and transmission of individually identifiable health information and places restrictions on the use of such information for marketing communications; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the U.S. Physician Payment Sunshine Act, which requires applicable manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;) information related to &#8220;payments or other transfers of value&#8221; made to physicians and teaching hospitals and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">laws and regulations that apply to sales or marketing arrangements; apply to healthcare items or services reimbursed by non-governmental third-party payers, including private insurers; require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines; that restrict payments that may be made to healthcare providers; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">similar and other laws and regulations in the U.S. (federal, state and local), in the EU (including member countries) and other countries and jurisdictions.  </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, the Healthcare Reform Law, among other things, amended the intent requirements of the U.S. Anti-Kickback Statute and the criminal statutes governing healthcare fraud. A person or entity can now be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. In addition, the Healthcare Reform Law provided that the government may assert that a claim including items or services resulting from a violation of the U.S. Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the U.S. False Claims Act. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ensuring our compliance with applicable healthcare and other laws and regulations involves substantial costs, and it is possible that governmental authorities or third parties will assert that our business practices fail to comply with these laws and regulations. If our operations are found to be in violation of any of such laws and regulations, we may be subject to significant civil, criminal and administrative damages, penalties and fines, as well exclusion from participation in government healthcare programs, curtailment or restructuring of our operations and reputational harm, any of which could have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If a successful product liability or clinical trial claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, we could incur substantial liability. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The use of our drug candidates in clinical trials and the sale of any products for which we obtain marketing approval will expose us to the risk of product liability and clinical trial liability claims. Product liability claims might be brought against us by consumers, healthcare providers or others selling or otherwise coming into contact with our products. Clinical trial liability claims may be filed against us for damages suffered by clinical trial subjects or their families. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">decreased demand for any approved drug candidates; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">impairment of our business reputation; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">withdrawal of clinical trial participants; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">costs of related litigation; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">distraction of management&#8217;s attention; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">substantial monetary awards to patients or other claimants; and </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">loss of revenues; and the inability to successfully commercialize any approved drug candidates. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have clinical trial liability insurance coverage for all of our clinical trials. However, our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for any of our drug candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain this product liability insurance on commercially reasonable terms. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our ordinary share price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</span></div><div style="text-indent:24.75pt;text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Dependence on Third Parties </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet established deadlines for the completion of any such clinical trials. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have the ability to independently conduct clinical trials for our drug candidates, and we rely on third parties, such as consultants, contract research organizations, medical institutions and clinical investigators, to assist us with these activities. Our reliance on these third parties for clinical development activities results in reduced control over these activities. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. Although we have and will enter into agreements with these third parties, we will be responsible for confirming that our clinical trials are conducted in accordance with their general investigational plans and protocols. Moreover, the FDA, the EMA and other comparable regulatory authorities require us to comply with regulations and standards, commonly referred to as cGCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected. Our reliance on third parties does not relieve us of these responsibilities and requirements. If we or any of our third-party contractors fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or other comparable regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with cGCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;To date, we believe our consultants, contract research organizations and other third parties with which we are working have performed well; however, if these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe that there are a number of other third-party contractors we could engage to continue these activities, we may not be able to enter into arrangements with alternative third-party contractors or to do so on commercially reasonable terms, which may result in a delay </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of our planned clinical trials. Accordingly, we may be delayed in obtaining regulatory approvals for our drug candidates and may be delayed in our efforts to successfully develop our drug candidates. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our third-party contractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and nonclinical programs. If third-party contractors do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results of operations and the commercial prospects for our drug candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we do not establish additional strategic collaborations, we may have to alter our research, development and/or commercialization plans. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research, development and potential commercialization of our drug candidates will require substantial additional cash to fund expenses. Our strategy includes potentially collaborating with additional leading pharmaceutical and biotechnology companies to assist us in furthering research, development and/or potential commercialization of some of our drug candidates, in some or all geographies. It may be difficult to enter into one or more of such collaborations in the future. We face significant competition in seeking appropriate collaborators and these collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on acceptable terms, or at all, in which case we may have to curtail the development of a particular drug candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring our drug candidates to market and generate product revenue. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have no manufacturing capacity and depend on third-party manufacturers to supply us with nonclinical and clinical trial supplies of all of our drug candidates, and we will depend on third-party manufacturers to supply us with any drug products for commercial sale if we obtain marketing approval from the FDA, the EMA or any other comparable regulatory authority for any of our drug candidates. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of our drug candidates. We instead contract with and rely on third parties to manufacture, package, label, store, test and distribute nonclinical and clinical supplies of our drug candidates, and we plan to continue to do so for the foreseeable future. We also rely on third-party consultants to assist us with managing these third-parties and with our manufacturing strategy. If any of these third-parties fail to perform these activities for us, nonclinical or clinical development of our drug candidates could be delayed, which could have an adverse effect on our business, financial condition, results of operations and growth prospects. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the FDA, the EMA or any other comparable regulatory authority approves any of our drug candidates for commercial sale, we expect to continue to rely, at least initially, on third-parties to manufacture, package, label, store, test and distribute commercial supplies of such approved drug product. Significant scale-up of manufacturing may require additional comparability validation studies, which the FDA, the EMA or other comparable regulatory authorities must review and approve. Our third-party manufacturers might not be able to successfully establish such comparability or increase their manufacturing capacity in a timely or economic manner, or at all. If our third-party manufacturers are unable to successfully establish comparability or increase their manufacturing capacity for any drug product, and we are unable to timely establish our own manufacturing capabilities, the commercial launch of that drug product could be delayed or there could be a shortage in supply, which could have an adverse effect on our business, financial condition, results of operations and growth prospects. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our third-party manufacturers&#8217; facilities could be damaged by fire, power interruption, information system failure, natural disaster or other similar event, which could cause a delay or shortage in supplies of our drug candidates, which could have an adverse effect on our business, financial condition, results of operations and growth prospects. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our drug candidates require, and any future drug product will require, precise, high quality manufacturing, packaging, labeling, storage and testing that meet stringent cGMP, other regulatory requirements and other standards. Our third-party manufacturers are subject to ongoing periodic and unannounced inspections by the FDA, the EMA and other comparable regulatory authorities to ensure compliance with these cGMPs, other regulatory requirements and other standards. We do not have control over, and are dependent upon, our third-party manufacturers&#8217; compliance with these cGMPs, regulations and standards. Any failure by a third-party manufacturer to comply with these cGMPs, regulations or standards or that compromises </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the safety of any of our drug candidates or any drug product could cause a delay or suspension of production of nonclinical or clinical supplies of our drug candidates or commercial supplies of drug products, cause a delay or suspension of nonclinical or clinical development, product approval and commercialization of our drug candidates or drug products, result in seizure or recall of clinical or commercial supplies, result in fines and civil penalties, result in liability for any patient injury or death or otherwise increase our costs, any of which could have an adverse effect on our business, financial condition, results of operations and growth prospects. If a third-party manufacturer cannot or fails to perform its contractual commitments, does not have sufficient capacity to meet our nonclinical, clinical or eventual commercial requirements or fails to meet cGMPs, regulations or other standards, we may be required to replace it or qualify an additional third-party manufacturer. Although we believe there are a number of potential alternative manufacturers, the number of manufacturers with the necessary manufacturing and regulatory expertise and facilities to manufacture biologics like our antibodies is limited. In addition, we could incur significant additional costs and delays in identifying and qualifying any new third-party manufacturer, due to the technology transfer to such new manufacturer and because the FDA, the EMA and other comparable regulatory authorities must approve any new manufacturer prior to manufacturing our drug candidates. Such approval would require successful technology transfer, comparability and other testing and compliance inspections. Transferring manufacturing to a new manufacturer could therefore interrupt supply, delay our clinical trials and any commercial launch and/or increase our costs for our drug candidates, any of which could have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Roche, with whom we are collaborating on development of prasinezumab, manufactured clinical supplies for the Phase 2 clinical trial for prasinezumab and is expected to do so for any subsequent clinical trials of prasinezumab. We are dependent on Roche to continue to manufacture these clinical supplies. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rentschler Biopharma SE (&#8220;Rentschler&#8221;) is our third-party manufacturer of clinical supplies of our drug candidate PRX004. We are dependent on Rentschler to manufacture these clinical supplies in order to initiate any other clinical trial for PRX004.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on third-party suppliers for the raw materials required for the production of our drug candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, quality and delivery schedules. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our products until a new source of supply, if any, could be identified and qualified. Although we believe there are currently several other suppliers of these raw materials, we may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our drug candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Intellectual Property </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to adequately protect or enforce the intellectual property relating to our drug candidates our ability to successfully commercialize our drug candidates will be harmed. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success depends in part on our ability to obtain patent protection both in the U.S. and in other countries for our drug candidates. Our ability to protect our drug candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents. Due to evolving legal standards relating to the patentability, validity and enforceability of patents covering pharmaceutical inventions and the scope of claims made under these patents, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Accordingly, rights under any issued patents may not provide us with sufficient protection for our drug candidates or provide sufficient protection to afford us a commercial advantage against competitive products or processes. Additionally, our ability to obtain patent protection for our drug candidates also depends on our collaborators, partners, contractors, and employees involved in the generation of intellectual property to carry out their contractual duties, including those to assign relevant intellectual property rights developed on our behalf to us.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us or our affiliates. Even if patents have issued or will issue, we cannot guarantee that the claims of these patents are or will be valid or enforceable or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us. Patent applications in the U.S. are maintained in confidence for up to 18 months after their filing. In some cases, however, patent applications remain confidential in the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) for the entire time prior to issuance as a U.S. patent. Similarly, publication of discoveries in the scientific or patent literature often lags </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">behind actual discoveries. Consequently, we cannot be certain that we or our licensors or co-owners were the first to invent, or the first to file patent applications on, our drug candidates or their use as drugs. In the event that a third party has also filed a U.S. patent application relating to our drug candidates or a similar invention, we may have to participate in interference or derivation proceedings declared by the USPTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial and it is possible that our efforts would be unsuccessful, resulting in a loss of our U.S. patent position. Furthermore, we may not have identified all U.S. and non-U.S. patents or published applications that affect our business either by blocking our ability to commercialize our drugs or by covering similar technologies. Composition-of-matter patents on the biological or chemical active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our patent applications covering composition-of-matter of our product candidates will be considered patentable by the USPTO and courts in the U.S. or by the patent offices and courts in other countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be found invalid or unenforceable if challenged. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2011 patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In 2011, the U.S. Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation, and switch the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO subsequently developed new regulations and procedures to govern administration of the Leahy-Smith Act, but many of the substantive changes to patent law associated with the Leahy-Smith Act continue to be the subject of litigation and USPTO rule changes. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review, or other patent office proceedings or litigation, in the U.S. or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as in the U.S. and many companies have encountered significant difficulties in protecting and defending such rights in other jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property rights in other jurisdictions, our business prospects could be substantially harmed. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We license patent rights from third-party owners. Such licenses may be subject to early termination if we fail to comply with our obligations in our licenses with third parties, which could result in the loss of rights or technology that are material to our business. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to licenses that give us rights to third-party intellectual property that is necessary or useful for our business, and we may enter into additional licenses in the future. Under these license agreements we are obligated to pay the licensor fees, which may include annual license fees, milestone payments, royalties, a percentage of revenues associated with the licensed technology and a percentage of sublicensing revenue. In addition, under certain of such agreements, we are required to diligently pursue the development of products using the licensed technology. If we fail to comply with these obligations and fail to cure our breach within a specified period of time, the licensor may have the right to terminate the applicable license, in which event we could lose valuable rights and technology that are material to our business. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the licensor retains control of prosecution of the patents and patent applications licensed to us, we may have limited or no control over the manner in which the licensor chooses to prosecute or maintain its patents and patent applications and have limited or no right to continue to prosecute any patents or patent applications that the licensor elects to abandon. </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Litigation regarding patents, patent applications and other proprietary rights may be expensive and time consuming. If we are involved in such litigation, it could cause delays in bringing drug candidates to market and harm our ability to operate. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Although we are not currently aware of any litigation or other proceedings or third-party claims of intellectual property infringement related to our drug candidates, the pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights. Other parties may hold or obtain patents in the future and allege that the use of our technologies infringes these patent claims or that we are employing their proprietary technology without authorization. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, third parties may challenge or infringe upon our existing or future patents. Proceedings involving our patents or patent applications or those of others could result in adverse decisions regarding: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the patentability of our inventions relating to our drug candidates; and/or </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the enforceability, validity or scope of protection offered by our patents relating to our drug candidates. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">incur substantial monetary damages; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">encounter significant delays in bringing our drug candidates to market; and/or </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">be precluded from participating in the manufacture, use or sale of our drug candidates or methods of treatment requiring licenses. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to adequately prevent disclosure of trade secrets and other proprietary information. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable; however, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our employees were previously employed at universities, Elan or Elan subsidiaries, or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Ordinary Shares</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The market price of our ordinary shares may fluctuate widely. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ordinary shares commenced trading on The Nasdaq Global Market on December&#160;21, 2012 and currently trade on The Nasdaq Global Select Market. We cannot predict the prices at which our ordinary shares may trade. The market price of our ordinary shares may fluctuate widely, depending upon many factors, some of which may be beyond our control, including: </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our ability to obtain financing as needed; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">progress in and results from our ongoing or future nonclinical research and clinical trials; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our collaborations with third parties, including with Roche and BMS; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">failure or delays in advancing our nonclinical drug candidates or other drug candidates we may develop in the future into clinical trials; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">results of clinical trials conducted by others, including on drugs that would compete with our drug candidates; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">issues in manufacturing our drug candidates; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">regulatory developments or enforcement in the U.S. and other countries; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">developments or disputes concerning patents or other proprietary rights; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">introduction of technological innovations or new commercial products by our competitors; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">changes in estimates or recommendations by securities analysts, if any, who cover our company; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">public concern over our drug candidates; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">litigation; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">future sales of our ordinary shares by us or by existing shareholders; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">general market conditions; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">changes in the structure of healthcare payment systems; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">failure of any of our drug candidates, if approved, to achieve commercial success; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">economic and other external factors or other disasters or crises; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">period-to-period fluctuations in our financial results; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">overall fluctuations in U.S. equity markets; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">our quarterly or annual results, or those of other companies in our industry; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">announcements by us or our competitors of significant acquisitions or dispositions; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">the operating and ordinary share price performance of other comparable companies; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">investor perception of our company and the drug development industry; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">natural or environmental disasters that investors believe may affect us; </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">changes in tax laws or regulations applicable to our business or the interpretations of those tax laws and regulations by taxing authorities; or </span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt;">fluctuations in the budgets of federal, state and local governmental entities around the world. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These and other external factors may cause the market price and demand for our ordinary shares to fluctuate substantially, which may limit or prevent investors from readily selling their ordinary shares and may otherwise negatively affect the liquidity of our ordinary shares. In particular, stock markets in general have experienced volatility that has often been unrelated to the </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">operating performance of a particular company. These broad market fluctuations may adversely affect the trading price of our ordinary shares. Some companies that experienced volatility in the trading price of their stock have been the subject of securities class action litigation.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Your percentage ownership in Prothena may be diluted in the future. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As with any publicly traded company, your percentage ownership in us may be diluted in the future because of equity issuances for acquisitions, capital raising transactions or otherwise. We may need to raise additional capital in the future. If we are able to raise additional capital, we may issue equity or convertible debt instruments, which may severely dilute your ownership interest in us. In addition, we intend to continue to grant option awards to our directors, officers and employees, which would dilute your ownership stake in us.  As of June&#160;30, 2020, the number of ordinary shares available for issuance pursuant to outstanding and future equity awards under our equity plan was 10,074,384.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to maintain effective internal controls, our business could be adversely affected. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to the reporting and other obligations under the U.S. Securities Exchange Act of 1934, as amended, including the requirements of Section&#160;404 of the U.S. Sarbanes-Oxley Act, which require annual management assessments of the effectiveness of our internal control over financial reporting. In addition, under Section 404(b) of the U.S. Sarbanes-Oxley Act, if we are either an &#8220;accelerated filer&#8221; or &#8220;large accelerated filer,&#8221; our independent registered public accounting firm must attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with accounting principles generally accepted in the U.S. During the course of our review and testing of our internal controls, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our consolidated financial statements may be materially misstated. We, or our independent registered public accounting firm (if required), may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We cannot provide assurance that a material weakness will not occur in the future, or that we will be able to conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section&#160;404 and the related rules and regulations of the SEC when required. A material weakness in internal control over financial reporting is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim consolidated financial statements will not be prevented or detected on a timely basis by the company&#8217;s internal controls. If we cannot in the future favorably assess, or our independent registered public accounting firm (if required), is unable to provide an unqualified attestation report on, the effectiveness of our internal controls over financial reporting, investor confidence in the reliability of our financial reports may be adversely affected, which could have a material adverse effect on our share price. In addition, any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Select Market or other adverse consequences that would have an adverse effect on our business, financial position and results of operations.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we were treated as a passive foreign investment company for U.S. federal income tax purposes, it could result in adverse U.S. federal income tax consequences to United States holders of our ordinary shares</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Significant potential adverse U.S. federal income tax implications generally apply to U.S. investors owning shares of a passive foreign investment company (&#8220;PFIC&#8221;), directly or indirectly. In general, we would be a PFIC for a taxable year if either (i) 75% or more of our income constitutes passive income (the &#8220;income test&#8221;), or (ii) 50% or more of our assets produce passive income (the &#8220;asset test&#8221;). Changes in the composition of our active or passive income, passive assets or fair market value may cause us to become a PFIC. A separate determination must be made each taxable year as to whether we are a PFIC (after the close of each taxable year). </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not believe we were a PFIC for U.S. federal income tax purposes for our taxable year- ended December 31, 2019, or any prior year.  However, the application of the PFIC rules is subject to uncertainties in a number of respects, and we cannot </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">assure that the U.S. Internal Revenue Service (the &#8220;IRS&#8221;) will not take a contrary position. We also cannot assure that we will not be a PFIC for U.S. federal income tax purposes for any future taxable year.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to successfully maintain our tax rates, which could adversely affect our business and financial condition, results of operations and growth prospects.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are incorporated in Ireland and maintain subsidiaries or offices in Ireland and the U.S. We are able to achieve a low average tax rate through the performance of certain functions and ownership of certain assets in tax-efficient jurisdictions, together with intra-group service agreements. However, changes in tax laws in any of these jurisdictions could adversely affect our ability to do so in the future. Taxing authorities, such as the IRS, actively audit and otherwise challenge these types of arrangements, and have done so in our industry. We are subject to reviews and audits by the IRS and other taxing authorities from time to time, and the IRS or other taxing authority may challenge our structure and inter-group arrangements. Responding to or defending against challenges from taxing authorities could be expensive and time consuming, and could divert management&#8217;s time and focus away from operating our business. We cannot predict whether and when taxing authorities will conduct an audit, challenge our tax structure or the cost involved in responding to any such audit or challenge. If we are unsuccessful, we may be required to pay taxes for prior periods, interest, fines or penalties, and may be obligated to pay increased taxes in the future, all of which could have an adverse effect on our business, financial condition, results of operations or growth prospects.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Future changes to the tax laws relating to multinational corporations could adversely affect us.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Under current law, we are treated as a foreign corporation for U.S. federal tax purposes. However, changes to the U.S. Internal Revenue Code, U.S. Treasury Regulations or other IRS guidance thereunder could adversely affect our status as a foreign corporation or otherwise affect our effective tax rate. For example, in 2017 the United States enacted tax reform that contained significant changes to corporate taxation, including a provision that would require capitalization and amortization of research and development costs in tax years beginning after December 31, 2021. In addition, the U.S. Congress, the IRS, the Organization for Economic Co-operation and Development and other governments and agencies in jurisdictions where we do business have recently focused on issues related to the taxation of multinational corporations, and specifically in the area of &#8220;base erosion and profit shifting,&#8221; where payments are made between affiliates from a jurisdiction with high tax rates to a jurisdiction with lower tax rates. As a result, the tax laws in the U.S. and other countries in which we do business could change on a prospective or retroactive basis, and any such changes could have an adverse effect on our business, financial condition, results of operations or growth prospects.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Irish law differs from the laws in effect in the United States and may afford less protection to holders of our ordinary shares. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It may not be possible to enforce court judgments obtained in the U.S. against us in Ireland based on the civil liability provisions of the U.S. federal or state securities laws. In addition, there is uncertainty as to whether the courts of Ireland would recognize or enforce judgments of U.S. courts obtained against us or our directors or officers based on the civil liabilities provisions of the U.S. federal or state securities laws or hear actions against us or those persons based on those laws. We have been advised that the U.S. currently does not have a treaty with Ireland providing for the reciprocal recognition and enforcement of judgments in civil and commercial matters. Therefore, a final judgment for the payment of money rendered by any U.S. federal or state court based on civil liability, whether or not based solely on federal or state securities laws, would not automatically be enforceable in Ireland. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As an Irish incorporated company, we are governed by the Irish Companies Act 2014 (the &#8220;Companies Act&#8221;), which differs in some material respects from laws generally applicable to U.S. corporations and shareholders, including, among others, differences relating to interested director and officer transactions and shareholder lawsuits. Likewise, the duties of directors and officers of an Irish company generally are owed to the company only. Shareholders of Irish companies generally do not have a personal right of action against directors or officers of the company and may exercise such rights of action on behalf of the company only in limited circumstances. Accordingly, holders of our ordinary shares may have more difficulty protecting their interests than would holders of securities of a corporation incorporated in a jurisdiction of the U.S. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Irish law differs from the laws in effect in the United States with respect to defending unwanted takeover proposals and may give our board of directors less ability to control negotiations with hostile offerors. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to the Irish Takeover Panel Act, 1997, Takeover Rules, 2013. Under those Irish Takeover Rules, our Board is not permitted to take any action that might frustrate an offer for our ordinary shares once our Board has received an approach that may lead to an offer or has reason to believe that such an offer is or may be imminent, subject to certain exceptions. Potentially frustrating actions such as (i)&#160;the issue of ordinary shares, options or convertible securities, (ii)&#160;material acquisitions or disposals, (iii)&#160;entering into contracts other than in the ordinary course of business, or (iv)&#160;any action, other than seeking alternative offers, which may result in frustration of an offer, are prohibited during the course of an offer or at any earlier time during which our Board has reason to believe an offer is or may be imminent. These provisions may give our Board </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">less ability to control negotiations with hostile offerors and protect the interests of holders of ordinary shares than would be the case for a corporation incorporated in a jurisdiction of the U.S.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Irish law requires that our shareholders renew every five years the authority of our Board of Directors to issue shares and to do so for cash without applying the statutory pre-emption right, and if our shareholders do not renew these authorizations by May 17, 2022 (or any renewal is subject to limitations), our ability to raise additional capital to fund our operations would be limited.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As an Irish incorporated company, we are governed by the Companies Act.&#160;The Companies Act requires that every five years our shareholders renew the separate authorities of our Board to (a) allot and issue shares, and (b) opt out of the statutory pre-emption right that otherwise applies to share issuances for cash (which pre-emption right would require that shares issued for cash be offered to our existing shareholders on a pro rata basis before the shares may be issued to new shareholders). At our shareholders' annual general meeting held on May 17, 2017, our shareholders authorized our Board to issue ordinary shares up to the amount of our authorized share capital, and to opt out of the statutory pre-emption right for such issuances. Under Irish law, these authorizations will expire on May 17, 2022, five years after our shareholders last renewed these authorizations. Irish law requires that our shareholders renew the authority for our Board to issue ordinary shares by a resolution approved by not less than 50% of the votes cast at a general meeting of our shareholders. Irish law requires that our shareholders renew the authority of our Board to opt out of the statutory pre-emption right in share issuances for cash by a resolution approved by not less than 75% of the votes cast at a general meeting of our shareholders. If these authorizations are not renewed before May 17, 2022, or are renewed with limitations, our Board would be limited in its ability to issue shares, which would limit our ability to raise additional capital to fund our operations, including the research, development and potential commercialization of our product candidates.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Transfers of our ordinary shares may be subject to Irish stamp duty. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Irish stamp duty may be payable in respect of transfers of our ordinary shares (currently at the rate of 1% of the price paid or the market value of the shares acquired, if greater). </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Irish Stamp Duties Consolidation Act, 1999 (the &#8220;Stamp Duties Act&#8221;), a transfer of our ordinary shares from a seller who holds shares through DTC to a buyer who holds the acquired shares through DTC should not be subject to Irish stamp duty. Shareholders may also transfer their shares into or out of DTC without giving rise to Irish stamp duty provided that there is no change in the beneficial ownership of such shares and the transfer into or out of  DTC is not effected in contemplation of a subsequent sale of such shares to a third party; in order to benefit from this exemption from Irish stamp duty, the seller must confirm to us that there is no change in the ultimate beneficial ownership of the shares as a result of the transfer and there is no agreement for the sale of the shares by the beneficial owner to a third party being contemplated.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A transfer of our ordinary shares (i)&#160;by a seller who holds shares outside of DTC to any buyer, or (ii)&#160;by a seller who holds the shares through DTC to a buyer who holds the acquired shares outside of DTC, may be subject to Irish stamp duty. Payment of any Irish stamp duty is generally a legal obligation of the transferee.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any Irish stamp duty payable on transfers of our ordinary shares could adversely affect the price of those shares. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We do not anticipate paying cash dividends, and accordingly, shareholders must rely on ordinary share appreciation for any return on their investment. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We anticipate losing money for the foreseeable future and, even if we do ever turn a profit, we intend to retain future earnings, if any, for the development, operation and expansion of our business. Thus, we do not anticipate declaring or paying any cash dividends for the foreseeable future. Therefore, the success of an investment in our ordinary shares will depend upon appreciation in their value and in order to receive any income or realize a return on your investment, you will need to sell your Prothena ordinary shares. There can be no assurance that our ordinary shares will maintain their price or appreciate in value. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Dividends paid by us may be subject to Irish dividend withholding tax. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we do not currently anticipate paying cash dividends, if we were to do so in the future, a dividend withholding tax (currently at a rate of 25%) may arise. A number of exemptions from dividend withholding tax exist such that shareholders resident in the U.S. and shareholders resident in other countries that have entered into a double taxation treaty with Ireland may be entitled to exemptions from dividend withholding tax subject to the completion of certain dividend withholding tax declaration forms. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shareholders entitled to an exemption from Irish dividend withholding tax on any dividends received from us will not be subject to Irish income tax in respect of those dividends, unless they have some connection with Ireland other than their </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">shareholding (for example, they are resident in Ireland). Shareholders who receive dividends subject to Irish dividend withholding tax will generally have no further liability to Irish income tax on those dividends. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prothena ordinary shares received by means of a gift or inheritance could be subject to Irish capital acquisitions tax. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Irish capital acquisitions tax (&#8220;CAT&#8221;) could apply to a gift or inheritance of our ordinary shares irrespective of the place of residence, ordinary residence or domicile of the parties. This is because our ordinary shares will be regarded as property situated in Ireland. The person who receives the gift or inheritance has primary liability for CAT. Gifts and inheritances passing between spouses are exempt from CAT. It is recommended that each shareholder consult his or her own tax advisor as to the tax consequences of holding our ordinary shares or receiving dividends from us.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_97"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_100"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_103"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not Applicable.</span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_106"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;5. OTHER INFORMATION</span></div><div style="text-indent:24.75pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_109"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;6. EXHIBITS</span></div><div><span><br/></span></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_112"></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> EXHIBIT INDEX</span></div><div style="margin-bottom:3pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:7.852%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.441%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.588%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.503%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Previously Filed</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit<br/>No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">File No.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filing Date</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed Herewith</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1#</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1559053/000155905320000015/prta20208-kex101xfirstamen.htm">First Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-35676</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/22/2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2#</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="prta2020q210-qxex102fi.htm">First Amendment to the </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="prta2020q210-qxex102fi.htm">Prothena Corporation plc 2020 Employment Inducement Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3#</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="prta2020q210-qxex10320.htm">Form of Option Award Agreement </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration: underline;-sec-extract:exhibit;" href="prta2020q210-qxex10320.htm">under the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (used beginning March 2, 2020) </a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="prta2020q210-qxex311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="prta2020q210-qxex312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="prta2020q210-qxex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:-31.5pt;padding-left:31.5pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_______________</span></div><div style="text-indent:-31.5pt;padding-left:31.5pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">#&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Indicates management contract or compensatory plan or arrangement.</span></div><div style="text-indent:-31.5pt;padding-left:31.5pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Exhibit 32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.</span></div><div style="text-indent:-31.5pt;padding-left:31.5pt;text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><div id="id78a5ecf693745eb81aedf6e125c6b7c_115"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:5.771%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.401%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.463%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.900%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.465%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated: </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 6, 2020</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Prothena Corporation plc</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Registrant)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-bottom:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Gene G. Kinney</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gene G. Kinney</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-bottom:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Tran B. Nguyen</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tran B. Nguyen</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Operating Officer and Chief Financial Officer</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>prta2020q210-qxex102fi.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ic8e659b6be1940bea4b97f3d0cde8d9f_31"></div><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Exhibit 10.2</font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">FIRST AMENDMENT TO THE</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">PROTHENA CORPORATION PLC</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">This First Amendment (this &#8220;First Amendment&#8221;) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (&#8220;2020 EIIP&#8221;), was made and adopted by the Board of Directors (&#8220;Board&#8221;) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the &#8220;Company&#8221;), on April 1, 2020 (the &#8220;Amendment Date&#8221;).</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">RECITALS</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, the Company maintains the 2020 EIIP&#59; and</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, the Board believes it is in the best interests of the Company and its shareholders to amend the 2020 EIIP to increase the number of ordinary shares authorized for issuance under the 2020 EIIP.</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">NOW, THEREFORE, BE IT RESOLVED</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">, that the 2020 EIIP is hereby amended as follows, effective as of the Amendment Date&#58;</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">AMENDMENT</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8pt;">Section 2.28 of the 2020 EIIP is hereby amended and restated in its entirety as follows&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8220;2.28 &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;">Overall Share Limit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8221; means 360,000 Shares.&#8221;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8pt;">This First Amendment shall be and hereby is incorporated into and forms a part of the 2020 EIIP, and except as expressly provided herein, all terms and conditions of the 2020 EIIP shall remain in full force and effect.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>prta2020q210-qxex10320.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i18ae043ca2fa484eb04eec48fc428d95_31"></div><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.3</font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">PROTHENA CORPORATION PLC</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Option Award Agreement &#8211; Cover Sheet</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Prothena Corporation plc, an Irish public limited company (the &#8220;Company&#8221;), hereby grants an Option to acquire its Shares to the individual named below.  The terms and conditions of the Option are set forth in this cover sheet, in the attached Option Award Agreement and in the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (the &#8220;Plan&#8221;).  All capitalized terms used but not defined in this cover sheet and the attached Option Award Agreement will have the meanings ascribed to such terms in the Plan.    </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:33.634%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.689%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:59.477%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Granted to&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#91; &#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Grant Date&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#91; &#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Shares subject to the Option&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#91; &#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Exercise Price per Share&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">$&#91; &#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Expiration Date&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#91; &#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Vesting Start Date&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#91; &#93;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Vesting Schedule&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#91; &#93;</font></div></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">By signing this cover sheet, you agree to all of the terms and conditions described in the attachment and in the Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Signature&#58; _____________________                         Date&#58; _______________ </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">            &#91; &#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Company&#58; ___________________________ </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">           </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">     &#91;Authorized Officer&#93;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">PROTHENA CORPORATION PLC</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Option Award Agreement</font></div><div style="text-align:center;"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:22.519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:70.597%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Inducement Award</font></div></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">You acknowledge that the Plan and any Awards granted thereunder are intended to conform with the requirements of the rules promulgated by The Nasdaq Stock Market, including without limitation, Nasdaq Listing Rule 5635(c)(4). Accordingly, you acknowledge that you have not been previously employed in any capacity by the Company or any Subsidiary, or if previously employed, are commencing employment following a bona-fide period of non-employment with the Company and its Subsidiaries, and that the grant of this Option is an inducement material to your agreement to enter into employment with the Company or a Subsidiary.</font></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Nonqualified Stock Option</font></div></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">This Option is intended to be a Nonqualified Stock Option and not an Incentive Stock Option (ISO), and will be interpreted accordingly.</font></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Vesting</font></div></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Your right to exercise this Option vests in increments over the &#91; &#93;-year (&#91; &#93;-year) period, commencing on the Vesting Start Date, as shown on the cover sheet. The percentage of the total number of Shares for which this Option will vest and become exercisable is as follows&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#91; &#93;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">The vesting will be cumulative and will not exceed 100% of the Shares subject to the Option. If the vesting results in fractional Shares, the number of Shares that vests on the relevant vesting date will be rounded down to the nearest whole number.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Except as otherwise provided in the Plan, the entire Option vests and becomes exercisable if (i) within twenty-four (24) months following a Change in Control, your employment with the Company or one of its Subsidiaries is terminated for any reason other than Cause (as defined below) or you resign for Good Reason (as defined below)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;"> &#91;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">(such a resignation or termination being hereinafter referred to as an &#8220;Involuntary Termination&#8221;)&#93;&#59; (ii) you die while you are still an employee of the Company or a Subsidiary, as applicable&#59; or (iii) your service as an employee of the Company or a Subsidiary, as applicable, terminates because of your Total and Permanent </font></div></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:22.519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:70.597%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Disability (as defined below). &#91;In addition, except as otherwise provided above or in the Plan, the number of Shares subject to the Option that would have vested and become exercisable had you remained employed for the &#91; &#93;-month (&#91; &#93;) period following an Involuntary Termination shall become vested and exercisable as of the date of your Involuntary Termination.&#93;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">As used herein, and except as otherwise defined in an employment agreement between you and the Company or one of its Subsidiaries to the extent applicable, &#8220;Cause&#8221; shall mean any of the following&#58; (a) your willful breach, habitual neglect, or poor performance of your job duties and responsibilities, as determined by the Company in its sole discretion&#59; (b) your conviction (or the entry of a guilty plea or plea of</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;"> nolo contendr</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">e) of any crime, excluding minor traffic offenses&#59; (c) your commission of an act of dishonesty or breach of fiduciary duty&#59; (d) your commission of a material violation of any of the personnel policies of the Company or a Subsidiary, as applicable, including but not limited to, violations of the Company&#8217;s confidentiality or stock trading policies or its policies against any form of harassment&#59; or (e) any action or omission by you, which, as reasonably determined by the Company, is contrary to the business interest, reputation or goodwill of the Company or a Subsidiary.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">As used herein, and except as otherwise defined in an employment agreement between you and the Company or one of its Subsidiaries to the extent applicable, &#8220;Good Reason&#8221; means (a) a material diminution in your authority, duties or responsibilities or a material diminution in your total base compensation (in each case, as determined by the Company in its sole discretion), or (b) that your primary job site is relocated and your new location increases your commute between home and work by at least thirty (30) miles (however, this does not apply to field-based sales representatives or similar field-based positions) or in the Company&#8217;s reasonable opinion, the new location requires that you move your home to a new location at least thirty (30) miles away from your home immediately prior to the change. </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">In order to receive the benefits of a resignation for &#8220;Good Reason&#8221;, you must provide your employer with written notice within ninety (90) days after the occurrence of such event and the employer shall then have thirty (30) days to cure such event. If the employer does not cure the event giving rise to Good Reason, your employment will terminate on the first day immediately following the end of the thirty (30) day cure period.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">Except as provided above or as otherwise provided in a written employment agreement between you and the Company or one of its Subsidiaries, all Shares will cease vesting as of the date your service with the Company or a Subsidiary, as applicable, has terminated for any reasons.  </font></div><div style="text-align:justify;"><font><br></font></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:22.519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:70.597%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Term</font></div></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Your Option will expire in any event at the close of business at the Company&#8217;s registered office on the &#91; &#93; anniversary of the Grant Date, as shown on the cover sheet. (It will expire earlier if your service with the Company or a Subsidiary, as applicable, terminates &#8211; as described below.)</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Death</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">If you die prior to expiration of this Option, then your right to purchase vested Shares under this Option will expire at the close of business at the Company&#8217;s registered office on the date that is twelve (12) months after the date of death (or on the &#91; &#93; anniversary of the Grant Date, if earlier). During that twelve-month (12) period, your estate or heirs may exercise this Option.</font></div></td></tr><tr><td colspan="6" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Disability</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">If your service as an employee of the Company or a Subsidiary, as applicable, terminates because of your Total and Permanent Disability, then your right to purchase vested Shares under this Option will expire at the close of business at the Company&#8217;s registered office on the date that is twelve (12) months after your termination date (or on the &#91; &#93; anniversary of the Grant Date, if earlier). &#8220;Total and Permanent Disability&#8221; means that you are unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted, or can be expected to last, for a continuous period of not less than one year.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">&#91;Involuntary Termination&#93;</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#91;If your service as an employee of the Company or a Subsidiary, as applicable, terminates by reason of an Involuntary Termination, then your right to purchase vested Shares under this Option will expire at the close of business at the Company&#8217;s registered office on the date that is &#91; &#93; (&#91; &#93;) months after your termination date (or on the &#91; &#93; anniversary of the Grant Date, if earlier).&#93;</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Other Termination</font></div></td><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">If your service as an employee of the Company or a Subsidiary, as applicable, terminates for any reason other than those set forth in the immediately preceding two paragraphs, then your right to purchase vested Shares under this Option will expire at the close of business at the Company&#8217;s registered office on the 90th day after your termination date (or on the &#91; &#93; anniversary of the Grant Date, if earlier).</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">The Company determines when your service with the Company or a Subsidiary, as applicable, terminates for this purpose.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:22.519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:70.597%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Leaves of Absence</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">For purposes of this Option, your service does not terminate when you go on a military leave, a sick leave or another </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;">bona fide</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> leave of absence, if the leave was approved by the Company in writing. But your service will be treated as terminating ninety (90) days after you went on leave, unless your right to return to active work is guaranteed by law or by a contract. Your service terminates, in any event, when the approved leave ends, unless you immediately return to active work.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">The Company determines which leaves count for this purpose.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Restrictions on Exercise</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">The Company will not permit you to exercise this Option if the issuance of Shares at that time would violate any law, regulation or Company policy.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Notice of Exercise</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">When you wish to exercise this Option, you must complete and execute such documents, if any, and complete such processes, that the Company or a securities broker approved by the Company may require to accomplish the Option exercise (&#8220;Notice of Exercise&#8221;).</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">If someone else wants to exercise this Option after your death, that person must prove to the Company&#8217;s satisfaction that he or she is entitled to do so.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Form of Payment</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">When you submit your Notice of Exercise, you must include payment of the exercise price for the Shares you are purchasing. Payment may be made in one (or a combination of both) of the following forms&#58;</font></div><div style="text-align:justify;"><font><br></font></div></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Your personal check, a cashier&#8217;s check or a money order.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Irrevocable directions to a securities broker approved by the Company to sell your Shares subject to the Option and to deliver all or a portion of the sale proceeds to the Company in payment of the exercise price. (The balance of the sale proceeds, if any, less withholding taxes, will be delivered to you.) The directions must be given by signing forms, if any, provided by the Company or the securities broker.</font></div></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">With the consent of the Administrator, payment may also be made by any other method set forth in Section 6.5 of the Plan.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Taxes</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">You will not be allowed to exercise this Option unless you make acceptable arrangements to pay any taxes that may be due as a result of the Option exercise.</font></div></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:22.519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:70.597%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Restrictions on Resale</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">By signing this Agreement, you agree not to sell any Shares received upon exercise of the Option at a time when applicable laws, regulations or Company policies prohibit a sale.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Transfer of Option</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Prior to your death, only you may exercise this Option. You cannot transfer or assign this Option. For instance, you may not sell this Option or use it as security for a loan. If you attempt to do any of these things, this Option will immediately become invalid. You may, however, dispose of this Option in your will.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Regardless of any marital property settlement agreement, the Company or a securities broker, as applicable, is not obligated to honor a Notice of Exercise from your former spouse, nor is the Company or the securities broker obligated to recognize your former spouse&#8217;s interest in your Option in any other way.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Retention Rights</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Neither your Option nor this Agreement gives you the right to be retained by the Company or any Subsidiary in any capacity. The Company and its Subsidiaries reserve the right to terminate your service at any time, with or without Cause.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Shareholder Rights</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">You, or your estate or heirs, have no rights as a shareholder of the Company with respect to any Shares subject to the Option until a proper Notice of Exercise has been submitted, the exercise price has been tendered and you, or your estate or heirs, become a holder of such Shares. No adjustments are made for dividends or other rights if the applicable record date occurs before a proper Notice of Exercise has been submitted and the exercise price has been tendered, except as described in the Plan.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Adjustments</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">In the event of a stock split, a stock dividend or a similar change in Company stock, the number of Shares covered by this Option and the exercise price per Share may be adjusted pursuant to the Plan. In the event where the Company is a party to a merger, this Option will be handled in accordance with the Plan.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Electronic Communications</font></div><div><font><br></font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">You agree to contract electronically regarding your participation in the Plan and to the receipt of electronic notifications, documents, payments or other communications from the Company in connection with the Plan, to the normal electronic mail address used by you for the purposes of your employment or such other address as may be from time to time notified for that purpose by you to the Company.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:22.519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.242%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:70.597%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Severability</font></div><div><font><br></font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">All the terms and provisions of this Agreement are distinct and severable, and if any term or provision is held unenforceable, illegal or void in whole or in part by any court, regulatory authority or other competent authority it shall to that extent be deemed not to form part of this Agreement, and the enforceability, legality and validity of the remainder of this Agreement will not be affected&#59; if any invalid, unenforceable or illegal provision would be valid, enforceable or legal if some part of it were deleted, the provision shall apply with whatever modification is necessary to make it valid, enforceable and legal.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Applicable Law</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">This Agreement will be interpreted and enforced under the laws of Ireland.</font></div></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">The Plan and Other Agreements</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">The text of the Plan and any amendments thereto are incorporated in this Agreement by reference.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">This Agreement and the Plan constitute the entire understanding between you and the Company regarding this Option. Any prior agreements, commitments or negotiations concerning this Option are superseded</font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;">By signing the cover sheet of this Agreement, you agree to all of the terms and conditions described above and in the Plan and evidence your acceptance of the powers of the Committee of the Board of Directors of the Company that administers the Plan.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>prta2020q210-qxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ia4c12944599c429cbbe3d808926b3f0f_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO RULE 13a-14(a)&#47;15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Gene G. Kinney, certify that&#58;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Prothena Corporation plc&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:40.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:40.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:40.5pt;padding-right:4.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:40.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:40.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;margin-top:9pt;"><font><br></font></div><div style="text-align:justify;margin-top:9pt;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:3.449%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:29.075%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:61.476%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Gene G. Kinney</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gene G. Kinney</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>prta2020q210-qxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i67f9054125f04aa3a41fe9db2a4b6fb4_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO RULE 13a-14(a)&#47;15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Tran B. Nguyen, certify that&#58;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Prothena Corporation plc&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:40.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:40.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:40.5pt;padding-right:4.5pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:40.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:40.5pt;padding-right:4.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;margin-top:9pt;"><font><br></font></div><div style="text-align:justify;margin-top:9pt;"><font><br></font></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.417%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:28.893%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:61.690%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Tran B. Nguyen</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tran B. Nguyen</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>prta2020q210-qxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i04cbb48600c2400aaec140c833efece7_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION 906</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Gene G. Kinney, President and Chief Executive Officer of Prothena Corporation plc (the &#8220;Company&#8221;) and Tran B. Nguyen, Chief Financial Officer of the Company, each hereby certify that, to the best of his knowledge&#58;</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June&#160;30, 2020, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act&#59; and</font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify;margin-top:9pt;"><font><br></font></div><div style="text-align:justify;margin-top:9pt;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:3.449%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:29.075%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:61.476%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Gene G. Kinney</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gene G. Kinney</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:30pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:30pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:30pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Tran B. Nguyen</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tran B. Nguyen</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section&#160;1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>prta-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:38da442c-e5f6-4ed8-bb27-93106113c3da,g:af883291-30ed-4afd-a355-adc261f9a88c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:prta="http://www.prothena.com/20200630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.prothena.com/20200630">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prta-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prta-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prta-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prta-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.prothena.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.prothena.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.prothena.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAdditionalInformationDetail" roleURI="http://www.prothena.com/role/OrganizationAdditionalInformationDetail">
        <link:definition>2402401 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.prothena.com/role/FairValueMeasurements">
        <link:definition>2106103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetail" roleURI="http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>2407403 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItems" roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItems">
        <link:definition>2108104 - Disclosure - Composition of Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItemsTables" roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsTables">
        <link:definition>2309301 - Disclosure - Composition of Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail" roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail">
        <link:definition>2410404 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItemsAdditionalInformationDetail" roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsAdditionalInformationDetail">
        <link:definition>2411405 - Disclosure - Composition of Certain Balance Sheet Items - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail" roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail">
        <link:definition>2412406 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerOrdinaryShare" roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShare">
        <link:definition>2113105 - Disclosure - Net Loss Per Ordinary Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerOrdinaryShareTables" roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareTables">
        <link:definition>2314302 - Disclosure - Net Loss Per Ordinary Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail" roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail">
        <link:definition>2415407 - Disclosure - Net Loss Per Ordinary Share - Calculation of Basic and Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail" roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail">
        <link:definition>2416408 - Disclosure - Net Loss Per Ordinary Share - Ordinary Shares Equivalent Not Included in Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.prothena.com/role/CommitmentandContingencies">
        <link:definition>2117106 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.prothena.com/role/CommitmentsandContingenciesTables">
        <link:definition>2318303 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLeaseNarrativeDetails" roleURI="http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails">
        <link:definition>2419409 - Disclosure - Commitment and Contingencies - Lease Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDublinLeaseDetails" roleURI="http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails">
        <link:definition>2420410 - Disclosure - Commitment and Contingencies - Dublin Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails" roleURI="http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails">
        <link:definition>2421411 - Disclosure - Commitment and Contingencies - Schedule of Lease Liability Maturity Analysis and Future Minimum Rentals to be Received - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails" roleURI="http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails">
        <link:definition>2422412 - Disclosure - Commitment and Contingencies Commitment and Contingencies - Commitment Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesContractualObligationsDetails" roleURI="http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails">
        <link:definition>2423413 - Disclosure - Commitment and Contingencies - Contractual Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreements" roleURI="http://www.prothena.com/role/SignificantAgreements">
        <link:definition>2124107 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsRocheLicenseAgreementDetails" roleURI="http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails">
        <link:definition>2425414 - Disclosure - Significant Agreements - Roche License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAgreementsCelgeneCollaborationAgreementDetails" roleURI="http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails">
        <link:definition>2426415 - Disclosure - Significant Agreements - Celgene Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.prothena.com/role/ShareholdersEquity">
        <link:definition>2127108 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.prothena.com/role/ShareholdersEquityDetails">
        <link:definition>2428416 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.prothena.com/role/ShareBasedCompensation">
        <link:definition>2129109 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.prothena.com/role/ShareBasedCompensationTables">
        <link:definition>2330304 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetail" roleURI="http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail">
        <link:definition>2431417 - Disclosure - Share-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail" roleURI="http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail">
        <link:definition>2432418 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationFairValueofOptionsGrantedDetail" roleURI="http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail">
        <link:definition>2433419 - Disclosure - Share-Based Compensation - Fair Value of Options Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail" roleURI="http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail">
        <link:definition>2434420 - Disclosure - Share-based Compensation - Share-based Compensation Plan - Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.prothena.com/role/IncomeTaxes">
        <link:definition>2135110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2436421 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="prta_DevelopmentServicesAdditional" abstract="false" name="DevelopmentServicesAdditional" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_OrdinaryShareMember" abstract="true" name="OrdinaryShareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram" abstract="false" name="CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_BuildtosuitLeaseTermofContract" abstract="false" name="BuildtosuitLeaseTermofContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prta_DeferredSharesValue" abstract="false" name="DeferredSharesValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_CelgeneMember" abstract="true" name="CelgeneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_MilestoneAchievementClinicalMilestone" abstract="false" name="MilestoneAchievementClinicalMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_LicenseAgreementMilestonePaymentsPaymentTerm" abstract="false" name="LicenseAgreementMilestonePaymentsPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prta_CompositionofCertainBalanceSheetItemsAbstract" abstract="true" name="CompositionofCertainBalanceSheetItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="prta_PurchaseandContractualObligationDueinFifthYear" abstract="false" name="PurchaseandContractualObligationDueinFifthYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_PurchaseandContractualObligationTotal" abstract="false" name="PurchaseandContractualObligationTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_SignificantAgreementsTextBlock" abstract="false" name="SignificantAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="prta_PurchaseandContractualObligationDueinSecondYear" abstract="false" name="PurchaseandContractualObligationDueinSecondYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones" abstract="false" name="LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_LicenseAgreementTable" abstract="true" name="LicenseAgreementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram" abstract="false" name="CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_SubleaserentalsAnnualBaseRentInitialAmount" abstract="false" name="SubleaserentalsAnnualBaseRentInitialAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_ASC605AllocatedConsiderationtoDeliverables" abstract="false" name="ASC605AllocatedConsiderationtoDeliverables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_CollaborativeAgreementAbstract" abstract="true" name="CollaborativeAgreementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="prta_PurchaseandContractualObligationDueinThirdYear" abstract="false" name="PurchaseandContractualObligationDueinThirdYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_A2020EmploymentInducementIncentivePlanMember" abstract="true" name="A2020EmploymentInducementIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" abstract="false" name="SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_SupplyServicesMember" abstract="true" name="SupplyServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities" abstract="false" name="ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_PurchaseandContractualObligationRemainderofFiscalYear" abstract="false" name="PurchaseandContractualObligationRemainderofFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental" abstract="false" name="OperatingLeasesSubleaseRentalsAreaofSubleaseRental" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones" abstract="false" name="LicenseAgreementPotentialAlternativeCommercialSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_LicenseAgreementDevelopmentServicesPaymentTerm" abstract="false" name="LicenseAgreementDevelopmentServicesPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" abstract="false" name="LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="prta_PotentialWithholdingTaxRate" abstract="false" name="PotentialWithholdingTaxRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="prta_OperatingLeasesImprovementAllowance" abstract="false" name="OperatingLeasesImprovementAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_AccruedResearchAndDevelopmentCurrent" abstract="false" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_INDandDevelopmentServicesMember" abstract="true" name="INDandDevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_LicensingAgreementCostAllocationPercentage" abstract="false" name="LicensingAgreementCostAllocationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="prta_CollaborationAgreementExerciseFeeperProgram" abstract="false" name="CollaborationAgreementExerciseFeeperProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_LesseeOperatingLeaseLiabilityNominalPayments" abstract="false" name="LesseeOperatingLeaseLiabilityNominalPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_DevelopmentCostsReimbursementMember" abstract="true" name="DevelopmentCostsReimbursementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary" abstract="false" name="LineofCreditFacilityFaceAmountReductiononFifthAnniversary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_InitialTransactionPrice" abstract="false" name="InitialTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_DeferredSharesShareIssued" abstract="false" name="DeferredSharesShareIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="prta_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_DublinIrelandMember" abstract="true" name="DublinIrelandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="prta_CollaborationRevenueLicenseUpfrontPayment" abstract="false" name="CollaborationRevenueLicenseUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_DeferredSharesParValue" abstract="false" name="DeferredSharesParValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction" abstract="false" name="ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_LicenseAgreementsMember" abstract="true" name="LicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_PurchaseandContractualObligationDueAfterFifthYear" abstract="false" name="PurchaseandContractualObligationDueAfterFifthYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_CollaborationAgreementUpfrontPayment" abstract="false" name="CollaborationAgreementUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction" abstract="false" name="ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_Amortizationofrightofuseasset" abstract="false" name="Amortizationofrightofuseasset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_IncreaseDecreaseinOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseinOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_CollaborationAgreementTermofAgreement" abstract="false" name="CollaborationAgreementTermofAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prta_AmendedAndRestated2018LongTermIncentivePlanMember" abstract="true" name="AmendedAndRestated2018LongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord" abstract="false" name="OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="prta_CollaborationRevenue" abstract="false" name="CollaborationRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_AllocatedConsiderationtoPerformanceObligations" abstract="false" name="AllocatedConsiderationtoPerformanceObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_CollaborationProgramGlobalRightsMember" abstract="true" name="CollaborationProgramGlobalRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_SaleofStockPremiumReceivedonTransaction" abstract="false" name="SaleofStockPremiumReceivedonTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones" abstract="false" name="LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_PurchaseandContractualObligationDueinFourthYear" abstract="false" name="PurchaseandContractualObligationDueinFourthYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_A2012LongTermIncentivePlanMember" abstract="true" name="A2012LongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_CollaborationAgreementUpfrontPaymentPaymentTerm" abstract="false" name="CollaborationAgreementUpfrontPaymentPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prta_ResearchReimbursementMember" abstract="true" name="ResearchReimbursementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_DeferredSharesSharesAuthorized" abstract="false" name="DeferredSharesSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="prta_ReductionofBuildtosuitLeaseObligation" abstract="false" name="ReductionofBuildtosuitLeaseObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed" abstract="false" name="CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="prta_MilestonePaymentReceivedClinicalMilestone" abstract="false" name="MilestonePaymentReceivedClinicalMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_CollaborationProgramUSRightsMember" abstract="true" name="CollaborationProgramUSRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_OperatingLeaseArea" abstract="false" name="OperatingLeaseArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease" abstract="false" name="OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="prta_LicenseAgreementLineItems" abstract="true" name="LicenseAgreementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="prta_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="prta_MaximumNumberofSharestobeIssuedISOExercise" abstract="false" name="MaximumNumberofSharestobeIssuedISOExercise" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice" abstract="false" name="CollaborationAgreementExpectedAllocationofInitialTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_OperatingLeasesSubleaseRentalsTermofContract" abstract="false" name="OperatingLeasesSubleaseRentalsTermofContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prta_ClinicalProductSupplyMember" abstract="true" name="ClinicalProductSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_RoyaltyBearingLicenseMember" abstract="true" name="RoyaltyBearingLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" abstract="false" name="ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace" abstract="false" name="LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="prta_NumberofVotes" abstract="false" name="NumberofVotes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="prta_DeferredSharesShareOutstanding" abstract="false" name="DeferredSharesShareOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract" abstract="true" name="PurchaseandContractualObligationsFiscalYearMaturityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm" abstract="false" name="CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prta_CollaborationAgreementExtensionFeeperExtensionPeriod" abstract="false" name="CollaborationAgreementExtensionFeeperExtensionPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets" abstract="false" name="NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram" abstract="false" name="CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary" abstract="false" name="LineofCreditFacilityFaceAmountReductiononThirdAnniversary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>prta-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:38da442c-e5f6-4ed8-bb27-93106113c3da,g:af883291-30ed-4afd-a355-adc261f9a88c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.prothena.com/role/CoverPage" xlink:type="simple" xlink:href="prta-20200630.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_aecb5d7d-bc2d-4d7a-a151-f0efe4bda4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d59673eb-a057-46a8-b2ed-77db4c892e35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aecb5d7d-bc2d-4d7a-a151-f0efe4bda4d8" xlink:to="loc_us-gaap_AccountsPayableCurrent_d59673eb-a057-46a8-b2ed-77db4c892e35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_AccruedResearchAndDevelopmentCurrent_65902dad-bf8a-4b3b-a392-1c3aea54458a" xlink:href="prta-20200630.xsd#prta_AccruedResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aecb5d7d-bc2d-4d7a-a151-f0efe4bda4d8" xlink:to="loc_prta_AccruedResearchAndDevelopmentCurrent_65902dad-bf8a-4b3b-a392-1c3aea54458a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_33c9523a-de43-4927-b74b-60fa378f5940" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aecb5d7d-bc2d-4d7a-a151-f0efe4bda4d8" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_33c9523a-de43-4927-b74b-60fa378f5940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_95e62130-e02c-45f9-95ff-7b19119dda40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aecb5d7d-bc2d-4d7a-a151-f0efe4bda4d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_95e62130-e02c-45f9-95ff-7b19119dda40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cd56442c-a795-4760-838e-5de540b68d88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aecb5d7d-bc2d-4d7a-a151-f0efe4bda4d8" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cd56442c-a795-4760-838e-5de540b68d88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3a33c999-7822-4fbc-8e86-60b541d4ed62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_88e4623a-8d95-4c7f-bb78-8476327380ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_3a33c999-7822-4fbc-8e86-60b541d4ed62" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_88e4623a-8d95-4c7f-bb78-8476327380ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3cec0b42-ae44-4ba6-905b-2c84e3e4955f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_3a33c999-7822-4fbc-8e86-60b541d4ed62" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3cec0b42-ae44-4ba6-905b-2c84e3e4955f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ccfb9124-657d-44a3-8fd7-380cf6a4367b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_3a33c999-7822-4fbc-8e86-60b541d4ed62" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ccfb9124-657d-44a3-8fd7-380cf6a4367b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1da887a9-b74d-400d-ba97-6f4de63dd9ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5854eb30-0c08-45ca-8a83-96de3a898055" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1da887a9-b74d-400d-ba97-6f4de63dd9ce" xlink:to="loc_us-gaap_LiabilitiesCurrent_5854eb30-0c08-45ca-8a83-96de3a898055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3651997a-80e0-4eb4-abc5-334749a23914" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1da887a9-b74d-400d-ba97-6f4de63dd9ce" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_3651997a-80e0-4eb4-abc5-334749a23914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_42f5664c-e5ec-4177-b1dd-4ae84bdf56fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_17e20ddb-7104-48f3-85ca-d6738bb41a43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_42f5664c-e5ec-4177-b1dd-4ae84bdf56fa" xlink:to="loc_us-gaap_Liabilities_17e20ddb-7104-48f3-85ca-d6738bb41a43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7dbcd886-43f3-4a23-b2be-6dd6aeeb2294" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_42f5664c-e5ec-4177-b1dd-4ae84bdf56fa" xlink:to="loc_us-gaap_StockholdersEquity_7dbcd886-43f3-4a23-b2be-6dd6aeeb2294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_99e0f74d-7aa6-41dc-883f-a0318e4401b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e95ba438-6313-4368-83c3-cdced5ca570b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_99e0f74d-7aa6-41dc-883f-a0318e4401b9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e95ba438-6313-4368-83c3-cdced5ca570b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4c3f43aa-f3d8-4209-b77a-833083938079" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_99e0f74d-7aa6-41dc-883f-a0318e4401b9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4c3f43aa-f3d8-4209-b77a-833083938079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9483765a-9e06-402e-a8eb-b8d8d3d6c24e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_99e0f74d-7aa6-41dc-883f-a0318e4401b9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9483765a-9e06-402e-a8eb-b8d8d3d6c24e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0575472a-9561-49c4-ab49-b81b5ee156ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5e4bae86-3c7b-4917-809a-857462b57e71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0575472a-9561-49c4-ab49-b81b5ee156ba" xlink:to="loc_us-gaap_AssetsCurrent_5e4bae86-3c7b-4917-809a-857462b57e71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_793ef070-ced2-43dc-98b1-19e4239f789f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0575472a-9561-49c4-ab49-b81b5ee156ba" xlink:to="loc_us-gaap_AssetsNoncurrent_793ef070-ced2-43dc-98b1-19e4239f789f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1e1d132d-5a21-439e-a7ef-b3fecc8946b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesValue_f8b77c2a-a4a0-483e-900e-c29ece39e7f9" xlink:href="prta-20200630.xsd#prta_DeferredSharesValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e1d132d-5a21-439e-a7ef-b3fecc8946b3" xlink:to="loc_prta_DeferredSharesValue_f8b77c2a-a4a0-483e-900e-c29ece39e7f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7800dd75-14b5-4cc7-967f-ea9ae6f39df0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e1d132d-5a21-439e-a7ef-b3fecc8946b3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7800dd75-14b5-4cc7-967f-ea9ae6f39df0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f43c8f83-f42e-4885-a644-c2b1fc585c87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e1d132d-5a21-439e-a7ef-b3fecc8946b3" xlink:to="loc_us-gaap_CommonStockValue_f43c8f83-f42e-4885-a644-c2b1fc585c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_94773b62-cd05-49f1-b153-b7ab58e6be03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e1d132d-5a21-439e-a7ef-b3fecc8946b3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_94773b62-cd05-49f1-b153-b7ab58e6be03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_0adf9ac4-32d9-420b-b87b-71e8ca4336c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2caba4d7-3dc5-49f1-a2e3-cf8581bcf718" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0adf9ac4-32d9-420b-b87b-71e8ca4336c8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2caba4d7-3dc5-49f1-a2e3-cf8581bcf718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3d883cdb-24ae-451a-8d86-d4e89c461d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0adf9ac4-32d9-420b-b87b-71e8ca4336c8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3d883cdb-24ae-451a-8d86-d4e89c461d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_196e6b1f-3e7c-4843-b2eb-b85dc8df62f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0adf9ac4-32d9-420b-b87b-71e8ca4336c8" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_196e6b1f-3e7c-4843-b2eb-b85dc8df62f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e5e7ab81-9aa7-4de2-a7b1-7b076feffaf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0adf9ac4-32d9-420b-b87b-71e8ca4336c8" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e5e7ab81-9aa7-4de2-a7b1-7b076feffaf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2d096a2b-d6ba-4f84-b73f-eafde3ee9a92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0adf9ac4-32d9-420b-b87b-71e8ca4336c8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2d096a2b-d6ba-4f84-b73f-eafde3ee9a92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e36b8456-f7cd-4b0b-9a1b-7a6036275945" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4f541237-627c-4cec-ae8d-aa71469c9ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e36b8456-f7cd-4b0b-9a1b-7a6036275945" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4f541237-627c-4cec-ae8d-aa71469c9ac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4bebad60-f222-4ecf-b06b-28d03bea38da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e36b8456-f7cd-4b0b-9a1b-7a6036275945" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4bebad60-f222-4ecf-b06b-28d03bea38da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d502926e-24bf-418a-ad23-a4e92586e2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_89c82437-9683-4055-b562-5476db167766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d502926e-24bf-418a-ad23-a4e92586e2d5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_89c82437-9683-4055-b562-5476db167766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_dfc63596-33fe-46b1-ba9c-e2593a9c1076" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d502926e-24bf-418a-ad23-a4e92586e2d5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_dfc63596-33fe-46b1-ba9c-e2593a9c1076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_4dd2c306-efa5-4af9-8a87-799b0ae391a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d502926e-24bf-418a-ad23-a4e92586e2d5" xlink:to="loc_us-gaap_RestructuringCosts_4dd2c306-efa5-4af9-8a87-799b0ae391a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7ef1af5a-6129-4bda-be59-845b10b5a02a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_e9733668-0d25-4849-916e-eeaa8a7b2f40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7ef1af5a-6129-4bda-be59-845b10b5a02a" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_e9733668-0d25-4849-916e-eeaa8a7b2f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a12c73aa-4436-4ba1-ae8b-246e9ba66ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7ef1af5a-6129-4bda-be59-845b10b5a02a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a12c73aa-4436-4ba1-ae8b-246e9ba66ce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d06310dc-975f-4029-b0ee-11ed272301f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2c4b07c8-5b1a-4a90-b769-f0dd3f823be2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d06310dc-975f-4029-b0ee-11ed272301f7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2c4b07c8-5b1a-4a90-b769-f0dd3f823be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_356eeccd-30cb-45bb-88fe-2dbec3de9216" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d06310dc-975f-4029-b0ee-11ed272301f7" xlink:to="loc_us-gaap_OperatingExpenses_356eeccd-30cb-45bb-88fe-2dbec3de9216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c0c1d1d1-bff5-4c9a-8811-a5a98d720f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ec81c3de-1744-4045-a6ed-e1c4c3197007" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c0c1d1d1-bff5-4c9a-8811-a5a98d720f0f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ec81c3de-1744-4045-a6ed-e1c4c3197007" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f3f71164-76f4-4c7b-b95c-b01284333e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c0c1d1d1-bff5-4c9a-8811-a5a98d720f0f" xlink:to="loc_us-gaap_OperatingIncomeLoss_f3f71164-76f4-4c7b-b95c-b01284333e6a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f5999fb-00c0-416d-a740-b039ff6d668b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aa0b7165-e459-4a64-a06a-609b312e2b93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f5999fb-00c0-416d-a740-b039ff6d668b" xlink:to="loc_us-gaap_NetIncomeLoss_aa0b7165-e459-4a64-a06a-609b312e2b93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7a6f892b-acbb-400e-8bcc-0af5ec639a06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f5999fb-00c0-416d-a740-b039ff6d668b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7a6f892b-acbb-400e-8bcc-0af5ec639a06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_bb47b9b7-9f09-43bb-ae7a-fd683dfd3129" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f5999fb-00c0-416d-a740-b039ff6d668b" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_bb47b9b7-9f09-43bb-ae7a-fd683dfd3129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_Amortizationofrightofuseasset_df62d394-6e97-4ac8-946b-2b67032706db" xlink:href="prta-20200630.xsd#prta_Amortizationofrightofuseasset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f5999fb-00c0-416d-a740-b039ff6d668b" xlink:to="loc_prta_Amortizationofrightofuseasset_df62d394-6e97-4ac8-946b-2b67032706db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1384db8a-5ac2-4ef3-bc29-549c8f5edc82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f5999fb-00c0-416d-a740-b039ff6d668b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1384db8a-5ac2-4ef3-bc29-549c8f5edc82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9d23ee38-e180-4155-9d33-e33c4402ccc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f5999fb-00c0-416d-a740-b039ff6d668b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9d23ee38-e180-4155-9d33-e33c4402ccc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_681bf125-ac46-4578-8bf0-d5470dfbefbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f5999fb-00c0-416d-a740-b039ff6d668b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_681bf125-ac46-4578-8bf0-d5470dfbefbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_e9f23232-5b91-4f80-a9f6-398177445037" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f5999fb-00c0-416d-a740-b039ff6d668b" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_e9f23232-5b91-4f80-a9f6-398177445037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_IncreaseDecreaseinOperatingLeaseLiability_58d3289b-3a16-4dc9-9c91-6a0834265948" xlink:href="prta-20200630.xsd#prta_IncreaseDecreaseinOperatingLeaseLiability"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f5999fb-00c0-416d-a740-b039ff6d668b" xlink:to="loc_prta_IncreaseDecreaseinOperatingLeaseLiability_58d3289b-3a16-4dc9-9c91-6a0834265948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8692f8ae-8700-4c50-adb9-0c3820abc4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f5999fb-00c0-416d-a740-b039ff6d668b" xlink:to="loc_us-gaap_ShareBasedCompensation_8692f8ae-8700-4c50-adb9-0c3820abc4b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a026af7-50ea-45f9-b6f8-50968c33afd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61f89aa9-f73b-407d-ba25-1f11a192ee50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a026af7-50ea-45f9-b6f8-50968c33afd2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61f89aa9-f73b-407d-ba25-1f11a192ee50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_f29af398-e331-40f4-9c78-76c6206e5380" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a026af7-50ea-45f9-b6f8-50968c33afd2" xlink:to="loc_us-gaap_RestrictedCashCurrent_f29af398-e331-40f4-9c78-76c6206e5380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_10098457-649b-4c39-a977-b37fa98ca0ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a026af7-50ea-45f9-b6f8-50968c33afd2" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_10098457-649b-4c39-a977-b37fa98ca0ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb9621f5-ab08-4802-b40b-53a2ff466915" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_82015b5d-90a3-4661-925d-037043c01d55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb9621f5-ab08-4802-b40b-53a2ff466915" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_82015b5d-90a3-4661-925d-037043c01d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b65a9857-2ec1-4bc7-acf2-cb676ec725de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb9621f5-ab08-4802-b40b-53a2ff466915" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b65a9857-2ec1-4bc7-acf2-cb676ec725de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2cdc020e-bf54-43bd-9cb7-ba55e67be24f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb9621f5-ab08-4802-b40b-53a2ff466915" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2cdc020e-bf54-43bd-9cb7-ba55e67be24f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e33a33cf-2399-481e-b56c-ea65a921117d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_2e3feca0-2a34-4388-be61-c07abd068021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e33a33cf-2399-481e-b56c-ea65a921117d" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_2e3feca0-2a34-4388-be61-c07abd068021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_b3e3aece-351a-4e1c-987b-97a28d246e97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e33a33cf-2399-481e-b56c-ea65a921117d" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_b3e3aece-351a-4e1c-987b-97a28d246e97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e21ef4f-e265-4b3b-885f-b5cdde2bfaf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_673c1e7f-7dd1-47cc-aa87-57ceffa901d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8e21ef4f-e265-4b3b-885f-b5cdde2bfaf3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_673c1e7f-7dd1-47cc-aa87-57ceffa901d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/Organization" xlink:type="simple" xlink:href="prta-20200630.xsd#Organization"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/Organization" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/OrganizationAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#OrganizationAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/OrganizationAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="prta-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="prta-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="prta-20200630.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItems" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItems"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItems" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsTables"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_75c6ac72-821f-4a81-b06a-164c226ffd19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9f5fe123-6cfe-49ec-a2f7-477617fce91d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_75c6ac72-821f-4a81-b06a-164c226ffd19" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9f5fe123-6cfe-49ec-a2f7-477617fce91d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_11a62078-51bf-46d2-a41d-5a30fbf439d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_75c6ac72-821f-4a81-b06a-164c226ffd19" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_11a62078-51bf-46d2-a41d-5a30fbf439d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bfa713fb-085f-442e-9aaf-a14856d48bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_fbfb0ea1-a35a-4407-a07e-ff3eaddb4227" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_bfa713fb-085f-442e-9aaf-a14856d48bcf" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_fbfb0ea1-a35a-4407-a07e-ff3eaddb4227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_8b2b76ce-55cd-43c9-92b7-2a8dc8f6b486" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_bfa713fb-085f-442e-9aaf-a14856d48bcf" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_8b2b76ce-55cd-43c9-92b7-2a8dc8f6b486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_9d7a2ff8-e588-44b9-bdcf-d92cbf23e35b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_bfa713fb-085f-442e-9aaf-a14856d48bcf" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_9d7a2ff8-e588-44b9-bdcf-d92cbf23e35b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_44e335ad-0820-4ab9-92ee-6dfbab36847c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_48a3282c-8dfa-4fb6-af49-f7a348933a20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_44e335ad-0820-4ab9-92ee-6dfbab36847c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_48a3282c-8dfa-4fb6-af49-f7a348933a20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a87add6c-58b6-4979-ba5a-6b67bcfa6581" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_44e335ad-0820-4ab9-92ee-6dfbab36847c" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a87add6c-58b6-4979-ba5a-6b67bcfa6581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_f1022fa6-8a1f-480d-9c05-04760b50d740" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_44e335ad-0820-4ab9-92ee-6dfbab36847c" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_f1022fa6-8a1f-480d-9c05-04760b50d740" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShare" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShare"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareTables" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShareTables"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingencies"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CommitmentandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesLeaseNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesDublinLeaseDetails"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_d8997c73-6455-4bb7-93d7-2bad330c8033" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_40283317-25e2-4405-90b9-e8dd6ffba36b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_d8997c73-6455-4bb7-93d7-2bad330c8033" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_40283317-25e2-4405-90b9-e8dd6ffba36b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_2dd93340-878b-4a30-9331-8f5f7112fb31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_d8997c73-6455-4bb7-93d7-2bad330c8033" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_2dd93340-878b-4a30-9331-8f5f7112fb31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_4c8ffd49-417d-4f46-8348-1dca17211aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_d8997c73-6455-4bb7-93d7-2bad330c8033" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_4c8ffd49-417d-4f46-8348-1dca17211aa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_aa07558d-0be9-4c12-bc26-6779e415a9a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_d8997c73-6455-4bb7-93d7-2bad330c8033" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_aa07558d-0be9-4c12-bc26-6779e415a9a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a7745da7-4afe-49ba-b142-9bee3009ab62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cae7bb94-1242-453d-ad22-29fef0f4cbaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a7745da7-4afe-49ba-b142-9bee3009ab62" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cae7bb94-1242-453d-ad22-29fef0f4cbaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_748a43fc-3256-402a-953f-0dd28139dd28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a7745da7-4afe-49ba-b142-9bee3009ab62" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_748a43fc-3256-402a-953f-0dd28139dd28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_99c5bf96-35d5-4301-a347-3574407ace93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a7745da7-4afe-49ba-b142-9bee3009ab62" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_99c5bf96-35d5-4301-a347-3574407ace93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6cb68637-ea4c-4406-ba62-d689cb2cc8ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a7745da7-4afe-49ba-b142-9bee3009ab62" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6cb68637-ea4c-4406-ba62-d689cb2cc8ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesContractualObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinFifthYear_1704cad9-7385-4302-ba3f-6f5a2d9ae1ce" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinFifthYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_192cd9e4-bd8c-47f7-8731-954bb3c2c6ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationDueinFifthYear_1704cad9-7385-4302-ba3f-6f5a2d9ae1ce" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_192cd9e4-bd8c-47f7-8731-954bb3c2c6ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_25eabb0f-077f-4c14-9609-c18156115972" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationDueinFifthYear_1704cad9-7385-4302-ba3f-6f5a2d9ae1ce" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_25eabb0f-077f-4c14-9609-c18156115972" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_1265aa2f-290f-4b2f-aed6-ef60ecaea0bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_8559fd29-aa6d-4ed0-a3cd-7fae684d2238" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_1265aa2f-290f-4b2f-aed6-ef60ecaea0bf" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_8559fd29-aa6d-4ed0-a3cd-7fae684d2238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_a51bee46-b723-4d25-951d-95b2655f8aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_1265aa2f-290f-4b2f-aed6-ef60ecaea0bf" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_a51bee46-b723-4d25-951d-95b2655f8aeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_07ee9565-e1db-43a9-888f-4d8ee9de5730" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_1265aa2f-290f-4b2f-aed6-ef60ecaea0bf" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_07ee9565-e1db-43a9-888f-4d8ee9de5730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_4d2fb558-9f14-48cb-b50c-f606e081d931" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_1265aa2f-290f-4b2f-aed6-ef60ecaea0bf" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_4d2fb558-9f14-48cb-b50c-f606e081d931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_d38371c5-6088-4f36-a346-8514cbe42a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_1265aa2f-290f-4b2f-aed6-ef60ecaea0bf" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_d38371c5-6088-4f36-a346-8514cbe42a7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_89b7cf72-f016-45ac-8eb1-cad43a0ec8fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_1265aa2f-290f-4b2f-aed6-ef60ecaea0bf" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_89b7cf72-f016-45ac-8eb1-cad43a0ec8fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueAfterFifthYear_438ba6d8-55f1-49fd-ac91-cf536cb98618" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueAfterFifthYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_08be1a67-6595-4b94-9947-08f9e2421d13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationDueAfterFifthYear_438ba6d8-55f1-49fd-ac91-cf536cb98618" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_08be1a67-6595-4b94-9947-08f9e2421d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_3ad04b9f-952f-4fac-b908-bd11e33c6dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationDueAfterFifthYear_438ba6d8-55f1-49fd-ac91-cf536cb98618" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_3ad04b9f-952f-4fac-b908-bd11e33c6dc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinFourthYear_4759dc5f-e6ed-48a6-8366-39c7d800bd05" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinFourthYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_f2be522f-9af5-41fe-9f3a-160f30b96cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationDueinFourthYear_4759dc5f-e6ed-48a6-8366-39c7d800bd05" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_f2be522f-9af5-41fe-9f3a-160f30b96cbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_3cf6ea33-f3a3-4eae-b56e-366c2de135e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationDueinFourthYear_4759dc5f-e6ed-48a6-8366-39c7d800bd05" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_3cf6ea33-f3a3-4eae-b56e-366c2de135e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinSecondYear_36a2af0a-2568-4c56-a6a2-ab2adc3bd084" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinSecondYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_7f0a2d09-143a-4558-907f-d60581ad42b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationDueinSecondYear_36a2af0a-2568-4c56-a6a2-ab2adc3bd084" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_7f0a2d09-143a-4558-907f-d60581ad42b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_81115151-632d-457c-83f3-540e224cd0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationDueinSecondYear_36a2af0a-2568-4c56-a6a2-ab2adc3bd084" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_81115151-632d-457c-83f3-540e224cd0dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationTotal_f882b587-55ab-4562-825f-985e8a386a47" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationTotal"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationRemainderofFiscalYear_7c770f3e-ca14-4349-9ccd-24a0939f86d9" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationRemainderofFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationTotal_f882b587-55ab-4562-825f-985e8a386a47" xlink:to="loc_prta_PurchaseandContractualObligationRemainderofFiscalYear_7c770f3e-ca14-4349-9ccd-24a0939f86d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinSecondYear_2bc94f78-02b3-4f59-ad44-a5f92781cfca" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationTotal_f882b587-55ab-4562-825f-985e8a386a47" xlink:to="loc_prta_PurchaseandContractualObligationDueinSecondYear_2bc94f78-02b3-4f59-ad44-a5f92781cfca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinThirdYear_6da9d78d-821a-4357-b132-e25af39d8d32" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinThirdYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationTotal_f882b587-55ab-4562-825f-985e8a386a47" xlink:to="loc_prta_PurchaseandContractualObligationDueinThirdYear_6da9d78d-821a-4357-b132-e25af39d8d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinFourthYear_72e71ffd-aac0-46ba-8cf2-08101496e57c" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinFourthYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationTotal_f882b587-55ab-4562-825f-985e8a386a47" xlink:to="loc_prta_PurchaseandContractualObligationDueinFourthYear_72e71ffd-aac0-46ba-8cf2-08101496e57c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinFifthYear_d526e77e-7444-4146-9fca-e4adee45859f" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinFifthYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationTotal_f882b587-55ab-4562-825f-985e8a386a47" xlink:to="loc_prta_PurchaseandContractualObligationDueinFifthYear_d526e77e-7444-4146-9fca-e4adee45859f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueAfterFifthYear_89fff309-4b99-4a1d-a4ee-43117d922395" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueAfterFifthYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationTotal_f882b587-55ab-4562-825f-985e8a386a47" xlink:to="loc_prta_PurchaseandContractualObligationDueAfterFifthYear_89fff309-4b99-4a1d-a4ee-43117d922395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_f0259a07-35c5-4d56-9372-674533803c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_7358bfbd-1090-40a8-9144-8726b236ee5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_f0259a07-35c5-4d56-9372-674533803c2e" xlink:to="loc_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_7358bfbd-1090-40a8-9144-8726b236ee5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_6405c93d-d940-4033-92f9-918634763f87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_f0259a07-35c5-4d56-9372-674533803c2e" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_6405c93d-d940-4033-92f9-918634763f87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_fbb54bb5-4a0d-451d-8e0c-039efe01c9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_f0259a07-35c5-4d56-9372-674533803c2e" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_fbb54bb5-4a0d-451d-8e0c-039efe01c9ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_1b264c08-d8e9-4545-b077-67bd155714be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_f0259a07-35c5-4d56-9372-674533803c2e" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_1b264c08-d8e9-4545-b077-67bd155714be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_b5179fa0-e6b1-4e01-9cf7-1b33e0fcd538" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_f0259a07-35c5-4d56-9372-674533803c2e" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_b5179fa0-e6b1-4e01-9cf7-1b33e0fcd538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_005c427e-6e30-431d-b23c-45268fdd0de2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_f0259a07-35c5-4d56-9372-674533803c2e" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_005c427e-6e30-431d-b23c-45268fdd0de2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinThirdYear_b77b961a-3c4d-44ae-a5ac-912e88ff882d" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinThirdYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_458c19c3-055d-40ed-a9d2-fa44c26b4b3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationDueinThirdYear_b77b961a-3c4d-44ae-a5ac-912e88ff882d" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_458c19c3-055d-40ed-a9d2-fa44c26b4b3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_4b7e2ff4-356c-47e4-8a2c-bdaf95e84fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationDueinThirdYear_b77b961a-3c4d-44ae-a5ac-912e88ff882d" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_4b7e2ff4-356c-47e4-8a2c-bdaf95e84fd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationRemainderofFiscalYear_ef07ca09-a17d-4f73-a29a-377f674a372f" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationRemainderofFiscalYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_760eaba3-9797-40f7-b681-94d514426db4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationRemainderofFiscalYear_ef07ca09-a17d-4f73-a29a-377f674a372f" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_760eaba3-9797-40f7-b681-94d514426db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_46288051-af68-45e1-a54c-61fdc9e9301f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prta_PurchaseandContractualObligationRemainderofFiscalYear_ef07ca09-a17d-4f73-a29a-377f674a372f" xlink:to="loc_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_46288051-af68-45e1-a54c-61fdc9e9301f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/SignificantAgreements" xlink:type="simple" xlink:href="prta-20200630.xsd#SignificantAgreements"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/SignificantAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#SignificantAgreementsRocheLicenseAgreementDetails"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#SignificantAgreementsCelgeneCollaborationAgreementDetails"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/ShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/ShareBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationFairValueofOptionsGrantedDetail"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/IncomeTaxes" xlink:type="simple" xlink:href="prta-20200630.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>prta-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:38da442c-e5f6-4ed8-bb27-93106113c3da,g:af883291-30ed-4afd-a355-adc261f9a88c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CoverPage" xlink:type="simple" xlink:href="prta-20200630.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CoverPage" xlink:type="extended" id="ia2745d583d1340629819c8c51fe9a631_CoverPage"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i2e501099c3a14a8696b267850eeaea41_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="id0857a04e6514e4abf789edd7e0df3b9_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="iec6d5c4ca4654b938c5d4e833f2fbede_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f858b37-e235-40fa-aa83-b37e48e302d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f858b37-e235-40fa-aa83-b37e48e302d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d19c7edb-a86c-4476-90e1-7a81c1270132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d19c7edb-a86c-4476-90e1-7a81c1270132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_43c5f3a6-b194-45ca-aa94-1927fdd1c17b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_43c5f3a6-b194-45ca-aa94-1927fdd1c17b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_1ed72369-106e-4ee3-b2cc-7683a2c0fe5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:to="loc_us-gaap_RestructuringCosts_1ed72369-106e-4ee3-b2cc-7683a2c0fe5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7a2d6938-297e-4a07-8897-94b0c2bacf15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:to="loc_us-gaap_OperatingExpenses_7a2d6938-297e-4a07-8897-94b0c2bacf15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_32f14b19-2fc8-45dc-bade-f20d7cab2352" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_OperatingIncomeLoss_32f14b19-2fc8-45dc-bade-f20d7cab2352" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e51ee2dd-ec34-4dea-9662-6bb04b0b1fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e51ee2dd-ec34-4dea-9662-6bb04b0b1fc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_a9fec004-43ab-4430-a588-ea105c38b112" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e51ee2dd-ec34-4dea-9662-6bb04b0b1fc5" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_a9fec004-43ab-4430-a588-ea105c38b112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1deba353-ca6f-458e-9131-60ae9ab17585" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e51ee2dd-ec34-4dea-9662-6bb04b0b1fc5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1deba353-ca6f-458e-9131-60ae9ab17585" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_758ca36a-9021-4215-b72f-965d2b78c297" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e51ee2dd-ec34-4dea-9662-6bb04b0b1fc5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_758ca36a-9021-4215-b72f-965d2b78c297" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_472a0db9-e76b-48ea-b21a-ebb110c4cf76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_472a0db9-e76b-48ea-b21a-ebb110c4cf76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1cba1295-8424-43b9-9514-c877a170e326" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1cba1295-8424-43b9-9514-c877a170e326" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_817390a8-96ec-43ac-a830-e689d6222584" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_NetIncomeLoss_817390a8-96ec-43ac-a830-e689d6222584" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_a03dc349-15e0-4472-8845-c384f07e66cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_a03dc349-15e0-4472-8845-c384f07e66cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b0a62558-838b-487a-a6ff-c8cccb0a4368" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b0a62558-838b-487a-a6ff-c8cccb0a4368" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_357f2ac5-4767-49dd-9729-abd1af3623b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_StatementTable_357f2ac5-4767-49dd-9729-abd1af3623b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b2129a95-6569-4b0f-abab-4a0befb069a6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_357f2ac5-4767-49dd-9729-abd1af3623b7" xlink:to="loc_srt_ProductOrServiceAxis_b2129a95-6569-4b0f-abab-4a0befb069a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b2129a95-6569-4b0f-abab-4a0befb069a6_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b2129a95-6569-4b0f-abab-4a0befb069a6" xlink:to="loc_srt_ProductsAndServicesDomain_b2129a95-6569-4b0f-abab-4a0befb069a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99c56ba9-104c-4b97-a75b-bd68c9e1b2cb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b2129a95-6569-4b0f-abab-4a0befb069a6" xlink:to="loc_srt_ProductsAndServicesDomain_99c56ba9-104c-4b97-a75b-bd68c9e1b2cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationMember_180b4f1d-3034-43a2-9c05-c355b9849afc" xlink:href="prta-20200630.xsd#prta_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_99c56ba9-104c-4b97-a75b-bd68c9e1b2cb" xlink:to="loc_prta_CollaborationMember_180b4f1d-3034-43a2-9c05-c355b9849afc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_147079dd-ae0f-4aa0-8edf-91d1f41f1029" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_99c56ba9-104c-4b97-a75b-bd68c9e1b2cb" xlink:to="loc_us-gaap_LicenseMember_147079dd-ae0f-4aa0-8edf-91d1f41f1029" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i4d3db96536ae4752ae6d6127ef88c7d7_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="ibcce081f00d340f39e3a57683145141f_CondensedConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_77b4b9b9-e1bf-4447-b2b4-f82feeb688a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_SharesOutstanding_77b4b9b9-e1bf-4447-b2b4-f82feeb688a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e03fcc0-82a3-40da-b65a-f91e6eee22e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e03fcc0-82a3-40da-b65a-f91e6eee22e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_7019e3c0-9579-4858-ba55-0adf8411076b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_7019e3c0-9579-4858-ba55-0adf8411076b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_25152058-7bfc-499b-8f50-7c23dd666f80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_25152058-7bfc-499b-8f50-7c23dd666f80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0fed2f7b-127f-491d-9dd6-b15e5303e2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0fed2f7b-127f-491d-9dd6-b15e5303e2c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b8b20310-42c5-4156-9adc-e3ee27ac937d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b8b20310-42c5-4156-9adc-e3ee27ac937d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8310b5d9-8f81-490f-aca5-8e3e88c2ef74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_NetIncomeLoss_8310b5d9-8f81-490f-aca5-8e3e88c2ef74" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1d286f50-9859-4684-b813-96011b92b4e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d20d470b-e196-439a-87b5-480941a8ef11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e3ebae37-67ae-409b-8e00-580424f3f3df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_StatementTable_e3ebae37-67ae-409b-8e00-580424f3f3df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_511dbe4c-267f-461a-a838-9143d30c839c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e3ebae37-67ae-409b-8e00-580424f3f3df" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_511dbe4c-267f-461a-a838-9143d30c839c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_511dbe4c-267f-461a-a838-9143d30c839c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_511dbe4c-267f-461a-a838-9143d30c839c" xlink:to="loc_us-gaap_EquityComponentDomain_511dbe4c-267f-461a-a838-9143d30c839c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe7e5c7f-1a72-4bd0-ab4d-915b15e1f6c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_511dbe4c-267f-461a-a838-9143d30c839c" xlink:to="loc_us-gaap_EquityComponentDomain_fe7e5c7f-1a72-4bd0-ab4d-915b15e1f6c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OrdinaryShareMember_0a3f4313-5a8c-4cbe-91de-f9a3c8bd906b" xlink:href="prta-20200630.xsd#prta_OrdinaryShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe7e5c7f-1a72-4bd0-ab4d-915b15e1f6c4" xlink:to="loc_prta_OrdinaryShareMember_0a3f4313-5a8c-4cbe-91de-f9a3c8bd906b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d38f5097-1212-4dd2-9e59-da1b2ef06ded" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe7e5c7f-1a72-4bd0-ab4d-915b15e1f6c4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d38f5097-1212-4dd2-9e59-da1b2ef06ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d2cfc9ee-ef0c-4146-b37d-d867b79a8ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe7e5c7f-1a72-4bd0-ab4d-915b15e1f6c4" xlink:to="loc_us-gaap_RetainedEarningsMember_d2cfc9ee-ef0c-4146-b37d-d867b79a8ad2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7a070f1c-dee8-4195-9620-86201a8fe801" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e3ebae37-67ae-409b-8e00-580424f3f3df" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7a070f1c-dee8-4195-9620-86201a8fe801" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7a070f1c-dee8-4195-9620-86201a8fe801_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7a070f1c-dee8-4195-9620-86201a8fe801" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7a070f1c-dee8-4195-9620-86201a8fe801_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_220390b8-50ba-498d-b71b-da1e8c0a367c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7a070f1c-dee8-4195-9620-86201a8fe801" xlink:to="loc_us-gaap_TypeOfAdoptionMember_220390b8-50ba-498d-b71b-da1e8c0a367c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_80d135cc-4ed0-47a4-91eb-16552bcb6e55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_220390b8-50ba-498d-b71b-da1e8c0a367c" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_80d135cc-4ed0-47a4-91eb-16552bcb6e55" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/Organization" xlink:type="simple" xlink:href="prta-20200630.xsd#Organization"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/Organization" xlink:type="extended" id="ifa433d9348de48a784e5cd850479a860_Organization"/>
  <link:roleRef roleURI="http://www.prothena.com/role/OrganizationAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#OrganizationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/OrganizationAdditionalInformationDetail" xlink:type="extended" id="ifc46602c91254091947306553773c329_OrganizationAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="prta-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i944e5eb92ac94116a8431d527cbc931d_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="prta-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ib897835d770c43fab3ec53cf5e05e708_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i3162193c5bfd4994955ab77da6ccfb7c_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5bd6f227-2811-41c0-9079-e4b22b184ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_94f40479-a9ae-4bff-866b-c9d3430b402a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5bd6f227-2811-41c0-9079-e4b22b184ae7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_94f40479-a9ae-4bff-866b-c9d3430b402a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_eadb1253-5857-4063-9595-c951ad751975" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5bd6f227-2811-41c0-9079-e4b22b184ae7" xlink:to="loc_us-gaap_ConcentrationRiskTable_eadb1253-5857-4063-9595-c951ad751975" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c0f35755-114e-4be1-8dec-9b6e29b83cf1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_eadb1253-5857-4063-9595-c951ad751975" xlink:to="loc_srt_StatementGeographicalAxis_c0f35755-114e-4be1-8dec-9b6e29b83cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c0f35755-114e-4be1-8dec-9b6e29b83cf1_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c0f35755-114e-4be1-8dec-9b6e29b83cf1" xlink:to="loc_srt_SegmentGeographicalDomain_c0f35755-114e-4be1-8dec-9b6e29b83cf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9a82e4a8-0567-4dd5-bfeb-c0d7113621d7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c0f35755-114e-4be1-8dec-9b6e29b83cf1" xlink:to="loc_srt_SegmentGeographicalDomain_9a82e4a8-0567-4dd5-bfeb-c0d7113621d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a0191510-f317-41f2-b003-142d572b7b88" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9a82e4a8-0567-4dd5-bfeb-c0d7113621d7" xlink:to="loc_country_US_a0191510-f317-41f2-b003-142d572b7b88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_12be7c9e-31b2-4900-a851-e78b3f242e18" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9a82e4a8-0567-4dd5-bfeb-c0d7113621d7" xlink:to="loc_country_IE_12be7c9e-31b2-4900-a851-e78b3f242e18" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="prta-20200630.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/FairValueMeasurements" xlink:type="extended" id="i2b8979ddb2cf495a934d0e636c05926c_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended" id="i90f525db87744efa8cc72b0ef93ee2eb_FairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7a81a1d0-5ede-4955-b85e-a8747213e108" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_ed46aabb-223f-4cf2-a605-d9b60b161bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7a81a1d0-5ede-4955-b85e-a8747213e108" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_ed46aabb-223f-4cf2-a605-d9b60b161bdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1a16676a-6379-4e0e-84d5-4d13ed63bfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7a81a1d0-5ede-4955-b85e-a8747213e108" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1a16676a-6379-4e0e-84d5-4d13ed63bfa5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_439e3f7f-f6f7-4cd3-88d1-aa99dc1c7554" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1a16676a-6379-4e0e-84d5-4d13ed63bfa5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_439e3f7f-f6f7-4cd3-88d1-aa99dc1c7554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_439e3f7f-f6f7-4cd3-88d1-aa99dc1c7554_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_439e3f7f-f6f7-4cd3-88d1-aa99dc1c7554" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_439e3f7f-f6f7-4cd3-88d1-aa99dc1c7554_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45f05a4c-fa36-4f7b-96b1-2be80022b002" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_439e3f7f-f6f7-4cd3-88d1-aa99dc1c7554" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45f05a4c-fa36-4f7b-96b1-2be80022b002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ccf58b14-3168-4db4-87c8-0e3bd46308f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45f05a4c-fa36-4f7b-96b1-2be80022b002" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ccf58b14-3168-4db4-87c8-0e3bd46308f9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItems" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItems"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItems" xlink:type="extended" id="i34e14468293a4c2489662a63f55a41ad_CompositionofCertainBalanceSheetItems"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsTables"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsTables" xlink:type="extended" id="i7f3bc9f316e04e739a51791feafd7ad7_CompositionofCertainBalanceSheetItemsTables"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail" xlink:type="extended" id="i88d8981ed6be4f2fb5b967c2fe4b606b_CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsAdditionalInformationDetail" xlink:type="extended" id="i74cac0a4cf8640b7847ed45afe8f186c_CompositionofCertainBalanceSheetItemsAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended" id="i2138cca3f588440ea24755a13baeb9cd_CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShare" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShare"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShare" xlink:type="extended" id="i9e7b44b67e294ad397016fdb9e4ab0b2_NetLossPerOrdinaryShare"/>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareTables" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShareTables"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShareTables" xlink:type="extended" id="i947789cf8e314f8bab67334d5b83ccb0_NetLossPerOrdinaryShareTables"/>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail" xlink:type="extended" id="i0526afdc4be544adba014f17a4a003a1_NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail"/>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail" xlink:type="extended" id="ic2d6ef3f52bd47a795aa244965bee164_NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_633764b7-edc0-4d77-99c2-43626c690fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d47b1ec7-81e0-4d90-8659-1efb0defe40d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_633764b7-edc0-4d77-99c2-43626c690fd9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d47b1ec7-81e0-4d90-8659-1efb0defe40d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47fcdde2-d54c-48e2-865e-14277b4efbd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_633764b7-edc0-4d77-99c2-43626c690fd9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47fcdde2-d54c-48e2-865e-14277b4efbd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178bb8bc-2862-4b67-ba29-7bcf115939ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47fcdde2-d54c-48e2-865e-14277b4efbd4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178bb8bc-2862-4b67-ba29-7bcf115939ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_178bb8bc-2862-4b67-ba29-7bcf115939ba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178bb8bc-2862-4b67-ba29-7bcf115939ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_178bb8bc-2862-4b67-ba29-7bcf115939ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec7f0e39-9506-4eba-8080-250e683a5aca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178bb8bc-2862-4b67-ba29-7bcf115939ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec7f0e39-9506-4eba-8080-250e683a5aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c1386547-ac1e-46c0-9c69-f46a01d59ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec7f0e39-9506-4eba-8080-250e683a5aca" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c1386547-ac1e-46c0-9c69-f46a01d59ecc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingencies"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CommitmentandContingencies" xlink:type="extended" id="i2086df280aaa4f7a8346460b93e97a89_CommitmentandContingencies"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="ie2151b3fc4034d91b177c031948af6ce_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesLeaseNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails" xlink:type="extended" id="i259697c2d1a94a9cb022ab970a3ae670_CommitmentandContingenciesLeaseNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3582accf-d00c-48fb-8ed3-e0b041e542cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_OperatingLeaseCost_3582accf-d00c-48fb-8ed3-e0b041e542cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_415ff26c-8f7c-4d5e-ad6c-23356b15cb96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_OperatingLeasePayments_415ff26c-8f7c-4d5e-ad6c-23356b15cb96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b58bbf60-c113-4178-be21-ab537871be4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b58bbf60-c113-4178-be21-ab537871be4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeaseArea_465ac4b0-f10f-4216-aae2-05649ebf9515" xlink:href="prta-20200630.xsd#prta_OperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeaseArea_465ac4b0-f10f-4216-aae2-05649ebf9515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3b208ccf-b1bb-43c5-8341-e10cc9117648" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3b208ccf-b1bb-43c5-8341-e10cc9117648" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_BuildtosuitLeaseTermofContract_033f5abe-85cc-492a-beb1-5d212702a665" xlink:href="prta-20200630.xsd#prta_BuildtosuitLeaseTermofContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_BuildtosuitLeaseTermofContract_033f5abe-85cc-492a-beb1-5d212702a665" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseExpirationDate1_214e4251-547c-44be-a658-37aceca42b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_LeaseExpirationDate1_214e4251-547c-44be-a658-37aceca42b5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_0ab867bb-3cd0-471f-9645-b379c399fe94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_0ab867bb-3cd0-471f-9645-b379c399fe94" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesImprovementAllowance_83f82f37-1dc4-4533-aa6e-ac1227bc2973" xlink:href="prta-20200630.xsd#prta_OperatingLeasesImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeasesImprovementAllowance_83f82f37-1dc4-4533-aa6e-ac1227bc2973" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1ddd836d-25bb-4b01-ab74-15f44d9b11ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1ddd836d-25bb-4b01-ab74-15f44d9b11ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary_c29567ce-d425-4f5c-8c86-674fb5b41318" xlink:href="prta-20200630.xsd#prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary_c29567ce-d425-4f5c-8c86-674fb5b41318" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary_1dbfa275-ccdb-47f1-a8f5-85c6f38e6aac" xlink:href="prta-20200630.xsd#prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary_1dbfa275-ccdb-47f1-a8f5-85c6f38e6aac" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_0bfa1f51-f9ce-4c80-8c8c-830b01f2f7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_LineOfCredit_0bfa1f51-f9ce-4c80-8c8c-830b01f2f7e9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9db3731f-bd70-44fe-b9ce-30f80fc7cb17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9db3731f-bd70-44fe-b9ce-30f80fc7cb17" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental_95e1bacc-6dfa-4e96-afe0-15d08f775f59" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental_95e1bacc-6dfa-4e96-afe0-15d08f775f59" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_2973b901-4e4a-41bb-a72b-46419781ae8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_SubleaseIncome_2973b901-4e4a-41bb-a72b-46419781ae8c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SubleaserentalsAnnualBaseRentInitialAmount_cc408c92-dff9-4c53-bae5-a7f7bdca0fd5" xlink:href="prta-20200630.xsd#prta_SubleaserentalsAnnualBaseRentInitialAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_SubleaserentalsAnnualBaseRentInitialAmount_cc408c92-dff9-4c53-bae5-a7f7bdca0fd5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease_f17e3117-5a92-4801-a5c3-b51a75efe658" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease_f17e3117-5a92-4801-a5c3-b51a75efe658" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsTermofContract_c777c3aa-a519-47c9-8a02-f4f014ff1a0f" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsTermofContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeasesSubleaseRentalsTermofContract_c777c3aa-a519-47c9-8a02-f4f014ff1a0f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord_8fd183e2-73ac-46f0-9328-d0d1a46030a4" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord_8fd183e2-73ac-46f0-9328-d0d1a46030a4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bc468bfa-b8ba-4b2a-8152-4dba73db0548" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_LossContingenciesTable_bc468bfa-b8ba-4b2a-8152-4dba73db0548" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_514d1ad7-c6a0-47f3-8460-a5983b59ef7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bc468bfa-b8ba-4b2a-8152-4dba73db0548" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_514d1ad7-c6a0-47f3-8460-a5983b59ef7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_514d1ad7-c6a0-47f3-8460-a5983b59ef7f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_514d1ad7-c6a0-47f3-8460-a5983b59ef7f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_514d1ad7-c6a0-47f3-8460-a5983b59ef7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_5f0255ca-3472-4458-ae88-af5fb8bdfd1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_514d1ad7-c6a0-47f3-8460-a5983b59ef7f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_5f0255ca-3472-4458-ae88-af5fb8bdfd1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_7f297294-4203-4d1c-a1fd-001cddc55812" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_5f0255ca-3472-4458-ae88-af5fb8bdfd1f" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_7f297294-4203-4d1c-a1fd-001cddc55812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_da1ef03c-21dd-4e90-96f7-710dd4a4c69a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bc468bfa-b8ba-4b2a-8152-4dba73db0548" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_da1ef03c-21dd-4e90-96f7-710dd4a4c69a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_da1ef03c-21dd-4e90-96f7-710dd4a4c69a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_da1ef03c-21dd-4e90-96f7-710dd4a4c69a" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_da1ef03c-21dd-4e90-96f7-710dd4a4c69a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_4365e635-6dcd-4b46-8772-c213bf737544" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_da1ef03c-21dd-4e90-96f7-710dd4a4c69a" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_4365e635-6dcd-4b46-8772-c213bf737544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOperatingLeaseMember_d23c91b1-83d6-454e-b629-169c5d689041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_4365e635-6dcd-4b46-8772-c213bf737544" xlink:to="loc_us-gaap_PropertySubjectToOperatingLeaseMember_d23c91b1-83d6-454e-b629-169c5d689041" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesDublinLeaseDetails"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails" xlink:type="extended" id="iffc43bd3e88841c9a31fa8d9e9f699ba_CommitmentandContingenciesDublinLeaseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace_4c3778ca-5684-4ce5-972b-3f77727230ba" xlink:href="prta-20200630.xsd#prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:to="loc_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace_4c3778ca-5684-4ce5-972b-3f77727230ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4ac10e47-321f-4d2f-95a3-05d08708d8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4ac10e47-321f-4d2f-95a3-05d08708d8bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0783b0f4-de08-47a4-8487-c24ee42e2df3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0783b0f4-de08-47a4-8487-c24ee42e2df3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1bf07e7-2863-4f41-bc68-22a05d003aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1bf07e7-2863-4f41-bc68-22a05d003aa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4e606b6c-0dd4-4dfc-b1a5-47ca14bf5736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4e606b6c-0dd4-4dfc-b1a5-47ca14bf5736" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_90e314a0-2b27-4b0b-8a3b-b89e3245c7d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4e606b6c-0dd4-4dfc-b1a5-47ca14bf5736" xlink:to="loc_srt_StatementGeographicalAxis_90e314a0-2b27-4b0b-8a3b-b89e3245c7d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_90e314a0-2b27-4b0b-8a3b-b89e3245c7d6_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_90e314a0-2b27-4b0b-8a3b-b89e3245c7d6" xlink:to="loc_srt_SegmentGeographicalDomain_90e314a0-2b27-4b0b-8a3b-b89e3245c7d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6c4c8458-b8d8-4d86-b7ce-1d951d3e65d9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_90e314a0-2b27-4b0b-8a3b-b89e3245c7d6" xlink:to="loc_srt_SegmentGeographicalDomain_6c4c8458-b8d8-4d86-b7ce-1d951d3e65d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DublinIrelandMember_0d2cfb38-ef56-4994-9d94-5bce4af64c81" xlink:href="prta-20200630.xsd#prta_DublinIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6c4c8458-b8d8-4d86-b7ce-1d951d3e65d9" xlink:to="loc_prta_DublinIrelandMember_0d2cfb38-ef56-4994-9d94-5bce4af64c81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails" xlink:type="extended" id="id1bbacc08a2640ef8f2956fce87dcb91_CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"/>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails" xlink:type="extended" id="i37b74d24034b45d8b64d8c9211069278_CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_d4cbb79d-fa86-49a3-9762-ad9b7e1c615d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:to="loc_us-gaap_PurchaseObligation_d4cbb79d-fa86-49a3-9762-ad9b7e1c615d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_3c014a30-d17e-4985-899a-f98ea4f24cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_3c014a30-d17e-4985-899a-f98ea4f24cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_5eb0e95b-9138-49ef-958f-3391f60a03df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:to="loc_us-gaap_ContractualObligation_5eb0e95b-9138-49ef-958f-3391f60a03df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities_049ea89c-a02f-4601-b8bf-7eed525ba52e" xlink:href="prta-20200630.xsd#prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:to="loc_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities_049ea89c-a02f-4601-b8bf-7eed525ba52e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_0520a99e-1ffe-4eb3-bb86-513c5e650788" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_0520a99e-1ffe-4eb3-bb86-513c5e650788" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_62f8c647-f77e-422d-a014-8fab14e3ed03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0520a99e-1ffe-4eb3-bb86-513c5e650788" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_62f8c647-f77e-422d-a014-8fab14e3ed03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_62f8c647-f77e-422d-a014-8fab14e3ed03_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_62f8c647-f77e-422d-a014-8fab14e3ed03" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_62f8c647-f77e-422d-a014-8fab14e3ed03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1dfa2e2e-441a-41c2-aff4-bb7600ea3b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_62f8c647-f77e-422d-a014-8fab14e3ed03" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1dfa2e2e-441a-41c2-aff4-bb7600ea3b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_58d59b2f-28d4-446c-a41a-d4cb0ae62093" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1dfa2e2e-441a-41c2-aff4-bb7600ea3b7c" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_58d59b2f-28d4-446c-a41a-d4cb0ae62093" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e6de3aec-0088-477a-b4a1-725ac3c91eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1dfa2e2e-441a-41c2-aff4-bb7600ea3b7c" xlink:to="loc_us-gaap_LicensingAgreementsMember_e6de3aec-0088-477a-b4a1-725ac3c91eb8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesContractualObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails" xlink:type="extended" id="ifefbe03de74e46c7a8f274a9e9b985ce_CommitmentandContingenciesContractualObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_c279d575-9241-42eb-92a3-4960cf2ab44b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_c279d575-9241-42eb-92a3-4960cf2ab44b" xlink:to="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_ef7ff725-e79c-4634-8c61-05f302d569f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligation_ef7ff725-e79c-4634-8c61-05f302d569f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_721afad5-be7b-41e0-8f7a-923380b3df50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_721afad5-be7b-41e0-8f7a-923380b3df50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_af8d40cc-df63-4705-afac-f3c985e19e21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_af8d40cc-df63-4705-afac-f3c985e19e21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_7267ac95-257e-4e5c-a047-84ceaa7c6210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_7267ac95-257e-4e5c-a047-84ceaa7c6210" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_7030f78d-0ba4-4f3a-86dc-2c64509b7019" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_7030f78d-0ba4-4f3a-86dc-2c64509b7019" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_f0ade9fd-dbf8-4113-aa26-1fb8f740fac7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_f0ade9fd-dbf8-4113-aa26-1fb8f740fac7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_25223e91-2005-45ba-b36f-e6e6427f420e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_25223e91-2005-45ba-b36f-e6e6427f420e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_c279d575-9241-42eb-92a3-4960cf2ab44b" xlink:to="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_2badeb7a-09d8-47df-bfb8-a1bc2ef87459" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligation_2badeb7a-09d8-47df-bfb8-a1bc2ef87459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_cf0ffbba-8f86-49fa-bf0a-5a8b79aee542" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_cf0ffbba-8f86-49fa-bf0a-5a8b79aee542" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_3e8be648-863d-4187-bcf7-ae4d4d0918c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_3e8be648-863d-4187-bcf7-ae4d4d0918c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_c08ebb0d-9d33-4d74-b273-f4cc23fb91d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_c08ebb0d-9d33-4d74-b273-f4cc23fb91d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_b4ae14e0-3f1e-4a91-8492-5ace3ef7a38d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_b4ae14e0-3f1e-4a91-8492-5ace3ef7a38d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_4d41d4bd-2879-43d7-9c16-e5298426b55d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_4d41d4bd-2879-43d7-9c16-e5298426b55d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_cad4f345-1143-4f8f-adcb-3f961ae4a264" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_cad4f345-1143-4f8f-adcb-3f961ae4a264" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_c279d575-9241-42eb-92a3-4960cf2ab44b" xlink:to="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationTotal_38a40b47-6a6c-40bb-967a-628c154feb0a" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationTotal_38a40b47-6a6c-40bb-967a-628c154feb0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationRemainderofFiscalYear_c3ee3bac-c32d-4e7a-b274-c5d36a9e42fc" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationRemainderofFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationRemainderofFiscalYear_c3ee3bac-c32d-4e7a-b274-c5d36a9e42fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinSecondYear_d48ca5c0-9152-492c-8a88-b43e95c971af" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationDueinSecondYear_d48ca5c0-9152-492c-8a88-b43e95c971af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinThirdYear_ab52e4f2-a138-4163-80af-0dd777380c8b" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationDueinThirdYear_ab52e4f2-a138-4163-80af-0dd777380c8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinFourthYear_3ba73f07-93e2-425d-8144-618352d19466" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinFourthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationDueinFourthYear_3ba73f07-93e2-425d-8144-618352d19466" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinFifthYear_c8f658f1-dd88-4dad-953e-b253c1f23e3d" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationDueinFifthYear_c8f658f1-dd88-4dad-953e-b253c1f23e3d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueAfterFifthYear_725c0c98-755e-4e3b-8f7a-54a97d5e06ae" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueAfterFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationDueAfterFifthYear_725c0c98-755e-4e3b-8f7a-54a97d5e06ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_620d5772-de26-4b44-8ee5-29113a92e586" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_c279d575-9241-42eb-92a3-4960cf2ab44b" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_620d5772-de26-4b44-8ee5-29113a92e586" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_781be9be-a349-4810-a8ac-19082445a300" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_620d5772-de26-4b44-8ee5-29113a92e586" xlink:to="loc_us-gaap_OtherCommitmentsAxis_781be9be-a349-4810-a8ac-19082445a300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_781be9be-a349-4810-a8ac-19082445a300_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_781be9be-a349-4810-a8ac-19082445a300" xlink:to="loc_us-gaap_OtherCommitmentsDomain_781be9be-a349-4810-a8ac-19082445a300_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_b258810c-0c8a-48dc-85c7-078dd5b6df07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_781be9be-a349-4810-a8ac-19082445a300" xlink:to="loc_us-gaap_OtherCommitmentsDomain_b258810c-0c8a-48dc-85c7-078dd5b6df07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementsMember_30485e20-ece7-4bf1-a4ef-bf8be39181b7" xlink:href="prta-20200630.xsd#prta_LicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b258810c-0c8a-48dc-85c7-078dd5b6df07" xlink:to="loc_prta_LicenseAgreementsMember_30485e20-ece7-4bf1-a4ef-bf8be39181b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/SignificantAgreements" xlink:type="simple" xlink:href="prta-20200630.xsd#SignificantAgreements"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/SignificantAgreements" xlink:type="extended" id="ia531d8d25b68494da9aa92626f0855b4_SignificantAgreements"/>
  <link:roleRef roleURI="http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#SignificantAgreementsRocheLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails" xlink:type="extended" id="icd0745e5b3dc4242b2ca241a88e9ce52_SignificantAgreementsRocheLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:href="prta-20200630.xsd#prta_LicenseAgreementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationRevenueLicenseUpfrontPayment_20fc143e-356d-4434-87e6-cc8313056952" xlink:href="prta-20200630.xsd#prta_CollaborationRevenueLicenseUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_CollaborationRevenueLicenseUpfrontPayment_20fc143e-356d-4434-87e6-cc8313056952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_MilestonePaymentReceivedClinicalMilestone_2ca8e38c-a1e4-4e9c-b236-c72c051e7209" xlink:href="prta-20200630.xsd#prta_MilestonePaymentReceivedClinicalMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_MilestonePaymentReceivedClinicalMilestone_2ca8e38c-a1e4-4e9c-b236-c72c051e7209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_MilestoneAchievementClinicalMilestone_f1f75759-b5d4-4f5f-a380-ec763f46bca7" xlink:href="prta-20200630.xsd#prta_MilestoneAchievementClinicalMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_MilestoneAchievementClinicalMilestone_f1f75759-b5d4-4f5f-a380-ec763f46bca7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones_7522e1c4-bcf6-404a-9bc0-064831ac7a16" xlink:href="prta-20200630.xsd#prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones_7522e1c4-bcf6-404a-9bc0-064831ac7a16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones_d7060f62-26ab-440c-9060-a047e61f4175" xlink:href="prta-20200630.xsd#prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones_d7060f62-26ab-440c-9060-a047e61f4175" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicensingAgreementCostAllocationPercentage_c8b07074-4273-4faf-b5b1-93a6d01fe989" xlink:href="prta-20200630.xsd#prta_LicensingAgreementCostAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicensingAgreementCostAllocationPercentage_c8b07074-4273-4faf-b5b1-93a6d01fe989" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage_42685b6f-ff71-4773-b866-76abececaacb" xlink:href="prta-20200630.xsd#prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage_42685b6f-ff71-4773-b866-76abececaacb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones_f449f023-047c-41d7-a5e4-153baee6a5de" xlink:href="prta-20200630.xsd#prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones_f449f023-047c-41d7-a5e4-153baee6a5de" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DevelopmentServicesAdditional_66358994-4eea-4ede-a9cb-bdf817655d18" xlink:href="prta-20200630.xsd#prta_DevelopmentServicesAdditional"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_DevelopmentServicesAdditional_66358994-4eea-4ede-a9cb-bdf817655d18" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_83317308-d4b2-45c1-be09-36ee2fa9c78a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_83317308-d4b2-45c1-be09-36ee2fa9c78a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_InitialTransactionPrice_9b321581-4829-422b-85c9-a15bab4bf7d6" xlink:href="prta-20200630.xsd#prta_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_InitialTransactionPrice_9b321581-4829-422b-85c9-a15bab4bf7d6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_AllocatedConsiderationtoPerformanceObligations_4ea4a106-39b3-423b-81ba-1cf30f928c5b" xlink:href="prta-20200630.xsd#prta_AllocatedConsiderationtoPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_AllocatedConsiderationtoPerformanceObligations_4ea4a106-39b3-423b-81ba-1cf30f928c5b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ASC605AllocatedConsiderationtoDeliverables_f0dde687-e573-4049-9b7c-84b57d2361ce" xlink:href="prta-20200630.xsd#prta_ASC605AllocatedConsiderationtoDeliverables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_ASC605AllocatedConsiderationtoDeliverables_f0dde687-e573-4049-9b7c-84b57d2361ce" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementDevelopmentServicesPaymentTerm_569556c9-7f97-48b1-8b4a-1c2c9fae2c01" xlink:href="prta-20200630.xsd#prta_LicenseAgreementDevelopmentServicesPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicenseAgreementDevelopmentServicesPaymentTerm_569556c9-7f97-48b1-8b4a-1c2c9fae2c01" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementMilestonePaymentsPaymentTerm_9f8e2740-0bd2-4fc6-92d5-38bbd1102f69" xlink:href="prta-20200630.xsd#prta_LicenseAgreementMilestonePaymentsPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicenseAgreementMilestonePaymentsPaymentTerm_9f8e2740-0bd2-4fc6-92d5-38bbd1102f69" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationRevenue_31ae1eb3-ac0b-4778-b4d4-dd1d52cfceb2" xlink:href="prta-20200630.xsd#prta_CollaborationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_CollaborationRevenue_31ae1eb3-ac0b-4778-b4d4-dd1d52cfceb2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense_c0215742-f072-46dc-8a35-93a50d4dba20" xlink:href="prta-20200630.xsd#prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense_c0215742-f072-46dc-8a35-93a50d4dba20" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6778d70f-1e76-4b58-a3d5-8990edda75ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6778d70f-1e76-4b58-a3d5-8990edda75ca" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementTable_e2477312-46fb-4d63-b681-abfe372b84be" xlink:href="prta-20200630.xsd#prta_LicenseAgreementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicenseAgreementTable_e2477312-46fb-4d63-b681-abfe372b84be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd99de6a-5bb2-4846-a058-fd424a5ae0a7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prta_LicenseAgreementTable_e2477312-46fb-4d63-b681-abfe372b84be" xlink:to="loc_srt_ProductOrServiceAxis_fd99de6a-5bb2-4846-a058-fd424a5ae0a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd99de6a-5bb2-4846-a058-fd424a5ae0a7_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fd99de6a-5bb2-4846-a058-fd424a5ae0a7" xlink:to="loc_srt_ProductsAndServicesDomain_fd99de6a-5bb2-4846-a058-fd424a5ae0a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fd99de6a-5bb2-4846-a058-fd424a5ae0a7" xlink:to="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_RoyaltyBearingLicenseMember_bafde1ed-79b8-472a-beca-b538bff1e1b8" xlink:href="prta-20200630.xsd#prta_RoyaltyBearingLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:to="loc_prta_RoyaltyBearingLicenseMember_bafde1ed-79b8-472a-beca-b538bff1e1b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_INDandDevelopmentServicesMember_b4a1d2ad-096d-431d-a489-26a92722308b" xlink:href="prta-20200630.xsd#prta_INDandDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:to="loc_prta_INDandDevelopmentServicesMember_b4a1d2ad-096d-431d-a489-26a92722308b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SupplyServicesMember_5b74f873-a067-416a-b719-e0c607f7c258" xlink:href="prta-20200630.xsd#prta_SupplyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:to="loc_prta_SupplyServicesMember_5b74f873-a067-416a-b719-e0c607f7c258" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ClinicalProductSupplyMember_f1d45ec0-5364-4826-8180-58601bb86b12" xlink:href="prta-20200630.xsd#prta_ClinicalProductSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:to="loc_prta_ClinicalProductSupplyMember_f1d45ec0-5364-4826-8180-58601bb86b12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5242ec4f-112e-447d-9f17-f82ac2bc5108" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prta_LicenseAgreementTable_e2477312-46fb-4d63-b681-abfe372b84be" xlink:to="loc_srt_CounterpartyNameAxis_5242ec4f-112e-447d-9f17-f82ac2bc5108" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5242ec4f-112e-447d-9f17-f82ac2bc5108_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5242ec4f-112e-447d-9f17-f82ac2bc5108" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5242ec4f-112e-447d-9f17-f82ac2bc5108_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee01080f-a07d-4248-98ba-ce1096708dd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5242ec4f-112e-447d-9f17-f82ac2bc5108" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee01080f-a07d-4248-98ba-ce1096708dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_RocheMember_75401ec7-5d10-4093-9f11-6f9b517d3814" xlink:href="prta-20200630.xsd#prta_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee01080f-a07d-4248-98ba-ce1096708dd8" xlink:to="loc_prta_RocheMember_75401ec7-5d10-4093-9f11-6f9b517d3814" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3c8190b1-aa2b-4392-9a1f-781f5f3ed4ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prta_LicenseAgreementTable_e2477312-46fb-4d63-b681-abfe372b84be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3c8190b1-aa2b-4392-9a1f-781f5f3ed4ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c8190b1-aa2b-4392-9a1f-781f5f3ed4ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3c8190b1-aa2b-4392-9a1f-781f5f3ed4ca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c8190b1-aa2b-4392-9a1f-781f5f3ed4ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e0ea4c6-d1c4-4698-bace-5d7df48c01d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3c8190b1-aa2b-4392-9a1f-781f5f3ed4ca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e0ea4c6-d1c4-4698-bace-5d7df48c01d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_42a23c5a-bf82-491b-b3af-f777b637e170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e0ea4c6-d1c4-4698-bace-5d7df48c01d8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_42a23c5a-bf82-491b-b3af-f777b637e170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DevelopmentCostsReimbursementMember_97ff7df2-2afa-46fa-b471-064956a8b3a9" xlink:href="prta-20200630.xsd#prta_DevelopmentCostsReimbursementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e0ea4c6-d1c4-4698-bace-5d7df48c01d8" xlink:to="loc_prta_DevelopmentCostsReimbursementMember_97ff7df2-2afa-46fa-b471-064956a8b3a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ResearchReimbursementMember_e3a9c2de-2a93-440a-abff-0fe6b6eb4370" xlink:href="prta-20200630.xsd#prta_ResearchReimbursementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e0ea4c6-d1c4-4698-bace-5d7df48c01d8" xlink:to="loc_prta_ResearchReimbursementMember_e3a9c2de-2a93-440a-abff-0fe6b6eb4370" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c1886c4-209d-4bb9-8027-4a70607efbff" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c1886c4-209d-4bb9-8027-4a70607efbff_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b36a8226-d465-4884-b814-928de965d9bc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_RocheMember_e4742afc-45ed-49c6-923e-486a585bb227" xlink:href="prta-20200630.xsd#prta_RocheMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3a525818-f918-4040-b6f0-fb8b75246ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a525818-f918-4040-b6f0-fb8b75246ce3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6e0fef15-5e82-495d-aa42-e7664ed1563b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_25e8b509-ec8b-4313-9975-cbc4396a0465" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#SignificantAgreementsCelgeneCollaborationAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails" xlink:type="extended" id="i6eb7ce7a73264471be7c6d3bb055c6c5_SignificantAgreementsCelgeneCollaborationAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementUpfrontPayment_414e68d6-b83a-4e90-9410-ce71dadc0d62" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementUpfrontPayment_414e68d6-b83a-4e90-9410-ce71dadc0d62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2cde2e91-5692-4be0-a862-c7950292aecf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2cde2e91-5692-4be0-a862-c7950292aecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f64ab808-4e4f-4675-bf5e-1302fdcdaa42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f64ab808-4e4f-4675-bf5e-1302fdcdaa42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e8878678-0fb8-42df-8a52-9b36c52063d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e8878678-0fb8-42df-8a52-9b36c52063d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementExerciseFeeperProgram_b1f6f2b3-c9cc-40f1-8318-2986309ce0e1" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementExerciseFeeperProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementExerciseFeeperProgram_b1f6f2b3-c9cc-40f1-8318-2986309ce0e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram_0f418e44-624a-4fe6-9f0a-3950aab1de8e" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram_0f418e44-624a-4fe6-9f0a-3950aab1de8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementTermofAgreement_5e8f3e04-e688-473a-9561-61d4aee07013" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementTermofAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementTermofAgreement_5e8f3e04-e688-473a-9561-61d4aee07013" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed_8e0f0208-dfc1-46ed-baf2-58b1ddc7dc5f" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed_8e0f0208-dfc1-46ed-baf2-58b1ddc7dc5f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementExtensionFeeperExtensionPeriod_0fee6eb7-eaaa-4ae8-84f2-4456795899ad" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementExtensionFeeperExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementExtensionFeeperExtensionPeriod_0fee6eb7-eaaa-4ae8-84f2-4456795899ad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_InitialTransactionPrice_12251ec6-4667-4273-b9b7-4b5f199d02e9" xlink:href="prta-20200630.xsd#prta_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_InitialTransactionPrice_12251ec6-4667-4273-b9b7-4b5f199d02e9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SaleofStockPremiumReceivedonTransaction_a0a4225e-7557-4437-bf13-59f3873ff973" xlink:href="prta-20200630.xsd#prta_SaleofStockPremiumReceivedonTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_SaleofStockPremiumReceivedonTransaction_a0a4225e-7557-4437-bf13-59f3873ff973" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice_b824d546-c0aa-4de7-865f-114af91115f2" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice_b824d546-c0aa-4de7-865f-114af91115f2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementUpfrontPaymentPaymentTerm_b31796fe-0c73-4820-8a79-35db50a2eff1" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementUpfrontPaymentPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementUpfrontPaymentPaymentTerm_b31796fe-0c73-4820-8a79-35db50a2eff1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm_6e226cc8-7f7c-4c1e-9e78-144e8eb659ce" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm_6e226cc8-7f7c-4c1e-9e78-144e8eb659ce" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram_23ed01f4-161f-495e-b64e-4ebff98e7b53" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram_23ed01f4-161f-495e-b64e-4ebff98e7b53" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram_7bc48ee1-1e62-4b43-8be8-8eac6a722b62" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram_7bc48ee1-1e62-4b43-8be8-8eac6a722b62" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_165ada4a-d9fa-4595-801b-021c1ee456b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_165ada4a-d9fa-4595-801b-021c1ee456b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_165ada4a-d9fa-4595-801b-021c1ee456b7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_165ada4a-d9fa-4595-801b-021c1ee456b7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_165ada4a-d9fa-4595-801b-021c1ee456b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_522396da-c673-4a68-aaa6-9e1542f9aa0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_165ada4a-d9fa-4595-801b-021c1ee456b7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_522396da-c673-4a68-aaa6-9e1542f9aa0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_3d8f40b3-2569-4cdb-93c0-a8a66977a474" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_522396da-c673-4a68-aaa6-9e1542f9aa0e" xlink:to="loc_us-gaap_CollaborativeArrangementMember_3d8f40b3-2569-4cdb-93c0-a8a66977a474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bce8c653-e19c-4609-a18c-16874f2eeb98" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:to="loc_srt_CounterpartyNameAxis_bce8c653-e19c-4609-a18c-16874f2eeb98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bce8c653-e19c-4609-a18c-16874f2eeb98_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bce8c653-e19c-4609-a18c-16874f2eeb98" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bce8c653-e19c-4609-a18c-16874f2eeb98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454ae39d-6fe7-48c1-9d62-3bf5e1bd9e14" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bce8c653-e19c-4609-a18c-16874f2eeb98" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454ae39d-6fe7-48c1-9d62-3bf5e1bd9e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CelgeneMember_17e76e2b-9b1c-40f9-94bc-b19e64c26c5d" xlink:href="prta-20200630.xsd#prta_CelgeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454ae39d-6fe7-48c1-9d62-3bf5e1bd9e14" xlink:to="loc_prta_CelgeneMember_17e76e2b-9b1c-40f9-94bc-b19e64c26c5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationProgramUSRightsMember_90c8403c-0b26-4c71-9119-0360c2175da6" xlink:href="prta-20200630.xsd#prta_CollaborationProgramUSRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454ae39d-6fe7-48c1-9d62-3bf5e1bd9e14" xlink:to="loc_prta_CollaborationProgramUSRightsMember_90c8403c-0b26-4c71-9119-0360c2175da6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationProgramGlobalRightsMember_7b0085a3-4c7c-4ca7-b08a-ed7951aa6f10" xlink:href="prta-20200630.xsd#prta_CollaborationProgramGlobalRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454ae39d-6fe7-48c1-9d62-3bf5e1bd9e14" xlink:to="loc_prta_CollaborationProgramGlobalRightsMember_7b0085a3-4c7c-4ca7-b08a-ed7951aa6f10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_91a0655d-fb50-4cae-8980-e1da15769d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_91a0655d-fb50-4cae-8980-e1da15769d4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91a0655d-fb50-4cae-8980-e1da15769d4a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_91a0655d-fb50-4cae-8980-e1da15769d4a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91a0655d-fb50-4cae-8980-e1da15769d4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0f9ae01-d49f-4005-bb62-535452505640" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_91a0655d-fb50-4cae-8980-e1da15769d4a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0f9ae01-d49f-4005-bb62-535452505640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f8cc96d3-db0b-45ea-bba7-41bc522efe26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0f9ae01-d49f-4005-bb62-535452505640" xlink:to="loc_us-gaap_PrivatePlacementMember_f8cc96d3-db0b-45ea-bba7-41bc522efe26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bed73528-f2e9-454a-921a-198bd429c09f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:to="loc_srt_ProductOrServiceAxis_bed73528-f2e9-454a-921a-198bd429c09f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bed73528-f2e9-454a-921a-198bd429c09f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bed73528-f2e9-454a-921a-198bd429c09f" xlink:to="loc_srt_ProductsAndServicesDomain_bed73528-f2e9-454a-921a-198bd429c09f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0c56d5da-81ed-4eff-bdad-bc399806c73a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bed73528-f2e9-454a-921a-198bd429c09f" xlink:to="loc_srt_ProductsAndServicesDomain_0c56d5da-81ed-4eff-bdad-bc399806c73a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationProgramUSRightsMember_fabb8fab-9fd9-496c-a2a5-22626d03272b" xlink:href="prta-20200630.xsd#prta_CollaborationProgramUSRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0c56d5da-81ed-4eff-bdad-bc399806c73a" xlink:to="loc_prta_CollaborationProgramUSRightsMember_fabb8fab-9fd9-496c-a2a5-22626d03272b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationProgramGlobalRightsMember_aeed945b-8055-4bc9-a55d-bfb9ad4d8116" xlink:href="prta-20200630.xsd#prta_CollaborationProgramGlobalRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0c56d5da-81ed-4eff-bdad-bc399806c73a" xlink:to="loc_prta_CollaborationProgramGlobalRightsMember_aeed945b-8055-4bc9-a55d-bfb9ad4d8116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b11984c7-6bdd-4a88-a4d2-d278bf312d2c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:to="loc_srt_RangeAxis_b11984c7-6bdd-4a88-a4d2-d278bf312d2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b11984c7-6bdd-4a88-a4d2-d278bf312d2c_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b11984c7-6bdd-4a88-a4d2-d278bf312d2c" xlink:to="loc_srt_RangeMember_b11984c7-6bdd-4a88-a4d2-d278bf312d2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c6e6825-0165-4b17-8ad6-35677dfd7222" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b11984c7-6bdd-4a88-a4d2-d278bf312d2c" xlink:to="loc_srt_RangeMember_1c6e6825-0165-4b17-8ad6-35677dfd7222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_41eae4b6-6379-43d4-ba1b-9148456f3dbe" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c6e6825-0165-4b17-8ad6-35677dfd7222" xlink:to="loc_srt_MinimumMember_41eae4b6-6379-43d4-ba1b-9148456f3dbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cea213fe-8aa0-419e-a2d2-b5e4497596f4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c6e6825-0165-4b17-8ad6-35677dfd7222" xlink:to="loc_srt_MaximumMember_cea213fe-8aa0-419e-a2d2-b5e4497596f4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/ShareholdersEquity" xlink:type="extended" id="i38b56b7e43744985ba4660258bfbd140_ShareholdersEquity"/>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/ShareholdersEquityDetails" xlink:type="extended" id="iae1bf897fe6342b4b7ec7cd0117a5600_ShareholdersEquityDetails"/>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/ShareBasedCompensation" xlink:type="extended" id="i5c6b105fc78e48af8bef4d1efc1d1ba2_ShareBasedCompensation"/>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationTables" xlink:type="extended" id="i996e8caba97d4f1fb82f5cd1f9923396_ShareBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="i29bca9bbb8944ab79ebc6b7c6d5b2917_ShareBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1781953d-2660-4670-a239-667ce68437a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1781953d-2660-4670-a239-667ce68437a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2f75d2de-d13e-423f-9add-4b4f81840140" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2f75d2de-d13e-423f-9add-4b4f81840140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_MaximumNumberofSharestobeIssuedISOExercise_c95381a5-a008-4aee-9319-c9ed1bfca243" xlink:href="prta-20200630.xsd#prta_MaximumNumberofSharestobeIssuedISOExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_prta_MaximumNumberofSharestobeIssuedISOExercise_c95381a5-a008-4aee-9319-c9ed1bfca243" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c262a43a-9d3f-4a9d-a73b-7cd5394503c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c262a43a-9d3f-4a9d-a73b-7cd5394503c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8dfeb0d7-e06c-4475-9375-9a4541dd2dee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8dfeb0d7-e06c-4475-9375-9a4541dd2dee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a1ee1324-d3aa-410b-98c6-f20f000257a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a1ee1324-d3aa-410b-98c6-f20f000257a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_59b94e55-e76d-41b7-866b-0fa9e81249fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_59b94e55-e76d-41b7-866b-0fa9e81249fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5dba040d-d5de-470f-938b-b23167c2b7db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5dba040d-d5de-470f-938b-b23167c2b7db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a47885d-248c-48fa-b985-8140aa5bd8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a47885d-248c-48fa-b985-8140aa5bd8fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a2728a6e-f02a-44e8-b6b4-306df3f9be1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a2728a6e-f02a-44e8-b6b4-306df3f9be1a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_36303f6f-3850-4ef9-8336-c8c15589e7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_36303f6f-3850-4ef9-8336-c8c15589e7ba" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_64e0ef06-ed85-4828-816b-0a213790eb6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_64e0ef06-ed85-4828-816b-0a213790eb6d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f7abc536-56d9-4dbe-a1b2-863d054cb6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f7abc536-56d9-4dbe-a1b2-863d054cb6d3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b7a5264-e75e-4b85-a74a-e58b44f11a30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b7a5264-e75e-4b85-a74a-e58b44f11a30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d13a5ef5-97a8-462d-b9d1-031b7bcc8828" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b7a5264-e75e-4b85-a74a-e58b44f11a30" xlink:to="loc_us-gaap_PlanNameAxis_d13a5ef5-97a8-462d-b9d1-031b7bcc8828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d13a5ef5-97a8-462d-b9d1-031b7bcc8828_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d13a5ef5-97a8-462d-b9d1-031b7bcc8828" xlink:to="loc_us-gaap_PlanNameDomain_d13a5ef5-97a8-462d-b9d1-031b7bcc8828_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_814479e0-6c59-4e17-be03-45cb6af67180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d13a5ef5-97a8-462d-b9d1-031b7bcc8828" xlink:to="loc_us-gaap_PlanNameDomain_814479e0-6c59-4e17-be03-45cb6af67180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_AmendedAndRestated2018LongTermIncentivePlanMember_a4496f4a-0256-4035-94c5-734792cfcc2a" xlink:href="prta-20200630.xsd#prta_AmendedAndRestated2018LongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_814479e0-6c59-4e17-be03-45cb6af67180" xlink:to="loc_prta_AmendedAndRestated2018LongTermIncentivePlanMember_a4496f4a-0256-4035-94c5-734792cfcc2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_A2012LongTermIncentivePlanMember_997aeae3-08c2-4904-a2fc-d6680f4f6cba" xlink:href="prta-20200630.xsd#prta_A2012LongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_814479e0-6c59-4e17-be03-45cb6af67180" xlink:to="loc_prta_A2012LongTermIncentivePlanMember_997aeae3-08c2-4904-a2fc-d6680f4f6cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_A2020EmploymentInducementIncentivePlanMember_ec8b619d-5209-449f-99bf-f95c9508e1eb" xlink:href="prta-20200630.xsd#prta_A2020EmploymentInducementIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_814479e0-6c59-4e17-be03-45cb6af67180" xlink:to="loc_prta_A2020EmploymentInducementIncentivePlanMember_ec8b619d-5209-449f-99bf-f95c9508e1eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f7079cee-6e01-45a7-9aec-0e968cfa3c04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b7a5264-e75e-4b85-a74a-e58b44f11a30" xlink:to="loc_us-gaap_AwardTypeAxis_f7079cee-6e01-45a7-9aec-0e968cfa3c04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7079cee-6e01-45a7-9aec-0e968cfa3c04_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f7079cee-6e01-45a7-9aec-0e968cfa3c04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7079cee-6e01-45a7-9aec-0e968cfa3c04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_692014bf-128d-48aa-975d-5a56e5b14eb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f7079cee-6e01-45a7-9aec-0e968cfa3c04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_692014bf-128d-48aa-975d-5a56e5b14eb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9f986981-64a0-444d-b4c3-a2569cf2f73f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_692014bf-128d-48aa-975d-5a56e5b14eb5" xlink:to="loc_us-gaap_CommonStockMember_9f986981-64a0-444d-b4c3-a2569cf2f73f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail" xlink:type="extended" id="ic3ab75afdbd1497a87f3d942129ca3a8_ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42c5f0eb-9562-454c-a342-c2ede32a66d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cf23df1a-5634-4262-b56a-b34bc219c30d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42c5f0eb-9562-454c-a342-c2ede32a66d2" xlink:to="loc_us-gaap_ShareBasedCompensation_cf23df1a-5634-4262-b56a-b34bc219c30d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc182b29-4faf-4860-8767-e99ae7cd7543" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42c5f0eb-9562-454c-a342-c2ede32a66d2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc182b29-4faf-4860-8767-e99ae7cd7543" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dd569e74-7bf9-42e4-a485-13640e5f22e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc182b29-4faf-4860-8767-e99ae7cd7543" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dd569e74-7bf9-42e4-a485-13640e5f22e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dd569e74-7bf9-42e4-a485-13640e5f22e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd569e74-7bf9-42e4-a485-13640e5f22e9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dd569e74-7bf9-42e4-a485-13640e5f22e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70c37d4f-3342-4cb6-ba54-1877e5b654c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd569e74-7bf9-42e4-a485-13640e5f22e9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_70c37d4f-3342-4cb6-ba54-1877e5b654c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e6729860-300d-4864-9e7d-97ab02b439dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_70c37d4f-3342-4cb6-ba54-1877e5b654c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e6729860-300d-4864-9e7d-97ab02b439dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_26e72574-9211-4e29-ab00-c9cae006e1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_70c37d4f-3342-4cb6-ba54-1877e5b654c9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_26e72574-9211-4e29-ab00-c9cae006e1d0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationFairValueofOptionsGrantedDetail"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail" xlink:type="extended" id="i691d1ed34c7847d38e6536767fede23d_ShareBasedCompensationFairValueofOptionsGrantedDetail"/>
  <link:roleRef roleURI="http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail" xlink:type="extended" id="i6dbd06cbfe574490b689c9e04928958a_SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"/>
  <link:roleRef roleURI="http://www.prothena.com/role/IncomeTaxes" xlink:type="simple" xlink:href="prta-20200630.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/IncomeTaxes" xlink:type="extended" id="i8b36773e6b32453b9eace9f36745f390_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i402ba6bac54541838a4320a7c39d482b_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:href="prta-20200630.xsd#prta_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_eeba553d-45fc-416f-a377-2cadc169d5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_eeba553d-45fc-416f-a377-2cadc169d5c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_47492f08-c5d3-456f-80e7-1efcf8e7c010" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_47492f08-c5d3-456f-80e7-1efcf8e7c010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision_3fae1b2a-d5d1-4b48-935e-95e305ee61a5" xlink:href="prta-20200630.xsd#prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision_3fae1b2a-d5d1-4b48-935e-95e305ee61a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets_9aedf00f-794b-4381-8581-ef1e9b3530db" xlink:href="prta-20200630.xsd#prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets_9aedf00f-794b-4381-8581-ef1e9b3530db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a2aa7b13-5470-4910-b8c5-c8599cedea80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a2aa7b13-5470-4910-b8c5-c8599cedea80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PotentialWithholdingTaxRate_a9d56a92-6824-48f0-840f-2acb8b28f1b9" xlink:href="prta-20200630.xsd#prta_PotentialWithholdingTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_prta_PotentialWithholdingTaxRate_a9d56a92-6824-48f0-840f-2acb8b28f1b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_IncomeTaxesTable_7d91a632-0f4b-4b11-9249-21b16f6f0916" xlink:href="prta-20200630.xsd#prta_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_prta_IncomeTaxesTable_7d91a632-0f4b-4b11-9249-21b16f6f0916" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ffc4ab0f-8404-4964-8ed3-d509a700af97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prta_IncomeTaxesTable_7d91a632-0f4b-4b11-9249-21b16f6f0916" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ffc4ab0f-8404-4964-8ed3-d509a700af97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ffc4ab0f-8404-4964-8ed3-d509a700af97_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ffc4ab0f-8404-4964-8ed3-d509a700af97" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ffc4ab0f-8404-4964-8ed3-d509a700af97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4813790c-f78e-4bba-9947-956f43fd96b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ffc4ab0f-8404-4964-8ed3-d509a700af97" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4813790c-f78e-4bba-9947-956f43fd96b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_1c5334f9-5af8-4878-b907-cfe3a3fa9037" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4813790c-f78e-4bba-9947-956f43fd96b6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_1c5334f9-5af8-4878-b907-cfe3a3fa9037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_0fb5673b-e84f-4745-a727-3b4f46e330f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prta_IncomeTaxesTable_7d91a632-0f4b-4b11-9249-21b16f6f0916" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_0fb5673b-e84f-4745-a727-3b4f46e330f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_0fb5673b-e84f-4745-a727-3b4f46e330f2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_0fb5673b-e84f-4745-a727-3b4f46e330f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_0fb5673b-e84f-4745-a727-3b4f46e330f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_86a43271-fbe7-417c-ae30-89baf8630e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_0fb5673b-e84f-4745-a727-3b4f46e330f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_86a43271-fbe7-417c-ae30-89baf8630e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember_f04c894b-5579-4af6-b310-c7fb5395f6dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_86a43271-fbe7-417c-ae30-89baf8630e1d" xlink:to="loc_us-gaap_RevenueCommissionersIrelandMember_f04c894b-5579-4af6-b310-c7fb5395f6dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_713f4bf0-ca75-4711-b2b4-d3021a93c7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_86a43271-fbe7-417c-ae30-89baf8630e1d" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_713f4bf0-ca75-4711-b2b4-d3021a93c7fc" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>prta-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:38da442c-e5f6-4ed8-bb27-93106113c3da,g:af883291-30ed-4afd-a355-adc261f9a88c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_prta_A2012LongTermIncentivePlanMember_2b215454-d42f-4e8b-9018-59f047c51ee1_terseLabel_en-US" xlink:label="lab_prta_A2012LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Long Term Incentive Plan</link:label>
    <link:label id="lab_prta_A2012LongTermIncentivePlanMember_label_en-US" xlink:label="lab_prta_A2012LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Long Term Incentive Plan [Member]</link:label>
    <link:label id="lab_prta_A2012LongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_prta_A2012LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2012 Long Term Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_A2012LongTermIncentivePlanMember" xlink:href="prta-20200630.xsd#prta_A2012LongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_A2012LongTermIncentivePlanMember" xlink:to="lab_prta_A2012LongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_d9f4ad73-002e-4244-88dd-fbffd6222217_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1462846-2582-4707-927d-002bc40b051e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a74a2ad-6e51-409b-ad18-01100dd7f88e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_80ef53b4-01e9-4c1c-8c26-131e36b3c1b5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit has been used</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram_77a7e760-d4b3-455d-9a2e-bc2220d72c28_terseLabel_en-US" xlink:label="lab_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, potential commercial milestone payments per program</link:label>
    <link:label id="lab_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram_label_en-US" xlink:label="lab_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Potential Commercial Milestone Payments Per Program</link:label>
    <link:label id="lab_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram_documentation_en-US" xlink:label="lab_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Potential Commercial Milestone Payments Per Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram" xlink:to="lab_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_148ce542-215c-4a6a-914b-10912af4b3b2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_AccruedResearchAndDevelopmentCurrent_e2a461fc-0235-4682-810e-8a56513f114b_terseLabel_en-US" xlink:label="lab_prta_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development</link:label>
    <link:label id="lab_prta_AccruedResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_prta_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Current</link:label>
    <link:label id="lab_prta_AccruedResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_prta_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_AccruedResearchAndDevelopmentCurrent" xlink:href="prta-20200630.xsd#prta_AccruedResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_AccruedResearchAndDevelopmentCurrent" xlink:to="lab_prta_AccruedResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_AmendedAndRestated2018LongTermIncentivePlanMember_a8656ff7-2075-4cc0-b81f-06c911907c67_terseLabel_en-US" xlink:label="lab_prta_AmendedAndRestated2018LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Long Term Incentive Plan</link:label>
    <link:label id="lab_prta_AmendedAndRestated2018LongTermIncentivePlanMember_label_en-US" xlink:label="lab_prta_AmendedAndRestated2018LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2018 Long Term Incentive Plan [Member]</link:label>
    <link:label id="lab_prta_AmendedAndRestated2018LongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_prta_AmendedAndRestated2018LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated 2018 Long Term Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_AmendedAndRestated2018LongTermIncentivePlanMember" xlink:href="prta-20200630.xsd#prta_AmendedAndRestated2018LongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_AmendedAndRestated2018LongTermIncentivePlanMember" xlink:to="lab_prta_AmendedAndRestated2018LongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d4764a1-bdc0-4219-8d37-10b7a5050c1b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_5144855a-8527-431c-a29c-3a70eef625fa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies [line item]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_70679c6b-c8d2-46eb-9772-c5e070561b05_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions_20cfbcd0-1805-471a-abeb-349213f0836d_verboseLabel_en-US" xlink:label="lab_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested</link:label>
    <link:label id="lab_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions_label_en-US" xlink:label="lab_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options</link:label>
    <link:label id="lab_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions_documentation_en-US" xlink:label="lab_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions" xlink:href="prta-20200630.xsd#prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions" xlink:to="lab_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4478955f-f77c-4aea-b491-82191c21aece_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage_009ebfee-302c-43ca-b7dc-59a3cdfee8e5_terseLabel_en-US" xlink:label="lab_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, portion of revenue and expenses attributable to company, percentage</link:label>
    <link:label id="lab_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage_label_en-US" xlink:label="lab_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement, Portion of Revenue and Expenses Attributable to Company, Percentage</link:label>
    <link:label id="lab_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage_documentation_en-US" xlink:label="lab_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement, Portion of Revenue and Expenses Attributable to Company, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" xlink:href="prta-20200630.xsd#prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" xlink:to="lab_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CelgeneMember_bce1c9f0-fde6-4a19-ad91-fcf8ee8fe361_terseLabel_en-US" xlink:label="lab_prta_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene</link:label>
    <link:label id="lab_prta_CelgeneMember_label_en-US" xlink:label="lab_prta_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene [Member]</link:label>
    <link:label id="lab_prta_CelgeneMember_documentation_en-US" xlink:label="lab_prta_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CelgeneMember" xlink:href="prta-20200630.xsd#prta_CelgeneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CelgeneMember" xlink:to="lab_prta_CelgeneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_7b129fce-dea0-483c-b111-6755910561a8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Due in Third Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:to="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CompositionofCertainBalanceSheetItemsAbstract_b26838ff-d3d7-4712-b7e3-97f3961ef134_terseLabel_en-US" xlink:label="lab_prta_CompositionofCertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of Certain Balance Sheet Items [Abstract]</link:label>
    <link:label id="lab_prta_CompositionofCertainBalanceSheetItemsAbstract_label_en-US" xlink:label="lab_prta_CompositionofCertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of Certain Balance Sheet Items [Abstract]</link:label>
    <link:label id="lab_prta_CompositionofCertainBalanceSheetItemsAbstract_documentation_en-US" xlink:label="lab_prta_CompositionofCertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of Certain Balance Sheet Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CompositionofCertainBalanceSheetItemsAbstract" xlink:href="prta-20200630.xsd#prta_CompositionofCertainBalanceSheetItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract" xlink:to="lab_prta_CompositionofCertainBalanceSheetItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e94fe5cc-15d2-4b9f-8a08-78c6e2c060b0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets_32720c33-8e1c-4cce-afab-91c6a9207317_negatedTerseLabel_en-US" xlink:label="lab_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of new accounting pronouncement</link:label>
    <link:label id="lab_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets_label_en-US" xlink:label="lab_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Cumulative Effect of Change on Deferred Tax Assets</link:label>
    <link:label id="lab_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets_documentation_en-US" xlink:label="lab_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Cumulative Effect of Change on Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets" xlink:href="prta-20200630.xsd#prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets" xlink:to="lab_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_bc95e99d-fba1-4faf-be0b-23993ae3644e_verboseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to suppliers included in accrued current liabilities</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1cb3e762-06d9-4505-b00a-e6b36d439e8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19456c37-bdbe-413c-9b66-ef056cc4c39a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e06b5a1c-de63-4e5a-8a68-7b230670a052_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3b424300-2dbe-4b87-a6ca-835ff3e34281_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c303a179-0c5f-414b-9a8e-9cf88bf40447_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice_d0d11b3e-fc4f-40f4-a6ab-658b32fa4060_terseLabel_en-US" xlink:label="lab_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, expected allocation of initial transaction price</link:label>
    <link:label id="lab_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice_label_en-US" xlink:label="lab_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Expected Allocation of Initial Transaction Price</link:label>
    <link:label id="lab_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice_documentation_en-US" xlink:label="lab_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Expected Allocation of Initial Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice" xlink:to="lab_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c8247447-4ef3-46f1-8349-86182be21b09_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49293886-503c-4204-a114-3eb5e81ba069_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_069a8a5b-0b0a-4ada-8551-fafcff479a40_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_271f7d91-4e65-4091-87e1-133f2c6a4649_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_320b5793-e454-46e3-900e-1e297289ad8e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, vested (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationMember_c27f51c1-cf20-46d8-8037-da080afc836b_terseLabel_en-US" xlink:label="lab_prta_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration</link:label>
    <link:label id="lab_prta_CollaborationMember_label_en-US" xlink:label="lab_prta_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_prta_CollaborationMember_documentation_en-US" xlink:label="lab_prta_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationMember" xlink:href="prta-20200630.xsd#prta_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationMember" xlink:to="lab_prta_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_60289578-7b87-4745-a63a-4b52ad475b51_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_84b9845a-aafa-44f6-a25a-0d792a2cab60_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b380a962-3927-4ec6-a45d-9fc933fcbad9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_ad9a785d-2750-4294-b13f-abd2e2cd9236_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable, current</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_e3cc436c-0e3b-453c-a93e-a2c3f187a967_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationAgreementUpfrontPaymentPaymentTerm_9409a2ed-c17c-41b6-8b64-201ba34dc05c_terseLabel_en-US" xlink:label="lab_prta_CollaborationAgreementUpfrontPaymentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, upfront payment, payment term</link:label>
    <link:label id="lab_prta_CollaborationAgreementUpfrontPaymentPaymentTerm_label_en-US" xlink:label="lab_prta_CollaborationAgreementUpfrontPaymentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment, Payment Term</link:label>
    <link:label id="lab_prta_CollaborationAgreementUpfrontPaymentPaymentTerm_documentation_en-US" xlink:label="lab_prta_CollaborationAgreementUpfrontPaymentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementUpfrontPaymentPaymentTerm" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementUpfrontPaymentPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationAgreementUpfrontPaymentPaymentTerm" xlink:to="lab_prta_CollaborationAgreementUpfrontPaymentPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_83be52dc-c365-43ca-9dde-5bf6b2bbb0aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LesseeOperatingLeaseLiabilityNominalPayments_30c4aa8c-51b8-4eb8-b648-74670e154327_negatedTerseLabel_en-US" xlink:label="lab_prta_LesseeOperatingLeaseLiabilityNominalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nominal lease payments</link:label>
    <link:label id="lab_prta_LesseeOperatingLeaseLiabilityNominalPayments_label_en-US" xlink:label="lab_prta_LesseeOperatingLeaseLiabilityNominalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Nominal Payments</link:label>
    <link:label id="lab_prta_LesseeOperatingLeaseLiabilityNominalPayments_documentation_en-US" xlink:label="lab_prta_LesseeOperatingLeaseLiabilityNominalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Nominal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LesseeOperatingLeaseLiabilityNominalPayments" xlink:href="prta-20200630.xsd#prta_LesseeOperatingLeaseLiabilityNominalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LesseeOperatingLeaseLiabilityNominalPayments" xlink:to="lab_prta_LesseeOperatingLeaseLiabilityNominalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_778e4248-fac0-46c0-ae33-4e13edfaa919_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_a265b9c9-a2ec-459a-8950-f2f7518355d6_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments due over lease term</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9a9a84a8-d01c-4854-8721-1fa8e1a79b73_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5be5d604-5feb-4ddc-92d5-708c225da495_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets recorded upon adoption of ASC 842</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_48076eda-e6f2-4489-8175-057f1f1de22c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_f70e3b50-4b48-49ac-90ee-67b0abef12c8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseExpirationDate1_3d5fadff-138b-4416-9a70-f0c5df95c083_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseExpirationDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease expiration date</link:label>
    <link:label id="lab_us-gaap_LeaseExpirationDate1_label_en-US" xlink:label="lab_us-gaap_LeaseExpirationDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseExpirationDate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1" xlink:to="lab_us-gaap_LeaseExpirationDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_90ef22ce-309a-4dde-9879-a4dbbf2b3cb9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction_3fa94423-2809-48d9-bc0f-60ca079af089_negatedTerseLabel_en-US" xlink:label="lab_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of capitalized interest under build-to-suit lease upon adoption of ASC 842</link:label>
    <link:label id="lab_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction_label_en-US" xlink:label="lab_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of Capitalized Interest During Construction Period for Build-to-suit Lease Transaction</link:label>
    <link:label id="lab_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction_documentation_en-US" xlink:label="lab_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of Capitalized Interest During Construction Period for Build-to-suit Lease Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction" xlink:href="prta-20200630.xsd#prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction" xlink:to="lab_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_bd92dfa4-7c6b-40b0-b8fa-a532e556bc63_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8748ab16-f6b5-4497-928b-989b4216380d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bf36762-60df-4b79-9516-583146d487a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_116e2921-f82a-43a0-83c2-4eb35ec5cbd1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_556374b6-87d2-43c2-9fcc-981ce754497e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationRevenue_58b236c2-e357-456e-b125-7a4bb39205ce_terseLabel_en-US" xlink:label="lab_prta_CollaborationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_prta_CollaborationRevenue_label_en-US" xlink:label="lab_prta_CollaborationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:label id="lab_prta_CollaborationRevenue_documentation_en-US" xlink:label="lab_prta_CollaborationRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationRevenue" xlink:href="prta-20200630.xsd#prta_CollaborationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationRevenue" xlink:to="lab_prta_CollaborationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_71cabca7-1b83-4711-8090-1a3a47f7af54_verboseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (6 months)</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9231e08e-345a-43b5-bd6d-4bd3c3801038_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_92ad490c-ebbb-4209-87fc-81feb89cacad_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average ordinary shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsTermofContract_6cb5e2ec-9640-4411-86c9-62a4b4bfe990_terseLabel_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsTermofContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-sublease rentals, term of contract</link:label>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsTermofContract_label_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsTermofContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease Rentals, Term of Contract</link:label>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsTermofContract_documentation_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsTermofContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease Rentals, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsTermofContract" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsTermofContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_OperatingLeasesSubleaseRentalsTermofContract" xlink:to="lab_prta_OperatingLeasesSubleaseRentalsTermofContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_01b5b1c1-2317-4e16-882c-3fe47c1061d4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share subscription agreement, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7bbf7f3f-6513-4746-9506-12b18bd11a29_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f1045352-4b14-4797-a5cd-cfbf68e22cdc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_4427f602-4784-4088-aa5f-33464257e4f0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3dd6ad84-485f-45a5-abcd-f1e204dd75ad_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_8052ad93-4c4d-4180-a2a3-8ff82d2c1aea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_9078e0bc-4ae9-4863-927e-bc140788dd16_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LicenseAgreementTable_0d06a18b-c350-4752-93a8-d7999cc8d815_terseLabel_en-US" xlink:label="lab_prta_LicenseAgreementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Table]</link:label>
    <link:label id="lab_prta_LicenseAgreementTable_label_en-US" xlink:label="lab_prta_LicenseAgreementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Table]</link:label>
    <link:label id="lab_prta_LicenseAgreementTable_documentation_en-US" xlink:label="lab_prta_LicenseAgreementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementTable" xlink:href="prta-20200630.xsd#prta_LicenseAgreementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LicenseAgreementTable" xlink:to="lab_prta_LicenseAgreementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_2fab2286-47dc-40cf-aa02-95ab514dbec3_verboseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e34dd369-20c3-4240-948f-bd1b76e8efe5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_742b2504-2134-4ae2-83bc-b68a3efcf4af_verboseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_0613c255-3b84-4132-afb1-4b182f097097_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative adjustment to accumulated deficit upon adoption of ASC-842</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a9b7f251-9215-4fd6-adf4-2643138c57be_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinThirdYear_1ccdb107-594a-443b-9ec6-3082e72dca4f_totalLabel_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinThirdYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinThirdYear_label_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Due in Third Year</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinThirdYear_documentation_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinThirdYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Due in Third Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinThirdYear" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_PurchaseandContractualObligationDueinThirdYear" xlink:to="lab_prta_PurchaseandContractualObligationDueinThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_3acaa724-26fe-4b31-a5c1-22aa8f4ffd78_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d9bad552-5d2e-4f6e-a72b-a09c22d5d8e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2961328f-4f53-4346-b802-c250a1d1fad0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0c8883a5-4dd7-4c32-89da-869649c1354c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones_80017dff-58d3-4fd2-88ea-1df3c1384c59_terseLabel_en-US" xlink:label="lab_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, potential payment for achievement of non U.S. commercial sales milestones</link:label>
    <link:label id="lab_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones_label_en-US" xlink:label="lab_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Payment for Achievement of non U.S. Commercial Sales Milestones</link:label>
    <link:label id="lab_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones_documentation_en-US" xlink:label="lab_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Payment for Achievement of non U.S. Commercial Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones" xlink:href="prta-20200630.xsd#prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones" xlink:to="lab_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_da4de398-a78f-4b59-89ba-79528dcda1be_verboseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Fourth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_67f048fb-6f40-4608-a4cd-8c99f23bac16_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ecc660f4-2f19-4ba3-9e31-d4d684bf33d1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f6a8b5f5-acd5-468e-ae6c-c3966212d115_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision_0797a238-c19e-4e35-8ded-1e90677bfa47_terseLabel_en-US" xlink:label="lab_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net tax shortfall (excess tax benefit) booked to income tax provision, amount</link:label>
    <link:label id="lab_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision_label_en-US" xlink:label="lab_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Net Tax Shortfall (Excess Tax Benefit) Amount Booked to Income Tax Provision</link:label>
    <link:label id="lab_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision_documentation_en-US" xlink:label="lab_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Net Tax Shortfall (Excess Tax Benefit) Amount Booked to Income Tax Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" xlink:href="prta-20200630.xsd#prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" xlink:to="lab_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_dfc89d64-5c46-48b9-a0fb-498556a790e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a03166fe-2783-41bb-9aec-8e39e97b4d22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6c55e173-115f-41da-be56-7a37b69dd990_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f0724ec7-e1be-4f8d-b7b4-58b480876cb0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9f49f74-e5ca-4394-b6a3-572081b22380_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, outstanding beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5183e1d3-1533-4166-9e9f-8e95a4c766e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, outstanding ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_90022287-d8ac-4e55-bb77-b76558d2f5dd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_6e07357f-647b-4f4a-b9df-43405e70d162_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3848863-8653-4676-ae7d-70ba64c1288a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_a99003a4-7508-408d-a036-c52096355642_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-Sublease Rental</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_InitialTransactionPrice_fccba846-9cd2-4270-b596-069b709b06a5_terseLabel_en-US" xlink:label="lab_prta_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, initial transaction price</link:label>
    <link:label id="lab_prta_InitialTransactionPrice_283809d8-659d-48e9-bf8d-63bb357c606b_verboseLabel_en-US" xlink:label="lab_prta_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, initial transaction price</link:label>
    <link:label id="lab_prta_InitialTransactionPrice_label_en-US" xlink:label="lab_prta_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Transaction Price</link:label>
    <link:label id="lab_prta_InitialTransactionPrice_documentation_en-US" xlink:label="lab_prta_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customers, Initial Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_InitialTransactionPrice" xlink:href="prta-20200630.xsd#prta_InitialTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_InitialTransactionPrice" xlink:to="lab_prta_InitialTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48eb331e-c68c-44b8-af36-2628a351ddf2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4f3d1d6c-127a-47f0-abf0-e98948f397b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_6ae0ec9e-aa47-4fe4-a662-bc63f92b53ec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bf33a979-3e1f-41e1-82c8-bd1fdfe776ad_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_d77e155e-9022-4257-8102-b3fcc8fe167f_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_26bd6c08-f90a-4807-a58e-f405c3bc4daf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_56ced301-4b8d-4635-97dc-1bed133d5d6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4affff06-b628-48b8-8b37-71f9a13d1a08_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b2313f59-7aae-4a45-9281-13b8fc812511_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares, number of outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_eee94a7d-83df-442b-a8b5-cbb69368ddfc_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1f73fd6b-a440-4c0e-b19f-56311cafe870_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1ee71ba1-e34f-405e-b16c-1985a710208e_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation cost not yet recognized, Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_25b0a535-5f26-42d0-9749-dc2297d3ac29_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_1f7f3062-5f5e-42a3-9d65-77a5d8382f7c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_315ab738-b3e0-4678-99dc-e2741d9f68d3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_cbc05663-828f-49e8-88b5-f08095972448_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_36d7fd43-50bc-455c-a698-3768368026e1_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b1182fd9-2f54-4595-a3e6-92a75fd77511_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborativeAgreementAbstract_7bb0e750-e6f7-4d62-b56c-0e23e27de6ac_terseLabel_en-US" xlink:label="lab_prta_CollaborativeAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement [Abstract]</link:label>
    <link:label id="lab_prta_CollaborativeAgreementAbstract_label_en-US" xlink:label="lab_prta_CollaborativeAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement [Abstract]</link:label>
    <link:label id="lab_prta_CollaborativeAgreementAbstract_documentation_en-US" xlink:label="lab_prta_CollaborativeAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborativeAgreementAbstract" xlink:href="prta-20200630.xsd#prta_CollaborativeAgreementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborativeAgreementAbstract" xlink:to="lab_prta_CollaborativeAgreementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract_641a7340-2fbc-4ee6-bc88-e0801d76e4d6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligations, Fiscal Year Maturity</link:label>
    <link:label id="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c4d88267-2cb5-4182-8c13-2bd382a67ee1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_da0e9ed2-3657-48ff-9edc-000bdcf6b929_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0150eeae-922c-4250-9855-9aba3e00140c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, future minimum payments due</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50c97611-5487-4e09-a30c-9a7068074892_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2af16253-4b5b-485d-b7f7-ef0d3d0038fb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_43c186f9-b5b2-4062-bcac-3b7bd35c2b4e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c5c5b189-fc38-4af2-a254-f9f0ca76fd18_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_DeferredSharesShareIssued_ee394f56-11d0-4e8f-9175-77fe0bff438e_terseLabel_en-US" xlink:label="lab_prta_DeferredSharesShareIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro deferred shares, number of issued shares (in shares)</link:label>
    <link:label id="lab_prta_DeferredSharesShareIssued_label_en-US" xlink:label="lab_prta_DeferredSharesShareIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares Share Issued</link:label>
    <link:label id="lab_prta_DeferredSharesShareIssued_documentation_en-US" xlink:label="lab_prta_DeferredSharesShareIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares Share Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesShareIssued" xlink:href="prta-20200630.xsd#prta_DeferredSharesShareIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_DeferredSharesShareIssued" xlink:to="lab_prta_DeferredSharesShareIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_40518c1c-5fda-4e3f-90dc-981a4e5f6dd5_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_f9d1af9c-154e-466f-b67b-1013cce33993_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueAfterFifthYear_036c6bf6-490e-41a0-a2f0-a0eca87c7791_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueAfterFifthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due after Fifth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:to="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_ba16c2e8-6040-4ab9-82f9-ebdbe6ec3396_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e8b32d1b-d959-42e3-90aa-135661d2adcc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_624d82d8-11fc-4d98-9606-d2d3cdade513_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_63732ac6-f1ee-4f24-a3ea-dc946cb84496_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cecce26c-6dbc-473d-b38d-8f0bca188f23_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e00904c-fb7a-4ca4-ba6d-23001254d62d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5d470334-ce00-47d4-941d-2e8f9f2cc4ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_345a5af6-6a71-4803-afe8-9b34c6440e89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options granted to employees (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_29098799-f156-4a8f-8b42-7d768bc57adb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord_7435d3b9-5428-4e05-8fcf-494d259aae5b_terseLabel_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-sublease rentals, percent of rental gain attributable to sublandlord</link:label>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord_label_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease Rentals, Percent of Rental Gain Attributable to Sublandlord</link:label>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord_documentation_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease Rentals, Percent of Rental Gain Attributable to Sublandlord</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord" xlink:to="lab_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_99a357a1-ea59-4759-9d54-b70d43b23e9f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, Dublin, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5468c56e-84ef-41f6-bfad-e4ade8ae49c4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c23feef8-cd72-4058-a607-96742a59a8f9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed_cfa05d82-4200-428b-ab29-e553db14358d_terseLabel_en-US" xlink:label="lab_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, number of additional 12 month period extension allowed</link:label>
    <link:label id="lab_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed_label_en-US" xlink:label="lab_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number of Additional 12 Month Period Extension Allowed</link:label>
    <link:label id="lab_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed_documentation_en-US" xlink:label="lab_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number of Additional 12 Month Period Extension Allowed per contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed" xlink:to="lab_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_597d805b-7169-4431-bee6-17d550b43143_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_57cfb0c7-958b-45ef-99cb-090e78688364_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c43ea894-a98b-4d11-99b0-8f8acbb60b48_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4c70213b-4c6e-4cb6-a68a-acec0dc0e9df_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_296ba795-20c6-43b9-a1b0-36cf250a1fe4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of ordinary shares upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_ac33087d-73ee-498a-8a14-f12b4e85a32b_verboseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Second Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2a1f92db-34bf-4d5b-bdd0-29aee83dc6de_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f74a6c15-ddf9-4547-864c-d4e0f440f116_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_8c49dbbe-b724-4903-8a72-f3f08d657bda_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92c85a5-d454-4e23-a90e-304461adc379_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_40bef4e9-7440-4cdc-972d-59f03193ad6f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_86191448-9bc9-4c5a-8c46-b73d1f72fe32_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_SignificantAgreementsTextBlock_cc4a1092-1cc5-4203-abe4-d0366dd5bcb3_terseLabel_en-US" xlink:label="lab_prta_SignificantAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_prta_SignificantAgreementsTextBlock_label_en-US" xlink:label="lab_prta_SignificantAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Agreements [Text Block]</link:label>
    <link:label id="lab_prta_SignificantAgreementsTextBlock_documentation_en-US" xlink:label="lab_prta_SignificantAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Agreements [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SignificantAgreementsTextBlock" xlink:href="prta-20200630.xsd#prta_SignificantAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_SignificantAgreementsTextBlock" xlink:to="lab_prta_SignificantAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f753ad29-2fbd-4ff6-9eb1-1a8a5de5e1fd_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_cccfa1c7-feed-449f-98b0-fbe7bd514325_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f0db2d77-390e-48ce-be30-13efe2d10c94_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dcc0704f-a83e-4134-bd1b-6cac9efa8b46_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_066d87e7-91fe-4a73-b81a-6cfdd7a83ca1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b73d38e1-7328-4c7c-9285-c9e4683b18ba_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_ca8ac006-c356-46be-9978-683f3ce7865b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_78d3f7c9-1c73-4577-9721-15b20c2fca0b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_0efe818b-489c-4508-8db3-299ad0259a68_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_fe4dd493-5331-4a74-a60e-7a2b2a1b2a9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_500ecc86-0228-4693-ad9c-bfe88754ef06_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationRevenueLicenseUpfrontPayment_9c58f36f-2d82-4560-878f-e96589da35f9_terseLabel_en-US" xlink:label="lab_prta_CollaborationRevenueLicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue, license, upfront payment</link:label>
    <link:label id="lab_prta_CollaborationRevenueLicenseUpfrontPayment_label_en-US" xlink:label="lab_prta_CollaborationRevenueLicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue, License, Upfront Payment</link:label>
    <link:label id="lab_prta_CollaborationRevenueLicenseUpfrontPayment_documentation_en-US" xlink:label="lab_prta_CollaborationRevenueLicenseUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue, License, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationRevenueLicenseUpfrontPayment" xlink:href="prta-20200630.xsd#prta_CollaborationRevenueLicenseUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationRevenueLicenseUpfrontPayment" xlink:to="lab_prta_CollaborationRevenueLicenseUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_0e372199-695a-4940-a40b-ec1ba78fdc0f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2a589a06-dc0d-48ba-83d2-a79791a16ac8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3226e16c-6b70-46e1-b83e-e991fe5a03c4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueAfterFifthYear_3b70d3bf-c378-4716-8020-dda957fee317_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueAfterFifthYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Due after Fifth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="lab_us-gaap_ContractualObligationDueAfterFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental_f052a382-749f-45f4-bf92-6521b50a9fde_terseLabel_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of sub-sublease rental</link:label>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental_label_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease Rentals, Area of Sublease Rental</link:label>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental_documentation_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease Rentals, Area of Sublease Rental</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental" xlink:to="lab_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_83ea045f-ae92-43b3-860c-da82f94715d1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LicenseAgreementDevelopmentServicesPaymentTerm_1aff57a5-9fc0-42e3-9a31-532218ed50eb_terseLabel_en-US" xlink:label="lab_prta_LicenseAgreementDevelopmentServicesPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, development services, payment term</link:label>
    <link:label id="lab_prta_LicenseAgreementDevelopmentServicesPaymentTerm_label_en-US" xlink:label="lab_prta_LicenseAgreementDevelopmentServicesPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Development Services, Payment Term</link:label>
    <link:label id="lab_prta_LicenseAgreementDevelopmentServicesPaymentTerm_documentation_en-US" xlink:label="lab_prta_LicenseAgreementDevelopmentServicesPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Development Services, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementDevelopmentServicesPaymentTerm" xlink:href="prta-20200630.xsd#prta_LicenseAgreementDevelopmentServicesPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LicenseAgreementDevelopmentServicesPaymentTerm" xlink:to="lab_prta_LicenseAgreementDevelopmentServicesPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36766202-f6ab-4353-a68d-12f4e655291c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share subscription agreement, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_815ff0fa-12f3-4893-8755-af01cf9f131b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8348fab9-a1eb-4e2b-825b-22da40a5c830_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3117daec-2670-4fa3-bd51-a44e6fd45404_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_53ef7c29-5c8c-4df2-a64b-175e1e7ecc0a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share subscription agreement, number of ordinary shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_03911d86-324e-4c86-9de2-5537f6902c3d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_04ae9cea-3673-47b4-af8b-9b0fd35a994e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_0ef24f51-2061-414a-82f2-ecd702e1187c_verboseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Third Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_95214908-b264-4eb0-a817-d132d899c01e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_3b4a10c8-8300-46d4-bbdb-1034362d9091_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1a25e05f-c661-4541-bd48-66808757cb49_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, vested and expected to vest ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f1098977-be2d-417e-806d-0cd80ff7aec0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2b9741e6-1eb7-4752-89c4-c39147799736_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares Equivalent Not Included in Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_877487f9-fdae-4900-a981-414c4a8887c7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6c295e17-9973-474b-96b1-4f91976d8127_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_MilestonePaymentReceivedClinicalMilestone_87e7efdf-8791-4e9b-a142-7f9df1c62e28_terseLabel_en-US" xlink:label="lab_prta_MilestonePaymentReceivedClinicalMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received, clinical milestone</link:label>
    <link:label id="lab_prta_MilestonePaymentReceivedClinicalMilestone_label_en-US" xlink:label="lab_prta_MilestonePaymentReceivedClinicalMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Received, Clinical Milestone</link:label>
    <link:label id="lab_prta_MilestonePaymentReceivedClinicalMilestone_documentation_en-US" xlink:label="lab_prta_MilestonePaymentReceivedClinicalMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Received, Clinical Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_MilestonePaymentReceivedClinicalMilestone" xlink:href="prta-20200630.xsd#prta_MilestonePaymentReceivedClinicalMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_MilestonePaymentReceivedClinicalMilestone" xlink:to="lab_prta_MilestonePaymentReceivedClinicalMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_DeferredSharesValue_85e0435d-93fe-4fa3-9e67-1f2b07aa50cd_terseLabel_en-US" xlink:label="lab_prta_DeferredSharesValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro deferred shares</link:label>
    <link:label id="lab_prta_DeferredSharesValue_label_en-US" xlink:label="lab_prta_DeferredSharesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares Value</link:label>
    <link:label id="lab_prta_DeferredSharesValue_documentation_en-US" xlink:label="lab_prta_DeferredSharesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesValue" xlink:href="prta-20200630.xsd#prta_DeferredSharesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_DeferredSharesValue" xlink:to="lab_prta_DeferredSharesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_8d7c761f-1d62-4297-9d2e-c764775ce57d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash paid against operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f45d1b89-5436-4e53-8a26-7d9f569842a9_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d3c4414d-d4d8-4431-9f31-28ff75a30f85_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LicenseAgreementsMember_25f0c94b-a84e-4e30-88dd-7269e40f0638_terseLabel_en-US" xlink:label="lab_prta_LicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Member]</link:label>
    <link:label id="lab_prta_LicenseAgreementsMember_label_en-US" xlink:label="lab_prta_LicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Member]</link:label>
    <link:label id="lab_prta_LicenseAgreementsMember_documentation_en-US" xlink:label="lab_prta_LicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementsMember" xlink:href="prta-20200630.xsd#prta_LicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LicenseAgreementsMember" xlink:to="lab_prta_LicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_26231e5c-e32b-4065-ab1d-9d1aaf2be9bd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Due in Fourth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_367d0783-8eca-4a4c-9137-367e53a8b75a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a3b2663b-03cb-4c2a-aa6c-ad4fb7458d98_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a798b057-1eb0-4f37-9cf6-95915410ace3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_PurchaseandContractualObligationTotal_8f8a5817-aa5f-4dc5-b069-dc6fa3b7e9b3_totalLabel_en-US" xlink:label="lab_prta_PurchaseandContractualObligationTotal" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationTotal_label_en-US" xlink:label="lab_prta_PurchaseandContractualObligationTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Total</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationTotal_documentation_en-US" xlink:label="lab_prta_PurchaseandContractualObligationTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationTotal" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_PurchaseandContractualObligationTotal" xlink:to="lab_prta_PurchaseandContractualObligationTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0c7f8bab-d950-495a-b128-544e3b5fae8a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b844ad93-1fda-4ad3-8570-5c3246b24a6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized shares for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a4835c13-046b-45cb-94cb-c5d684fc3753_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_60988561-216e-46d4-afee-b8b2b4a8a870_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_18fd3b99-30d7-48ac-87d3-c1dde50640e7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_ClinicalProductSupplyMember_87869265-924e-422d-8d64-05256c6fee7f_terseLabel_en-US" xlink:label="lab_prta_ClinicalProductSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Product Supply</link:label>
    <link:label id="lab_prta_ClinicalProductSupplyMember_label_en-US" xlink:label="lab_prta_ClinicalProductSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Product Supply [Member]</link:label>
    <link:label id="lab_prta_ClinicalProductSupplyMember_documentation_en-US" xlink:label="lab_prta_ClinicalProductSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Product Supply [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ClinicalProductSupplyMember" xlink:href="prta-20200630.xsd#prta_ClinicalProductSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_ClinicalProductSupplyMember" xlink:to="lab_prta_ClinicalProductSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones_ce63c094-b739-4bd8-8222-e93479eb8703_terseLabel_en-US" xlink:label="lab_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, potential payment upon achievement of development, regulatory and various first commercial sales milestones</link:label>
    <link:label id="lab_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones_label_en-US" xlink:label="lab_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Payment Upon Achievement of Development, Regulatory and Various First Commercial Sales Milestones</link:label>
    <link:label id="lab_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones_documentation_en-US" xlink:label="lab_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Payment Upon Achievement of Development, Regulatory and Various First Commercial Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones" xlink:href="prta-20200630.xsd#prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones" xlink:to="lab_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ea25318f-30af-4747-a888-ef2600bce8f0_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8a10e70b-c2f2-4e98-a040-327682235963_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_IncomeTaxesTable_74c06b44-0b02-4a09-92d6-22613dc9a0b4_terseLabel_en-US" xlink:label="lab_prta_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_prta_IncomeTaxesTable_label_en-US" xlink:label="lab_prta_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_prta_IncomeTaxesTable_documentation_en-US" xlink:label="lab_prta_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_IncomeTaxesTable" xlink:href="prta-20200630.xsd#prta_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_IncomeTaxesTable" xlink:to="lab_prta_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_84ef85a9-3c98-4383-acfc-b2497a1cba08_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1145ee04-7f6b-40ae-b67d-a3b5b66303b8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_34eb7c7e-e4d7-434e-90e9-7bff5df781e2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d39fe6ef-225e-4820-8e81-14a274973bd3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_3d9247d2-0ad3-4519-801d-9ff6bf4c6f8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_e753491e-ed26-4f21-a0fe-4112a5952eb8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Due in Second Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear" xlink:to="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1fdc5dc1-8098-40e4-b1ed-225029adc923_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b7644c9f-36f9-4c98-ad6a-d0d3ce2e6891_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_dfcbaaa2-2c8f-41eb-8a4c-a3b84a1f63e3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LicenseAgreementMilestonePaymentsPaymentTerm_e861ea03-6159-4b66-bd95-a65eea054284_terseLabel_en-US" xlink:label="lab_prta_LicenseAgreementMilestonePaymentsPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, milestone payments, payment term</link:label>
    <link:label id="lab_prta_LicenseAgreementMilestonePaymentsPaymentTerm_label_en-US" xlink:label="lab_prta_LicenseAgreementMilestonePaymentsPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payments, Payment Term</link:label>
    <link:label id="lab_prta_LicenseAgreementMilestonePaymentsPaymentTerm_documentation_en-US" xlink:label="lab_prta_LicenseAgreementMilestonePaymentsPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payments, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementMilestonePaymentsPaymentTerm" xlink:href="prta-20200630.xsd#prta_LicenseAgreementMilestonePaymentsPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LicenseAgreementMilestonePaymentsPaymentTerm" xlink:to="lab_prta_LicenseAgreementMilestonePaymentsPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2d878726-5114-46b3-b061-dcde01c49a13_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease_95f5bb27-7efd-488d-adc3-7a9c1b2d957e_terseLabel_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-sublease rentals, percent annual rent increase</link:label>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease_label_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease Rentals, Percent Annual Rent Increase</link:label>
    <link:label id="lab_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease_documentation_en-US" xlink:label="lab_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Sublease Rentals, Percent Annual Rent Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease" xlink:to="lab_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f2834005-0596-406a-ae32-8ef8d481d783_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ae14a237-e9ca-409b-ad9e-c8d81b4a85a0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638872db-b868-4889-a15d-c772d71a8d61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Company's Share Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e0acf2e3-590a-43ca-9de1-05777848aa9b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f58c7462-f74d-4853-9fb9-d8ed1cf22f1a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_139da413-93da-48f1-ba41-fcf063643d06_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c3d11673-45c6-46d4-80ba-41524b26f4a7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_88e23293-094f-45de-8514-820d5f7d39a2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_62c0040f-26be-42d1-b9d0-976a09b8a549_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_61ab30ca-c2e2-4696-8c69-e16520d3ab09_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_f6ab9871-49e7-4ab2-a51a-6b45723ec35f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinSecondYear_7c745734-3a2c-422d-9080-e15f80bce7ae_totalLabel_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinSecondYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinSecondYear_label_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Due in Second Year</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinSecondYear_documentation_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinSecondYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Due in Second Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinSecondYear" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_PurchaseandContractualObligationDueinSecondYear" xlink:to="lab_prta_PurchaseandContractualObligationDueinSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_07506217-9ba2-41b5-b8c2-7bd4569a636a_verboseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received, Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_3f0d8a6e-0044-455e-b28c-48f84968652b_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligations</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_873c990d-5a30-49e7-aee5-8246371f89ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_cc3c8ca6-80fe-495f-9789-27b65cadb39d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cd89eaa4-39c8-4bd6-8053-cf13060d6839_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense_b44fd2ac-f8ca-4b89-ad6e-56ff079e5e78_terseLabel_en-US" xlink:label="lab_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost sharing payments recognized as research and development expense</link:label>
    <link:label id="lab_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Payment To Collaboration Partner Recorded As Research And Development Expense</link:label>
    <link:label id="lab_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Payment To Collaboration Partner Recorded As Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" xlink:href="prta-20200630.xsd#prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" xlink:to="lab_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_08018348-10c6-4bd9-9eb9-dbcafa51209b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, vested (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinFourthYear_52014ec4-bb11-4aec-baff-5b23633c9620_totalLabel_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinFourthYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinFourthYear_label_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Due in Fourth Year</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinFourthYear_documentation_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinFourthYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Due in Fourth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinFourthYear" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_PurchaseandContractualObligationDueinFourthYear" xlink:to="lab_prta_PurchaseandContractualObligationDueinFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2246a648-0bc6-4017-aa06-23856450403f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a215e9bb-48df-4b56-ad8b-3eb43f0b0900_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a38271c0-3fe0-4bc1-8e6e-8c6d9eb5981e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_e87a472d-8d4a-45ee-8751-a6524a906274_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d5c944ea-e145-428f-8236-4607c624a680_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_c1420a97-c96b-41bb-9d9c-2639934a8104_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ce1da3a4-5309-46ff-9c4f-508922c59a0b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of lease liability maturity analysis and future minimum rentals to be received</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_AllocatedConsiderationtoPerformanceObligations_b8fc7b6d-6378-4925-aa1d-a3ba88393719_terseLabel_en-US" xlink:label="lab_prta_AllocatedConsiderationtoPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated consideration to performance obligations</link:label>
    <link:label id="lab_prta_AllocatedConsiderationtoPerformanceObligations_label_en-US" xlink:label="lab_prta_AllocatedConsiderationtoPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Consideration to Performance Obligations</link:label>
    <link:label id="lab_prta_AllocatedConsiderationtoPerformanceObligations_documentation_en-US" xlink:label="lab_prta_AllocatedConsiderationtoPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Allocated Consideration ( Amount of Transaction Price Allocated to each Performance Obligation)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_AllocatedConsiderationtoPerformanceObligations" xlink:href="prta-20200630.xsd#prta_AllocatedConsiderationtoPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_AllocatedConsiderationtoPerformanceObligations" xlink:to="lab_prta_AllocatedConsiderationtoPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f34befa7-0a1f-436e-8b61-2d92b66d2561_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1d820fc6-21aa-4131-9bc5-b1f8ac78b379_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_8b86803d-40ec-4657-a41a-89360fdddd5b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_fe0ccb38-bce7-4831-bfeb-fc8f593573bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_PurchaseandContractualObligationRemainderofFiscalYear_3052ce58-4dd9-48d5-86e0-5101b7c9403c_totalLabel_en-US" xlink:label="lab_prta_PurchaseandContractualObligationRemainderofFiscalYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationRemainderofFiscalYear_label_en-US" xlink:label="lab_prta_PurchaseandContractualObligationRemainderofFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Remainder of Fiscal Year</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationRemainderofFiscalYear_documentation_en-US" xlink:label="lab_prta_PurchaseandContractualObligationRemainderofFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationRemainderofFiscalYear" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationRemainderofFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_PurchaseandContractualObligationRemainderofFiscalYear" xlink:to="lab_prta_PurchaseandContractualObligationRemainderofFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4257976d-74a6-426e-a185-f4ad95a59888_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_DeferredSharesSharesAuthorized_f3f00eb9-73c5-4165-af36-64760cac4284_terseLabel_en-US" xlink:label="lab_prta_DeferredSharesSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro deferred shares, number of shares authorized (in shares)</link:label>
    <link:label id="lab_prta_DeferredSharesSharesAuthorized_label_en-US" xlink:label="lab_prta_DeferredSharesSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares Shares Authorized</link:label>
    <link:label id="lab_prta_DeferredSharesSharesAuthorized_documentation_en-US" xlink:label="lab_prta_DeferredSharesSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesSharesAuthorized" xlink:href="prta-20200630.xsd#prta_DeferredSharesSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_DeferredSharesSharesAuthorized" xlink:to="lab_prta_DeferredSharesSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_99ddf3fa-e835-4f49-9a2e-0d5d25e5d9db_terseLabel_en-US" xlink:label="lab_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligations, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_documentation_en-US" xlink:label="lab_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligations, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract" xlink:to="lab_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_38f12e63-b172-4192-a7c2-bb37c28bdf30_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_832936b6-b7c6-4c6e-8e43-ef18933a75e5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationProgramUSRightsMember_9abffd96-1091-4386-8712-84415f3eaf1f_terseLabel_en-US" xlink:label="lab_prta_CollaborationProgramUSRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Program, US Rights</link:label>
    <link:label id="lab_prta_CollaborationProgramUSRightsMember_label_en-US" xlink:label="lab_prta_CollaborationProgramUSRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Program, US Rights [Member]</link:label>
    <link:label id="lab_prta_CollaborationProgramUSRightsMember_documentation_en-US" xlink:label="lab_prta_CollaborationProgramUSRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Program, US Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationProgramUSRightsMember" xlink:href="prta-20200630.xsd#prta_CollaborationProgramUSRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationProgramUSRightsMember" xlink:to="lab_prta_CollaborationProgramUSRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_RoyaltyBearingLicenseMember_be9d7e30-8a51-4c4a-b7ca-5561a7898a5e_terseLabel_en-US" xlink:label="lab_prta_RoyaltyBearingLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Bearing License</link:label>
    <link:label id="lab_prta_RoyaltyBearingLicenseMember_label_en-US" xlink:label="lab_prta_RoyaltyBearingLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Bearing License [Member]</link:label>
    <link:label id="lab_prta_RoyaltyBearingLicenseMember_documentation_en-US" xlink:label="lab_prta_RoyaltyBearingLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Bearing License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_RoyaltyBearingLicenseMember" xlink:href="prta-20200630.xsd#prta_RoyaltyBearingLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_RoyaltyBearingLicenseMember" xlink:to="lab_prta_RoyaltyBearingLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bbf37b7c-153f-4b23-94c9-76a7424eebbd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary_0ce5cf4c-0d89-49e9-be8d-ee091ed9e5fa_terseLabel_en-US" xlink:label="lab_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount reduction on third anniversary</link:label>
    <link:label id="lab_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary_label_en-US" xlink:label="lab_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Face Amount Reduction on Third Anniversary</link:label>
    <link:label id="lab_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary_documentation_en-US" xlink:label="lab_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Face Amount Reduction on Third Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary" xlink:href="prta-20200630.xsd#prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary" xlink:to="lab_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_08269978-9b20-488c-aa09-041fea2ec791_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_7fede4e5-6bc0-4052-87ff-61b0e7e3c36b_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6f0b04ca-16f2-43db-8b36-8c7e73fb5ee3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_df85c065-0b0d-4e35-ae80-78f3e9b60df6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOperatingLeaseMember_b2fbac40-979a-4826-a5eb-349767c7c1da_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current SSF Facility operating lease under ASC 842</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOperatingLeaseMember_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to Operating Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOperatingLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOperatingLeaseMember" xlink:to="lab_us-gaap_PropertySubjectToOperatingLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram_23e49a75-9b25-45e6-a50e-9bc4811d89e3_terseLabel_en-US" xlink:label="lab_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, potential regulatory and commercial milestone payments per program</link:label>
    <link:label id="lab_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram_label_en-US" xlink:label="lab_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Potential Regulatory and Commercial Milestone Payments Per Program</link:label>
    <link:label id="lab_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram_documentation_en-US" xlink:label="lab_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Potential Regulatory and Commercial Milestone Payments Per Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram" xlink:to="lab_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationProgramGlobalRightsMember_f6fa041f-fc3d-49d1-a547-75f9a0df6e9f_terseLabel_en-US" xlink:label="lab_prta_CollaborationProgramGlobalRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Program, Global Rights</link:label>
    <link:label id="lab_prta_CollaborationProgramGlobalRightsMember_label_en-US" xlink:label="lab_prta_CollaborationProgramGlobalRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Program, Global Rights [Member]</link:label>
    <link:label id="lab_prta_CollaborationProgramGlobalRightsMember_documentation_en-US" xlink:label="lab_prta_CollaborationProgramGlobalRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Program, Global Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationProgramGlobalRightsMember" xlink:href="prta-20200630.xsd#prta_CollaborationProgramGlobalRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationProgramGlobalRightsMember" xlink:to="lab_prta_CollaborationProgramGlobalRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e8ececd5-0bec-4c7c-a6b9-9ce45d63dbb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0b0240c5-940a-4a16-9796-c94a3b829700_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_1c59331c-85f3-4b73-9f49-445a4ab93d61_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_a4658b3c-e1d5-45ff-afca-e5b0224c510a_totalLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a1c8bc80-8320-49d1-ab9f-151c8cadb838_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LicensingAgreementCostAllocationPercentage_01ebb366-be19-4949-891e-785b78cd959f_terseLabel_en-US" xlink:label="lab_prta_LicensingAgreementCostAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, cost allocation, percentage</link:label>
    <link:label id="lab_prta_LicensingAgreementCostAllocationPercentage_label_en-US" xlink:label="lab_prta_LicensingAgreementCostAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement, Cost Allocation, Percentage</link:label>
    <link:label id="lab_prta_LicensingAgreementCostAllocationPercentage_documentation_en-US" xlink:label="lab_prta_LicensingAgreementCostAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement, Cost Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicensingAgreementCostAllocationPercentage" xlink:href="prta-20200630.xsd#prta_LicensingAgreementCostAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LicensingAgreementCostAllocationPercentage" xlink:to="lab_prta_LicensingAgreementCostAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary_3987e5de-fc19-41a3-ac4e-7b5891db800a_terseLabel_en-US" xlink:label="lab_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount reduction on fifth anniversary</link:label>
    <link:label id="lab_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary_label_en-US" xlink:label="lab_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Face Amount Reduction on Fifth Anniversary</link:label>
    <link:label id="lab_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary_documentation_en-US" xlink:label="lab_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Face Amount Reduction on Fifth Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary" xlink:href="prta-20200630.xsd#prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary" xlink:to="lab_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_185679c5-8f9a-462c-ac8f-bc73efe4bdc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f4a7bf34-d9e0-4aed-8da8-b006e6ffa5a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8bdabd7c-b41e-4ad3-beb4-ae29f598d43e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Preparation and Presentation of Financial Information</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationAgreementUpfrontPayment_d2577486-9e81-4b61-a3aa-f74eec068ac1_terseLabel_en-US" xlink:label="lab_prta_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, upfront payment</link:label>
    <link:label id="lab_prta_CollaborationAgreementUpfrontPayment_label_en-US" xlink:label="lab_prta_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:label id="lab_prta_CollaborationAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_prta_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementUpfrontPayment" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationAgreementUpfrontPayment" xlink:to="lab_prta_CollaborationAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_d366d5f0-b2f7-4b49-a2b1-0f773470af52_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LicenseAgreementLineItems_609d6659-0822-4558-a581-e4ecdc8ed333_terseLabel_en-US" xlink:label="lab_prta_LicenseAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Line Items]</link:label>
    <link:label id="lab_prta_LicenseAgreementLineItems_label_en-US" xlink:label="lab_prta_LicenseAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Line Items]</link:label>
    <link:label id="lab_prta_LicenseAgreementLineItems_documentation_en-US" xlink:label="lab_prta_LicenseAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for License Agreement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementLineItems" xlink:href="prta-20200630.xsd#prta_LicenseAgreementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LicenseAgreementLineItems" xlink:to="lab_prta_LicenseAgreementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_7c1dcbee-0aa8-4a5f-8ed2-06c811e9df4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_f9cc57d0-70f5-44c5-8b96-23fee27a6c02_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_DevelopmentCostsReimbursementMember_03dfd14c-6f89-4649-8d2b-960ec3091469_terseLabel_en-US" xlink:label="lab_prta_DevelopmentCostsReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Costs Reimbursement</link:label>
    <link:label id="lab_prta_DevelopmentCostsReimbursementMember_label_en-US" xlink:label="lab_prta_DevelopmentCostsReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Costs Reimbursement [Member]</link:label>
    <link:label id="lab_prta_DevelopmentCostsReimbursementMember_documentation_en-US" xlink:label="lab_prta_DevelopmentCostsReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Costs Reimbursement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DevelopmentCostsReimbursementMember" xlink:href="prta-20200630.xsd#prta_DevelopmentCostsReimbursementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_DevelopmentCostsReimbursementMember" xlink:to="lab_prta_DevelopmentCostsReimbursementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fd77488a-1845-451f-bd3b-f4bd4cc85066_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_da2fe3b8-123f-4c10-8816-165665e06fba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares, number of authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_DeferredSharesParValue_241ab46b-d2f3-4386-9f78-829db6ef9b03_terseLabel_en-US" xlink:label="lab_prta_DeferredSharesParValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro deferred shares, nominal value (in euros per share)</link:label>
    <link:label id="lab_prta_DeferredSharesParValue_label_en-US" xlink:label="lab_prta_DeferredSharesParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares Par Value</link:label>
    <link:label id="lab_prta_DeferredSharesParValue_documentation_en-US" xlink:label="lab_prta_DeferredSharesParValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesParValue" xlink:href="prta-20200630.xsd#prta_DeferredSharesParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_DeferredSharesParValue" xlink:to="lab_prta_DeferredSharesParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1ba9114d-ae97-4d4e-9d96-0f3b7ab6aaa9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram_ef8103ca-9b7f-495a-8eeb-82735f5d3370_terseLabel_en-US" xlink:label="lab_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, potential regulatory milestone payments per program</link:label>
    <link:label id="lab_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram_label_en-US" xlink:label="lab_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Potential Regulatory Milestone Payments Per Program</link:label>
    <link:label id="lab_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram_documentation_en-US" xlink:label="lab_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Potential Regulatory Milestone Payments Per Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram" xlink:to="lab_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7c797972-40ea-455c-a36f-39b65f6b9bf6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_205bf75b-ae80-4ff0-bde6-d08fe37b5551_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_72bba8d2-a4f2-4ee4-badd-606cfed2b928_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_76772bb5-eb2e-4a21-9ecc-52c3fd5f9e96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ad71eb87-2f6a-4a06-a356-752e9b499868_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_30dc0d10-a9dd-41c0-8454-e9c96c914287_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7e039657-58d7-445b-8804-cd03638e626d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculation of Basic and Diluted Net Income or Loss Per Ordinary Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_05ab5a7f-9ab2-4773-9a2c-907f1dcf39cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_SubleaserentalsAnnualBaseRentInitialAmount_d840845c-df67-49ac-9ac6-260360bda71a_terseLabel_en-US" xlink:label="lab_prta_SubleaserentalsAnnualBaseRentInitialAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-sublease rentals, initial annual base rent</link:label>
    <link:label id="lab_prta_SubleaserentalsAnnualBaseRentInitialAmount_label_en-US" xlink:label="lab_prta_SubleaserentalsAnnualBaseRentInitialAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease rentals, Annual Base Rent, Initial Amount</link:label>
    <link:label id="lab_prta_SubleaserentalsAnnualBaseRentInitialAmount_documentation_en-US" xlink:label="lab_prta_SubleaserentalsAnnualBaseRentInitialAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Annual Base Rent from Sub-sublease, Initial Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SubleaserentalsAnnualBaseRentInitialAmount" xlink:href="prta-20200630.xsd#prta_SubleaserentalsAnnualBaseRentInitialAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_SubleaserentalsAnnualBaseRentInitialAmount" xlink:to="lab_prta_SubleaserentalsAnnualBaseRentInitialAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace_941a1e7a-5e01-4d3d-a8b9-f879dc05aecf_terseLabel_en-US" xlink:label="lab_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, Dublin, area of office space (in sq ft)</link:label>
    <link:label id="lab_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace_label_en-US" xlink:label="lab_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangement, Operating Leases, Area of Office Space</link:label>
    <link:label id="lab_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace_documentation_en-US" xlink:label="lab_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangement, Operating Leases, Area of Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace" xlink:href="prta-20200630.xsd#prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace" xlink:to="lab_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_cd111a0c-d67a-4faa-98d4-89f6ed278ee0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cc0083ea-2bfa-4dbd-9e68-8f9e02523702_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (6 months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8d55522b-21aa-4a9b-bdab-a54a828c5480_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_2729bc13-46d2-450f-9a7e-7162a66719ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, Dublin, term of contract (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities_5a4eabcd-1437-4485-8216-6801b002eeb5_terseLabel_en-US" xlink:label="lab_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligations under license agreements included in accrued current liabilities</link:label>
    <link:label id="lab_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities_label_en-US" xlink:label="lab_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligations under License Agreements included in accrued current liabilities</link:label>
    <link:label id="lab_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities_documentation_en-US" xlink:label="lab_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligations under License Agreements included in accrued current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities" xlink:href="prta-20200630.xsd#prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities" xlink:to="lab_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_SupplyServicesMember_1a5dac88-0f1b-46c0-8965-1df55d79487b_terseLabel_en-US" xlink:label="lab_prta_SupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Services</link:label>
    <link:label id="lab_prta_SupplyServicesMember_label_en-US" xlink:label="lab_prta_SupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Services [Member]</link:label>
    <link:label id="lab_prta_SupplyServicesMember_documentation_en-US" xlink:label="lab_prta_SupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SupplyServicesMember" xlink:href="prta-20200630.xsd#prta_SupplyServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_SupplyServicesMember" xlink:to="lab_prta_SupplyServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones_f2c7ed3a-6eb2-4512-bd5d-010cf81df11a_terseLabel_en-US" xlink:label="lab_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, potential alternative commercial sales milestones</link:label>
    <link:label id="lab_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones_label_en-US" xlink:label="lab_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Alternative Commercial Sales Milestones</link:label>
    <link:label id="lab_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones_documentation_en-US" xlink:label="lab_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Potential Alternative Commercial Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones" xlink:href="prta-20200630.xsd#prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones" xlink:to="lab_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d8f1000-62bd-411a-98d0-5c17598ecb20_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_RocheMember_3a2bfd99-54f2-4511-8827-c32e9e13e2dc_terseLabel_en-US" xlink:label="lab_prta_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_prta_RocheMember_label_en-US" xlink:label="lab_prta_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_prta_RocheMember_documentation_en-US" xlink:label="lab_prta_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_RocheMember" xlink:href="prta-20200630.xsd#prta_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_RocheMember" xlink:to="lab_prta_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c3522cbf-ed79-4d20-a6ab-01a3fc8366c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_IncomeTaxesLineItems_0bb03eca-764a-4d5e-b10e-39f3535be971_terseLabel_en-US" xlink:label="lab_prta_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_prta_IncomeTaxesLineItems_label_en-US" xlink:label="lab_prta_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_prta_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_prta_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_IncomeTaxesLineItems" xlink:href="prta-20200630.xsd#prta_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_IncomeTaxesLineItems" xlink:to="lab_prta_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_ReductionofBuildtosuitLeaseObligation_7fcde413-3fb3-4454-ac42-8f9cc69d960c_negatedTerseLabel_en-US" xlink:label="lab_prta_ReductionofBuildtosuitLeaseObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of build-to-suit lease obligation upon adoption of ASC 842</link:label>
    <link:label id="lab_prta_ReductionofBuildtosuitLeaseObligation_label_en-US" xlink:label="lab_prta_ReductionofBuildtosuitLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of Build-to-suit Lease Obligation</link:label>
    <link:label id="lab_prta_ReductionofBuildtosuitLeaseObligation_documentation_en-US" xlink:label="lab_prta_ReductionofBuildtosuitLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of Build-to-suit Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ReductionofBuildtosuitLeaseObligation" xlink:href="prta-20200630.xsd#prta_ReductionofBuildtosuitLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_ReductionofBuildtosuitLeaseObligation" xlink:to="lab_prta_ReductionofBuildtosuitLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cfe11c7f-a3a9-441e-be75-e3150d5e5fb5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c9be4cb2-7c78-4d26-8d0c-574bed233fc2_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_a68e22a3-b824-4e75-ad30-f7734ba972fa_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b538ccc6-6a25-4452-90b4-6a8b7a2656df_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_BuildtosuitLeaseTermofContract_61dc8d76-d835-4344-828e-98aaec38f971_verboseLabel_en-US" xlink:label="lab_prta_BuildtosuitLeaseTermofContract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, current SSF facility, term of contract</link:label>
    <link:label id="lab_prta_BuildtosuitLeaseTermofContract_label_en-US" xlink:label="lab_prta_BuildtosuitLeaseTermofContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build-to-suit Lease, Term of Contract</link:label>
    <link:label id="lab_prta_BuildtosuitLeaseTermofContract_documentation_en-US" xlink:label="lab_prta_BuildtosuitLeaseTermofContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build-to-suit Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_BuildtosuitLeaseTermofContract" xlink:href="prta-20200630.xsd#prta_BuildtosuitLeaseTermofContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_BuildtosuitLeaseTermofContract" xlink:to="lab_prta_BuildtosuitLeaseTermofContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fdb7d0a6-683a-4fd0-96d9-c9a4e28f71d3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_039683c8-8742-4bd6-9e4e-9c4839e881e2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5142b396-1b46-4131-add8-93364770a219_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9f29a98e-bfd9-41b0-a1e5-65c1bed37518_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accruals and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_SaleofStockPremiumReceivedonTransaction_429237f0-6eee-499d-8df2-af2d8c27449a_terseLabel_en-US" xlink:label="lab_prta_SaleofStockPremiumReceivedonTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share subscription agreement, premium received on transaction</link:label>
    <link:label id="lab_prta_SaleofStockPremiumReceivedonTransaction_label_en-US" xlink:label="lab_prta_SaleofStockPremiumReceivedonTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Premium Received on Transaction</link:label>
    <link:label id="lab_prta_SaleofStockPremiumReceivedonTransaction_documentation_en-US" xlink:label="lab_prta_SaleofStockPremiumReceivedonTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Premium Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SaleofStockPremiumReceivedonTransaction" xlink:href="prta-20200630.xsd#prta_SaleofStockPremiumReceivedonTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_SaleofStockPremiumReceivedonTransaction" xlink:to="lab_prta_SaleofStockPremiumReceivedonTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_05a9cc3f-a02f-45aa-b115-5e23e8cdcfea_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds at carrying value</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_9f67392c-4315-420b-8bba-1d71e23f3fae_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a5c23345-7a1e-400d-af6d-f861eab19831_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, vested and expected to vest, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_335ca9f5-d0d6-4566-82d2-1a553fbd19b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_4044a883-67b6-4063-9e00-b98c87919c0d_verboseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Fifth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction_675260b3-61a6-4d2d-9dfa-0dde8655e2b2_negatedTerseLabel_en-US" xlink:label="lab_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of amounts capitalized under build-to-suit lease upon adoption of ASC 842</link:label>
    <link:label id="lab_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction_label_en-US" xlink:label="lab_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of Amounts Capitalized Under Build-to-suit Lease Transaction</link:label>
    <link:label id="lab_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction_documentation_en-US" xlink:label="lab_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of Amounts Capitalized Under Build-to-suit Lease Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction" xlink:href="prta-20200630.xsd#prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction" xlink:to="lab_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_e9a3f7ae-04b5-49f4-8c8c-83e1775a8fcd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_76f5a1d6-ca52-4fb2-891c-4abffc90c0b6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_6cf2fe31-d59e-4937-83ec-51a65b8688af_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b6887dff-2403-4e22-ad25-508344a8db47_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected recognition period of share-based compensation not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_IncreaseDecreaseinOperatingLeaseLiability_3c5a0c8c-9c8b-44f9-833c-025b561ae4ff_negatedTerseLabel_en-US" xlink:label="lab_prta_IncreaseDecreaseinOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_prta_IncreaseDecreaseinOperatingLeaseLiability_label_en-US" xlink:label="lab_prta_IncreaseDecreaseinOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label id="lab_prta_IncreaseDecreaseinOperatingLeaseLiability_documentation_en-US" xlink:label="lab_prta_IncreaseDecreaseinOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_IncreaseDecreaseinOperatingLeaseLiability" xlink:href="prta-20200630.xsd#prta_IncreaseDecreaseinOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_IncreaseDecreaseinOperatingLeaseLiability" xlink:to="lab_prta_IncreaseDecreaseinOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_918f13d8-8674-47f2-84bf-47ebf5a20340_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_OrdinaryShareMember_aac66a7d-1738-483a-bef9-ca36c0dc200e_terseLabel_en-US" xlink:label="lab_prta_OrdinaryShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Share</link:label>
    <link:label id="lab_prta_OrdinaryShareMember_label_en-US" xlink:label="lab_prta_OrdinaryShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Share [Member]</link:label>
    <link:label id="lab_prta_OrdinaryShareMember_documentation_en-US" xlink:label="lab_prta_OrdinaryShareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OrdinaryShareMember" xlink:href="prta-20200630.xsd#prta_OrdinaryShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_OrdinaryShareMember" xlink:to="lab_prta_OrdinaryShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_650ce54f-c6a6-4309-a3d2-ec406a5fccba_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_0df687ca-d4d5-4d76-bba1-86f925ed7c8d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_0fcb6bd0-8859-4ebb-bc87-14c40b3faf69_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_MaximumNumberofSharestobeIssuedISOExercise_3656273c-9d8d-4746-8095-a038476bb46c_terseLabel_en-US" xlink:label="lab_prta_MaximumNumberofSharestobeIssuedISOExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares to be issued - ISO exercise (in shares)</link:label>
    <link:label id="lab_prta_MaximumNumberofSharestobeIssuedISOExercise_label_en-US" xlink:label="lab_prta_MaximumNumberofSharestobeIssuedISOExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Number of Shares to be Issued - ISO Exercise</link:label>
    <link:label id="lab_prta_MaximumNumberofSharestobeIssuedISOExercise_documentation_en-US" xlink:label="lab_prta_MaximumNumberofSharestobeIssuedISOExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Number of Shares that may be Issued pursuant to the exercise of Incentive Stock Options under the 2018 LTIP.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_MaximumNumberofSharestobeIssuedISOExercise" xlink:href="prta-20200630.xsd#prta_MaximumNumberofSharestobeIssuedISOExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_MaximumNumberofSharestobeIssuedISOExercise" xlink:to="lab_prta_MaximumNumberofSharestobeIssuedISOExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d3ef0a03-d09d-40ca-90a3-0c7e2acd1501_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_28c5caa8-95a5-4598-9ead-3047400bdbb1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_72fa1a35-757f-4663-bb72-eec07e4f0ca9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInFifthYear_8e333380-c9dc-48c8-a31d-71b581dffe76_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Due in Fifth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFifthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_a17b740b-bff0-41a2-bdb9-aabdcba78da2_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_28c90f28-681d-47c0-a46e-46ee5b51021d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:to="lab_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ab4fcbec-9c66-4c56-b2bf-9778bacf52b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_8c7091bb-799d-47a7-86b7-66b3f735cc62_terseLabel_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contractual Obligations by Fiscal Year Maturity</link:label>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_label_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_058aa638-0c30-471d-9945-6f905652c1e7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_48d333d1-5267-4456-a84e-7c1cec3a2275_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_PotentialWithholdingTaxRate_a8724807-d769-4852-a559-831b82919105_terseLabel_en-US" xlink:label="lab_prta_PotentialWithholdingTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential withholding tax rate</link:label>
    <link:label id="lab_prta_PotentialWithholdingTaxRate_label_en-US" xlink:label="lab_prta_PotentialWithholdingTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Withholding Tax Rate</link:label>
    <link:label id="lab_prta_PotentialWithholdingTaxRate_documentation_en-US" xlink:label="lab_prta_PotentialWithholdingTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Withholding Tax Rate for cumulative unremitted earnings of the Company's subsidiaries if they were distributed as dividends.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PotentialWithholdingTaxRate" xlink:href="prta-20200630.xsd#prta_PotentialWithholdingTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_PotentialWithholdingTaxRate" xlink:to="lab_prta_PotentialWithholdingTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_ee5795f4-8b51-45f3-ba50-871a87f4126e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_169381cd-a276-42aa-b271-fb572838f16b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_b906f6b1-f15b-49f3-ba9d-5beae8240707_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_933f465c-e54f-4c06-86eb-9fc8957751ea_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_60f964cb-eaf5-4606-9af6-47630714b7cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1e83f14a-1350-4701-ba4a-6640095eb552_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_ef539e1b-6afa-4433-99fd-ec440acd4cd5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_A2020EmploymentInducementIncentivePlanMember_62524216-117e-4c6f-bf05-cb614449c0dd_terseLabel_en-US" xlink:label="lab_prta_A2020EmploymentInducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employment Inducement Incentive Plan</link:label>
    <link:label id="lab_prta_A2020EmploymentInducementIncentivePlanMember_label_en-US" xlink:label="lab_prta_A2020EmploymentInducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employment Inducement Incentive Plan [Member]</link:label>
    <link:label id="lab_prta_A2020EmploymentInducementIncentivePlanMember_documentation_en-US" xlink:label="lab_prta_A2020EmploymentInducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employment Inducement Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_A2020EmploymentInducementIncentivePlanMember" xlink:href="prta-20200630.xsd#prta_A2020EmploymentInducementIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_A2020EmploymentInducementIncentivePlanMember" xlink:to="lab_prta_A2020EmploymentInducementIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_DevelopmentServicesAdditional_7e53e9dc-d26a-4898-a6a3-e062daddcc8a_terseLabel_en-US" xlink:label="lab_prta_DevelopmentServicesAdditional" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development reimbursement</link:label>
    <link:label id="lab_prta_DevelopmentServicesAdditional_label_en-US" xlink:label="lab_prta_DevelopmentServicesAdditional" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Services, Additional</link:label>
    <link:label id="lab_prta_DevelopmentServicesAdditional_documentation_en-US" xlink:label="lab_prta_DevelopmentServicesAdditional" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Services, Additional - Recorded as Collaboration Revenue under ASC 606 starting Jan. 1, 2018. Prior to that, it was recorded as an offset to R&amp;D Expense under ASC 605.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DevelopmentServicesAdditional" xlink:href="prta-20200630.xsd#prta_DevelopmentServicesAdditional"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_DevelopmentServicesAdditional" xlink:to="lab_prta_DevelopmentServicesAdditional" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_INDandDevelopmentServicesMember_daa1e06d-2588-40ab-9504-90a2c2973e15_terseLabel_en-US" xlink:label="lab_prta_INDandDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IND and Development Services</link:label>
    <link:label id="lab_prta_INDandDevelopmentServicesMember_label_en-US" xlink:label="lab_prta_INDandDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IND and Development Services [Member]</link:label>
    <link:label id="lab_prta_INDandDevelopmentServicesMember_documentation_en-US" xlink:label="lab_prta_INDandDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IND and Development Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_INDandDevelopmentServicesMember" xlink:href="prta-20200630.xsd#prta_INDandDevelopmentServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_INDandDevelopmentServicesMember" xlink:to="lab_prta_INDandDevelopmentServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5bac1af9-b1db-464b-927e-d4d3aae5b3a5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_70480fb8-acd9-4f98-91bf-f69524c18597_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares, number of issued shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_19a9c412-5e09-40fc-8ab1-22f8766d8aee_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ordinary Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9396e77e-18cd-4b28-9e73-cb906651d473_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_89152c90-d36f-42d3-af44-adbe787a8aba_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_cdb624e9-5b56-4e9f-b491-cc5a3151b940_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_cbef1cc8-b5f2-4294-b583-1990fe1b922d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_23771b1c-790b-4f0b-bd12-d1e2c96c27b1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Per Ordinary Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2593888b-cb5f-426b-8260-e58e45b5a621_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationAgreementExerciseFeeperProgram_3cb235fe-636f-4f4e-8475-1e3065c8bed6_terseLabel_en-US" xlink:label="lab_prta_CollaborationAgreementExerciseFeeperProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, exercise fee per program</link:label>
    <link:label id="lab_prta_CollaborationAgreementExerciseFeeperProgram_label_en-US" xlink:label="lab_prta_CollaborationAgreementExerciseFeeperProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Exercise Fee per Program</link:label>
    <link:label id="lab_prta_CollaborationAgreementExerciseFeeperProgram_documentation_en-US" xlink:label="lab_prta_CollaborationAgreementExerciseFeeperProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Exercise Fee per Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementExerciseFeeperProgram" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementExerciseFeeperProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationAgreementExerciseFeeperProgram" xlink:to="lab_prta_CollaborationAgreementExerciseFeeperProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_97367f96-05cd-45d3-aa0f-74e593aa803e_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_563acae7-d426-4a7f-a130-e894478ec3fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dff994be-aab9-41c6-8732-9dc004b27c90_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bea96396-ed76-4984-9d89-fba28952b055_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_36d4909b-756d-402b-a69f-682e9562c931_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_OperatingLeasesImprovementAllowance_d424ea33-c792-4a05-849a-5a0ba343d6d2_terseLabel_en-US" xlink:label="lab_prta_OperatingLeasesImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_prta_OperatingLeasesImprovementAllowance_label_en-US" xlink:label="lab_prta_OperatingLeasesImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Improvement Allowance</link:label>
    <link:label id="lab_prta_OperatingLeasesImprovementAllowance_documentation_en-US" xlink:label="lab_prta_OperatingLeasesImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesImprovementAllowance" xlink:href="prta-20200630.xsd#prta_OperatingLeasesImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_OperatingLeasesImprovementAllowance" xlink:to="lab_prta_OperatingLeasesImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueCommissionersIrelandMember_ca871b8c-2d33-476f-8431-f910e0a07429_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Commissioners, Ireland</link:label>
    <link:label id="lab_us-gaap_RevenueCommissionersIrelandMember_label_en-US" xlink:label="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Commissioners, Ireland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueCommissionersIrelandMember" xlink:to="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_c20fef10-496a-4f4c-995e-a0555adbc63b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_19673aac-7455-4034-b793-34f403b8263d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC-842</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_e161e67e-a00e-4eec-bc7e-931da9d3468d_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_b0ea9df3-ff28-4b66-b1a8-ddd5548210ca_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_97a13cab-cfca-4f88-9811-efdca3b4c9af_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_OperatingLeaseArea_58673f1d-ffc4-4050-94e1-f0a66520452c_terseLabel_en-US" xlink:label="lab_prta_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease (area)</link:label>
    <link:label id="lab_prta_OperatingLeaseArea_label_en-US" xlink:label="lab_prta_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease (Area)</link:label>
    <link:label id="lab_prta_OperatingLeaseArea_documentation_en-US" xlink:label="lab_prta_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease (Area)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeaseArea" xlink:href="prta-20200630.xsd#prta_OperatingLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_OperatingLeaseArea" xlink:to="lab_prta_OperatingLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_a0138c24-5350-4e77-be09-aa0d663ff0e4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased computer software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareGross" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ffc6e82-1c0c-4cd4-8fa2-a0f49fc9aff8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a0e5564a-d4c0-416f-a976-0b6f9123016a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_913f468b-2991-4eaa-9fb0-43cf96f7f438_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_ASC605AllocatedConsiderationtoDeliverables_18b33870-3d95-4f7d-99d7-8ba9de9ef867_terseLabel_en-US" xlink:label="lab_prta_ASC605AllocatedConsiderationtoDeliverables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 605 allocated consideration to deliverables</link:label>
    <link:label id="lab_prta_ASC605AllocatedConsiderationtoDeliverables_label_en-US" xlink:label="lab_prta_ASC605AllocatedConsiderationtoDeliverables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 605 Allocated Consideration to Deliverables</link:label>
    <link:label id="lab_prta_ASC605AllocatedConsiderationtoDeliverables_documentation_en-US" xlink:label="lab_prta_ASC605AllocatedConsiderationtoDeliverables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 605 - Transaction Price Allocation of Consideration to Deliverables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ASC605AllocatedConsiderationtoDeliverables" xlink:href="prta-20200630.xsd#prta_ASC605AllocatedConsiderationtoDeliverables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_ASC605AllocatedConsiderationtoDeliverables" xlink:to="lab_prta_ASC605AllocatedConsiderationtoDeliverables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_5df22226-9cb3-4b18-a769-c2b22bedd81d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2b2159cc-99ed-4b56-b98f-fab16e38209c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_ddcd4f9a-63b5-4a71-8489-dc73ff1101f0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_dc3a0557-0844-4f93-bbb3-eaf0ec26e850_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_2d11db40-0dc9-4710-9ef2-ed43eeec4c72_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d92c7b44-4d71-43f8-8f66-c2a813191bf4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_DeferredSharesShareOutstanding_3249eb48-01dd-4311-9b20-be6ce53a7f81_terseLabel_en-US" xlink:label="lab_prta_DeferredSharesShareOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro deferred shares, number of outstanding shares (in shares)</link:label>
    <link:label id="lab_prta_DeferredSharesShareOutstanding_label_en-US" xlink:label="lab_prta_DeferredSharesShareOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares Share Outstanding</link:label>
    <link:label id="lab_prta_DeferredSharesShareOutstanding_documentation_en-US" xlink:label="lab_prta_DeferredSharesShareOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Shares Share Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesShareOutstanding" xlink:href="prta-20200630.xsd#prta_DeferredSharesShareOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_DeferredSharesShareOutstanding" xlink:to="lab_prta_DeferredSharesShareOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_60bb026e-1227-4fd8-9793-8cf4e4a0ecd9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_80a8f2a0-0e8b-4cf4-8fec-2969ff08e429_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_401fbcf0-e871-4d47-abba-8c854d00ee60_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationAgreementTermofAgreement_8be14999-a205-4f88-9849-4ec1cf16bde3_terseLabel_en-US" xlink:label="lab_prta_CollaborationAgreementTermofAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, term of agreement</link:label>
    <link:label id="lab_prta_CollaborationAgreementTermofAgreement_label_en-US" xlink:label="lab_prta_CollaborationAgreementTermofAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Term of Agreement</link:label>
    <link:label id="lab_prta_CollaborationAgreementTermofAgreement_documentation_en-US" xlink:label="lab_prta_CollaborationAgreementTermofAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Term of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementTermofAgreement" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementTermofAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationAgreementTermofAgreement" xlink:to="lab_prta_CollaborationAgreementTermofAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_71cbaa54-753f-45ea-ab00-26713351d7e8_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_01d9d37f-a9dd-4e60-850d-00f6f7e1dfa9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_MilestoneAchievementClinicalMilestone_40a60ecd-3fcf-47ef-a81f-ad6cde541c33_terseLabel_en-US" xlink:label="lab_prta_MilestoneAchievementClinicalMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement, clinical milestone</link:label>
    <link:label id="lab_prta_MilestoneAchievementClinicalMilestone_label_en-US" xlink:label="lab_prta_MilestoneAchievementClinicalMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement, Clinical Milestone</link:label>
    <link:label id="lab_prta_MilestoneAchievementClinicalMilestone_documentation_en-US" xlink:label="lab_prta_MilestoneAchievementClinicalMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement, Clinical Milestone -recognized where milestone was achieved at the end of the period presented.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_MilestoneAchievementClinicalMilestone" xlink:href="prta-20200630.xsd#prta_MilestoneAchievementClinicalMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_MilestoneAchievementClinicalMilestone" xlink:to="lab_prta_MilestoneAchievementClinicalMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_939e52f3-152c-4903-ba56-681c1e70dcc2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_DublinIrelandMember_e92fdb64-397a-43fa-85f7-91195ac8d1be_terseLabel_en-US" xlink:label="lab_prta_DublinIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dublin, Ireland</link:label>
    <link:label id="lab_prta_DublinIrelandMember_label_en-US" xlink:label="lab_prta_DublinIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dublin, Ireland [Member]</link:label>
    <link:label id="lab_prta_DublinIrelandMember_documentation_en-US" xlink:label="lab_prta_DublinIrelandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dublin, Ireland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DublinIrelandMember" xlink:href="prta-20200630.xsd#prta_DublinIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_DublinIrelandMember" xlink:to="lab_prta_DublinIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_209fe647-b54c-4288-9693-b112bf308bde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_NumberofVotes_19f8ead8-2035-4fee-8c4f-06a1ed6ee266_verboseLabel_en-US" xlink:label="lab_prta_NumberofVotes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Votes per share</link:label>
    <link:label id="lab_prta_NumberofVotes_label_en-US" xlink:label="lab_prta_NumberofVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes</link:label>
    <link:label id="lab_prta_NumberofVotes_documentation_en-US" xlink:label="lab_prta_NumberofVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_NumberofVotes" xlink:href="prta-20200630.xsd#prta_NumberofVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_NumberofVotes" xlink:to="lab_prta_NumberofVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_e382a7a5-fe03-4b13-988c-2aef4e6112e7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" xlink:to="lab_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_c5e9944b-d298-4fd3-b111-e54bccae0e02_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_b955137d-e7fe-47e7-91cf-9fe30d4c197c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring credits</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_d8965a47-674c-4d6d-bda3-aaa676d7d573_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2c2a3f13-0bf9-4800-a43c-8baf0cbaf199_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f7485cbb-7a9d-4d2f-8c2c-f45239f6d4bd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase ordinary shares not included in diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_89965934-7b02-4c1e-9680-5fb82c1b1cc6_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_532fb8e4-e100-4ed5-b9ee-9becb0dc48cf_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e96fa07-75ae-4a8c-8620-f62396a23351_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9b297474-fee4-4249-88b1-147169a0f424_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7aca0693-6950-45b2-9dbf-7b551cc3dc3b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a63e62e8-6e6e-4453-8d1d-31b8d6d8742d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_dfcfc385-b864-4ddb-8faf-3410c942dd19_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_PurchaseandContractualObligationDueAfterFifthYear_626a992f-b361-4da0-b5a6-3c97a8d1395a_totalLabel_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationDueAfterFifthYear_label_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Due After Fifth Year</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationDueAfterFifthYear_documentation_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Due After Fifth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueAfterFifthYear" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueAfterFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_PurchaseandContractualObligationDueAfterFifthYear" xlink:to="lab_prta_PurchaseandContractualObligationDueAfterFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_04fde092-a2f6-43df-9f36-1573da7dce71_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase ordinary shares</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_Amortizationofrightofuseasset_6278364b-2b8d-4591-9b68-0fae67d15f71_terseLabel_en-US" xlink:label="lab_prta_Amortizationofrightofuseasset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_prta_Amortizationofrightofuseasset_label_en-US" xlink:label="lab_prta_Amortizationofrightofuseasset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">amortizationofrightofuseasset</link:label>
    <link:label id="lab_prta_Amortizationofrightofuseasset_documentation_en-US" xlink:label="lab_prta_Amortizationofrightofuseasset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use asset from operating lease presented on statement of cash flow as adjustment to net loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_Amortizationofrightofuseasset" xlink:href="prta-20200630.xsd#prta_Amortizationofrightofuseasset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_Amortizationofrightofuseasset" xlink:to="lab_prta_Amortizationofrightofuseasset" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationAgreementExtensionFeeperExtensionPeriod_3738ac81-7cd5-45ed-935d-6ff93237508e_terseLabel_en-US" xlink:label="lab_prta_CollaborationAgreementExtensionFeeperExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, extension fee per extension period</link:label>
    <link:label id="lab_prta_CollaborationAgreementExtensionFeeperExtensionPeriod_label_en-US" xlink:label="lab_prta_CollaborationAgreementExtensionFeeperExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Extension Fee per Extension Period</link:label>
    <link:label id="lab_prta_CollaborationAgreementExtensionFeeperExtensionPeriod_documentation_en-US" xlink:label="lab_prta_CollaborationAgreementExtensionFeeperExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Extension Fee per Extension Period (12-Months)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementExtensionFeeperExtensionPeriod" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementExtensionFeeperExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationAgreementExtensionFeeperExtensionPeriod" xlink:to="lab_prta_CollaborationAgreementExtensionFeeperExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinFifthYear_0036f001-dab8-45d2-8cbe-ea5903d2b78d_totalLabel_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinFifthYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinFifthYear_label_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Due in Fifth Year</link:label>
    <link:label id="lab_prta_PurchaseandContractualObligationDueinFifthYear_documentation_en-US" xlink:label="lab_prta_PurchaseandContractualObligationDueinFifthYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Contractual Obligation, Due in Fifth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinFifthYear" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_PurchaseandContractualObligationDueinFifthYear" xlink:to="lab_prta_PurchaseandContractualObligationDueinFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_ff3441fd-172b-4c3a-8c57-bf2dcef9ab7b_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligations under license agreements</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_15b1bcff-2dc8-4d13-a4eb-5a02eee721a0_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm_e16667e6-ffdf-4887-bf80-e7b0f62d5b11_terseLabel_en-US" xlink:label="lab_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, option fees and milestone payments, payment term</link:label>
    <link:label id="lab_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm_label_en-US" xlink:label="lab_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option Fees and Milestone Payments, Payment Term</link:label>
    <link:label id="lab_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm_documentation_en-US" xlink:label="lab_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option Fees and Milestone Payments, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm" xlink:to="lab_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_prta_ResearchReimbursementMember_a8bc3b3b-47ea-46a2-89dc-5b011845b31c_terseLabel_en-US" xlink:label="lab_prta_ResearchReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Reimbursement</link:label>
    <link:label id="lab_prta_ResearchReimbursementMember_label_en-US" xlink:label="lab_prta_ResearchReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Reimbursement [Member]</link:label>
    <link:label id="lab_prta_ResearchReimbursementMember_documentation_en-US" xlink:label="lab_prta_ResearchReimbursementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Reimbursement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ResearchReimbursementMember" xlink:href="prta-20200630.xsd#prta_ResearchReimbursementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prta_ResearchReimbursementMember" xlink:to="lab_prta_ResearchReimbursementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_feddb0af-9be0-4f57-838d-0304d245bcc8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_a1260c31-245f-4a0e-bd0e-cf87935fa148_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_3017daf2-ca5c-466b-aad0-1d9a7eabfabe_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>prta-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:38da442c-e5f6-4ed8-bb27-93106113c3da,g:af883291-30ed-4afd-a355-adc261f9a88c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.prothena.com/role/CoverPage" xlink:type="simple" xlink:href="prta-20200630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_62d21dca-ee00-4da1-ba31-f7dc23610ebe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_DocumentType_62d21dca-ee00-4da1-ba31-f7dc23610ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_38894ef6-41cb-45f6-9a0a-6913397c4086" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_DocumentQuarterlyReport_38894ef6-41cb-45f6-9a0a-6913397c4086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3b89f525-b9bb-47d6-9a09-9233cbb50620" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_DocumentPeriodEndDate_3b89f525-b9bb-47d6-9a09-9233cbb50620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_fff56006-4a7b-484e-b9ae-43ba9bbc9575" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_DocumentTransitionReport_fff56006-4a7b-484e-b9ae-43ba9bbc9575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4a7cf815-9f50-4518-be78-cd7ca00b770a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityFileNumber_4a7cf815-9f50-4518-be78-cd7ca00b770a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c4d35744-82a4-4ed6-ac84-20de3d37a219" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityRegistrantName_c4d35744-82a4-4ed6-ac84-20de3d37a219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_da95d22c-f474-4c8d-ab8a-90e93154cc1d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_da95d22c-f474-4c8d-ab8a-90e93154cc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ff32c2c2-999d-4927-b1d6-c09c9337eaa8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityTaxIdentificationNumber_ff32c2c2-999d-4927-b1d6-c09c9337eaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8f0b6814-cd62-4f9e-9fc1-2d43e43ce14b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityAddressAddressLine1_8f0b6814-cd62-4f9e-9fc1-2d43e43ce14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_97b399e8-b521-4705-b40b-e4698e9a22f3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityAddressAddressLine2_97b399e8-b521-4705-b40b-e4698e9a22f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c92116b2-1386-4031-970c-86653e09be53" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityAddressCityOrTown_c92116b2-1386-4031-970c-86653e09be53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2371859b-8b20-4cc2-8a20-415a84a7e9ab" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityAddressPostalZipCode_2371859b-8b20-4cc2-8a20-415a84a7e9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_a3150eba-3939-477b-b001-b65c4b7c02d4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityAddressCountry_a3150eba-3939-477b-b001-b65c4b7c02d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_478ab9eb-681d-44f1-88f2-d3b694c74410" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_CountryRegion_478ab9eb-681d-44f1-88f2-d3b694c74410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_db1fce25-3f42-4818-ae5b-130d674d3fc0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_CityAreaCode_db1fce25-3f42-4818-ae5b-130d674d3fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_31ad9299-606e-411f-bac9-c6971436aa42" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_LocalPhoneNumber_31ad9299-606e-411f-bac9-c6971436aa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3dfe9dee-0d75-4353-a014-ed5b47cd6755" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_Security12bTitle_3dfe9dee-0d75-4353-a014-ed5b47cd6755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2e8ee6f6-84d0-4e30-a0bb-7f9a885b3cbc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_TradingSymbol_2e8ee6f6-84d0-4e30-a0bb-7f9a885b3cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dbaced38-e316-4444-9da9-503fc22bc779" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_SecurityExchangeName_dbaced38-e316-4444-9da9-503fc22bc779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_233ee974-b247-490f-86d2-a181c33716d9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityCurrentReportingStatus_233ee974-b247-490f-86d2-a181c33716d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7e8a4a96-b2ea-47c8-b562-32ae2fdde0a0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityInteractiveDataCurrent_7e8a4a96-b2ea-47c8-b562-32ae2fdde0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d14e5e1b-5a4a-4e4f-8ebf-32baf37013ba" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityFilerCategory_d14e5e1b-5a4a-4e4f-8ebf-32baf37013ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a7383ee2-8e64-43c7-aed8-16eb07f55f21" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntitySmallBusiness_a7383ee2-8e64-43c7-aed8-16eb07f55f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4d4fecd0-d707-4405-a658-f2ed127f3afc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityEmergingGrowthCompany_4d4fecd0-d707-4405-a658-f2ed127f3afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_48f38850-cb55-4f61-bba2-f5624d33a584" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityShellCompany_48f38850-cb55-4f61-bba2-f5624d33a584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c34e3b2c-5516-4c78-85c9-d58b52584921" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c34e3b2c-5516-4c78-85c9-d58b52584921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2ccd46fd-5fe5-4bbe-b9da-bc8b6af18dfc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_AmendmentFlag_2ccd46fd-5fe5-4bbe-b9da-bc8b6af18dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a603b963-fe1c-4e89-8e64-9685d1f129ee" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_DocumentFiscalYearFocus_a603b963-fe1c-4e89-8e64-9685d1f129ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_287c2669-0a1c-4299-87ed-ad64c946d202" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_287c2669-0a1c-4299-87ed-ad64c946d202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e27651e8-0a22-4ebb-94ea-6475f457d7fc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_EntityCentralIndexKey_e27651e8-0a22-4ebb-94ea-6475f457d7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_875d7db1-7d1d-42c5-a13e-d31029d1e0a2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9b093e8e-b6fb-40c0-ab94-a0c134008ab2" xlink:to="loc_dei_CurrentFiscalYearEndDate_875d7db1-7d1d-42c5-a13e-d31029d1e0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ef1c265c-de6f-4442-bac0-bfb48768d7cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9f620392-d0f4-4e7f-acfc-9da56e2deb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef1c265c-de6f-4442-bac0-bfb48768d7cc" xlink:to="loc_us-gaap_AssetsAbstract_9f620392-d0f4-4e7f-acfc-9da56e2deb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a0933ab4-6bda-40c0-afc5-91393a698c51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9f620392-d0f4-4e7f-acfc-9da56e2deb3c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a0933ab4-6bda-40c0-afc5-91393a698c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0e9627e-5a17-4478-88a3-96f4481cbd00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a0933ab4-6bda-40c0-afc5-91393a698c51" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0e9627e-5a17-4478-88a3-96f4481cbd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7091da0e-4210-4a53-abe2-3f0db84a5d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a0933ab4-6bda-40c0-afc5-91393a698c51" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7091da0e-4210-4a53-abe2-3f0db84a5d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4aef8278-bf7f-4ca2-96a1-ec52f8456f05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a0933ab4-6bda-40c0-afc5-91393a698c51" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4aef8278-bf7f-4ca2-96a1-ec52f8456f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e8e3e6f9-ffda-4c69-abe3-ffed650f65e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a0933ab4-6bda-40c0-afc5-91393a698c51" xlink:to="loc_us-gaap_AssetsCurrent_e8e3e6f9-ffda-4c69-abe3-ffed650f65e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_1dd33506-4ccb-40a7-83c5-aeb124dbfb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9f620392-d0f4-4e7f-acfc-9da56e2deb3c" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_1dd33506-4ccb-40a7-83c5-aeb124dbfb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b219ee5d-2709-414d-a6ac-610cde58e7dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1dd33506-4ccb-40a7-83c5-aeb124dbfb9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b219ee5d-2709-414d-a6ac-610cde58e7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e0814f24-69a6-4ef2-a645-77bca41d8377" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1dd33506-4ccb-40a7-83c5-aeb124dbfb9d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e0814f24-69a6-4ef2-a645-77bca41d8377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2b98970f-5460-46ad-9f3b-15ffba4d895a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1dd33506-4ccb-40a7-83c5-aeb124dbfb9d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2b98970f-5460-46ad-9f3b-15ffba4d895a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9ada6022-ade7-4e3e-96b3-9cece5bfac48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1dd33506-4ccb-40a7-83c5-aeb124dbfb9d" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9ada6022-ade7-4e3e-96b3-9cece5bfac48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fdac0cd0-0bb6-453e-9c5a-a1aa730ca47f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1dd33506-4ccb-40a7-83c5-aeb124dbfb9d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fdac0cd0-0bb6-453e-9c5a-a1aa730ca47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_f9e014b3-85b6-4ef6-aebb-d1fc710a6e26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1dd33506-4ccb-40a7-83c5-aeb124dbfb9d" xlink:to="loc_us-gaap_AssetsNoncurrent_f9e014b3-85b6-4ef6-aebb-d1fc710a6e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3391f932-b201-46d9-b963-0c8dc4ce8e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9f620392-d0f4-4e7f-acfc-9da56e2deb3c" xlink:to="loc_us-gaap_Assets_3391f932-b201-46d9-b963-0c8dc4ce8e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67c9d73c-b9ce-4739-9a0e-fe2e758d2ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef1c265c-de6f-4442-bac0-bfb48768d7cc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67c9d73c-b9ce-4739-9a0e-fe2e758d2ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0123de1a-6d1a-4dbd-9082-f3da4780e43f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67c9d73c-b9ce-4739-9a0e-fe2e758d2ca7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0123de1a-6d1a-4dbd-9082-f3da4780e43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_74e3861d-d384-4565-9844-1c7cb7c4ddeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0123de1a-6d1a-4dbd-9082-f3da4780e43f" xlink:to="loc_us-gaap_AccountsPayableCurrent_74e3861d-d384-4565-9844-1c7cb7c4ddeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_AccruedResearchAndDevelopmentCurrent_dee05ac0-be13-4952-8977-b6814fd7cf51" xlink:href="prta-20200630.xsd#prta_AccruedResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0123de1a-6d1a-4dbd-9082-f3da4780e43f" xlink:to="loc_prta_AccruedResearchAndDevelopmentCurrent_dee05ac0-be13-4952-8977-b6814fd7cf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_af11e512-d3f7-4077-ab24-7bf645334494" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0123de1a-6d1a-4dbd-9082-f3da4780e43f" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_af11e512-d3f7-4077-ab24-7bf645334494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6e75672c-e2bf-48de-91fc-0b4f6f4f9451" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0123de1a-6d1a-4dbd-9082-f3da4780e43f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6e75672c-e2bf-48de-91fc-0b4f6f4f9451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_892935f2-b1f4-41db-913f-5f786ab9d4df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0123de1a-6d1a-4dbd-9082-f3da4780e43f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_892935f2-b1f4-41db-913f-5f786ab9d4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_51cfc30f-b93f-40eb-9157-1bf6d5320a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0123de1a-6d1a-4dbd-9082-f3da4780e43f" xlink:to="loc_us-gaap_LiabilitiesCurrent_51cfc30f-b93f-40eb-9157-1bf6d5320a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_bafdfd42-8f7d-4411-a65c-3b8177391505" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67c9d73c-b9ce-4739-9a0e-fe2e758d2ca7" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_bafdfd42-8f7d-4411-a65c-3b8177391505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_03edae7d-35a9-4f75-9bbf-fd5d229aac11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_bafdfd42-8f7d-4411-a65c-3b8177391505" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_03edae7d-35a9-4f75-9bbf-fd5d229aac11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4feed61d-54d3-4616-831b-b0c41a653b57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_bafdfd42-8f7d-4411-a65c-3b8177391505" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4feed61d-54d3-4616-831b-b0c41a653b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c39396ea-492d-4f89-b219-9c3f61c4c5f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_bafdfd42-8f7d-4411-a65c-3b8177391505" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c39396ea-492d-4f89-b219-9c3f61c4c5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3bdcc220-3a22-4e9e-8150-e0356c8d52aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_bafdfd42-8f7d-4411-a65c-3b8177391505" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_3bdcc220-3a22-4e9e-8150-e0356c8d52aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_803909fc-2164-4204-94bc-fe4b5bc9f5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67c9d73c-b9ce-4739-9a0e-fe2e758d2ca7" xlink:to="loc_us-gaap_Liabilities_803909fc-2164-4204-94bc-fe4b5bc9f5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ac77ab82-1eb9-435f-96ad-9a588eadf034" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67c9d73c-b9ce-4739-9a0e-fe2e758d2ca7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ac77ab82-1eb9-435f-96ad-9a588eadf034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_bdc39b9e-1a44-40fc-bdc4-ea6c69f3d679" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67c9d73c-b9ce-4739-9a0e-fe2e758d2ca7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_bdc39b9e-1a44-40fc-bdc4-ea6c69f3d679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesValue_0faaac41-717a-4e61-9c1a-7bd95bab910a" xlink:href="prta-20200630.xsd#prta_DeferredSharesValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bdc39b9e-1a44-40fc-bdc4-ea6c69f3d679" xlink:to="loc_prta_DeferredSharesValue_0faaac41-717a-4e61-9c1a-7bd95bab910a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9ce6fbd5-4ed1-4ff9-aa46-c6448ad42e46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bdc39b9e-1a44-40fc-bdc4-ea6c69f3d679" xlink:to="loc_us-gaap_CommonStockValue_9ce6fbd5-4ed1-4ff9-aa46-c6448ad42e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b6623deb-ff94-479e-8b63-af80552de1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bdc39b9e-1a44-40fc-bdc4-ea6c69f3d679" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b6623deb-ff94-479e-8b63-af80552de1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77a92f2b-ef09-4087-9e8e-a858da5e96e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bdc39b9e-1a44-40fc-bdc4-ea6c69f3d679" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77a92f2b-ef09-4087-9e8e-a858da5e96e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_378bed83-ed9b-4e38-8b09-8f4e825ef88a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_bdc39b9e-1a44-40fc-bdc4-ea6c69f3d679" xlink:to="loc_us-gaap_StockholdersEquity_378bed83-ed9b-4e38-8b09-8f4e825ef88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6230132-c319-4a89-a53d-6cca54ad8f81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67c9d73c-b9ce-4739-9a0e-fe2e758d2ca7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6230132-c319-4a89-a53d-6cca54ad8f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b6966e30-cdf1-4e7b-97a8-5c5dec79bcda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesParValue_fc009be0-a797-422f-b32a-5aba82b29f19" xlink:href="prta-20200630.xsd#prta_DeferredSharesParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6966e30-cdf1-4e7b-97a8-5c5dec79bcda" xlink:to="loc_prta_DeferredSharesParValue_fc009be0-a797-422f-b32a-5aba82b29f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesSharesAuthorized_31289e0b-074f-4bdf-86a5-8b289b3341e9" xlink:href="prta-20200630.xsd#prta_DeferredSharesSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6966e30-cdf1-4e7b-97a8-5c5dec79bcda" xlink:to="loc_prta_DeferredSharesSharesAuthorized_31289e0b-074f-4bdf-86a5-8b289b3341e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesShareIssued_b391c390-fd9d-4074-ab61-17b9ebf0bd3c" xlink:href="prta-20200630.xsd#prta_DeferredSharesShareIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6966e30-cdf1-4e7b-97a8-5c5dec79bcda" xlink:to="loc_prta_DeferredSharesShareIssued_b391c390-fd9d-4074-ab61-17b9ebf0bd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesShareOutstanding_62079ee8-6747-4d00-b3d6-6343ecb837d5" xlink:href="prta-20200630.xsd#prta_DeferredSharesShareOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6966e30-cdf1-4e7b-97a8-5c5dec79bcda" xlink:to="loc_prta_DeferredSharesShareOutstanding_62079ee8-6747-4d00-b3d6-6343ecb837d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cf13ace7-516a-48e8-8c93-a75b75e9abc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6966e30-cdf1-4e7b-97a8-5c5dec79bcda" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cf13ace7-516a-48e8-8c93-a75b75e9abc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4172f08a-8f83-4871-a02b-7cfec5546cca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6966e30-cdf1-4e7b-97a8-5c5dec79bcda" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4172f08a-8f83-4871-a02b-7cfec5546cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c85c6467-7487-45a3-9035-f54b13982054" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6966e30-cdf1-4e7b-97a8-5c5dec79bcda" xlink:to="loc_us-gaap_CommonStockSharesIssued_c85c6467-7487-45a3-9035-f54b13982054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6d40f9fa-7efd-4eae-a2ea-aab4e1720cb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b6966e30-cdf1-4e7b-97a8-5c5dec79bcda" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6d40f9fa-7efd-4eae-a2ea-aab4e1720cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_abc5c5db-edb3-4cef-9c63-7fb3bdd6e644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_357f2ac5-4767-49dd-9729-abd1af3623b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_abc5c5db-edb3-4cef-9c63-7fb3bdd6e644" xlink:to="loc_us-gaap_StatementTable_357f2ac5-4767-49dd-9729-abd1af3623b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b2129a95-6569-4b0f-abab-4a0befb069a6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_357f2ac5-4767-49dd-9729-abd1af3623b7" xlink:to="loc_srt_ProductOrServiceAxis_b2129a95-6569-4b0f-abab-4a0befb069a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99c56ba9-104c-4b97-a75b-bd68c9e1b2cb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b2129a95-6569-4b0f-abab-4a0befb069a6" xlink:to="loc_srt_ProductsAndServicesDomain_99c56ba9-104c-4b97-a75b-bd68c9e1b2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationMember_180b4f1d-3034-43a2-9c05-c355b9849afc" xlink:href="prta-20200630.xsd#prta_CollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_99c56ba9-104c-4b97-a75b-bd68c9e1b2cb" xlink:to="loc_prta_CollaborationMember_180b4f1d-3034-43a2-9c05-c355b9849afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_147079dd-ae0f-4aa0-8edf-91d1f41f1029" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_99c56ba9-104c-4b97-a75b-bd68c9e1b2cb" xlink:to="loc_us-gaap_LicenseMember_147079dd-ae0f-4aa0-8edf-91d1f41f1029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_357f2ac5-4767-49dd-9729-abd1af3623b7" xlink:to="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f858b37-e235-40fa-aa83-b37e48e302d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f858b37-e235-40fa-aa83-b37e48e302d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d19c7edb-a86c-4476-90e1-7a81c1270132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d19c7edb-a86c-4476-90e1-7a81c1270132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_43c5f3a6-b194-45ca-aa94-1927fdd1c17b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_43c5f3a6-b194-45ca-aa94-1927fdd1c17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_1ed72369-106e-4ee3-b2cc-7683a2c0fe5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:to="loc_us-gaap_RestructuringCosts_1ed72369-106e-4ee3-b2cc-7683a2c0fe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7a2d6938-297e-4a07-8897-94b0c2bacf15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_74d2533b-65dd-401d-bd7d-f75e8a6518fd" xlink:to="loc_us-gaap_OperatingExpenses_7a2d6938-297e-4a07-8897-94b0c2bacf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_32f14b19-2fc8-45dc-bade-f20d7cab2352" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_OperatingIncomeLoss_32f14b19-2fc8-45dc-bade-f20d7cab2352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e51ee2dd-ec34-4dea-9662-6bb04b0b1fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e51ee2dd-ec34-4dea-9662-6bb04b0b1fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_a9fec004-43ab-4430-a588-ea105c38b112" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e51ee2dd-ec34-4dea-9662-6bb04b0b1fc5" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_a9fec004-43ab-4430-a588-ea105c38b112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1deba353-ca6f-458e-9131-60ae9ab17585" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e51ee2dd-ec34-4dea-9662-6bb04b0b1fc5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1deba353-ca6f-458e-9131-60ae9ab17585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_758ca36a-9021-4215-b72f-965d2b78c297" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_e51ee2dd-ec34-4dea-9662-6bb04b0b1fc5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_758ca36a-9021-4215-b72f-965d2b78c297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_472a0db9-e76b-48ea-b21a-ebb110c4cf76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_472a0db9-e76b-48ea-b21a-ebb110c4cf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1cba1295-8424-43b9-9514-c877a170e326" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1cba1295-8424-43b9-9514-c877a170e326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_817390a8-96ec-43ac-a830-e689d6222584" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_NetIncomeLoss_817390a8-96ec-43ac-a830-e689d6222584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_a03dc349-15e0-4472-8845-c384f07e66cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_a03dc349-15e0-4472-8845-c384f07e66cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b0a62558-838b-487a-a6ff-c8cccb0a4368" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e45abfe-de87-42b9-b891-69cae5ce063c" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b0a62558-838b-487a-a6ff-c8cccb0a4368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed3a6bd2-a48f-4347-8cc8-95318f3fc69d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed3a6bd2-a48f-4347-8cc8-95318f3fc69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1662cb3b-46de-461d-9142-b418a9346435" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed3a6bd2-a48f-4347-8cc8-95318f3fc69d" xlink:to="loc_us-gaap_NetIncomeLoss_1662cb3b-46de-461d-9142-b418a9346435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4bc5165-247b-4623-bbdb-b92874b5be3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed3a6bd2-a48f-4347-8cc8-95318f3fc69d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4bc5165-247b-4623-bbdb-b92874b5be3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f4b33c63-2520-449e-9b26-91a044e6655c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4bc5165-247b-4623-bbdb-b92874b5be3b" xlink:to="loc_us-gaap_ShareBasedCompensation_f4b33c63-2520-449e-9b26-91a044e6655c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f9096cd4-46a5-4569-afba-7722d92342bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4bc5165-247b-4623-bbdb-b92874b5be3b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f9096cd4-46a5-4569-afba-7722d92342bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ebfbc047-d998-4a9e-be73-b0128b43a8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4bc5165-247b-4623-bbdb-b92874b5be3b" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ebfbc047-d998-4a9e-be73-b0128b43a8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_Amortizationofrightofuseasset_06ede33b-14e0-488b-81a7-f517a4053e0e" xlink:href="prta-20200630.xsd#prta_Amortizationofrightofuseasset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4bc5165-247b-4623-bbdb-b92874b5be3b" xlink:to="loc_prta_Amortizationofrightofuseasset_06ede33b-14e0-488b-81a7-f517a4053e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35adf16e-f521-431e-9bb6-dab04a1f40cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed3a6bd2-a48f-4347-8cc8-95318f3fc69d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35adf16e-f521-431e-9bb6-dab04a1f40cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a5b9d7d1-fa0a-4e3e-a551-bec3074f7219" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35adf16e-f521-431e-9bb6-dab04a1f40cb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a5b9d7d1-fa0a-4e3e-a551-bec3074f7219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1cd8d8f0-8883-4d1d-9466-7fb175a501c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35adf16e-f521-431e-9bb6-dab04a1f40cb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1cd8d8f0-8883-4d1d-9466-7fb175a501c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_21ded4e2-e660-4d23-b25d-387c68e275e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35adf16e-f521-431e-9bb6-dab04a1f40cb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_21ded4e2-e660-4d23-b25d-387c68e275e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_f61b1252-6bb3-4640-b4ce-ea445e22c09a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35adf16e-f521-431e-9bb6-dab04a1f40cb" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_f61b1252-6bb3-4640-b4ce-ea445e22c09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_IncreaseDecreaseinOperatingLeaseLiability_c4268dc7-88e1-4ee4-95b0-e2c7523e6504" xlink:href="prta-20200630.xsd#prta_IncreaseDecreaseinOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35adf16e-f521-431e-9bb6-dab04a1f40cb" xlink:to="loc_prta_IncreaseDecreaseinOperatingLeaseLiability_c4268dc7-88e1-4ee4-95b0-e2c7523e6504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae56cb0b-4602-460d-a7a5-71e3e38bd748" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_35adf16e-f521-431e-9bb6-dab04a1f40cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae56cb0b-4602-460d-a7a5-71e3e38bd748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_557e330c-4ef1-4629-9848-913dae70ba29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_557e330c-4ef1-4629-9848-913dae70ba29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_23be1fc1-360f-45ac-b904-eb1920830a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_557e330c-4ef1-4629-9848-913dae70ba29" xlink:to="loc_us-gaap_PaymentsToAcquireMachineryAndEquipment_23be1fc1-360f-45ac-b904-eb1920830a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0d8d59a5-9e09-4d50-8798-872344891cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_557e330c-4ef1-4629-9848-913dae70ba29" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0d8d59a5-9e09-4d50-8798-872344891cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0a4b188-887a-422e-b06e-951fe8fa3bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_557e330c-4ef1-4629-9848-913dae70ba29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0a4b188-887a-422e-b06e-951fe8fa3bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ddbc913-103d-46ea-b1d9-f976b6374c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ddbc913-103d-46ea-b1d9-f976b6374c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_bbed7075-0910-40ce-9c39-ae06823a8cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ddbc913-103d-46ea-b1d9-f976b6374c1f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_bbed7075-0910-40ce-9c39-ae06823a8cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa27f69a-4f57-4d7f-8850-a44c6495e92b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ddbc913-103d-46ea-b1d9-f976b6374c1f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa27f69a-4f57-4d7f-8850-a44c6495e92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bb7a3a7c-274b-4495-a4d4-e1ebebbf701b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bb7a3a7c-274b-4495-a4d4-e1ebebbf701b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32db4a48-05ac-4595-90ef-20c4ed837037" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32db4a48-05ac-4595-90ef-20c4ed837037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59079ccd-89e9-48b5-8031-b734a94add6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59079ccd-89e9-48b5-8031-b734a94add6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_a997c519-ec48-422f-bfe0-c879e0379c30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_a997c519-ec48-422f-bfe0-c879e0379c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_567c7058-9362-4e0b-895e-baf56b6d573e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_a997c519-ec48-422f-bfe0-c879e0379c30" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_567c7058-9362-4e0b-895e-baf56b6d573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c30b84c6-3005-4f5f-ba1b-fe61083da1c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c30b84c6-3005-4f5f-ba1b-fe61083da1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_ba91ddb6-8d4b-402d-a793-6ecb9b994d51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c30b84c6-3005-4f5f-ba1b-fe61083da1c5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_ba91ddb6-8d4b-402d-a793-6ecb9b994d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_840fbf7f-a4a5-4fd6-b6f7-33ad2f7b773b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c30b84c6-3005-4f5f-ba1b-fe61083da1c5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_840fbf7f-a4a5-4fd6-b6f7-33ad2f7b773b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ReductionofBuildtosuitLeaseObligation_689b7245-d2b8-4772-a6b4-3d8be368a3e9" xlink:href="prta-20200630.xsd#prta_ReductionofBuildtosuitLeaseObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c30b84c6-3005-4f5f-ba1b-fe61083da1c5" xlink:to="loc_prta_ReductionofBuildtosuitLeaseObligation_689b7245-d2b8-4772-a6b4-3d8be368a3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction_4c24373b-2013-4ca2-87c3-8ed24c6aea4d" xlink:href="prta-20200630.xsd#prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c30b84c6-3005-4f5f-ba1b-fe61083da1c5" xlink:to="loc_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction_4c24373b-2013-4ca2-87c3-8ed24c6aea4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction_f2725118-08d8-416a-97a4-7a4feef0a0c5" xlink:href="prta-20200630.xsd#prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c30b84c6-3005-4f5f-ba1b-fe61083da1c5" xlink:to="loc_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction_f2725118-08d8-416a-97a4-7a4feef0a0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_50e25bdb-02af-4ba4-8703-ff95bb994fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_50e25bdb-02af-4ba4-8703-ff95bb994fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_642b6cb3-cc6c-4af1-971e-a18b81908653" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_RestrictedCashCurrent_642b6cb3-cc6c-4af1-971e-a18b81908653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_aedc4ca6-a824-4828-b0d8-2d041edb9ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_aedc4ca6-a824-4828-b0d8-2d041edb9ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a4357d7e-ffc9-4704-a20e-6868e1b9a248" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_022cf016-81a0-4fe4-ad82-b6a6a6985de2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a4357d7e-ffc9-4704-a20e-6868e1b9a248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="prta-20200630.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f2523015-878f-4fbe-bebb-d479094be395" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e3ebae37-67ae-409b-8e00-580424f3f3df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f2523015-878f-4fbe-bebb-d479094be395" xlink:to="loc_us-gaap_StatementTable_e3ebae37-67ae-409b-8e00-580424f3f3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_511dbe4c-267f-461a-a838-9143d30c839c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3ebae37-67ae-409b-8e00-580424f3f3df" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_511dbe4c-267f-461a-a838-9143d30c839c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe7e5c7f-1a72-4bd0-ab4d-915b15e1f6c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_511dbe4c-267f-461a-a838-9143d30c839c" xlink:to="loc_us-gaap_EquityComponentDomain_fe7e5c7f-1a72-4bd0-ab4d-915b15e1f6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OrdinaryShareMember_0a3f4313-5a8c-4cbe-91de-f9a3c8bd906b" xlink:href="prta-20200630.xsd#prta_OrdinaryShareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe7e5c7f-1a72-4bd0-ab4d-915b15e1f6c4" xlink:to="loc_prta_OrdinaryShareMember_0a3f4313-5a8c-4cbe-91de-f9a3c8bd906b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d38f5097-1212-4dd2-9e59-da1b2ef06ded" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe7e5c7f-1a72-4bd0-ab4d-915b15e1f6c4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d38f5097-1212-4dd2-9e59-da1b2ef06ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d2cfc9ee-ef0c-4146-b37d-d867b79a8ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe7e5c7f-1a72-4bd0-ab4d-915b15e1f6c4" xlink:to="loc_us-gaap_RetainedEarningsMember_d2cfc9ee-ef0c-4146-b37d-d867b79a8ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7a070f1c-dee8-4195-9620-86201a8fe801" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3ebae37-67ae-409b-8e00-580424f3f3df" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7a070f1c-dee8-4195-9620-86201a8fe801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_220390b8-50ba-498d-b71b-da1e8c0a367c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_7a070f1c-dee8-4195-9620-86201a8fe801" xlink:to="loc_us-gaap_TypeOfAdoptionMember_220390b8-50ba-498d-b71b-da1e8c0a367c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_80d135cc-4ed0-47a4-91eb-16552bcb6e55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_220390b8-50ba-498d-b71b-da1e8c0a367c" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_80d135cc-4ed0-47a4-91eb-16552bcb6e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3ebae37-67ae-409b-8e00-580424f3f3df" xlink:to="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_77b4b9b9-e1bf-4447-b2b4-f82feeb688a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_SharesOutstanding_77b4b9b9-e1bf-4447-b2b4-f82feeb688a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e03fcc0-82a3-40da-b65a-f91e6eee22e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8e03fcc0-82a3-40da-b65a-f91e6eee22e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_7019e3c0-9579-4858-ba55-0adf8411076b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_7019e3c0-9579-4858-ba55-0adf8411076b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_25152058-7bfc-499b-8f50-7c23dd666f80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_25152058-7bfc-499b-8f50-7c23dd666f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0fed2f7b-127f-491d-9dd6-b15e5303e2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0fed2f7b-127f-491d-9dd6-b15e5303e2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b8b20310-42c5-4156-9adc-e3ee27ac937d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b8b20310-42c5-4156-9adc-e3ee27ac937d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8310b5d9-8f81-490f-aca5-8e3e88c2ef74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_NetIncomeLoss_8310b5d9-8f81-490f-aca5-8e3e88c2ef74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1d286f50-9859-4684-b813-96011b92b4e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_SharesOutstanding_1d286f50-9859-4684-b813-96011b92b4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d20d470b-e196-439a-87b5-480941a8ef11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_507fc1e4-aa61-445e-9620-847ddefb8835" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d20d470b-e196-439a-87b5-480941a8ef11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/Organization" xlink:type="simple" xlink:href="prta-20200630.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92c22b92-fa30-4dd0-b520-5637abc0e29d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3b8418b4-a09f-4559-8ce8-c8de9538e418" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92c22b92-fa30-4dd0-b520-5637abc0e29d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3b8418b4-a09f-4559-8ce8-c8de9538e418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/OrganizationAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#OrganizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/OrganizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8d5960b-894e-4fed-8a4f-b88cd4c21dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3578201-4d79-4d7c-ab3d-3b75e3a519b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8d5960b-894e-4fed-8a4f-b88cd4c21dad" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3578201-4d79-4d7c-ab3d-3b75e3a519b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b734f936-ac14-42b3-a762-89a6ee64af4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8d5960b-894e-4fed-8a4f-b88cd4c21dad" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b734f936-ac14-42b3-a762-89a6ee64af4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="prta-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_79d8e3fb-bcbe-4c35-8d86-4dd316c9b47d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d5814212-5a7d-4999-bcff-137214731487" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79d8e3fb-bcbe-4c35-8d86-4dd316c9b47d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d5814212-5a7d-4999-bcff-137214731487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="prta-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d78305ed-89ca-457f-903e-03a7dd9319b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e622126d-8936-435f-9a67-fb811c112779" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d78305ed-89ca-457f-903e-03a7dd9319b0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e622126d-8936-435f-9a67-fb811c112779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_18844e69-1798-4234-8ba9-b6877edf5879" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d78305ed-89ca-457f-903e-03a7dd9319b0" xlink:to="loc_us-gaap_UseOfEstimates_18844e69-1798-4234-8ba9-b6877edf5879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2d3d6e40-8e89-40eb-8f9e-01da68a4eab4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d78305ed-89ca-457f-903e-03a7dd9319b0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2d3d6e40-8e89-40eb-8f9e-01da68a4eab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_87adb49a-57dd-44e2-993e-54d9a8e665e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d78305ed-89ca-457f-903e-03a7dd9319b0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_87adb49a-57dd-44e2-993e-54d9a8e665e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_be71d89b-6f3e-45dc-9fea-fb1148decac4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_eadb1253-5857-4063-9595-c951ad751975" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_be71d89b-6f3e-45dc-9fea-fb1148decac4" xlink:to="loc_us-gaap_ConcentrationRiskTable_eadb1253-5857-4063-9595-c951ad751975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c0f35755-114e-4be1-8dec-9b6e29b83cf1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_eadb1253-5857-4063-9595-c951ad751975" xlink:to="loc_srt_StatementGeographicalAxis_c0f35755-114e-4be1-8dec-9b6e29b83cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9a82e4a8-0567-4dd5-bfeb-c0d7113621d7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c0f35755-114e-4be1-8dec-9b6e29b83cf1" xlink:to="loc_srt_SegmentGeographicalDomain_9a82e4a8-0567-4dd5-bfeb-c0d7113621d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a0191510-f317-41f2-b003-142d572b7b88" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9a82e4a8-0567-4dd5-bfeb-c0d7113621d7" xlink:to="loc_country_US_a0191510-f317-41f2-b003-142d572b7b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_12be7c9e-31b2-4900-a851-e78b3f242e18" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9a82e4a8-0567-4dd5-bfeb-c0d7113621d7" xlink:to="loc_country_IE_12be7c9e-31b2-4900-a851-e78b3f242e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5bd6f227-2811-41c0-9079-e4b22b184ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_eadb1253-5857-4063-9595-c951ad751975" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_5bd6f227-2811-41c0-9079-e4b22b184ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_94f40479-a9ae-4bff-866b-c9d3430b402a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5bd6f227-2811-41c0-9079-e4b22b184ae7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_94f40479-a9ae-4bff-866b-c9d3430b402a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="prta-20200630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0f42383e-355c-41fc-9408-8d1428135933" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6519a368-b645-484b-a374-bd1d59f4a870" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0f42383e-355c-41fc-9408-8d1428135933" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6519a368-b645-484b-a374-bd1d59f4a870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b1ec6b38-8136-4c5a-a983-967b8b0a3899" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1a16676a-6379-4e0e-84d5-4d13ed63bfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b1ec6b38-8136-4c5a-a983-967b8b0a3899" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1a16676a-6379-4e0e-84d5-4d13ed63bfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_439e3f7f-f6f7-4cd3-88d1-aa99dc1c7554" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1a16676a-6379-4e0e-84d5-4d13ed63bfa5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_439e3f7f-f6f7-4cd3-88d1-aa99dc1c7554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45f05a4c-fa36-4f7b-96b1-2be80022b002" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_439e3f7f-f6f7-4cd3-88d1-aa99dc1c7554" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45f05a4c-fa36-4f7b-96b1-2be80022b002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ccf58b14-3168-4db4-87c8-0e3bd46308f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45f05a4c-fa36-4f7b-96b1-2be80022b002" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ccf58b14-3168-4db4-87c8-0e3bd46308f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7a81a1d0-5ede-4955-b85e-a8747213e108" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1a16676a-6379-4e0e-84d5-4d13ed63bfa5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7a81a1d0-5ede-4955-b85e-a8747213e108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_ed46aabb-223f-4cf2-a605-d9b60b161bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7a81a1d0-5ede-4955-b85e-a8747213e108" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_ed46aabb-223f-4cf2-a605-d9b60b161bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItems" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_cac56852-95b4-410b-8b24-06d37213f474" xlink:href="prta-20200630.xsd#prta_CompositionofCertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_7165ed59-161f-4ed6-8226-4109f876945b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_cac56852-95b4-410b-8b24-06d37213f474" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_7165ed59-161f-4ed6-8226-4109f876945b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_9e5f6b06-5f96-446b-8901-d13b1a4e7a1f" xlink:href="prta-20200630.xsd#prta_CompositionofCertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_478bc183-3c48-433c-b3c2-532cbafbefb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_9e5f6b06-5f96-446b-8901-d13b1a4e7a1f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_478bc183-3c48-433c-b3c2-532cbafbefb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6af733b0-cb2a-4550-a51c-eb90e6cb7e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_9e5f6b06-5f96-446b-8901-d13b1a4e7a1f" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6af733b0-cb2a-4550-a51c-eb90e6cb7e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_1bd3c51a-ddab-4ff3-a0e8-e1f7aba203c4" xlink:href="prta-20200630.xsd#prta_CompositionofCertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_b8a99c89-d1de-403d-9ab9-69f6311adbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_1bd3c51a-ddab-4ff3-a0e8-e1f7aba203c4" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_b8a99c89-d1de-403d-9ab9-69f6311adbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_c290d72d-e5f1-42f3-abee-5bd255d87327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_1bd3c51a-ddab-4ff3-a0e8-e1f7aba203c4" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_c290d72d-e5f1-42f3-abee-5bd255d87327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareGross_623d78db-397d-4e48-b345-7900aea52c29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_1bd3c51a-ddab-4ff3-a0e8-e1f7aba203c4" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareGross_623d78db-397d-4e48-b345-7900aea52c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d1e8608c-0158-4c57-a372-424ec372f17c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_1bd3c51a-ddab-4ff3-a0e8-e1f7aba203c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d1e8608c-0158-4c57-a372-424ec372f17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_391e70ef-adda-4c8d-a936-87711aeef3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_1bd3c51a-ddab-4ff3-a0e8-e1f7aba203c4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_391e70ef-adda-4c8d-a936-87711aeef3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_80055228-dca0-4696-81c7-8ad0dc09fe5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_1bd3c51a-ddab-4ff3-a0e8-e1f7aba203c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_80055228-dca0-4696-81c7-8ad0dc09fe5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_d6127fd4-8e87-4068-8e13-d24c2edb1748" xlink:href="prta-20200630.xsd#prta_CompositionofCertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_36e134f8-5327-486e-af89-7e902313aede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_d6127fd4-8e87-4068-8e13-d24c2edb1748" xlink:to="loc_us-gaap_Depreciation_36e134f8-5327-486e-af89-7e902313aede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_6f9adaa8-3933-418a-ace4-45dc6a284ce5" xlink:href="prta-20200630.xsd#prta_CompositionofCertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3e1c7ee5-8ce6-45fa-a6b2-5dd77e4c2429" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_6f9adaa8-3933-418a-ace4-45dc6a284ce5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3e1c7ee5-8ce6-45fa-a6b2-5dd77e4c2429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3329f374-3ec6-4951-a134-cae4da0b4f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_6f9adaa8-3933-418a-ace4-45dc6a284ce5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3329f374-3ec6-4951-a134-cae4da0b4f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_ff2b8c95-f6bf-4a0f-80ff-73ece412b78a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_6f9adaa8-3933-418a-ace4-45dc6a284ce5" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_ff2b8c95-f6bf-4a0f-80ff-73ece412b78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_801941e9-5347-4331-b5a7-8275e244d794" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CompositionofCertainBalanceSheetItemsAbstract_6f9adaa8-3933-418a-ace4-45dc6a284ce5" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_801941e9-5347-4331-b5a7-8275e244d794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShare" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShare"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_392c8897-1d68-4f2a-bd77-bc7e390e45b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_27521417-c314-48a4-9c5e-572d7cf03300" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_392c8897-1d68-4f2a-bd77-bc7e390e45b4" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_27521417-c314-48a4-9c5e-572d7cf03300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareTables" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShareTables"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_eac458b0-ecd9-4419-ae66-6f2401504140" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_455533f2-d844-4d3b-8e63-11f0b0b91b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eac458b0-ecd9-4419-ae66-6f2401504140" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_455533f2-d844-4d3b-8e63-11f0b0b91b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c51564bb-ac82-4085-a50e-fc6415e6f6da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eac458b0-ecd9-4419-ae66-6f2401504140" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c51564bb-ac82-4085-a50e-fc6415e6f6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f22402cd-131b-49db-a42e-ab011f633b04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_5863448a-0921-4982-b803-55d3a9f9704f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f22402cd-131b-49db-a42e-ab011f633b04" xlink:to="loc_us-gaap_NetIncomeLossAbstract_5863448a-0921-4982-b803-55d3a9f9704f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15e6525b-1fa3-4035-8628-0e85154edfdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_5863448a-0921-4982-b803-55d3a9f9704f" xlink:to="loc_us-gaap_NetIncomeLoss_15e6525b-1fa3-4035-8628-0e85154edfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_637760ea-78f8-42af-b196-0e0c76aa9b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f22402cd-131b-49db-a42e-ab011f633b04" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_637760ea-78f8-42af-b196-0e0c76aa9b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3d968d61-3ab1-43d5-b088-e02a9767d1f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_637760ea-78f8-42af-b196-0e0c76aa9b4d" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3d968d61-3ab1-43d5-b088-e02a9767d1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_143841ef-38e9-4913-9d8e-fc983d026aee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f22402cd-131b-49db-a42e-ab011f633b04" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_143841ef-38e9-4913-9d8e-fc983d026aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_30cb33e4-d7b7-4ea3-babb-d20a53bd7020" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_143841ef-38e9-4913-9d8e-fc983d026aee" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_30cb33e4-d7b7-4ea3-babb-d20a53bd7020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8b57a664-f72a-4110-a09a-95ccbbe1d30b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47fcdde2-d54c-48e2-865e-14277b4efbd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8b57a664-f72a-4110-a09a-95ccbbe1d30b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47fcdde2-d54c-48e2-865e-14277b4efbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178bb8bc-2862-4b67-ba29-7bcf115939ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47fcdde2-d54c-48e2-865e-14277b4efbd4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178bb8bc-2862-4b67-ba29-7bcf115939ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec7f0e39-9506-4eba-8080-250e683a5aca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_178bb8bc-2862-4b67-ba29-7bcf115939ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec7f0e39-9506-4eba-8080-250e683a5aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c1386547-ac1e-46c0-9c69-f46a01d59ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec7f0e39-9506-4eba-8080-250e683a5aca" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c1386547-ac1e-46c0-9c69-f46a01d59ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_633764b7-edc0-4d77-99c2-43626c690fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47fcdde2-d54c-48e2-865e-14277b4efbd4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_633764b7-edc0-4d77-99c2-43626c690fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d47b1ec7-81e0-4d90-8659-1efb0defe40d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_633764b7-edc0-4d77-99c2-43626c690fd9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d47b1ec7-81e0-4d90-8659-1efb0defe40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7c3a48-0db4-4940-87d3-ed3c4cae2ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5cc47140-5af3-4385-813c-3751e7f88412" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2a7c3a48-0db4-4940-87d3-ed3c4cae2ab4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5cc47140-5af3-4385-813c-3751e7f88412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b3440488-8a8c-49f8-98ab-cee89a67b7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_53af0c78-165d-44c5-895f-b168b5bd2aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b3440488-8a8c-49f8-98ab-cee89a67b7a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_53af0c78-165d-44c5-895f-b168b5bd2aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_f15283f5-f9b0-42aa-8c38-a5078edb1a7b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b3440488-8a8c-49f8-98ab-cee89a67b7a8" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_f15283f5-f9b0-42aa-8c38-a5078edb1a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesLeaseNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_177a79b1-5290-4f9a-9bcd-64243df6c6e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bc468bfa-b8ba-4b2a-8152-4dba73db0548" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_177a79b1-5290-4f9a-9bcd-64243df6c6e2" xlink:to="loc_us-gaap_LossContingenciesTable_bc468bfa-b8ba-4b2a-8152-4dba73db0548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_514d1ad7-c6a0-47f3-8460-a5983b59ef7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bc468bfa-b8ba-4b2a-8152-4dba73db0548" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_514d1ad7-c6a0-47f3-8460-a5983b59ef7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_5f0255ca-3472-4458-ae88-af5fb8bdfd1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_514d1ad7-c6a0-47f3-8460-a5983b59ef7f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_5f0255ca-3472-4458-ae88-af5fb8bdfd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_7f297294-4203-4d1c-a1fd-001cddc55812" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_5f0255ca-3472-4458-ae88-af5fb8bdfd1f" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_7f297294-4203-4d1c-a1fd-001cddc55812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_da1ef03c-21dd-4e90-96f7-710dd4a4c69a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bc468bfa-b8ba-4b2a-8152-4dba73db0548" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_da1ef03c-21dd-4e90-96f7-710dd4a4c69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_4365e635-6dcd-4b46-8772-c213bf737544" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_da1ef03c-21dd-4e90-96f7-710dd4a4c69a" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_4365e635-6dcd-4b46-8772-c213bf737544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOperatingLeaseMember_d23c91b1-83d6-454e-b629-169c5d689041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_4365e635-6dcd-4b46-8772-c213bf737544" xlink:to="loc_us-gaap_PropertySubjectToOperatingLeaseMember_d23c91b1-83d6-454e-b629-169c5d689041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bc468bfa-b8ba-4b2a-8152-4dba73db0548" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3582accf-d00c-48fb-8ed3-e0b041e542cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_OperatingLeaseCost_3582accf-d00c-48fb-8ed3-e0b041e542cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_415ff26c-8f7c-4d5e-ad6c-23356b15cb96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_OperatingLeasePayments_415ff26c-8f7c-4d5e-ad6c-23356b15cb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b58bbf60-c113-4178-be21-ab537871be4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b58bbf60-c113-4178-be21-ab537871be4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeaseArea_465ac4b0-f10f-4216-aae2-05649ebf9515" xlink:href="prta-20200630.xsd#prta_OperatingLeaseArea"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeaseArea_465ac4b0-f10f-4216-aae2-05649ebf9515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3b208ccf-b1bb-43c5-8341-e10cc9117648" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3b208ccf-b1bb-43c5-8341-e10cc9117648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_BuildtosuitLeaseTermofContract_033f5abe-85cc-492a-beb1-5d212702a665" xlink:href="prta-20200630.xsd#prta_BuildtosuitLeaseTermofContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_BuildtosuitLeaseTermofContract_033f5abe-85cc-492a-beb1-5d212702a665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseExpirationDate1_214e4251-547c-44be-a658-37aceca42b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_LeaseExpirationDate1_214e4251-547c-44be-a658-37aceca42b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_0ab867bb-3cd0-471f-9645-b379c399fe94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_0ab867bb-3cd0-471f-9645-b379c399fe94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesImprovementAllowance_83f82f37-1dc4-4533-aa6e-ac1227bc2973" xlink:href="prta-20200630.xsd#prta_OperatingLeasesImprovementAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeasesImprovementAllowance_83f82f37-1dc4-4533-aa6e-ac1227bc2973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1ddd836d-25bb-4b01-ab74-15f44d9b11ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1ddd836d-25bb-4b01-ab74-15f44d9b11ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary_c29567ce-d425-4f5c-8c86-674fb5b41318" xlink:href="prta-20200630.xsd#prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary_c29567ce-d425-4f5c-8c86-674fb5b41318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary_1dbfa275-ccdb-47f1-a8f5-85c6f38e6aac" xlink:href="prta-20200630.xsd#prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary_1dbfa275-ccdb-47f1-a8f5-85c6f38e6aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_0bfa1f51-f9ce-4c80-8c8c-830b01f2f7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_LineOfCredit_0bfa1f51-f9ce-4c80-8c8c-830b01f2f7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9db3731f-bd70-44fe-b9ce-30f80fc7cb17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9db3731f-bd70-44fe-b9ce-30f80fc7cb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental_95e1bacc-6dfa-4e96-afe0-15d08f775f59" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental_95e1bacc-6dfa-4e96-afe0-15d08f775f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_2973b901-4e4a-41bb-a72b-46419781ae8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_us-gaap_SubleaseIncome_2973b901-4e4a-41bb-a72b-46419781ae8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SubleaserentalsAnnualBaseRentInitialAmount_cc408c92-dff9-4c53-bae5-a7f7bdca0fd5" xlink:href="prta-20200630.xsd#prta_SubleaserentalsAnnualBaseRentInitialAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_SubleaserentalsAnnualBaseRentInitialAmount_cc408c92-dff9-4c53-bae5-a7f7bdca0fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease_f17e3117-5a92-4801-a5c3-b51a75efe658" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease_f17e3117-5a92-4801-a5c3-b51a75efe658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsTermofContract_c777c3aa-a519-47c9-8a02-f4f014ff1a0f" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsTermofContract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeasesSubleaseRentalsTermofContract_c777c3aa-a519-47c9-8a02-f4f014ff1a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord_8fd183e2-73ac-46f0-9328-d0d1a46030a4" xlink:href="prta-20200630.xsd#prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6ba36727-97b4-43ec-a699-405c3f462037" xlink:to="loc_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord_8fd183e2-73ac-46f0-9328-d0d1a46030a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesDublinLeaseDetails"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d636cb73-ab9f-4263-833e-2887f020a79a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4e606b6c-0dd4-4dfc-b1a5-47ca14bf5736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d636cb73-ab9f-4263-833e-2887f020a79a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4e606b6c-0dd4-4dfc-b1a5-47ca14bf5736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_90e314a0-2b27-4b0b-8a3b-b89e3245c7d6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4e606b6c-0dd4-4dfc-b1a5-47ca14bf5736" xlink:to="loc_srt_StatementGeographicalAxis_90e314a0-2b27-4b0b-8a3b-b89e3245c7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6c4c8458-b8d8-4d86-b7ce-1d951d3e65d9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_90e314a0-2b27-4b0b-8a3b-b89e3245c7d6" xlink:to="loc_srt_SegmentGeographicalDomain_6c4c8458-b8d8-4d86-b7ce-1d951d3e65d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DublinIrelandMember_0d2cfb38-ef56-4994-9d94-5bce4af64c81" xlink:href="prta-20200630.xsd#prta_DublinIrelandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6c4c8458-b8d8-4d86-b7ce-1d951d3e65d9" xlink:to="loc_prta_DublinIrelandMember_0d2cfb38-ef56-4994-9d94-5bce4af64c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4e606b6c-0dd4-4dfc-b1a5-47ca14bf5736" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace_4c3778ca-5684-4ce5-972b-3f77727230ba" xlink:href="prta-20200630.xsd#prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:to="loc_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace_4c3778ca-5684-4ce5-972b-3f77727230ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4ac10e47-321f-4d2f-95a3-05d08708d8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4ac10e47-321f-4d2f-95a3-05d08708d8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0783b0f4-de08-47a4-8487-c24ee42e2df3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0783b0f4-de08-47a4-8487-c24ee42e2df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1bf07e7-2863-4f41-bc68-22a05d003aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_607bb61f-afa0-4899-a563-e647b8492d65" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1bf07e7-2863-4f41-bc68-22a05d003aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_54c68de1-8f26-4089-baa5-085bfa1e3ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_da340c80-7d30-4886-8056-abfcf3c8d74a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_54c68de1-8f26-4089-baa5-085bfa1e3ff1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_da340c80-7d30-4886-8056-abfcf3c8d74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7cd15dae-9b79-48c3-8c01-d79a506ec74d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_da340c80-7d30-4886-8056-abfcf3c8d74a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7cd15dae-9b79-48c3-8c01-d79a506ec74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5fe19c56-ccd0-42cc-b1ee-a80ac6d4f43a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_da340c80-7d30-4886-8056-abfcf3c8d74a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5fe19c56-ccd0-42cc-b1ee-a80ac6d4f43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5bda893f-23ae-4b6b-ac06-a2f22eef8614" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_da340c80-7d30-4886-8056-abfcf3c8d74a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5bda893f-23ae-4b6b-ac06-a2f22eef8614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_43677952-6a67-4ddb-aa78-485c988a20bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_da340c80-7d30-4886-8056-abfcf3c8d74a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_43677952-6a67-4ddb-aa78-485c988a20bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_11ad82d1-7139-4ae3-a2c4-d23b6a5d638b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_da340c80-7d30-4886-8056-abfcf3c8d74a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_11ad82d1-7139-4ae3-a2c4-d23b6a5d638b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5e7b245c-956e-47c5-927f-6d887037e85c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_da340c80-7d30-4886-8056-abfcf3c8d74a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5e7b245c-956e-47c5-927f-6d887037e85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LesseeOperatingLeaseLiabilityNominalPayments_84a1d18b-f32b-4735-946e-30a08cdb59a8" xlink:href="prta-20200630.xsd#prta_LesseeOperatingLeaseLiabilityNominalPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_da340c80-7d30-4886-8056-abfcf3c8d74a" xlink:to="loc_prta_LesseeOperatingLeaseLiabilityNominalPayments_84a1d18b-f32b-4735-946e-30a08cdb59a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e9ba84f3-d5e4-4bb4-82a6-da014a47f58b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_da340c80-7d30-4886-8056-abfcf3c8d74a" xlink:to="loc_us-gaap_OperatingLeaseLiability_e9ba84f3-d5e4-4bb4-82a6-da014a47f58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_af651b4c-f2f2-4046-a092-eceb2f5ac31c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_54c68de1-8f26-4089-baa5-085bfa1e3ff1" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_af651b4c-f2f2-4046-a092-eceb2f5ac31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_b5726cf0-03a4-434d-9da7-0f362a297676" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_af651b4c-f2f2-4046-a092-eceb2f5ac31c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_b5726cf0-03a4-434d-9da7-0f362a297676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_9a9ed06e-a5b1-41e9-ae20-4a6e0f316bea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_af651b4c-f2f2-4046-a092-eceb2f5ac31c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_9a9ed06e-a5b1-41e9-ae20-4a6e0f316bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_e1bcef93-94b0-41b7-bfac-8bf8d93901c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_af651b4c-f2f2-4046-a092-eceb2f5ac31c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_e1bcef93-94b0-41b7-bfac-8bf8d93901c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_eaed29b0-36f7-48d3-b2bc-8c73bf67ff3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_af651b4c-f2f2-4046-a092-eceb2f5ac31c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_eaed29b0-36f7-48d3-b2bc-8c73bf67ff3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a1e09834-bec4-4b76-9a73-66de98590e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_af651b4c-f2f2-4046-a092-eceb2f5ac31c" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a1e09834-bec4-4b76-9a73-66de98590e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_29f503e2-8928-4c97-9fe0-0374b830e969" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_0520a99e-1ffe-4eb3-bb86-513c5e650788" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_29f503e2-8928-4c97-9fe0-0374b830e969" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_0520a99e-1ffe-4eb3-bb86-513c5e650788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_62f8c647-f77e-422d-a014-8fab14e3ed03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0520a99e-1ffe-4eb3-bb86-513c5e650788" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_62f8c647-f77e-422d-a014-8fab14e3ed03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1dfa2e2e-441a-41c2-aff4-bb7600ea3b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_62f8c647-f77e-422d-a014-8fab14e3ed03" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1dfa2e2e-441a-41c2-aff4-bb7600ea3b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_58d59b2f-28d4-446c-a41a-d4cb0ae62093" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1dfa2e2e-441a-41c2-aff4-bb7600ea3b7c" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_58d59b2f-28d4-446c-a41a-d4cb0ae62093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e6de3aec-0088-477a-b4a1-725ac3c91eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1dfa2e2e-441a-41c2-aff4-bb7600ea3b7c" xlink:to="loc_us-gaap_LicensingAgreementsMember_e6de3aec-0088-477a-b4a1-725ac3c91eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_0520a99e-1ffe-4eb3-bb86-513c5e650788" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_d4cbb79d-fa86-49a3-9762-ad9b7e1c615d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:to="loc_us-gaap_PurchaseObligation_d4cbb79d-fa86-49a3-9762-ad9b7e1c615d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_3c014a30-d17e-4985-899a-f98ea4f24cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_3c014a30-d17e-4985-899a-f98ea4f24cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_5eb0e95b-9138-49ef-958f-3391f60a03df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:to="loc_us-gaap_ContractualObligation_5eb0e95b-9138-49ef-958f-3391f60a03df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities_049ea89c-a02f-4601-b8bf-7eed525ba52e" xlink:href="prta-20200630.xsd#prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_e8d3dc19-56aa-4b06-8125-63fc1d50099d" xlink:to="loc_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities_049ea89c-a02f-4601-b8bf-7eed525ba52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#CommitmentandContingenciesContractualObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e22527d4-6c1c-4676-aa71-6b6c1c3a5317" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_620d5772-de26-4b44-8ee5-29113a92e586" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e22527d4-6c1c-4676-aa71-6b6c1c3a5317" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_620d5772-de26-4b44-8ee5-29113a92e586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_781be9be-a349-4810-a8ac-19082445a300" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_620d5772-de26-4b44-8ee5-29113a92e586" xlink:to="loc_us-gaap_OtherCommitmentsAxis_781be9be-a349-4810-a8ac-19082445a300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_b258810c-0c8a-48dc-85c7-078dd5b6df07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_781be9be-a349-4810-a8ac-19082445a300" xlink:to="loc_us-gaap_OtherCommitmentsDomain_b258810c-0c8a-48dc-85c7-078dd5b6df07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementsMember_30485e20-ece7-4bf1-a4ef-bf8be39181b7" xlink:href="prta-20200630.xsd#prta_LicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b258810c-0c8a-48dc-85c7-078dd5b6df07" xlink:to="loc_prta_LicenseAgreementsMember_30485e20-ece7-4bf1-a4ef-bf8be39181b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_c279d575-9241-42eb-92a3-4960cf2ab44b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_620d5772-de26-4b44-8ee5-29113a92e586" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_c279d575-9241-42eb-92a3-4960cf2ab44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_c279d575-9241-42eb-92a3-4960cf2ab44b" xlink:to="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_ef7ff725-e79c-4634-8c61-05f302d569f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligation_ef7ff725-e79c-4634-8c61-05f302d569f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_721afad5-be7b-41e0-8f7a-923380b3df50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_721afad5-be7b-41e0-8f7a-923380b3df50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_af8d40cc-df63-4705-afac-f3c985e19e21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_af8d40cc-df63-4705-afac-f3c985e19e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_7267ac95-257e-4e5c-a047-84ceaa7c6210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_7267ac95-257e-4e5c-a047-84ceaa7c6210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_7030f78d-0ba4-4f3a-86dc-2c64509b7019" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_7030f78d-0ba4-4f3a-86dc-2c64509b7019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_f0ade9fd-dbf8-4113-aa26-1fb8f740fac7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_f0ade9fd-dbf8-4113-aa26-1fb8f740fac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_25223e91-2005-45ba-b36f-e6e6427f420e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e5ef719e-8404-4c0a-9b3e-6219fc96fe17" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_25223e91-2005-45ba-b36f-e6e6427f420e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_c279d575-9241-42eb-92a3-4960cf2ab44b" xlink:to="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_2badeb7a-09d8-47df-bfb8-a1bc2ef87459" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligation_2badeb7a-09d8-47df-bfb8-a1bc2ef87459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_cf0ffbba-8f86-49fa-bf0a-5a8b79aee542" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_cf0ffbba-8f86-49fa-bf0a-5a8b79aee542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_3e8be648-863d-4187-bcf7-ae4d4d0918c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_3e8be648-863d-4187-bcf7-ae4d4d0918c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_c08ebb0d-9d33-4d74-b273-f4cc23fb91d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_c08ebb0d-9d33-4d74-b273-f4cc23fb91d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_b4ae14e0-3f1e-4a91-8492-5ace3ef7a38d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_b4ae14e0-3f1e-4a91-8492-5ace3ef7a38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_4d41d4bd-2879-43d7-9c16-e5298426b55d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_4d41d4bd-2879-43d7-9c16-e5298426b55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_cad4f345-1143-4f8f-adcb-3f961ae4a264" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_248c23d6-7b27-4e1f-883e-6ee4448914ad" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_cad4f345-1143-4f8f-adcb-3f961ae4a264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_c279d575-9241-42eb-92a3-4960cf2ab44b" xlink:to="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationTotal_38a40b47-6a6c-40bb-967a-628c154feb0a" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationTotal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationTotal_38a40b47-6a6c-40bb-967a-628c154feb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationRemainderofFiscalYear_c3ee3bac-c32d-4e7a-b274-c5d36a9e42fc" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationRemainderofFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationRemainderofFiscalYear_c3ee3bac-c32d-4e7a-b274-c5d36a9e42fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinSecondYear_d48ca5c0-9152-492c-8a88-b43e95c971af" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinSecondYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationDueinSecondYear_d48ca5c0-9152-492c-8a88-b43e95c971af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinThirdYear_ab52e4f2-a138-4163-80af-0dd777380c8b" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinThirdYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationDueinThirdYear_ab52e4f2-a138-4163-80af-0dd777380c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinFourthYear_3ba73f07-93e2-425d-8144-618352d19466" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinFourthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationDueinFourthYear_3ba73f07-93e2-425d-8144-618352d19466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueinFifthYear_c8f658f1-dd88-4dad-953e-b253c1f23e3d" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueinFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationDueinFifthYear_c8f658f1-dd88-4dad-953e-b253c1f23e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PurchaseandContractualObligationDueAfterFifthYear_725c0c98-755e-4e3b-8f7a-54a97d5e06ae" xlink:href="prta-20200630.xsd#prta_PurchaseandContractualObligationDueAfterFifthYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract_27708e46-8151-4087-b8dd-e266a108568b" xlink:to="loc_prta_PurchaseandContractualObligationDueAfterFifthYear_725c0c98-755e-4e3b-8f7a-54a97d5e06ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/SignificantAgreements" xlink:type="simple" xlink:href="prta-20200630.xsd#SignificantAgreements"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/SignificantAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborativeAgreementAbstract_c70d3913-5efc-495b-9d47-ee00e6313cd1" xlink:href="prta-20200630.xsd#prta_CollaborativeAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SignificantAgreementsTextBlock_fdd59188-8295-4dcc-b4cc-180f2275380f" xlink:href="prta-20200630.xsd#prta_SignificantAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CollaborativeAgreementAbstract_c70d3913-5efc-495b-9d47-ee00e6313cd1" xlink:to="loc_prta_SignificantAgreementsTextBlock_fdd59188-8295-4dcc-b4cc-180f2275380f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#SignificantAgreementsRocheLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborativeAgreementAbstract_c24296a9-c3ab-4b5c-9b6c-3cd4f9f750e3" xlink:href="prta-20200630.xsd#prta_CollaborativeAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementTable_e2477312-46fb-4d63-b681-abfe372b84be" xlink:href="prta-20200630.xsd#prta_LicenseAgreementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CollaborativeAgreementAbstract_c24296a9-c3ab-4b5c-9b6c-3cd4f9f750e3" xlink:to="loc_prta_LicenseAgreementTable_e2477312-46fb-4d63-b681-abfe372b84be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd99de6a-5bb2-4846-a058-fd424a5ae0a7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementTable_e2477312-46fb-4d63-b681-abfe372b84be" xlink:to="loc_srt_ProductOrServiceAxis_fd99de6a-5bb2-4846-a058-fd424a5ae0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fd99de6a-5bb2-4846-a058-fd424a5ae0a7" xlink:to="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_RoyaltyBearingLicenseMember_bafde1ed-79b8-472a-beca-b538bff1e1b8" xlink:href="prta-20200630.xsd#prta_RoyaltyBearingLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:to="loc_prta_RoyaltyBearingLicenseMember_bafde1ed-79b8-472a-beca-b538bff1e1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_INDandDevelopmentServicesMember_b4a1d2ad-096d-431d-a489-26a92722308b" xlink:href="prta-20200630.xsd#prta_INDandDevelopmentServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:to="loc_prta_INDandDevelopmentServicesMember_b4a1d2ad-096d-431d-a489-26a92722308b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SupplyServicesMember_5b74f873-a067-416a-b719-e0c607f7c258" xlink:href="prta-20200630.xsd#prta_SupplyServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:to="loc_prta_SupplyServicesMember_5b74f873-a067-416a-b719-e0c607f7c258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ClinicalProductSupplyMember_f1d45ec0-5364-4826-8180-58601bb86b12" xlink:href="prta-20200630.xsd#prta_ClinicalProductSupplyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0835df4d-26ff-40cd-b01e-82ada7d6c77c" xlink:to="loc_prta_ClinicalProductSupplyMember_f1d45ec0-5364-4826-8180-58601bb86b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5242ec4f-112e-447d-9f17-f82ac2bc5108" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementTable_e2477312-46fb-4d63-b681-abfe372b84be" xlink:to="loc_srt_CounterpartyNameAxis_5242ec4f-112e-447d-9f17-f82ac2bc5108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee01080f-a07d-4248-98ba-ce1096708dd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5242ec4f-112e-447d-9f17-f82ac2bc5108" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee01080f-a07d-4248-98ba-ce1096708dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_RocheMember_75401ec7-5d10-4093-9f11-6f9b517d3814" xlink:href="prta-20200630.xsd#prta_RocheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ee01080f-a07d-4248-98ba-ce1096708dd8" xlink:to="loc_prta_RocheMember_75401ec7-5d10-4093-9f11-6f9b517d3814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3c8190b1-aa2b-4392-9a1f-781f5f3ed4ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementTable_e2477312-46fb-4d63-b681-abfe372b84be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3c8190b1-aa2b-4392-9a1f-781f5f3ed4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e0ea4c6-d1c4-4698-bace-5d7df48c01d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3c8190b1-aa2b-4392-9a1f-781f5f3ed4ca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e0ea4c6-d1c4-4698-bace-5d7df48c01d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_42a23c5a-bf82-491b-b3af-f777b637e170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e0ea4c6-d1c4-4698-bace-5d7df48c01d8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_42a23c5a-bf82-491b-b3af-f777b637e170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DevelopmentCostsReimbursementMember_97ff7df2-2afa-46fa-b471-064956a8b3a9" xlink:href="prta-20200630.xsd#prta_DevelopmentCostsReimbursementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e0ea4c6-d1c4-4698-bace-5d7df48c01d8" xlink:to="loc_prta_DevelopmentCostsReimbursementMember_97ff7df2-2afa-46fa-b471-064956a8b3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ResearchReimbursementMember_e3a9c2de-2a93-440a-abff-0fe6b6eb4370" xlink:href="prta-20200630.xsd#prta_ResearchReimbursementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e0ea4c6-d1c4-4698-bace-5d7df48c01d8" xlink:to="loc_prta_ResearchReimbursementMember_e3a9c2de-2a93-440a-abff-0fe6b6eb4370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2c1886c4-209d-4bb9-8027-4a70607efbff" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b36a8226-d465-4884-b814-928de965d9bc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_RocheMember_e4742afc-45ed-49c6-923e-486a585bb227" xlink:href="prta-20200630.xsd#prta_RocheMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3a525818-f918-4040-b6f0-fb8b75246ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6e0fef15-5e82-495d-aa42-e7664ed1563b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_25e8b509-ec8b-4313-9975-cbc4396a0465" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:href="prta-20200630.xsd#prta_LicenseAgreementLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementTable_e2477312-46fb-4d63-b681-abfe372b84be" xlink:to="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationRevenueLicenseUpfrontPayment_20fc143e-356d-4434-87e6-cc8313056952" xlink:href="prta-20200630.xsd#prta_CollaborationRevenueLicenseUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_CollaborationRevenueLicenseUpfrontPayment_20fc143e-356d-4434-87e6-cc8313056952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_MilestonePaymentReceivedClinicalMilestone_2ca8e38c-a1e4-4e9c-b236-c72c051e7209" xlink:href="prta-20200630.xsd#prta_MilestonePaymentReceivedClinicalMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_MilestonePaymentReceivedClinicalMilestone_2ca8e38c-a1e4-4e9c-b236-c72c051e7209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_MilestoneAchievementClinicalMilestone_f1f75759-b5d4-4f5f-a380-ec763f46bca7" xlink:href="prta-20200630.xsd#prta_MilestoneAchievementClinicalMilestone"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_MilestoneAchievementClinicalMilestone_f1f75759-b5d4-4f5f-a380-ec763f46bca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones_7522e1c4-bcf6-404a-9bc0-064831ac7a16" xlink:href="prta-20200630.xsd#prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones_7522e1c4-bcf6-404a-9bc0-064831ac7a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones_d7060f62-26ab-440c-9060-a047e61f4175" xlink:href="prta-20200630.xsd#prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones_d7060f62-26ab-440c-9060-a047e61f4175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicensingAgreementCostAllocationPercentage_c8b07074-4273-4faf-b5b1-93a6d01fe989" xlink:href="prta-20200630.xsd#prta_LicensingAgreementCostAllocationPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicensingAgreementCostAllocationPercentage_c8b07074-4273-4faf-b5b1-93a6d01fe989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage_42685b6f-ff71-4773-b866-76abececaacb" xlink:href="prta-20200630.xsd#prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage_42685b6f-ff71-4773-b866-76abececaacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones_f449f023-047c-41d7-a5e4-153baee6a5de" xlink:href="prta-20200630.xsd#prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones_f449f023-047c-41d7-a5e4-153baee6a5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DevelopmentServicesAdditional_66358994-4eea-4ede-a9cb-bdf817655d18" xlink:href="prta-20200630.xsd#prta_DevelopmentServicesAdditional"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_DevelopmentServicesAdditional_66358994-4eea-4ede-a9cb-bdf817655d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_83317308-d4b2-45c1-be09-36ee2fa9c78a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_83317308-d4b2-45c1-be09-36ee2fa9c78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_InitialTransactionPrice_9b321581-4829-422b-85c9-a15bab4bf7d6" xlink:href="prta-20200630.xsd#prta_InitialTransactionPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_InitialTransactionPrice_9b321581-4829-422b-85c9-a15bab4bf7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_AllocatedConsiderationtoPerformanceObligations_4ea4a106-39b3-423b-81ba-1cf30f928c5b" xlink:href="prta-20200630.xsd#prta_AllocatedConsiderationtoPerformanceObligations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_AllocatedConsiderationtoPerformanceObligations_4ea4a106-39b3-423b-81ba-1cf30f928c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ASC605AllocatedConsiderationtoDeliverables_f0dde687-e573-4049-9b7c-84b57d2361ce" xlink:href="prta-20200630.xsd#prta_ASC605AllocatedConsiderationtoDeliverables"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_ASC605AllocatedConsiderationtoDeliverables_f0dde687-e573-4049-9b7c-84b57d2361ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementDevelopmentServicesPaymentTerm_569556c9-7f97-48b1-8b4a-1c2c9fae2c01" xlink:href="prta-20200630.xsd#prta_LicenseAgreementDevelopmentServicesPaymentTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicenseAgreementDevelopmentServicesPaymentTerm_569556c9-7f97-48b1-8b4a-1c2c9fae2c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_LicenseAgreementMilestonePaymentsPaymentTerm_9f8e2740-0bd2-4fc6-92d5-38bbd1102f69" xlink:href="prta-20200630.xsd#prta_LicenseAgreementMilestonePaymentsPaymentTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_LicenseAgreementMilestonePaymentsPaymentTerm_9f8e2740-0bd2-4fc6-92d5-38bbd1102f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationRevenue_31ae1eb3-ac0b-4778-b4d4-dd1d52cfceb2" xlink:href="prta-20200630.xsd#prta_CollaborationRevenue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_CollaborationRevenue_31ae1eb3-ac0b-4778-b4d4-dd1d52cfceb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense_c0215742-f072-46dc-8a35-93a50d4dba20" xlink:href="prta-20200630.xsd#prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense_c0215742-f072-46dc-8a35-93a50d4dba20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6778d70f-1e76-4b58-a3d5-8990edda75ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_LicenseAgreementLineItems_77cfc465-df2b-46c0-97d9-3c4e111a6794" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6778d70f-1e76-4b58-a3d5-8990edda75ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#SignificantAgreementsCelgeneCollaborationAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborativeAgreementAbstract_25e259dd-efbd-4659-b449-c345e8c12d4d" xlink:href="prta-20200630.xsd#prta_CollaborativeAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_CollaborativeAgreementAbstract_25e259dd-efbd-4659-b449-c345e8c12d4d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_165ada4a-d9fa-4595-801b-021c1ee456b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_165ada4a-d9fa-4595-801b-021c1ee456b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_522396da-c673-4a68-aaa6-9e1542f9aa0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_165ada4a-d9fa-4595-801b-021c1ee456b7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_522396da-c673-4a68-aaa6-9e1542f9aa0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_3d8f40b3-2569-4cdb-93c0-a8a66977a474" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_522396da-c673-4a68-aaa6-9e1542f9aa0e" xlink:to="loc_us-gaap_CollaborativeArrangementMember_3d8f40b3-2569-4cdb-93c0-a8a66977a474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bce8c653-e19c-4609-a18c-16874f2eeb98" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:to="loc_srt_CounterpartyNameAxis_bce8c653-e19c-4609-a18c-16874f2eeb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454ae39d-6fe7-48c1-9d62-3bf5e1bd9e14" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bce8c653-e19c-4609-a18c-16874f2eeb98" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454ae39d-6fe7-48c1-9d62-3bf5e1bd9e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CelgeneMember_17e76e2b-9b1c-40f9-94bc-b19e64c26c5d" xlink:href="prta-20200630.xsd#prta_CelgeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454ae39d-6fe7-48c1-9d62-3bf5e1bd9e14" xlink:to="loc_prta_CelgeneMember_17e76e2b-9b1c-40f9-94bc-b19e64c26c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationProgramUSRightsMember_90c8403c-0b26-4c71-9119-0360c2175da6" xlink:href="prta-20200630.xsd#prta_CollaborationProgramUSRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454ae39d-6fe7-48c1-9d62-3bf5e1bd9e14" xlink:to="loc_prta_CollaborationProgramUSRightsMember_90c8403c-0b26-4c71-9119-0360c2175da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationProgramGlobalRightsMember_7b0085a3-4c7c-4ca7-b08a-ed7951aa6f10" xlink:href="prta-20200630.xsd#prta_CollaborationProgramGlobalRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454ae39d-6fe7-48c1-9d62-3bf5e1bd9e14" xlink:to="loc_prta_CollaborationProgramGlobalRightsMember_7b0085a3-4c7c-4ca7-b08a-ed7951aa6f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_91a0655d-fb50-4cae-8980-e1da15769d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_91a0655d-fb50-4cae-8980-e1da15769d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0f9ae01-d49f-4005-bb62-535452505640" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_91a0655d-fb50-4cae-8980-e1da15769d4a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0f9ae01-d49f-4005-bb62-535452505640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f8cc96d3-db0b-45ea-bba7-41bc522efe26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c0f9ae01-d49f-4005-bb62-535452505640" xlink:to="loc_us-gaap_PrivatePlacementMember_f8cc96d3-db0b-45ea-bba7-41bc522efe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bed73528-f2e9-454a-921a-198bd429c09f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:to="loc_srt_ProductOrServiceAxis_bed73528-f2e9-454a-921a-198bd429c09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0c56d5da-81ed-4eff-bdad-bc399806c73a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bed73528-f2e9-454a-921a-198bd429c09f" xlink:to="loc_srt_ProductsAndServicesDomain_0c56d5da-81ed-4eff-bdad-bc399806c73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationProgramUSRightsMember_fabb8fab-9fd9-496c-a2a5-22626d03272b" xlink:href="prta-20200630.xsd#prta_CollaborationProgramUSRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0c56d5da-81ed-4eff-bdad-bc399806c73a" xlink:to="loc_prta_CollaborationProgramUSRightsMember_fabb8fab-9fd9-496c-a2a5-22626d03272b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationProgramGlobalRightsMember_aeed945b-8055-4bc9-a55d-bfb9ad4d8116" xlink:href="prta-20200630.xsd#prta_CollaborationProgramGlobalRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0c56d5da-81ed-4eff-bdad-bc399806c73a" xlink:to="loc_prta_CollaborationProgramGlobalRightsMember_aeed945b-8055-4bc9-a55d-bfb9ad4d8116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b11984c7-6bdd-4a88-a4d2-d278bf312d2c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:to="loc_srt_RangeAxis_b11984c7-6bdd-4a88-a4d2-d278bf312d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c6e6825-0165-4b17-8ad6-35677dfd7222" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b11984c7-6bdd-4a88-a4d2-d278bf312d2c" xlink:to="loc_srt_RangeMember_1c6e6825-0165-4b17-8ad6-35677dfd7222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_41eae4b6-6379-43d4-ba1b-9148456f3dbe" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c6e6825-0165-4b17-8ad6-35677dfd7222" xlink:to="loc_srt_MinimumMember_41eae4b6-6379-43d4-ba1b-9148456f3dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cea213fe-8aa0-419e-a2d2-b5e4497596f4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c6e6825-0165-4b17-8ad6-35677dfd7222" xlink:to="loc_srt_MaximumMember_cea213fe-8aa0-419e-a2d2-b5e4497596f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c41108bb-bc40-4dd2-8290-c4f76bae5e6f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementUpfrontPayment_414e68d6-b83a-4e90-9410-ce71dadc0d62" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementUpfrontPayment_414e68d6-b83a-4e90-9410-ce71dadc0d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2cde2e91-5692-4be0-a862-c7950292aecf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2cde2e91-5692-4be0-a862-c7950292aecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f64ab808-4e4f-4675-bf5e-1302fdcdaa42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f64ab808-4e4f-4675-bf5e-1302fdcdaa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e8878678-0fb8-42df-8a52-9b36c52063d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e8878678-0fb8-42df-8a52-9b36c52063d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementExerciseFeeperProgram_b1f6f2b3-c9cc-40f1-8318-2986309ce0e1" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementExerciseFeeperProgram"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementExerciseFeeperProgram_b1f6f2b3-c9cc-40f1-8318-2986309ce0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram_0f418e44-624a-4fe6-9f0a-3950aab1de8e" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram_0f418e44-624a-4fe6-9f0a-3950aab1de8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementTermofAgreement_5e8f3e04-e688-473a-9561-61d4aee07013" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementTermofAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementTermofAgreement_5e8f3e04-e688-473a-9561-61d4aee07013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed_8e0f0208-dfc1-46ed-baf2-58b1ddc7dc5f" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed_8e0f0208-dfc1-46ed-baf2-58b1ddc7dc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementExtensionFeeperExtensionPeriod_0fee6eb7-eaaa-4ae8-84f2-4456795899ad" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementExtensionFeeperExtensionPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementExtensionFeeperExtensionPeriod_0fee6eb7-eaaa-4ae8-84f2-4456795899ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_InitialTransactionPrice_12251ec6-4667-4273-b9b7-4b5f199d02e9" xlink:href="prta-20200630.xsd#prta_InitialTransactionPrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_InitialTransactionPrice_12251ec6-4667-4273-b9b7-4b5f199d02e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SaleofStockPremiumReceivedonTransaction_a0a4225e-7557-4437-bf13-59f3873ff973" xlink:href="prta-20200630.xsd#prta_SaleofStockPremiumReceivedonTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_SaleofStockPremiumReceivedonTransaction_a0a4225e-7557-4437-bf13-59f3873ff973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice_b824d546-c0aa-4de7-865f-114af91115f2" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice_b824d546-c0aa-4de7-865f-114af91115f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementUpfrontPaymentPaymentTerm_b31796fe-0c73-4820-8a79-35db50a2eff1" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementUpfrontPaymentPaymentTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementUpfrontPaymentPaymentTerm_b31796fe-0c73-4820-8a79-35db50a2eff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm_6e226cc8-7f7c-4c1e-9e78-144e8eb659ce" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm_6e226cc8-7f7c-4c1e-9e78-144e8eb659ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram_23ed01f4-161f-495e-b64e-4ebff98e7b53" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram_23ed01f4-161f-495e-b64e-4ebff98e7b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram_7bc48ee1-1e62-4b43-8be8-8eac6a722b62" xlink:href="prta-20200630.xsd#prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_174de527-983f-427c-b40c-151f25af35a8" xlink:to="loc_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram_7bc48ee1-1e62-4b43-8be8-8eac6a722b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5a73ebfb-9cea-4106-8e13-cf3fc19c9efd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_451e25a9-51f2-4ef4-8290-1f9c8e0bf5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5a73ebfb-9cea-4106-8e13-cf3fc19c9efd" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_451e25a9-51f2-4ef4-8290-1f9c8e0bf5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e870e8e2-0286-4d72-a6b2-594f519f56b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4812bce8-603d-4bd3-a6ee-09e5f7884a53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e870e8e2-0286-4d72-a6b2-594f519f56b4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4812bce8-603d-4bd3-a6ee-09e5f7884a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2eabf390-1f56-4454-ba73-7289f2ae0d60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e870e8e2-0286-4d72-a6b2-594f519f56b4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2eabf390-1f56-4454-ba73-7289f2ae0d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9538d3e9-f40a-4f51-813c-2104a86182cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e870e8e2-0286-4d72-a6b2-594f519f56b4" xlink:to="loc_us-gaap_CommonStockSharesIssued_9538d3e9-f40a-4f51-813c-2104a86182cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_13134066-262a-4cf2-a5fe-be9b4aa33a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e870e8e2-0286-4d72-a6b2-594f519f56b4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_13134066-262a-4cf2-a5fe-be9b4aa33a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_NumberofVotes_cd65a170-4343-41f8-9925-7b15ed8ee9a9" xlink:href="prta-20200630.xsd#prta_NumberofVotes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e870e8e2-0286-4d72-a6b2-594f519f56b4" xlink:to="loc_prta_NumberofVotes_cd65a170-4343-41f8-9925-7b15ed8ee9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesSharesAuthorized_23211f36-5040-4aaa-89d4-c0e23910da05" xlink:href="prta-20200630.xsd#prta_DeferredSharesSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e870e8e2-0286-4d72-a6b2-594f519f56b4" xlink:to="loc_prta_DeferredSharesSharesAuthorized_23211f36-5040-4aaa-89d4-c0e23910da05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesParValue_55379272-8e1a-4d91-9487-f569f20fca88" xlink:href="prta-20200630.xsd#prta_DeferredSharesParValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e870e8e2-0286-4d72-a6b2-594f519f56b4" xlink:to="loc_prta_DeferredSharesParValue_55379272-8e1a-4d91-9487-f569f20fca88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_DeferredSharesShareOutstanding_004b8bba-ac8d-489a-838f-70642fcb1e1e" xlink:href="prta-20200630.xsd#prta_DeferredSharesShareOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e870e8e2-0286-4d72-a6b2-594f519f56b4" xlink:to="loc_prta_DeferredSharesShareOutstanding_004b8bba-ac8d-489a-838f-70642fcb1e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8409e32e-4708-48f6-a271-bc3e79dbbba3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_29569ced-2737-4f01-adfd-e4acc3f3e859" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8409e32e-4708-48f6-a271-bc3e79dbbba3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_29569ced-2737-4f01-adfd-e4acc3f3e859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631491ef-1eed-4b60-a03c-0a1e52bb148d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_262995db-1b90-4dbf-b973-aca76fd9ee5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631491ef-1eed-4b60-a03c-0a1e52bb148d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_262995db-1b90-4dbf-b973-aca76fd9ee5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e6ac4dbb-9669-4f11-8228-bf9756a96879" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631491ef-1eed-4b60-a03c-0a1e52bb148d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e6ac4dbb-9669-4f11-8228-bf9756a96879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_825371d8-50d9-4d90-8cf6-1c2b3e6e6410" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631491ef-1eed-4b60-a03c-0a1e52bb148d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_825371d8-50d9-4d90-8cf6-1c2b3e6e6410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27af7f92-743e-436a-91bc-9e6ec54b1a93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b7a5264-e75e-4b85-a74a-e58b44f11a30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27af7f92-743e-436a-91bc-9e6ec54b1a93" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b7a5264-e75e-4b85-a74a-e58b44f11a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d13a5ef5-97a8-462d-b9d1-031b7bcc8828" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b7a5264-e75e-4b85-a74a-e58b44f11a30" xlink:to="loc_us-gaap_PlanNameAxis_d13a5ef5-97a8-462d-b9d1-031b7bcc8828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_814479e0-6c59-4e17-be03-45cb6af67180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d13a5ef5-97a8-462d-b9d1-031b7bcc8828" xlink:to="loc_us-gaap_PlanNameDomain_814479e0-6c59-4e17-be03-45cb6af67180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_AmendedAndRestated2018LongTermIncentivePlanMember_a4496f4a-0256-4035-94c5-734792cfcc2a" xlink:href="prta-20200630.xsd#prta_AmendedAndRestated2018LongTermIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_814479e0-6c59-4e17-be03-45cb6af67180" xlink:to="loc_prta_AmendedAndRestated2018LongTermIncentivePlanMember_a4496f4a-0256-4035-94c5-734792cfcc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_A2012LongTermIncentivePlanMember_997aeae3-08c2-4904-a2fc-d6680f4f6cba" xlink:href="prta-20200630.xsd#prta_A2012LongTermIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_814479e0-6c59-4e17-be03-45cb6af67180" xlink:to="loc_prta_A2012LongTermIncentivePlanMember_997aeae3-08c2-4904-a2fc-d6680f4f6cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_A2020EmploymentInducementIncentivePlanMember_ec8b619d-5209-449f-99bf-f95c9508e1eb" xlink:href="prta-20200630.xsd#prta_A2020EmploymentInducementIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_814479e0-6c59-4e17-be03-45cb6af67180" xlink:to="loc_prta_A2020EmploymentInducementIncentivePlanMember_ec8b619d-5209-449f-99bf-f95c9508e1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f7079cee-6e01-45a7-9aec-0e968cfa3c04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b7a5264-e75e-4b85-a74a-e58b44f11a30" xlink:to="loc_us-gaap_AwardTypeAxis_f7079cee-6e01-45a7-9aec-0e968cfa3c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_692014bf-128d-48aa-975d-5a56e5b14eb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f7079cee-6e01-45a7-9aec-0e968cfa3c04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_692014bf-128d-48aa-975d-5a56e5b14eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9f986981-64a0-444d-b4c3-a2569cf2f73f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_692014bf-128d-48aa-975d-5a56e5b14eb5" xlink:to="loc_us-gaap_CommonStockMember_9f986981-64a0-444d-b4c3-a2569cf2f73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8b7a5264-e75e-4b85-a74a-e58b44f11a30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1781953d-2660-4670-a239-667ce68437a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1781953d-2660-4670-a239-667ce68437a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2f75d2de-d13e-423f-9add-4b4f81840140" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2f75d2de-d13e-423f-9add-4b4f81840140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_MaximumNumberofSharestobeIssuedISOExercise_c95381a5-a008-4aee-9319-c9ed1bfca243" xlink:href="prta-20200630.xsd#prta_MaximumNumberofSharestobeIssuedISOExercise"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_prta_MaximumNumberofSharestobeIssuedISOExercise_c95381a5-a008-4aee-9319-c9ed1bfca243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c262a43a-9d3f-4a9d-a73b-7cd5394503c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c262a43a-9d3f-4a9d-a73b-7cd5394503c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8dfeb0d7-e06c-4475-9375-9a4541dd2dee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8dfeb0d7-e06c-4475-9375-9a4541dd2dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a1ee1324-d3aa-410b-98c6-f20f000257a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a1ee1324-d3aa-410b-98c6-f20f000257a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_59b94e55-e76d-41b7-866b-0fa9e81249fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_59b94e55-e76d-41b7-866b-0fa9e81249fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5dba040d-d5de-470f-938b-b23167c2b7db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5dba040d-d5de-470f-938b-b23167c2b7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a47885d-248c-48fa-b985-8140aa5bd8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a47885d-248c-48fa-b985-8140aa5bd8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a2728a6e-f02a-44e8-b6b4-306df3f9be1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a2728a6e-f02a-44e8-b6b4-306df3f9be1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_36303f6f-3850-4ef9-8336-c8c15589e7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_36303f6f-3850-4ef9-8336-c8c15589e7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_64e0ef06-ed85-4828-816b-0a213790eb6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_64e0ef06-ed85-4828-816b-0a213790eb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f7abc536-56d9-4dbe-a1b2-863d054cb6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98f16328-4c05-4a90-8f94-178e465a544a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f7abc536-56d9-4dbe-a1b2-863d054cb6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f6015445-b947-47d9-b5a9-4d69e07b06d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc182b29-4faf-4860-8767-e99ae7cd7543" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f6015445-b947-47d9-b5a9-4d69e07b06d1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc182b29-4faf-4860-8767-e99ae7cd7543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dd569e74-7bf9-42e4-a485-13640e5f22e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc182b29-4faf-4860-8767-e99ae7cd7543" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dd569e74-7bf9-42e4-a485-13640e5f22e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70c37d4f-3342-4cb6-ba54-1877e5b654c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dd569e74-7bf9-42e4-a485-13640e5f22e9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_70c37d4f-3342-4cb6-ba54-1877e5b654c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e6729860-300d-4864-9e7d-97ab02b439dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_70c37d4f-3342-4cb6-ba54-1877e5b654c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e6729860-300d-4864-9e7d-97ab02b439dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_26e72574-9211-4e29-ab00-c9cae006e1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_70c37d4f-3342-4cb6-ba54-1877e5b654c9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_26e72574-9211-4e29-ab00-c9cae006e1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42c5f0eb-9562-454c-a342-c2ede32a66d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc182b29-4faf-4860-8767-e99ae7cd7543" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42c5f0eb-9562-454c-a342-c2ede32a66d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cf23df1a-5634-4262-b56a-b34bc219c30d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_42c5f0eb-9562-454c-a342-c2ede32a66d2" xlink:to="loc_us-gaap_ShareBasedCompensation_cf23df1a-5634-4262-b56a-b34bc219c30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#ShareBasedCompensationFairValueofOptionsGrantedDetail"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25928283-07bc-4b06-b6ed-8659ecf0b915" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bed1d52a-c7f0-434d-ab5a-dee117867acc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25928283-07bc-4b06-b6ed-8659ecf0b915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bed1d52a-c7f0-434d-ab5a-dee117867acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0e099346-5035-4511-8173-8d53b5b5a5a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25928283-07bc-4b06-b6ed-8659ecf0b915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0e099346-5035-4511-8173-8d53b5b5a5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b489c406-fe0d-497c-9aee-58ddbc62e148" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25928283-07bc-4b06-b6ed-8659ecf0b915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b489c406-fe0d-497c-9aee-58ddbc62e148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2ec397a4-1179-4e94-afe2-efd88e6fe62c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25928283-07bc-4b06-b6ed-8659ecf0b915" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2ec397a4-1179-4e94-afe2-efd88e6fe62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cad35f97-045e-4770-a239-c9f5afb97baa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25928283-07bc-4b06-b6ed-8659ecf0b915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cad35f97-045e-4770-a239-c9f5afb97baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail" xlink:type="simple" xlink:href="prta-20200630.xsd#SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc7f8015-fc40-46dc-9e9a-097811d48350" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f1dccdf-b348-438f-a6fd-29ec8df65e15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc7f8015-fc40-46dc-9e9a-097811d48350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f1dccdf-b348-438f-a6fd-29ec8df65e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8752f2de-049e-4a0c-b657-72690122fae0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f1dccdf-b348-438f-a6fd-29ec8df65e15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8752f2de-049e-4a0c-b657-72690122fae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_b7bd2e86-e4ee-4c06-830a-6e1621c706ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f1dccdf-b348-438f-a6fd-29ec8df65e15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_b7bd2e86-e4ee-4c06-830a-6e1621c706ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0484e906-ebe1-4c9c-ae80-f25794f4c506" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f1dccdf-b348-438f-a6fd-29ec8df65e15" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0484e906-ebe1-4c9c-ae80-f25794f4c506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_de1bfacd-fba9-49e4-899c-4e7dfe692f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f1dccdf-b348-438f-a6fd-29ec8df65e15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_de1bfacd-fba9-49e4-899c-4e7dfe692f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1875d343-a614-4f44-b53d-d985c021f9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f1dccdf-b348-438f-a6fd-29ec8df65e15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1875d343-a614-4f44-b53d-d985c021f9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ca9f704-0e66-4764-b5ef-6f55f9f5e288" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f1dccdf-b348-438f-a6fd-29ec8df65e15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ca9f704-0e66-4764-b5ef-6f55f9f5e288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ce74326e-49b4-4287-a849-f0b42337e82f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f1dccdf-b348-438f-a6fd-29ec8df65e15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ce74326e-49b4-4287-a849-f0b42337e82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8ccbc435-f845-4c2d-b66b-5d4894e6a8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f1dccdf-b348-438f-a6fd-29ec8df65e15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8ccbc435-f845-4c2d-b66b-5d4894e6a8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b522267-88bf-4891-b0a9-280f72b71246" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc7f8015-fc40-46dc-9e9a-097811d48350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b522267-88bf-4891-b0a9-280f72b71246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_01e88efb-792d-487d-a627-e7b61f93b589" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b522267-88bf-4891-b0a9-280f72b71246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_01e88efb-792d-487d-a627-e7b61f93b589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c42d052a-5ccd-4f6a-9271-179c08d90946" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b522267-88bf-4891-b0a9-280f72b71246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c42d052a-5ccd-4f6a-9271-179c08d90946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a2c6345f-7055-4f7a-820c-c475f20bc8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b522267-88bf-4891-b0a9-280f72b71246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a2c6345f-7055-4f7a-820c-c475f20bc8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_128fde3c-c494-49c4-ab15-3dd632fc1313" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b522267-88bf-4891-b0a9-280f72b71246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_128fde3c-c494-49c4-ab15-3dd632fc1313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dbaf94fd-e6c0-4d9e-a0f7-785fbe4f5904" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b522267-88bf-4891-b0a9-280f72b71246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dbaf94fd-e6c0-4d9e-a0f7-785fbe4f5904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f4376aec-32c6-4f4f-bf4c-ea7fd7fbf8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b522267-88bf-4891-b0a9-280f72b71246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f4376aec-32c6-4f4f-bf4c-ea7fd7fbf8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0b6b795a-0188-48e3-a00d-eaced9f4a6e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b522267-88bf-4891-b0a9-280f72b71246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0b6b795a-0188-48e3-a00d-eaced9f4a6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_982ac239-db36-4705-9147-b303d04d4820" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2b522267-88bf-4891-b0a9-280f72b71246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_982ac239-db36-4705-9147-b303d04d4820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_02ebd031-6362-413c-97ae-5d32bd69b64f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc7f8015-fc40-46dc-9e9a-097811d48350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_02ebd031-6362-413c-97ae-5d32bd69b64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f31a837a-2034-49e4-86c0-197c687e1522" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_02ebd031-6362-413c-97ae-5d32bd69b64f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f31a837a-2034-49e4-86c0-197c687e1522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_62d4c867-1f2f-473e-8429-9f6b8bf5185d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_02ebd031-6362-413c-97ae-5d32bd69b64f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_62d4c867-1f2f-473e-8429-9f6b8bf5185d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8aced372-a884-4675-a682-f4bdd816622b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_02ebd031-6362-413c-97ae-5d32bd69b64f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8aced372-a884-4675-a682-f4bdd816622b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c6d89f1c-7650-44df-bbf0-0ab5f4a6443a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_02ebd031-6362-413c-97ae-5d32bd69b64f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c6d89f1c-7650-44df-bbf0-0ab5f4a6443a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0d47b30c-f610-4909-b582-f54b7025952b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_02ebd031-6362-413c-97ae-5d32bd69b64f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0d47b30c-f610-4909-b582-f54b7025952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions_bbe5796d-b19d-49d9-aea6-7ba7479330db" xlink:href="prta-20200630.xsd#prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_02ebd031-6362-413c-97ae-5d32bd69b64f" xlink:to="loc_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions_bbe5796d-b19d-49d9-aea6-7ba7479330db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/IncomeTaxes" xlink:type="simple" xlink:href="prta-20200630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b9f4fda7-1afc-465a-bacc-5516adf65df9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a1855b69-4feb-4b87-af98-e45495373618" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b9f4fda7-1afc-465a-bacc-5516adf65df9" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a1855b69-4feb-4b87-af98-e45495373618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="prta-20200630.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_18660c7e-207c-49fa-8ad3-0d1ddc6894e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_IncomeTaxesTable_7d91a632-0f4b-4b11-9249-21b16f6f0916" xlink:href="prta-20200630.xsd#prta_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18660c7e-207c-49fa-8ad3-0d1ddc6894e2" xlink:to="loc_prta_IncomeTaxesTable_7d91a632-0f4b-4b11-9249-21b16f6f0916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ffc4ab0f-8404-4964-8ed3-d509a700af97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_IncomeTaxesTable_7d91a632-0f4b-4b11-9249-21b16f6f0916" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ffc4ab0f-8404-4964-8ed3-d509a700af97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4813790c-f78e-4bba-9947-956f43fd96b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ffc4ab0f-8404-4964-8ed3-d509a700af97" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4813790c-f78e-4bba-9947-956f43fd96b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_1c5334f9-5af8-4878-b907-cfe3a3fa9037" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_4813790c-f78e-4bba-9947-956f43fd96b6" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_1c5334f9-5af8-4878-b907-cfe3a3fa9037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_0fb5673b-e84f-4745-a727-3b4f46e330f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_IncomeTaxesTable_7d91a632-0f4b-4b11-9249-21b16f6f0916" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_0fb5673b-e84f-4745-a727-3b4f46e330f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_86a43271-fbe7-417c-ae30-89baf8630e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_0fb5673b-e84f-4745-a727-3b4f46e330f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_86a43271-fbe7-417c-ae30-89baf8630e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember_f04c894b-5579-4af6-b310-c7fb5395f6dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_86a43271-fbe7-417c-ae30-89baf8630e1d" xlink:to="loc_us-gaap_RevenueCommissionersIrelandMember_f04c894b-5579-4af6-b310-c7fb5395f6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_713f4bf0-ca75-4711-b2b4-d3021a93c7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_86a43271-fbe7-417c-ae30-89baf8630e1d" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_713f4bf0-ca75-4711-b2b4-d3021a93c7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:href="prta-20200630.xsd#prta_IncomeTaxesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_IncomeTaxesTable_7d91a632-0f4b-4b11-9249-21b16f6f0916" xlink:to="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_eeba553d-45fc-416f-a377-2cadc169d5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_eeba553d-45fc-416f-a377-2cadc169d5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_47492f08-c5d3-456f-80e7-1efcf8e7c010" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_47492f08-c5d3-456f-80e7-1efcf8e7c010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision_3fae1b2a-d5d1-4b48-935e-95e305ee61a5" xlink:href="prta-20200630.xsd#prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision_3fae1b2a-d5d1-4b48-935e-95e305ee61a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets_9aedf00f-794b-4381-8581-ef1e9b3530db" xlink:href="prta-20200630.xsd#prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets_9aedf00f-794b-4381-8581-ef1e9b3530db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a2aa7b13-5470-4910-b8c5-c8599cedea80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a2aa7b13-5470-4910-b8c5-c8599cedea80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prta_PotentialWithholdingTaxRate_a9d56a92-6824-48f0-840f-2acb8b28f1b9" xlink:href="prta-20200630.xsd#prta_PotentialWithholdingTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prta_IncomeTaxesLineItems_f4a00c6b-f49e-4620-81d9-f07fb407b1d2" xlink:to="loc_prta_PotentialWithholdingTaxRate_a9d56a92-6824-48f0-840f-2acb8b28f1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>prta-20200630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:prta="http://www.prothena.com/20200630"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="prta-20200630.xsd" xlink:type="simple"/>
    <context id="idb76403e4028485ca36aacfa08b19700_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2076d6dfdfd942b4a9a3009e044262c6_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie5802a61ace64fa5b6a039e8e96e1697_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ecda07bc4ba4408a09994ddf7154fb8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3a01076460454a2eac50eac78fcb4c4e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if3d1c0ac6b42476b8901a5b86894d8a8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if407b818af644e46b2c8fd3f4ef0916b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i37e74aa909674a31a31bf76e13ce1a5f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i699a71835ede41ffb63bc12dc5058195_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie5d2e09455d741d0af7adef0326a9464_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i735a4a62bab9471a84edda62005153d0_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0a5677df40f949d086dd9086c825700e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i50ab40dc0079467b9798e55723340f88_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iecc1dc4b8e3a409780b630469f43a9e2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifb1f6a961f634e87b2d33d5dc95c15fa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic0a37738944a4b5da8bacd6100c18c37_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i033a9b5c0519456bbe6ff44d9d446f2e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8a8e6071ca4d4f418bf2650962cca842_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idbd0a1f2b3f648e0bcca646f1febd857_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i59896a4eae7b4d1cadd70ccca76ef293_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ief7a957fd4e343de80e8f3dd3bd7c665_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2b53209923b24243a79113052e4c7869_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i244c64bf960045f0800d51e075bbe10e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i033cbd2485614a1a80c8930dd799a610_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2a18c2130f0248389ca0f5818a9bea98_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if139ce926c9c4e47b596fdf915376cf8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i11412c4befdf4ea0807e0b06f12cfe03_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7b323be88ba54d09b5f05f59648156ba_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8bb18a09ab4f41a08e2c1022903f9906_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i654c8eaba7c84a3ba5bb798a14bf89b4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3911131dcd2547b8b1b797508b9ffa15_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iaeb9f2b53bed498ca4df974ff5e0eb3f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i58f9f83b1ec94f83ba9e88d181f91f31_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia217e25a3bae43ae8dce414a766f8967_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7447e849c70240ebb46c71019b182af5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i529cd4e894eb4d85b99f95e755920f22_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f79eb93966141d7a3a13adc3ac38d49_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1514bd0122184324869e45816a840dff_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i359327a4643e466ca3a685787fdbf791_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id3888cc09d684fd7b2c05fab7e9b2a3a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0d6464030811498ea45278866f1f669b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8799a9e7d9a5439bbef0dd2887838f26_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8b149813b9fd4ba6a6381399eba9055f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i06f9dd74ab7b4824a2d89b866088ebdf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia3b99b92bd8c4e959e5259476524c341_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie594e8889b9b4963ae70ebdb928a145b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iec113c33f31b44c790f21ee119a59cfc_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prta:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3f59203e494b4d0aa54e4354c6b66ab5_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7b64af079f774a46a8be8b6571368300_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i11d3275580fa4bd1961ee805e56db0d0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idf82b12dcb0a4510a9e8d227e7f54b0f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i35e6e65a4d584b26a679bc03ea55c9d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2330f117cb341549ed1cb65fe74eff0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id7e67ec9f2a141d3afb5af2d44c43cf4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i54b797a322b643859e1d254057908a54_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifdeb4d65f9b2469ca2008e311f8a3473_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iededd3a706834ae081db1b4deff0a8bb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic3fa83c08da0419a82890f9cdd288a03_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i03363be070604a69a801733692c0eb01_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8154f8e4fb0a43068ce1feebb738c177_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="iaa84acb8305c4045b894b70949b443e0_I20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="ie5ee13ac88c14078b954248c161c0e37_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ibaf705e3bc94419cad46238812fd99d7_I20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="i2d1009cc88444495b1b71ed313bd65be_D20160401-20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="ibbc0b76aa18c4b81ab20c7e33334019e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id8c8f6072f864cafae096d1bc47eb2f8_D20180718-20180718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <startDate>2018-07-18</startDate>
            <endDate>2018-07-18</endDate>
        </period>
    </context>
    <context id="i218bb3aa60ae4e83aa3e4a7e671866cf_I20180718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <instant>2018-07-18</instant>
        </period>
    </context>
    <context id="i7fcd1972dc354290ba6864c10a7dfd26_D20180924-20180924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <startDate>2018-09-24</startDate>
            <endDate>2018-09-24</endDate>
        </period>
    </context>
    <context id="i9a5e914e22c04ed09c890f4bac3875ee_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prta:DublinIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i71ec87774e684456b390ddadf981db10_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prta:DublinIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4d734226c866410c9fa6e63cc16602c0_I20180927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prta:DublinIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-27</instant>
        </period>
    </context>
    <context id="i9ee0a5361cff4ddb8357d8b71f892efb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iec44022c93d44923a6ba45741b5572ca_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">prta:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if3b8cf0763bb4f5397b004275677c01b_D20140201-20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-02-01</startDate>
            <endDate>2014-02-28</endDate>
        </period>
    </context>
    <context id="iaaed79f2beb64ec6a2029bcf63a64073_D20140501-20140531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-05-01</startDate>
            <endDate>2014-05-31</endDate>
        </period>
    </context>
    <context id="ib00e147a1cff4155afb7ec6051700710_D20170601-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i74335244f76841eb87c826533b83cc37_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if675ef5553934becb22c4267dbb63ed6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prta:DevelopmentCostsReimbursementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic854f60120d74aedb489b48755f518b9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibca1ba5c855446de877d16de250feabe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i073a0b78fb35421ba6e8592c0a197dfe_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icb959663c6fb41d287b63b8363fda883_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:RoyaltyBearingLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5ba8be9d9c3a400b803bd9eaae95a8ee_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:INDandDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icd6584a0477e41a785e2b634ec00c3ec_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:SupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0175d817a5f44f01ac9efd8385decd07_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:RoyaltyBearingLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia759813a15794ad4bdcf62a8a938c100_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:INDandDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic7b2c3d5be4540b6921b9e212efe9451_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:ClinicalProductSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic84e2a6f4eb048d58a8ce416274ea456_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:SupplyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0c607e622d1f49aa8ceca2e000427c5e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia09f6d9b318949658f4b5edbbc1060d4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prta:ResearchReimbursementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iec0766c4dcbb452d92267a1537fc4521_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5da9211e8d7c43f6be07d56a02195be6_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic027828db76f4a93885ac0251d9ed379_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i10bc3926f14143428f8b45360781a239_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf958f5bfd554f5db359067fc2e7e217_I20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-20</instant>
        </period>
    </context>
    <context id="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-20</startDate>
            <endDate>2018-03-20</endDate>
        </period>
    </context>
    <context id="i823dfe17698f4577941dc181be64c092_I20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-20</instant>
        </period>
    </context>
    <context id="ibb2d17fa473c4e86a3e307306a386a61_D20180320-20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramUSRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-20</startDate>
            <endDate>2018-03-20</endDate>
        </period>
    </context>
    <context id="i781ce1f9fb114a1288a2399d11b4d4a5_D20180320-20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramGlobalRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-20</startDate>
            <endDate>2018-03-20</endDate>
        </period>
    </context>
    <context id="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-20</startDate>
            <endDate>2018-03-20</endDate>
        </period>
    </context>
    <context id="i1a7adf1102ac42aa80af37c1765abece_I20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">prta:CelgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-20</instant>
        </period>
    </context>
    <context id="ifa4c2edd44bb4660bab9e79530b6b7fe_I20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramUSRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-20</instant>
        </period>
    </context>
    <context id="ie08072583f71487086cd63ba104febe6_I20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramUSRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-20</instant>
        </period>
    </context>
    <context id="i754447b94e7e46e1832a0a572e8edf4d_I20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramGlobalRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-20</instant>
        </period>
    </context>
    <context id="i9a50341614dd4cabbccefeba93a88fd1_I20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramGlobalRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-20</instant>
        </period>
    </context>
    <context id="i2f99a1d0727d46a9adc11dcafd022744_I20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramUSRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-20</instant>
        </period>
    </context>
    <context id="ib5d8e1da3a7d44d8a442dd98f2a66211_I20180320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prta:CollaborationProgramGlobalRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-20</instant>
        </period>
    </context>
    <context id="if308d0f707774e83b68197d8cba203b0_D20180515-20180515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <startDate>2018-05-15</startDate>
            <endDate>2018-05-15</endDate>
        </period>
    </context>
    <context id="i044cf0c67aab4755b4c3d1811b2ed835_D20200519-20200519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:AmendedAndRestated2018LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-19</startDate>
            <endDate>2020-05-19</endDate>
        </period>
    </context>
    <context id="i963269705b7b4e5f9ae3a71c1c9ff5bd_I20180515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:AmendedAndRestated2018LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-15</instant>
        </period>
    </context>
    <context id="i8c7ac19e5f714d5c9b45c2f8f4858855_D20180515-20180515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:AmendedAndRestated2018LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-15</startDate>
            <endDate>2018-05-15</endDate>
        </period>
    </context>
    <context id="i21f801f178cb46208ea96162e7973433_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:AmendedAndRestated2018LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i84637f79b65c470f84d8f4b8fb8e16cf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:AmendedAndRestated2018LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifc344697e4b14499a86b91af81b71dcf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:A2012LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i13cded138cc145cf8025f23802654b94_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:A2020EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i6f0f422fe8fd406e815795229f9d4c4a_D20200225-20200225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:A2020EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-25</startDate>
            <endDate>2020-02-25</endDate>
        </period>
    </context>
    <context id="i5e195fad49074becb102c91d64d9ebb5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prta:A2020EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3afaf46701c249838b3b57dcd7cd2fd1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i619b94a5d1c748048b980c4beb1d3f80_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5770524a4fb64c908398d01f9b105d07_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6af301e0d5464d0f8688b96cc7ecbcc2_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia19f4446d12d455d8ed873aacb41c471_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1d8293363e094a25a626f7be205cd571_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0c7537c8b63e44b2b5a02d22312caaac_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ida53c60bb2f6447e8d6a93e583eb07f7_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i44af5ba0fe6a40a0b2d7a1b155ed8d12_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iea1807fc55f1435bb318a4fb39dde186_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ied6043afc98548c7ae9c22d39f61cb44_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iacb3936c27de4e4c87eba688149d459e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3729d833e9b64a35af79dd7d137d50e1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3dbe480e059f408dbac0ebcadbd9f854_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib78a576b8afe40d2aaeedaae8a663a59_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i051466dca10b47ce8e0373f83d6dd3c4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001559053</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="agreement_term">
        <measure>prta:agreement_term</measure>
    </unit>
    <unit id="vote">
        <measure>prta:vote</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180L2ZyYWc6NDRhNjMzNWU5NjAyNDY0Njk4NmU0ZmQwMzEyZDEzMmYvdGFibGU6NTM4ODc1OTczZTI4NGIxMjg0N2RjYjU2OTcyNzRlY2MvdGFibGVyYW5nZTo1Mzg4NzU5NzNlMjg0YjEyODQ3ZGNiNTY5NzI3NGVjY181LTEtMS0xLTA_af77d210-f787-4a46-b256-0647c7fb3a06">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180L2ZyYWc6NDRhNjMzNWU5NjAyNDY0Njk4NmU0ZmQwMzEyZDEzMmYvdGFibGU6NTM4ODc1OTczZTI4NGIxMjg0N2RjYjU2OTcyNzRlY2MvdGFibGVyYW5nZTo1Mzg4NzU5NzNlMjg0YjEyODQ3ZGNiNTY5NzI3NGVjY184LTEtMS0xLTA_2f3e0d60-11fb-4d16-a94f-b3a0c19d0568">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180L2ZyYWc6NDRhNjMzNWU5NjAyNDY0Njk4NmU0ZmQwMzEyZDEzMmYvdGFibGU6NTM4ODc1OTczZTI4NGIxMjg0N2RjYjU2OTcyNzRlY2MvdGFibGVyYW5nZTo1Mzg4NzU5NzNlMjg0YjEyODQ3ZGNiNTY5NzI3NGVjY185LTEtMS0xLTA_de1d0801-a5f6-40c9-9ec4-4800508e5c83">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180L2ZyYWc6NDRhNjMzNWU5NjAyNDY0Njk4NmU0ZmQwMzEyZDEzMmYvdGFibGU6NTM4ODc1OTczZTI4NGIxMjg0N2RjYjU2OTcyNzRlY2MvdGFibGVyYW5nZTo1Mzg4NzU5NzNlMjg0YjEyODQ3ZGNiNTY5NzI3NGVjY18xMS0xLTEtMS0w_0c9de5fb-2f6f-4b13-a752-5337bac5c62a">0001559053</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180L2ZyYWc6NDRhNjMzNWU5NjAyNDY0Njk4NmU0ZmQwMzEyZDEzMmYvdGFibGU6NTM4ODc1OTczZTI4NGIxMjg0N2RjYjU2OTcyNzRlY2MvdGFibGVyYW5nZTo1Mzg4NzU5NzNlMjg0YjEyODQ3ZGNiNTY5NzI3NGVjY18xMi0xLTEtMS0w_be9f9cfe-fb18-4bb8-bc4d-d679601e3eba">--12-31</dei:CurrentFiscalYearEndDate>
    <prta:BuildtosuitLeaseTermofContract
      contextRef="i8154f8e4fb0a43068ce1feebb738c177_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181Mi9mcmFnOmIwZmIwM2FmNTQ4ZTRhZjk4ZTUzMmM4NDc5ZDM4NzU3L3RhYmxlOmQ4NDA1YjExYmE3NzQzNmE4MWRjNGU1N2MwODRiYzQxL3RhYmxlcmFuZ2U6ZDg0MDViMTFiYTc3NDM2YTgxZGM0ZTU3YzA4NGJjNDFfMi0yLTEtMS0w_4843c4a9-6bd8-4d92-9791-887fd13e865e">P7Y9M30D</prta:BuildtosuitLeaseTermofContract>
    <prta:CollaborationAgreementUpfrontPaymentPaymentTerm
      contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzk0Njc_0bf4cdb7-932a-472a-9ad8-2ce5f72c6492">P10D</prta:CollaborationAgreementUpfrontPaymentPaymentTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i84637f79b65c470f84d8f4b8fb8e16cf_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTcwNDI0MzAyMzk3NDM_37e1f852-c414-4fe4-86e8-7b6225eb6fa8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ifc344697e4b14499a86b91af81b71dcf_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTQ0Mw_743a930b-b10b-459b-82c5-ed0937653214">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i6f0f422fe8fd406e815795229f9d4c4a_D20200225-20200225"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTkzNw_cef9d024-7d91-407e-8091-cfdb99879f97">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dei:DocumentType
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18yNzQ4Nzc5MDcxMjU4_ca2dca6b-209b-4fce-86fb-830300ddd0a9">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6N2FhMWQyMTM2OWUxNGVhYjk4NjZlOWNjNDdkYWJkZTcvdGFibGVyYW5nZTo3YWExZDIxMzY5ZTE0ZWFiOTg2NmU5Y2M0N2RhYmRlN18wLTAtMS0xLTE0OQ_2c47b713-3083-4eb9-bcfb-cec780752c82">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18zMjk4NTM0ODg1Mjcz_1fa34c8f-5727-4162-9f99-898af6a464e3">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6ZTM5NzBkOTc1ODgzNDhkZDgwZGY1MGQyZGQ2NzZmNmQvdGFibGVyYW5nZTplMzk3MGQ5NzU4ODM0OGRkODBkZjUwZDJkZDY3NmY2ZF8wLTAtMS0xLTE1MQ_5f2df131-a9fd-4b09-8d08-2a08d5b84467">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18zMjk4NTM0ODg1MTkw_810ab8e8-9bdb-4be2-9a7d-a311f050f5e3">001-35676</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18yNzQ4Nzc5MDcxMjc3_7cf95eea-1305-4411-be57-f8610ffa04f3">PROTHENA CORPORATION PUBLIC LIMITED COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6N2Q5OGI2MDA0MGUzNDdhMjg2NzkyMGM3YjVhM2NhYWQvdGFibGVyYW5nZTo3ZDk4YjYwMDQwZTM0N2EyODY3OTIwYzdiNWEzY2FhZF8wLTAtMS0xLTE2MA_44d5584b-29e1-4d6a-a8c2-f2ba7ea956e0">L2</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6N2Q5OGI2MDA0MGUzNDdhMjg2NzkyMGM3YjVhM2NhYWQvdGFibGVyYW5nZTo3ZDk4YjYwMDQwZTM0N2EyODY3OTIwYzdiNWEzY2FhZF8wLTItMS0xLTE2Mg_29c508a3-1d48-40a4-b816-f4de7a1ef611">98-1111119</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6YjQ5NzhjZGNmNTQzNDJiZWFjMGQ4ZjIyZmUxNDAyZWUvdGFibGVyYW5nZTpiNDk3OGNkY2Y1NDM0MmJlYWMwZDhmMjJmZTE0MDJlZV8wLTAtMS0xLTE5NQ_e06dc253-c97c-4c0c-a855-d65b14f64b49">77 Sir John Rogerson&#x2019;s Quay, Block C</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6YjQ5NzhjZGNmNTQzNDJiZWFjMGQ4ZjIyZmUxNDAyZWUvdGFibGVyYW5nZTpiNDk3OGNkY2Y1NDM0MmJlYWMwZDhmMjJmZTE0MDJlZV8xLTAtMS0xLTE5NQ_d32c7225-216a-459b-988e-dfdeeeb7b52a">Grand Canal Docklands</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6YjQ5NzhjZGNmNTQzNDJiZWFjMGQ4ZjIyZmUxNDAyZWUvdGFibGVyYW5nZTpiNDk3OGNkY2Y1NDM0MmJlYWMwZDhmMjJmZTE0MDJlZV8yLTAtMS0xLTE5NQ_05368501-39ce-4888-893a-b4a446aee5c7">Dublin 2,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6YjQ5NzhjZGNmNTQzNDJiZWFjMGQ4ZjIyZmUxNDAyZWUvdGFibGVyYW5nZTpiNDk3OGNkY2Y1NDM0MmJlYWMwZDhmMjJmZTE0MDJlZV8yLTEtMS0xLTE5NQ_41d8e404-a781-4cbb-b2c0-80b26e380068">D02 T804,</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6YjQ5NzhjZGNmNTQzNDJiZWFjMGQ4ZjIyZmUxNDAyZWUvdGFibGVyYW5nZTpiNDk3OGNkY2Y1NDM0MmJlYWMwZDhmMjJmZTE0MDJlZV8yLTItMS0xLTE5NQ_36a1b40d-b1e6-40f4-ad30-6218a5d46f95">IE</dei:EntityAddressCountry>
    <dei:CountryRegion
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18yNzQ4Nzc5MDcxMzM3_ca05930e-05f0-4aa4-ab45-e0ded8b5bf53">353</dei:CountryRegion>
    <dei:CityAreaCode
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18yNzQ4Nzc5MDcxMzQy_43ed435d-f09f-4b8d-b473-0e3da641e3b3">1</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18yNzQ4Nzc5MDcxMzQ0_21735a9d-5252-416b-bc1b-5680e071caed">236-2500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6MWI1ZmQ4MWJhODM0NGFmMzkyYjViNWE2MGJmY2JkYzcvdGFibGVyYW5nZToxYjVmZDgxYmE4MzQ0YWYzOTJiNWI1YTYwYmZjYmRjN18xLTAtMS0xLTE5Nw_36df0320-b65a-405a-8359-9587a4596bf1">Ordinary Shares, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6MWI1ZmQ4MWJhODM0NGFmMzkyYjViNWE2MGJmY2JkYzcvdGFibGVyYW5nZToxYjVmZDgxYmE4MzQ0YWYzOTJiNWI1YTYwYmZjYmRjN18xLTEtMS0xLTE5Nw_6d304e33-3e4d-4925-99b4-bbf7d04f3f71">PRTA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6MWI1ZmQ4MWJhODM0NGFmMzkyYjViNWE2MGJmY2JkYzcvdGFibGVyYW5nZToxYjVmZDgxYmE4MzQ0YWYzOTJiNWI1YTYwYmZjYmRjN18xLTItMS0xLTE5Nw_d15d28db-9469-44df-8e34-2ee3f414b47c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18zMjk4NTM0ODg1MTg3_752584ab-bcd8-435b-82a7-c4aa96d697ae">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18zMjk4NTM0ODg1MTg4_95aa5640-b1be-44dc-935d-96cc24b6d6e1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6ZTg4YzFmMGQ4ODY0NGEyZTllN2U5MTllMGUwYjU0MDAvdGFibGVyYW5nZTplODhjMWYwZDg4NjQ0YTJlOWU3ZTkxOWUwZTBiNTQwMF8wLTItMS0xLTIwOQ_c2f1d925-c0c6-4ecd-8121-ca6c6194a1ae">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6ZTg4YzFmMGQ4ODY0NGEyZTllN2U5MTllMGUwYjU0MDAvdGFibGVyYW5nZTplODhjMWYwZDg4NjQ0YTJlOWU3ZTkxOWUwZTBiNTQwMF8yLTMtMS0xLTIxMQ_b440bfb9-e648-41a9-8125-2ee1ad237755">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGFibGU6ZTg4YzFmMGQ4ODY0NGEyZTllN2U5MTllMGUwYjU0MDAvdGFibGVyYW5nZTplODhjMWYwZDg4NjQ0YTJlOWU3ZTkxOWUwZTBiNTQwMF8zLTMtMS0xLTIxMw_c1ec703b-55fe-4e44-bc07-afcd680001ce">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18zMjk4NTM0ODg1MTg5_4f828d5f-c945-40b6-93ce-5f3cbbf52bf7">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2076d6dfdfd942b4a9a3009e044262c6_I20200731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xL2ZyYWc6NTIzYTA4ZDgxN2MyNGM5NDk5MmEzMmE5NzkyNWRkZmMvdGV4dHJlZ2lvbjo1MjNhMDhkODE3YzI0Yzk0OTkyYTMyYTk3OTI1ZGRmY18xODA0_c90ad8af-8be1-4657-a075-f68860bd6c1c"
      unitRef="shares">39911413</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNC0xLTEtMS0w_6e6b4a91-8880-4a03-95c2-167432c79c22"
      unitRef="usd">333942000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNC0zLTEtMS0w_1fa4490d-e5c1-42c7-b725-5e33ec0ac74b"
      unitRef="usd">375723000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNS0xLTEtMS0w_2bcbf77f-6854-4b34-b282-7f684230b533"
      unitRef="usd">56000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNS0zLTEtMS0w_72422637-094e-4dab-956b-d7c08b8cfad0"
      unitRef="usd">68000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNi0xLTEtMS0w_fcc3f624-bd53-4528-b51b-5c7c2a829194"
      unitRef="usd">7125000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNi0zLTEtMS0w_cbe63728-6bcc-4032-a765-b89b156d2a70"
      unitRef="usd">2584000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNy0xLTEtMS0w_80c99b4e-e974-4e7b-8c58-4daff9aadbcc"
      unitRef="usd">341123000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNy0zLTEtMS0w_f2bef614-6020-40ea-8fff-705bc3149503"
      unitRef="usd">378375000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfOS0xLTEtMS0w_28493b27-09df-4c9e-8976-5fa0a95bfe72"
      unitRef="usd">3215000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfOS0zLTEtMS0w_13a5b45b-78df-4d91-aba6-e3c8253543b0"
      unitRef="usd">3874000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTAtMS0xLTEtMA_2cac4af0-960e-4d7e-809a-65315c6254cc"
      unitRef="usd">20570000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTAtMy0xLTEtMA_47b96b2b-b22a-4b00-a244-f101ec17f789"
      unitRef="usd">23274000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTEtMS0xLTEtMA_858543bf-1aee-4436-a0c7-611649f5b764"
      unitRef="usd">11017000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTEtMy0xLTEtMA_f8f65f8b-f30d-496b-a85c-a5d27a4d068b"
      unitRef="usd">9956000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTItMS0xLTEtMA_c5d90d58-bca0-441d-9182-3654e4ff64cc"
      unitRef="usd">2704000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTItMy0xLTEtMA_14b379fd-3576-48fa-a04a-d8584c686110"
      unitRef="usd">2704000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTMtMS0xLTEtMA_e4166aff-4264-454c-a2dc-6dcc07f14f3f"
      unitRef="usd">304000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTMtMy0xLTEtMA_dfd9cc55-b79d-477f-bba6-4e9631680604"
      unitRef="usd">1085000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTQtMS0xLTEtMA_d8e1201e-25cc-4bff-bd78-d097352d614c"
      unitRef="usd">37810000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTQtMy0xLTEtMA_f601ed26-317b-49d7-8ba8-d4bad5fbec56"
      unitRef="usd">40893000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTUtMS0xLTEtMA_5e6a9468-961f-4b95-92b8-364a376692c3"
      unitRef="usd">378933000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTUtMy0xLTEtMA_20c52362-57cb-409e-a89e-aa345dabc649"
      unitRef="usd">419268000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTgtMS0xLTEtMA_88bdac67-74f6-4989-bdec-f3da10a8c491"
      unitRef="usd">2124000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTgtMy0xLTEtMA_771d0f67-5997-41be-bdde-ef0092c8c85a"
      unitRef="usd">1242000</us-gaap:AccountsPayableCurrent>
    <prta:AccruedResearchAndDevelopmentCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTktMS0xLTEtMA_ad9ad8af-f5de-4264-8d49-8e06b94a7a9d"
      unitRef="usd">6152000</prta:AccruedResearchAndDevelopmentCurrent>
    <prta:AccruedResearchAndDevelopmentCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMTktMy0xLTEtMA_ef4f0718-93cc-450b-aba9-5d811e3f3048"
      unitRef="usd">5826000</prta:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjAtMS0xLTEtMA_e63a1c3c-9a60-47c8-a0f1-1a295a2c3a7b"
      unitRef="usd">221000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjAtMy0xLTEtMA_85e55a20-47c3-4f33-b712-efd202ee7255"
      unitRef="usd">5000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjEtMS0xLTEtMA_17245c1e-f202-4708-ae47-58c1621d5894"
      unitRef="usd">5304000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjEtMy0xLTEtMA_b2ef9ed7-6640-4cbb-87cd-308240a072ba"
      unitRef="usd">5101000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjItMS0xLTEtMA_ddf4e9ab-cc61-4e96-919c-043746423ab0"
      unitRef="usd">4743000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjItMy0xLTEtMA_4aba84a9-633c-41fc-9cdc-c5659a7c267d"
      unitRef="usd">5540000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjMtMS0xLTEtMA_14592055-e109-4669-97b4-041807969209"
      unitRef="usd">18544000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjMtMy0xLTEtMA_94811d63-cbeb-4560-a3d0-c1404b57aa29"
      unitRef="usd">17714000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjUtMS0xLTEtMA_ecf0a295-04eb-4f34-bfe6-7a913f51f828"
      unitRef="usd">110242000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjUtMy0xLTEtMA_b22534c4-25e7-44c2-9eb7-196e79d84099"
      unitRef="usd">110242000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjYtMS0xLTEtMA_faab32e7-d4df-4a32-8695-7b3f0a5caf27"
      unitRef="usd">15150000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjYtMy0xLTEtMA_e173bf12-6d20-4132-8c49-5834d91b1bd0"
      unitRef="usd">17838000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjctMS0xLTEtMA_70837eac-42fb-4bff-add6-75c403f1fdea"
      unitRef="usd">553000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjctMy0xLTEtMA_688eb972-3798-4818-9dca-7bf27a2b0434"
      unitRef="usd">553000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjgtMS0xLTEtMA_b8e1962d-663f-4928-9938-b334a57b4f8b"
      unitRef="usd">125945000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjgtMy0xLTEtMA_15929cb2-140c-4014-b820-80ecaabf8dea"
      unitRef="usd">128633000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjktMS0xLTEtMA_af7149cf-1a82-4b28-a8c7-f3c55765324f"
      unitRef="usd">144489000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMjktMy0xLTEtMA_83bc526f-6fde-4904-b142-0b5eaabb5dbe"
      unitRef="usd">146347000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzAtMS0xLTEtMA_e5a60894-298a-47c2-9ff3-30abb7b534a0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzAtMy0xLTEtMA_d2f8473e-11a8-480b-b6a6-35b241423e4f"
      unitRef="usd"
      xsi:nil="true"/>
    <prta:DeferredSharesParValue
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzItMC0xLTEtMzQzL3RleHRyZWdpb246MjEyODg5ZTAxNjJhNDhjYWFmZDY3YmM2MGM2ODA5ZDRfMzI5ODUzNDg4MzM3NQ_5a3fb322-2af3-4858-9537-1140a1fe28fc"
      unitRef="eurPerShare">22</prta:DeferredSharesParValue>
    <prta:DeferredSharesParValue
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzItMC0xLTEtMzQzL3RleHRyZWdpb246MjEyODg5ZTAxNjJhNDhjYWFmZDY3YmM2MGM2ODA5ZDRfMzI5ODUzNDg4MzM3NQ_dc7ac8a7-8886-43a2-a6f0-338b7352d881"
      unitRef="eurPerShare">22</prta:DeferredSharesParValue>
    <prta:DeferredSharesValue
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzItMS0xLTEtMA_7be428fd-bd72-4dd4-be6f-1832170a1fd6"
      unitRef="usd">0</prta:DeferredSharesValue>
    <prta:DeferredSharesValue
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzItMy0xLTEtMA_ad3c3182-182a-439c-98ab-439249dd17aa"
      unitRef="usd">0</prta:DeferredSharesValue>
    <prta:DeferredSharesSharesAuthorized
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzMtMC0xLTEtMjU1Ni90ZXh0cmVnaW9uOmVhNTg0NmNiNjcyODRlMWQ5ODRmYWZmZWY4ODZlZTUzXzE2NDkyNjc0NDE3Mzk_48e27ede-ef43-4b7f-b44c-4330864a0229"
      unitRef="shares">10000</prta:DeferredSharesSharesAuthorized>
    <prta:DeferredSharesSharesAuthorized
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzMtMC0xLTEtMjU1Ni90ZXh0cmVnaW9uOmVhNTg0NmNiNjcyODRlMWQ5ODRmYWZmZWY4ODZlZTUzXzE2NDkyNjc0NDE3Mzk_7492f75e-bf31-497b-b1b6-62b742d6a3b5"
      unitRef="shares">10000</prta:DeferredSharesSharesAuthorized>
    <prta:DeferredSharesSharesAuthorized
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzMtMC0xLTEtMjU1Ni90ZXh0cmVnaW9uOmVhNTg0NmNiNjcyODRlMWQ5ODRmYWZmZWY4ODZlZTUzXzE2NDkyNjc0NDE3Mzk_9419a155-f094-45b1-859d-5b7d91aec99b"
      unitRef="shares">10000</prta:DeferredSharesSharesAuthorized>
    <prta:DeferredSharesSharesAuthorized
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzMtMC0xLTEtMjU1Ni90ZXh0cmVnaW9uOmVhNTg0NmNiNjcyODRlMWQ5ODRmYWZmZWY4ODZlZTUzXzE2NDkyNjc0NDE3Mzk_d34f3e91-2b48-410a-9ce1-9ab7141ca16a"
      unitRef="shares">10000</prta:DeferredSharesSharesAuthorized>
    <prta:DeferredSharesShareOutstanding
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_07c2a6bf-d591-4414-9ad1-30d6662e56ce"
      unitRef="shares">0</prta:DeferredSharesShareOutstanding>
    <prta:DeferredSharesShareIssued
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_22eac314-f0c0-4c7b-a012-000ec44648f3"
      unitRef="shares">0</prta:DeferredSharesShareIssued>
    <prta:DeferredSharesShareOutstanding
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_53e3bd1a-4b27-4261-bea8-2d9d8acc971b"
      unitRef="shares">0</prta:DeferredSharesShareOutstanding>
    <prta:DeferredSharesShareOutstanding
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_5c674dcf-67a8-4634-9452-19d23ea6cb08"
      unitRef="shares">0</prta:DeferredSharesShareOutstanding>
    <prta:DeferredSharesShareOutstanding
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_67db6464-ccec-4fb8-a2f8-fa85fd0d5145"
      unitRef="shares">0</prta:DeferredSharesShareOutstanding>
    <prta:DeferredSharesShareIssued
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_a92ab6f0-b2df-4ded-bf74-19144365d946"
      unitRef="shares">0</prta:DeferredSharesShareIssued>
    <prta:DeferredSharesShareIssued
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_b041e136-244d-4340-852c-383ba4c76069"
      unitRef="shares">0</prta:DeferredSharesShareIssued>
    <prta:DeferredSharesShareIssued
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzQtMC0xLTEtMjU1OC90ZXh0cmVnaW9uOjgyNjI1M2IyNDUwYjQ1ODA5YTdiOTg2YjIyNjlmMjQ2XzEwOTk1MTE2Mjc4OTI_befc2b65-9e13-43a4-948d-7a2ed3121eb6"
      unitRef="shares">0</prta:DeferredSharesShareIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzUtMC0xLTEtNDkzNy90ZXh0cmVnaW9uOjI5NmJmZDIwNjNhNjQ0N2U5ZWUxOTNjOTFjNzc1OTk0XzEwOTk1MTE2Mjc4MTg_11550f18-8dc4-403b-a565-3fb370d18893"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzUtMC0xLTEtNDkzNy90ZXh0cmVnaW9uOjI5NmJmZDIwNjNhNjQ0N2U5ZWUxOTNjOTFjNzc1OTk0XzEwOTk1MTE2Mjc4MTg_d303e466-58fd-44f6-9ebe-b29407254a58"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockValue
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzUtMS0xLTEtMA_2d7b725e-87a4-4fad-ab29-80d66b7556a8"
      unitRef="usd">399000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzUtMy0xLTEtMA_e134b993-0d9a-474c-af34-1224f31df3ec"
      unitRef="usd">399000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzYtMC0xLTEtMjU2MC90ZXh0cmVnaW9uOmRkMjI3OTg5ZmRiZTQxZTM5ZmI4MWI1ZmU5NjZhZmNkXzEwOTk1MTE2Mjc4NjE_004c3949-ea3a-44c1-8014-c73d16b68bf9"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzYtMC0xLTEtMjU2MC90ZXh0cmVnaW9uOmRkMjI3OTg5ZmRiZTQxZTM5ZmI4MWI1ZmU5NjZhZmNkXzEwOTk1MTE2Mjc4NjE_a0ad84a7-cbb3-45bd-8c5f-98c86d20d959"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzYtMC0xLTEtMjU2MC90ZXh0cmVnaW9uOmRkMjI3OTg5ZmRiZTQxZTM5ZmI4MWI1ZmU5NjZhZmNkXzEwOTk1MTE2Mjc4NjE_ef294dc4-5aa9-417c-b17f-58a3e32f0e12"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzYtMC0xLTEtMjU2MC90ZXh0cmVnaW9uOmRkMjI3OTg5ZmRiZTQxZTM5ZmI4MWI1ZmU5NjZhZmNkXzEwOTk1MTE2Mjc4NjE_fd82d6c5-a1f6-423c-be46-fff78888c424"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ1NA_51c3f548-bf2b-4a6a-adaa-313353774b6f"
      unitRef="shares">39911413</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ1NA_7e7b8192-2702-4a86-9d0c-7d2208ff76f5"
      unitRef="shares">39911413</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ1NA_b961d89f-d316-43d2-9752-00cf295aa8f2"
      unitRef="shares">39911413</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ1NA_ec03dd18-17d6-4d4e-8e33-6e0105934b0b"
      unitRef="shares">39911413</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ2Nw_38ba33b4-bdbf-48c4-ba3c-6f54d885ae3a"
      unitRef="shares">39898561</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ2Nw_74c40d48-9d28-489d-80e8-b290f165f9f1"
      unitRef="shares">39898561</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ2Nw_bbefe083-a8c1-434a-9288-0370881aba1f"
      unitRef="shares">39898561</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzctMC0xLTEtMzQ3L3RleHRyZWdpb246YzhlODk1MzJjZTk1NDkyYjgwOGYwOTNhZmQ1ODgyMjVfMzI5ODUzNDg4MzQ2Nw_f2e54b3e-4c1d-429a-88b2-c3c8e128a3fe"
      unitRef="shares">39898561</us-gaap:CommonStockSharesIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzgtMS0xLTEtMA_10207a17-2947-4709-95a6-e7f9f29e1f36"
      unitRef="usd">955781000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzgtMy0xLTEtMA_0d1a9187-b55b-4a4d-88be-5d8d3fa58ccc"
      unitRef="usd">944407000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzktMS0xLTEtMA_743d7069-1cab-405a-82dc-f975a1f78453"
      unitRef="usd">-721736000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfMzktMy0xLTEtMA_a72c099e-c58d-493a-a688-aeb475f2c262"
      unitRef="usd">-671885000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNDAtMS0xLTEtMA_b5695730-4510-4f21-b479-a8d72a193611"
      unitRef="usd">234444000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNDAtMy0xLTEtMA_5a338a83-cf94-4705-b4c2-d10ad76bfc89"
      unitRef="usd">272921000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNDEtMS0xLTEtMA_f5212125-7615-4cab-ba63-8e8c5676abd3"
      unitRef="usd">378933000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18xNi9mcmFnOmE4N2MwZGI1NTc2ZTQwN2Q5NzNlM2EzMmNkNTBlMGU3L3RhYmxlOjkxNmYzYmViMzc0ZjQ2MGU4ZDM2Y2U3ZTBmN2NkZDJjL3RhYmxlcmFuZ2U6OTE2ZjNiZWIzNzRmNDYwZThkMzZjZTdlMGY3Y2RkMmNfNDEtMy0xLTEtMA_8c1c1bed-a91e-433b-8246-39a61bce3a62"
      unitRef="usd">419268000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ecda07bc4ba4408a09994ddf7154fb8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMi0yLTEtMS00MzY_4b1f5624-c968-40a1-965d-9331a6ec2c14"
      unitRef="usd">145000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a01076460454a2eac50eac78fcb4c4e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMi00LTEtMS00MzY_06f2ed4b-f4b8-405d-b17d-4e8f9053a4de"
      unitRef="usd">167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3d1c0ac6b42476b8901a5b86894d8a8_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMi0yLTEtMS0w_946f647a-a5f6-4bb8-8563-4b8b08c8574b"
      unitRef="usd">286000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if407b818af644e46b2c8fd3f4ef0916b_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMi00LTEtMS0w_7ba2a6ff-6f7e-40fb-8d6e-070e2fd7ce6e"
      unitRef="usd">353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37e74aa909674a31a31bf76e13ce1a5f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy0yLTEtMS0xODQy_a1e0e7e3-43dd-4915-8be1-1f0ed4d13bcb"
      unitRef="usd">50000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i699a71835ede41ffb63bc12dc5058195_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy00LTEtMS0xODQy_86a36854-60d6-4152-9859-cb31edf61422"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5d2e09455d741d0af7adef0326a9464_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy02LTEtMS0xODQy_8b2d51c5-1d87-48d2-b9ed-bc59995dc538"
      unitRef="usd">50000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i735a4a62bab9471a84edda62005153d0_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy04LTEtMS0xODQy_65d490f2-4afd-4061-a0ee-070df513e6b2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy0yLTEtMS00Mzk_34595b08-ac58-40d5-97b7-162ed8d7272f"
      unitRef="usd">195000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy00LTEtMS00Mzk_d6c2d3fb-342a-4a4b-82e7-bb049a02f9bb"
      unitRef="usd">167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy0yLTEtMS0w_f9b771e1-955e-48c8-9b90-63f46aeffb08"
      unitRef="usd">336000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMy00LTEtMS0w_def65d5e-5939-4660-a8dd-32b43e3fdf5e"
      unitRef="usd">353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNS0yLTEtMS00NDE_7c222edf-d5ef-4145-964e-6457acf46124"
      unitRef="usd">17271000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNS00LTEtMS00NDE_d3328ccd-385e-4827-8867-cbf722def7ef"
      unitRef="usd">9583000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNS0yLTEtMS0w_578f49b1-664d-4338-bc99-deb6807305b8"
      unitRef="usd">32519000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNS00LTEtMS0w_4f1af8d6-1ad4-40de-b260-5eca9c384555"
      unitRef="usd">22879000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNi0yLTEtMS00NDE_3d3c2b3e-70dc-41a4-b95c-eeeeaaf1b710"
      unitRef="usd">9656000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNi00LTEtMS00NDE_c1903ae8-2170-42d6-aabf-5908c2dadf5a"
      unitRef="usd">9081000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNi0yLTEtMS0w_9f798808-03df-4863-8c58-8b300c964b30"
      unitRef="usd">19397000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNi00LTEtMS0w_d4d909c7-31d3-4ee3-878f-0aa1a9b22231"
      unitRef="usd">18986000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCosts
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNy0yLTEtMS00NDE_c7564e3e-c443-4b96-9b2a-725d896ce568"
      unitRef="usd">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNy00LTEtMS00NDE_bbc956ca-77ed-4a38-89ba-564e661ab576"
      unitRef="usd">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNy0yLTEtMS0w_43a44b36-3ea2-4191-8c51-ac1a3ed2d07e"
      unitRef="usd">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfNy00LTEtMS0w_cd83d1ed-8b06-4014-b993-cd1770f46463"
      unitRef="usd">-61000</us-gaap:RestructuringCosts>
    <us-gaap:OperatingExpenses
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOC0yLTEtMS00NDE_79bcd56c-dd23-49c5-ac2b-e9e4938a2b1d"
      unitRef="usd">26927000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOC00LTEtMS00NDE_1ab2e0f2-0019-4d41-a4c5-17c7e005c3fa"
      unitRef="usd">18664000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOC0yLTEtMS0w_7c37aa97-baa2-46e0-ba3e-630abd21aed1"
      unitRef="usd">51916000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOC00LTEtMS0w_3ea20456-01aa-43b6-a570-0b44ac5508e1"
      unitRef="usd">41804000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOS0yLTEtMS00NDM_344e8e85-b5e7-44f4-931b-d4fe099e0ec1"
      unitRef="usd">-26732000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOS00LTEtMS00NDM_0ea5d8a5-a4fb-43b8-af62-b34ade783ca0"
      unitRef="usd">-18497000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOS0yLTEtMS0w_cb51cddf-f44d-4369-a0eb-ff61252d7a64"
      unitRef="usd">-51580000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfOS00LTEtMS0w_5b984e29-5d83-4f49-b630-2646dc098b63"
      unitRef="usd">-41451000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTEtMi0xLTEtNDQ1_6137a804-6d98-4fb5-b7c4-a446ec215c82"
      unitRef="usd">179000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTEtNC0xLTEtNDQ1_d9f2187f-822a-4555-9d2b-a57d71ccef5b"
      unitRef="usd">2296000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTEtMi0xLTEtMA_16e117b9-8fe5-4685-b1ff-01ac0451485e"
      unitRef="usd">1316000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTEtNC0xLTEtMA_c95899bf-169b-45fa-a217-59f5434e5049"
      unitRef="usd">4600000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTItMi0xLTEtNDQ1_587e6413-9beb-4496-93c0-f9851a4692a8"
      unitRef="usd">16000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTItNC0xLTEtNDQ1_92e2a463-fcb9-44e8-a9ba-9851bfa72f4e"
      unitRef="usd">235000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTItMi0xLTEtMA_1138d53c-879d-425e-926c-a758710019e5"
      unitRef="usd">-8000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTItNC0xLTEtMA_dbfc284a-fb22-49b0-b1aa-26bd0f23a116"
      unitRef="usd">218000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTMtMi0xLTEtNDQ1_0f75dc76-ec07-43f5-986f-9c44fdb36b42"
      unitRef="usd">195000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTMtNC0xLTEtNDQ1_2b0a525d-453b-4d90-a209-c34a1b5fc5ad"
      unitRef="usd">2531000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTMtMi0xLTEtMA_675a4d60-a414-481a-94f6-756f9764df5b"
      unitRef="usd">1308000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTMtNC0xLTEtMA_a83d0a38-b14b-49ce-a4eb-59c9a57943f3"
      unitRef="usd">4818000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTQtMi0xLTEtNDQ4_1e4278a3-43e7-4215-b09e-814df5197886"
      unitRef="usd">-26537000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTQtNC0xLTEtNDQ4_0d54ec33-af90-4754-a00d-af17b707be1c"
      unitRef="usd">-15966000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTQtMi0xLTEtMA_96a9773b-711c-4e88-9eff-b7ba1ffd288c"
      unitRef="usd">-50272000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTQtNC0xLTEtMA_1f43cae0-681c-44cd-8416-8a4cb3cbf0f3"
      unitRef="usd">-36633000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTUtMi0xLTEtNDQ4_e847b91e-eb93-4e24-9936-56df8ca107a1"
      unitRef="usd">-255000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTUtNC0xLTEtNDQ4_6abb0bff-bf69-4ca7-8c51-25da907bc4f9"
      unitRef="usd">-156000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTUtMi0xLTEtMA_506cec37-4f3e-4ae1-a086-0d3abe20a258"
      unitRef="usd">-421000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTUtNC0xLTEtMA_307012c1-8a42-44bc-9072-b9e3469c3412"
      unitRef="usd">42000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iecc1dc4b8e3a409780b630469f43a9e2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTYtMi0xLTEtNDQ4_2597014a-4ae1-4274-93a4-941fd76b0bab"
      unitRef="usd">-26282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTYtNC0xLTEtNDQ4_96e8b75b-014f-44a5-86fd-3500be3c9bce"
      unitRef="usd">-15810000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTYtMi0xLTEtMA_02e31282-9fae-458d-94f2-411267ec2ea5"
      unitRef="usd">-49851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTYtNC0xLTEtMA_338c52b4-6bcb-455d-acc0-ccb4e45210e6"
      unitRef="usd">-36675000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTctMi0xLTEtNDQ4_d266d575-5030-4477-ba4d-2835a40e2f1c"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTctNC0xLTEtNDQ4_7850d1a1-b770-401d-879b-9bc95e8f7284"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTctMi0xLTEtMA_9f407341-5848-4bee-a7cb-3be7d80f0121"
      unitRef="usdPerShare">-1.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTctNC0xLTEtMA_d2a2a5d6-9ba1-4022-9d28-1958de5c13ed"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTgtMi0xLTEtNDUw_f32170c6-b4c0-44ae-a8cf-5bf073c6c98c"
      unitRef="shares">39911000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTgtNC0xLTEtNDUw_5423f330-4689-41ec-af98-96d47d690d98"
      unitRef="shares">39872000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTgtMi0xLTEtMA_ff38ab72-3972-4d1d-89ae-324c92ec853e"
      unitRef="shares">39910000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yMi9mcmFnOjE5NTZjNmY4ZjQ1ODRlODdhNGVlNjBmZTExMjVmMWQyL3RhYmxlOjJkOWJkNjhjNDdiYzQ4ZWU5YWQzZjFjMzA2YjM1OGJmL3RhYmxlcmFuZ2U6MmQ5YmQ2OGM0N2JjNDhlZTlhZDNmMWMzMDZiMzU4YmZfMTgtNC0xLTEtMA_b13373d7-0186-4e4c-b943-66260302308d"
      unitRef="shares">39868000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMy0xLTEtMS0w_02e31282-9fae-458d-94f2-411267ec2ea5"
      unitRef="usd">-49851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMy0zLTEtMS0w_6cb584d4-7786-449e-9eac-22545db8896e"
      unitRef="usd">-36675000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNS0xLTEtMS0w_a463ec3b-7bec-4bc9-b191-f2382f458951"
      unitRef="usd">765000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNS0zLTEtMS0w_42fce8dc-dd44-49c0-a1b3-8db9a38b4671"
      unitRef="usd">772000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNi0xLTEtMS0w_4cd12d01-6069-4edb-ad95-0f0c7a9d82b1"
      unitRef="usd">11223000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNi0zLTEtMS0w_44d6e6f7-0e41-4c63-a8dd-84a78fb4b190"
      unitRef="usd">12482000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNy0xLTEtMS0w_942715d2-5398-42c0-95c2-8b8f20d80440"
      unitRef="usd">-1061000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfNy0zLTEtMS0w_9e25c1e9-e4cb-4dcf-a727-57ceb70b5af3"
      unitRef="usd">-784000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <prta:Amortizationofrightofuseasset
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfOC0xLTEtMS0w_2fe4c2fb-961e-4f6a-aec0-2c7ba0926660"
      unitRef="usd">2704000</prta:Amortizationofrightofuseasset>
    <prta:Amortizationofrightofuseasset
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfOC0zLTEtMS0w_824074f2-7a0b-4257-abe4-4dd80ecdc717"
      unitRef="usd">2603000</prta:Amortizationofrightofuseasset>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTAtMS0xLTEtMA_cc0e22f3-a91c-4676-a321-f2ab1433c34c"
      unitRef="usd">-12000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTAtMy0xLTEtMA_fea7c69c-f452-4c7c-94ff-98539b0c6d53"
      unitRef="usd">-2000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTEtMS0xLTEtMA_84e64cff-7b1f-4dd8-ac43-46e240377b25"
      unitRef="usd">3760000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTEtMy0xLTEtMA_823081d8-765d-4d66-b09c-1bf64d04bcc2"
      unitRef="usd">15593000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTItMS0xLTEtMA_e00d72df-8955-4bfe-8f59-d2419622bb5d"
      unitRef="usd">589000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTItMy0xLTEtMA_08047018-df8a-493a-bbf1-296cf681e8de"
      unitRef="usd">10414000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInRestructuringReserve
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTMtMS0xLTEtMA_04b70d8b-d34f-4964-9056-b4734230521b"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInRestructuringReserve>
    <us-gaap:IncreaseDecreaseInRestructuringReserve
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTMtMy0xLTEtMA_47ad5791-d528-47ee-b6bc-5d80ad21f1ab"
      unitRef="usd">-461000</us-gaap:IncreaseDecreaseInRestructuringReserve>
    <prta:IncreaseDecreaseinOperatingLeaseLiability
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTQtMS0xLTEtMA_9b79a450-a920-4cf5-a601-e384278b6be0"
      unitRef="usd">2485000</prta:IncreaseDecreaseinOperatingLeaseLiability>
    <prta:IncreaseDecreaseinOperatingLeaseLiability
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTQtMy0xLTEtMA_a4dc0d8d-2cfc-4e28-ba05-40f1616fc509"
      unitRef="usd">2298000</prta:IncreaseDecreaseinOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTUtMS0xLTEtMA_4a966ca7-cfa5-49e2-a774-3c875a9795c3"
      unitRef="usd">-41864000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTUtMy0xLTEtMA_44eded05-7b89-4d38-86dd-1c6743ffd4ea"
      unitRef="usd">-29538000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTctMS0xLTEtMA_0166c0f6-6915-4698-8ba1-1b60ead8dca3"
      unitRef="usd">68000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTctMy0xLTEtMA_5820fb4f-83b9-48b5-84e1-6f30ce8eb89a"
      unitRef="usd">200000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTgtMS0xLTEtMA_732becaf-e046-4d46-9db7-7db5d14c08d4"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTgtMy0xLTEtMA_3c5b31f3-e1f3-4fb5-a4b4-fec2baf7c391"
      unitRef="usd">8000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTktMS0xLTEtMA_0d74c949-ac80-4bb0-a158-8aad2acff07e"
      unitRef="usd">-68000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMTktMy0xLTEtMA_0b4472e7-cdd2-41c5-a4ec-f40b745c239e"
      unitRef="usd">-192000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjEtMS0xLTEtMA_c8e03e73-8c1e-4477-9269-26f390e02b08"
      unitRef="usd">151000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjEtMy0xLTEtMA_501489e2-bc90-4621-b7c0-10a9a0891c80"
      unitRef="usd">215000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjItMS0xLTEtMA_2627bf16-7555-4a4a-b49b-4b7669dfecdf"
      unitRef="usd">151000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjItMy0xLTEtMA_1f20856d-f7a9-4177-bf27-caac0533fc6f"
      unitRef="usd">215000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjMtMS0xLTEtMA_cff6be96-c1ee-42ed-ba17-608d2df41722"
      unitRef="usd">-41781000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjMtMy0xLTEtMA_2d91e8d4-ccbe-4785-8e66-2ef0106b89bd"
      unitRef="usd">-29515000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjQtMS0xLTEtMA_dddc7605-6b8e-40e4-a749-6e7b736c1b64"
      unitRef="usd">378427000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifb1f6a961f634e87b2d33d5dc95c15fa_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjQtMy0xLTEtMA_89cbee8e-0082-4791-be32-336a35bba9d8"
      unitRef="usd">431715000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjUtMS0xLTEtMA_986335a5-65cb-4f72-8a2d-30c3dd521cf1"
      unitRef="usd">336646000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjUtMy0xLTEtMA_685fe036-a1bb-4b14-a881-92fdf7310783"
      unitRef="usd">402200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjgtMS0xLTEtMA_d8161a8d-d0c6-4c1e-a321-53dc426ee536"
      unitRef="usd">417000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMjgtMy0xLTEtMA_3d4c803e-8e0b-477f-aa23-8804f090ad98"
      unitRef="usd">755000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzEtMS0xLTEtMA_7a408055-8e0f-42cf-bdee-05a34051c3c4"
      unitRef="usd">43000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzEtMy0xLTEtMA_0c605c29-202f-4a50-987d-85eabebb971e"
      unitRef="usd">12000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzItMS0xLTEtMA_cb78321d-130a-4ad4-92c3-fbfb7c3b69ae"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzItMy0xLTEtMA_a687a6be-56c4-4e62-8985-1db828ca93f2"
      unitRef="usd">28530000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <prta:ReductionofBuildtosuitLeaseObligation
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzMtMS0xLTEtMA_89d22974-8faf-4eec-ac8f-bb752ed168a8"
      unitRef="usd">0</prta:ReductionofBuildtosuitLeaseObligation>
    <prta:ReductionofBuildtosuitLeaseObligation
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzMtMy0xLTEtMA_afdd0608-ef30-49df-9d66-7194b051718d"
      unitRef="usd">51546000</prta:ReductionofBuildtosuitLeaseObligation>
    <prta:ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzQtMS0xLTEtMA_683b3b73-cb7e-43ae-9a81-7c19eb9449b9"
      unitRef="usd">0</prta:ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction>
    <prta:ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzQtMy0xLTEtMA_84cec338-a924-4596-965b-9965011ad1c5"
      unitRef="usd">46760000</prta:ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction>
    <prta:ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzUtMS0xLTEtMA_ca0f5124-99b7-4cda-826a-776edcfc6d34"
      unitRef="usd">0</prta:ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction>
    <prta:ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjgxN2ZmYTc2NTA4YTRlY2M5NmY0ZmFkYzVjZmRiNWFlL3RhYmxlcmFuZ2U6ODE3ZmZhNzY1MDhhNGVjYzk2ZjRmYWRjNWNmZGI1YWVfMzUtMy0xLTEtMA_0faab2e8-9a9b-449c-b769-fa51ea1d39c3"
      unitRef="usd">1099000</prta:ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfMi0xLTEtMS0w_6e6b4a91-8880-4a03-95c2-167432c79c22"
      unitRef="usd">333942000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfMi0zLTEtMS0w_9e22031a-3a11-49f8-a1a3-13159488f507"
      unitRef="usd">398144000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfMy0xLTEtMS0w_0aeeb086-72f1-4adc-a9a3-acf2e26f5ee7"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfMy0zLTEtMS0w_0a8c46b5-5ad4-492f-9e69-bd4c3eb9437d"
      unitRef="usd">1352000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfNC0xLTEtMS0w_c5d90d58-bca0-441d-9182-3654e4ff64cc"
      unitRef="usd">2704000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfNC0zLTEtMS0w_20ac8952-d827-4e89-ba6b-e3f869f8c4c3"
      unitRef="usd">2704000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfNS0xLTEtMS0w_82120af3-f431-434e-94a3-16010336f213"
      unitRef="usd">336646000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yNS9mcmFnOjk4YWY1MGM2YThmZjQ3ZjRiZTIxY2JjMjkyOTI0MWI0L3RhYmxlOjUwOTU4Mjg4YTBiMTQ3ZGI5ZjIwZGEwMWYyM2RhNmIzL3RhYmxlcmFuZ2U6NTA5NTgyODhhMGIxNDdkYjlmMjBkYTAxZjIzZGE2YjNfNS0zLTEtMS0w_32fea267-6271-4234-b7f9-1975163e0ef0"
      unitRef="usd">402200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SharesOutstanding
      contextRef="i033a9b5c0519456bbe6ff44d9d446f2e_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfMy0xLTEtMS00OTE_b9b752e1-5f70-4941-bd05-153b304d4782"
      unitRef="shares">39911413</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i033a9b5c0519456bbe6ff44d9d446f2e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfMy0zLTEtMS00OTE_cad71660-e073-4aa6-a419-198ef8bed8b9"
      unitRef="usd">399000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a8e6071ca4d4f418bf2650962cca842_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfMy01LTEtMS00OTE_5f6d6718-ea92-4ed3-8f86-162994ef772a"
      unitRef="usd">950094000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idbd0a1f2b3f648e0bcca646f1febd857_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfMy03LTEtMS00OTE_74f3d549-853e-444a-bdc9-fe02c465de3d"
      unitRef="usd">-695454000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59896a4eae7b4d1cadd70ccca76ef293_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfMy05LTEtMS00OTM_1f6eee21-b2eb-4c97-90c0-243f354578e4"
      unitRef="usd">255039000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ief7a957fd4e343de80e8f3dd3bd7c665_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNC01LTEtMS01MDE_617df660-5064-47da-81d4-7edf1cd0aa4d"
      unitRef="usd">5687000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNC05LTEtMS01MDQ_e3c5f02f-b74a-4bda-ada0-4e7501db658a"
      unitRef="usd">5687000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="iecc1dc4b8e3a409780b630469f43a9e2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNi03LTEtMS00OTU_fdcc34a0-24a0-4e06-bab1-2f34bcef7ed3"
      unitRef="usd">-26282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNi05LTEtMS00OTg_0e2e708a-83e1-45cb-a094-0bf357499891"
      unitRef="usd">-26282000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i2b53209923b24243a79113052e4c7869_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNy0xLTEtMS01MTY_d69d1384-16c6-4333-b959-cd12d1de504f"
      unitRef="shares">39911413</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b53209923b24243a79113052e4c7869_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNy0zLTEtMS01MTY_ebd083bf-5ba9-43c7-891f-bfd3f4a13711"
      unitRef="usd">399000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i244c64bf960045f0800d51e075bbe10e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNy01LTEtMS01MTY_f08dd6c8-6800-4417-b31a-e3e093a183c4"
      unitRef="usd">955781000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i033cbd2485614a1a80c8930dd799a610_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNy03LTEtMS01MTY_16ebb939-6ae3-414e-9983-a86f9709b599"
      unitRef="usd">-721736000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjFkY2MzYjU2NjM3MzRiMzU5MDZmNDI5YWVlZWE3NmUzL3RhYmxlcmFuZ2U6MWRjYzNiNTY2MzczNGIzNTkwNmY0MjlhZWVlYTc2ZTNfNy05LTEtMS01MTk_530ad475-3bf0-4ef8-8861-8f289885093c"
      unitRef="usd">234444000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i2a18c2130f0248389ca0f5818a9bea98_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfMy0xLTEtMS00NjI1_881cada9-7a4c-461b-9add-3ad544e054e5"
      unitRef="shares">39864561</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a18c2130f0248389ca0f5818a9bea98_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfMy0zLTEtMS00NjI1_0815d9a5-7c5f-4743-ba5d-59b8c2ce0673"
      unitRef="usd">399000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if139ce926c9c4e47b596fdf915376cf8_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfMy01LTEtMS00NjI1_f5d3c824-3d8a-45b5-8dc6-f54f37af9ee1"
      unitRef="usd">926804000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i11412c4befdf4ea0807e0b06f12cfe03_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfMy03LTEtMS00NjI1_9301cf0b-8bc5-407b-82f2-e920e72e7cf0"
      unitRef="usd">-615073000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b323be88ba54d09b5f05f59648156ba_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfMy05LTEtMS00NjI1_91864bd3-3f3d-465d-a39b-4c2cd6a324cc"
      unitRef="usd">312130000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i8bb18a09ab4f41a08e2c1022903f9906_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNC01LTEtMS00NjI1_c74bd77c-87e7-4d53-8cf3-77ccb6b0ffb5"
      unitRef="usd">6277000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNC05LTEtMS00NjI1_865301f3-3f5a-4649-9ccf-8f1ac5a7b1ca"
      unitRef="usd">6277000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i654c8eaba7c84a3ba5bb798a14bf89b4_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNS0xLTEtMS00NjI1_38781607-5447-415e-bc17-1d0c4e5f3be4"
      unitRef="shares">32000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8bb18a09ab4f41a08e2c1022903f9906_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNS01LTEtMS00NjI1_1778df3b-8acb-413c-be40-75299eff5a71"
      unitRef="usd">210000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNS05LTEtMS00NjI1_a2a198a0-7fc6-4b46-90ee-3b357e31aced"
      unitRef="usd">210000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="i3911131dcd2547b8b1b797508b9ffa15_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNi03LTEtMS00NjI1_5b899edb-acaf-4549-a89c-24fefe0b54a4"
      unitRef="usd">-15810000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNi05LTEtMS00NjI1_fbdeb1f3-0c71-4261-a073-b675ec9e0bc7"
      unitRef="usd">-15810000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iaeb9f2b53bed498ca4df974ff5e0eb3f_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNy0xLTEtMS00NjI1_73e71ea7-6b64-4740-97b2-b1f4e5e5732f"
      unitRef="shares">39896561</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaeb9f2b53bed498ca4df974ff5e0eb3f_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNy0zLTEtMS00NjI1_048f7af8-63ad-407d-bf1d-aa82924a1ec3"
      unitRef="usd">399000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58f9f83b1ec94f83ba9e88d181f91f31_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNy01LTEtMS00NjI1_f37513b4-7489-4c9b-a9ae-2a02d2aefd9f"
      unitRef="usd">933291000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia217e25a3bae43ae8dce414a766f8967_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNy03LTEtMS00NjI1_7e3174f7-d0d9-4d24-8ef1-be042a14e0e5"
      unitRef="usd">-630883000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjExZGE1YTc2M2FkMzRkZmU4OWQyNjVhNTFhYjgwNGJkL3RhYmxlcmFuZ2U6MTFkYTVhNzYzYWQzNGRmZTg5ZDI2NWE1MWFiODA0YmRfNy05LTEtMS00NjI1_48e92209-f872-45d5-8710-c124db07a308"
      unitRef="usd">302807000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i7447e849c70240ebb46c71019b182af5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfMy0xLTEtMS0w_ebb7e6f6-5ebd-4650-ab4a-8e6acebd591f"
      unitRef="shares">39898561</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7447e849c70240ebb46c71019b182af5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfMy0zLTEtMS0w_01e48847-7b23-4e72-8229-e7399e1e7086"
      unitRef="usd">399000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i529cd4e894eb4d85b99f95e755920f22_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfMy01LTEtMS0w_a57a18dc-482f-43c0-aa3e-087234986e9a"
      unitRef="usd">944407000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f79eb93966141d7a3a13adc3ac38d49_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfMy03LTEtMS0w_2050cd0b-a669-46ef-bd92-531acc1ad7bb"
      unitRef="usd">-671885000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfMy05LTEtMS0w_95e6e9cb-9da6-4801-964c-356688c7926c"
      unitRef="usd">272921000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i1514bd0122184324869e45816a840dff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNC01LTEtMS0w_aa2c8a14-aaf7-4809-b137-31e9a8e04b20"
      unitRef="usd">11223000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNC05LTEtMS0w_7212bfd2-c2c5-4a0b-a844-5d94800b28fb"
      unitRef="usd">11223000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i359327a4643e466ca3a685787fdbf791_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNS0xLTEtMS0w_ea8553ae-d6f0-4dbf-bf2f-d30920249123"
      unitRef="shares">12852</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1514bd0122184324869e45816a840dff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNS01LTEtMS0w_d30e1964-090b-4f60-8569-f4ba4c34e962"
      unitRef="usd">151000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNS05LTEtMS0w_e6aa163d-e406-4adc-aca4-a87cd885b32d"
      unitRef="usd">151000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="id3888cc09d684fd7b2c05fab7e9b2a3a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNi03LTEtMS0w_a5a1481b-9348-4b42-9401-eb4f09f72a10"
      unitRef="usd">-49851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNi05LTEtMS0w_1f251553-cab7-48e3-8efd-60544cf16411"
      unitRef="usd">-49851000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i2b53209923b24243a79113052e4c7869_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNy0xLTEtMS0w_d69d1384-16c6-4333-b959-cd12d1de504f"
      unitRef="shares">39911413</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b53209923b24243a79113052e4c7869_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNy0zLTEtMS0w_ebd083bf-5ba9-43c7-891f-bfd3f4a13711"
      unitRef="usd">399000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i244c64bf960045f0800d51e075bbe10e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNy01LTEtMS0w_f08dd6c8-6800-4417-b31a-e3e093a183c4"
      unitRef="usd">955781000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i033cbd2485614a1a80c8930dd799a610_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNy03LTEtMS0w_16ebb939-6ae3-414e-9983-a86f9709b599"
      unitRef="usd">-721736000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOjU4OGM3MGUwZTI2NzQwYzJhYzQ0MDlmZGY0MjU5NWFmL3RhYmxlcmFuZ2U6NTg4YzcwZTBlMjY3NDBjMmFjNDQwOWZkZjQyNTk1YWZfNy05LTEtMS0w_530ad475-3bf0-4ef8-8861-8f289885093c"
      unitRef="usd">234444000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i0d6464030811498ea45278866f1f669b_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfMy0xLTEtMS0w_2764468f-42cc-485e-a0f1-ffe305a639da"
      unitRef="shares">39863711</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d6464030811498ea45278866f1f669b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfMy0zLTEtMS0w_bcd7ac17-6f47-419f-901a-120f29775def"
      unitRef="usd">399000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8799a9e7d9a5439bbef0dd2887838f26_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfMy01LTEtMS0w_0ccc1d83-36aa-43a6-b224-80d9d34275f5"
      unitRef="usd">920594000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b149813b9fd4ba6a6381399eba9055f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfMy03LTEtMS0w_4e1cf69c-1f64-44f0-8471-f0b54965d2af"
      unitRef="usd">-597995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb1f6a961f634e87b2d33d5dc95c15fa_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfMy05LTEtMS0w_7e6efb0d-1a71-4eeb-b14a-40eda9777d4a"
      unitRef="usd">322998000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i06f9dd74ab7b4824a2d89b866088ebdf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNC03LTEtMS0w_ca72f6eb-43fd-44a9-9702-1864edf6118f"
      unitRef="usd">3787000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="ia3b99b92bd8c4e959e5259476524c341_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNC05LTEtMS0w_ad3cdece-7f4a-417d-b028-f28670c51ae1"
      unitRef="usd">3787000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ie594e8889b9b4963ae70ebdb928a145b_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNS01LTEtMS0w_abd80694-1e07-4d06-ae5b-36a783ad4816"
      unitRef="usd">12482000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNS05LTEtMS0w_a6f636cc-75b8-4ae5-a9ed-ff31e3c698d3"
      unitRef="usd">12482000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iec113c33f31b44c790f21ee119a59cfc_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNi0xLTEtMS0w_39e814b9-4be5-4621-be3c-6c79815d0b5d"
      unitRef="shares">32850</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie594e8889b9b4963ae70ebdb928a145b_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNi01LTEtMS0w_a80725e8-4008-4fca-8f7e-28b0c5fb26b6"
      unitRef="usd">215000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNi05LTEtMS0w_ad9de5d5-0df2-49a8-8922-0849ed29ade5"
      unitRef="usd">215000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="i3f59203e494b4d0aa54e4354c6b66ab5_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNy03LTEtMS0w_b083ccea-7a09-49ae-971c-99e0e398b49c"
      unitRef="usd">-36675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfNy05LTEtMS0w_e27930ec-d133-40d1-a63e-5b58457c8889"
      unitRef="usd">-36675000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iaeb9f2b53bed498ca4df974ff5e0eb3f_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfOC0xLTEtMS0w_4107287b-cc9c-403d-b57c-a1909551dbe8"
      unitRef="shares">39896561</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaeb9f2b53bed498ca4df974ff5e0eb3f_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfOC0zLTEtMS0w_bb5f4e44-c2da-454c-ae8d-89f4094eca14"
      unitRef="usd">399000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58f9f83b1ec94f83ba9e88d181f91f31_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfOC01LTEtMS0w_ff3e99ec-a687-4de2-b7af-33d2b56f1e31"
      unitRef="usd">933291000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia217e25a3bae43ae8dce414a766f8967_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfOC03LTEtMS0w_79f1a6af-69df-4b7c-8154-7efd9d003676"
      unitRef="usd">-630883000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0a37738944a4b5da8bacd6100c18c37_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18yOC9mcmFnOjhiYTAxZTc0ZTI0YzQyMDk5NjgyZDVjN2MyMDllYTU3L3RhYmxlOmVmOGE3ZmMwNmU5MjQyMGJiYTNiNTcyNzU0YTUxMjk2L3RhYmxlcmFuZ2U6ZWY4YTdmYzA2ZTkyNDIwYmJhM2I1NzI3NTRhNTEyOTZfOC05LTEtMS0w_70bf18e4-ab38-4945-b26d-ebb4b1a8ed6d"
      unitRef="usd">302807000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNC9mcmFnOmI5ZDk0MmEzYjUxOTQ1NTM4MzU0MDg5YzU2MjM3ZTFiL3RleHRyZWdpb246YjlkOTQyYTNiNTE5NDU1MzgzNTQwODljNTYyMzdlMWJfMzQwMQ_a0e4d1e6-30c3-40a9-a136-4ecdc28d902a">Organization&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"&gt;Prothena Corporation plc (&#x201c;Prothena&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage neuroscience company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases. Fueled by our deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which our ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena's partnered programs include prasinezumab (PRX002/RG7935), in collaboration with Roche for the potential treatment of Parkinson&#x2019;s disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer&#x2019;s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) or other neurodegenerative diseases. The Company's proprietary programs include PRX004 for the potential treatment of ATTR amyloidosis, and programs that target A&#x3b2; (Amyloid beta) for the potential treatment of Alzheimer&#x2019;s disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company was formed on September 26, 2012, under the laws of Ireland and re-registered as an Irish public limited company on October 25, 2012. The Company's ordinary shares began trading on The Nasdaq Global Market under the symbol &#x201c;PRTA&#x201d; on December 21, 2012, and currently trade on The Nasdaq Global Select Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Liquidity and Business Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company had an accumulated deficit of $721.7 million and cash and cash equivalents of $333.9 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Based on the Company's business plans, management believes that the Company&#x2019;s cash and cash equivalents at June&#160;30, 2020, are sufficient to meet its obligations for at least the next twelve months. To operate beyond such period, or if the Company elects to increase its spending on research and development programs significantly above current long-term plans or enters into potential licenses and or other acquisitions of complementary technologies, products or companies, the Company may need additional capital. The Company expects to continue to finance future cash needs that exceed its cash from operating activities primarily through its current cash and cash equivalents, its collaborations with Roche and Bristol-Myers Squibb, and, to the extent necessary, through proceeds from public or private equity or debt financings, loans and other collaborative agreements with corporate partners or other arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The Company is subject to a number of risks, including but not limited to: the uncertainty of the Company&#x2019;s research and development (&#x201c;R&amp;amp;D&#x201d;) efforts resulting in future successful commercial products; obtaining regulatory approval for its product candidates; its ability to successfully commercialize its product candidates, if approved; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; the outbreak of the novel strain of coronavirus SARS-CoV-2; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the healthcare industry.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNC9mcmFnOmI5ZDk0MmEzYjUxOTQ1NTM4MzU0MDg5YzU2MjM3ZTFiL3RleHRyZWdpb246YjlkOTQyYTNiNTE5NDU1MzgzNTQwODljNTYyMzdlMWJfMTA5OTUxMTYzMTE5MA_331afb90-634b-44d3-91dd-200cd7ec74b5"
      unitRef="usd">-721700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNC9mcmFnOmI5ZDk0MmEzYjUxOTQ1NTM4MzU0MDg5YzU2MjM3ZTFiL3RleHRyZWdpb246YjlkOTQyYTNiNTE5NDU1MzgzNTQwODljNTYyMzdlMWJfMTA5OTUxMTYzMTE5NQ_1cf49ee5-e3cf-49a7-ad42-27c69e9edb10"
      unitRef="usd">333900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNjY0Nw_a4c9c326-8356-4eef-93f9-e50440230c82">Summary of Significant Accounting Policies&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Preparation and Presentation of Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;These accompanying Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with the accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;) and with the instructions for Form 10-Q and Regulation S-X statements. Accordingly, they do not include all of the information and notes required for complete financial statements. These interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March&#160;3, 2020 (the &#x201c;2019 Form 10-K&#x201d;). These Unaudited Interim Condensed Consolidated Financial Statements are presented in U.S. dollars, which is the functional currency of the Company and its consolidated subsidiaries. These Unaudited Interim Condensed Consolidated Financial Statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying Unaudited Interim Condensed Consolidated Financial Statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements, however certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures.  On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There were no significant changes to the accounting policies during the six months ended June 30, 2020, from the significant accounting policies described in Note 2 of the Notes to Consolidated Financial Statements in the 2019 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segment and Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company operates in one segment. The Company&#x2019;s chief operating decision maker (the &#x201c;CODM&#x201d;), its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM reviews all financial information on a consolidated basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits.  The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The receivables recorded in the Condensed Consolidated Balance Sheet include amounts due from a Roche entity located in Switzerland. Revenue recorded in the Condensed Consolidated Statements of Operations consists of reimbursement from Roche for research and development services. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  As of June&#160;30, 2020, $3.2 million of the Company&#x2019;s property and equipment, net were held in the U.S. and none were in Ireland.  As of December&#160;31, 2019, $3.9 million of the Company's property and equipment, net were held in the U.S. and none were in Ireland. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 18, 2019, the Finance Accounting Standards Board ("FASB") issued Accounting Standards Update 2019-12 ("ASU 2019-12"), Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes as part of the FASB&#x2019;s overall initiative to reduce complexity in accounting standards.  Amendments include removal of certain exceptions to the general principles of ASC 740, Income Taxes, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. While not required to be adopted until 2021 for most calendar year public business entities (and 2022 for other entities), early adoption is permitted for any financial statements. The Company does not expect the adoption of ASU 2019-12 to have a significant impact on its &lt;/span&gt;&lt;/div&gt;consolidated financial statements. The Company will continue to evaluate the impact of ASU 2019-12 on its consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNjY0OA_5fe872ac-ef75-4ff1-b1b9-0d8853808e2d">&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Preparation and Presentation of Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;These accompanying Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with the accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;) and with the instructions for Form 10-Q and Regulation S-X statements. Accordingly, they do not include all of the information and notes required for complete financial statements. These interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March&#160;3, 2020 (the &#x201c;2019 Form 10-K&#x201d;). These Unaudited Interim Condensed Consolidated Financial Statements are presented in U.S. dollars, which is the functional currency of the Company and its consolidated subsidiaries. These Unaudited Interim Condensed Consolidated Financial Statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying Unaudited Interim Condensed Consolidated Financial Statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements, however certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNjYzNQ_4ece2fe4-e494-4d71-b8e3-4ef7c9364362">&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures.  On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNjYyMw_543934f1-4e37-4815-8c0e-2fcebd0bf752">&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segment and Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company operates in one segment. The Company&#x2019;s chief operating decision maker (the &#x201c;CODM&#x201d;), its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM reviews all financial information on a consolidated basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits.  The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The receivables recorded in the Condensed Consolidated Balance Sheet include amounts due from a Roche entity located in Switzerland. Revenue recorded in the Condensed Consolidated Statements of Operations consists of reimbursement from Roche for research and development services. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;  As of June&#160;30, 2020, $3.2 million of the Company&#x2019;s property and equipment, net were held in the U.S. and none were in Ireland.  As of December&#160;31, 2019, $3.9 million of the Company's property and equipment, net were held in the U.S. and none were in Ireland. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7b64af079f774a46a8be8b6571368300_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNDgxOA_cf7e11c0-8f45-4901-bf89-11f29eb8c22c"
      unitRef="usd">3200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i11d3275580fa4bd1961ee805e56db0d0_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNDg5Mg_ca60df0d-474d-4032-a534-f24221279097"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idf82b12dcb0a4510a9e8d227e7f54b0f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNDkyMw_bcca38d3-f96f-403c-a469-876bdc4bed1e"
      unitRef="usd">3900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i35e6e65a4d584b26a679bc03ea55c9d0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNDk5Nw_30e4f423-7d04-4b7d-95b3-b52489d80fc5"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y18zNy9mcmFnOjU5YzI3ZTQ3ZTUwODRmOWY5ZGZlMzQ3NmFjZmVlNTUyL3RleHRyZWdpb246NTljMjdlNDdlNTA4NGY5ZjlkZmUzNDc2YWNmZWU1NTJfNjY1MQ_99e68dc5-15aa-4bb4-b18e-5ec066b0ae71">&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 18, 2019, the Finance Accounting Standards Board ("FASB") issued Accounting Standards Update 2019-12 ("ASU 2019-12"), Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes as part of the FASB&#x2019;s overall initiative to reduce complexity in accounting standards.  Amendments include removal of certain exceptions to the general principles of ASC 740, Income Taxes, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. While not required to be adopted until 2021 for most calendar year public business entities (and 2022 for other entities), early adoption is permitted for any financial statements. The Company does not expect the adoption of ASU 2019-12 to have a significant impact on its &lt;/span&gt;&lt;/div&gt;consolidated financial statements. The Company will continue to evaluate the impact of ASU 2019-12 on its consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180MC9mcmFnOmYxN2YyMTM5NzQ4YjQxZGRhYmU0MDMwNzk4MTdkNWY3L3RleHRyZWdpb246ZjE3ZjIxMzk3NDhiNDFkZGFiZTQwMzA3OTgxN2Q1ZjdfMjI0MA_df1f999c-d5b4-468a-ad9f-5bcbc42c0645">Fair Value Measurements&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents.&#160;Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-49.5pt;padding-left:72pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level&#160;1&#160;&#x2014;&#160;Observable inputs such as quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-49.5pt;padding-left:72pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level&#160;2&#160; &#x2014;&#160;Include other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and credit ratings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-49.5pt;padding-left:72pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities, and low market interest rates, if applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Based on the fair value hierarchy, the Company classifies its cash equivalents within Level 1. This is because the Company values its cash equivalents using quoted market prices. The Company&#x2019;s Level 1 securities consisted of $287.0 million and $338.2 million in money market funds included in cash and cash equivalents at June&#160;30, 2020, and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="ib2330f117cb341549ed1cb65fe74eff0_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180MC9mcmFnOmYxN2YyMTM5NzQ4YjQxZGRhYmU0MDMwNzk4MTdkNWY3L3RleHRyZWdpb246ZjE3ZjIxMzk3NDhiNDFkZGFiZTQwMzA3OTgxN2Q1ZjdfMjEzOQ_deb67441-8569-4aee-b556-afbc85729e9d"
      unitRef="usd">287000000.0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="id7e67ec9f2a141d3afb5af2d44c43cf4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180MC9mcmFnOmYxN2YyMTM5NzQ4YjQxZGRhYmU0MDMwNzk4MTdkNWY3L3RleHRyZWdpb246ZjE3ZjIxMzk3NDhiNDFkZGFiZTQwMzA3OTgxN2Q1ZjdfMjE0Ng_2a89d208-5505-4a0d-8d3e-225b422921dc"
      unitRef="usd">338200000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfMzI5_96d99ad9-6ab0-4c73-8a62-7a068ae7bda9">Composition of Certain Balance Sheet Items&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.876%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Purchased computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Depreciation expense was $0.4 million and $0.8 million for the three and six months ended June&#160;30, 2020, respectively, compared to $0.4 million and $0.8 million for the three and six months ended June&#160;30, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;margin-top:14pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfMzIz_5183ee71-c737-4b2c-85e4-fa51c2be85e3">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:73.659%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.876%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Purchased computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfMi0xLTEtMS0w_a26fdbfc-079d-41b9-b8bd-2c1f1711d76c"
      unitRef="usd">9334000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfMi0zLTEtMS0w_cbdaa25f-3e7c-43c3-addd-22805a7734af"
      unitRef="usd">9312000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfMy0xLTEtMS0w_52668dc2-6984-4944-bad4-f9dacb1102dc"
      unitRef="usd">1261000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfMy0zLTEtMS0w_ba8beb48-7641-4477-8723-6023b2f0ea55"
      unitRef="usd">1261000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNC0xLTEtMS0w_90e7574a-3654-4ac4-bee1-f5c13f3d6c31"
      unitRef="usd">1392000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNC0zLTEtMS0w_c41a5f47-b2a2-4c76-bfa1-823f51fec414"
      unitRef="usd">1308000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNS0xLTEtMS0w_b955d4f4-2f45-49ca-9f19-51fd68010199"
      unitRef="usd">11987000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNS0zLTEtMS0w_49c9aba1-3a06-42b2-9349-5ff97659a5a1"
      unitRef="usd">11881000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNi0xLTEtMS0w_a6ff944a-6c56-4382-93d3-1f58d618f862"
      unitRef="usd">8772000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNi0zLTEtMS0w_65519dda-d769-442a-872a-98d3b40d1d71"
      unitRef="usd">8007000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNy0xLTEtMS0w_c6efacf6-f1be-4f30-86c3-6b7550920c44"
      unitRef="usd">3215000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOmUzYTQ2ZmFiNTFhNzQ4ZDJhOGQ2NzUyMzU1MzJmNWYwL3RhYmxlcmFuZ2U6ZTNhNDZmYWI1MWE3NDhkMmE4ZDY3NTIzNTUzMmY1ZjBfNy0zLTEtMS0w_4708e4d2-15b5-449c-b3b1-3560755a9584"
      unitRef="usd">3874000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfMTc2_b5418a42-d83c-43c8-93ed-343a7034b5df"
      unitRef="usd">400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfNjA0NzMxMzk1MzE3MA_de709b21-e61e-4b35-937b-c9589a13ffa3"
      unitRef="usd">800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfNjA0NzMxMzk1MzE3NQ_aebb808c-b763-4228-9e11-ef72de8e9a2e"
      unitRef="usd">400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfNjA0NzMxMzk1MzE3OQ_aeb7e555-2031-4062-b071-c42afdc12faa"
      unitRef="usd">800000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RleHRyZWdpb246OWY5MjVmYzAzNmQ4NGE1MDgzMWZiOWQxNTMxZWRlYTdfMzE4_363518f9-46fa-487c-8470-e8b4e699bd85">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfMi0xLTEtMS0w_0e329ddf-4296-4cb7-9d97-511f074cc6ce"
      unitRef="usd">3355000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfMi0zLTEtMS0w_746415a4-761e-4f2f-be32-bc1bee36da48"
      unitRef="usd">4818000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfMy0xLTEtMS0w_527597b8-93ae-44af-8c65-35450712a987"
      unitRef="usd">715000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfMy0zLTEtMS0w_d5ac0efe-3414-4b8e-9b5b-14c5393b52dc"
      unitRef="usd">400000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfNC0xLTEtMS0w_75c3573e-7251-4d55-842a-75cbb85447c4"
      unitRef="usd">673000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfNC0zLTEtMS0w_0b8b44bc-15a1-4501-952b-71556dec2133"
      unitRef="usd">322000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfNS0xLTEtMS0w_b065483a-933e-44ea-8112-58a2f7ee9506"
      unitRef="usd">4743000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180My9mcmFnOjlmOTI1ZmMwMzZkODRhNTA4MzFmYjlkMTUzMWVkZWE3L3RhYmxlOjllNzk0YzZhMzJmNDQ2NTg5NTNjYjcyYmQwNzFlMzAxL3RhYmxlcmFuZ2U6OWU3OTRjNmEzMmY0NDY1ODk1M2NiNzJiZDA3MWUzMDFfNS0zLTEtMS0w_a4dd31f4-7144-49d3-bf49-eecba18d7cac"
      unitRef="usd">5540000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RleHRyZWdpb246Mjc3OGExNDI3YTg4NDZjOGE3YzczZjIxNDEwYTgzOGFfOTAx_07dd3598-7046-4f0d-996b-80989a82bab9">Net Loss Per Ordinary Share&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net income (loss) per ordinary share is calculated by dividing net income (loss) by the weighted-average number of ordinary shares outstanding during the period. Shares used in diluted net income per ordinary share would include the dilutive effect of ordinary shares potentially issuable upon the exercise of stock options outstanding. However, potentially issuable ordinary shares are not used in computing diluted net loss per ordinary share as their effect would be anti-dilutive due to the loss recorded during the three and six months ended June&#160;30, 2020, and 2019, and therefore diluted net loss per share is equal to basic net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss per ordinary share was determined as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.040%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.517%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.381%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.517%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.381%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.517%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.521%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(26,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(49,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(36,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average ordinary shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The equivalent ordinary shares not included in diluted net loss per share because their effect would be anti-dilutive are as&#160;follows&#160;(in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.222%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.723%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options to purchase ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RleHRyZWdpb246Mjc3OGExNDI3YTg4NDZjOGE3YzczZjIxNDEwYTgzOGFfOTAy_3651fcb5-8f78-4d7e-86ff-5bb7ae848670">&lt;div style="text-indent:24.75pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss per ordinary share was determined as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.040%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.517%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.381%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.517%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.381%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.517%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.521%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(26,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(49,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(36,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average ordinary shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="iecc1dc4b8e3a409780b630469f43a9e2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfMy0xLTEtMS0yMjM4_2597014a-4ae1-4274-93a4-941fd76b0bab"
      unitRef="usd">-26282000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfMy0zLTEtMS0yMjM4_96e8b75b-014f-44a5-86fd-3500be3c9bce"
      unitRef="usd">-15810000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfMy0xLTEtMS0w_02e31282-9fae-458d-94f2-411267ec2ea5"
      unitRef="usd">-49851000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfMy0zLTEtMS0w_338c52b4-6bcb-455d-acc0-ccb4e45210e6"
      unitRef="usd">-36675000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNS0xLTEtMS0yMjQ1_f32170c6-b4c0-44ae-a8cf-5bf073c6c98c"
      unitRef="shares">39911000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNS0zLTEtMS0yMjQ1_5423f330-4689-41ec-af98-96d47d690d98"
      unitRef="shares">39872000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNS0xLTEtMS0w_ff38ab72-3972-4d1d-89ae-324c92ec853e"
      unitRef="shares">39910000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNS0zLTEtMS0w_b13373d7-0186-4e4c-b943-66260302308d"
      unitRef="shares">39868000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNy0xLTEtMS0yMjUw_d266d575-5030-4477-ba4d-2835a40e2f1c"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNy0zLTEtMS0yMjUw_7850d1a1-b770-401d-879b-9bc95e8f7284"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNy0xLTEtMS0w_9f407341-5848-4bee-a7cb-3be7d80f0121"
      unitRef="usdPerShare">-1.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjE5YTNmOWNhNTI3YjQ5NzlhN2U3NjRkZTU2MDAyNDY5L3RhYmxlcmFuZ2U6MTlhM2Y5Y2E1MjdiNDk3OWE3ZTc2NGRlNTYwMDI0NjlfNy0zLTEtMS0w_d2a2a5d6-9ba1-4022-9d28-1958de5c13ed"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RleHRyZWdpb246Mjc3OGExNDI3YTg4NDZjOGE3YzczZjIxNDEwYTgzOGFfOTA0_136c1965-8598-491d-82e3-049f995d822f">&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The equivalent ordinary shares not included in diluted net loss per share because their effect would be anti-dilutive are as&#160;follows&#160;(in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.222%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.723%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options to purchase ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i54b797a322b643859e1d254057908a54_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjVmNTRmOTBkNTIxNTQ3ZTdhOTVjOWIxYTY5ZWE5Yzg3L3RhYmxlcmFuZ2U6NWY1NGY5MGQ1MjE1NDdlN2E5NWM5YjFhNjllYTljODdfMi0xLTEtMS0yMjcy_77e65605-95fc-4a54-964c-a004c9947b90"
      unitRef="shares">8672000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifdeb4d65f9b2469ca2008e311f8a3473_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjVmNTRmOTBkNTIxNTQ3ZTdhOTVjOWIxYTY5ZWE5Yzg3L3RhYmxlcmFuZ2U6NWY1NGY5MGQ1MjE1NDdlN2E5NWM5YjFhNjllYTljODdfMi0zLTEtMS0yMjcy_0d942d2a-fff0-423a-82da-e04a7f5911e9"
      unitRef="shares">7168000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iededd3a706834ae081db1b4deff0a8bb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjVmNTRmOTBkNTIxNTQ3ZTdhOTVjOWIxYTY5ZWE5Yzg3L3RhYmxlcmFuZ2U6NWY1NGY5MGQ1MjE1NDdlN2E5NWM5YjFhNjllYTljODdfMi0xLTEtMS0w_6addf28d-ca3e-4c94-aefc-3cd9f0615e08"
      unitRef="shares">8672000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic3fa83c08da0419a82890f9cdd288a03_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180Ni9mcmFnOjI3NzhhMTQyN2E4ODQ2YzhhN2M3M2YyMTQxMGE4MzhhL3RhYmxlOjVmNTRmOTBkNTIxNTQ3ZTdhOTVjOWIxYTY5ZWE5Yzg3L3RhYmxlcmFuZ2U6NWY1NGY5MGQ1MjE1NDdlN2E5NWM5YjFhNjllYTljODdfMi0zLTEtMS0w_bd5a820e-8f71-4dae-b449-36a1f437f468"
      unitRef="shares">7168000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2Mjc3MA_208ebc77-1b5e-490f-8b61-3e0dbaaf2000">Commitments and Contingencies&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Lease Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted ASC 842, Leases effective January 1, 2019. Prior period amounts have not been adjusted and continued to be reported in accordance with the Company&#x2019;s historical accounting under ASC 840. For lease arrangements entered prior to the adoption of ASC 842, right-of-use asset and lease liability are determined based on the present value of minimum lease payments over the remaining lease term and the Company&#x2019;s incremental borrowing rate based on information available as of January 1, 2019. The right-of-use asset also includes any lease prepayments made and excludes unamortized lease incentives including rent abatements and/or concessions and rent holidays. Tenant improvements made by the Company as a lessee, in which such improvements are deemed to be owned by the lessor, are viewed as lease prepayments by the Company and are included in the right-of-use asset. Lease expense is recognized on a straight-line basis over the expected lease term. Total operating lease cost was $1.6 million and $3.2 million for the three and six months ended June&#160;30, 2020, respectively, and $1.6 million and $3.2 million three and six months ended June&#160;30, 2019, respectively. Total cash paid against the operating lease liability was $1.5 million and $3.0 million for the three and six months ended June&#160;30, 2020, respectively, and $1.4 million and $2.9 million three and six months ended June&#160;30, 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the purpose of estimating the incremental borrowing rate in the adoption of ASC 842, the Company inquired with banks that had a business relationship with the Company to determine the Company's collateralized incremental borrowing rate. The discount rate used to determine the lease liability was 4.25%. There was no change in the accounting of the Sub-Sublease (as defined below) of the Current SSF Facility (as defined below) upon adoption of ASC 842. Furthermore, the Company's operating lease in Dublin is not included in the lease liability and right-of-use asset recorded due to its nominal amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company performed an evaluation of its other contracts with customers and suppliers in accordance with ASC 842 and have determined that, except for the leases described below, a nominal operating lease for medical monitoring equipment and a nominal operating lease for office equipment, none of the Company&#x2019;s contracts contain a lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Current SSF Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2016, the Company entered into a noncancelable operating sublease (the &#x201c;Lease&#x201d;) to lease 128,751 square feet of office and laboratory space in South San Francisco, California, U.S. (the &#x201c;Current SSF Facility&#x201d;). Subsequently, in April 2016, the Company took possession of the Current SSF Facility. The Lease includes a free rent period and escalating rent payments and has a remaining lease term of 3.50 years that expires on December&#160;31, 2023, unless terminated earlier.  The Company's obligation to pay rent commenced on August 1, 2016. The Company is obligated to make lease payments totaling approximately $39.2 million over the lease term. The Lease further provides that the Company is obligated to pay to the sublandlord and master landlord certain costs, including taxes and operating expenses. The Lease is considered an operating lease under ASC 842. Prior to the Company's adoption of ASC 842, this Lease was considered a build-to-suit lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; In connection with this Lease, the Company received a tenant improvement allowance of $14.2 million from the sublandlord and the master landlord, for the costs associated with the design, development and construction of tenant improvements for the Current SSF Facility. The Company is obligated to fund all costs incurred in excess of the tenant improvement allowance. The initial measurement of right-of-use asset for the Lease includes the tenant improvement added by the Company wherein the lessor was deemed the accounting owner, net of the tenant improvement allowance received from the sublandlord and the master landlord. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company obtained a standby letter of credit in April 2016 in the initial amount of $4.1 million, which may be drawn down by the sublandlord in the event the Company fails to fully and faithfully perform all of its obligations under the Lease and to compensate the sublandlord for all losses and damages the sublandlord may suffer as a result of the occurrence of any default on the part of Company not cured within the applicable cure period. This standby letter of credit is collateralized by a certificate of deposit of the same amount which is classified as restricted cash. The Company was entitled to a $1.4 million reduction in the face amount of the standby letter of credit on the third anniversary of the contractual rent commencement, which was received in 2019, and another $1.4 million on the fifth anniversary of the contractual rent commencement. As a condition to the reduction of the standby letter of credit amount, no uncured default by the Company shall then exist under the Lease.  As of June&#160;30, 2020, none of the remaining standby letter of credit amount of $2.7 million has been used.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Sub-Sublease of Current SSF Facility &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On July&#160;18, 2018, the Company entered into a Sub-Sublease Agreement (the &#x201c;Sub-Sublease&#x201d;) with Assembly Biosciences, Inc. (the &#x201c;Sub-Subtenant&#x201d;) to sub-sublease approximately 46,641 square feet of office and laboratory space of the Current SSF Facility to the Sub-Subtenant. The Sub-Sublease is considered an operating lease under ASC 842. There was no change in the accounting of the Sub-Sublease of the Current SSF Facility upon the Company's adoption of ASC 842. For the three and six months ended June 30, 2020, the Company recorded $0.7 million and $1.5 million, respectively, and $0.7 million and $1.5 million three and six months ended June&#160;30, 2019, respectively, of sub-lease rental income as an offset to its operating expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Sub-Sublease provides for initial annual base rent for the complete Sub-Subleased Premises of approximately $2.7 million, with increases of approximately 3.5% in annual base rent on September 1, 2019 and each anniversary thereof. The Sub-Sublease rental income excludes reimbursements for executory costs received from the Sub-Subtenant. The Sub-Sublease became effective on September&#160;24, 2018, and has a term of 5.2 years which terminates on December&#160;15, 2023. The Sub-Sublease will terminate if the Lease or the corresponding master lease terminates. The Company or the Sub-Subtenant may elect, subject to limitations set forth in the Sub-Sublease, to terminate the Sub-Sublease following a material casualty or condemnation affecting the Subleased Premises. The Company may terminate the Sub-Sublease following an event of default, which is defined in the Sub-Sublease to include, among other things, non-payment of amounts owing by the Sub-Subtenant under the Sub-Sublease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is required under the Lease to pay to the sublandlord 50% of that portion of the cash sums and other economic consideration received from the Sub-Subtenant that exceeds the base rent paid by the Company to the sublandlord after deducting certain of the Company&#x2019;s costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Dublin&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company entered into an agreement to lease 133 square feet of office space in Dublin, Ireland (the "Dublin Lease"). The current one year lease term expires on November&#160;30, 2020. The Dublin Lease also has an automatic renewal clause, pursuant to which the agreement will be extended automatically for successive periods equal to the current term but no less than three months, unless the agreement is cancelled by the Company. This operating lease is not included in the lease liability and operating lease right-of-use asset recorded due to its nominal amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of  June&#160;30, 2020, the Company is obligated to make lease payments over the remaining term of the Dublin Lease of approximately &#x20ac;10,000, or $11,000 as converted using an exchange rate as of June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum payments under the above-described noncancelable operating leases, including a reconciliation to the lease liabilities recognized in the Condensed Consolidated Balance Sheets, and future minimum rentals to be received under the Sub-Sublease as of June&#160;30, 2020, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.269%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.134%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.137%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sub-Sublease Rental&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less:  Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nominal lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Indemnity Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has entered into indemnification agreements with its current and former directors and officers and certain key employees. These agreements contain provisions that may require the Company, among other things, to indemnify such persons against certain liabilities that may arise because of their status or service and advance their expenses incurred as a result of any indemnifiable proceedings brought against them. The obligations of the Company pursuant to the indemnification agreements continue during such time as the indemnified person serves the Company and continues thereafter until such time as a claim can be brought. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer liability insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts paid. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of June&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the normal course of business, the Company enters into various firm purchase commitments primarily related to research and development activities. As of June&#160;30, 2020, the Company had non-cancelable purchase commitments to suppliers for $4.0 million of which $0.4 million is included in accrued current liabilities, and contractual obligations under license agreements of $1.1 million of which $0.1 million is included in accrued current liabilities. The following is a summary of the Company's non-cancelable purchase commitments and contractual obligations as of June&#160;30, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.082%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.402%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Purchase Obligations&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contractual obligations under license agreements&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:13.5pt;padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;margin-top:6pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Purchase obligations consist of non-cancelable purchase commitments to suppliers.&lt;/span&gt;&lt;/div&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Excludes future obligations pursuant to the cost-sharing arrangement under the Company's License Agreement with Roche. Amounts of such obligations, if any, cannot be determined at this time.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjU3MQ_fc4f17ac-18b1-4e5f-9fe4-73092ef4b44f"
      unitRef="usd">1600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMTA1Nw_e2453a69-5322-4d6b-9a70-5f605fb6a3a1"
      unitRef="usd">3200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjYwNQ_4f01b497-e36d-4c06-8832-72f631045ed3"
      unitRef="usd">1600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjYxMg_15820c95-4727-4221-8890-8d1b8ad349f9"
      unitRef="usd">3200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjY5Mg_031a37fe-83a9-4b4b-8a49-3f88aa095e71"
      unitRef="usd">1500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMTE1OA_0285857b-bf2d-4744-9b24-ea9bfdf21ee8"
      unitRef="usd">3000000.0</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjcxOQ_67748a58-de2b-4257-8657-3c6a47644eae"
      unitRef="usd">1400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjcyNg_7576d683-d243-4250-847d-09ac0db7ae02"
      unitRef="usd">2900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i03363be070604a69a801733692c0eb01_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMTUwNA_99b99972-53db-49a3-8d44-9515b76ebc5e"
      unitRef="number">0.0425</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <prta:OperatingLeaseArea
      contextRef="i8154f8e4fb0a43068ce1feebb738c177_D20160301-20160331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMjI3Mg_850915dd-c7cf-4056-af1e-1f42446afb77"
      unitRef="sqft">128751</prta:OperatingLeaseArea>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMjU3Ng_e0f1df37-ec67-482b-8297-383defede416">P3Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseExpirationDate1
      contextRef="i8154f8e4fb0a43068ce1feebb738c177_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMjU5NQ_fc9366db-7247-4983-b6b1-3bd7b0a42b9d">2023-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue
      contextRef="iaa84acb8305c4045b894b70949b443e0_I20160430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMjc2NA_06bff288-0181-4bd6-b8da-d8cad28a4867"
      unitRef="usd">39200000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <prta:OperatingLeasesImprovementAllowance
      contextRef="ie5ee13ac88c14078b954248c161c0e37_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMzE4Ng_13aed1b1-c238-453c-a63e-3d34136f46c0"
      unitRef="usd">14200000</prta:OperatingLeasesImprovementAllowance>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="ibaf705e3bc94419cad46238812fd99d7_I20160430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMzgwNw_5a7c1479-bc41-4d73-a56b-18732b62ccc9"
      unitRef="usd">4100000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <prta:LineofCreditFacilityFaceAmountReductiononThirdAnniversary
      contextRef="i2d1009cc88444495b1b71ed313bd65be_D20160401-20160430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNDMyMg_ad4c736d-b2af-47dc-980a-bfff5e9a9887"
      unitRef="usd">1400000</prta:LineofCreditFacilityFaceAmountReductiononThirdAnniversary>
    <prta:LineofCreditFacilityFaceAmountReductiononFifthAnniversary
      contextRef="i2d1009cc88444495b1b71ed313bd65be_D20160401-20160430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNDQ4OQ_a8f1f1a9-6367-4c9b-beee-4f1fb65d9199"
      unitRef="usd">1400000</prta:LineofCreditFacilityFaceAmountReductiononFifthAnniversary>
    <us-gaap:LineOfCredit
      contextRef="ibbc0b76aa18c4b81ab20c7e33334019e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNDcwNg_05ed9c27-4c11-4fbf-a6e2-7b5fe12d1263"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfMTA5OTUxMTYzNzUxMA_f6c4d18c-e000-4748-9a11-a6866517fa8f"
      unitRef="usd">2700000</us-gaap:RestrictedCashNoncurrent>
    <prta:OperatingLeasesSubleaseRentalsAreaofSubleaseRental
      contextRef="id8c8f6072f864cafae096d1bc47eb2f8_D20180718-20180718"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNDk4MQ_2ec71f1a-bffe-480c-b845-956ddf7b5e51"
      unitRef="sqft">46641</prta:OperatingLeasesSubleaseRentalsAreaofSubleaseRental>
    <us-gaap:SubleaseIncome
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2Mjc4OA_ae2b0156-53a6-4bc0-abf7-eb08e89a2dae"
      unitRef="usd">700000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNTMwOA_a4d9a51a-4e21-4e56-9e0b-63e21d76c438"
      unitRef="usd">1500000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjgwMQ_40a0b584-0694-4e7c-8828-1b96adc2c14a"
      unitRef="usd">700000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjA0NzMxMzk2MjgwOA_5dd1f444-3293-4231-ac0e-7589ce2bc59d"
      unitRef="usd">1500000</us-gaap:SubleaseIncome>
    <prta:SubleaserentalsAnnualBaseRentInitialAmount
      contextRef="i218bb3aa60ae4e83aa3e4a7e671866cf_I20180718"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNTUxNQ_dc91be89-8aec-4910-9c7b-3888e30b2845"
      unitRef="usd">2700000</prta:SubleaserentalsAnnualBaseRentInitialAmount>
    <prta:OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease
      contextRef="id8c8f6072f864cafae096d1bc47eb2f8_D20180718-20180718"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNTU1MQ_1b12b3ed-110a-4be6-9be7-554ae10717c1"
      unitRef="number">0.035</prta:OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease>
    <prta:OperatingLeasesSubleaseRentalsTermofContract
      contextRef="i7fcd1972dc354290ba6864c10a7dfd26_D20180924-20180924"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNTc5Mg_a26ad5d4-c4be-4691-b254-e71eed5ee291">P5Y2M12D</prta:OperatingLeasesSubleaseRentalsTermofContract>
    <prta:OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord
      contextRef="id8c8f6072f864cafae096d1bc47eb2f8_D20180718-20180718"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjQwMg_e6ae4ec3-9b28-4df7-82d7-1778c41730be"
      unitRef="number">0.50</prta:OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord>
    <prta:LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace
      contextRef="i9a5e914e22c04ed09c890f4bac3875ee_D20180901-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjY3Mw_c3bc0dec-2226-463f-8f0e-1587b7851ca5"
      unitRef="sqft">133</prta:LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i71ec87774e684456b390ddadf981db10_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjc1Nw_3386278a-daec-40cf-8906-f664d77927da">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i4d734226c866410c9fa6e63cc16602c0_I20180927"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNjk3NQ_47801157-ddad-4b84-918f-370f833dfdf2">P3M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i71ec87774e684456b390ddadf981db10_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNzI4NQ_93118d02-ebec-4b72-a703-71f29f09c528"
      unitRef="eur">10000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i71ec87774e684456b390ddadf981db10_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfNzI5Mg_beb930b4-d239-4151-bf77-077b5bf19650"
      unitRef="usd">11000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5NA_56255ecd-8194-476e-ab51-c2df7937e8ec">&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future minimum payments under the above-described noncancelable operating leases, including a reconciliation to the lease liabilities recognized in the Condensed Consolidated Balance Sheets, and future minimum rentals to be received under the Sub-Sublease as of June&#160;30, 2020, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.269%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.134%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.137%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sub-Sublease Rental&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (6 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less:  Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nominal lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMS0yLTEtMS0w_c1e053fb-5164-4c59-a80f-ef5511ec4ea9"
      unitRef="usd">3040000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMS00LTEtMS0w_2be51eeb-9ee2-4ff2-bb5e-745f7d5247c9"
      unitRef="usd">1438000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMi0yLTEtMS0w_eaf6bea8-e658-4931-a6c7-2cd2b3890a99"
      unitRef="usd">6165000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMi00LTEtMS0w_06229de4-2350-47fb-b945-ba666605bfa8"
      unitRef="usd">2944000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMy0yLTEtMS0w_6692f125-dce1-44e7-b036-f6b07ac39326"
      unitRef="usd">6350000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfMy00LTEtMS0w_8903aba6-5752-4bf7-84f6-f2abe07ed206"
      unitRef="usd">3047000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNC0yLTEtMS0w_00052881-e848-4583-83d6-83566d6e612a"
      unitRef="usd">6535000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNC00LTEtMS0w_4eb15821-f2ce-4fa5-88cb-4d0286b31ca0"
      unitRef="usd">3019000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNS0yLTEtMS0w_789d6b44-cf58-4893-906c-b718e23ebe3e"
      unitRef="usd">22090000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNS00LTEtMS0w_12839347-1886-4255-a528-eec578aba8a9"
      unitRef="usd">10448000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNi0yLTEtMS0w_ba29dfa2-7741-49f7-9f3a-103498796122"
      unitRef="usd">1625000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <prta:LesseeOperatingLeaseLiabilityNominalPayments
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfNy0yLTEtMS0w_bd20be4d-6ae8-4657-983f-ab14190272c7"
      unitRef="usd">11000</prta:LesseeOperatingLeaseLiabilityNominalPayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjg3MDE4ZWM5NmQxNDQ5YTRhMDBhODdjODI4NjAxN2U3L3RhYmxlcmFuZ2U6ODcwMThlYzk2ZDE0NDlhNGEwMGE4N2M4Mjg2MDE3ZTdfOC0yLTEtMS0w_d6050698-e9c3-4028-b662-918c452ec18f"
      unitRef="usd">20454000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PurchaseObligation
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTA4Ng_b90c43e7-5b76-4c95-a964-a50a1b7740f8"
      unitRef="usd">4000000.0</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i9ee0a5361cff4ddb8357d8b71f892efb_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTA5OA_62c2c82a-7d43-455c-943a-48a57da6fda2"
      unitRef="usd">400000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:ContractualObligation
      contextRef="iec44022c93d44923a6ba45741b5572ca_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTIwMQ_fde6ccd4-16ea-45d6-bf85-b96393ef489a"
      unitRef="usd">1100000</us-gaap:ContractualObligation>
    <prta:ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities
      contextRef="i9ee0a5361cff4ddb8357d8b71f892efb_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTIxMw_9e695609-56d0-49c8-8eb4-bfdc8f435f87"
      unitRef="usd">100000</prta:ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5Ng_a530d4f4-292c-4b57-a881-44d3b6c91ca7">The following is a summary of the Company's non-cancelable purchase commitments and contractual obligations as of June&#160;30, 2020 (in thousands):&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.082%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.394%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.402%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Purchase Obligations&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contractual obligations under license agreements&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt; (2)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:13.5pt;padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;margin-top:6pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Purchase obligations consist of non-cancelable purchase commitments to suppliers.&lt;/span&gt;&lt;/div&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Excludes future obligations pursuant to the cost-sharing arrangement under the Company's License Agreement with Roche. Amounts of such obligations, if any, cannot be determined at this time.&lt;/span&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0yLTEtMS0w_5f3108b4-003e-4217-97a9-918ad4eff694"
      unitRef="usd">3959000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS00LTEtMS0w_0d6a5349-1f1d-4ee2-bf18-2da78d46b732"
      unitRef="usd">3959000</us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS02LTEtMS0w_968e18ff-f704-40e1-af8e-ade8d713a7d5"
      unitRef="usd">0</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS04LTEtMS0w_3ec32750-c162-4cbe-a782-73b16508ce2a"
      unitRef="usd">0</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligationDueInFourthYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMC0xLTEtMA_ed5c89f7-7a2d-4b6f-b487-7eca19bf639f"
      unitRef="usd">0</us-gaap:PurchaseObligationDueInFourthYear>
    <us-gaap:PurchaseObligationDueInFifthYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMi0xLTEtMA_0b3aeffe-6172-4012-aac6-b156ff07d4e6"
      unitRef="usd">0</us-gaap:PurchaseObligationDueInFifthYear>
    <us-gaap:PurchaseObligationDueAfterFifthYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xNC0xLTEtMA_e2091f3a-244a-47c5-a346-3a51b3732344"
      unitRef="usd">0</us-gaap:PurchaseObligationDueAfterFifthYear>
    <us-gaap:ContractualObligation
      contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0yLTEtMS0w_27166e2e-f2bf-45c2-889c-3e5de0a062f3"
      unitRef="usd">1075000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
      contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi00LTEtMS0w_1fa28666-44ab-4ba3-a3f7-564d7a236b83"
      unitRef="usd">285000</us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi02LTEtMS0w_216f6b01-ebe6-41d8-8814-5b4e6a8c3b1d"
      unitRef="usd">95000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi04LTEtMS0w_298f6cfa-762b-416b-9a52-e0f6c5e01f00"
      unitRef="usd">80000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMC0xLTEtMA_cb5c692b-52a0-4e68-8193-10c979c52cb3"
      unitRef="usd">80000</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMi0xLTEtMA_350d758a-8b8b-4f0f-9fec-3804b88e6df1"
      unitRef="usd">70000</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueAfterFifthYear
      contextRef="i6e8ce75690cb4acdab6e9a11d9d8acfd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xNC0xLTEtMA_c91b8d3a-9589-4833-8207-44eef2597f50"
      unitRef="usd">465000</us-gaap:ContractualObligationDueAfterFifthYear>
    <prta:PurchaseandContractualObligationTotal
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy0yLTEtMS0w_0d787b55-c98f-41b6-8b78-709719eb94a7"
      unitRef="usd">5034000</prta:PurchaseandContractualObligationTotal>
    <prta:PurchaseandContractualObligationRemainderofFiscalYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy00LTEtMS0w_128ce0d5-e131-45ba-8443-40ec8a97b1d1"
      unitRef="usd">4244000</prta:PurchaseandContractualObligationRemainderofFiscalYear>
    <prta:PurchaseandContractualObligationDueinSecondYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy02LTEtMS0w_86733ff6-5190-4b53-bac6-c82a922a6e4d"
      unitRef="usd">95000</prta:PurchaseandContractualObligationDueinSecondYear>
    <prta:PurchaseandContractualObligationDueinThirdYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy04LTEtMS0w_1230ff70-e034-45b0-9cca-fe515eb81b7c"
      unitRef="usd">80000</prta:PurchaseandContractualObligationDueinThirdYear>
    <prta:PurchaseandContractualObligationDueinFourthYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy0xMC0xLTEtMA_7bfc8525-3185-476b-a957-749b48cf5474"
      unitRef="usd">80000</prta:PurchaseandContractualObligationDueinFourthYear>
    <prta:PurchaseandContractualObligationDueinFifthYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy0xMi0xLTEtMA_5d502055-cf69-410a-9afa-b337f335113a"
      unitRef="usd">70000</prta:PurchaseandContractualObligationDueinFifthYear>
    <prta:PurchaseandContractualObligationDueAfterFifthYear
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMy0xNC0xLTEtMA_266f782b-520b-4269-8e7b-9d87bb2885d3"
      unitRef="usd">465000</prta:PurchaseandContractualObligationDueAfterFifthYear>
    <prta:SignificantAgreementsTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTA5OTUxMTY2OTkyNw_db30af57-dddb-4afd-b6dc-adcedc69225d">Significant Agreements&lt;div style="text-indent:9pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Roche License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2013, the Company through its wholly owned subsidiary Prothena Biosciences Limited and Prothena Biosciences Inc entered into a License, Development, and Commercialization Agreement (the &#x201c;License Agreement&#x201d;) with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together, &#x201c;Roche&#x201d;) to develop and commercialize certain antibodies that target &#x3b1;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;-&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;synuclein, including prasinezumab, which are referred to collectively as &#x201c;Licensed Products.&#x201d; Upon the effectiveness of the License Agreement in January 2014, the Company granted to Roche an exclusive, worldwide license to develop, make, have made, use, sell, offer to sell, import and export the Licensed Products. The Company retained certain rights to conduct development of the Licensed Products and an option to co-promote prasinezumab in the U.S. During the term of the License Agreement, the Company and Roche will work exclusively with each other to research and develop antibody products targeting alpha-synuclein (or &#x3b1;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;-&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;synuclein) potentially including incorporation of Roche&#x2019;s proprietary Brain Shuttle&#x2122; technology to potentially increase delivery of therapeutic antibodies to the brain. The License Agreement provided for Roche making an upfront payment to the Company of $30.0 million, which was received in February 2014; making a clinical milestone payment of $15.0 million upon initiation of the Phase 1 study for prasinezumab, which was received in May 2014; and making a clinical milestone payment of $30.0 million upon dosing of the first patient in the Phase 2 study for prasinezumab, which was achieved in June 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For prasinezumab, Roche is also obligated to pay:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:40.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt; up to $350.0 million upon the achievement of development, regulatory and various first commercial sales milestones;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:40.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt; up to an additional $175.0 million upon achievement of ex-U.S. commercial sales milestones; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:40.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt; tiered, high single-digit to high double-digit royalties in the teens on ex-U.S. annual net sales, subject to certain adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Roche bore 100% of the cost of conducting the research collaboration under the License Agreement during the research term, which expired December 31, 2017. In the U.S., the parties share all development and commercialization costs, as well as profits, all of which will be allocated 70% to Roche and 30% to the Company, for prasinezumab in the Parkinson&#x2019;s disease indication, as well as any other Licensed Products and/or indications for which the Company opts in to participate in co-development and co-funding. After the completion of specific clinical trial activities, the Company may opt out of the co-development and cost and profit sharing on any co-developed Licensed Products and instead receive U.S. commercial sales milestones totaling up to $155.0 million and tiered, single-digit to high double-digit royalties in the teens based on U.S. annual net sales, subject to certain adjustments, with respect to the applicable Licensed Product.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company filed an Investigational New Drug Application (&#x201c;IND&#x201d;) with the FDA for prasinezumab and subsequently initiated a Phase 1 study in 2014. Following the Phase 1 studies, Roche became primarily responsible for developing, obtaining and maintaining regulatory approval for and commercializing Licensed Products. Roche also became responsible for the clinical and commercial manufacture and supply of Licensed Products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, the Company has an option under the License Agreement to co-promote prasinezumab in the U.S. in the Parkinson&#x2019;s disease indication. If the Company exercises such option, it may also elect to co-promote additional Licensed Products in the U.S. approved for Parkinson&#x2019;s disease. Outside the U.S., Roche will have responsibility for developing and commercializing the Licensed Products. Roche bears all costs that are specifically related to obtaining or maintaining regulatory approval outside the U.S. and will pay the Company a variable royalty based on annual net sales of the Licensed Products outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;While Roche will record product revenue from sales of the Licensed Products, the Company and Roche will share in the net profits and losses of sales of the prasinezumab for the Parkinson's disease indication in the U.S. on a 70%/30% basis with the Company receiving 30% of the profit and losses provided that the Company has not exercised its opt-out right.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The License Agreement continues on a country-by-country basis until the expiration of all payment obligations under the License Agreement. The License Agreement may also be terminated (i) by Roche at will after the first anniversary of the effective date of the License Agreement, either in its entirety or on a Licensed Product-by-Licensed Product basis, upon 90 days&#x2019; prior written notice to the Company prior to first commercial sale and 180 days&#x2019; prior written notice to Prothena after first commercial sale, (ii) by either party, either in its entirety or on a Licensed Product-by-Licensed Product or region-by-region &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:9pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;basis, upon written notice in connection with a material breach uncured 90 days after initial written notice, and (iii) by either party, in its entirety, upon insolvency of the other party. The License Agreement may be terminated by either party on a patent-by-patent and country-by-country basis if the other party challenges a given patent in a given country. The Company&#x2019;s rights to co-develop Licensed Products under the License Agreement will terminate if the Company commences certain studies for certain types of competitive products. The Company&#x2019;s rights to co-promote Licensed Products under the License Agreement will terminate if the Company commences a Phase 3 study for such competitive products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The License Agreement cannot be assigned by either party without the prior written consent of the other party, except to an affiliate of such party or in the event of a merger or acquisition of such party, subject to certain conditions. The License Agreement also includes customary provisions regarding, among other things, confidentiality, intellectual property ownership, patent prosecution, enforcement and defense, representations and warranties, indemnification, insurance, and arbitration and dispute resolution.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaboration Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The License Agreement was evaluated under ASC 808, Collaborative Agreements.  At the outset of the License Agreement, the Company concluded that it did not qualify as collaboration under ASC 808 because the Company does not share significant risks due to the net profit and loss split (under which Roche incurs substantially more of the costs of the collaboration) and because of the Company&#x2019;s opt-out provision. The Company believes that Roche will be the principal in future sales transactions with third parties as Roche will be the primary obligor bearing inventory and credit risk. The Company will record its share of pre-tax commercial profit generated from the collaboration as collaboration revenue once the Company can conclude it is probable that a significant revenue reversal will not occur in future periods. Prior to commercialization of a Licensed Product, the Company&#x2019;s portion of the expenses related to the License Agreement reflected on its income statement will be limited to R&amp;amp;D expenses. After commercialization, if the Company opts-in to co-detail commercialization, expenses related to commercial capabilities, including expenses related to the establishment of a field sales force and other activities to support the Company&#x2019;s commercialization efforts, will be recorded as sales, general and administrative (&#x201c;SG&amp;amp;A&#x201d;) expense and will be factored into the computation of the profit and loss share. The Company will record the receivable related to commercialization activities as collaboration revenue once the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Adoption of ASC 606, Revenue from Contracts with Customers &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted ASC 606, Revenue from Contracts with Customers, as of January 1, 2018, using the modified retrospective transition method. The Company recognized the cumulative effect of applying the new revenue standard as an adjustment to the opening balance of the accumulated deficit as of January 1, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of January 1, 2018, the Company did not record any changes to the opening balance of the accumulated deficit since the cumulative effect of applying the new revenue standard was the same as applying ASC 605. The impact of the adoption of ASC 606 to revenues for the year ended December&#160;31, 2018, was an increase of $1.0 million, which represents the revenue recognized for the development services provided by the Company during the period that is reimbursable by Roche. Historically, the Company recorded such reimbursement as an offset against its R&amp;amp;D expenses under ASC 605. Upon the adoption of ASC 606, the reimbursement for development services is now included as part of the Company&#x2019;s collaboration revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The License Agreement was evaluated under ASC 606. The License Agreement includes the following distinct performance obligations: (1) the Company&#x2019;s grant of an exclusive royalty bearing license, with the right to sublicense to develop and commercialize certain antibodies that target &#x3b1;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;-&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;synuclein, including prasinezumab, and the initial know how transfer which was delivered at the effective date (the &#x201c;Royalty Bearing License&#x201d;); (2) the Company&#x2019;s obligation to supply clinical material as requested by Roche for a period up to twelve months (the &#x201c;Clinical Product Supply Obligation&#x201d;); (3) the Company&#x2019;s obligation to provide manufacturing related services to Roche for a period up to twelve months (the &#x201c;Supply Services Obligation&#x201d;); (4) the Company&#x2019;s obligation to prepare and file the IND (the &#x201c;IND Obligation&#x201d;); and (5) the Company&#x2019;s obligation to provide development activities under the development plan during Phase 1 clinical trials (the &#x201c;Development Services Obligation&#x201d;). Revenue allocated to the above performance obligations under the License Agreement are recognized when the Company has satisfied its obligations either at a point in time or over a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company concluded that the Royalty Bearing License and the Clinical Product Supply Obligation were satisfied at a point in time. The Royalty Bearing License is considered to be a functional intellectual property, in which the revenue would be recognized at the point in time since (a) the Company concluded that the license to Roche has a significant stand-alone &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;functionality, (b) the Company does not expect the functionality of the intellectual property to be substantially changed during the license period as a result of activities of Prothena, and (c) Prothena&#x2019;s activities transfer a good or service to Roche. The Clinical Product Supply Obligation does not meet criteria for over time recognition; as such, the revenue related to such performance obligation was recognized the point in time at which Roche obtained control of manufactured supplies, which occurred during the first quarter of 2014. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company concluded that the Supply Services Obligation, the IND Obligation and the Development Services Obligation were satisfied over time. The Company utilized an input method measure of progress by basing the recognition period on the efforts or inputs towards satisfying the performance obligation (i.e. costs incurred and the time elapsed to complete the related performance obligations). The Company determined that such input method provides an appropriate measure of progress toward complete satisfaction of such performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, and December&#160;31, 2019, there were no remaining performance obligations under License Agreement since the obligations related to research and development activities were only for the Phase 1 clinical trial and the remaining obligations were delivered or performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Transaction Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;According to ASC 606-10-32-2, the transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Factors considered in the determination of the transaction price include, among other things, estimated selling price of the license and costs for clinical supply and development costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The initial transaction price under the License Agreement, pursuant to ASC 606, was $55.1 million, including $45.0 million for the Royalty Bearing License, $9.1 million for the IND and Development Services Obligations, and $1.1 million for the Supply Services Obligation. The $45.0 million for the Royalty Bearing License included the upfront payment of $30.0 million and the clinical milestone payment of $15.0 million upon initiation of the Phase 1 clinical trial of prasinezumab, both of which were made in 2014. The remaining transaction price amounts the Company expected to receive as reimbursements were based on costs expected to be paid to third parties and other costs to be incurred by the Company in order to satisfy its performance obligations. They are considered to be variable considerations not subject to constraint. The Company did not incur any incremental costs, such as commissions, to obtain or fulfill the License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under ASC 606, the transaction price was allocated to the performance obligations as follows: $48.9 million to the Royalty Bearing License; $4.6 million to the IND and Development Services Obligations; $1.1 million to the Clinical Product Supply Obligation; and $0.6 million to the Supply Services Obligation. As of June&#160;30, 2020, the aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied is $nil. Prior to the adoption of ASC 606, the transaction price was allocated to the deliverables as follows: $35.6 million to the Royalty Bearing License; $3.3 million to the IND and Development Services Obligations; $0.8 million to the Clinical Product Supply Obligation; and $0.4 million to the Supply Services Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company allocated the initial transaction price to the Royalty Bearing License and other performance obligations using the relative selling price method based on its best estimate of selling price for the Royalty Bearing License and third party evidence for the remaining performance obligations. The best estimate of selling price for the Royalty Bearing License was based on a discounted cash flow model. The key assumptions used in the discounted cash flow model used to determine the best estimate of selling price for the Royalty Bearing License included the market opportunity for commercialization of prasinezumab in the U.S. and the royalty territory (for licensed products that are jointly funded the royalty territory is worldwide except for the U.S., and for all licensed products that are not jointly funded the Royalty Territory is worldwide), the probability of successfully developing and commercializing prasinezumab, the estimated remaining development costs for prasinezumab, and the estimated time to commercialization of prasinezumab. The Company concluded that a change in the assumptions used to determine the best estimate of selling price (&#x201c;BESP&#x201d;) of the license deliverable would not have a significant effect on the allocation of arrangement consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s discounted cash flow model included several market conditions and entity-specific inputs, including the likelihood that clinical trials for prasinezumab will be successful, the likelihood that regulatory approval will be obtained and the product commercialized, the appropriate discount rate, the market locations, size and potential market share of the product, the expected life of the product, and the competitive environment for the product. The market assumptions were generated using a patient-based forecasting approach, with key epidemiological, market penetration, dosing, compliance, length of treatment and pricing assumptions derived from primary and secondary market research, referenced from third-party sources.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Significant Payment Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Payments for development services are due within 45 days after receiving an invoice from the Company. Variable considerations related to clinical and regulatory milestone payments are constrained due to high likelihood of a revenue reversal. The payment term for all milestone payments are due within 45 days after the achievement of the relevant milestone and receipt by Roche of an invoice for such an amount from the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;According to ASC 606-10-32-17, a significant financing component does not exist if a substantial amount of the consideration promised by the customer is variable, and the amount or timing of that consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the customer or the entity. Since a &#x201c;substantial amount of the consideration&#x201d; promised by Roche to the Company is variable (i.e., is in the form of either milestone payments or sales-based royalties) and the amount of such variable consideration varies based upon the occurrence or nonoccurrence of future events that are not within the control of either Roche or the Company (i.e., are largely subject to regulatory approval), the License Agreement does not have a significant financing component.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Optional Goods and Services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;An option for additional goods or services exists when a customer has a present contractual right that allows it to choose the amount of additional distinct goods or services that are purchased. Prior to the customer&#x2019;s exercise of that right, the vendor is not presently obligated to provide those goods or services. ASC 606-10-25-18(j) requires recognition of an option as a distinct performance obligation when the option provides a customer with a material right.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to the distinct performance obligations noted above, the Company was obligated to provide indeterminate research services for up to three years ending in 2017 at rates that were not significantly discounted and fully reimbursable by Roche (the &#x201c;Research Services&#x201d;). The amount for any such Research Services was not fixed and determinable and was not at a significant incremental discount. There were no refund rights, concessions or performance bonuses to consider. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluated the obligation to perform Research Services under ASC 606-10-55-42 and 55-43 to determine whether it gave Roche a &#x201c;material right&#x201d;. According to ASC 606-10-55-43, if a customer has the option to acquire an additional good or services at a price that would reflect the standalone selling price for that good or service, that option does not provide the customer with a material right even if the option can be exercised only by entering into a previous contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company concluded that Roche&#x2019;s option to have the Company perform Research Services did not represent a &#x201c;material right&#x201d; to Roche that it would not have received without entering into the License Agreement. As a result, Roche&#x2019;s option to acquire additional Research Services was not considered a performance obligation at the outset of the License Agreement under ASC 606. Accordingly, this deliverable will become new performance obligation for Prothena when Roche asks Prothena to conduct such Research Services. As of June&#160;30, 2020, there were no remaining Research Services performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Post Contract Deliverables&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Any development services provided by the Company after performance of the Development Service Obligation are not considered a contractual performance obligation under the License Agreement, since the License Agreement does not require the Company to provide any development services after completion of the Development Service Obligation. However, the collaboration&#x2019;s Joint Steering Committee approved continued funding for additional development services to be provided by the Company (the &#x201c;Additional Development Services&#x201d;).  Under the License Agreement and upon the adoption of ASC 606, the Company recognizes the reimbursements for Additional Development Services as collaboration revenue as earned. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue and Expense Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognized $0.1 million and $0.3&#160;million as collaboration revenue from Roche for the three and six months ended June&#160;30, 2020, respectively, as compared to $0.2&#160;million and $0.4&#160;million for the three and six months ended June&#160;30, 2019, respectively. Cost sharing payments to Roche are recorded as R&amp;amp;D expenses. The Company recognized $4.5 million and $8.5 million in R&amp;amp;D expenses for payments made to Roche during the three and six months ended June&#160;30, 2020, respectively, as compared to $1.1 million and $4.0 million for the three and six months ended June&#160;30, 2019, respectively. The Company had accounts receivable from Roche of $4,000 and $2,000 at June&#160;30, 2020 and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Milestone Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the License Agreement, only if the U.S. and or global options are exercised, the Company is eligible to receive milestone payments upon the achievement of development, regulatory and various first commercial sales milestones. Milestone payments are evaluated under ASC Topic 606. Factors considered in this determination included scientific and regulatory risk that must be overcome to achieve each milestone, the level of effort and investment required to achieve the milestone, and the monetary value attributed to the milestone. Accordingly, the Company estimates payments in the transaction price based on the most likely approach, which considers the single most likely amount in a range of possible amounts related to the achievement of these milestones. Additionally, milestone payments are included in the transaction price only when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods when the milestone is achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company excludes the milestone payments and royalties in the initial transaction price calculation because such payments are considered to be variable considerations with constraint. Such milestone payments and royalties will be recognized as revenue once the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The clinical and regulatory milestones under the License Agreement after the point at which the Company could opt-out are considered to be variable considerations with constraint due to the fact that active participation in the development activities that generate the milestones is not required under the License Agreement, and the Company can opt-out of these activities. There are no refunds or claw-back provisions and the milestones are uncertain of occurrence even after the Company has opted out. Based on this determination, these milestones will be recognized when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Collaboration Agreement with Bristol-Myers Squibb&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On March&#160;20, 2018, the Company, through its wholly owned subsidiary Prothena Biosciences Limited, entered into a Master Collaboration Agreement (the &#x201c;Collaboration Agreement&#x201d;) with Celgene Switzerland LLC (&#x201c;Celgene&#x201d;), a subsidiary of Celgene Corporation (which was acquired by Bristol-Myers Squibb ("BMS") in November 2019), pursuant to which Prothena granted to Celgene a right to elect in its sole discretion to exclusively license rights both in the U.S. (the &#x201c;US Rights&#x201d;) and on a global basis (the &#x201c;Global Rights&#x201d;), with respect to the Company&#x2019;s programs to develop and commercialize antibodies targeting Tau, TDP-43 and an undisclosed target (the &#x201c;Collaboration Targets&#x201d;). For each such program, BMS may exercise its US Rights at the IND filing, and if it so exercises such US Rights would also have a right to expand the license to Global Rights. If BMS exercises its US Rights for a program, then following the first to occur of (a) completion by the Company, in its discretion and at its cost, of Phase 1 clinical trials for such program or (b) the date on which BMS elects to assume responsibility for completing such Phase 1 clinical trials (at its cost), BMS would have decision making authority over development activities and all regulatory, manufacturing and commercialization activities in the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Collaboration Agreement provided for Celgene making an upfront payment to the Company of $100.0 million, which was received in April 2018, plus future potential license exercise payments and regulatory and commercial milestones for each program under the Collaboration Agreement, as well as royalties on net sales of any resulting marketed products. In connection with the Collaboration Agreement, the Company and Celgene entered into a Share Subscription Agreement on March&#160;20, 2018, under which Celgene subscribed to 1,174,536 of the Company&#x2019;s ordinary shares for a price of $42.57 per share, for a total of approximately $50.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;BMS US and Global Rights and Licenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On a program-by-program basis, beginning on the effective date of the Collaboration Agreement and ending on the date that the IND Option term expires for such program (which generally occurs sixty days after the date on which Prothena delivers to BMS the first complete data package for an IND that was filed for a lead candidate from the relevant program), BMS may elect in its sole discretion to exercise its US Rights to receive an exclusive license to develop, manufacture and commercialize antibodies targeting the applicable Collaboration Target in the U.S. (the &#x201c;US License&#x201d;). If BMS exercises its US Rights for a collaboration program, it is obligated to pay the Company an exercise fee of approximately $80.0 million per program. Thereafter, following the first to occur of (a) completion by the Company, in its discretion and at its cost, of Phase 1 clinical trials for such program or (b) BMS&#x2019;s election to assume responsibility to complete such Phase 1 clinical trials (at its cost), BMS would have the sole right to  develop, manufacture and commercialize antibody products targeting the relevant Collaboration Target for such program (the &#x201c;Collaboration Products&#x201d;) in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On a program-by-program basis, following completion of a Phase 1 clinical trial for a collaboration program for which BMS has previously exercised its US Rights, BMS may elect in its sole discretion to exercise its Global Rights with respect to such collaboration program to receive a worldwide, exclusive license to develop, manufacture and commercialize antibodies targeting the applicable Collaboration Target (the &#x201c;Global License&#x201d;). If BMS exercises its Global Rights, BMS would be obligated to pay the Company an additional exercise fee of $55.0 million for such collaboration program. The Global Rights would then replace the US Rights for that collaboration program, and BMS would have decision making authority over developing, obtaining and maintaining regulatory approval for, manufacturing and commercializing the Collaboration Products worldwide.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;After BMS&#x2019;s exercise of Global Rights for a collaboration program, the Company is eligible to receive up to $562.5 million in regulatory and commercial milestones per program. Following an exercise by BMS of either US Rights or Global Rights for such collaboration program, the Company will also be eligible to receive tiered royalties on net sales of Collaboration Products ranging from high single digit to high teen percentages, on a weighted average basis depending on the achievement of certain net sales thresholds. Such exercise fees, milestones and royalty payments are subject to certain reductions as specified in the Collaboration Agreement, the agreement for US Rights and the agreement for Global Rights.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;BMS will continue to pay royalties on a Collaboration Product-by-Collaboration Product and country-by-country basis, until the latest of (i) expiration of certain patents covering the Collaboration Product, (ii) expiration of all regulatory exclusivity for the Collaboration Product, and (iii) an agreed period of time after the first commercial sale of the Collaboration Product in the applicable country (the &#x201c;Royalty Term&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Term and Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The research term under the Collaboration Agreement continues for a period of six years, which BMS may extend for up to two additional 12-month periods by paying an extension fee of $10.0 million per extension period.  The term of the Collaboration Agreement continues until the last to occur of the following: (i) expiration of the research term; (ii) expiration of all US Rights terms; and (iii) expiration of all Global Rights terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The term of any US License or Global License would continue on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of all Royalty Terms under such agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Collaboration Agreement may be terminated (i) by either party on a program-by-program basis if the other party remains in material breach of the Collaboration Agreement following a cure period to remedy the material breach, (ii) by BMS at will on a program-by-program basis or in its entirety, (iii) by either party, in its entirety, upon insolvency of the other party, or (iv) by Prothena, in its entirety, if BMS challenges a patent licensed by Prothena to BMS under the Collaboration Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Share Subscription Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the terms of the Collaboration Agreement, the Company entered into a Share Subscription Agreement (the &#x201c;SSA&#x201d;) with Celgene, pursuant to which the Company issued, and Celgene subscribed for, 1,174,536 of the Company&#x2019;s ordinary shares (the &#x201c;Shares&#x201d;) for an aggregate subscription price of approximately $50.0 million, pursuant to the terms and conditions thereof.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the SSA, BMS (formerly Celgene) is subject to certain transfer restrictions. In addition, BMS will be entitled to request the registration of the Shares with the U.S. Securities and Exchange Commission on Form S-3ASR or Form S-3 following termination of the transfer restrictions if the Shares cannot be resold without restriction pursuant to Rule 144 promulgated under the U.S. Securities Act of 1933, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaboration Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Collaboration Agreement was evaluated under ASC 808, Collaborative Agreements. At the outset of the Collaboration Agreement, the Company concluded that it does not qualify as collaboration under ASC 808 because the Company does not share significant risks due to economics of the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the Collaboration Agreement and concluded that it represented a contract with a customer within the scope of ASC 606. Per ASC 606, a performance obligation is defined as a promise to transfer a good or service or a series of distinct goods or services. At inception of the Collaboration Agreement, the Company is not obligated to transfer the US License or Global License to BMS unless BMS exercises its US Rights or Global Rights, respectively, and the Company is not &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;obligated to perform development activities under the development plan during preclinical and Phase 1 clinical trials including the regulatory filing of the IND. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The discovery, preclinical and clinical development activities performed by the Company are to be performed at the Company&#x2019;s discretion and are not promised goods or services and therefore are not considered performance obligations under ASC 606, unless and until the Company agrees to perform the Phase 1 clinical studies (after the IND option exercise) that are determined to be performance obligations at the time the option is exercised. Per the terms of the Collaboration Agreement, the Company may conduct discovery activities to characterize, identify and generate antibodies to become collaboration candidates that target such Collaboration Target, and thereafter may pre-clinically develop collaboration candidates to identify lead candidates that target such Collaboration Target and file an IND with the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) for a Phase 1 clinical trial for such lead candidates. In the event the Company agrees to be involved in a Phase 1 clinical study, the Company will further evaluate whether any such promise represents a performance obligation at the time the option is exercised. If it is concluded that the Company has obligated itself to an additional performance obligation besides the license granted at IND option exercise, then the effects of the changes in the arrangement will be evaluated under the modification guidance of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is not obligated to perform manufacturing activities. Per the terms of the Collaboration Agreement, to the extent that the Company, at its discretion, conducts a program, the Company shall be responsible for the manufacture of collaboration candidates and collaboration products for use in such program, as well as the associated costs. Delivery of manufactured compound (clinical product supply) is not deemed a performance obligation under ASC 606 as the Company is not obligated to transfer supply of collaboration product to BMS unless BMS exercises its right to participate in the Phase 1 development.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Compensation for the Company&#x2019;s provision of inventory supply, to the extent requested by BMS would be paid to Prothena by BMS at a reasonable stand-alone selling price for such supply. Given that (i) there is substantial uncertainty about the development of the programs, (ii) the pricing for the inventory is at its standalone selling price and (iii) the manufacturing services require the entity to transfer additional goods or services that are incremental to the goods and services provided prior to the resolution of the contingency, the Company&#x2019;s supply of product is not a material right. Therefore, the inventory supply is not considered a performance obligation unless and until, requested by BMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to the grant of the US License after BMS exercises its US Rights for a program, BMS is entitled to receive certain ancillary development services from the Company, such as technology transfer assistance, regulatory support, safety data reporting activities and transition supply, if requested by BMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to the grant of the Global License after BMS exercises the Global Rights for a program, BMS is entitled to receive certain ancillary development services from Prothena, such as ongoing clinical trial support upon request by BMS, transition supply, if requested by BMS, and regulatory support for coordination of pharmacovigilance matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluated the potential obligations to transfer the US Licenses and Global Licenses and performance of the ancillary development services subsequent to exercise of the US Rights and Global Rights, if the options are exercised by BMS, under ASC 606-10-55-42 and 55-43 to determine whether the US Rights or the Global Rights provided BMS a &#x201c;material right&#x201d; and concluded that BMS&#x2019;s options to exercise its US Rights and Global Rights represented &#x201c;material rights&#x201d; to BMS that it would not have received without entering into the Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There are a total of six options including US Rights and Global Rights to acquire a US License and a Global License, respectively, and rights to request certain development services (following exercise of the US Rights and Global Rights, respectively) for each of the three programs. Per ASC 606, the US Rights and Global Rights are material rights and therefore are performance obligations. The goods and services underlying the options are not accounted for as separate performance obligations, but rather become performance obligations, if and when, an option is exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Transaction Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;According to ASC 606-10-32-2, the transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Factors considered in the determination of the transaction price included, among other things, estimated selling price of the license and costs for clinical supply and development costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The initial transaction price under the Collaboration Agreement, pursuant to ASC 606, was $110.2 million, including the $100.0 million upfront payment and $10.2 million premium on the ordinary shares purchased under the SSA. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;expects that the initial transaction price will be allocated across the US Rights and Global Rights for each program in a range of approximately $15-$25 million and $10-$18 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company did not include the option fees in the initial transaction price because such fees are contingent on the options to the US Rights and the Global Rights being exercised. Upon the exercise of the US Rights and the Global Rights for a program, the Company will have the obligation to deliver the US License and Global License and provide certain ancillary development services if requested by BMS, subsequent to its exercise of the US Rights and Global Rights, respectively, for such program. The Company will include the option fees in the transaction price at the point in time a material right is exercised. In addition, the Company did not include in the initial transaction price certain clinical and regulatory milestone payments since they relate to licenses for which BMS has not yet exercised its option to obtain and these variable considerations are constrained due to the likelihood of a significant revenue reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At the inception of the Collaboration Agreement, the Company did not transfer any goods or services to BMS (formerly Celgene) that are material. Accordingly, the Company has concluded that the initial transaction price will be recognized as contract liability and will be deferred until the Company transfers control of goods or services to BMS (which would be when BMS exercises the US Right or Global Right and receives control of the US License or Global License for at least one of the programs),&#160;or when the IND Option term expires if BMS does not exercise the US Right (which is generally sixty days after the date on which Prothena delivers to BMS the first complete data package for an IND that was filed for a lead candidate from the relevant program), or when the Phase 1 Option term expires if BMS does not exercise the Global Right (which is generally ninety days after the date on which Prothena delivers to BMS the first complete data package for a Phase 1 clinical trial for a lead candidate from the relevant program)&#160;or at the termination of the Collaboration Agreement, whichever occurs first. At such point that the Company transfers control of goods or services to BMS, or when the option expires, the Company will recognize revenue as a continuation of the original contract. Under this approach, the Company will treat the consideration allocated to the material right as an addition to the consideration for the goods or services underlying the contract option. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At inception of the Collaboration Agreement, the Company estimated the standalone selling price for each performance obligation (i.e., the US Rights and Global Rights by program). The estimate of standalone selling price for the US Rights and Global Rights by program was based on the adjusted market assessment approach using a discounted cash flow model. The key assumptions used in the discounted cash flow model included the market opportunity for commercialization of each program in the U.S. or globally depending on the license, the probability of successfully developing and commercializing a given program target, the estimated remaining development costs for the respective program, the estimated time to commercialization of the drug for that program and a discount rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Significant Payment Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The upfront payment of $100.0 million was due within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzk0Njc_0bf4cdb7-932a-472a-9ad8-2ce5f72c6492"&gt;ten&lt;/span&gt; business days after the effective date of the Collaboration Agreement and was received in April 2018, while all option fees and milestone payments are due within 30 days after the achievement of the relevant milestone by BMS or receipt by BMS of an invoice for such an amount from the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Collaboration Agreement does not have a significant financing component since a substantial amount of consideration promised by BMS to the Company is variable and the amount of such variable consideration varies based upon the occurrence or non-occurrence of future events that are not within the control of either BMS or the Company. Variable considerations related to clinical and regulatory milestone payments and option fees are constrained due to the likelihood of a significant revenue reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Milestone and Royalties Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is eligible to receive milestone payments of up to $90.0 million per program upon the achievement of certain specified regulatory milestones and milestone payments of up to $375.0 million per program upon the achievement of certain specified commercial sales milestones under the US License for such program. The Company is also eligible to receive milestone payments of up to $187.5 million per program upon the achievement of certain specified regulatory milestones and milestone payments of up $375.0 million per program upon the achievement of certain specified commercial sale milestones under the Global License for such program. Milestone payments are evaluated under ASC Topic 606. Factors considered in this determination included scientific and regulatory risk that must be overcome to achieve each milestone, the level of effort and investment required to achieve the milestone, and the monetary value attributed to the milestone. Accordingly, the Company estimates payments in the transaction price based on the most likely approach, which considers the single most likely amount in a range of possible amounts related to the achievement of these milestones. Additionally, milestone payments are included in the transaction price only when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company excluded the milestone payments and royalties in the initial transaction price because such payments are considered to be variable considerations with constraint. Such milestone payments and royalties will be recognized as revenue at a point in time when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company did not achieve any clinical and regulatory milestones under the Collaboration Agreement during the three and six months ended June&#160;30, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;</prta:SignificantAgreementsTextBlock>
    <prta:CollaborationRevenueLicenseUpfrontPayment
      contextRef="if3b8cf0763bb4f5397b004275677c01b_D20140201-20140228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI4Ng_f3eb06db-8454-46c0-a887-d116564fe323"
      unitRef="usd">30000000.0</prta:CollaborationRevenueLicenseUpfrontPayment>
    <prta:MilestonePaymentReceivedClinicalMilestone
      contextRef="iaaed79f2beb64ec6a2029bcf63a64073_D20140501-20140531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM2Ng_ee8229ac-bac6-4e4c-a2a7-d6ee5f20b590"
      unitRef="usd">15000000.0</prta:MilestonePaymentReceivedClinicalMilestone>
    <prta:MilestoneAchievementClinicalMilestone
      contextRef="ib00e147a1cff4155afb7ec6051700710_D20170601-20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTQ5OQ_042e6620-baae-4bb2-a777-02efdd3d636e"
      unitRef="usd">30000000.0</prta:MilestoneAchievementClinicalMilestone>
    <prta:LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones
      contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTY2NQ_f677a8a5-6b68-4018-9543-9450aad68410"
      unitRef="usd">350000000.0</prta:LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones>
    <prta:LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones
      contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTc4NA_3e1258af-28ed-4ddc-9d91-9137d0c5b5b2"
      unitRef="usd">175000000.0</prta:LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones>
    <prta:LicensingAgreementCostAllocationPercentage
      contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTk5MQ_c929b567-2a43-4c32-965a-7285cab4724f"
      unitRef="number">1</prta:LicensingAgreementCostAllocationPercentage>
    <prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage
      contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjI2MQ_078e2451-06bc-4d0f-a95a-c562af657a72"
      unitRef="number">0.70</prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage>
    <prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage
      contextRef="i74335244f76841eb87c826533b83cc37_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjI3Nw_c5755f38-8cad-4d72-909f-961dcf8475e1"
      unitRef="number">0.30</prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage>
    <prta:LicenseAgreementPotentialAlternativeCommercialSalesMilestones
      contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjcyOQ_5ab4ea6c-91ef-4928-8c7e-08a1539178bf"
      unitRef="usd">155000000.0</prta:LicenseAgreementPotentialAlternativeCommercialSalesMilestones>
    <prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage
      contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDE5MQ_078e2451-06bc-4d0f-a95a-c562af657a72"
      unitRef="number">0.70</prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage>
    <prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage
      contextRef="i74335244f76841eb87c826533b83cc37_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDE5NA_c5755f38-8cad-4d72-909f-961dcf8475e1"
      unitRef="number">0.30</prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage>
    <prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage
      contextRef="i74335244f76841eb87c826533b83cc37_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDIzMA_c5755f38-8cad-4d72-909f-961dcf8475e1"
      unitRef="number">0.30</prta:LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage>
    <prta:DevelopmentServicesAdditional
      contextRef="if675ef5553934becb22c4267dbb63ed6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfODU0MA_728e67e8-a25f-46b3-b542-52467a026a15"
      unitRef="usd">1000000.0</prta:DevelopmentServicesAdditional>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic854f60120d74aedb489b48755f518b9_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTE2Mjc_17f6aa0e-c585-4fb8-b993-a752851b5059"
      unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ibca1ba5c855446de877d16de250feabe_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTE2Mjc_46419f89-d60c-4de9-925d-152e5faca9d7"
      unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <prta:InitialTransactionPrice
      contextRef="i073a0b78fb35421ba6e8592c0a197dfe_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI1NDQ_c802221b-4636-4f62-befc-eafc15174c11"
      unitRef="usd">55100000</prta:InitialTransactionPrice>
    <prta:InitialTransactionPrice
      contextRef="icb959663c6fb41d287b63b8363fda883_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI1NTg_2880fe80-b8d4-414f-958c-11b673702295"
      unitRef="usd">45000000.0</prta:InitialTransactionPrice>
    <prta:InitialTransactionPrice
      contextRef="i5ba8be9d9c3a400b803bd9eaae95a8ee_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI1OTQ_a24c9560-4027-4575-9554-704e8729ac5a"
      unitRef="usd">9100000</prta:InitialTransactionPrice>
    <prta:InitialTransactionPrice
      contextRef="icd6584a0477e41a785e2b634ec00c3ec_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI2NTE_15fae11f-7282-434c-ad7d-42f4c15cd8f0"
      unitRef="usd">1100000</prta:InitialTransactionPrice>
    <prta:InitialTransactionPrice
      contextRef="icb959663c6fb41d287b63b8363fda883_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI2OTQ_2880fe80-b8d4-414f-958c-11b673702295"
      unitRef="usd">45000000.0</prta:InitialTransactionPrice>
    <prta:CollaborationRevenueLicenseUpfrontPayment
      contextRef="if3b8cf0763bb4f5397b004275677c01b_D20140201-20140228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI3NjE_f3eb06db-8454-46c0-a887-d116564fe323"
      unitRef="usd">30000000.0</prta:CollaborationRevenueLicenseUpfrontPayment>
    <prta:MilestonePaymentReceivedClinicalMilestone
      contextRef="iaaed79f2beb64ec6a2029bcf63a64073_D20140501-20140531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTI4MDI_ee8229ac-bac6-4e4c-a2a7-d6ee5f20b590"
      unitRef="usd">15000000.0</prta:MilestonePaymentReceivedClinicalMilestone>
    <prta:AllocatedConsiderationtoPerformanceObligations
      contextRef="i0175d817a5f44f01ac9efd8385decd07_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM0Mjg_d7ff3dd8-fd82-4fd5-bba4-994684d4092d"
      unitRef="usd">48900000</prta:AllocatedConsiderationtoPerformanceObligations>
    <prta:AllocatedConsiderationtoPerformanceObligations
      contextRef="ia759813a15794ad4bdcf62a8a938c100_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM0NjM_a52630f2-7ede-470d-bfe1-14a79c9f3a63"
      unitRef="usd">4600000</prta:AllocatedConsiderationtoPerformanceObligations>
    <prta:AllocatedConsiderationtoPerformanceObligations
      contextRef="ic7b2c3d5be4540b6921b9e212efe9451_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM1MTU_40fe55a3-3810-4e71-94fa-0be344c0dc44"
      unitRef="usd">1100000</prta:AllocatedConsiderationtoPerformanceObligations>
    <prta:AllocatedConsiderationtoPerformanceObligations
      contextRef="ic84e2a6f4eb048d58a8ce416274ea456_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM1NjU_b7f05eb2-d54c-417c-a5d7-dfa015c9f2e3"
      unitRef="usd">600000</prta:AllocatedConsiderationtoPerformanceObligations>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic854f60120d74aedb489b48755f518b9_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM3MjQ_17f6aa0e-c585-4fb8-b993-a752851b5059"
      unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ibca1ba5c855446de877d16de250feabe_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM3MjQ_46419f89-d60c-4de9-925d-152e5faca9d7"
      unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <prta:ASC605AllocatedConsiderationtoDeliverables
      contextRef="i0175d817a5f44f01ac9efd8385decd07_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM4MzA_56259151-c81a-4469-b2af-71952cd2cc4b"
      unitRef="usd">35600000</prta:ASC605AllocatedConsiderationtoDeliverables>
    <prta:ASC605AllocatedConsiderationtoDeliverables
      contextRef="ia759813a15794ad4bdcf62a8a938c100_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM4NjU_7ba8a7a6-b7cd-46a9-a434-00c030b4eb95"
      unitRef="usd">3300000</prta:ASC605AllocatedConsiderationtoDeliverables>
    <prta:ASC605AllocatedConsiderationtoDeliverables
      contextRef="ic7b2c3d5be4540b6921b9e212efe9451_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM5MTc_7d29a8bf-5187-4655-99ea-1579e074aa5e"
      unitRef="usd">800000</prta:ASC605AllocatedConsiderationtoDeliverables>
    <prta:ASC605AllocatedConsiderationtoDeliverables
      contextRef="ic84e2a6f4eb048d58a8ce416274ea456_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTM5Njc_7acd0159-71e6-4174-a238-4e8ba9e3be44"
      unitRef="usd">400000</prta:ASC605AllocatedConsiderationtoDeliverables>
    <prta:LicenseAgreementDevelopmentServicesPaymentTerm
      contextRef="i0c607e622d1f49aa8ceca2e000427c5e_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTYxMTA_f4b73d80-8353-4132-9342-b53abdc326d4">P45D</prta:LicenseAgreementDevelopmentServicesPaymentTerm>
    <prta:LicenseAgreementMilestonePaymentsPaymentTerm
      contextRef="i0c607e622d1f49aa8ceca2e000427c5e_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTYzNjI_abcd7e95-5602-4177-a8cc-1b88186ffebc">P45D</prta:LicenseAgreementMilestonePaymentsPaymentTerm>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia09f6d9b318949658f4b5edbbc1060d4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTkzMjA_9a412c9b-07a6-483f-ac40-87ba1a0fb96e"
      unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <prta:CollaborationRevenue
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMTA5OTUxMTY2OTkzMQ_cf5d1ba9-7dfe-447a-b043-66108a441179"
      unitRef="usd">100000</prta:CollaborationRevenue>
    <prta:CollaborationRevenue
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjA0NzMxMzk5NDk3OQ_7065e8af-ff8f-477f-a770-a16bbaa93e6c"
      unitRef="usd">300000</prta:CollaborationRevenue>
    <prta:CollaborationRevenue
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjU5NzA2OTgwOTQxNg_655134f0-a2a9-47d4-ad66-59be01d80d39"
      unitRef="usd">200000</prta:CollaborationRevenue>
    <prta:CollaborationRevenue
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjA0NzMxMzk5NTAwNg_a18a2803-c6e0-4456-88d7-854924bf6037"
      unitRef="usd">400000</prta:CollaborationRevenue>
    <prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense
      contextRef="iec0766c4dcbb452d92267a1537fc4521_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjA0NzMxMzk5NTEyMg_f0fca562-eb7b-4828-8617-6d53d7b88fb7"
      unitRef="usd">4500000</prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense>
    <prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense
      contextRef="i0839fcc25ca9435088d7d44e078e72fd_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjAzMjk_f28a0593-2520-4eea-80fb-59ed6cca9ba8"
      unitRef="usd">8500000</prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense>
    <prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense
      contextRef="i5da9211e8d7c43f6be07d56a02195be6_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjA0NzMxMzk5NTIzMw_62faf824-80d5-4b13-958a-865975f12185"
      unitRef="usd">1100000</prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense>
    <prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense
      contextRef="ic027828db76f4a93885ac0251d9ed379_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNjA0NzMxMzk5NTI0NQ_59257c22-8a60-4410-9f21-e330f3018836"
      unitRef="usd">4000000.0</prta:ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i073a0b78fb35421ba6e8592c0a197dfe_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjA0Njg_e7b08d51-d54f-45cf-9926-8328f6675e44"
      unitRef="usd">4000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i10bc3926f14143428f8b45360781a239_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjA0NzU_507f4d6c-5428-4470-b0b7-5babf3228c2f"
      unitRef="usd">2000</us-gaap:AccountsReceivableNetCurrent>
    <prta:CollaborationAgreementUpfrontPayment
      contextRef="idf958f5bfd554f5db359067fc2e7e217_I20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjQwMjg_70c4380c-17ac-4d3e-a9d6-362def5e1833"
      unitRef="usd">100000000.0</prta:CollaborationAgreementUpfrontPayment>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjQ0MzQ_d6e98a2f-5c44-40f0-a029-40461563e3a5"
      unitRef="shares">1174536</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i823dfe17698f4577941dc181be64c092_I20180320"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjQ0ODU_84ee0fe7-aef9-4b43-acff-081769bdc82e"
      unitRef="usdPerShare">42.57</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjQ1Mjg_9fb7824d-0732-4df6-90c0-ab25cf6ceef1"
      unitRef="usd">50000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <prta:CollaborationAgreementExerciseFeeperProgram
      contextRef="ibb2d17fa473c4e86a3e307306a386a61_D20180320-20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjUyODM_677a456b-724b-4603-94d7-6988ce42f866"
      unitRef="usd">80000000.0</prta:CollaborationAgreementExerciseFeeperProgram>
    <prta:CollaborationAgreementExerciseFeeperProgram
      contextRef="i781ce1f9fb114a1288a2399d11b4d4a5_D20180320-20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjYyOTY_018ef881-0e3c-4c2a-bcfd-e75447166247"
      unitRef="usd">55000000.0</prta:CollaborationAgreementExerciseFeeperProgram>
    <prta:CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram
      contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjY3MTE_3663cc2f-b060-48ff-9bf1-1e6c09823026"
      unitRef="usd">562500000</prta:CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram>
    <prta:CollaborationAgreementTermofAgreement
      contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjc4NDA_2035f8bb-a8a0-4ab6-9526-c6dee32f433a">P6Y</prta:CollaborationAgreementTermofAgreement>
    <prta:CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed
      contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjc4NzU_8df49550-bd73-4e02-86ac-a7fdd8d57c93"
      unitRef="agreement_term">2</prta:CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed>
    <prta:CollaborationAgreementExtensionFeeperExtensionPeriod
      contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjc5MzY_1fa42f23-1a63-4a25-89a3-ffb816151df0"
      unitRef="usd">10000000.0</prta:CollaborationAgreementExtensionFeeperExtensionPeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjkxMTU_d6e98a2f-5c44-40f0-a029-40461563e3a5"
      unitRef="shares">1174536</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMjkyMTk_9fb7824d-0732-4df6-90c0-ab25cf6ceef1"
      unitRef="usd">50000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <prta:InitialTransactionPrice
      contextRef="i1a7adf1102ac42aa80af37c1765abece_I20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzU5MDE_1b6ba73e-58d8-49be-813c-2d0e7cb80954"
      unitRef="usd">110200000</prta:InitialTransactionPrice>
    <prta:CollaborationAgreementUpfrontPayment
      contextRef="idf958f5bfd554f5db359067fc2e7e217_I20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzU5MTk_70c4380c-17ac-4d3e-a9d6-362def5e1833"
      unitRef="usd">100000000.0</prta:CollaborationAgreementUpfrontPayment>
    <prta:SaleofStockPremiumReceivedonTransaction
      contextRef="i67b088da45a0403d8abb818ef6a6e41d_D20180320-20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzU5NDI_d112fc57-2a81-43d4-9bef-8f5b144d5820"
      unitRef="usd">10200000</prta:SaleofStockPremiumReceivedonTransaction>
    <prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice
      contextRef="ifa4c2edd44bb4660bab9e79530b6b7fe_I20180320"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzYxNTg_2e0f3d99-9ef9-40eb-8060-57ced64d23a9"
      unitRef="usd">15000000</prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice>
    <prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice
      contextRef="ie08072583f71487086cd63ba104febe6_I20180320"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzYxNjE_22dcda5a-d685-4edd-bb92-c54d3a5813a3"
      unitRef="usd">25000000</prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice>
    <prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice
      contextRef="i754447b94e7e46e1832a0a572e8edf4d_I20180320"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzYxNjg_398d1943-77db-48a6-9079-4158332a6319"
      unitRef="usd">10000000</prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice>
    <prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice
      contextRef="i9a50341614dd4cabbccefeba93a88fd1_I20180320"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzYxNzE_eebc7db9-f658-46d1-a875-968d8ed5480b"
      unitRef="usd">18000000</prta:CollaborationAgreementExpectedAllocationofInitialTransactionPrice>
    <prta:CollaborationAgreementUpfrontPayment
      contextRef="idf958f5bfd554f5db359067fc2e7e217_I20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzk0NDk_70c4380c-17ac-4d3e-a9d6-362def5e1833"
      unitRef="usd">100000000.0</prta:CollaborationAgreementUpfrontPayment>
    <prta:CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm
      contextRef="ib3af3029eed3421a82c2f0230468f71d_D20180320-20180320"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzk2MzI_33e0a263-923f-45ec-838e-3cd6243f6761">P30D</prta:CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm>
    <prta:CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram
      contextRef="i2f99a1d0727d46a9adc11dcafd022744_I20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDAzNzE_c513d87d-49db-4a1c-b0ea-27b019873cc9"
      unitRef="usd">90000000.0</prta:CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram>
    <prta:CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram
      contextRef="i2f99a1d0727d46a9adc11dcafd022744_I20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDA0ODI_ab4438aa-7362-47ed-9861-5486bfd044ad"
      unitRef="usd">375000000.0</prta:CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram>
    <prta:CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram
      contextRef="ib5d8e1da3a7d44d8a442dd98f2a66211_I20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDA2NzQ_b3225e2e-35a8-4b6d-8e0b-621e55680651"
      unitRef="usd">187500000</prta:CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram>
    <prta:CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram
      contextRef="ib5d8e1da3a7d44d8a442dd98f2a66211_I20180320"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfNDA3ODI_c63aa5d6-1d71-41dc-9ac0-0becb30e41d6"
      unitRef="usd">375000000.0</prta:CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfNzA4_866cb1d8-d69e-44f6-b1bf-2447a7eaadc7">Shareholders' Equity&lt;div style="text-indent:9pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Ordinary Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company had 100,000,000 ordinary shares authorized for issuance with a par value of $0.01 per ordinary share and 39,911,413 ordinary shares issued and outstanding. Each ordinary share is entitled to one vote and, on a pro rata basis, to dividends when declared and the remaining assets of the Company in the event of a winding up.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Euro Deferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company had 10,000 Euro Deferred Shares authorized for issuance with a nominal value of &#x20ac;22&#160;per share. No Euro Deferred Shares are outstanding at June&#160;30, 2020. The rights and restrictions attaching to the Euro Deferred Shares rank &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;pari passu&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; with the ordinary shares and are treated as a single class in all respects.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfNzE_97a55bdd-496d-45d2-bbc4-d336bc6c25d1"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfMTM0_ac37072b-697c-4eaf-8817-047c8e63fae2"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfMTYw_7f7e2eed-eb3e-4414-9b13-4737894487be"
      unitRef="shares">39911413</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfMTYw_e3c70a11-79d1-4ced-bfef-654219e57795"
      unitRef="shares">39911413</us-gaap:CommonStockSharesOutstanding>
    <prta:NumberofVotes
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfMjM4_8d1d7315-4867-4044-b7ea-94d7ab9b3160"
      unitRef="vote">1</prta:NumberofVotes>
    <prta:DeferredSharesSharesAuthorized
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfNDE2_a79f75a7-4f9c-4362-b1aa-488620182e4a"
      unitRef="shares">10000</prta:DeferredSharesSharesAuthorized>
    <prta:DeferredSharesParValue
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfNDg4_18801aec-9d9b-434b-b18e-cfe199120e06"
      unitRef="eurPerShare">22</prta:DeferredSharesParValue>
    <prta:DeferredSharesShareOutstanding
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182MS9mcmFnOjk0ZWNlZjlkYzFiOTRlNWY5YTg4Mjg5N2I1MDkzMmFkL3RleHRyZWdpb246OTRlY2VmOWRjMWI5NGU1ZjlhODgyODk3YjUwOTMyYWRfNTAy_93c7935f-45b7-49b3-92cf-09107c87643d"
      unitRef="shares">0</prta:DeferredSharesShareOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if308d0f707774e83b68197d8cba203b0_D20180515-20180515"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjQ1Nw_d9661960-c106-4a63-976a-f8accc2a6ba7">Share-Based Compensation&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2018 Long Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2018, the Company&#x2019;s shareholders approved the 2018 Long Term Incentive Plan. In May 2020, the Company's shareholders approved an amendment to the 2018 Long Term Incentive Plan (as amended, the &#x201c;2018 LTIP&#x201d;) to increase the number of ordinary shares available for issuance under that Plan by 1,500,000 ordinary shares. Under the 2018 LTIP, the number of ordinary shares authorized for issuance under the 2018 LTIP is equal to the sum of (a) 3,300,000 ordinary shares, (b) 1,177,933 ordinary shares that were available for issuance under the 2012 LTIP as of the May 15, 2018, effective date of the 2018 LTIP, and (c) any ordinary shares subject to issued and outstanding awards under the 2012 Long Term Incentive Plan (the &#x201c;2012 LTIP&#x201d;) that expire, are cancelled or otherwise terminate following the effective date of the 2018 LTIP; provided, that no more than 2,500,000 ordinary shares may be issued pursuant to the exercise of ISOs. The 2018 LTIP provides for the grant of ISOs, NQSOs, SARs, restricted shares, RSUs, performance bonus awards, performance share units awards, dividend equivalents and other share or cash-based awards to eligible individuals. Options under the 2018 LTIP may be granted for periods up to ten years. All options issued to date have had a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTcwNDI0MzAyMzk3NDM_37e1f852-c414-4fe4-86e8-7b6225eb6fa8"&gt;ten&lt;/span&gt; year life. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Amended and Restated 2012 Long Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to the effective date of the 2018 LTIP, employees and consultants of the Company, its subsidiaries and affiliates, as well as members of the Company&#x2019;s Board of Directors, received equity awards under the 2012 LTIP. Options under the 2012 LTIP were granted for periods up to ten years. All options issued to date have had a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTQ0Mw_743a930b-b10b-459b-82c5-ed0937653214"&gt;ten&lt;/span&gt; year life.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2020 Employment Inducement Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On February 25, 2020, the Company's Board of Directors approved the 2020 Employment Inducement Incentive Plan. On April 1, 2020, the Company's Board of Directors approved an amendment to the 2020 Employment Inducement Incentive Plan (as amended, the "2020 EIIP") to increase the ordinary shares available for issuance under that Plan by 120,000 ordinary shares. The 2020 EIIP provides for the grant of NQSOs, SARs, restricted shares, RSUs, performance bonus awards, performance share units awards, or other share or cash-based awards to eligible individuals. Options under the 2020 EIIP may be granted for periods up to ten years. All options issued to date have had a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTkzNw_cef9d024-7d91-407e-8091-cfdb99879f97"&gt;ten&lt;/span&gt; year life. As of June&#160;30, 2020, the number of ordinary shares authorized for issuance under the 2020 EIIP was 360,000 and no ordinary shares remained available for future awards under the 2020 EIIP, although the Company's Board of Directors reserves the right to amend the 2020 EIIP to increase the number of ordinary shares available and to make additional awards to key new hires.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Shares Available for Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company granted 263,500 and 145,000 options during the three months ended June 30, 2020, and 2019, respectively, and 1,718,950 and 997,975 options during the six months ended June 30, 2020 and 2019, respectively, in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;aggregate under its equity plans. The Company&#x2019;s option awards generally vest over four years. As of June&#160;30, 2020, 1,402,179 ordinary shares remained available for grant under the 2018 LTIP, and options to purchase 8,672,205 ordinary shares in aggregate under the Company's equity plans were outstanding with a weighted-average exercise price of approximately $21.09 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company estimates the fair value of share-based compensation on the date of grant using an option-pricing model. The Company uses the Black-Scholes model to value share-based compensation, excluding RSUs, which the Company values using the fair market value of its ordinary shares on the date of grant. The Black-Scholes option-pricing model determines the fair value of share-based payment awards based on the share price on the date of grant and is affected by assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, the Company&#x2019;s share price, volatility over the expected life of the awards and actual and projected employee stock option exercise behaviors.  Since the Company does not have sufficient historical employee share option exercise data, the simplified method has been used to estimate the expected life of all options. The Company uses its historical volatility for the Company&#x2019;s stock to estimate expected volatility starting January 1, 2018. Although the fair value of share options granted by the Company is estimated by the Black-Scholes model, the estimated fair value may not be indicative of the fair value observed in a willing buyer and seller market transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As share-based compensation expense recognized in the Condensed Consolidated Financial Statements is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. Forfeitures were estimated based on estimated future turnover and historical experience.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Share-based compensation expense will continue to have an adverse impact on the Company&#x2019;s results of operations, although it will have no impact on its overall financial position. The amount of unearned share-based compensation currently estimated to be expensed from now through the year 2024 related to unvested share-based payment awards at June&#160;30, 2020, is $41.8 million. The weighted-average period over which the unearned share-based compensation is expected to be recognized is 2.63 years. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate and/or increase any remaining unearned share-based compensation expense. Future share-based compensation expense and unearned share-based compensation will increase to the extent that the Company grants additional equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Share-based compensation expense recorded in these Condensed Consolidated Financial Statements for the three and six months ended June&#160;30, 2020, and 2019 was based on awards granted under the 2012 LTIP, the 2018 LTIP, and the 2020 EIIP. The following table summarizes share-based compensation expense for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.543%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.602%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognized tax benefits from share-based awards of $1.1 million and $1.2 million for the three months ended June 30, 2020, and 2019, and $2.2 million and $2.5 million for the six months ended June 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the options granted to employees and non-employee directors during the three and six months ended June&#160;30, 2020, and 2019 was estimated as of the grant date using the Black-Scholes option-pricing model assuming the weighted-average assumptions listed in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.274%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$7.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$6.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$8.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$9.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period for each award. Each of the inputs discussed above is subjective and generally requires significant management judgment to determine.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company&#x2019;s stock option activity during the six months ended June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:47.853%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.549%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.555%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,008,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,718,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,672,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,194,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,500,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The total intrinsic value of options exercised was approximately none and $103,000 during the three months ended June 30, 2020, and 2019, respectively, and $35,000 and $109,000 during the six months ended June 30, 2020 and 2019, respectively, determined as of the date of exercise.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i044cf0c67aab4755b4c3d1811b2ed835_D20200519-20200519"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTY0OTI2NzQ0OTQ0MA_a6e66a8d-a853-43cb-8c0b-11a3c6e0dff5"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i963269705b7b4e5f9ae3a71c1c9ff5bd_I20180515"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTY0OTI2NzQ0OTUxNw_e8a6677b-8c3b-4fe5-abb9-8a972829fab2"
      unitRef="shares">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i8c7ac19e5f714d5c9b45c2f8f4858855_D20180515-20180515"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjQz_3547e2bc-56cd-4f90-8acc-182a16995c11"
      unitRef="shares">1177933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <prta:MaximumNumberofSharestobeIssuedISOExercise
      contextRef="i21f801f178cb46208ea96162e7973433_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTAwNg_b6a5147e-54a8-4fc1-9351-7e1965d3fce8"
      unitRef="shares">2500000</prta:MaximumNumberofSharestobeIssuedISOExercise>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i8c7ac19e5f714d5c9b45c2f8f4858855_D20180515-20180515"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMzI5ODUzNDg5NDIwMA_3d59bfb6-89c2-40fe-8365-ab581dabe1cd">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ifc344697e4b14499a86b91af81b71dcf_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTM5NQ_743a930b-b10b-459b-82c5-ed0937653214">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i13cded138cc145cf8025f23802654b94_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTY0OTI2NzQ0OTI0MQ_41058eec-0c09-48db-ae6f-4588fa6dd2ef"
      unitRef="shares">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i6f0f422fe8fd406e815795229f9d4c4a_D20200225-20200225"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMzI5ODUzNDg5NDIxOA_fc749ea5-4320-41d8-b7cd-2336908d9ea3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i5e195fad49074becb102c91d64d9ebb5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjAzOQ_dd607cf6-36f3-40db-aafa-90546c4b689b"
      unitRef="shares">360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5e195fad49074becb102c91d64d9ebb5_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjA0Ng_80bca8a3-7b00-43a4-b680-4a606846bb69"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTI2Mw_8c33ef02-2b91-49eb-92cc-3de80cb1f00c"
      unitRef="shares">263500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTI3MA_938a11f8-cfd6-437c-b063-60a865a818dd"
      unitRef="shares">145000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTI4OA_1fa491fe-186e-45c5-abe1-5548060f00d9"
      unitRef="shares">1718950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTM1Mw_e314cd13-93ba-4751-8397-305221d163b1"
      unitRef="shares">997975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjQ5NA_2039f285-0e55-4e9f-b4e8-07a0db8273ad">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i21f801f178cb46208ea96162e7973433_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjUxNA_d5f9d96a-d85e-4d0f-aec1-3979b57fa90c"
      unitRef="shares">1402179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjYwNw_e65dbe05-e1b6-41ee-9270-046ffbc2012c"
      unitRef="shares">8672205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMjc0NQ_22bb2221-c57e-46c7-ab3f-96f400558297"
      unitRef="usdPerShare">21.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNDgxOA_229f5551-9341-4c18-a194-df5b370b739f"
      unitRef="usd">41800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNDkzMQ_97a431c2-92b2-4cc9-8ea6-d06cee733ad7">P2Y7M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjQ2Mg_85353c26-c90c-4a7d-8104-6d58c2af9650">The following table summarizes share-based compensation expense for the periods presented (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.543%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.602%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i3afaf46701c249838b3b57dcd7cd2fd1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMi0yLTEtMS0w_51a65944-2387-4489-87b0-8d89b3338237"
      unitRef="usd">2058000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i619b94a5d1c748048b980c4beb1d3f80_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMi00LTEtMS0w_e6b22d09-0361-4ed0-90f9-fc1fb955e621"
      unitRef="usd">2100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5770524a4fb64c908398d01f9b105d07_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMi02LTEtMS0xMDEx_038ff162-af03-45c5-8c0f-0e5c4472a516"
      unitRef="usd">4075000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6af301e0d5464d0f8688b96cc7ecbcc2_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMi04LTEtMS0xMDEx_58d41ffd-1d44-4209-a96b-3a63e84882db"
      unitRef="usd">4199000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia19f4446d12d455d8ed873aacb41c471_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMy0yLTEtMS0w_7c888ec9-4f74-462e-a723-7ddb4c9ec137"
      unitRef="usd">3629000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1d8293363e094a25a626f7be205cd571_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMy00LTEtMS0w_39f8d378-1a37-4169-8c69-dafc6cfe0ff2"
      unitRef="usd">4177000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0c7537c8b63e44b2b5a02d22312caaac_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMy02LTEtMS0xMDEx_824388fb-7770-44c0-a51a-e58a487306d4"
      unitRef="usd">7148000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ida53c60bb2f6447e8d6a93e583eb07f7_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfMy04LTEtMS0xMDEx_6f42733e-5cde-4033-b9d5-8fe93f491bae"
      unitRef="usd">8283000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfNC0yLTEtMS0w_b0bf9824-bc0b-48e6-9f53-6065a1b7f7ff"
      unitRef="usd">5687000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfNC00LTEtMS0w_95434ce9-91ab-4695-9256-99ad86cd016c"
      unitRef="usd">6277000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfNC02LTEtMS0xMDE0_384585cf-936d-4500-8644-b3a90886477d"
      unitRef="usd">11223000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOjhiNTAwYTRjNTUxMzQ5OTdhNzFiMmY4MWZlYWRhYjU0L3RhYmxlcmFuZ2U6OGI1MDBhNGM1NTEzNDk5N2E3MWIyZjgxZmVhZGFiNTRfNC04LTEtMS0xMDE0_1ccced97-3f9c-4780-b5a1-d15729325373"
      unitRef="usd">12482000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i44af5ba0fe6a40a0b2d7a1b155ed8d12_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQ0Mw_2c1e9166-a9e8-44f1-bb31-90ba66918bdf"
      unitRef="usd">1100000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="iea1807fc55f1435bb318a4fb39dde186_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQ0NQ_9e5461ba-f44f-4beb-b262-16a3e45dae79"
      unitRef="usd">1200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ied6043afc98548c7ae9c22d39f61cb44_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQzNA_306c6ca4-0c95-45bc-84f8-e8f76fb17c84"
      unitRef="usd">2200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="iacb3936c27de4e4c87eba688149d459e_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQ0MQ_d9fffcba-d442-4d2c-9327-379c77b4a723"
      unitRef="usd">2500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjQ1Mw_62d0b64d-0da6-48a0-aa7f-2f113a0a2c52">&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the options granted to employees and non-employee directors during the three and six months ended June&#160;30, 2020, and 2019 was estimated as of the grant date using the Black-Scholes option-pricing model assuming the weighted-average assumptions listed in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.274%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$7.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$6.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$8.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$9.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMi0xLTEtMS0xMDgz_fda49c42-62c6-44b7-8371-f9746b54fcd9"
      unitRef="number">0.796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMi0zLTEtMS0xMDg3_c73508ce-400f-452b-922c-f76291ca5319"
      unitRef="number">0.815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMi0xLTEtMS0w_aecefa09-af41-4434-9f2a-8effdf8fe278"
      unitRef="number">0.812</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMi0zLTEtMS0w_7cab9803-282a-4aff-8c31-3e7106515be0"
      unitRef="number">0.815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMy0xLTEtMS0xMDgz_43275bb3-f24b-4d8d-927a-ab3de978d1c5"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMy0zLTEtMS0xMDg3_e3730202-b83d-4dea-8d21-af80abf60a95"
      unitRef="number">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMy0xLTEtMS0w_9345c6c1-22d9-4b8e-b63a-9310318fff1c"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfMy0zLTEtMS0w_86059dae-644b-46bf-b8d2-a110a6a71877"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNC0xLTEtMS0xMDgz_8133bc54-4d82-44b6-bc47-9d8dbdb81acc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNC0zLTEtMS0xMDg3_3cf3f1e9-8839-40dc-b31b-530a80ba4a34"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNC0xLTEtMS0w_5c6e0d90-ae59-4abf-9159-b625ad680b20"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNC0zLTEtMS0w_027230cb-2f0c-404f-b268-e74188a0505a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNS0xLTEtMS0xMDgz_78ba580e-1d02-4cc5-84aa-67c7fc5fe8a7">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNS0zLTEtMS0xMDg3_2ea0f94d-2e8a-4ccc-b226-df70357389e6">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNS0xLTEtMS0w_8981855a-cefc-4ea0-b4ba-ce702c718470">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNS0zLTEtMS0w_2d11b63a-648b-41ea-ab95-fa673215ccd1">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNi0xLTEtMS0xMDgz_31c7f8f4-f18b-49a2-b43f-f581e0d689e6"
      unitRef="usdPerShare">7.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNi0zLTEtMS0xMDg3_777c3e6d-ccc4-4112-b4f1-67738cceacf5"
      unitRef="usdPerShare">6.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNi0xLTEtMS0w_5c2f8b30-271c-4abf-b1dc-f239cc7747ad"
      unitRef="usdPerShare">8.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmFjYmFhYzExNWJhZTQ3NjA5OGE5ZTJiYzQ4NWQwZWZjL3RhYmxlcmFuZ2U6YWNiYWFjMTE1YmFlNDc2MDk4YTllMmJjNDg1ZDBlZmNfNi0zLTEtMS0w_fc251590-249c-484f-95ba-9cbc8fc11842"
      unitRef="usdPerShare">9.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjQ4OQ_e8235c8c-fa6a-491f-a99d-31413a447f54">&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company&#x2019;s stock option activity during the six months ended June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:47.853%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.257%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.549%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.555%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,008,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,718,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(20,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,672,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,194,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,500,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMS0xLTEtMS0w_7ffb9a0a-497c-4acb-9afb-9605e89f834e"
      unitRef="shares">7008403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMS0zLTEtMS0w_25758e18-1594-4832-ae3f-32149c4d3583"
      unitRef="usdPerShare">23.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3729d833e9b64a35af79dd7d137d50e1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMS01LTEtMS0w_504e18a8-4f92-41fa-875f-ceedb723666b">P7Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie5802a61ace64fa5b6a039e8e96e1697_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMS03LTEtMS0w_338f8ec7-11ca-4fbb-92e0-53312fce1c75"
      unitRef="usd">11901000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMi0xLTEtMS0w_25b06a7b-d2f6-4e6f-90d7-35407d8fda8d"
      unitRef="shares">1718950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMi0zLTEtMS0w_94d82a2a-604f-4028-aae4-e09cc6e3695d"
      unitRef="usdPerShare">11.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMy0xLTEtMS0w_3e628c76-16d2-45fe-bb52-5a1cd8b24e18"
      unitRef="shares">12852</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfMy0zLTEtMS0w_10bdc9aa-3e84-41ea-8ea8-eec7f0ed7c2f"
      unitRef="usdPerShare">11.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNC0xLTEtMS0w_262c52e4-0941-4d6f-98a1-9165481fde0d"
      unitRef="shares">20960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNC0zLTEtMS0w_e443a9bc-1415-4a47-a624-678f155ead41"
      unitRef="usdPerShare">11.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNS0xLTEtMS0w_df7e9d08-6258-47da-975a-19cc11372da7"
      unitRef="shares">21336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNS0zLTEtMS0w_205df9b6-b457-4cc4-bc74-9ec2cb9009eb"
      unitRef="usdPerShare">33.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNi0xLTEtMS0w_e65dbe05-e1b6-41ee-9270-046ffbc2012c"
      unitRef="shares">8672205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNi0zLTEtMS0w_22bb2221-c57e-46c7-ab3f-96f400558297"
      unitRef="usdPerShare">21.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNi01LTEtMS0w_e4dfc852-df5e-4af1-b7fc-648a87ce6ab6">P7Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNi03LTEtMS0w_31cac94b-cc19-49f5-8d69-109473ee8eac"
      unitRef="usd">2426000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNy0xLTEtMS0w_9f8472e4-6a19-4674-8ddd-8d53315a0855"
      unitRef="shares">8194918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNy0zLTEtMS0w_a72a0113-24da-4e8f-9839-be85645cb295"
      unitRef="usdPerShare">21.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNy01LTEtMS0w_424fe0f5-1398-4fee-b504-e4a0d6ae66dc">P7Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfNy03LTEtMS0w_b1fa478a-02be-4240-88b3-94d9e43f1fb5"
      unitRef="usd">2407000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfOC0xLTEtMS0w_e3427fef-d1e4-4411-8040-5f780e2f9012"
      unitRef="shares">4500202</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfOC0zLTEtMS0w_e6962e2c-5b75-44c4-8f4d-ddfe4e2c388a"
      unitRef="usdPerShare">26.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfOC01LTEtMS0w_2d5b88a7-271b-48b0-92b2-de0b0c13a7f6">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <prta:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions
      contextRef="i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RhYmxlOmNkNWVhZmMwMWUxNTQzMjdhYTY4M2RjODA3YWNlMzZmL3RhYmxlcmFuZ2U6Y2Q1ZWFmYzAxZTE1NDMyN2FhNjgzZGM4MDdhY2UzNmZfOC03LTEtMS0w_0e0fbb02-3986-470a-8f9a-ec7b791c252a"
      unitRef="usd">2254000</prta:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i44af5ba0fe6a40a0b2d7a1b155ed8d12_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTUyMw_bc38788a-db1b-4e61-a5e2-9951aa7d217f"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iea1807fc55f1435bb318a4fb39dde186_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTUyOA_776fa5e6-6ce2-444e-98ee-8b046e353522"
      unitRef="usd">103000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ied6043afc98548c7ae9c22d39f61cb44_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQ3Ng_1f3cad2e-0005-4e6b-866a-f1e92c0ad552"
      unitRef="usd">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iacb3936c27de4e4c87eba688149d459e_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfNjA0NzMxMzk1OTQ4NA_fdf36621-aef7-4c55-bc15-245c089c099c"
      unitRef="usd">109000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMzE0Nw_a4bb4445-6954-4bcc-b4c9-cfb6b8e59323">Income Taxes&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The major taxing jurisdictions for the Company are Ireland and the U.S. The Company recorded an income tax benefit of $255,000 and $421,000 for the three and six months ended June&#160;30, 2020, respectively, as compared to an income tax benefit of $156,000 and an income tax provision of $42,000 for the three and six months ended June&#160;30, 2019, respectively.&#160;The provision for income taxes differs from the statutory tax rate of 12.5% applicable to Ireland primarily due to Irish net operating losses for which a tax provision benefit is not recognized, U.S. income taxed at different rates, and net tax shortfall from cancellations of stock options. The income tax provision reflects the estimate of the effective tax rate expected to be applicable for the full year and the Company re-evaluates this estimate each quarter based on its forecasted tax expense for the full year. Jurisdictions with a projected loss for the year where no tax benefit can be recognized are excluded from the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to ASU 2016-09, the Company recorded a net tax shortfall of a nominal amount and $0.1&#160;million for the three and six months ended June&#160;30, 2020, respectively, and a net tax shortfall of $0.3&#160;million and $1.0&#160;million for the three and six months ended June&#160;30, 2019, respectively, all of which were recorded as part of its income tax provision in the Condensed Consolidated Statements of Operations. The Company&#x2019;s income tax expense will continue to be impacted by fluctuations in stock price between the grant dates and the exercise dates of its option awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 1, 2019, the Company adopted ASC 842, and it recorded a reduction in deferred tax assets of $1.0 million as part of the $3.8 million change in the opening balance of the accumulated deficit for the cumulative effect of applying ASC 842.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company's deferred tax assets are composed primarily of its Irish subsidiaries' net operating loss carryovers, state net operating loss carryforwards available to reduce future taxable income of the Company's U.S. subsidiaries, federal and California tax credit carryforwards, share-based compensation and other temporary differences. The Company maintains a valuation allowance against certain U.S. federal and state and Irish deferred tax assets. Each reporting period, the Company evaluates the need for a valuation allowance on its deferred tax assets by jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;No provision for income tax in Ireland has been recognized on undistributed earnings of the Company&#x2019;s U.S. subsidiaries. The Company considers the U.S. earnings to be indefinitely reinvested. The Company's Swiss subsidiary, Prothena Switzerland GmbH ("PSG") has ceased operations and the Company finalized the liquidation of PSG in May 2020. Unremitted earnings may be subject to withholding taxes (potentially at 5% in the U.S.) and Irish taxes (potentially at a rate of 12.5%) if they were to be distributed as dividends. However, Ireland allows a credit against Irish taxes for U.S. taxes withheld, and as of June&#160;30, 2020, the Company's current year net operating losses in Ireland are sufficient to offset any potential dividend income received from its overseas subsidiaries.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfNjA0NzMxMzk1NjAxMA_5d7b26b7-2af5-4fbb-89c0-63e553b582ab"
      unitRef="usd">-255000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfNjA0NzMxMzk1NjAwMw_90d9c9e2-c559-449a-b0a3-1b45ec13b2bf"
      unitRef="usd">-421000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfNjA0NzMxMzk1NjAwOA_fd7dab2a-d811-4a2f-b415-15b79d233d13"
      unitRef="usd">-156000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfNjA0NzMxMzk1NjAyOA_816038d9-e97d-4eb8-9647-1b03d4b771f3"
      unitRef="usd">42000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3dbe480e059f408dbac0ebcadbd9f854_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMjgx_6dc95edd-7ad4-4f42-9813-8cb8cc44eef3"
      unitRef="number">0.125</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
      contextRef="i0a5677df40f949d086dd9086c825700e_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMTE1NDQ4NzIwOTUxODY_6baf63dc-e8e9-4155-a7ab-ba72c97d1dd3"
      unitRef="usd">0</prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision>
    <prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
      contextRef="idb76403e4028485ca36aacfa08b19700_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfOTQ0_f9a4252b-b114-4899-8670-514d9bf59c14"
      unitRef="usd">100000</prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision>
    <prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
      contextRef="i50ab40dc0079467b9798e55723340f88_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMTE1NDQ4NzIwOTUyMTY_c1e2158b-8e3a-4ebf-ba33-f3afdc034d27"
      unitRef="usd">300000</prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision>
    <prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
      contextRef="ib612099e198c4efab25951ab36aa97c6_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMTE1NDQ4NzIwOTUyMDI_d8d07b05-4659-49d0-a56b-0d4cbb56d9ac"
      unitRef="usd">1000000.0</prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision>
    <prta:NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets
      contextRef="ib78a576b8afe40d2aaeedaae8a663a59_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMTM3Mg_353c6631-981f-4abd-aad1-69bd2c4a04cd"
      unitRef="usd">1000000.0</prta:NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib78a576b8afe40d2aaeedaae8a663a59_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMTM5MA_f0c29f68-e974-42ac-91f4-ce3fb3689785"
      unitRef="usd">3800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <prta:PotentialWithholdingTaxRate
      contextRef="i051466dca10b47ce8e0373f83d6dd3c4_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMjc4OA_63a53263-e447-4652-a85d-050602cf32dd"
      unitRef="number">0.05</prta:PotentialWithholdingTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3dbe480e059f408dbac0ebcadbd9f854_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y183MC9mcmFnOjM4ZDFmYTAzMDgxMzQ0NzVhNTYzMzRiNGU4YTI4OTc3L3RleHRyZWdpb246MzhkMWZhMDMwODEzNDQ3NWE1NjMzNGI0ZThhMjg5NzdfMjg0Ng_a251c023-931c-4229-8b77-c89e3b712b5f"
      unitRef="number">0.125</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMC0xLTEtMA_ed5c89f7-7a2d-4b6f-b487-7eca19bf639f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMC0xLTEtMA_ed5c89f7-7a2d-4b6f-b487-7eca19bf639f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTA4Ng_b90c43e7-5b76-4c95-a964-a50a1b7740f8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTA4Ng_b90c43e7-5b76-4c95-a964-a50a1b7740f8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS00LTEtMS0w_0d6a5349-1f1d-4ee2-bf18-2da78d46b732"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS00LTEtMS0w_0d6a5349-1f1d-4ee2-bf18-2da78d46b732"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xNC0xLTEtMA_e2091f3a-244a-47c5-a346-3a51b3732344"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xNC0xLTEtMA_e2091f3a-244a-47c5-a346-3a51b3732344"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS02LTEtMS0w_968e18ff-f704-40e1-af8e-ade8d713a7d5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS02LTEtMS0w_968e18ff-f704-40e1-af8e-ade8d713a7d5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMi0xLTEtMA_0b3aeffe-6172-4012-aac6-b156ff07d4e6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMi0xLTEtMA_0b3aeffe-6172-4012-aac6-b156ff07d4e6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0yLTEtMS0w_5f3108b4-003e-4217-97a9-918ad4eff694"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0yLTEtMS0w_5f3108b4-003e-4217-97a9-918ad4eff694"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS04LTEtMS0w_3ec32750-c162-4cbe-a782-73b16508ce2a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS04LTEtMS0w_3ec32750-c162-4cbe-a782-73b16508ce2a"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Purchase obligations consist of non-cancelable purchase commitments to suppliers.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMC0xLTEtMA_ed5c89f7-7a2d-4b6f-b487-7eca19bf639f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTA4Ng_b90c43e7-5b76-4c95-a964-a50a1b7740f8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS00LTEtMS0w_0d6a5349-1f1d-4ee2-bf18-2da78d46b732"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xNC0xLTEtMA_e2091f3a-244a-47c5-a346-3a51b3732344"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS02LTEtMS0w_968e18ff-f704-40e1-af8e-ade8d713a7d5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0xMi0xLTEtMA_0b3aeffe-6172-4012-aac6-b156ff07d4e6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS0yLTEtMS0w_5f3108b4-003e-4217-97a9-918ad4eff694"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMS04LTEtMS0w_3ec32750-c162-4cbe-a782-73b16508ce2a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTcxMg_637b2040-9a54-4dfc-a9a8-57e1b5ea3b8b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xNC0xLTEtMA_c91b8d3a-9589-4833-8207-44eef2597f50"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xNC0xLTEtMA_c91b8d3a-9589-4833-8207-44eef2597f50"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi02LTEtMS0w_216f6b01-ebe6-41d8-8814-5b4e6a8c3b1d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi02LTEtMS0w_216f6b01-ebe6-41d8-8814-5b4e6a8c3b1d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi04LTEtMS0w_298f6cfa-762b-416b-9a52-e0f6c5e01f00"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi04LTEtMS0w_298f6cfa-762b-416b-9a52-e0f6c5e01f00"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi00LTEtMS0w_1fa28666-44ab-4ba3-a3f7-564d7a236b83"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi00LTEtMS0w_1fa28666-44ab-4ba3-a3f7-564d7a236b83"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0yLTEtMS0w_27166e2e-f2bf-45c2-889c-3e5de0a062f3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0yLTEtMS0w_27166e2e-f2bf-45c2-889c-3e5de0a062f3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMC0xLTEtMA_cb5c692b-52a0-4e68-8193-10c979c52cb3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMC0xLTEtMA_cb5c692b-52a0-4e68-8193-10c979c52cb3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMi0xLTEtMA_350d758a-8b8b-4f0f-9fec-3804b88e6df1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMi0xLTEtMA_350d758a-8b8b-4f0f-9fec-3804b88e6df1"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5MQ_d26b4a34-2365-4ad3-86c2-aef2e41ba8e2" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5MQ_d26b4a34-2365-4ad3-86c2-aef2e41ba8e2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Excludes future obligations pursuant to the cost-sharing arrangement under the Company's License Agreement with Roche. Amounts of such obligations, if any, cannot be determined at this time.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xNC0xLTEtMA_c91b8d3a-9589-4833-8207-44eef2597f50"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5MQ_d26b4a34-2365-4ad3-86c2-aef2e41ba8e2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi02LTEtMS0w_216f6b01-ebe6-41d8-8814-5b4e6a8c3b1d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5MQ_d26b4a34-2365-4ad3-86c2-aef2e41ba8e2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi04LTEtMS0w_298f6cfa-762b-416b-9a52-e0f6c5e01f00"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5MQ_d26b4a34-2365-4ad3-86c2-aef2e41ba8e2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi00LTEtMS0w_1fa28666-44ab-4ba3-a3f7-564d7a236b83"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5MQ_d26b4a34-2365-4ad3-86c2-aef2e41ba8e2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0yLTEtMS0w_27166e2e-f2bf-45c2-889c-3e5de0a062f3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5MQ_d26b4a34-2365-4ad3-86c2-aef2e41ba8e2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMC0xLTEtMA_cb5c692b-52a0-4e68-8193-10c979c52cb3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5MQ_d26b4a34-2365-4ad3-86c2-aef2e41ba8e2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RhYmxlOjM3NzI5OWYwMDA5NjQ3ZjFhODVhOGY2ZmZhZjkwNmVkL3RhYmxlcmFuZ2U6Mzc3Mjk5ZjAwMDk2NDdmMWE4NWE4ZjZmZmFmOTA2ZWRfMi0xMi0xLTEtMA_350d758a-8b8b-4f0f-9fec-3804b88e6df1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y180OS9mcmFnOjExMmJjZGFiYjdiYTQ4MjlhMjA4ZTU5M2ViZDM2ZTZlL3RleHRyZWdpb246MTEyYmNkYWJiN2JhNDgyOWEyMDhlNTkzZWJkMzZlNmVfOTY5MQ_d26b4a34-2365-4ad3-86c2-aef2e41ba8e2"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717685619800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTHENA CORPORATION PUBLIC LIMITED COMPANY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1111119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">77 Sir John Rogerson&#8217;s Quay, Block C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Grand Canal Docklands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin 2,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">D02 T804,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">236-2500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PRTA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Ordinary Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,911,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001559053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717685374232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 333,942<span></span>
</td>
<td class="nump">$ 375,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,125<span></span>
</td>
<td class="nump">2,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">341,123<span></span>
</td>
<td class="nump">378,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,215<span></span>
</td>
<td class="nump">3,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">20,570<span></span>
</td>
<td class="nump">23,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">11,017<span></span>
</td>
<td class="nump">9,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">37,810<span></span>
</td>
<td class="nump">40,893<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">378,933<span></span>
</td>
<td class="nump">419,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,124<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">6,152<span></span>
</td>
<td class="nump">5,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable, current</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">5,304<span></span>
</td>
<td class="nump">5,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">4,743<span></span>
</td>
<td class="nump">5,540<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,544<span></span>
</td>
<td class="nump">17,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">110,242<span></span>
</td>
<td class="nump">110,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, non-current</a></td>
<td class="nump">15,150<span></span>
</td>
<td class="nump">17,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">125,945<span></span>
</td>
<td class="nump">128,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">144,489<span></span>
</td>
<td class="nump">146,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_DeferredSharesValue', window );">Euro deferred shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">955,781<span></span>
</td>
<td class="nump">944,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(721,736)<span></span>
</td>
<td class="num">(671,885)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">234,444<span></span>
</td>
<td class="nump">272,921<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 378,933<span></span>
</td>
<td class="nump">$ 419,268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_DeferredSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_DeferredSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717681861912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_DeferredSharesParValue', window );">Euro deferred shares, nominal value (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_DeferredSharesSharesAuthorized', window );">Euro deferred shares, number of shares authorized (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_DeferredSharesShareIssued', window );">Euro deferred shares, number of issued shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_DeferredSharesShareOutstanding', window );">Euro deferred shares, number of outstanding shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, number of authorized shares (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, number of issued shares (in shares)</a></td>
<td class="nump">39,911,413<span></span>
</td>
<td class="nump">39,911,413<span></span>
</td>
<td class="nump">39,898,561<span></span>
</td>
<td class="nump">39,898,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, number of outstanding shares (in shares)</a></td>
<td class="nump">39,911,413<span></span>
</td>
<td class="nump">39,911,413<span></span>
</td>
<td class="nump">39,898,561<span></span>
</td>
<td class="nump">39,898,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_DeferredSharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares Par Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_DeferredSharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_DeferredSharesShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares Share Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_DeferredSharesShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_DeferredSharesShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares Share Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_DeferredSharesShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_DeferredSharesSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_DeferredSharesSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717681897096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 195,000<span></span>
</td>
<td class="nump">$ 167,000<span></span>
</td>
<td class="nump">$ 336,000<span></span>
</td>
<td class="nump">$ 353,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,271,000<span></span>
</td>
<td class="nump">9,583,000<span></span>
</td>
<td class="nump">32,519,000<span></span>
</td>
<td class="nump">22,879,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,656,000<span></span>
</td>
<td class="nump">9,081,000<span></span>
</td>
<td class="nump">19,397,000<span></span>
</td>
<td class="nump">18,986,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(61,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">26,927,000<span></span>
</td>
<td class="nump">18,664,000<span></span>
</td>
<td class="nump">51,916,000<span></span>
</td>
<td class="nump">41,804,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(26,732,000)<span></span>
</td>
<td class="num">(18,497,000)<span></span>
</td>
<td class="num">(51,580,000)<span></span>
</td>
<td class="num">(41,451,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">179,000<span></span>
</td>
<td class="nump">2,296,000<span></span>
</td>
<td class="nump">1,316,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">235,000<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">195,000<span></span>
</td>
<td class="nump">2,531,000<span></span>
</td>
<td class="nump">1,308,000<span></span>
</td>
<td class="nump">4,818,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">(26,537,000)<span></span>
</td>
<td class="num">(15,966,000)<span></span>
</td>
<td class="num">(50,272,000)<span></span>
</td>
<td class="num">(36,633,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="num">(255,000)<span></span>
</td>
<td class="num">(156,000)<span></span>
</td>
<td class="num">(421,000)<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,282,000)<span></span>
</td>
<td class="num">$ (15,810,000)<span></span>
</td>
<td class="num">$ (49,851,000)<span></span>
</td>
<td class="num">$ (36,675,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (1.25)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">39,911<span></span>
</td>
<td class="nump">39,872<span></span>
</td>
<td class="nump">39,910<span></span>
</td>
<td class="nump">39,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_CollaborationMember', window );">Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="nump">$ 167,000<span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
<td class="nump">$ 353,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=prta_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=prta_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717681772904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (49,851)<span></span>
</td>
<td class="num">$ (36,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="nump">11,223<span></span>
</td>
<td class="nump">12,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">765<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(1,061)<span></span>
</td>
<td class="num">(784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_Amortizationofrightofuseasset', window );">Amortization of right-of-use assets</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">2,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Prepaid and other assets</a></td>
<td class="num">(3,760)<span></span>
</td>
<td class="num">(15,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accruals and other liabilities</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">10,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestructuringReserve', window );">Restructuring liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_IncreaseDecreaseinOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,485)<span></span>
</td>
<td class="num">(2,298)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(41,864)<span></span>
</td>
<td class="num">(29,538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of ordinary shares upon exercise of stock options</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(41,781)<span></span>
</td>
<td class="num">(29,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the year</a></td>
<td class="nump">378,427<span></span>
</td>
<td class="nump">431,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">336,646<span></span>
</td>
<td class="nump">402,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Acquisition of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets recorded upon adoption of ASC 842</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_ReductionofBuildtosuitLeaseObligation', window );">Reduction of build-to-suit lease obligation upon adoption of ASC 842</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(51,546)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction', window );">Reduction of amounts capitalized under build-to-suit lease upon adoption of ASC 842</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(46,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction', window );">Reduction of capitalized interest under build-to-suit lease upon adoption of ASC 842</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,099)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">$ 336,646<span></span>
</td>
<td class="nump">$ 402,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_Amortizationofrightofuseasset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of right-of-use asset from operating lease presented on statement of cash flow as adjustment to net loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_Amortizationofrightofuseasset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_IncreaseDecreaseinOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_IncreaseDecreaseinOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction of Amounts Capitalized Under Build-to-suit Lease Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_ReductionofBuildtosuitLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction of Build-to-suit Lease Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_ReductionofBuildtosuitLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction of Capitalized Interest During Construction Period for Build-to-suit Lease Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717682771080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Ordinary Share</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative adjustment to accumulated deficit upon adoption of ASC-842 | ASC-842</a></td>
<td class="nump">$ 3,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,787<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,863,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">322,998<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">$ 920,594<span></span>
</td>
<td class="num">(597,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="nump">12,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of ordinary shares upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of ordinary shares upon exercise of stock options</a></td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,675)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,896,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">302,807<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">933,291<span></span>
</td>
<td class="num">(630,883)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,864,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">312,130<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">926,804<span></span>
</td>
<td class="num">(615,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="nump">6,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of ordinary shares upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of ordinary shares upon exercise of stock options</a></td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,810)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,896,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">302,807<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">933,291<span></span>
</td>
<td class="num">(630,883)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,898,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">272,921<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">944,407<span></span>
</td>
<td class="num">(671,885)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="nump">$ 11,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of ordinary shares upon exercise of stock options (in shares)</a></td>
<td class="nump">12,852<span></span>
</td>
<td class="nump">12,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of ordinary shares upon exercise of stock options</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(49,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,851)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,911,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">234,444<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">955,781<span></span>
</td>
<td class="num">(721,736)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,911,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">255,039<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">950,094<span></span>
</td>
<td class="num">(695,454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="nump">5,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,282)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,911,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 234,444<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">$ 955,781<span></span>
</td>
<td class="num">$ (721,736)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717677270488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Prothena Corporation plc (&#8220;Prothena&#8221; or the &#8220;Company&#8221;) is a clinical-stage neuroscience company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases. Fueled by our deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which our ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena's partnered programs include prasinezumab (PRX002/RG7935), in collaboration with Roche for the potential treatment of Parkinson&#8217;s disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer&#8217;s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) or other neurodegenerative diseases. The Company's proprietary programs include PRX004 for the potential treatment of ATTR amyloidosis, and programs that target A&#946; (Amyloid beta) for the potential treatment of Alzheimer&#8217;s disease.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company was formed on September 26, 2012, under the laws of Ireland and re-registered as an Irish public limited company on October 25, 2012. The Company's ordinary shares began trading on The Nasdaq Global Market under the symbol &#8220;PRTA&#8221; on December 21, 2012, and currently trade on The Nasdaq Global Select Market.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity and Business Risks</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company had an accumulated deficit of $721.7 million and cash and cash equivalents of $333.9 million. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on the Company's business plans, management believes that the Company&#8217;s cash and cash equivalents at June&#160;30, 2020, are sufficient to meet its obligations for at least the next twelve months. To operate beyond such period, or if the Company elects to increase its spending on research and development programs significantly above current long-term plans or enters into potential licenses and or other acquisitions of complementary technologies, products or companies, the Company may need additional capital. The Company expects to continue to finance future cash needs that exceed its cash from operating activities primarily through its current cash and cash equivalents, its collaborations with Roche and Bristol-Myers Squibb, and, to the extent necessary, through proceeds from public or private equity or debt financings, loans and other collaborative agreements with corporate partners or other arrangements.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company is subject to a number of risks, including but not limited to: the uncertainty of the Company&#8217;s research and development (&#8220;R&amp;D&#8221;) efforts resulting in future successful commercial products; obtaining regulatory approval for its product candidates; its ability to successfully commercialize its product candidates, if approved; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; the outbreak of the novel strain of coronavirus SARS-CoV-2; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the healthcare industry.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717679307416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Preparation and Presentation of Financial Information</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These accompanying Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with the accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the instructions for Form 10-Q and Regulation S-X statements. Accordingly, they do not include all of the information and notes required for complete financial statements. These interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto contained in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;3, 2020 (the &#8220;2019 Form 10-K&#8221;). These Unaudited Interim Condensed Consolidated Financial Statements are presented in U.S. dollars, which is the functional currency of the Company and its consolidated subsidiaries. These Unaudited Interim Condensed Consolidated Financial Statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current year presentation.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Financial Information</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Unaudited Interim Condensed Consolidated Financial Statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements, however certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures.  On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Accounting Policies</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no significant changes to the accounting policies during the six months ended June 30, 2020, from the significant accounting policies described in Note 2 of the Notes to Consolidated Financial Statements in the 2019 Form 10-K.</span></div><div style="text-indent:9pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segment and Concentration of Risks</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company operates in one segment. The Company&#8217;s chief operating decision maker (the &#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM reviews all financial information on a consolidated basis.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits.  The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The receivables recorded in the Condensed Consolidated Balance Sheet include amounts due from a Roche entity located in Switzerland. Revenue recorded in the Condensed Consolidated Statements of Operations consists of reimbursement from Roche for research and development services. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  As of June&#160;30, 2020, $3.2 million of the Company&#8217;s property and equipment, net were held in the U.S. and none were in Ireland.  As of December&#160;31, 2019, $3.9 million of the Company's property and equipment, net were held in the U.S. and none were in Ireland. </span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 18, 2019, the Finance Accounting Standards Board ("FASB") issued Accounting Standards Update 2019-12 ("ASU 2019-12"), Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes as part of the FASB&#8217;s overall initiative to reduce complexity in accounting standards.  Amendments include removal of certain exceptions to the general principles of ASC 740, Income Taxes, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. While not required to be adopted until 2021 for most calendar year public business entities (and 2022 for other entities), early adoption is permitted for any financial statements. The Company does not expect the adoption of ASU 2019-12 to have a significant impact on its </span></div>consolidated financial statements. The Company will continue to evaluate the impact of ASU 2019-12 on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717677209352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents.&#160;Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></div><div style="text-indent:-49.5pt;padding-left:72pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;1&#160;&#8212;&#160;Observable inputs such as quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="text-indent:-49.5pt;padding-left:72pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;2&#160; &#8212;&#160;Include other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves, foreign exchange rates, and credit ratings.</span></div><div style="text-indent:-49.5pt;padding-left:72pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities, and low market interest rates, if applicable. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on the fair value hierarchy, the Company classifies its cash equivalents within Level 1. This is because the Company values its cash equivalents using quoted market prices. The Company&#8217;s Level 1 securities consisted of $287.0 million and $338.2 million in money market funds included in cash and cash equivalents at June&#160;30, 2020, and December&#160;31, 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717679307416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CompositionofCertainBalanceSheetItemsAbstract', window );"><strong>Composition of Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Composition of Certain Balance Sheet Items</a></td>
<td class="text">Composition of Certain Balance Sheet Items<div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, net</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consisted of the following (in thousands):</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:73.659%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.876%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Machinery and equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchased computer software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,392&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,881&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,772)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,007)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,874&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation expense was $0.4 million and $0.8 million for the three and six months ended June&#160;30, 2020, respectively, compared to $0.4 million and $0.8 million for the three and six months ended June&#160;30, 2019, respectively.</span></div><div style="text-indent:9pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Current Liabilities</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current liabilities consisted of the following (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payroll and related expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,818&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">673&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,540&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CompositionofCertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Composition of Certain Balance Sheet Items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CompositionofCertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717678594264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Ordinary Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Ordinary Share</a></td>
<td class="text">Net Loss Per Ordinary Share<div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net income (loss) per ordinary share is calculated by dividing net income (loss) by the weighted-average number of ordinary shares outstanding during the period. Shares used in diluted net income per ordinary share would include the dilutive effect of ordinary shares potentially issuable upon the exercise of stock options outstanding. However, potentially issuable ordinary shares are not used in computing diluted net loss per ordinary share as their effect would be anti-dilutive due to the loss recorded during the three and six months ended June&#160;30, 2020, and 2019, and therefore diluted net loss per share is equal to basic net loss per share.</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per ordinary share was determined as follows (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:42.040%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.517%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.381%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.381%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.521%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(26,282)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,810)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,851)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,675)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average ordinary shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,872&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,910&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.66)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.40)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.25)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.92)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The equivalent ordinary shares not included in diluted net loss per share because their effect would be anti-dilutive are as&#160;follows&#160;(in&#160;thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.723%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase ordinary shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,672&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,672&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717678591880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Lease Commitments</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted ASC 842, Leases effective January 1, 2019. Prior period amounts have not been adjusted and continued to be reported in accordance with the Company&#8217;s historical accounting under ASC 840. For lease arrangements entered prior to the adoption of ASC 842, right-of-use asset and lease liability are determined based on the present value of minimum lease payments over the remaining lease term and the Company&#8217;s incremental borrowing rate based on information available as of January 1, 2019. The right-of-use asset also includes any lease prepayments made and excludes unamortized lease incentives including rent abatements and/or concessions and rent holidays. Tenant improvements made by the Company as a lessee, in which such improvements are deemed to be owned by the lessor, are viewed as lease prepayments by the Company and are included in the right-of-use asset. Lease expense is recognized on a straight-line basis over the expected lease term. Total operating lease cost was $1.6 million and $3.2 million for the three and six months ended June&#160;30, 2020, respectively, and $1.6 million and $3.2 million three and six months ended June&#160;30, 2019, respectively. Total cash paid against the operating lease liability was $1.5 million and $3.0 million for the three and six months ended June&#160;30, 2020, respectively, and $1.4 million and $2.9 million three and six months ended June&#160;30, 2019, respectively. </span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the purpose of estimating the incremental borrowing rate in the adoption of ASC 842, the Company inquired with banks that had a business relationship with the Company to determine the Company's collateralized incremental borrowing rate. The discount rate used to determine the lease liability was 4.25%. There was no change in the accounting of the Sub-Sublease (as defined below) of the Current SSF Facility (as defined below) upon adoption of ASC 842. Furthermore, the Company's operating lease in Dublin is not included in the lease liability and right-of-use asset recorded due to its nominal amount.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company performed an evaluation of its other contracts with customers and suppliers in accordance with ASC 842 and have determined that, except for the leases described below, a nominal operating lease for medical monitoring equipment and a nominal operating lease for office equipment, none of the Company&#8217;s contracts contain a lease.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="padding-left:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Current SSF Facility</span></div><div style="padding-left:22.5pt;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2016, the Company entered into a noncancelable operating sublease (the &#8220;Lease&#8221;) to lease 128,751 square feet of office and laboratory space in South San Francisco, California, U.S. (the &#8220;Current SSF Facility&#8221;). Subsequently, in April 2016, the Company took possession of the Current SSF Facility. The Lease includes a free rent period and escalating rent payments and has a remaining lease term of 3.50 years that expires on December&#160;31, 2023, unless terminated earlier.  The Company's obligation to pay rent commenced on August 1, 2016. The Company is obligated to make lease payments totaling approximately $39.2 million over the lease term. The Lease further provides that the Company is obligated to pay to the sublandlord and master landlord certain costs, including taxes and operating expenses. The Lease is considered an operating lease under ASC 842. Prior to the Company's adoption of ASC 842, this Lease was considered a build-to-suit lease. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In connection with this Lease, the Company received a tenant improvement allowance of $14.2 million from the sublandlord and the master landlord, for the costs associated with the design, development and construction of tenant improvements for the Current SSF Facility. The Company is obligated to fund all costs incurred in excess of the tenant improvement allowance. The initial measurement of right-of-use asset for the Lease includes the tenant improvement added by the Company wherein the lessor was deemed the accounting owner, net of the tenant improvement allowance received from the sublandlord and the master landlord. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company obtained a standby letter of credit in April 2016 in the initial amount of $4.1 million, which may be drawn down by the sublandlord in the event the Company fails to fully and faithfully perform all of its obligations under the Lease and to compensate the sublandlord for all losses and damages the sublandlord may suffer as a result of the occurrence of any default on the part of Company not cured within the applicable cure period. This standby letter of credit is collateralized by a certificate of deposit of the same amount which is classified as restricted cash. The Company was entitled to a $1.4 million reduction in the face amount of the standby letter of credit on the third anniversary of the contractual rent commencement, which was received in 2019, and another $1.4 million on the fifth anniversary of the contractual rent commencement. As a condition to the reduction of the standby letter of credit amount, no uncured default by the Company shall then exist under the Lease.  As of June&#160;30, 2020, none of the remaining standby letter of credit amount of $2.7 million has been used.</span></div><div style="padding-left:22.5pt;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sub-Sublease of Current SSF Facility </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July&#160;18, 2018, the Company entered into a Sub-Sublease Agreement (the &#8220;Sub-Sublease&#8221;) with Assembly Biosciences, Inc. (the &#8220;Sub-Subtenant&#8221;) to sub-sublease approximately 46,641 square feet of office and laboratory space of the Current SSF Facility to the Sub-Subtenant. The Sub-Sublease is considered an operating lease under ASC 842. There was no change in the accounting of the Sub-Sublease of the Current SSF Facility upon the Company's adoption of ASC 842. For the three and six months ended June 30, 2020, the Company recorded $0.7 million and $1.5 million, respectively, and $0.7 million and $1.5 million three and six months ended June&#160;30, 2019, respectively, of sub-lease rental income as an offset to its operating expenses. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Sub-Sublease provides for initial annual base rent for the complete Sub-Subleased Premises of approximately $2.7 million, with increases of approximately 3.5% in annual base rent on September 1, 2019 and each anniversary thereof. The Sub-Sublease rental income excludes reimbursements for executory costs received from the Sub-Subtenant. The Sub-Sublease became effective on September&#160;24, 2018, and has a term of 5.2 years which terminates on December&#160;15, 2023. The Sub-Sublease will terminate if the Lease or the corresponding master lease terminates. The Company or the Sub-Subtenant may elect, subject to limitations set forth in the Sub-Sublease, to terminate the Sub-Sublease following a material casualty or condemnation affecting the Subleased Premises. The Company may terminate the Sub-Sublease following an event of default, which is defined in the Sub-Sublease to include, among other things, non-payment of amounts owing by the Sub-Subtenant under the Sub-Sublease.</span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required under the Lease to pay to the sublandlord 50% of that portion of the cash sums and other economic consideration received from the Sub-Subtenant that exceeds the base rent paid by the Company to the sublandlord after deducting certain of the Company&#8217;s costs.</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="padding-left:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dublin</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company entered into an agreement to lease 133 square feet of office space in Dublin, Ireland (the "Dublin Lease"). The current one year lease term expires on November&#160;30, 2020. The Dublin Lease also has an automatic renewal clause, pursuant to which the agreement will be extended automatically for successive periods equal to the current term but no less than three months, unless the agreement is cancelled by the Company. This operating lease is not included in the lease liability and operating lease right-of-use asset recorded due to its nominal amount. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of  June&#160;30, 2020, the Company is obligated to make lease payments over the remaining term of the Dublin Lease of approximately &#8364;10,000, or $11,000 as converted using an exchange rate as of June&#160;30, 2020.</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum payments under the above-described noncancelable operating leases, including a reconciliation to the lease liabilities recognized in the Condensed Consolidated Balance Sheets, and future minimum rentals to be received under the Sub-Sublease as of June&#160;30, 2020, are as follows (in thousands):</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.269%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.134%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.137%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sub-Sublease Rental</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (6 months)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,438&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,165&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,047&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,090&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,448&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less:  Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,625)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nominal lease payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,454&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:9pt;"><span><br/></span></div><div style="text-indent:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indemnity Obligations</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has entered into indemnification agreements with its current and former directors and officers and certain key employees. These agreements contain provisions that may require the Company, among other things, to indemnify such persons against certain liabilities that may arise because of their status or service and advance their expenses incurred as a result of any indemnifiable proceedings brought against them. The obligations of the Company pursuant to the indemnification agreements continue during such time as the indemnified person serves the Company and continues thereafter until such time as a claim can be brought. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer liability insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts paid. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of June&#160;30, 2020 and 2019.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Commitments</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into various firm purchase commitments primarily related to research and development activities. As of June&#160;30, 2020, the Company had non-cancelable purchase commitments to suppliers for $4.0 million of which $0.4 million is included in accrued current liabilities, and contractual obligations under license agreements of $1.1 million of which $0.1 million is included in accrued current liabilities. The following is a summary of the Company's non-cancelable purchase commitments and contractual obligations as of June&#160;30, 2020 (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:34.082%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.402%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Purchase Obligations</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contractual obligations under license agreements</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (2)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,075&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">285&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">465&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:13.5pt;padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,034&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,244&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">465&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">________________</span></div><div style="text-indent:27pt;text-align:justify;margin-top:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">Purchase obligations consist of non-cancelable purchase commitments to suppliers.</span></div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">Excludes future obligations pursuant to the cost-sharing arrangement under the Company's License Agreement with Roche. Amounts of such obligations, if any, cannot be determined at this time.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717682356248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborativeAgreementAbstract', window );"><strong>Collaborative Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_SignificantAgreementsTextBlock', window );">License Agreements</a></td>
<td class="text">Significant Agreements<div style="text-indent:9pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Roche License Agreement</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2013, the Company through its wholly owned subsidiary Prothena Biosciences Limited and Prothena Biosciences Inc entered into a License, Development, and Commercialization Agreement (the &#8220;License Agreement&#8221;) with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together, &#8220;Roche&#8221;) to develop and commercialize certain antibodies that target &#945;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">synuclein, including prasinezumab, which are referred to collectively as &#8220;Licensed Products.&#8221; Upon the effectiveness of the License Agreement in January 2014, the Company granted to Roche an exclusive, worldwide license to develop, make, have made, use, sell, offer to sell, import and export the Licensed Products. The Company retained certain rights to conduct development of the Licensed Products and an option to co-promote prasinezumab in the U.S. During the term of the License Agreement, the Company and Roche will work exclusively with each other to research and develop antibody products targeting alpha-synuclein (or &#945;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">synuclein) potentially including incorporation of Roche&#8217;s proprietary Brain Shuttle&#8482; technology to potentially increase delivery of therapeutic antibodies to the brain. The License Agreement provided for Roche making an upfront payment to the Company of $30.0 million, which was received in February 2014; making a clinical milestone payment of $15.0 million upon initiation of the Phase 1 study for prasinezumab, which was received in May 2014; and making a clinical milestone payment of $30.0 million upon dosing of the first patient in the Phase 2 study for prasinezumab, which was achieved in June 2017.</span></div><div style="padding-left:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For prasinezumab, Roche is also obligated to pay:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"> up to $350.0 million upon the achievement of development, regulatory and various first commercial sales milestones;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"> up to an additional $175.0 million upon achievement of ex-U.S. commercial sales milestones; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"> tiered, high single-digit to high double-digit royalties in the teens on ex-U.S. annual net sales, subject to certain adjustments.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Roche bore 100% of the cost of conducting the research collaboration under the License Agreement during the research term, which expired December 31, 2017. In the U.S., the parties share all development and commercialization costs, as well as profits, all of which will be allocated 70% to Roche and 30% to the Company, for prasinezumab in the Parkinson&#8217;s disease indication, as well as any other Licensed Products and/or indications for which the Company opts in to participate in co-development and co-funding. After the completion of specific clinical trial activities, the Company may opt out of the co-development and cost and profit sharing on any co-developed Licensed Products and instead receive U.S. commercial sales milestones totaling up to $155.0 million and tiered, single-digit to high double-digit royalties in the teens based on U.S. annual net sales, subject to certain adjustments, with respect to the applicable Licensed Product.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company filed an Investigational New Drug Application (&#8220;IND&#8221;) with the FDA for prasinezumab and subsequently initiated a Phase 1 study in 2014. Following the Phase 1 studies, Roche became primarily responsible for developing, obtaining and maintaining regulatory approval for and commercializing Licensed Products. Roche also became responsible for the clinical and commercial manufacture and supply of Licensed Products.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the Company has an option under the License Agreement to co-promote prasinezumab in the U.S. in the Parkinson&#8217;s disease indication. If the Company exercises such option, it may also elect to co-promote additional Licensed Products in the U.S. approved for Parkinson&#8217;s disease. Outside the U.S., Roche will have responsibility for developing and commercializing the Licensed Products. Roche bears all costs that are specifically related to obtaining or maintaining regulatory approval outside the U.S. and will pay the Company a variable royalty based on annual net sales of the Licensed Products outside the U.S.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While Roche will record product revenue from sales of the Licensed Products, the Company and Roche will share in the net profits and losses of sales of the prasinezumab for the Parkinson's disease indication in the U.S. on a 70%/30% basis with the Company receiving 30% of the profit and losses provided that the Company has not exercised its opt-out right.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The License Agreement continues on a country-by-country basis until the expiration of all payment obligations under the License Agreement. The License Agreement may also be terminated (i) by Roche at will after the first anniversary of the effective date of the License Agreement, either in its entirety or on a Licensed Product-by-Licensed Product basis, upon 90 days&#8217; prior written notice to the Company prior to first commercial sale and 180 days&#8217; prior written notice to Prothena after first commercial sale, (ii) by either party, either in its entirety or on a Licensed Product-by-Licensed Product or region-by-region </span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">basis, upon written notice in connection with a material breach uncured 90 days after initial written notice, and (iii) by either party, in its entirety, upon insolvency of the other party. The License Agreement may be terminated by either party on a patent-by-patent and country-by-country basis if the other party challenges a given patent in a given country. The Company&#8217;s rights to co-develop Licensed Products under the License Agreement will terminate if the Company commences certain studies for certain types of competitive products. The Company&#8217;s rights to co-promote Licensed Products under the License Agreement will terminate if the Company commences a Phase 3 study for such competitive products.</span></div><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The License Agreement cannot be assigned by either party without the prior written consent of the other party, except to an affiliate of such party or in the event of a merger or acquisition of such party, subject to certain conditions. The License Agreement also includes customary provisions regarding, among other things, confidentiality, intellectual property ownership, patent prosecution, enforcement and defense, representations and warranties, indemnification, insurance, and arbitration and dispute resolution.</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration Accounting</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The License Agreement was evaluated under ASC 808, Collaborative Agreements.  At the outset of the License Agreement, the Company concluded that it did not qualify as collaboration under ASC 808 because the Company does not share significant risks due to the net profit and loss split (under which Roche incurs substantially more of the costs of the collaboration) and because of the Company&#8217;s opt-out provision. The Company believes that Roche will be the principal in future sales transactions with third parties as Roche will be the primary obligor bearing inventory and credit risk. The Company will record its share of pre-tax commercial profit generated from the collaboration as collaboration revenue once the Company can conclude it is probable that a significant revenue reversal will not occur in future periods. Prior to commercialization of a Licensed Product, the Company&#8217;s portion of the expenses related to the License Agreement reflected on its income statement will be limited to R&amp;D expenses. After commercialization, if the Company opts-in to co-detail commercialization, expenses related to commercial capabilities, including expenses related to the establishment of a field sales force and other activities to support the Company&#8217;s commercialization efforts, will be recorded as sales, general and administrative (&#8220;SG&amp;A&#8221;) expense and will be factored into the computation of the profit and loss share. The Company will record the receivable related to commercialization activities as collaboration revenue once the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Adoption of ASC 606, Revenue from Contracts with Customers </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted ASC 606, Revenue from Contracts with Customers, as of January 1, 2018, using the modified retrospective transition method. The Company recognized the cumulative effect of applying the new revenue standard as an adjustment to the opening balance of the accumulated deficit as of January 1, 2018. </span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of January 1, 2018, the Company did not record any changes to the opening balance of the accumulated deficit since the cumulative effect of applying the new revenue standard was the same as applying ASC 605. The impact of the adoption of ASC 606 to revenues for the year ended December&#160;31, 2018, was an increase of $1.0 million, which represents the revenue recognized for the development services provided by the Company during the period that is reimbursable by Roche. Historically, the Company recorded such reimbursement as an offset against its R&amp;D expenses under ASC 605. Upon the adoption of ASC 606, the reimbursement for development services is now included as part of the Company&#8217;s collaboration revenue.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Performance Obligations</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The License Agreement was evaluated under ASC 606. The License Agreement includes the following distinct performance obligations: (1) the Company&#8217;s grant of an exclusive royalty bearing license, with the right to sublicense to develop and commercialize certain antibodies that target &#945;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">synuclein, including prasinezumab, and the initial know how transfer which was delivered at the effective date (the &#8220;Royalty Bearing License&#8221;); (2) the Company&#8217;s obligation to supply clinical material as requested by Roche for a period up to twelve months (the &#8220;Clinical Product Supply Obligation&#8221;); (3) the Company&#8217;s obligation to provide manufacturing related services to Roche for a period up to twelve months (the &#8220;Supply Services Obligation&#8221;); (4) the Company&#8217;s obligation to prepare and file the IND (the &#8220;IND Obligation&#8221;); and (5) the Company&#8217;s obligation to provide development activities under the development plan during Phase 1 clinical trials (the &#8220;Development Services Obligation&#8221;). Revenue allocated to the above performance obligations under the License Agreement are recognized when the Company has satisfied its obligations either at a point in time or over a period of time.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that the Royalty Bearing License and the Clinical Product Supply Obligation were satisfied at a point in time. The Royalty Bearing License is considered to be a functional intellectual property, in which the revenue would be recognized at the point in time since (a) the Company concluded that the license to Roche has a significant stand-alone </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">functionality, (b) the Company does not expect the functionality of the intellectual property to be substantially changed during the license period as a result of activities of Prothena, and (c) Prothena&#8217;s activities transfer a good or service to Roche. The Clinical Product Supply Obligation does not meet criteria for over time recognition; as such, the revenue related to such performance obligation was recognized the point in time at which Roche obtained control of manufactured supplies, which occurred during the first quarter of 2014. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that the Supply Services Obligation, the IND Obligation and the Development Services Obligation were satisfied over time. The Company utilized an input method measure of progress by basing the recognition period on the efforts or inputs towards satisfying the performance obligation (i.e. costs incurred and the time elapsed to complete the related performance obligations). The Company determined that such input method provides an appropriate measure of progress toward complete satisfaction of such performance obligations.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, and December&#160;31, 2019, there were no remaining performance obligations under License Agreement since the obligations related to research and development activities were only for the Phase 1 clinical trial and the remaining obligations were delivered or performed.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Transaction Price</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">According to ASC 606-10-32-2, the transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Factors considered in the determination of the transaction price include, among other things, estimated selling price of the license and costs for clinical supply and development costs. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial transaction price under the License Agreement, pursuant to ASC 606, was $55.1 million, including $45.0 million for the Royalty Bearing License, $9.1 million for the IND and Development Services Obligations, and $1.1 million for the Supply Services Obligation. The $45.0 million for the Royalty Bearing License included the upfront payment of $30.0 million and the clinical milestone payment of $15.0 million upon initiation of the Phase 1 clinical trial of prasinezumab, both of which were made in 2014. The remaining transaction price amounts the Company expected to receive as reimbursements were based on costs expected to be paid to third parties and other costs to be incurred by the Company in order to satisfy its performance obligations. They are considered to be variable considerations not subject to constraint. The Company did not incur any incremental costs, such as commissions, to obtain or fulfill the License Agreement.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under ASC 606, the transaction price was allocated to the performance obligations as follows: $48.9 million to the Royalty Bearing License; $4.6 million to the IND and Development Services Obligations; $1.1 million to the Clinical Product Supply Obligation; and $0.6 million to the Supply Services Obligation. As of June&#160;30, 2020, the aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied is $nil. Prior to the adoption of ASC 606, the transaction price was allocated to the deliverables as follows: $35.6 million to the Royalty Bearing License; $3.3 million to the IND and Development Services Obligations; $0.8 million to the Clinical Product Supply Obligation; and $0.4 million to the Supply Services Obligation.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allocated the initial transaction price to the Royalty Bearing License and other performance obligations using the relative selling price method based on its best estimate of selling price for the Royalty Bearing License and third party evidence for the remaining performance obligations. The best estimate of selling price for the Royalty Bearing License was based on a discounted cash flow model. The key assumptions used in the discounted cash flow model used to determine the best estimate of selling price for the Royalty Bearing License included the market opportunity for commercialization of prasinezumab in the U.S. and the royalty territory (for licensed products that are jointly funded the royalty territory is worldwide except for the U.S., and for all licensed products that are not jointly funded the Royalty Territory is worldwide), the probability of successfully developing and commercializing prasinezumab, the estimated remaining development costs for prasinezumab, and the estimated time to commercialization of prasinezumab. The Company concluded that a change in the assumptions used to determine the best estimate of selling price (&#8220;BESP&#8221;) of the license deliverable would not have a significant effect on the allocation of arrangement consideration.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s discounted cash flow model included several market conditions and entity-specific inputs, including the likelihood that clinical trials for prasinezumab will be successful, the likelihood that regulatory approval will be obtained and the product commercialized, the appropriate discount rate, the market locations, size and potential market share of the product, the expected life of the product, and the competitive environment for the product. The market assumptions were generated using a patient-based forecasting approach, with key epidemiological, market penetration, dosing, compliance, length of treatment and pricing assumptions derived from primary and secondary market research, referenced from third-party sources.</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Significant Payment Terms</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payments for development services are due within 45 days after receiving an invoice from the Company. Variable considerations related to clinical and regulatory milestone payments are constrained due to high likelihood of a revenue reversal. The payment term for all milestone payments are due within 45 days after the achievement of the relevant milestone and receipt by Roche of an invoice for such an amount from the Company.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">According to ASC 606-10-32-17, a significant financing component does not exist if a substantial amount of the consideration promised by the customer is variable, and the amount or timing of that consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the customer or the entity. Since a &#8220;substantial amount of the consideration&#8221; promised by Roche to the Company is variable (i.e., is in the form of either milestone payments or sales-based royalties) and the amount of such variable consideration varies based upon the occurrence or nonoccurrence of future events that are not within the control of either Roche or the Company (i.e., are largely subject to regulatory approval), the License Agreement does not have a significant financing component.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Optional Goods and Services</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An option for additional goods or services exists when a customer has a present contractual right that allows it to choose the amount of additional distinct goods or services that are purchased. Prior to the customer&#8217;s exercise of that right, the vendor is not presently obligated to provide those goods or services. ASC 606-10-25-18(j) requires recognition of an option as a distinct performance obligation when the option provides a customer with a material right.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the distinct performance obligations noted above, the Company was obligated to provide indeterminate research services for up to three years ending in 2017 at rates that were not significantly discounted and fully reimbursable by Roche (the &#8220;Research Services&#8221;). The amount for any such Research Services was not fixed and determinable and was not at a significant incremental discount. There were no refund rights, concessions or performance bonuses to consider. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the obligation to perform Research Services under ASC 606-10-55-42 and 55-43 to determine whether it gave Roche a &#8220;material right&#8221;. According to ASC 606-10-55-43, if a customer has the option to acquire an additional good or services at a price that would reflect the standalone selling price for that good or service, that option does not provide the customer with a material right even if the option can be exercised only by entering into a previous contract.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that Roche&#8217;s option to have the Company perform Research Services did not represent a &#8220;material right&#8221; to Roche that it would not have received without entering into the License Agreement. As a result, Roche&#8217;s option to acquire additional Research Services was not considered a performance obligation at the outset of the License Agreement under ASC 606. Accordingly, this deliverable will become new performance obligation for Prothena when Roche asks Prothena to conduct such Research Services. As of June&#160;30, 2020, there were no remaining Research Services performance obligations. </span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Post Contract Deliverables</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any development services provided by the Company after performance of the Development Service Obligation are not considered a contractual performance obligation under the License Agreement, since the License Agreement does not require the Company to provide any development services after completion of the Development Service Obligation. However, the collaboration&#8217;s Joint Steering Committee approved continued funding for additional development services to be provided by the Company (the &#8220;Additional Development Services&#8221;).  Under the License Agreement and upon the adoption of ASC 606, the Company recognizes the reimbursements for Additional Development Services as collaboration revenue as earned. </span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue and Expense Recognition</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognized $0.1 million and $0.3&#160;million as collaboration revenue from Roche for the three and six months ended June&#160;30, 2020, respectively, as compared to $0.2&#160;million and $0.4&#160;million for the three and six months ended June&#160;30, 2019, respectively. Cost sharing payments to Roche are recorded as R&amp;D expenses. The Company recognized $4.5 million and $8.5 million in R&amp;D expenses for payments made to Roche during the three and six months ended June&#160;30, 2020, respectively, as compared to $1.1 million and $4.0 million for the three and six months ended June&#160;30, 2019, respectively. The Company had accounts receivable from Roche of $4,000 and $2,000 at June&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone Accounting</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the License Agreement, only if the U.S. and or global options are exercised, the Company is eligible to receive milestone payments upon the achievement of development, regulatory and various first commercial sales milestones. Milestone payments are evaluated under ASC Topic 606. Factors considered in this determination included scientific and regulatory risk that must be overcome to achieve each milestone, the level of effort and investment required to achieve the milestone, and the monetary value attributed to the milestone. Accordingly, the Company estimates payments in the transaction price based on the most likely approach, which considers the single most likely amount in a range of possible amounts related to the achievement of these milestones. Additionally, milestone payments are included in the transaction price only when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods when the milestone is achieved.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company excludes the milestone payments and royalties in the initial transaction price calculation because such payments are considered to be variable considerations with constraint. Such milestone payments and royalties will be recognized as revenue once the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The clinical and regulatory milestones under the License Agreement after the point at which the Company could opt-out are considered to be variable considerations with constraint due to the fact that active participation in the development activities that generate the milestones is not required under the License Agreement, and the Company can opt-out of these activities. There are no refunds or claw-back provisions and the milestones are uncertain of occurrence even after the Company has opted out. Based on this determination, these milestones will be recognized when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.</span></div><div style="text-indent:9pt;text-align:justify;margin-top:12pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration Agreement with Bristol-Myers Squibb</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Overview</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March&#160;20, 2018, the Company, through its wholly owned subsidiary Prothena Biosciences Limited, entered into a Master Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;) with Celgene Switzerland LLC (&#8220;Celgene&#8221;), a subsidiary of Celgene Corporation (which was acquired by Bristol-Myers Squibb ("BMS") in November 2019), pursuant to which Prothena granted to Celgene a right to elect in its sole discretion to exclusively license rights both in the U.S. (the &#8220;US Rights&#8221;) and on a global basis (the &#8220;Global Rights&#8221;), with respect to the Company&#8217;s programs to develop and commercialize antibodies targeting Tau, TDP-43 and an undisclosed target (the &#8220;Collaboration Targets&#8221;). For each such program, BMS may exercise its US Rights at the IND filing, and if it so exercises such US Rights would also have a right to expand the license to Global Rights. If BMS exercises its US Rights for a program, then following the first to occur of (a) completion by the Company, in its discretion and at its cost, of Phase 1 clinical trials for such program or (b) the date on which BMS elects to assume responsibility for completing such Phase 1 clinical trials (at its cost), BMS would have decision making authority over development activities and all regulatory, manufacturing and commercialization activities in the U.S. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Collaboration Agreement provided for Celgene making an upfront payment to the Company of $100.0 million, which was received in April 2018, plus future potential license exercise payments and regulatory and commercial milestones for each program under the Collaboration Agreement, as well as royalties on net sales of any resulting marketed products. In connection with the Collaboration Agreement, the Company and Celgene entered into a Share Subscription Agreement on March&#160;20, 2018, under which Celgene subscribed to 1,174,536 of the Company&#8217;s ordinary shares for a price of $42.57 per share, for a total of approximately $50.0 million.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BMS US and Global Rights and Licenses</span></div><div><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On a program-by-program basis, beginning on the effective date of the Collaboration Agreement and ending on the date that the IND Option term expires for such program (which generally occurs sixty days after the date on which Prothena delivers to BMS the first complete data package for an IND that was filed for a lead candidate from the relevant program), BMS may elect in its sole discretion to exercise its US Rights to receive an exclusive license to develop, manufacture and commercialize antibodies targeting the applicable Collaboration Target in the U.S. (the &#8220;US License&#8221;). If BMS exercises its US Rights for a collaboration program, it is obligated to pay the Company an exercise fee of approximately $80.0 million per program. Thereafter, following the first to occur of (a) completion by the Company, in its discretion and at its cost, of Phase 1 clinical trials for such program or (b) BMS&#8217;s election to assume responsibility to complete such Phase 1 clinical trials (at its cost), BMS would have the sole right to  develop, manufacture and commercialize antibody products targeting the relevant Collaboration Target for such program (the &#8220;Collaboration Products&#8221;) in the U.S.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On a program-by-program basis, following completion of a Phase 1 clinical trial for a collaboration program for which BMS has previously exercised its US Rights, BMS may elect in its sole discretion to exercise its Global Rights with respect to such collaboration program to receive a worldwide, exclusive license to develop, manufacture and commercialize antibodies targeting the applicable Collaboration Target (the &#8220;Global License&#8221;). If BMS exercises its Global Rights, BMS would be obligated to pay the Company an additional exercise fee of $55.0 million for such collaboration program. The Global Rights would then replace the US Rights for that collaboration program, and BMS would have decision making authority over developing, obtaining and maintaining regulatory approval for, manufacturing and commercializing the Collaboration Products worldwide.    </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After BMS&#8217;s exercise of Global Rights for a collaboration program, the Company is eligible to receive up to $562.5 million in regulatory and commercial milestones per program. Following an exercise by BMS of either US Rights or Global Rights for such collaboration program, the Company will also be eligible to receive tiered royalties on net sales of Collaboration Products ranging from high single digit to high teen percentages, on a weighted average basis depending on the achievement of certain net sales thresholds. Such exercise fees, milestones and royalty payments are subject to certain reductions as specified in the Collaboration Agreement, the agreement for US Rights and the agreement for Global Rights.  </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">BMS will continue to pay royalties on a Collaboration Product-by-Collaboration Product and country-by-country basis, until the latest of (i) expiration of certain patents covering the Collaboration Product, (ii) expiration of all regulatory exclusivity for the Collaboration Product, and (iii) an agreed period of time after the first commercial sale of the Collaboration Product in the applicable country (the &#8220;Royalty Term&#8221;).</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Term and Termination</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The research term under the Collaboration Agreement continues for a period of six years, which BMS may extend for up to two additional 12-month periods by paying an extension fee of $10.0 million per extension period.  The term of the Collaboration Agreement continues until the last to occur of the following: (i) expiration of the research term; (ii) expiration of all US Rights terms; and (iii) expiration of all Global Rights terms. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The term of any US License or Global License would continue on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of all Royalty Terms under such agreement. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Collaboration Agreement may be terminated (i) by either party on a program-by-program basis if the other party remains in material breach of the Collaboration Agreement following a cure period to remedy the material breach, (ii) by BMS at will on a program-by-program basis or in its entirety, (iii) by either party, in its entirety, upon insolvency of the other party, or (iv) by Prothena, in its entirety, if BMS challenges a patent licensed by Prothena to BMS under the Collaboration Agreement.  </span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share Subscription Agreement</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">  </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the Collaboration Agreement, the Company entered into a Share Subscription Agreement (the &#8220;SSA&#8221;) with Celgene, pursuant to which the Company issued, and Celgene subscribed for, 1,174,536 of the Company&#8217;s ordinary shares (the &#8220;Shares&#8221;) for an aggregate subscription price of approximately $50.0 million, pursuant to the terms and conditions thereof.  </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the SSA, BMS (formerly Celgene) is subject to certain transfer restrictions. In addition, BMS will be entitled to request the registration of the Shares with the U.S. Securities and Exchange Commission on Form S-3ASR or Form S-3 following termination of the transfer restrictions if the Shares cannot be resold without restriction pursuant to Rule 144 promulgated under the U.S. Securities Act of 1933, as amended.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaboration Accounting</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Collaboration Agreement was evaluated under ASC 808, Collaborative Agreements. At the outset of the Collaboration Agreement, the Company concluded that it does not qualify as collaboration under ASC 808 because the Company does not share significant risks due to economics of the collaboration.</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Performance Obligations</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the Collaboration Agreement and concluded that it represented a contract with a customer within the scope of ASC 606. Per ASC 606, a performance obligation is defined as a promise to transfer a good or service or a series of distinct goods or services. At inception of the Collaboration Agreement, the Company is not obligated to transfer the US License or Global License to BMS unless BMS exercises its US Rights or Global Rights, respectively, and the Company is not </span></div><div style="text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">obligated to perform development activities under the development plan during preclinical and Phase 1 clinical trials including the regulatory filing of the IND. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The discovery, preclinical and clinical development activities performed by the Company are to be performed at the Company&#8217;s discretion and are not promised goods or services and therefore are not considered performance obligations under ASC 606, unless and until the Company agrees to perform the Phase 1 clinical studies (after the IND option exercise) that are determined to be performance obligations at the time the option is exercised. Per the terms of the Collaboration Agreement, the Company may conduct discovery activities to characterize, identify and generate antibodies to become collaboration candidates that target such Collaboration Target, and thereafter may pre-clinically develop collaboration candidates to identify lead candidates that target such Collaboration Target and file an IND with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for a Phase 1 clinical trial for such lead candidates. In the event the Company agrees to be involved in a Phase 1 clinical study, the Company will further evaluate whether any such promise represents a performance obligation at the time the option is exercised. If it is concluded that the Company has obligated itself to an additional performance obligation besides the license granted at IND option exercise, then the effects of the changes in the arrangement will be evaluated under the modification guidance of ASC 606.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is not obligated to perform manufacturing activities. Per the terms of the Collaboration Agreement, to the extent that the Company, at its discretion, conducts a program, the Company shall be responsible for the manufacture of collaboration candidates and collaboration products for use in such program, as well as the associated costs. Delivery of manufactured compound (clinical product supply) is not deemed a performance obligation under ASC 606 as the Company is not obligated to transfer supply of collaboration product to BMS unless BMS exercises its right to participate in the Phase 1 development.  </span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Compensation for the Company&#8217;s provision of inventory supply, to the extent requested by BMS would be paid to Prothena by BMS at a reasonable stand-alone selling price for such supply. Given that (i) there is substantial uncertainty about the development of the programs, (ii) the pricing for the inventory is at its standalone selling price and (iii) the manufacturing services require the entity to transfer additional goods or services that are incremental to the goods and services provided prior to the resolution of the contingency, the Company&#8217;s supply of product is not a material right. Therefore, the inventory supply is not considered a performance obligation unless and until, requested by BMS.</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the grant of the US License after BMS exercises its US Rights for a program, BMS is entitled to receive certain ancillary development services from the Company, such as technology transfer assistance, regulatory support, safety data reporting activities and transition supply, if requested by BMS. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the grant of the Global License after BMS exercises the Global Rights for a program, BMS is entitled to receive certain ancillary development services from Prothena, such as ongoing clinical trial support upon request by BMS, transition supply, if requested by BMS, and regulatory support for coordination of pharmacovigilance matters.</span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the potential obligations to transfer the US Licenses and Global Licenses and performance of the ancillary development services subsequent to exercise of the US Rights and Global Rights, if the options are exercised by BMS, under ASC 606-10-55-42 and 55-43 to determine whether the US Rights or the Global Rights provided BMS a &#8220;material right&#8221; and concluded that BMS&#8217;s options to exercise its US Rights and Global Rights represented &#8220;material rights&#8221; to BMS that it would not have received without entering into the Agreement. </span></div><div style="text-indent:27pt;text-align:justify;"><span><br/></span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are a total of six options including US Rights and Global Rights to acquire a US License and a Global License, respectively, and rights to request certain development services (following exercise of the US Rights and Global Rights, respectively) for each of the three programs. Per ASC 606, the US Rights and Global Rights are material rights and therefore are performance obligations. The goods and services underlying the options are not accounted for as separate performance obligations, but rather become performance obligations, if and when, an option is exercised. </span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Transaction Price</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">According to ASC 606-10-32-2, the transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Factors considered in the determination of the transaction price included, among other things, estimated selling price of the license and costs for clinical supply and development costs. </span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial transaction price under the Collaboration Agreement, pursuant to ASC 606, was $110.2 million, including the $100.0 million upfront payment and $10.2 million premium on the ordinary shares purchased under the SSA. The Company </span></div><div style="text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">expects that the initial transaction price will be allocated across the US Rights and Global Rights for each program in a range of approximately $15-$25 million and $10-$18 million, respectively.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not include the option fees in the initial transaction price because such fees are contingent on the options to the US Rights and the Global Rights being exercised. Upon the exercise of the US Rights and the Global Rights for a program, the Company will have the obligation to deliver the US License and Global License and provide certain ancillary development services if requested by BMS, subsequent to its exercise of the US Rights and Global Rights, respectively, for such program. The Company will include the option fees in the transaction price at the point in time a material right is exercised. In addition, the Company did not include in the initial transaction price certain clinical and regulatory milestone payments since they relate to licenses for which BMS has not yet exercised its option to obtain and these variable considerations are constrained due to the likelihood of a significant revenue reversal.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the inception of the Collaboration Agreement, the Company did not transfer any goods or services to BMS (formerly Celgene) that are material. Accordingly, the Company has concluded that the initial transaction price will be recognized as contract liability and will be deferred until the Company transfers control of goods or services to BMS (which would be when BMS exercises the US Right or Global Right and receives control of the US License or Global License for at least one of the programs),&#160;or when the IND Option term expires if BMS does not exercise the US Right (which is generally sixty days after the date on which Prothena delivers to BMS the first complete data package for an IND that was filed for a lead candidate from the relevant program), or when the Phase 1 Option term expires if BMS does not exercise the Global Right (which is generally ninety days after the date on which Prothena delivers to BMS the first complete data package for a Phase 1 clinical trial for a lead candidate from the relevant program)&#160;or at the termination of the Collaboration Agreement, whichever occurs first. At such point that the Company transfers control of goods or services to BMS, or when the option expires, the Company will recognize revenue as a continuation of the original contract. Under this approach, the Company will treat the consideration allocated to the material right as an addition to the consideration for the goods or services underlying the contract option. </span></div><div style="text-indent:27pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At inception of the Collaboration Agreement, the Company estimated the standalone selling price for each performance obligation (i.e., the US Rights and Global Rights by program). The estimate of standalone selling price for the US Rights and Global Rights by program was based on the adjusted market assessment approach using a discounted cash flow model. The key assumptions used in the discounted cash flow model included the market opportunity for commercialization of each program in the U.S. or globally depending on the license, the probability of successfully developing and commercializing a given program target, the estimated remaining development costs for the respective program, the estimated time to commercialization of the drug for that program and a discount rate. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Significant Payment Terms</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The upfront payment of $100.0 million was due within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y181NS9mcmFnOmMxZGY1ZTE4YmUyNTRkN2RhZjU0MTc3MDM1YjA4N2RiL3RleHRyZWdpb246YzFkZjVlMThiZTI1NGQ3ZGFmNTQxNzcwMzViMDg3ZGJfMzk0Njc_0bf4cdb7-932a-472a-9ad8-2ce5f72c6492">ten</span> business days after the effective date of the Collaboration Agreement and was received in April 2018, while all option fees and milestone payments are due within 30 days after the achievement of the relevant milestone by BMS or receipt by BMS of an invoice for such an amount from the Company.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Collaboration Agreement does not have a significant financing component since a substantial amount of consideration promised by BMS to the Company is variable and the amount of such variable consideration varies based upon the occurrence or non-occurrence of future events that are not within the control of either BMS or the Company. Variable considerations related to clinical and regulatory milestone payments and option fees are constrained due to the likelihood of a significant revenue reversal.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone and Royalties Accounting</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is eligible to receive milestone payments of up to $90.0 million per program upon the achievement of certain specified regulatory milestones and milestone payments of up to $375.0 million per program upon the achievement of certain specified commercial sales milestones under the US License for such program. The Company is also eligible to receive milestone payments of up to $187.5 million per program upon the achievement of certain specified regulatory milestones and milestone payments of up $375.0 million per program upon the achievement of certain specified commercial sale milestones under the Global License for such program. Milestone payments are evaluated under ASC Topic 606. Factors considered in this determination included scientific and regulatory risk that must be overcome to achieve each milestone, the level of effort and investment required to achieve the milestone, and the monetary value attributed to the milestone. Accordingly, the Company estimates payments in the transaction price based on the most likely approach, which considers the single most likely amount in a range of possible amounts related to the achievement of these milestones. Additionally, milestone payments are included in the transaction price only when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company excluded the milestone payments and royalties in the initial transaction price because such payments are considered to be variable considerations with constraint. Such milestone payments and royalties will be recognized as revenue at a point in time when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not achieve any clinical and regulatory milestones under the Collaboration Agreement during the three and six months ended June&#160;30, 2020, and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborativeAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborativeAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_SignificantAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Agreements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_SignificantAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717678911288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders' Equity<div style="text-indent:9pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ordinary Shares</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company had 100,000,000 ordinary shares authorized for issuance with a par value of $0.01 per ordinary share and 39,911,413 ordinary shares issued and outstanding. Each ordinary share is entitled to one vote and, on a pro rata basis, to dividends when declared and the remaining assets of the Company in the event of a winding up.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Euro Deferred Shares</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company had 10,000 Euro Deferred Shares authorized for issuance with a nominal value of &#8364;22&#160;per share. No Euro Deferred Shares are outstanding at June&#160;30, 2020. The rights and restrictions attaching to the Euro Deferred Shares rank </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">pari passu</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with the ordinary shares and are treated as a single class in all respects.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717677255416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th"><div>May 15, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2018 Long Term Incentive Plan</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the Company&#8217;s shareholders approved the 2018 Long Term Incentive Plan. In May 2020, the Company's shareholders approved an amendment to the 2018 Long Term Incentive Plan (as amended, the &#8220;2018 LTIP&#8221;) to increase the number of ordinary shares available for issuance under that Plan by 1,500,000 ordinary shares. Under the 2018 LTIP, the number of ordinary shares authorized for issuance under the 2018 LTIP is equal to the sum of (a) 3,300,000 ordinary shares, (b) 1,177,933 ordinary shares that were available for issuance under the 2012 LTIP as of the May 15, 2018, effective date of the 2018 LTIP, and (c) any ordinary shares subject to issued and outstanding awards under the 2012 Long Term Incentive Plan (the &#8220;2012 LTIP&#8221;) that expire, are cancelled or otherwise terminate following the effective date of the 2018 LTIP; provided, that no more than 2,500,000 ordinary shares may be issued pursuant to the exercise of ISOs. The 2018 LTIP provides for the grant of ISOs, NQSOs, SARs, restricted shares, RSUs, performance bonus awards, performance share units awards, dividend equivalents and other share or cash-based awards to eligible individuals. Options under the 2018 LTIP may be granted for periods up to ten years. All options issued to date have had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTcwNDI0MzAyMzk3NDM_37e1f852-c414-4fe4-86e8-7b6225eb6fa8">ten</span> year life. </span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amended and Restated 2012 Long Term Incentive Plan</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the effective date of the 2018 LTIP, employees and consultants of the Company, its subsidiaries and affiliates, as well as members of the Company&#8217;s Board of Directors, received equity awards under the 2012 LTIP. Options under the 2012 LTIP were granted for periods up to ten years. All options issued to date have had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTQ0Mw_743a930b-b10b-459b-82c5-ed0937653214">ten</span> year life.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2020 Employment Inducement Incentive Plan</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 25, 2020, the Company's Board of Directors approved the 2020 Employment Inducement Incentive Plan. On April 1, 2020, the Company's Board of Directors approved an amendment to the 2020 Employment Inducement Incentive Plan (as amended, the "2020 EIIP") to increase the ordinary shares available for issuance under that Plan by 120,000 ordinary shares. The 2020 EIIP provides for the grant of NQSOs, SARs, restricted shares, RSUs, performance bonus awards, performance share units awards, or other share or cash-based awards to eligible individuals. Options under the 2020 EIIP may be granted for periods up to ten years. All options issued to date have had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ3OGE1ZWNmNjkzNzQ1ZWI4MWFlZGY2ZTEyNWM2YjdjL3NlYzpkNzhhNWVjZjY5Mzc0NWViODFhZWRmNmUxMjVjNmI3Y182Ny9mcmFnOjk3YWY0MzQ5MmViNTQzNzA4OWJkYzc5OGM2OWVhODJmL3RleHRyZWdpb246OTdhZjQzNDkyZWI1NDM3MDg5YmRjNzk4YzY5ZWE4MmZfMTkzNw_cef9d024-7d91-407e-8091-cfdb99879f97">ten</span> year life. As of June&#160;30, 2020, the number of ordinary shares authorized for issuance under the 2020 EIIP was 360,000 and no ordinary shares remained available for future awards under the 2020 EIIP, although the Company's Board of Directors reserves the right to amend the 2020 EIIP to increase the number of ordinary shares available and to make additional awards to key new hires.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Shares Available for Grant</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company granted 263,500 and 145,000 options during the three months ended June 30, 2020, and 2019, respectively, and 1,718,950 and 997,975 options during the six months ended June 30, 2020 and 2019, respectively, in </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">aggregate under its equity plans. The Company&#8217;s option awards generally vest over four years. As of June&#160;30, 2020, 1,402,179 ordinary shares remained available for grant under the 2018 LTIP, and options to purchase 8,672,205 ordinary shares in aggregate under the Company's equity plans were outstanding with a weighted-average exercise price of approximately $21.09 per share.</span></div><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-based Compensation Expense</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company estimates the fair value of share-based compensation on the date of grant using an option-pricing model. The Company uses the Black-Scholes model to value share-based compensation, excluding RSUs, which the Company values using the fair market value of its ordinary shares on the date of grant. The Black-Scholes option-pricing model determines the fair value of share-based payment awards based on the share price on the date of grant and is affected by assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, the Company&#8217;s share price, volatility over the expected life of the awards and actual and projected employee stock option exercise behaviors.  Since the Company does not have sufficient historical employee share option exercise data, the simplified method has been used to estimate the expected life of all options. The Company uses its historical volatility for the Company&#8217;s stock to estimate expected volatility starting January 1, 2018. Although the fair value of share options granted by the Company is estimated by the Black-Scholes model, the estimated fair value may not be indicative of the fair value observed in a willing buyer and seller market transaction.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As share-based compensation expense recognized in the Condensed Consolidated Financial Statements is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. Forfeitures were estimated based on estimated future turnover and historical experience.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Share-based compensation expense will continue to have an adverse impact on the Company&#8217;s results of operations, although it will have no impact on its overall financial position. The amount of unearned share-based compensation currently estimated to be expensed from now through the year 2024 related to unvested share-based payment awards at June&#160;30, 2020, is $41.8 million. The weighted-average period over which the unearned share-based compensation is expected to be recognized is 2.63 years. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate and/or increase any remaining unearned share-based compensation expense. Future share-based compensation expense and unearned share-based compensation will increase to the extent that the Company grants additional equity awards.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Share-based compensation expense recorded in these Condensed Consolidated Financial Statements for the three and six months ended June&#160;30, 2020, and 2019 was based on awards granted under the 2012 LTIP, the 2018 LTIP, and the 2020 EIIP. The following table summarizes share-based compensation expense for the periods presented (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:40.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.602%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,075&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,177&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,283&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,687&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,277&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,482&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognized tax benefits from share-based awards of $1.1 million and $1.2 million for the three months ended June 30, 2020, and 2019, and $2.2 million and $2.5 million for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the options granted to employees and non-employee directors during the three and six months ended June&#160;30, 2020, and 2019 was estimated as of the grant date using the Black-Scholes option-pricing model assuming the weighted-average assumptions listed in the following table:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.274%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.5%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.2%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average grant date fair value</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$7.52</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$6.58</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$8.19</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$9.06</span></td></tr></table></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period for each award. Each of the inputs discussed above is subjective and generally requires significant management judgment to determine.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s stock option activity during the six months ended June 30, 2020:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:47.853%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.555%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,008,403&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.24</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,901&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,718,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,852)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,960)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,336)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,672,205&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.37</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,426&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,194,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.27</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,500,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.04</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,254&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total intrinsic value of options exercised was approximately none and $103,000 during the three months ended June 30, 2020, and 2019, respectively, and $35,000 and $109,000 during the six months ended June 30, 2020 and 2019, respectively, determined as of the date of exercise.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717677326536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The major taxing jurisdictions for the Company are Ireland and the U.S. The Company recorded an income tax benefit of $255,000 and $421,000 for the three and six months ended June&#160;30, 2020, respectively, as compared to an income tax benefit of $156,000 and an income tax provision of $42,000 for the three and six months ended June&#160;30, 2019, respectively.&#160;The provision for income taxes differs from the statutory tax rate of 12.5% applicable to Ireland primarily due to Irish net operating losses for which a tax provision benefit is not recognized, U.S. income taxed at different rates, and net tax shortfall from cancellations of stock options. The income tax provision reflects the estimate of the effective tax rate expected to be applicable for the full year and the Company re-evaluates this estimate each quarter based on its forecasted tax expense for the full year. Jurisdictions with a projected loss for the year where no tax benefit can be recognized are excluded from the estimated annual effective tax rate.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to ASU 2016-09, the Company recorded a net tax shortfall of a nominal amount and $0.1&#160;million for the three and six months ended June&#160;30, 2020, respectively, and a net tax shortfall of $0.3&#160;million and $1.0&#160;million for the three and six months ended June&#160;30, 2019, respectively, all of which were recorded as part of its income tax provision in the Condensed Consolidated Statements of Operations. The Company&#8217;s income tax expense will continue to be impacted by fluctuations in stock price between the grant dates and the exercise dates of its option awards.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2019, the Company adopted ASC 842, and it recorded a reduction in deferred tax assets of $1.0 million as part of the $3.8 million change in the opening balance of the accumulated deficit for the cumulative effect of applying ASC 842.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company's deferred tax assets are composed primarily of its Irish subsidiaries' net operating loss carryovers, state net operating loss carryforwards available to reduce future taxable income of the Company's U.S. subsidiaries, federal and California tax credit carryforwards, share-based compensation and other temporary differences. The Company maintains a valuation allowance against certain U.S. federal and state and Irish deferred tax assets. Each reporting period, the Company evaluates the need for a valuation allowance on its deferred tax assets by jurisdiction.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No provision for income tax in Ireland has been recognized on undistributed earnings of the Company&#8217;s U.S. subsidiaries. The Company considers the U.S. earnings to be indefinitely reinvested. The Company's Swiss subsidiary, Prothena Switzerland GmbH ("PSG") has ceased operations and the Company finalized the liquidation of PSG in May 2020. Unremitted earnings may be subject to withholding taxes (potentially at 5% in the U.S.) and Irish taxes (potentially at a rate of 12.5%) if they were to be distributed as dividends. However, Ireland allows a credit against Irish taxes for U.S. taxes withheld, and as of June&#160;30, 2020, the Company's current year net operating losses in Ireland are sufficient to offset any potential dividend income received from its overseas subsidiaries.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717678702664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Preparation and Presentation of Financial Information</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Preparation and Presentation of Financial Information</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These accompanying Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with the accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;) and with the instructions for Form 10-Q and Regulation S-X statements. Accordingly, they do not include all of the information and notes required for complete financial statements. These interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto contained in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;3, 2020 (the &#8220;2019 Form 10-K&#8221;). These Unaudited Interim Condensed Consolidated Financial Statements are presented in U.S. dollars, which is the functional currency of the Company and its consolidated subsidiaries. These Unaudited Interim Condensed Consolidated Financial Statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current year presentation.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Financial Information</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Unaudited Interim Condensed Consolidated Financial Statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements, however certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures.  On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Segment and Concentration of Risk</a></td>
<td class="text"><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segment and Concentration of Risks</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company operates in one segment. The Company&#8217;s chief operating decision maker (the &#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM reviews all financial information on a consolidated basis.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits.  The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The receivables recorded in the Condensed Consolidated Balance Sheet include amounts due from a Roche entity located in Switzerland. Revenue recorded in the Condensed Consolidated Statements of Operations consists of reimbursement from Roche for research and development services. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  As of June&#160;30, 2020, $3.2 million of the Company&#8217;s property and equipment, net were held in the U.S. and none were in Ireland.  As of December&#160;31, 2019, $3.9 million of the Company's property and equipment, net were held in the U.S. and none were in Ireland. </span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-indent:9pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 18, 2019, the Finance Accounting Standards Board ("FASB") issued Accounting Standards Update 2019-12 ("ASU 2019-12"), Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes as part of the FASB&#8217;s overall initiative to reduce complexity in accounting standards.  Amendments include removal of certain exceptions to the general principles of ASC 740, Income Taxes, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. While not required to be adopted until 2021 for most calendar year public business entities (and 2022 for other entities), early adoption is permitted for any financial statements. The Company does not expect the adoption of ASU 2019-12 to have a significant impact on its </span></div>consolidated financial statements. The Company will continue to evaluate the impact of ASU 2019-12 on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717678589720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CompositionofCertainBalanceSheetItemsAbstract', window );"><strong>Composition of Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consisted of the following (in thousands):</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:73.659%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.876%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Machinery and equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,334&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,312&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,261&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchased computer software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,392&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,881&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,772)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,007)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,874&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current liabilities consisted of the following (in thousands):</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payroll and related expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,818&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">673&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,540&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CompositionofCertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Composition of Certain Balance Sheet Items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CompositionofCertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717677339848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Ordinary Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculation of Basic and Diluted Net Income or Loss Per Ordinary Share</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per ordinary share was determined as follows (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:42.040%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.517%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.381%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.381%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.517%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.521%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(26,282)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,810)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,851)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,675)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average ordinary shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,872&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,910&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.66)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.40)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.25)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.92)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Ordinary Shares Equivalent Not Included in Diluted Net Loss Per Share</a></td>
<td class="text"><div style="text-indent:24.75pt;text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The equivalent ordinary shares not included in diluted net loss per share because their effect would be anti-dilutive are as&#160;follows&#160;(in&#160;thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.723%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options to purchase ordinary shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,672&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,672&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717678566776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of lease liability maturity analysis and future minimum rentals to be received</a></td>
<td class="text"><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future minimum payments under the above-described noncancelable operating leases, including a reconciliation to the lease liabilities recognized in the Condensed Consolidated Balance Sheets, and future minimum rentals to be received under the Sub-Sublease as of June&#160;30, 2020, are as follows (in thousands):</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.269%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.134%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.137%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December&#160;31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sub-Sublease Rental</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (6 months)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,438&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,165&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,047&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,019&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,090&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,448&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less:  Present value adjustment</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,625)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nominal lease payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,454&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Contractual Obligations by Fiscal Year Maturity</a></td>
<td class="text">The following is a summary of the Company's non-cancelable purchase commitments and contractual obligations as of June&#160;30, 2020 (in thousands):<div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:34.082%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.394%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.402%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Purchase Obligations</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,959&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contractual obligations under license agreements</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"> (2)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,075&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">285&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">465&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:13.5pt;padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,034&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,244&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">465&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">________________</span></div><div style="text-indent:27pt;text-align:justify;margin-top:6pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">Purchase obligations consist of non-cancelable purchase commitments to suppliers.</span></div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">Excludes future obligations pursuant to the cost-sharing arrangement under the Company's License Agreement with Roche. Amounts of such obligations, if any, cannot be determined at this time.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717696685112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-Based Compensation Expense</a></td>
<td class="text">The following table summarizes share-based compensation expense for the periods presented (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:40.543%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.602%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,058&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,075&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,177&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,148&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,283&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,687&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,277&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,482&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Options Granted</a></td>
<td class="text"><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the options granted to employees and non-employee directors during the three and six months ended June&#160;30, 2020, and 2019 was estimated as of the grant date using the Black-Scholes option-pricing model assuming the weighted-average assumptions listed in the following table:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.274%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.5%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.2%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (in years)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average grant date fair value</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$7.52</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$6.58</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$8.19</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$9.06</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Company's Share Option Activity</a></td>
<td class="text"><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s stock option activity during the six months ended June 30, 2020:</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:47.853%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.257%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.549%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.555%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,008,403&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.24</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,901&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,718,950&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,852)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,960)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,336)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,672,205&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.37</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,426&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,194,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.50&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.27</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,500,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.04</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,254&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717679577640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (721,736)<span></span>
</td>
<td class="num">$ (671,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 333,942<span></span>
</td>
<td class="nump">$ 375,723<span></span>
</td>
<td class="nump">$ 398,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717682122504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Significant accounting policies [line item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 3,215<span></span>
</td>
<td class="nump">$ 3,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Significant accounting policies [line item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">IRELAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Significant accounting policies [line item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717677026248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds at carrying value</a></td>
<td class="nump">$ 287.0<span></span>
</td>
<td class="nump">$ 338.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717682573720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CompositionofCertainBalanceSheetItemsAbstract', window );"><strong>Composition of Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">$ 9,334<span></span>
</td>
<td class="nump">$ 9,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Purchased computer software</a></td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">11,987<span></span>
</td>
<td class="nump">11,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(8,772)<span></span>
</td>
<td class="num">(8,007)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 3,215<span></span>
</td>
<td class="nump">$ 3,874<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CompositionofCertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Composition of Certain Balance Sheet Items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CompositionofCertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717678702376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Balance Sheet Items - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CompositionofCertainBalanceSheetItemsAbstract', window );"><strong>Composition of Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CompositionofCertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Composition of Certain Balance Sheet Items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CompositionofCertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717675949624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Balance Sheet Items - Schedule of Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CompositionofCertainBalanceSheetItemsAbstract', window );"><strong>Composition of Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 3,355<span></span>
</td>
<td class="nump">$ 4,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 4,743<span></span>
</td>
<td class="nump">$ 5,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CompositionofCertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Composition of Certain Balance Sheet Items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CompositionofCertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717773245304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Ordinary Share - Calculation of Basic and Diluted Net Loss Per Share (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Net Income (Loss) Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,282)<span></span>
</td>
<td class="num">$ (15,810)<span></span>
</td>
<td class="num">$ (49,851)<span></span>
</td>
<td class="num">$ (36,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted Average Number of Shares Outstanding, Basic [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average ordinary shares outstanding (in shares)</a></td>
<td class="nump">39,911<span></span>
</td>
<td class="nump">39,872<span></span>
</td>
<td class="nump">39,910<span></span>
</td>
<td class="nump">39,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Earnings Per Share, Basic and Diluted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (1.25)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717675899496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Ordinary Share - Ordinary Shares Equivalent Not Included in Diluted Net Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options to purchase ordinary shares not included in diluted net loss per share (in shares)</a></td>
<td class="nump">8,672<span></span>
</td>
<td class="nump">7,168<span></span>
</td>
<td class="nump">8,672<span></span>
</td>
<td class="nump">7,168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717685848600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Lease Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 24, 2018</div></th>
<th class="th">
<div>Jul. 18, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Total cash paid against operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_OperatingLeaseArea', window );">Operating lease (area) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_BuildtosuitLeaseTermofContract', window );">Operating lease, current SSF facility, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 9 months 30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total lease payments due over lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_OperatingLeasesImprovementAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,704<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">$ 2,704<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental', window );">Area of sub-sublease rental | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_SubleaserentalsAnnualBaseRentInitialAmount', window );">Sub-sublease rentals, initial annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease', window );">Sub-sublease rentals, percent annual rent increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_OperatingLeasesSubleaseRentalsTermofContract', window );">Sub-sublease rentals, term of contract</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord', window );">Sub-sublease rentals, percent of rental gain attributable to sublandlord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=us-gaap_PropertySubjectToOperatingLeaseMember', window );">Current SSF Facility operating lease under ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary', window );">Face amount reduction on third anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary', window );">Face amount reduction on fifth anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit has been used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC-842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Discount rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_BuildtosuitLeaseTermofContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build-to-suit Lease, Term of Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_BuildtosuitLeaseTermofContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Face Amount Reduction on Fifth Anniversary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Face Amount Reduction on Third Anniversary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease (Area)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_OperatingLeasesImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_OperatingLeasesImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Sublease Rentals, Area of Sublease Rental</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Sublease Rentals, Percent Annual Rent Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Sublease Rentals, Percent of Rental Gain Attributable to Sublandlord</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_OperatingLeasesSubleaseRentalsTermofContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Sublease Rentals, Term of Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_OperatingLeasesSubleaseRentalsTermofContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_SubleaserentalsAnnualBaseRentInitialAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Annual Base Rent from Sub-sublease, Initial Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_SubleaserentalsAnnualBaseRentInitialAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=us-gaap_PropertySubjectToOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=us-gaap_PropertySubjectToOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717685906200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Dublin Lease (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 27, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating lease, future minimum payments due | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,090,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=prta_DublinIrelandMember', window );">Dublin, Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace', window );">Operating lease, Dublin, area of office space (in sq ft) | ft&#178;</a></td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, Dublin, term of contract (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, Dublin, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating lease, future minimum payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,000<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangement, Operating Leases, Area of Office Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=prta_DublinIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=prta_DublinIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717685575192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Schedule of Lease Liability Maturity Analysis and Future Minimum Rentals to be Received - (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (6 months)</a></td>
<td class="nump">$ 3,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">6,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">6,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">6,535<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">22,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustment</a></td>
<td class="num">(1,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LesseeOperatingLeaseLiabilityNominalPayments', window );">Nominal lease payments</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">20,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract', window );"><strong>Sub-Sublease Rental</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear', window );">2020 (6 months)</a></td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2021</a></td>
<td class="nump">2,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2022</a></td>
<td class="nump">3,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2023</a></td>
<td class="nump">3,019<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total</a></td>
<td class="nump">$ 10,448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LesseeOperatingLeaseLiabilityNominalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Nominal Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LesseeOperatingLeaseLiabilityNominalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor in fourth year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor in remainder of fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor in third fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor in second fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=119202524&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717678764888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies Commitment and Contingencies - Commitment Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 3,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Commitment to suppliers included in accrued current liabilities</a></td>
<td class="nump">400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities', window );">Contractual obligations under license agreements included in accrued current liabilities</a></td>
<td class="nump">100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligations under license agreements</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Purchase obligations consist of non-cancelable purchase commitments to suppliers.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligations under License Agreements included in accrued current liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717682491080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Contractual Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract', window );"><strong>Purchase Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total</a></td>
<td class="nump">$ 3,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">3,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFifthYear', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_PurchaseandContractualObligationTotal', window );">Total</a></td>
<td class="nump">5,034<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_PurchaseandContractualObligationRemainderofFiscalYear', window );">2020</a></td>
<td class="nump">4,244<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_PurchaseandContractualObligationDueinSecondYear', window );">2021</a></td>
<td class="nump">95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_PurchaseandContractualObligationDueinThirdYear', window );">2022</a></td>
<td class="nump">80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_PurchaseandContractualObligationDueinFourthYear', window );">2023</a></td>
<td class="nump">80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_PurchaseandContractualObligationDueinFifthYear', window );">2024</a></td>
<td class="nump">70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_PurchaseandContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=prta_LicenseAgreementsMember', window );">License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract', window );"><strong>Contractual obligations, Fiscal Year Maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">285<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2021</a></td>
<td class="nump">95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2022</a></td>
<td class="nump">80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2023</a></td>
<td class="nump">80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2024</a></td>
<td class="nump">70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">$ 465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Purchase obligations consist of non-cancelable purchase commitments to suppliers.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Excludes future obligations pursuant to the cost-sharing arrangement under the Company's License Agreement with Roche. Amounts of such obligations, if any, cannot be determined at this time.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_PurchaseandContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase and Contractual Obligation, Due After Fifth Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_PurchaseandContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_PurchaseandContractualObligationDueinFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase and Contractual Obligation, Due in Fifth Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_PurchaseandContractualObligationDueinFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_PurchaseandContractualObligationDueinFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase and Contractual Obligation, Due in Fourth Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_PurchaseandContractualObligationDueinFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_PurchaseandContractualObligationDueinSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase and Contractual Obligation, Due in Second Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_PurchaseandContractualObligationDueinSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_PurchaseandContractualObligationDueinThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase and Contractual Obligation, Due in Third Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_PurchaseandContractualObligationDueinThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_PurchaseandContractualObligationRemainderofFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase and Contractual Obligation, Remainder of Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_PurchaseandContractualObligationRemainderofFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_PurchaseandContractualObligationTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase and Contractual Obligation, Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_PurchaseandContractualObligationTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase and Contractual Obligations, Fiscal Year Maturity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing after the fifth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the fifth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the fourth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the second fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the third fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the remainder of the fiscal year following the latest fiscal year ended. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=prta_LicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=prta_LicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717674870424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements - Roche License Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>May 31, 2014</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationRevenue', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage', window );">License agreement, portion of revenue and expenses attributable to company, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=prta_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementDevelopmentServicesPaymentTerm', window );">License agreement, development services, payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementMilestonePaymentsPaymentTerm', window );">License agreement, milestone payments, payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=prta_RocheMember', window );">Roche | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationRevenueLicenseUpfrontPayment', window );">Collaboration revenue, license, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_MilestonePaymentReceivedClinicalMilestone', window );">Milestone payment received, clinical milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_MilestoneAchievementClinicalMilestone', window );">Milestone achievement, clinical milestone</a></td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones', window );">License agreement, potential payment upon achievement of development, regulatory and various first commercial sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones', window );">License agreement, potential payment for achievement of non U.S. commercial sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicensingAgreementCostAllocationPercentage', window );">License agreement, cost allocation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage', window );">License agreement, portion of revenue and expenses attributable to company, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones', window );">License agreement, potential alternative commercial sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_InitialTransactionPrice', window );">License agreement, initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense', window );">Cost sharing payments recognized as research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=prta_RocheMember', window );">Roche | Development Costs Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_DevelopmentServicesAdditional', window );">Development reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=prta_RocheMember', window );">Roche | Research Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_RoyaltyBearingLicenseMember', window );">Royalty Bearing License | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_AllocatedConsiderationtoPerformanceObligations', window );">Allocated consideration to performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_ASC605AllocatedConsiderationtoDeliverables', window );">ASC 605 allocated consideration to deliverables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_RoyaltyBearingLicenseMember', window );">Royalty Bearing License | Roche | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_InitialTransactionPrice', window );">License agreement, initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_INDandDevelopmentServicesMember', window );">IND and Development Services | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_AllocatedConsiderationtoPerformanceObligations', window );">Allocated consideration to performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_ASC605AllocatedConsiderationtoDeliverables', window );">ASC 605 allocated consideration to deliverables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_INDandDevelopmentServicesMember', window );">IND and Development Services | Roche | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_InitialTransactionPrice', window );">License agreement, initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_SupplyServicesMember', window );">Supply Services | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_AllocatedConsiderationtoPerformanceObligations', window );">Allocated consideration to performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_ASC605AllocatedConsiderationtoDeliverables', window );">ASC 605 allocated consideration to deliverables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_SupplyServicesMember', window );">Supply Services | Roche | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_InitialTransactionPrice', window );">License agreement, initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_ClinicalProductSupplyMember', window );">Clinical Product Supply | Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_AllocatedConsiderationtoPerformanceObligations', window );">Allocated consideration to performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_ASC605AllocatedConsiderationtoDeliverables', window );">ASC 605 allocated consideration to deliverables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_ASC605AllocatedConsiderationtoDeliverables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ASC 605 - Transaction Price Allocation of Consideration to Deliverables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_ASC605AllocatedConsiderationtoDeliverables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_AllocatedConsiderationtoPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Allocated Consideration ( Amount of Transaction Price Allocated to each Performance Obligation)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_AllocatedConsiderationtoPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationRevenueLicenseUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Revenue, License, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationRevenueLicenseUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_DevelopmentServicesAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Services, Additional - Recorded as Collaboration Revenue under ASC 606 starting Jan. 1, 2018. Prior to that, it was recorded as an offset to R&amp;D Expense under ASC 605.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_DevelopmentServicesAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract with Customers, Initial Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LicenseAgreementDevelopmentServicesPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Development Services, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LicenseAgreementDevelopmentServicesPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LicenseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for License Agreement [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LicenseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LicenseAgreementMilestonePaymentsPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payments, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LicenseAgreementMilestonePaymentsPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Potential Alternative Commercial Sales Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Potential Payment Upon Achievement of Development, Regulatory and Various First Commercial Sales Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Potential Payment for Achievement of non U.S. Commercial Sales Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LicensingAgreementCostAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreement, Cost Allocation, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LicensingAgreementCostAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreement, Portion of Revenue and Expenses Attributable to Company, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_MilestoneAchievementClinicalMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Achievement, Clinical Milestone -recognized where milestone was achieved at the end of the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_MilestoneAchievementClinicalMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_MilestonePaymentReceivedClinicalMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Received, Clinical Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_MilestonePaymentReceivedClinicalMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Payment To Collaboration Partner Recorded As Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=prta_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=prta_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=prta_DevelopmentCostsReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=prta_DevelopmentCostsReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=prta_ResearchReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=prta_ResearchReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=prta_RoyaltyBearingLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=prta_RoyaltyBearingLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=prta_INDandDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=prta_INDandDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=prta_SupplyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=prta_SupplyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=prta_ClinicalProductSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=prta_ClinicalProductSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717682798456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Agreements - Celgene Collaboration Agreement (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 20, 2018 </div>
<div>USD ($) </div>
<div>agreement_term </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_CollaborationProgramUSRightsMember', window );">Collaboration Program, US Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram', window );">Collaboration agreement, potential regulatory milestone payments per program</a></td>
<td class="nump">$ 90.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram', window );">Collaboration agreement, potential commercial milestone payments per program</a></td>
<td class="nump">375.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_CollaborationProgramUSRightsMember', window );">Collaboration Program, US Rights | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice', window );">Collaboration agreement, expected allocation of initial transaction price</a></td>
<td class="nump">15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_CollaborationProgramUSRightsMember', window );">Collaboration Program, US Rights | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice', window );">Collaboration agreement, expected allocation of initial transaction price</a></td>
<td class="nump">25.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_CollaborationProgramGlobalRightsMember', window );">Collaboration Program, Global Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram', window );">Collaboration agreement, potential regulatory milestone payments per program</a></td>
<td class="nump">187.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram', window );">Collaboration agreement, potential commercial milestone payments per program</a></td>
<td class="nump">375.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_CollaborationProgramGlobalRightsMember', window );">Collaboration Program, Global Rights | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice', window );">Collaboration agreement, expected allocation of initial transaction price</a></td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=prta_CollaborationProgramGlobalRightsMember', window );">Collaboration Program, Global Rights | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice', window );">Collaboration agreement, expected allocation of initial transaction price</a></td>
<td class="nump">18.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=prta_CelgeneMember', window );">Celgene</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementUpfrontPayment', window );">Collaboration agreement, upfront payment</a></td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram', window );">Collaboration agreement, potential regulatory and commercial milestone payments per program</a></td>
<td class="nump">$ 562.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementTermofAgreement', window );">Collaboration agreement, term of agreement</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed', window );">Collaboration agreement, number of additional 12 month period extension allowed | agreement_term</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementExtensionFeeperExtensionPeriod', window );">Collaboration agreement, extension fee per extension period</a></td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementUpfrontPaymentPaymentTerm', window );">Collaboration agreement, upfront payment, payment term</a></td>
<td class="text">10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm', window );">Collaboration agreement, option fees and milestone payments, payment term</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=prta_CelgeneMember', window );">Celgene | Collaboration Program, US Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementExerciseFeeperProgram', window );">Collaboration agreement, exercise fee per program</a></td>
<td class="nump">$ 80.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=prta_CelgeneMember', window );">Celgene | Collaboration Program, Global Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_CollaborationAgreementExerciseFeeperProgram', window );">Collaboration agreement, exercise fee per program</a></td>
<td class="nump">$ 55.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=prta_CelgeneMember', window );">Celgene | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Share subscription agreement, number of ordinary shares issued in transaction (in shares) | shares</a></td>
<td class="nump">1,174,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share subscription agreement, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 42.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Share subscription agreement, consideration received on transaction</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_SaleofStockPremiumReceivedonTransaction', window );">Share subscription agreement, premium received on transaction</a></td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Celgene</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_InitialTransactionPrice', window );">Collaboration agreement, initial transaction price</a></td>
<td class="nump">$ 110.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationAgreementExerciseFeeperProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Exercise Fee per Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationAgreementExerciseFeeperProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Expected Allocation of Initial Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationAgreementExtensionFeeperExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Extension Fee per Extension Period (12-Months)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationAgreementExtensionFeeperExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number of Additional 12 Month Period Extension Allowed per contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option Fees and Milestone Payments, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Potential Commercial Milestone Payments Per Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Potential Regulatory Milestone Payments Per Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Potential Regulatory and Commercial Milestone Payments Per Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationAgreementTermofAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Term of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationAgreementTermofAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_CollaborationAgreementUpfrontPaymentPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_CollaborationAgreementUpfrontPaymentPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract with Customers, Initial Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_SaleofStockPremiumReceivedonTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Premium Received on Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_SaleofStockPremiumReceivedonTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=prta_CollaborationProgramUSRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=prta_CollaborationProgramUSRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=prta_CollaborationProgramGlobalRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=prta_CollaborationProgramGlobalRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=prta_CelgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=prta_CelgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717685705144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>vote </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, number of authorized shares (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, number of issued shares (in shares)</a></td>
<td class="nump">39,911,413<span></span>
</td>
<td class="nump">39,911,413<span></span>
</td>
<td class="nump">39,898,561<span></span>
</td>
<td class="nump">39,898,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, number of outstanding shares (in shares)</a></td>
<td class="nump">39,911,413<span></span>
</td>
<td class="nump">39,911,413<span></span>
</td>
<td class="nump">39,898,561<span></span>
</td>
<td class="nump">39,898,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_NumberofVotes', window );">Votes per share | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_DeferredSharesSharesAuthorized', window );">Euro deferred shares, number of shares authorized (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_DeferredSharesParValue', window );">Euro deferred shares, nominal value (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_DeferredSharesShareOutstanding', window );">Euro deferred shares, number of outstanding shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_DeferredSharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares Par Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_DeferredSharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_DeferredSharesShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares Share Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_DeferredSharesShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_DeferredSharesSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Shares Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_DeferredSharesSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_NumberofVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Votes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_NumberofVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717685577304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 19, 2020</div></th>
<th class="th"><div>Apr. 01, 2020</div></th>
<th class="th"><div>Feb. 25, 2020</div></th>
<th class="th"><div>May 15, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of stock options granted to employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,500<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="nump">1,718,950<span></span>
</td>
<td class="nump">997,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,672,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,672,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,008,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based compensation cost not yet recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period of share-based compensation not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit from compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prta_AmendedAndRestated2018LongTermIncentivePlanMember', window );">2018 Long Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,177,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_MaximumNumberofSharestobeIssuedISOExercise', window );">Maximum number of shares to be issued - ISO exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Grant period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prta_A2012LongTermIncentivePlanMember', window );">2012 Long Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Grant period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prta_A2020EmploymentInducementIncentivePlanMember', window );">2020 Employment Inducement Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Grant period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_MaximumNumberofSharestobeIssuedISOExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Number of Shares that may be Issued pursuant to the exercise of Incentive Stock Options under the 2018 LTIP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_MaximumNumberofSharestobeIssuedISOExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prta_AmendedAndRestated2018LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prta_AmendedAndRestated2018LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prta_A2012LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prta_A2012LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prta_A2020EmploymentInducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prta_A2020EmploymentInducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717691718792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">$ 5,687<span></span>
</td>
<td class="nump">$ 6,277<span></span>
</td>
<td class="nump">$ 11,223<span></span>
</td>
<td class="nump">$ 12,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">2,058<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">4,075<span></span>
</td>
<td class="nump">4,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,629<span></span>
</td>
<td class="nump">$ 4,177<span></span>
</td>
<td class="nump">$ 7,148<span></span>
</td>
<td class="nump">$ 8,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717685359528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Fair Value of Options Granted (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">81.50%<span></span>
</td>
<td class="nump">81.20%<span></span>
</td>
<td class="nump">81.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 7.52<span></span>
</td>
<td class="nump">$ 6.58<span></span>
</td>
<td class="nump">$ 8.19<span></span>
</td>
<td class="nump">$ 9.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717686159544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Share-based Compensation Plan - Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,008,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, granted (in shares)</a></td>
<td class="nump">263,500<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="nump">1,718,950<span></span>
</td>
<td class="nump">997,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding ending balance (in shares)</a></td>
<td class="nump">8,672,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,672,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,008,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, vested and expected to vest ending balance (in shares)</a></td>
<td class="nump">8,194,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,194,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options, Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding ending balance (in dollars per share)</a></td>
<td class="nump">$ 21.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest, ending balance (in dollars per share)</a></td>
<td class="nump">21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, vested (in dollars per shares)</a></td>
<td class="nump">$ 26.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 2 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, vested and expected to vest (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, vested (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 2,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest, ending balance</a></td>
<td class="nump">2,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions', window );">Aggregate intrinsic value, vested</a></td>
<td class="nump">$ 2,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717682173848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (255,000)<span></span>
</td>
<td class="num">$ (156,000)<span></span>
</td>
<td class="num">$ (421,000)<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision', window );">Net tax shortfall (excess tax benefit) booked to income tax provision, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (721,736,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (721,736,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (671,885,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_RevenueCommissionersIrelandMember', window );">Revenue Commissioners, Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_PotentialWithholdingTaxRate', window );">Potential withholding tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC-842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets', window );">Cumulative effect of new accounting pronouncement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Income Taxes [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New Accounting Pronouncement, Cumulative Effect of Change on Deferred Tax Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_PotentialWithholdingTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Withholding Tax Rate for cumulative unremitted earnings of the Company's subsidiaries if they were distributed as dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_PotentialWithholdingTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Net Tax Shortfall (Excess Tax Benefit) Amount Booked to Income Tax Provision</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_RevenueCommissionersIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_RevenueCommissionersIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140717678948008">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashCurrent</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashCurrent</td>
<td class="nump">$ 1,352,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M@$-^@'/@DQ&+64A 0YY"&"88V3*(V'@8>$MVI$>P79=B'QN)5@2E= 6W"+W
MR)6QQ<8CPEMR,Y$H\, ?P>[\,:H(5Q8ERRNKC?(K(XV-!XA_.2\_XT9>.-)D
MC!$JPXN-QX23R&CQ%.;UPP&<CH,1*6.*C0>$;!NY4!6<7R@<P,9HE*'$QF/
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MRRUG/I?Z!7B^%D*=!OH#1:]Z\ ]02P,$%     @ ^(,&465XP\34!0  S!@
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MM#EM(QPD,YF*!RW!?C'I"LJ)G-15+O!TC3K,PB!)9[0$#V*"_6K2H7KP;)$
MO)1.BY[#+L0IF1,4/"@*CDZ2^D*P.U$(+;BW\.&AZ&-_U>]U=,=>YD04V[6<
M8&*M(ML*C,A,SX>"C^-C@*J!O%2\YDQEW?8DYX^PAV^KM!,XMC4=1].-B<,J
M2LA<+1FT!/O%Y$.5R9*;<L?[43U#OF)B2P4A> IK&\TEZ* FV"\G?[8B\F-)
MO?@A;7F(')7$8055W U*!@TA?@WY=+!W&N6 BY38$A'&X313'591% 8SI(.0
M$+^0'&ZBCI':^H"3*)P.JLLLCO&,CI#1Z<%_?!COI4ZL*V0H_L1?_'O95Y"J
M5<./2BJQ2SML (AUG#AN=T@\: #Q:X"5#<> [5J/(QQ-)<ME!AOA&44@@R(0
M_R&CRXEC*\P^*$21E0I^HT.^05C(*<>)RKW&G*PN_8C2<+JQ=MHE*SI'/"@-
M\2M-1WR,TA8-'(9ADDXI778K&L8SE(.\$+^\7,FR%-HH7W>NS&1E3@2\RH 8
MO?XH-4>K-TYT;V!SY791[UC&+Q<[([;JD2\VR'7+\3\$.NS\H%@D]9:LVRU3
M?"N+G*OZYY\2@N-?VO.:?O'>?@Q"0_U"\VNCI+E'ZTI7;5IS7WW8ZC'->Z_)
M(=Z@+M2O+I]4+BJF7GQDMEC0=+HXCQ@=T@UZ0OWGDG=Y+LSM)B21N?XX%Q4<
MIG8"DLH):A\ZTBB"/?^4U6$'"1?,)!(=777Y%0HVEDW9%.V-(4RYR(2SS%-;
M;\YC6'AT>H_D,ES%.)D[2-%!F>@IIY-Z=NT[L6W9(13&;;JY<-G%)"4S>S8Z
MZ!/UZY-53=MJ]1\[$3GN#AW'+H>=\]BU'%TUFWO^OYAZ$%6-"GX/CL';&.*H
M[NJ\>]%RU]X^WTFM9=D^;CD#>&, O]]+*+?[%W.AW?\#8_,O4$L#!!0    (
M /B#!E$2V%XQ3@,  "0-   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
MI5=M;]HP$/XK5E9-K521-UX[0&H)U39I&BK:]F':!T,,L>K8S':@F_;C=T[2
M--"4A)8/B>T\]]S=<[[@#'="WJN($(T>8L;5R(JTWES9MEI&),:J)3:$PY.5
MD#'6,)5K6VTDP6%J%#/;<YRN'6/*K?$P79O)\5 DFE%.9A*I)(ZQ_'-#F-B-
M+-=Z7+BCZTB;!7L\W. UF1/];3.3,+,+EI#&A"LJ.))D-;*NW:NIZQB#%/&=
MDITJC9%)92'$O9E\"D>68R(BC"RUH<!PVY()8<PP01R_<U*K\&D,R^-']MLT
M>4AF@169"/:#ACH:67T+A62%$Z;OQ.XCR1/J&+ZE8"J]HEV&[3D66B9*BS@W
MA@ABRK,[?LB%*!GX+QEXN8'7U,#/#?RF!NW<H-W4H),;I*G;6>ZI< '6>#R4
M8H>D00.;&:3JI]:@%^5FH\RUA*<4[/1X(G@(92<A@I$2C(98P^0&,\R7!,T-
ML4+G,RP)UQ'1=(G9Q=#6X-H0V,O<S4WFQGO!S>>$MY#O7"+/\9SW[_I^M_T!
MV4A%P*NR:P7IY 32LWJZX#A=0)9 YQHZ=] XQND)I,=CM*%T1?V\HGY>RN^_
MP#_74"]H7(W$"MU2#E6CF*&94#1MQ)_7"Z4EM..O(\[\PIF?.FN_X&R:2&&Z
MD$@)>R3+X1)Q ?L2?&XQ2P@ZIQP1P"FT(3+#7*!_Z%#/JBV4.>^ESLT+;COV
MO*&]+5?P*&0OIW:14_LU.27Q L('3;,5A!,="4G_ L9DF*U6-D+FKE,*T77@
MMY_(I!$J:(2:UJ'V=.D4NG3>I M5*BD>U&G2>1;AH1ZUB* 6,3V&V-.@6VC0
M?9,&\,>K-.8AY>N&0G1KA:A%!+6(Z3'$GA"]0HC>42&^2L@1SA&%!ALL2_T>
M"L:P/.CXLV.]/LG\]<LAMASW((\:T%XJ_2*5_FFI/)6SU./-JMFO;KR*=F^,
M#!HCITV0>Q(-"HD&KY7HI*X?/ O0'PQ<M^WZ!^HT!095P/Z@W^D>[IP&P#UI
M7.?IO.2\5IS37P>YKP82-48&E<A*D9H@,Y7LT@'3?#]\P7)-N4*,K,#4:?6
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M(%@8D'.=X&Q&&8'9_'! I]ZDX7&7-M>5L62-/QL[)>AM#[%_;FO<QK_;]+I
M X)PT.88P)$0L"4 ;FQ[3'HS1L;-V)=LI7W(F'J]PR'C#N>R>L1@X9D=:@[
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MH_D(I6Q-JTP_B.??V=X@"S 1F;)_T?->-ABAI%):Y/O%@"#G1?V?ONP=T5H
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M8G1U^@B8F"=X =ZO'7*6O["!X4>@L_\#4$L#!!0    ( /B#!E';EL^*,0L
M '<>   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULM5EM<]NX$?XK&+73
M2V84O\BYNUPNR8SMY-JTDR:UDK8SG7Z 2$A$3 (\@+2M_OH^NPM0I"(G=]?T
MBRV1P&)?GWT6>G;KPW6LC.G475.[^'Q6=5W[]/@X%I5I=#SRK7%XL_:AT1V^
MALUQ;(/1)6]JZN/%R<EWQXVV;O;B&3][%UX\\WU76V?>!17[IM%A>V%J?_M\
M=CK+#Z[LINKHP?&+9ZW>F*7I/K3O KX=#U)*VQ@7K7<JF/7SV?GITXO'M)X7
M_-V:VSCZK,B2E??7].5U^7QV0@J9VA0=2=#X=V,N35V3(*CQ<Y(Y&XZDC>//
M6?I/;#ML6>EH+GW]#UMVU?/9DYDJS5KW=7?E;_]DDCW?DKS"UY'_JEM9^_AL
MIHH^=KY)FZ%!8YW\UW?)#Z,-3T[NV;!(&Q:LMQS$6K[4G7[Q+/A;%6@UI-$'
M-I5W0SGK*"C++N"MQ;[NQ5*"H?Q:+>W&V;4MM.O4>5'XWG76;=0[7]O"FOCL
MN,-YM.NX2+(O1/;B'MG?J3?>=554KUQIRNG^8^@Y*+O(REXL/BOPS[T[4F<G
M<[4X69Q\1M[98/P9RSN[1]X!*]6_SE>Q"TB6?W_F@,?# 8_Y@,?_%^]^5C95
MZ]/8ZL(\GZ$<HPDW9O8K#E07.MI("]\%T^J@I4A<2=^C<9T\P/N?K-.NL+I6
MKYV@ +UX7V$5BJKP3:O=ED1_<+HO;6=*+.Q,L(VZ](B\BWB"3Q$GEYI>[R0N
M<8Q!C7=15?K&J)4Q3K6L$-99QP>$$JL-"J.K5%?)H<F:-E@(:FO8LS'.!%W7
M6WIOVD[VT_H/1\LC]> /OWNR6)S\^,?S\W?\\?3'AVSN(-8Z!+YGL(@*ABHJ
M>W5Z\NAOO.[*;/I:;%\^^J>*@^9'[-Y00I]Z.R=16U5ZY7P'D47=E]"XKLF3
M<LK.AR06RZ!\,#_WEDRF<\FEM>F,6@]^&I\FGK>_P<6Q\GU=PLF*\)O<4WCW
ML7<"D(,COBR(%/\K*X[UP72>!'5H 3NG7TI>D*M/O_\QJG/G>@BY,JT/G<)Q
MV;M_@9FU&<6!P[4T11]L1XE*A[VZ*RKM-BRVL9%;P@-:G**Z?'4Y!!6OWNA0
M5.I,@&*R<'%R^L/NZ+PG._5_RV#DK&JE>,0/;$GIZUJ'.%>WE852EGVFULGK
MD !#@W'%-F=(\AS;;2&V&!\<^U6TI=4!GODZ6N<<'556_ VJG"/%.2<3(*!7
MUE2V$C\@JHLZU=:NTDUMT=-T<M=..I8=J4L3**64;D2G(;%^"Z8$4]0:>;.V
M6"OY2G5('TFHQ*!36Z-#CF%2XU/OW@N(7Q,.R6O!U+R@M+&H?>R#D23KL^3Y
M(=3TXJ>H&T.$!0FG)>>TE. DB(<@ALZ>9W?[UKK4"!KMP--HR9SX&!$K1C9=
M?@11X:U#EJ>D\@YX[,A'-84 7B;/3#8X@R2)U+0(^[1::SL-04Y&/ +5XMP$
M)Y6&)4!-;_'$^C+N"I"K@P/ZR,"7Q>#[B?TI2Y4P8#S3ZA;N*B'MAMP3?*-R
M& _Y"A'PM^;& +53NNX#_-K[CD!^$D5Q"7R3',7Y?S 6GVN&U,M&&; S$3[Q
MC>T&+]QC_/T>I0+.'48\RXE'/2W'R[+V)0@&\>K](*&NT&;,78LD26U-8 _Y
MPD6&!_D@3TT$KSJX9G@Y/1UE&/F,5[&S<"Y<2':U(^HR0-:O@;Z, [;;CER:
MNG$<93P9U.AKHS[VY29%W@RZ4)R!+GW3B@N[2J,TUFNJ$/$*=3VHD;$,RF*]
M(2FUU2M;<ZNCLKHQKD\2R7NP!(_O 8,C]99R#%6V\5177.WSL=;F1M<]JTCP
M/2@\3WE'FPIJLP4<,Z95F20B$#LKLP9P1=*3:MJ#9I+5<]00<N01S4@E<Q@H
MK^4-U22W9#*DQ-[:MZ)?,I%?U 9;I:L-G8>D[2E/ %=93$:!U281:$%4%"0$
M+V^0G+Z/*:_ AZ]1VA&92'18%O$;V /_0(M/0C?RX H]"@KGC 9QBNC:JYI0
M&"@AW<.&HF]0M-3OYOM@)8@HW:;*D$RYCWPB9P\9I?0*8[-(U"%P$Z'XF5&^
MB*-V*9-2+=4FT3JJ2]T29D![QB^Q-OH^%.3>"U/H/@X5"R(BR,7BK"-"YXBZ
MHL%#[U'.H'_WC.-B6J/!<RV2G"RA8F5 XQ,[YB7#UJ,O#B/OZ51U:]@.%4>K
MA??%W*@/)6G9<U?AIF?O5"-#IZ&A4V%D-,/(.!^TFQQQ4*:)*(R5X"Y17;7(
M#DO$U_\R@*$=4]))Y)8#SK&$D *?=R!V9>-UG-2 8#,'!^D-W67[I% &GEU4
MU@QP#HM*I#W394*O,.'"EV]?OLD,>,XU=LF;7]VA4S.HOUW#129D2(D'F?VH
M=5#+V^^O.=O;/K0^IERN:U^(?LBFG)C_J(@2"F+E@.X?MNN1.)4;+=PG)4?F
M$##1Q0WSDMW:<4^^1\>C401E$I00<GVU"#D2A!,<M/=CQO4<(2&4TS@6:-H6
M)8EP\G% +'ZLH\ @?Z!& X,'QC<0< "KP1O@S!0/VUH7"1 _$< -K+*;*I_]
M,\J5.MMZ8IGM>HD6T[S55I)^2YVHL5VBBMRG1F8 9;GGR"&<E<X<%GRD7J+=
M11)5F3H-=BOMK@4RS%UAJ(E,3L'V/C"Q:8._L:706 :@,@F;^J'2D1%OA_XE
M:X7.&*5%T/EY[Y<=SPX=16RP%]G;MQE]S!WE 7>]4.ZH=E+JFSB%A(O$+9?$
M+47]75CC3LKG!YN)E-V-0B(2)9JPD%1UY0M2$7G:D1^*/%8M$8#_F  IH%%7
MH\;]"PX?81E<^'97Z2FC^7$PMEGU(4K#9&U$%RK[>UL_W5C98J_??_.UHO!%
M3V)B9>7W&L3OSXX6JK%U/:&44PQ"BL(1G8S%E$BMS$0.\>$6QFD_OGR2BQZ7
M.AS>O"8N1?$0)5XB+9H5X/GL=,[=@A7YX1Y%OOFZ*HS+JO1&ZLK?.IXBI/5@
M*"LRX<A4'LC;KXD2!.!OJXMKO0%H T4T42;Z1!0-70/H3$P @(Z=8*\=^FJ?
M41(J%5C-3(ZNOO+GV+=M;5.W<'PWP@4=>C!6J,TAW<,$PB"ZUZ*[*+K!C1FL
MF#Q;@86NLJ%\!'HD[,D?LL,D*\2$9( D<%9?[O1:NE9(&H]SFV'FD"EH=?LV
MS!/^$+2[F%H)W(4BQ><2;,COQB=/Y628?LJ\-/6 KJ,_:.N6"Q:T33L9SN@N
M)#++X]:>VFTT>_Y)@PTM95]:YGW98;2++LL[L]D2M% #G-"[X)TG?BD(@F%E
M2/33)SG1R2YIO6:\%\CC2ATPT5]X_%,/9C^=+R]F#P$%L4<Q'USZH267LN!'
MIPOL.5]^R-]FX#BO'>82H][K.]CVX+UO,0]\__CDX5,0U 9!6F\S[QB))^>/
M-^8[CBA;;*)%>KK#RHZ.CT*S(H_F.B9+=O3IAJ^ML0'U);,T#UAE7YAT%7Q'
MB)[F_W1$S#8#0N#=<GJ7%TSC;S3?.>=K"6J[><01&$T7YN,[=*P_7UZ22^9[
M)E,B9(,+X3@T(1A6/DT8FH8C:=KXO^</C<: &&-P8Z>H!W@&@;;&N(_O#X5H
M67&4,"V9)/DD4H4(HJWSH)/NRV4JTZ7G"W\ZKR8D/Y4!RR-O"^KR<%6ZV^M7
M(#MJU4?K3(S2+BF$#\A"[%SP3C$HOT3F8"_-570.VQZ)?\H5RW"/<>]U_:?P
M*A<CDC=9)CM_2%>RC*]V]&1600A0>IG?'/J)ZGCT8V!CPH9_\J2&#>?([X+#
MT^%7U7/Y,7&W7'Z2?:,#D"%B,%]CZ\G1]]_.T)?Y9T[YTOF6?UI<^:[S#7^L
M@, FT *\I[NO_(4.&'YK?O%?4$L#!!0    ( /B#!E&[[=3CCP4  % -   8
M    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULI5?O;]LV$/U7"*\8-L"U'3MM
MLS8)D+0KUF'%BG9M/PS[0$LGBRU%*B05U_OK]XZD9+EQ.F #\L.BCN_>W;T[
MTN=;ZS[[FBB(+XTV_F)2A] ^G<]]45,C_<RV9/"FLJZ1 8]N,_>M(UG&38V>
M+Q>+Q_-&*C.Y/(]K;]SEN>V"5H;>..&[II%N=TW:;B\F)Y-^X:W:U($7YI?G
MK=S0.PKOVS<.3_,!I50-&:^L$8ZJB\G5R=/K4[:/!A\4;?WHL^!(UM9^YH=7
MY<5DP81(4Q$80>+?+3TGK1D(-&XRYF1PR1O'GWOTES%VQ+*6GIY;_5&5H;Z8
MG$U$297L='AKM[]0CN<1XQ56^_A7;)/MZG0BBLX'V^3-8- HD_[++SD/HPUG
MBWLV+/.&9>2='$66+V20E^?.;H5C:Z#QAQAJW URRG!1W@6'MPK[PN5+J9SX
M('5'XC5)WSE"QH,_GP> L\F\R$#7"6AY#]!C\=J:4'OQLRFI/-P_!ZF!V;)G
M=KW\)N"OG9F)U6(JEHOEXAMXJR'25<1;_7ND+Y0OM.5@O?CS:NV#@SC^^H:/
MT\'':?1Q^O^S^9^ Q!\UB>>V::79B2:]\*(@%]!^HE)&FD))+:3W!&MI2J&5
M7"NM@H*A#*)BX-L(S#V!OBHZYY39L+:5GPIE"MV5O%!(7PNZZ13,V?E,O-QO
M5HPNZ(L*HG6JH"F0,!4\#'EO $_9V,X$?(3;K>UT*=;$_@AM6(I@!7I3,TID
M*ZP3K53Q!>IA?$4._'KZ.Q!C6^M*<GJ73&3J[#6%+9%!6[C/ &JE"ZI0R!%S
MOO(8.$4]'4?.Y+/U0V[ILL\E)SD1]G7/N*1 #IT'JV1K(^.N:=FY3^9'7.>8
M.T],G9/$B1F'.XH./ 'DB!ZB4&[,M<:S=$6]8];D@UQKA78O 0. 6#2!V2P*
M<%'(#3OA@ \XLA#82)FV [..PP IKA)[D3&-#87:EE;;#6M%F9P4!MSS>2I^
MHUO2XD1\_]W9\F3Y3/R^]N1N08MZ^.Q>W'0VP%'4AQ<_=$:6GS#1J/PQD2E9
M+,5>KE@;JU7U,SMG%\5,OI>#[U=1K) R(AFBBP61CG*YNA:Q'5)A[UXU2DO>
MA/;O4G?=\3@]LG%/^WZ4O'U/Q=B0H:>Q&(TM26?M[2L0J*B-NNFRIVVM.)%H
M$J\V1E5P"GGF*!G5CE,?JYEUR'J0)JG7Q7:KG&W&]MFPQ)DQ$Q^1/?1KVVJX
MP-LI8T&WD:5'\/83#E%1=0$]DN9"A=,\Z:K$,,V-3KU):GW/O2Q%'@M9SYUG
M01TTG[VCH/T04@;=!]D+)P-<=^Z64!5D!\<MSY^BEF9#\:U/J2T<E2K:8_^@
MF=6@F??FKK^A3KYK6^NXXNL=Q!@";)!,8_N$Q2)&?4YS?5*;.QZ4  BC 8WH
M2W9N6Z%8WMN#P3&+P_QHITOM;8^8YBP4%R(@CGY([N_DB&>+K8[D+TI,F3N6
MW9'8MS4=;_5$L)#.[>+DRC4%S-T#9Z3_Z=#_7Q\@J$]1))!T#"2M#8NMW$5B
MS!Z+KJ.#XVO*"G46\;,41HDK\<NG1DU8<J0E]QG.",QPQZ,9DNP!^$#$D9Z+
M>2 N/ONJ41/,Q'4_[L,]A9H>E+O0J"ZZE$=7N!L]+G:A1M+R_.3L8G3C9TV%
MY/J,L:*C>W!2!^7!U!\\<3[-QO>#J/<GS_PPL#T?]6FTQL.")S%7\\'R[,EL
M ;UH'>_)R-&#U>ILMAR6>*)90[O>6]69LF_2=))$DK'[OF:+QL)-CH:;7"K"
M"]2_66-FKTYX^>0GOC_XEHI4NMFQN]A\=,MMR&WB79YC@7C2A7=8';XN7*5;
M\MX\?==X+=T&DA6:*FQ=S)X\F@B7[N_I(=@VWIG7-N &'C_6^,I#C@WPOK+(
M?GY@!\.7J,M_ %!+ P04    " #X@P91?&]>PF #   ="   &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q,"YX;6RU5MV/VS8,_U<(XQYZ@!%_YNP$28!+VF$=
M>EC0P[J'80^*S<1")<N5Y,O=_OI1LI/FBC7 L.Y%M$3RQR^1\N*H]&?3(%IX
MEJ(URZ"QMIM'D:D:E,Q,5(<M<?9*2V9IJP^1Z32RVBM)$:5Q?!=)QMM@M?!G
M6[U:J-X*WN)6@^FE9/IEC4(=ET$2G X^\D-CW4&T6G3L@(]H?^NVFG;1&:7F
M$EO#50L:]\O@/IFO<R?O!3YQ/)J+;W"1[)3Z[#;OZV40.X=08&4= B/RA!L4
MP@&1&U]&S.!LTBE>?I_0?_*Q4RP[9G"CQ.^\MLTR* .H<<]Z83^JX\\XQC-U
M>)42QJ]P'&2G>0!5;ZR2HS)Y('D[4/8\YN%"H8R_HY"."JGW>S#DO7S++%LM
MM#J"=M*$YCY\J%Z;G..M*\JCU<3EI&=7&R4[9;C/D-K#!K6E2L*:"=96"(_^
M8KRW*,TBLF3/:475B+T>L-/O8-_!@VIM8^!=6V/]6C\B/\_.IB=GU^E5P%_Z
M=@)9'$(:I_$5O.P<?.;QLO\<//QQOS-6TQWZ\XK=_&PW]W;S_R7I5[%=$\]-
MQRI<!M2E!O43!O\FT*VFAM?V!5A;P[LO/>^H!6T(+4F\XN%K7J6H48W%VAFP
M#<)>">IXWA[@#9FRC>H-J9G;.5 9T9?Q+58H=Z@A2X::TI+,X(%5#46EO[$#
M-S +LRP?:)+"!Z1V;)2H@<M.JR=T4@:2,+U+QG7;ZZHAJ9K\DUUOR991>WMD
M&DDBFZ5NC4M(DG!6%HZ494+ QLQI8%2][ 5S,=5(R:PX&R8)><6DTI;_-1R\
M*<.B2&\=C>/B]FJ>;B +TV3J:5GDE(,+9'RF86L0CLS 33S)J>.%.)FD@_)\
M0./89]DV&M&S#7\&.?0;NG[[FF:7V9 FJ.G0ST#Q$OIT4!)JL.J'6DIFKRU-
MX%=2UK#IM78U_,#9C@NZB6A&3C5RQ 7G!UZF+7O1I.P=USA4<TRS\47(IJX8
M>5@FI2O<GFI/83,!KG=X15(%E2N/X]'?NR*#+$VO>._0BCPC.@VG>0S_-#&B
MBY$M41_\P^0"[UL[3._SZ?GMNQ]&_E?QX>%\8/K 6P,"]Z0:3XII 'IXC(:-
M59U_ ';*TG/B/QMZOU$[ >+OE;*GC3-P_B-8_0U02P,$%     @ ^(,&42HD
M\S#L P  N0D  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULI5;;;MLX
M$/V5@; /">!:LGR);=@&DK:+MMAF@[J[?5CL RV-+2(4J?!B)W^_0TI1Y<0Q
M"NR+35(S9\X9SI!<')2^-P6BA<=22+.,"FNK>1R;K,"2F;ZJ4-*7K=(ELS35
MN]A4&ED>G$H1ITDRB4O&9;1:A+4[O5HH9P67>*?!N+)D^ND&A3HLHT'TO/"-
M[PKK%^+5HF([7*/]J[K3-(M;E)R7* U7$C1NE]'U8'XS\O;!X&^.!],9@U>R
M4>K>3S[GRRCQA%!@9CT"H[\]OD<A/!#1>&@PHS:D=^R.G]%_#]I)RX89?*_$
M#Y[;8AE-(\AQRYRPW]3A$S9ZQAXO4\*$7SC4ML.K"#)GK"H;9V)0<EG_L\<F
M#QV':?*&0]HXI(%W'2BP_, L6RVT.H#VUH3F!T%J\"9R7/I-65M-7SGYV=4M
M[?L?RABX0PU_ZIQ+VAI8%TSC(K84P)O%60-V4X.E;X!-X*N2MC#P4>:8'_O'
M1*QEESZSNTG/ GYQL@_#I =IDB9G\(:MVF' &[Z!]Y%IR>6N5AM$PC_7&V,U
M%<>_9_!'+?XHX(_.9/.SS%2)<.&S>OF+:3V+ZOMR;BJ6X3*BQC.H]QB=VSBX
M889G(,F"-V1$(%.1J7HV-<&4&\B8R)Q@%G/8/$'.]YPL=B?<Z:LM$ ZATC%_
MQ_:HJ7%!NG+CD;<OP W0*6 LDP$O=]K_>03BP57>K]D:<(9"<TFAA?,L.I%/
M,#XH)[QY)ER. 2[X46\#;K?4[*>(5,JBM)P)\422C6,;@> J.A8\ #ZBSKA!
M[TD=E]V#JOR9<22@#Y_4 4ER[S3:RY">JU2V54=Z*J+I,]'1Z3-[2B4SGAG7
MSYIJU1OZ0('?M8IS1RE0041 TI@1$&%WLFT+C=XO!\,?H:P[%'V' O47MOW5
M"S9I,IC5(_*E$U)I/$VXK1]\<$QX%INV[(Z-^G![1NF!I.9H4=/I1C%HME6"
M[@H#%]QOCW*&V)@>[5*&E>W$9J5RTIK+.7P/$KN'#ZQ)Z]&"EQC4=4:WKJ02
MMDK/?U+\#2[222^=II=^.!CWIH,D#$>SWG0\",/AI#>Y&E_"!Y2*:-<(/U[V
MQ;EN&,YZL\' _TVOTGJ6A-ED>IRMX#MO6MIORYG-(&9)?S*YK >CFO:@GXZ;
ME1EI^N[K_<'Q/1-4PZ\X^HIM>NM53[Z(ML&,47'_4ITV)7UR9__'_JV/FI5*
ML'(Z*YAYG?LI;5@*5[T!Y;<[/G7HQYWKE.IC%QX-=$[Z:JMOUG:U?9=<U]?Q
M3_/Z4?.5Z1TG:@*WY)KTK\81Z/JA4$^LJL+EO%&6KOHP+.AMA=H;T/>MHK.F
MF?@ [6MM]1]02P,$%     @ ^(,&4=T!TG#E#P  <B\  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&ULM5H+;QLYDOXKA,]SFP!M69(EQYX\ ">SP68Q
MLQ.,=^^P6!P.5#=E<=(/+=GMQ_WZ^ZJ*[&9+LN/,S@XREM1-%JN*]?BJR#=W
MC?OB-\:TZKXJ:__V:-.VV^]/3WV^,97VDV9K:KQ9-Z[2+7ZZFU._=487/*DJ
M3^?3Z?EII6U]].X-/_OLWKUINK:TM?GLE.^J2KN']Z9L[MX>S8[B@U_LS::E
M!Z?OWFSUC;DV[=^VGQU^G?94"EN9VMNF5LZLWQY=S;Y_OZ#Q/."_K+GSR7=%
MDJR:Y@O]^%2\/9H20Z8T>4L4-#YNS0=3ED0(;/PST#SJEZ2)Z?=(_2/+#EE6
MVIL/3?G?MF@W;X\NCE1AUKHKVU^:NS^9(,^2Z.5-Z?FONI.QR_F1RCO?-E68
M# XJ6\NGO@]Z2"9<3!^9, \3YLRW+,1<_J!;_>Z-:^Z4H]&@1E]85)X-YFQ-
MFW+=.KRUF->^^]!4E6VAY5;INE ?FKJU]8VI<VO\F],6*]"XTSQ0>R_4YH]0
M.U<_@<#&JS_6A2G&\T_!6<_>/++W?OXDP3]W]42=33,UG\ZG3] [Z\4]8WIG
M7Q77[\NK?K ^+QO?.:/^<;7RK8/-_,\3JR[Z51>\ZN)W4O)SJ1V2X4<#&U7I
MF+]N^/=6UP]*%\VV-86ZNOZ@+A;S3(9[9=9KP_ZA_JSK#MZI9J3SV>5$?7:V
M<6IK\%$H734=T=QH#*V;5JV,@6L5O\)209;8R9F=#K_:!J_AN=O&T4M+/I@W
MKM!U;F#F[4:U VO_^1\7\]FKUR!M8?3.YKKDX1T+ISH8E ML3R<*'JE*EE0[
MIR&\B(H_QF&I+?.,]6D!EIDB0+,>Y';DK2?-^J0C&MX;V1JA65J]LJ5MH2^8
M0F% %*X'NN3_A0(IHHL@Z&E+;W79&2*.,;;JJD!DJQ^$J>86G-,$9RA*DC0R
M@LCRJH?48.O<L530PZIQL#B:Z'1K!BYL+5&9P]NMMJ5>E20-,;.WCV0&AZ0N
M?4.+E5UAR)X>(OO8MRA!I0O#C)K[,*ZK80FNM?]GHLY  F-A03Y08W;9Y%=@
MNC?74VP,3"0WGN*Z6# /VS2E+?2#!Z>FUGA@JZV#[A(65@^IJDA0C=4AALG(
MNNXV-M\@O>#/:*YL(GY$DVSN>#.%&A%H7,:C;A'TR8S] 27L+@Z^:4I0'9MW
M>U#%D^"3YAZ9E#3E(7#>W-2L/=HZ1:&&YY&OT_[:Q&QH7M[VBB:K@8X:,@SD
M9EC$8%%YXUMU!_:/9Y-SV&-9LFF U>.SR;Q_L&Z$<KMQ1C;6VWM52>@V%+H5
M J_I R_<Q?BM!(CR(1."3Z[P/,JSRS'E*%:N_0;^8Z'A&W@,9")N=X4=O#1(
MO-SE9_I[2[P8KS"?7/[+$G\,G&T[MVT\QQ'C6UN)I/3FB4@0;.Y@A$N-U=;_
M["P%1HZZ*UU_\7BOX70:.E:KSL/N/-EER='$;^QV+T*3\_2Q,'WQ!P_#*S$3
M^U.R43_.LL2A HF6(KM(T7GQS#'Q0YN\F,R7WS$)>!X]J!N5;RC^]ZH84@:4
M04^NN]4)_A=R+S 'F$V".2'2EW'8A\YQ&+J^_J@^ZES6/#"\V]+N[RL<.]DY
M$'*(BR;;4<^NZ8+9'\ 2/JSG-+H;1?;R$$7)_>!-<<31M (9"!JT+9&#"BEY
M<JJ>J"M)!V/K3K<5O%$:X?2M#&4S'64C>@T)Q5F=X) 7LQ!D:IS$;]]MMZ6E
M7P=R?- /#V38D.13LL&,LHK9MKV/E@))D&9R9U=1\_#!7K1===),\,^8 9YG
M"3_@I8'1;WO4]?3T9KVVX+B?DF%T;7KCV$G.@S;HFR:IA=;DL!U]JM5/VB$O
M(0*<C[4?(8NML7_$8YV3[B25#YSZWH)I,C$RG[[FO,+?9Z]?TO[+D-G\(GNU
MG*'"Z2A#K:FV@R!!1(8Y&EZIH:8'Y;<Z9X.\1LFV4=>P@8] 5#EY:*8^P*&A
MGMKJ3/UM<CT9+7](U,C-A/S.0YT80 $4"UP!E94'--"B9%.(?5X@P5,.*='C
MQP@X F91:PJ]/#C"5,(J'N8@RI-7,9&+(=*\@X ,RY]-EE/U8+0+41(9&-'3
M4Z[^P>2F6L$ASAA8S<\R8"&"$$J,6E.BQDQRATD*O2D*P.-OQ+>P5^!'&,N!
MU0'>!0M<=3=PK8#:SD<4*%8$$A(O*_W%[(+-EA(H2:2W0$#WE$>09I ,+Y/L
MW$.+$:+H-;N60*8(0EG2,"NA?8(3DB6@;3)4:+A$#&!-5QJ5 <!Z?)8;QPY#
M4,5G"59L];V1S1FL/D F/]IW=CH/QIR$K%UW3DN%>:Q? G?#9CR2,VVLH"B[
MI.L@2=JR.&F;$]_9-GK[)Q*DKD.+(63,2&-LYHC5!CF?2+5[ !<P'#&.@R;X
M.9XM4K3FFNJ@:NG9CGJS/HJR?BE--+GE;>K3.7;4WM09/H% FB% DK2MZ_*H
ME7TN?4_]<>=\S$36'<7@L@R,8=^)!"<\BO_>1[]_2CFR!%RVM13JH>1.< 9-
M/I ?([L[$>.Q98IB* NB''>$-?JL3*4"FT:L)W8@!PH+E!*U!-RO23.8Q+=L
M\5C-S8J\B:W*MQBQHOJMI?%@ ""LL.TX]D:$$94H,(&M;C&91:/+0C%5P;%1
M,!5.W]6J@'A1/2FC@2+,J1Z'B35*4B^;7Y8"8O"HW<C/@#O8*"+6Z".D#VX\
M[!ZKHZ%H23&!<.,N'[3;1*SD7,(3"EWIF[#CZ5"2RW?K-58(F<!W9;]I3<[&
M&;R1) E]OK[TUXX'1T$)PF%*\+((10D4Y9S'Z5W(3;1]\(W'-VL/3&.4YK!I
MD;]);@PN#!*F[1GVNC)Q)V7CB$P))\ <*6@A8>LLUY%47HVMB"R:JO>V%&?5
MXV('G(6P$$1;$V88+(=9>$R@H#*HA6VZAL$[3YV),#%BJ0[&.,J' L-$G#N6
M('@+F)!*BF%=+0!UQ'!8<VW7B'G?NB9#9DUCP'Y(UM*^*9+@^)3(HAF"D+!B
ML8MH0#O1Q6_(8/&$HJ!%XM^Q^D?@>XI-!Q#S%7[8Q^>35[V6" 1Q_XX*L,FX
M4"+C/H1D?Z[!"YQW=L$(Y>)),#NB>'7CC 3 %$.F0WHD*W4#G+A:8:GWMO&Y
MI=T!7OA4YY-#!"3.IE@8[G[2H^8Q&EJ<9^>+;\+'3Q6)P3Q&C(A[C>3_5MSR
MVXO<IYCE\O6K2&AH2SR_8;*#=:0N/9XF]A::*,LAR1QHLCPUX3<V63*2C,Q!
MU..D+P$TT%3<+:6]6*\)+X02^C$ .M)RCXXI[?39M*XIIJSB.@D<J[;PRS&-
M N#45):2%>69,6)//#43C^"NBCXX&A7+=UQ\[ZX/I5VCN)::)?2"I3S2^3@T
M4A0US?J I&.%]3U@P*)JU3F?0$-S;_*.W490WC[ ^9J7K$Q.N6PXCQ@),%_$
MJ#,4<;%H6P(R2\TF*:.OQ\9UVVPI==N!M>\LQ>(X3=EU@C[Z;71D690:8!T1
MF?55E*RW@]#<ON",/_AD,B/#_!5?N'RWE6T#_ GPE;=]S\4S#CH]IWL18-T0
MQN0R4)&%."M=5=A&RQQ1<C-5'8X.1-FAW;AOG&-YB/7G+5T'2,AXA=-?-J"3
MV%8[(!V[H6#UC'(7A3G.\02M;CRGOY-0\;(KA$,I639DV+&^A[2:+K17L3@3
M^J2[X//Q&G<Y_4X"+DID.NA*\ &WL7U7A:J614!@I#94WN<"V8*O.$IL0^3&
M% )F!P_G/OD.K#A4BZ_)5 O!,%!3K,,?[7#!?R>Q2YFJ:9SC83U]7A\:4&=G
MCR37OMLDA)'/J>4,[7!*/PK+L<Z/7LKVY"&-$>0A_TY[-4ECYB]47G%C)F0D
MF9U2E+.NC41\C3A%3?:<M&CNR#]*W9%K;1'3.BWRA%!".;<7D\/$B@)A*ZFG
M)Z6IK*$XZ+N<#[AN(^KWU%G$&F%CHDPLQ*IK*<5+$PEY/F0YR6Y#>VG$ X$)
M;A.6>Q5K*##V6L[/;S3O3OUW-9Z?T\\Z<'@: WZ[N[U[61'6?':^>#V;9M,I
MUFZH2IC1=R7-'="FI>GT0\+5?<!9?"RA]_FG)G]+M5P\ZNWY' (&H..M.1FZ
MUX]U=*7-G7; -*NU)J2FT\)CO$?6C,X/;81S8*"FJ(UOGH]22;3WNN1.PS5=
M$/&2-M=C$22[^_ZT/@2BPQ'SD%+DZ%3[$/J]>L$\-9W':O[E]^KOY+5\(V3<
M/OVYUT6XA3!:Z1=!';2">G$>W.&E.LNFBRF0S.+L@M[-U'DV.U^J>7:Y6-"#
M.1Z<+:<\[A5G>CQ8GBWI :"/'##.Y]GT<JJ.%4QCL;C ^MY_3_DN.="72PU2
ML,RR\_GR)6*,6/B.C;Z8S5X&$QP<Z1AK9XOE A4+95JNG9+N1AI1-]J/HZJ5
M*5SN<X*.?A].7\C;8@CA':7C&P1WQ,(<Z"OD&XZXX4>,]E\, CB0:/-@0E[W
M)B4?CS,8W,H!/:>>BIO5G!Q3%SZ<GA,)'N0X'AOM^; _'.=&=E*;[M?1S@8@
MV/7%C'54W;:=)R?VQMW&2DT7MVS@,B;"]:&]N-/=D</0H%UV2$A*694X5RO7
M= AUZ:ES:(RGC:EQQARE"VFL/;IY\6H,HJ:30QU*+E:JD-%<NL/".F-A0P,K
MO7H027G![9+=J28LQU0UI35;4;8@]PX2BE"5OI<@UK34_!DU T.0&,X5DO51
M?):%!(L EV+P[H.&?U(/EN(E@UU3O%:;Y@XXT8US@V#[:-&I02<^ADWJ'&__
M%A$O?Q ;8L*>G03V(->YN.*I:</'HH!QBJ649'0*W[A[*2J(Z))P5F@-#?;$
M"^URP?3TS4[_?V5*:^)6AB-^PPU1-UPA>H[J.'#K$KSP22L,B4K<L?(*1A0[
M&8,3=BA(QVY_(*JSRN3FT,_LW>F5LD^2=&JZ?40=?:H"B4*\2'"@*^0EM-W"
MNY$9U-HBB<-UD'#YWLI >^L@G;/E@]Q&$.NBR,P'J-S430\NJ$ID$9\!.$0O
M]4F2CP^RP-VC>*1-"CM>)'=)L(; PN-ITG*T?H2M=)X[N@,7PW2R%UGOP+$%
MN=_VAAWQ7:%DC_A<:.C0C]B8_08V) 8,Y9HERPYW<W=BW!_\L]3VE%B'+&P7
M)X3<3*\XLW,VYPR./PMIB$F@^QR73U/J"V3A8Z3YR^5E\LD5S?SUL[]]^-9]
M>3%_"3@R?04,<K%4ETMU,:5_KZ9J 5PB,AVK938]6^!SD<T7](EQQS0L_'E%
M?VC\_^[\QU+UXJ8,<0'I.0I]JTU/F.D_QD9."'0I\=VD1N7@B=]H3EO)E<L$
M)@ZV\F-0TE52,@&U_-+D&VIHQVI]+9DJ63:CG@O#"D@CMTO3VR)\" TSI=PV
M.70M]S2Y!PU =,.WO4E36%"N1/=/^POE5W*/>A@NM]%_TNX&@1U0;XVIT\FK
MY9'40?%'VVSY5O6J:5']\=>-T5 &#<#[=8.L&G[0 OTU^W?_#U!+ P04
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M!DS&.:*-]3NJ/G JY+,O]#=H%L#6<?10*."S$9M2F!Q5D@ T!(-(V3!!."L
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MI\VA8)@3%=H]&/9&V&T]*S=V>(?E3,TDUD8AN59*J7$,G1X0P49;YQ>K<I3
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MB@O[#0:,07/,DK<4ZPK4NB2 #'\%4:_(N?"2\>P,5FRMQ3JN*D9PZ>(/E6?
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M2R=D9]"5H$B6U";'*Q2(A +^U-YM_N:#@%CL,L2G9E/FK/FGRGK(!/#K>EQ
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M%U'$\"A=B&.""@$I:K8KDK9QBBL.+7N*TX\<H6V89LL13W"!7C ?)GS4_%:
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M:&5E=#$U+GAM;+5::7/;1A+]*U-<>=>J@BD O'U5R8F=*+5>:R4G^;"U'X;
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M1HD,Q01'<SSD'@9(F/>1H@>.?$; DH;QZM)8-3!J1SKT"-X#]P7=:]NP-UA
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M% 9OP'KEX6)[PPKZ;S)7?P)02P,$%     @ ^(,&417AL%<J"P  "A\  !D
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ME:(6,Q9KQ\*V"(T2U*N\V\,%B6!;-1AR,Y=S(-W1Z_X6*Y0[U) E8Q'HD]S
M':M:HJ/_%0?>P$V89?DX)BE\0&JD5HD:N.RU>D!G92 )T^MD^FX'7;5D51,_
MV0^68AG5V /32!;93>J^<0E)$MZ4A1O*,B%@8^;4ZM4@!\%<3C62"A5GXQU
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M9#PO,G1^=H'.$.7H>REJ17BA$JR-&$N)\_;BN^;B\,#%7VM^C2+_$H5^Z/?
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MYEU%6*BLKZ&ZHT5I3_*YT'@OV&:&-S=($X#O%T+H;<=<#LU_@=$?4$L#!!0
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MOP?.+[1(LM=W*Z&UB+*O6T9A*AD#N+\60N\OS!O!\FW\Y7]02P,$%     @
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MN:$:9C+_RE*SFG@CCZ20T3(W5W+] 6J'^I8OD;EV3[*NY@YBCR2E-I+78+2
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MS$"3ULG3YO1GJA2U"2''5V HX_J$'!$FR)>U+#0:ZY%OD*YUZL<UM<N*6G2
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MU55UC5<=(_/R)EQ*@_=JV5SCTP>478#S*RG-MF,=N,?4Y!=02P,$%     @
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M.J'R>I-[A7N\NN"%I&R>@;MT@B<&_3N[OE>G_V#7[];I/]7$#RT&.GP*-O,
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M(_,/>7E'B\Q^/%L(K45BFVM&(<+-"_!\*> X5'3,][CR<^KT/U!+ P04
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M;RX@#$#OK[A^NMW$.*C>A69_ 5!+ P04    " #X@P91=7A;BI %  !0&0
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M'K>_+>^;+X_*#6<'/WX6OU!+ P04    " #X@P91J,J'V:L!  !!&@  $P
M %M#;VYT96YT7U1Y<&5S72YX;6S-F<UNPC 0A%\%Y8J(L9W2'P&7MM>60U_
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #X@P915[T\RNX    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #X
M@P91F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( /B#!E% 9@:2AP4  +<6   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #X
M@P9197C#Q-0%  #,&   &               @('*#0  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ ^(,&41+87C%. P  ) T  !@
M         ("!U!,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( /B#!E'?? _65 4  )06   8              " @5@7  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #X@P91\OE#=*P&  !V&@
M&               @('B'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ ^(,&4<F&W 2R!0  UQL  !@              ("!Q",  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( /B#!E&T68]=]0<
M ! 2   8              " @:PI  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " #X@P91VY;/BC$+  !W'@  &               @('7
M,0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ^(,&4;OM
MU../!0  4 T  !@              ("!/CT  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( /B#!E%\;U["8 ,  !T(   9
M  " @0-#  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M^(,&42HD\S#L P  N0D  !D              ("!FD8  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " #X@P91W0'2<.4/  !R+P  &0
M            @(&]2@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( /B#!E'E;"#)QB0  (.&   9              " @=E:  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ^(,&46K09DT5 P
M-0<  !D              ("!UG\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " #X@P91;*X$C0D,  ">(P  &0              @($B
M@P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( /B#!E$<
M1&SU\ 8  )\1   9              " @6*/  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ ^(,&417AL%<J"P  "A\  !D
M     ("!B98  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M" #X@P91Q>6'<CT#  "+!P  &0              @('JH0  >&PO=V]R:W-H
M965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( /B#!E$+-C /5P,   8(   9
M              " @5ZE  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!
M A0#%     @ ^(,&48[X(82-!   90H  !D              ("![*@  'AL
M+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #X@P91-Y:'R]T$
M  !Z"P  &0              @(&PK0  >&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;%!+ 0(4 Q0    ( /B#!E'HPY@-<0(  .T%   9              "
M@<2R  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ ^(,&
M4=3#!&2) @  :0<  !D              ("!;+4  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " #X@P91-!@I-U,"   7!0  &0
M        @($LN   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( /B#!E$U*<OXY0(  !<(   9              " @;:Z  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ^(,&44NV^Z=P @  S 8
M !D              ("!TKT  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " #X@P91FBQ83HX"  "8!@  &0              @(%YP
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( /B#!E%A36XF
M8@,  " *   9              " @3[#  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ ^(,&4>.<7KS3 @  Q@<  !D
M ("!U\8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #X
M@P91-[S(?Z0%  "9%P  &0              @('AR0  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( /B#!E%_!OW%* ,  *4)   9
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M970S-2YX;6Q02P$"% ,4    " #X@P91"C9,UE<%  !:'0  &0
M    @($CY@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M /B#!E$2N=A\: ,  !<-   9              " @;'K  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ ^(,&475X6XJ0!0  4!D  !D
M             ("!4.\  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " #X@P91(QZ7B1P#  #*"@  &0              @($7]0  >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( /B#!E%.'.[G2@,
M +D+   9              " @6KX  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ ^(,&4?HO*$1/!0  /!@  !D              ("!
MZ_L  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #X@P91
M<& UN^,#   %#@  &0              @(%Q 0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( /B#!E%1@S1NW@$  ,($   9
M      " @8L% 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ ^(,&48DJRI%: @  6 P   T              ( !H <! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #X@P91EXJ[',     3 @  "P
M@ $E"@$ 7W)E;',O+G)E;'-02P$"% ,4    " #X@P91*,LV.\\#   L'0
M#P              @ $."P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M^(,&4>Y)W?^> 0  "!H  !H              ( !"@\! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ^(,&4:C*A]FK 0  01H  !,
M             ( !X! ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #,
,,P#<#0  O!(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - Composition of Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CompositionofCertainBalanceSheetItems</Role>
      <ShortName>Composition of Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Net Loss Per Ordinary Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/NetLossPerOrdinaryShare</Role>
      <ShortName>Net Loss Per Ordinary Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/SignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.prothena.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Composition of Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsTables</Role>
      <ShortName>Composition of Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.prothena.com/role/CompositionofCertainBalanceSheetItems</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Net Loss Per Ordinary Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/NetLossPerOrdinaryShareTables</Role>
      <ShortName>Net Loss Per Ordinary Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.prothena.com/role/NetLossPerOrdinaryShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2330304 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.prothena.com/role/ShareBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/OrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail</Role>
      <ShortName>Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Composition of Certain Balance Sheet Items - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsAdditionalInformationDetail</Role>
      <ShortName>Composition of Certain Balance Sheet Items - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Composition of Certain Balance Sheet Items - Schedule of Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Net Loss Per Ordinary Share - Calculation of Basic and Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Ordinary Share - Calculation of Basic and Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Net Loss Per Ordinary Share - Ordinary Shares Equivalent Not Included in Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Ordinary Share - Ordinary Shares Equivalent Not Included in Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Commitment and Contingencies - Lease Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Lease Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Commitment and Contingencies - Dublin Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails</Role>
      <ShortName>Commitment and Contingencies - Dublin Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Commitment and Contingencies - Schedule of Lease Liability Maturity Analysis and Future Minimum Rentals to be Received - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails</Role>
      <ShortName>Commitment and Contingencies - Schedule of Lease Liability Maturity Analysis and Future Minimum Rentals to be Received - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Commitment and Contingencies Commitment and Contingencies - Commitment Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies Commitment and Contingencies - Commitment Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Commitment and Contingencies - Contractual Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails</Role>
      <ShortName>Commitment and Contingencies - Contractual Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Significant Agreements - Roche License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails</Role>
      <ShortName>Significant Agreements - Roche License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Significant Agreements - Celgene Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails</Role>
      <ShortName>Significant Agreements - Celgene Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.prothena.com/role/ShareholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Share-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - Share-Based Compensation - Fair Value of Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail</Role>
      <ShortName>Share-Based Compensation - Fair Value of Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Share-based Compensation - Share-based Compensation Plan - Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail</Role>
      <ShortName>Share-based Compensation - Share-based Compensation Plan - Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="prta-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - prta-20200630.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - prta-20200630.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="prta-20200630.htm">prta-20200630.htm</File>
    <File>prta-20200630.xsd</File>
    <File>prta-20200630_cal.xml</File>
    <File>prta-20200630_def.xml</File>
    <File>prta-20200630_lab.xml</File>
    <File>prta-20200630_pre.xml</File>
    <File>prta2020q210-qxex102fi.htm</File>
    <File>prta2020q210-qxex10320.htm</File>
    <File>prta2020q210-qxex311.htm</File>
    <File>prta2020q210-qxex312.htm</File>
    <File>prta2020q210-qxex321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "prta-20200630.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 137,
   "dts": {
    "calculationLink": {
     "local": [
      "prta-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "prta-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "prta-20200630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "prta-20200630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prta-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "prta-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 412,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 3,
    "http://www.prothena.com/20200630": 2,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 10
   },
   "keyCustom": 66,
   "keyStandard": 274,
   "memberCustom": 17,
   "memberStandard": 20,
   "nsprefix": "prta",
   "nsuri": "http://www.prothena.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.prothena.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - Composition of Certain Balance Sheet Items",
     "role": "http://www.prothena.com/role/CompositionofCertainBalanceSheetItems",
     "shortName": "Composition of Certain Balance Sheet Items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Net Loss Per Ordinary Share",
     "role": "http://www.prothena.com/role/NetLossPerOrdinaryShare",
     "shortName": "Net Loss Per Ordinary Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - Commitment and Contingencies",
     "role": "http://www.prothena.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prta:SignificantAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Significant Agreements",
     "role": "http://www.prothena.com/role/SignificantAgreements",
     "shortName": "Significant Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prta:SignificantAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Shareholders' Equity",
     "role": "http://www.prothena.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "if308d0f707774e83b68197d8cba203b0_D20180515-20180515",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - Share-Based Compensation",
     "role": "http://www.prothena.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "if308d0f707774e83b68197d8cba203b0_D20180515-20180515",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - Income Taxes",
     "role": "http://www.prothena.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Composition of Certain Balance Sheet Items (Tables)",
     "role": "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsTables",
     "shortName": "Composition of Certain Balance Sheet Items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Net Loss Per Ordinary Share (Tables)",
     "role": "http://www.prothena.com/role/NetLossPerOrdinaryShareTables",
     "shortName": "Net Loss Per Ordinary Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.prothena.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330304 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.prothena.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization - Additional Information (Detail)",
     "role": "http://www.prothena.com/role/OrganizationAdditionalInformationDetail",
     "shortName": "Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i7b64af079f774a46a8be8b6571368300_I20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "ib2330f117cb341549ed1cb65fe74eff0_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "ib2330f117cb341549ed1cb65fe74eff0_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Detail)",
     "role": "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail",
     "shortName": "Composition of Certain Balance Sheet Items - Schedule of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Composition of Certain Balance Sheet Items - Additional Information (Detail)",
     "role": "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsAdditionalInformationDetail",
     "shortName": "Composition of Certain Balance Sheet Items - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Composition of Certain Balance Sheet Items - Schedule of Other Current Liabilities (Detail)",
     "role": "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail",
     "shortName": "Composition of Certain Balance Sheet Items - Schedule of Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Net Loss Per Ordinary Share - Calculation of Basic and Diluted Net Loss Per Share (Detail)",
     "role": "http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail",
     "shortName": "Net Loss Per Ordinary Share - Calculation of Basic and Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i54b797a322b643859e1d254057908a54_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Net Loss Per Ordinary Share - Ordinary Shares Equivalent Not Included in Diluted Net Loss Per Share (Detail)",
     "role": "http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail",
     "shortName": "Net Loss Per Ordinary Share - Ordinary Shares Equivalent Not Included in Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i54b797a322b643859e1d254057908a54_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "prta:DeferredSharesParValue",
      "reportCount": 1,
      "unitRef": "eurPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Commitment and Contingencies - Lease Narrative (Details)",
     "role": "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails",
     "shortName": "Commitment and Contingencies - Lease Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Commitment and Contingencies - Dublin Lease (Details)",
     "role": "http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails",
     "shortName": "Commitment and Contingencies - Dublin Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i9a5e914e22c04ed09c890f4bac3875ee_D20180901-20180930",
      "decimals": "0",
      "lang": "en-US",
      "name": "prta:LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Commitment and Contingencies - Schedule of Lease Liability Maturity Analysis and Future Minimum Rentals to be Received - (Details)",
     "role": "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails",
     "shortName": "Commitment and Contingencies - Schedule of Lease Liability Maturity Analysis and Future Minimum Rentals to be Received - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Commitment and Contingencies Commitment and Contingencies - Commitment Narrative (Details)",
     "role": "http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails",
     "shortName": "Commitment and Contingencies Commitment and Contingencies - Commitment Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i9ee0a5361cff4ddb8357d8b71f892efb_I20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Commitment and Contingencies - Contractual Obligations (Details)",
     "role": "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails",
     "shortName": "Commitment and Contingencies - Contractual Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "prta:CollaborationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Significant Agreements - Roche License Agreement (Details)",
     "role": "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails",
     "shortName": "Significant Agreements - Roche License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "prta:CollaborationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i2f99a1d0727d46a9adc11dcafd022744_I20180320",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "prta:CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Significant Agreements - Celgene Collaboration Agreement (Details)",
     "role": "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails",
     "shortName": "Significant Agreements - Celgene Collaboration Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i2f99a1d0727d46a9adc11dcafd022744_I20180320",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "prta:CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Shareholders' Equity (Details)",
     "role": "http://www.prothena.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "prta:NumberofVotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Share-Based Compensation - Additional Information (Detail)",
     "role": "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail",
     "shortName": "Share-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)",
     "role": "http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail",
     "shortName": "Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i3afaf46701c249838b3b57dcd7cd2fd1_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - Share-Based Compensation - Fair Value of Options Granted (Detail)",
     "role": "http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail",
     "shortName": "Share-Based Compensation - Fair Value of Options Granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "ie5802a61ace64fa5b6a039e8e96e1697_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Share-based Compensation - Share-based Compensation Plan - Option Activity (Detail)",
     "role": "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail",
     "shortName": "Share-based Compensation - Share-based Compensation Plan - Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i0a5677df40f949d086dd9086c825700e_D20200401-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "prta:SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "ia3b99b92bd8c4e959e5259476524c341_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity",
     "role": "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "ia3b99b92bd8c4e959e5259476524c341_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.prothena.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.prothena.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Fair Value Measurements",
     "role": "http://www.prothena.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "idb76403e4028485ca36aacfa08b19700_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - prta-20200630.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - prta-20200630.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prta-20200630.htm",
      "contextRef": "i5356f2d5a31c4a1a9f8fcda0261ee0c2_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "IRELAND"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region",
        "terseLabel": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Ordinary Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "prta_A2012LongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended and Restated 2012 Long Term Incentive Plan [Member]",
        "label": "2012 Long Term Incentive Plan [Member]",
        "terseLabel": "2012 Long Term Incentive Plan"
       }
      }
     },
     "localname": "A2012LongTermIncentivePlanMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_A2020EmploymentInducementIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2020 Employment Inducement Incentive Plan [Member]",
        "label": "2020 Employment Inducement Incentive Plan [Member]",
        "terseLabel": "2020 Employment Inducement Incentive Plan"
       }
      }
     },
     "localname": "A2020EmploymentInducementIncentivePlanMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_ASC605AllocatedConsiderationtoDeliverables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ASC 605 - Transaction Price Allocation of Consideration to Deliverables",
        "label": "ASC 605 Allocated Consideration to Deliverables",
        "terseLabel": "ASC 605 allocated consideration to deliverables"
       }
      }
     },
     "localname": "ASC605AllocatedConsiderationtoDeliverables",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Research And Development Current",
        "label": "Accrued Research And Development Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_AllocatedConsiderationtoPerformanceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Allocated Consideration ( Amount of Transaction Price Allocated to each Performance Obligation)",
        "label": "Allocated Consideration to Performance Obligations",
        "terseLabel": "Allocated consideration to performance obligations"
       }
      }
     },
     "localname": "AllocatedConsiderationtoPerformanceObligations",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_AmendedAndRestated2018LongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended and Restated 2018 Long Term Incentive Plan [Member]",
        "label": "Amended and Restated 2018 Long Term Incentive Plan [Member]",
        "terseLabel": "2018 Long Term Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestated2018LongTermIncentivePlanMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_Amortizationofrightofuseasset": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization of right-of-use asset from operating lease presented on statement of cash flow as adjustment to net loss",
        "label": "amortizationofrightofuseasset",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "Amortizationofrightofuseasset",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_BuildtosuitLeaseTermofContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Build-to-suit Lease, Term of Contract",
        "label": "Build-to-suit Lease, Term of Contract",
        "verboseLabel": "Operating lease, current SSF facility, term of contract"
       }
      }
     },
     "localname": "BuildtosuitLeaseTermofContract",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prta_CelgeneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Celgene [Member]",
        "label": "Celgene [Member]",
        "terseLabel": "Celgene"
       }
      }
     },
     "localname": "CelgeneMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_ClinicalProductSupplyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical Product Supply [Member]",
        "label": "Clinical Product Supply [Member]",
        "terseLabel": "Clinical Product Supply"
       }
      }
     },
     "localname": "ClinicalProductSupplyMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_CollaborationAgreementExerciseFeeperProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Exercise Fee per Program",
        "label": "Collaboration Agreement, Exercise Fee per Program",
        "terseLabel": "Collaboration agreement, exercise fee per program"
       }
      }
     },
     "localname": "CollaborationAgreementExerciseFeeperProgram",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Expected Allocation of Initial Transaction Price",
        "label": "Collaboration Agreement, Expected Allocation of Initial Transaction Price",
        "terseLabel": "Collaboration agreement, expected allocation of initial transaction price"
       }
      }
     },
     "localname": "CollaborationAgreementExpectedAllocationofInitialTransactionPrice",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_CollaborationAgreementExtensionFeeperExtensionPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Extension Fee per Extension Period (12-Months)",
        "label": "Collaboration Agreement, Extension Fee per Extension Period",
        "terseLabel": "Collaboration agreement, extension fee per extension period"
       }
      }
     },
     "localname": "CollaborationAgreementExtensionFeeperExtensionPeriod",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Number of Additional 12 Month Period Extension Allowed per contract",
        "label": "Collaboration Agreement, Number of Additional 12 Month Period Extension Allowed",
        "terseLabel": "Collaboration agreement, number of additional 12 month period extension allowed"
       }
      }
     },
     "localname": "CollaborationAgreementNumberofAdditional12MonthPeriodExtensionAllowed",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Option Fees and Milestone Payments, Payment Term",
        "label": "Collaboration Agreement, Option Fees and Milestone Payments, Payment Term",
        "terseLabel": "Collaboration agreement, option fees and milestone payments, payment term"
       }
      }
     },
     "localname": "CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Potential Commercial Milestone Payments Per Program",
        "label": "Collaboration Agreement, Potential Commercial Milestone Payments Per Program",
        "terseLabel": "Collaboration agreement, potential commercial milestone payments per program"
       }
      }
     },
     "localname": "CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Potential Regulatory Milestone Payments Per Program",
        "label": "Collaboration Agreement, Potential Regulatory Milestone Payments Per Program",
        "terseLabel": "Collaboration agreement, potential regulatory milestone payments per program"
       }
      }
     },
     "localname": "CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Potential Regulatory and Commercial Milestone Payments Per Program",
        "label": "Collaboration Agreement, Potential Regulatory and Commercial Milestone Payments Per Program",
        "terseLabel": "Collaboration agreement, potential regulatory and commercial milestone payments per program"
       }
      }
     },
     "localname": "CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_CollaborationAgreementTermofAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Term of Agreement",
        "label": "Collaboration Agreement, Term of Agreement",
        "terseLabel": "Collaboration agreement, term of agreement"
       }
      }
     },
     "localname": "CollaborationAgreementTermofAgreement",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prta_CollaborationAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Payment",
        "label": "Collaboration Agreement, Upfront Payment",
        "terseLabel": "Collaboration agreement, upfront payment"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPayment",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_CollaborationAgreementUpfrontPaymentPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Payment, Payment Term",
        "label": "Collaboration Agreement, Upfront Payment, Payment Term",
        "terseLabel": "Collaboration agreement, upfront payment, payment term"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPaymentPaymentTerm",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prta_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration",
        "label": "Collaboration [Member]",
        "terseLabel": "Collaboration"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_CollaborationProgramGlobalRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Program, Global Rights [Member]",
        "label": "Collaboration Program, Global Rights [Member]",
        "terseLabel": "Collaboration Program, Global Rights"
       }
      }
     },
     "localname": "CollaborationProgramGlobalRightsMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_CollaborationProgramUSRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Program, US Rights [Member]",
        "label": "Collaboration Program, US Rights [Member]",
        "terseLabel": "Collaboration Program, US Rights"
       }
      }
     },
     "localname": "CollaborationProgramUSRightsMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_CollaborationRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Revenue",
        "label": "Collaboration Revenue",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationRevenue",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_CollaborationRevenueLicenseUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Revenue, License, Upfront Payment",
        "label": "Collaboration Revenue, License, Upfront Payment",
        "terseLabel": "Collaboration revenue, license, upfront payment"
       }
      }
     },
     "localname": "CollaborationRevenueLicenseUpfrontPayment",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_CollaborativeAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement [Abstract]",
        "label": "Collaborative Agreement [Abstract]",
        "terseLabel": "Collaborative Agreement [Abstract]"
       }
      }
     },
     "localname": "CollaborativeAgreementAbstract",
     "nsuri": "http://www.prothena.com/20200630",
     "xbrltype": "stringItemType"
    },
    "prta_CompositionofCertainBalanceSheetItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Composition of Certain Balance Sheet Items [Abstract]",
        "label": "Composition of Certain Balance Sheet Items [Abstract]",
        "terseLabel": "Composition of Certain Balance Sheet Items [Abstract]"
       }
      }
     },
     "localname": "CompositionofCertainBalanceSheetItemsAbstract",
     "nsuri": "http://www.prothena.com/20200630",
     "xbrltype": "stringItemType"
    },
    "prta_ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual Obligations under License Agreements included in accrued current liabilities",
        "label": "Contractual Obligations under License Agreements included in accrued current liabilities",
        "terseLabel": "Contractual obligations under license agreements included in accrued current liabilities"
       }
      }
     },
     "localname": "ContractualObligationsunderLicenseAgreementsincludedinaccruedcurrentliabilities",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_DeferredSharesParValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Shares Par Value",
        "label": "Deferred Shares Par Value",
        "terseLabel": "Euro deferred shares, nominal value (in euros per share)"
       }
      }
     },
     "localname": "DeferredSharesParValue",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.prothena.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "prta_DeferredSharesShareIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Shares Share Issued",
        "label": "Deferred Shares Share Issued",
        "terseLabel": "Euro deferred shares, number of issued shares (in shares)"
       }
      }
     },
     "localname": "DeferredSharesShareIssued",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "prta_DeferredSharesShareOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Shares Share Outstanding",
        "label": "Deferred Shares Share Outstanding",
        "terseLabel": "Euro deferred shares, number of outstanding shares (in shares)"
       }
      }
     },
     "localname": "DeferredSharesShareOutstanding",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.prothena.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "prta_DeferredSharesSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Shares Shares Authorized",
        "label": "Deferred Shares Shares Authorized",
        "terseLabel": "Euro deferred shares, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "DeferredSharesSharesAuthorized",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.prothena.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "prta_DeferredSharesValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Shares Value",
        "label": "Deferred Shares Value",
        "terseLabel": "Euro deferred shares"
       }
      }
     },
     "localname": "DeferredSharesValue",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_DevelopmentCostsReimbursementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development Costs Reimbursement [Member]",
        "label": "Development Costs Reimbursement [Member]",
        "terseLabel": "Development Costs Reimbursement"
       }
      }
     },
     "localname": "DevelopmentCostsReimbursementMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_DevelopmentServicesAdditional": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development Services, Additional - Recorded as Collaboration Revenue under ASC 606 starting Jan. 1, 2018. Prior to that, it was recorded as an offset to R&amp;D Expense under ASC 605.",
        "label": "Development Services, Additional",
        "terseLabel": "Development reimbursement"
       }
      }
     },
     "localname": "DevelopmentServicesAdditional",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_DublinIrelandMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dublin, Ireland [Member]",
        "label": "Dublin, Ireland [Member]",
        "terseLabel": "Dublin, Ireland"
       }
      }
     },
     "localname": "DublinIrelandMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_INDandDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IND and Development Services [Member]",
        "label": "IND and Development Services [Member]",
        "terseLabel": "IND and Development Services"
       }
      }
     },
     "localname": "INDandDevelopmentServicesMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Income Taxes [Table]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prta_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prta_IncreaseDecreaseinOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease Liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "negatedTerseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseinOperatingLeaseLiability",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_InitialTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from Contract with Customers, Initial Transaction Price",
        "label": "Initial Transaction Price",
        "terseLabel": "License agreement, initial transaction price",
        "verboseLabel": "Collaboration agreement, initial transaction price"
       }
      }
     },
     "localname": "InitialTransactionPrice",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails",
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee Leasing Arrangement, Operating Leases, Area of Office Space",
        "label": "Lessee Leasing Arrangement, Operating Leases, Area of Office Space",
        "terseLabel": "Operating lease, Dublin, area of office space (in sq ft)"
       }
      }
     },
     "localname": "LesseeLeasingArrangementOperatingLeasesAreaofOfficeSpace",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "prta_LesseeOperatingLeaseLiabilityNominalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Nominal Payments",
        "label": "Lessee, Operating Lease, Liability, Nominal Payments",
        "negatedTerseLabel": "Nominal lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityNominalPayments",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_LicenseAgreementDevelopmentServicesPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Development Services, Payment Term",
        "label": "License Agreement, Development Services, Payment Term",
        "terseLabel": "License agreement, development services, payment term"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentServicesPaymentTerm",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prta_LicenseAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for License Agreement [Table]",
        "label": "License Agreement [Line Items]",
        "terseLabel": "License Agreement [Line Items]"
       }
      }
     },
     "localname": "LicenseAgreementLineItems",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prta_LicenseAgreementMilestonePaymentsPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Milestone Payments, Payment Term",
        "label": "License Agreement, Milestone Payments, Payment Term",
        "terseLabel": "License agreement, milestone payments, payment term"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentsPaymentTerm",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prta_LicenseAgreementPotentialAlternativeCommercialSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Potential Alternative Commercial Sales Milestones",
        "label": "License Agreement, Potential Alternative Commercial Sales Milestones",
        "terseLabel": "License agreement, potential alternative commercial sales milestones"
       }
      }
     },
     "localname": "LicenseAgreementPotentialAlternativeCommercialSalesMilestones",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Potential Payment Upon Achievement of Development, Regulatory and Various First Commercial Sales Milestones",
        "label": "License Agreement, Potential Payment Upon Achievement of Development, Regulatory and Various First Commercial Sales Milestones",
        "terseLabel": "License agreement, potential payment upon achievement of development, regulatory and various first commercial sales milestones"
       }
      }
     },
     "localname": "LicenseAgreementPotentialPaymentUponAchievementofDevelopmentRegulatoryandVariousFirstCommercialSalesMilestones",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement, Potential Payment for Achievement of non U.S. Commercial Sales Milestones",
        "label": "License Agreement, Potential Payment for Achievement of non U.S. Commercial Sales Milestones",
        "terseLabel": "License agreement, potential payment for achievement of non U.S. commercial sales milestones"
       }
      }
     },
     "localname": "LicenseAgreementPotentialPaymentforAchievementofnonU.S.CommercialSalesMilestones",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_LicenseAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement [Table]",
        "label": "License Agreement [Table]",
        "terseLabel": "License Agreement [Table]"
       }
      }
     },
     "localname": "LicenseAgreementTable",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prta_LicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreements [Member]",
        "label": "License Agreements [Member]",
        "terseLabel": "License Agreements [Member]"
       }
      }
     },
     "localname": "LicenseAgreementsMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_LicensingAgreementCostAllocationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing Agreement, Cost Allocation, Percentage",
        "label": "Licensing Agreement, Cost Allocation, Percentage",
        "terseLabel": "License agreement, cost allocation, percentage"
       }
      }
     },
     "localname": "LicensingAgreementCostAllocationPercentage",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prta_LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing Agreement, Portion of Revenue and Expenses Attributable to Company, Percentage",
        "label": "Licensing Agreement, Portion of Revenue and Expenses Attributable to Company, Percentage",
        "terseLabel": "License agreement, portion of revenue and expenses attributable to company, percentage"
       }
      }
     },
     "localname": "LicensingAgreementPortionofRevenueandExpensesAttributabletoCompanyPercentage",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prta_LineofCreditFacilityFaceAmountReductiononFifthAnniversary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line of Credit Facility, Face Amount Reduction on Fifth Anniversary",
        "label": "Line of Credit Facility, Face Amount Reduction on Fifth Anniversary",
        "terseLabel": "Face amount reduction on fifth anniversary"
       }
      }
     },
     "localname": "LineofCreditFacilityFaceAmountReductiononFifthAnniversary",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_LineofCreditFacilityFaceAmountReductiononThirdAnniversary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line of Credit Facility, Face Amount Reduction on Third Anniversary",
        "label": "Line of Credit Facility, Face Amount Reduction on Third Anniversary",
        "terseLabel": "Face amount reduction on third anniversary"
       }
      }
     },
     "localname": "LineofCreditFacilityFaceAmountReductiononThirdAnniversary",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_MaximumNumberofSharestobeIssuedISOExercise": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum Number of Shares that may be Issued pursuant to the exercise of Incentive Stock Options under the 2018 LTIP.",
        "label": "Maximum Number of Shares to be Issued - ISO Exercise",
        "terseLabel": "Maximum number of shares to be issued - ISO exercise (in shares)"
       }
      }
     },
     "localname": "MaximumNumberofSharestobeIssuedISOExercise",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "prta_MilestoneAchievementClinicalMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Achievement, Clinical Milestone -recognized where milestone was achieved at the end of the period presented.",
        "label": "Milestone Achievement, Clinical Milestone",
        "terseLabel": "Milestone achievement, clinical milestone"
       }
      }
     },
     "localname": "MilestoneAchievementClinicalMilestone",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_MilestonePaymentReceivedClinicalMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payment Received, Clinical Milestone",
        "label": "Milestone Payment Received, Clinical Milestone",
        "terseLabel": "Milestone payment received, clinical milestone"
       }
      }
     },
     "localname": "MilestonePaymentReceivedClinicalMilestone",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New Accounting Pronouncement, Cumulative Effect of Change on Deferred Tax Assets",
        "label": "New Accounting Pronouncement, Cumulative Effect of Change on Deferred Tax Assets",
        "negatedTerseLabel": "Cumulative effect of new accounting pronouncement"
       }
      }
     },
     "localname": "NewAccountingPronouncementCumulativeEffectofChangeonDeferredTaxAssets",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_NumberofVotes": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Votes",
        "label": "Number of Votes",
        "verboseLabel": "Votes per share"
       }
      }
     },
     "localname": "NumberofVotes",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "prta_OperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease (Area)",
        "label": "Operating Lease (Area)",
        "terseLabel": "Operating lease (area)"
       }
      }
     },
     "localname": "OperatingLeaseArea",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "prta_OperatingLeasesImprovementAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Improvement Allowance",
        "label": "Operating Leases, Improvement Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "OperatingLeasesImprovementAllowance",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_OperatingLeasesSubleaseRentalsAreaofSubleaseRental": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Sublease Rentals, Area of Sublease Rental",
        "label": "Operating Leases, Sublease Rentals, Area of Sublease Rental",
        "terseLabel": "Area of sub-sublease rental"
       }
      }
     },
     "localname": "OperatingLeasesSubleaseRentalsAreaofSubleaseRental",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "prta_OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Sublease Rentals, Percent Annual Rent Increase",
        "label": "Operating Leases, Sublease Rentals, Percent Annual Rent Increase",
        "terseLabel": "Sub-sublease rentals, percent annual rent increase"
       }
      }
     },
     "localname": "OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prta_OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Sublease Rentals, Percent of Rental Gain Attributable to Sublandlord",
        "label": "Operating Leases, Sublease Rentals, Percent of Rental Gain Attributable to Sublandlord",
        "terseLabel": "Sub-sublease rentals, percent of rental gain attributable to sublandlord"
       }
      }
     },
     "localname": "OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prta_OperatingLeasesSubleaseRentalsTermofContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Sublease Rentals, Term of Contract",
        "label": "Operating Leases, Sublease Rentals, Term of Contract",
        "terseLabel": "Sub-sublease rentals, term of contract"
       }
      }
     },
     "localname": "OperatingLeasesSubleaseRentalsTermofContract",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prta_OrdinaryShareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ordinary Share [Member]",
        "label": "Ordinary Share [Member]",
        "terseLabel": "Ordinary Share"
       }
      }
     },
     "localname": "OrdinaryShareMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_PotentialWithholdingTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Withholding Tax Rate for cumulative unremitted earnings of the Company's subsidiaries if they were distributed as dividends.",
        "label": "Potential Withholding Tax Rate",
        "terseLabel": "Potential withholding tax rate"
       }
      }
     },
     "localname": "PotentialWithholdingTaxRate",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prta_PurchaseandContractualObligationDueAfterFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 6.0,
       "parentTag": "prta_PurchaseandContractualObligationTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase and Contractual Obligation, Due After Fifth Year",
        "label": "Purchase and Contractual Obligation, Due After Fifth Year",
        "totalLabel": "Thereafter"
       }
      }
     },
     "localname": "PurchaseandContractualObligationDueAfterFifthYear",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_PurchaseandContractualObligationDueinFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 5.0,
       "parentTag": "prta_PurchaseandContractualObligationTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase and Contractual Obligation, Due in Fifth Year",
        "label": "Purchase and Contractual Obligation, Due in Fifth Year",
        "totalLabel": "2024"
       }
      }
     },
     "localname": "PurchaseandContractualObligationDueinFifthYear",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_PurchaseandContractualObligationDueinFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 4.0,
       "parentTag": "prta_PurchaseandContractualObligationTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase and Contractual Obligation, Due in Fourth Year",
        "label": "Purchase and Contractual Obligation, Due in Fourth Year",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "PurchaseandContractualObligationDueinFourthYear",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_PurchaseandContractualObligationDueinSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 2.0,
       "parentTag": "prta_PurchaseandContractualObligationTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase and Contractual Obligation, Due in Second Year",
        "label": "Purchase and Contractual Obligation, Due in Second Year",
        "totalLabel": "2021"
       }
      }
     },
     "localname": "PurchaseandContractualObligationDueinSecondYear",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_PurchaseandContractualObligationDueinThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 3.0,
       "parentTag": "prta_PurchaseandContractualObligationTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase and Contractual Obligation, Due in Third Year",
        "label": "Purchase and Contractual Obligation, Due in Third Year",
        "totalLabel": "2022"
       }
      }
     },
     "localname": "PurchaseandContractualObligationDueinThirdYear",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_PurchaseandContractualObligationRemainderofFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 1.0,
       "parentTag": "prta_PurchaseandContractualObligationTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase and Contractual Obligation, Remainder of Fiscal Year",
        "label": "Purchase and Contractual Obligation, Remainder of Fiscal Year",
        "totalLabel": "2020"
       }
      }
     },
     "localname": "PurchaseandContractualObligationRemainderofFiscalYear",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_PurchaseandContractualObligationTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase and Contractual Obligation, Total",
        "label": "Purchase and Contractual Obligation, Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PurchaseandContractualObligationTotal",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_PurchaseandContractualObligationsFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase and Contractual Obligations, Fiscal Year Maturity [Abstract]",
        "label": "Purchase and Contractual Obligations, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "PurchaseandContractualObligationsFiscalYearMaturityAbstract",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prta_ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction of Amounts Capitalized Under Build-to-suit Lease Transaction",
        "label": "Reduction of Amounts Capitalized Under Build-to-suit Lease Transaction",
        "negatedTerseLabel": "Reduction of amounts capitalized under build-to-suit lease upon adoption of ASC 842"
       }
      }
     },
     "localname": "ReductionofAmountsCapitalizedUnderBuildtosuitLeaseTransaction",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_ReductionofBuildtosuitLeaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction of Build-to-suit Lease Obligation",
        "label": "Reduction of Build-to-suit Lease Obligation",
        "negatedTerseLabel": "Reduction of build-to-suit lease obligation upon adoption of ASC 842"
       }
      }
     },
     "localname": "ReductionofBuildtosuitLeaseObligation",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction of Capitalized Interest During Construction Period for Build-to-suit Lease Transaction",
        "label": "Reduction of Capitalized Interest During Construction Period for Build-to-suit Lease Transaction",
        "negatedTerseLabel": "Reduction of capitalized interest under build-to-suit lease upon adoption of ASC 842"
       }
      }
     },
     "localname": "ReductionofCapitalizedInterestDuringConstructionPeriodforBuildtosuitLeaseTransaction",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Payment To Collaboration Partner Recorded As Research And Development Expense",
        "label": "Research And Development Payment To Collaboration Partner Recorded As Research And Development Expense",
        "terseLabel": "Cost sharing payments recognized as research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentPaymentToCollaborationPartnerRecordedAsResearchAndDevelopmentExpense",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_ResearchReimbursementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research Reimbursement [Member]",
        "label": "Research Reimbursement [Member]",
        "terseLabel": "Research Reimbursement"
       }
      }
     },
     "localname": "ResearchReimbursementMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_RoyaltyBearingLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Bearing License [Member]",
        "label": "Royalty Bearing License [Member]",
        "terseLabel": "Royalty Bearing License"
       }
      }
     },
     "localname": "RoyaltyBearingLicenseMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prta_SaleofStockPremiumReceivedonTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of Stock, Premium Received on Transaction",
        "label": "Sale of Stock, Premium Received on Transaction",
        "terseLabel": "Share subscription agreement, premium received on transaction"
       }
      }
     },
     "localname": "SaleofStockPremiumReceivedonTransaction",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options",
        "verboseLabel": "Aggregate intrinsic value, vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation, Net Tax Shortfall (Excess Tax Benefit) Amount Booked to Income Tax Provision",
        "label": "Share-based Compensation, Net Tax Shortfall (Excess Tax Benefit) Amount Booked to Income Tax Provision",
        "terseLabel": "Net tax shortfall (excess tax benefit) booked to income tax provision, amount"
       }
      }
     },
     "localname": "SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_SignificantAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Significant Agreements [Text Block]",
        "label": "Significant Agreements [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "SignificantAgreementsTextBlock",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prta_SubleaserentalsAnnualBaseRentInitialAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Leases, Annual Base Rent from Sub-sublease, Initial Amount",
        "label": "Sublease rentals, Annual Base Rent, Initial Amount",
        "terseLabel": "Sub-sublease rentals, initial annual base rent"
       }
      }
     },
     "localname": "SubleaserentalsAnnualBaseRentInitialAmount",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prta_SupplyServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supply Services [Member]",
        "label": "Supply Services [Member]",
        "terseLabel": "Supply Services"
       }
      }
     },
     "localname": "SupplyServicesMember",
     "nsuri": "http://www.prothena.com/20200630",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Contractual Obligations by Fiscal Year Maturity"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r50",
      "r74",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails",
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r97",
      "r124",
      "r126",
      "r224",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails",
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails",
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails",
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails",
      "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r98",
      "r124",
      "r127",
      "r226",
      "r227",
      "r229",
      "r238",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails",
      "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASC-842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails",
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r28",
      "r99",
      "r100",
      "r125"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r22",
      "r207",
      "r217"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable, current"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Current Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r44"
     ],
     "calculation": {
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r39",
      "r104"
     ],
     "calculation": {
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails",
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options to purchase ordinary shares not included in diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails",
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r206",
      "r216"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r49"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r133",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r180",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Preparation and Presentation of Financial Information"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases.",
        "label": "Capital Leases, Future Minimum Payments Due",
        "terseLabel": "Total lease payments due over lease term"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Capitalized Computer Software, Gross",
        "terseLabel": "Purchased computer software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r37",
      "r67"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.prothena.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r62",
      "r67",
      "r72"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the year",
        "totalLabel": "Total cash, cash equivalents and restricted cash, end of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r62",
      "r187"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails",
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r108",
      "r211",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r107",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitment and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Stock Option"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.prothena.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, number of authorized shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.prothena.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, number of issued shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.prothena.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, number of outstanding shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.prothena.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r84",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Segment and Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Significant accounting policies [line item]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r185",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "totalLabel": "Total",
        "verboseLabel": "Contractual obligations under license agreements"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails",
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueAfterFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due after Fifth Year",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "ContractualObligationDueAfterFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Fifth Year",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "ContractualObligationDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Fourth Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "ContractualObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Second Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "ContractualObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Third Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "ContractualObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Contractual Obligation, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Contractual obligations, Fiscal Year Maturity"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 2.0,
       "parentTag": "prta_PurchaseandContractualObligationRemainderofFiscalYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.",
        "label": "Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Cumulative adjustment to accumulated deficit upon adoption of ASC-842"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r170"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r65",
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r65",
      "r94"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Earnings Per Share, Basic and Diluted [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (Loss) Per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r167",
      "r168",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Effective income tax rate, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Expected recognition period of share-based compensation not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Share-based compensation cost not yet recognized, Stock Options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "verboseLabel": "Tax benefit from compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase ordinary shares"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r182",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r182",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r73",
      "r95",
      "r172"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes, net"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accruals and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRestructuringReserve": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.",
        "label": "Increase (Decrease) in Restructuring Reserve",
        "terseLabel": "Restructuring liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS) [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r6",
      "r103"
     ],
     "calculation": {
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails",
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of lease liability maturity analysis and future minimum rentals to be received"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "terseLabel": "Operating lease, future minimum payments due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails",
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "verboseLabel": "2020 (6 months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, Dublin, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, Dublin, term of contract (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesDublinLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Sub-Sublease Rental"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor in fourth year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessor, Operating Lease, Payments to be Received, Four Years",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor in remainder of fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year",
        "verboseLabel": "2020 (6 months)"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor in third fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessor, Operating Lease, Payments to be Received, Three Years",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor in second fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessor, Operating Lease, Payments to be Received, Two Years",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r210",
      "r220"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r23",
      "r208",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Line of credit has been used"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Line of credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long-term Purchase Commitment [Line Items]",
        "terseLabel": "Long-term Purchase Commitment [Line Items]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails",
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long-term Purchase Commitment [Table]",
        "terseLabel": "Long-term Purchase Commitment [Table]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails",
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r116",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r6",
      "r103"
     ],
     "calculation": {
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds at carrying value"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r63",
      "r66"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r66",
      "r80",
      "r212",
      "r223"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "auth_ref": [
      "r69",
      "r70",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "terseLabel": "Acquisition of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r195",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r192",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Total cash paid against operating lease liability"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r200",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r199",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Lease"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesScheduleofLeaseLiabilityMaturityAnalysisandFutureMinimumRentalstobeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r44"
     ],
     "calculation": {
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail",
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r118"
     ],
     "calculation": {
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for acquisition of machinery and equipment.",
        "label": "Payments to Acquire Machinery and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r133",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from disposal of fixed assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r162"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of ordinary shares upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r38",
      "r103"
     ],
     "calculation": {
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r105",
      "r221"
     ],
     "calculation": {
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsScheduleofPropertyandEquipmentDetail",
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertySubjectToOperatingLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property subject to an operating lease.",
        "label": "Property Subject to Operating Lease [Member]",
        "terseLabel": "Current SSF Facility operating lease under ASC 842"
       }
      }
     },
     "localname": "PropertySubjectToOperatingLeaseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r25",
      "r209",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "verboseLabel": "Commitment to suppliers included in accrued current liabilities"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesCommitmentandContingenciesCommitmentNarrativeDetails",
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueAfterFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing after the fifth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Due after Fifth Year",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "PurchaseObligationDueAfterFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the fifth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Due in Fifth Year",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "PurchaseObligationDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the fourth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Due in Fourth Year",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "PurchaseObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the second fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Due in Second Year",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the third fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Due in Third Year",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "PurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Purchase Obligation, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Purchase Obligations"
       }
      }
     },
     "localname": "PurchaseObligationFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails": {
       "order": 1.0,
       "parentTag": "prta_PurchaseandContractualObligationRemainderofFiscalYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the remainder of the fiscal year following the latest fiscal year ended. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Future Minimum Payments, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesContractualObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r166",
      "r230"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r1",
      "r13",
      "r72"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash, current"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r5",
      "r21",
      "r72",
      "r228"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails",
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Restructuring credits"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r120",
      "r219"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.prothena.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueCommissionersIrelandMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government of Ireland.",
        "label": "Revenue Commissioners, Ireland [Member]",
        "terseLabel": "Revenue Commissioners, Ireland"
       }
      }
     },
     "localname": "RevenueCommissionersIrelandMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r198",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right-of-use assets recorded upon adoption of ASC 842"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Share subscription agreement, consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Share subscription agreement, number of ordinary shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Share subscription agreement, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShareOrdinarySharesEquivalentNotIncludedinDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Ordinary Shares Equivalent Not Included in Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "verboseLabel": "Schedule of Collaborative Arrangements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Calculation of Basic and Diluted Net Income or Loss Per Ordinary Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r132",
      "r158",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r132",
      "r158",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r133",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r138",
      "r146",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Company's Share Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationSummaryofShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized shares for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Options, Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, vested (in dollars per shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Options, expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Number of stock options granted to employees (in shares)",
        "verboseLabel": "Options, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r140",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, outstanding ending balance (in shares)",
        "periodStartLabel": "Options, outstanding beginning balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, outstanding ending balance (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price, outstanding beginning balance (in dollars per share)",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest, ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Options, vested and expected to vest ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, vested and expected to vest, ending balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r131",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price, exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Grant period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r153",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareBasedCompensationFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, vested (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Options, Vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r48",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r119",
      "r120",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options, exercised (in shares)",
        "terseLabel": "Issuance of ordinary shares upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.prothena.com/role/SharebasedCompensationSharebasedCompensationPlanOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r119",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of ordinary shares upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r31",
      "r32",
      "r101"
     ],
     "calculation": {
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r176",
      "r177",
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r196",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Composition of Certain Balance Sheet Items"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CompositionofCertainBalanceSheetItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CommitmentandContingenciesLeaseNarrativeDetails",
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.prothena.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SignificantAgreementsCelgeneCollaborationAgreementDetails",
      "http://www.prothena.com/role/SignificantAgreementsRocheLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r82",
      "r83",
      "r85",
      "r86",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Shares used to compute basic and diluted net loss per share (in shares)",
        "verboseLabel": "Weighted-average ordinary shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.prothena.com/role/NetLossPerOrdinaryShareCalculationofBasicandDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919396-209981"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r231": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r232": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r233": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r234": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r235": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r236": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r237": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r238": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r239": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001559053-20-000026-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001559053-20-000026-xbrl.zip
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M)VY_DW>!B@G+K:3..L,5L9K'$.!GC 41+."Y=H$3M[_)^S]LA50J )-)AIN
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M DVAE %=\4038(S<8T-GUWQ_0W5Y%>1PC@:BDN6*>1ZUM"PRK!B&#_"#)'.
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M5N4U_5+TY!GGX @C=X1SB->T=(;8I//^%&'NA0NRI+^-+ GSH,F$:>\)N$D
M5RH29?"/%-R9[[8,A0_S)4N*AQNTY8MMMB "C,-/$Y7K$\J^;Q[Z"W*5"2=.
M:8HZ!8YEU'EIIZ#4)!.XYW8D5TH%&G\HY/IDN5)$'\-_[A[Z*^7\D1B1;. &
MJT%',8*I-R1('DQT3LPG_YF2.%^%^C";;.)28>(I-YIIQYQ0P0?E \VYZ]E?
MJC,6%0Q_NQFO6N[?W_![O*QJ[=8:Z(WST]=9_S[]%362&'",5@3B%=>8:V<T
M]F",C@0&#G0.5M3,BX"GL_!%*(4%Y98G)[DWN:FK#A!T&@!;D=M@S ^_G74!
M3X?TREQE1B(.@H/?A.A4:C!BZ;T"A^H]G8.53?,BX.DL0++$))X;-A(:N,C3
M5D$K9JUWG'BN%LX'?XBMV+$-D.]::-9;]6YO6$6VP%Z8!$U-WD4Z8G#&5%A)
M95(N4BQ\$$,1+Y(7GJJ(I^.'L5>"*:]SKV3.'77"8AHH981Z"\:\:'YXZE8\
M>4\<K&!>8N=HDIRKJ(.TAD6A6718);5HGGCJ5CQY7\RY3<)9G**T'%OL:%"6
M.)  .&5PT'/DB]?.;"=\O\=MWG&IW1JL+UM$3QMMWJ(U>2$2X4RXW((FQT;,
MA!")GH<.$K,BP.GXT1CRWN V>:,%S[/CT7A* S-)$F#$?([\Z+0%.*7>3QZ,
MC4E/58@\<J]5S/L(:\(-A#<FSI&7G+8 I^,#F:(F:,:B<9);)FQ2 )XJ$*:"
MP)'<$> D.F.\ZKB]U!X8++C(-8Y80#R/=7#6X^B\#2Z8!& V1\@UI(=5>[[6
M[QVU._6;Z["N\S3?8JL?!SLX=O/IL=.=R-[0TX$UI[052CIM4^0X4&MC#/"7
MME(R*T9M8K)T9U6H:^&XWQWNM?F^W:G$LS7O\TJ[>NOP<Z?=@H_#>:SN=QO8
MCHZ"<*$5 !&[>Z<!1A'>5V+ZJG5V=^SX5YI)"L*E#-X2[+CR44?,%$N:!1D"
M\XMFG)MY 67+-D9&.JHBW]S9G7O3K)^O9)#)T6KWJ'Y:LAW?:3=N"R&?LMSN
M'+X%0;*WHR/>)NM[*+7;O58N/R^E3KNY$U,W!_;LRX5;;W_[1'>^';!R/QQO
M?*M],,=;S6VV]6&#U/8KS<KQR67E<AL^;_+R_OM&[<,!K54W+BK[97IP'(X_
ML4KCX/+TI')Y=%39_W)<.SX0Y4N/X7-]:_W]46U_IUEI[IV7C[\<5YJ;[ #B
ME*U=T_3-]ZVMXXWS<O/C<>W#^SI<JWY0W>;EX\91^7B-UZI[HDR_U&OK9;A?
MK?&)[1P=-,\;6\=E5KG<%%O[!V?E]351.=YFM>/W1UOK7XZV\K,U:T>UXY.S
M2O/+R?@<N%>_1O<D/!<K'Y^(VO$:G'M"*^NA6=[?X!7X4SN&,YOOFUO5-0K/
MG,J[^.)3=:,'_YY]%8D1K!U$!9A%E/?]1D99@PP$68''E*3AI7D;SD;\U\Y%
M;3^<.LIE&9[AH%DY.=C_6*_0CT>5]<.+K?V-B_+Z4:-2/;FL[7\\*5_6&C"L
M"8:(5PZ_.H,]9U$AX91$W!N!K)$<68$M<4IQG/3<#<JD=8Q?Z1B+GE$E,/)$
M4AA.%Y%5FB+%')$":Q^I+8;S@>$\+[_#YX,A7?L:@_#:)(64I0%Q)Q/*6[,A
M%<$;&I<DQ-;%@#XPH/A*/W&05C .<4,B,)PQ4N02T8@&4-/ I5.,%L/YP'#2
MJ^$T4D>B4T))88XXQ)?()@TV'W(76)*7[XEB.!\T]_J5N6/'+'CBB"11@)\8
MPEMKO42.")D25N"G93&@#PUHY09^4FQ(8A91SBV"X '\.^/ 7:T@#H((RCA?
M*C7JK9.=GQ/1 0O-QRV5>NWYI)Z_P)7\>?GPJV3*4<PQ,E: M8?D@2M9C82*
MQ(EHF=-NJ=3NA-CYYU*.I-_>X?M% #!Q:ZC?<'XD6:JE!)K+K0,N81G8 E +
M(7D >L&DTZP EP>&\SJ>HHI(&6E$B;J$\LH_I+7QB$41(K98TE0,YT/#><TE
M*)%).DQ0;K.#. D:Y7D'",S YUGM(8((Q7 ^,)PW0P?OA)>&.B2HQ<!U)0PH
M,0P1[(TR7E#O"OU\<$!O< EOB-,!N(01VB"N&4.:8@5P&F.BPJ@D<#&@#VKH
M-=ME @<EM$4:F /B"2=D4@0$U9@[K:,,B10#^L" 7B=?J-%)^F21DF#UG$B7
MF1I%$<.O1<0D85QPW0>Y+CS3]M= I>,0*2"@10)Q&\#6)7AXB,YHY,19'>D#
M7'?XFVZ[W_&Q._SQ*$)DG#/UH?YM]1_PUZ@V+4]/19^D88J+Z#2Q,209"04$
M=\I_'=S@ZIQN[R*+KUEOH:.8V\:L,'G:^_.L'GI'*P3C___/I<&!J__HGMK6
MZC]<YRV</OP\O,IWU\KI>60;]</62EX'%3OY$OF,\0'.^I/#3KO?"LBW&^W.
M2N?0_4&%>#/^4\++^.]_#K_[&Q[\]V=JMX"SVV:]<;'RO]5Z,W9+E7A6VFDW
M;>M_WW1MJXNZL5-/PP.[]<NX0C2\R>#'L^&K*;@.J&(<ORJA@_?;JVQ6-]9+
MN]6UZL;N[9>;Y]?:W7BWM[-9W=S8+:U5UDL;_W[WK[7*AXW2NZUR>7-W=W.K
M,@?O2A_WKOL6[*1UV&NWWI36E]\MER@6W'SW?M-Y"7/G'?C][_ _?R,2_SD'
M,L&/>Y^OC_KOR6_=M)U#0*M>^W2%P8/,N!&^W]HIEW*JHM5N5?I-N(HOC:8P
MP1EFO'9*<LPBQU1S+;QETEIPO%@[8N"B]\U'EUHVSS:'6%]9;_M^GJ'-Q4E+
M(P\P'>]Z_HG6+@[VO:Q4-R\/JN!)UP_/*[1\4?E0%I7U$U%N;ES"'U&Y/('[
M[)S4FN5OX<,7'O[UL5&CC6_NN$W*QY4C\*0G6^L;[.!R$Q]<GN"MZLG%0;4,
M?T[85G63U#[L-.%^%_#\O'+I17G=PW/L\:_>TN M,!6*3:: /H*?30YIAAG&
M(01LS=(JP6A[X$"O);*Z.$8W-*='6=X/7_J&A9DI6MC=-_Z!A?U1MIV3TE8K
M_OVA%W+M7J_=7)'#=^I9UXA7+S5@7_F%&O:T&U?&'_X,]>YIPUZLU%N#6P].
M^O-;[/3R]KDCS8"!&A$F8Y:U8 /.U -JU@OCZX_XU/*03[WMA>^_9'"J_/'7
M/SWWIU\:NDPX?^3);P?//7QV&(0\H/]<8DOC,TYM".!G![I!3\__'/\\&MK\
MJT?JQPW+:L34NV],QQ?/WZ\0D-KX%YVA_+_7S0?LY986KG7JME'::]5].\12
M>?>6&M[6WD>^TM+JBP-]:G>:M@=GPV!UHU]Q[7;#V4:CW7/M\_O\P';?=@"F
M&A<[\;3=Z<VE2WA?=Q_V9(6^/RKO;U^4JV6ZM;]W7OGPY>C@^(17CFN-K?W*
M,82R.0@[J57]Z)PO<"_1JE7;[&!_X[RVOGE>OCP0\ ZXMO^^OE4]I/!\XH"6
M<87F,'FG42'Z[%-U+8>\.8^ M[:_4L^54X0AAC5#/#J#G <GXJ-7&BM!O:89
M9HWB\L\?^I&1G<VU!=U'O1^-X\\TH.V]M9WJQLZG@]+.QN>MG6KI\][.[MY:
MI5JJ;I4@H*E"U%(BK+2U4R+BC_#WTM;[4O5?&Z4;L<Y5G+/VKIJ_)H;Q6W(9
M0-S; 9+/$^%\I#M\W^Z4>D>Q])\Q$)2&!72E0?.OEZ>B-Q!J)1>#-N&*1\%>
M7$3;B:W[(.KSX'DVAF5^<PE0S^:LE^4,8-4RWEH_A//\99Y'8]SKA(2B*N?9
M*#+)&*2-MDE:+GED2ZL?^ZU88OA-*8_[7= I/2]XF@-JM]4I*%U!Z7YW2E?M
MP$O4<RYX[CE=K0K'7/YULE7U!"#PL@*P">>?P7.1\H?MB]J';5JYK,$]M^]P
MNM-&^?*$P3%P_A[?6@<(_; #D/O72>UX[ZRV#CQP_8!5FO!^[V]Q.E+>_BH2
M#8DP@JQ)N? 1 [X&K!$%207A-.=2C3@=+SC=2W.ZZLY:97=SP-Q^3.J&>8N"
MV?W$&UXOL"JE.OBY5C\OU5AYS>SBQF"YQWNX6V5PL[F$GA=B:]63LZ^:8.MT
MU,BXD*N>(K UJP*RC)"$!4XBLS483\2$5')QTXROE-N?\63^JUO:3CP<--=H
M]?)*KM_+VN[D\SW[JGPR(D:+",,"<4X(<E$HE+0D.,'0\@36]GEG"_Q$9:WT
M;FL'O,O:P-%\WOOKT^:[TJ?-\F!J]]U6^?-:Y6 ![/%'2?"-<^M[ WTJM5.I
M<Z5')=LM=4^CSTL-0ZG>*M5[W9(_&N0&?IPPG]WW?TT\FHN8DLMEB<TSXT:\
M3'[\)5T6^B=?__3<!Q^9/#;4G4:T.M+QUXY7)T&V7SU<C>'0=DX[[6^#Q>"=
MB]LYOJ$;RPN3.Z>CG:D&O:7>#0]^!W'Y7'JU\93$MMCZL$G+ZVNX_&$/PM=P
M5#X^I/G8\H<R.SC^<E2FE:.#_;OA:YO5UD_XP7&NX-L^@S 85^C&Q1:$K. !
MSPXN0[VROW%Y0.&9;X>OM+SVE?,@A.8.41,)XD%:9+6GN5;<JFB-D!$OK8Y:
M+LQR^#J\X"\9U5VF]ET.Z!5LZH[;F/! %N#T>/Y<M>>;H\8*PSYV<QRV3AIR
M-J\AY_ K-5Y@;1DB@6O$L>7(:2)1XB$J2V*2A"RM&HW(X#_S4]29'9?^"@ T
M";OY8^!#2^U.J=T[BIW2<;]3[X:ZSQH.=']0E%N_Z7,'AW8.;:M^.?CY[X47
M6$@O,*_ZO+F\L[R[7!INGA$[ P6^#=RE(7+__1'YW<4JZIU8$$JI6%9B=/W[
MH]#AE_?&;,HLXY]]__.S?_ZMY%</]N+75O(ISWVOYS)S:NF+2?G60NC$;G?T
MSR=0?#+'=._@.$]P'AW7/L"S5;>![GVLU_;?'Y<_;//:\>9%#>Y565^[J.WO
MW9T@K<.UX;TJ)P?T@%36R[C<_-@XV"^?U=:/FN7CC\U<"%=>_]BH?;D588K*
M]M>(9?!4,.2-\HA[["'"% (%*1SA27+'S=*J4J7=>J?TL7W4 @4YC)UNN_4_
M?].4J#^[I>V^O7A3^JO1]B>E=\\(0L?@!6?%F];YV$,+4YU#4Z6%J3YDJN=W
M3#4PZM5@ SPB+>+".&2TCBBD$&-TR@EJEU8_=&PKE-[9EFV4UL$D<V:H.RM6
M^<I4>6!?A5$^S2C?P<>M3K5]UBI,\B&3O+ACDE@PJ46>]#<^(JZU1MHPBQRW
MG$L;H_!J:76][X"6E^B;']=OSE),.8HR1C< PRAUVXUZ*&4-+LSH1V;TN=WM
MV4:M?CKG,QV3LZ2-FY:4.[6 ''AN]$ARRT>''/48:>RHC$S#X&NP)$Q+58WY
M=Y8T@UFNPHR>-+LXFE3,UG7?Q.+860V/*NSK$?:U>=.^0"3$<1R0([DO$DY@
M:8%A)"G15@0NDQ&/FTF<G7 K9[1&5I;O]H(F-I74Z$C%<Q7/::?>\O53H/#Q
M//I^WG$)?IWJ'FX*WS3Z^45*X&Q*V=L\)L?_(G1^80MLKZOOKK(:O=B(IT<P
M!*-JVS<W!MYVHBWEE08K5PQN*F]''O=VF!#TBC1HA,EY#-OS&4.\4.7B99E]
M]18+PW!$6"2,N+6 LXX+%'&(03OADF!+JRQO!W ;8U]50MF!@L[.+35]*0%M
M7WSE+ ;.1$ )FX2XT^ 2N6((1Q:LY"0R!P(BDQ1/WGJO\3ECS1P7+;R8B/!7
M & FK E(4$&''<B<)PX)F;?64<3;&)96*9.("OS=HLC%*6U]0D>/'[?T^.%;
MW]?1:X%<^B[PIDZ]5X=+#FNB8R>&TFF_T^WGXNA>NP1'#.:;"?W#_3VSKKQX
M>LWW5F9QSO:7"H?Q,B/L-5:C$KY,Q7.+@W^^@-8L<_;8%;2S4V;TJ\5Y=VL+
M7C_P&+Q2B'Y4/[12@A-B)ZMD7L!7[S4&RPHVK#\JO6O8;G>V4I:+-MX=.P@P
M=B^:KMTHAOH5A[HR6C ST.R-<W]D6X?PBU9I_Z@.O]FY\AF+6]"X&(G$:QX]
M<OD7A+H!<,TECQYF"<O[P(^;V_ L'X_RDO?*A_?-,AQW</PE%^_2\H>/S0/Z
M\>3@\KL62.=P3#/?ZZ"YP3.?/M@_N-RJ?H3S-LE!]>#LH E/W]PYKI [4\QG
M7YD,"3.*D9/"(H[A+\V$R:VJE>7"2)=(;LX!&F8[%Z7=(]N)W3>E4]LI?;.-
M?BS]-TB9Y+XSI6[^;E;2](4)/=*$1@YHZ'\*^WF$_6S<M!\9&.:1,00""(@;
M*I QCB/GD@IYT6I2)*];K:X5EC$7EO'=&C@@"M]/48T=SYA&S.T2[DD;S^9-
MXPE$!*J#0X9+@S@/">F8>Z?'R!(G/&_:"A09@O2*[0;[G]*'1MO9!L3Q#8CD
M2[D9:.P]/'7U\TF,>BL7HZ_042'RC';-^D'":+,5<A%]++F+DC^*_J34S!U2
MSX[B8/%(SF_<6!_^!_G[,,-T9+N#OB*A9!L-."*W&LI9D__TZSEGTFN77!P=
M !<>I4VNVK:T.Z.V+:,,RHW$RQ6M7@/YP->Y;4LIP+<0XN1#3SO1QT' 0VAI
MT#ZN6_H#K@=65^KV@85WC]IYN?JXD5WOR/;NOL69O?VH@P8I@Y-'+_+W-Z5<
M$?<'O?&V#@P8#G+'67'@I,'Q<&9^E-'%!ML@#YYD\*2VVRL97 KVHKL\O,[W
M?[]ZJ<F[?J<#CS5L!C7<C;G7[\XETKQ4:Y9#]E4)*G3>B\KYH!%GPB%-K4*>
M6VMDD$;9N+1Z$+^K@KPENU>9Q_MI6[+G)(1'O4>G..?XI-SU]W]7VO,YZOR5
MGG4?S#@C8/<7'_*!5I"_D5O+^ [0WJSW>N 1!MR@TVYE<MNX*$4@NA>EP=;H
MU@_**M9MSY9RGZN[#N_Z&C<G#7;Z<"0$QMF=[<3#_G"KEM(NJKZV8QL^SY6K
MBMV_3\\1W1C /'XCO_1[.R+^U0AK!0PN<L3%3& ],GFFV4CO*7?@BB(I'%'A
MB%[($?WV2%_OEFRI 2\82]9[0/J.S7"=P;&32?^]ORV!W:%[O^@VP47 73IC
M>@W V83!NGB38QRX',0$>3 /2S!D9[VC\=?+$/+$4HBIWAKT:AU4\.4Z,@KO
M^(.G&WQ-_AP?]N !/WRV\7$YQ!D=^X/''!]9;PV<V"A^HP[1<>1V,UQ;GH%>
M67I9,_R\*6^BEK&FKS$Q+< BU*M,>5.\;*A^E<GT94,>VSAL5GI&OT8*<A+-
M(CYEBQ\:UPVK'OYB8-JSM%1A/AMSW_6#,S"0\ZJMKY\P'\0+ \7/COVP?7_?
MN!R ==Z-#IC+.&+<YOR0'UR^;^;5'%OK![CR8>.B5FTT*G1/E.'?\H>]LX/C
M/5Q>7_NNS?G6^M%Q>?_@#.['*\?;^*#ZL;&UO\=JU9-S^/>L5OVK7JENGY5O
M-6W:/-O:_NII(B'/-GGL)>+1!Z0))<A;Z24QW)*< EN[RS)F91+JERWJ%7K!
MO!AWQ_=%3*,-5!_A<,=[L\)MIC"P/]&$XL'F\,$*=O=K_K)R7_ X2[!9,+K?
M7$-WAYF"8<!QE2X8_CC*!,SM,,^^FY_>GD%#'CV0_E_]+CQ9=SXGAB?*HR\^
M5<MC'GU>WO[J.,<N.8.BS,U/B3691XM<@D)LH$PI(1[> O+1W&ZVZ,EL/<UL
M(M , ?W&_6G>60+W^20CT\;PL6 _#.3Z;BC6 LL?PO++6UA^]M63Z!5F#@F1
M(N*1<^0\5L@F'Z0&C2 ^/F[KMWM1G- 9AZH?30S2Y3F<%TP_F7_+G1GNG3:L
MI_MJ0P85(1"ZM=J#@HY^-PZ.@B$:[I/;N]IT<5R=D:LV\KT:%_GF9W6X-=RV
MU(*7:^<IN6_U[B 4;-F6SW $ 6)NB9 /[O9L*]A.Z);RQAGU\*,EJ.P/^_=[
MI^%>J<'$)&:F7[$;R<LV+OG=ILR[1['1&%M/Z0^PB<'D]7"7J$?,#?^X\.@@
M=N^I1IH'#9ZVT]_-,IEG7_]B=53B*T^:ZB 2\H8+!!&91(;YB$1BWKDDJ$L/
M;]HZRS:[.-5(=V<T%@I:\U*38?.GC(+M\:K'P<K&;JG=[PV\>W;S@V+-$82\
M'Q1&@E/OM^I# !F>L'0;5"A6,LB0X'^&4\>ML0QC$S'G5%(OOVX.L$0QL@3P
M[.M-V^C^<^DVL*S TX5V;_3U/>L%VLUFWH:K[4^&2S6WKI\9O"80RSBXY.\$
M-^=;ZVOXJS?8!FT3TBYOK"4%Q 58"92DUA*[(#WQ2ZO,O#&$O.'DJEO36+BK
M>7=%4(J/_<;%T&89>5/*$OMQX=3C#>*!UBRG[2$_7<G=^G(-[JA@:I"#'$\R
MR>^B@*O3K.NV&_U>_',4H.";Y]],L][W'#?_SA<?ZH[25D2?I&&*B^@TL3$D
M&0D57CKEOZJE\3E'G>NPZ3 BUXGV!&*R7NRLV,:9O>@NO;U=;@;#<_.=GORH
M<]$!Z =-;.[?X?33NSGL<?2#-WP/:%8B&&T/JA<)^;.TO;>V4]W8^70PVC-\
MH=YUP*6W^X--6$L;@WCS8[\U(MP,#R'D@;4</VK*-$L>]0<C4%W[Z]-&WL#]
MW5:ENE&I[LY E>DO-%;29ID2\1H5FW)9Z<=>>*XF&>:J[_\TVL!^!J_XE)8S
M8P,3LUKN,M4GFY5ZE\?/A$QM6[/'3G%_!O=<VEPNO=^LK%7>;:Y]*FU6WF_M
ME ?DY-$9P-D<^7O\[!!;9L6O_JCLP,[FDWW7@6N8FBT==7(,_+>'XP:"![U8
M[3,FUV=;PVZ?H&>(NOU Q39[L3G*"X/M7\UU#/8G'?9*^*/?LOU0[\7P]P(&
M"AAX41A@<P@#@W3%K%>1O&OGA%2>OX1/@]T3!G6M?]D&&'@L[1[%"*8]3G:U
M8NDJ2,TK#M>CCX/\Z##[E7>#GL?JD\+D9]#DY1R:_%.+,1!A@VJ,6Q?A9EG,
M/A_X 7#<X . &%NG<2C_ZTY*/=" . "/;OU\W!LC7F7";N/++4@IN$0!+"\
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M@..-B(K<O\D!PW5!:12P44S0( G/73[4&TUFKSYVT=:N_[8)VM\5+"?6Y*,
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M47*?,5TYDAH_'+*>LZSF1IIW62E76J2SKI)7Y]! R!ER;)XY&*XRB1S \''
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M R8_* )UK$Q5]P** "@";5,$%HD26TI4I*+TO(J<V:B#CYQPJZ1,VDAULR8
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MPB(3)BYQ5M-@XRWG?&NQBJ2BDBO"&B^3R?K)=RB!1S.J@:X$SPEH(*!=PHO
M)O'*H0:;"VR42LF<WC;1%"\_967)_#P_1V,R'Z?(]_ -8'#U')H >"Y!N3DL
M#39OS(W 0E)Y\>(^@+\U.G5=4+9[L-<C5+4'K<&)\[::=N<#6$4^!H/NQ/?5
MW41U/4MG!(C7,_+"RC-#;]_@B_,3UZ_TH,H:]9NRL/GNX,3#8J)PHP1 HU!Y
MM0:,%EA1J>:TN@,,RKIAKP F+L$'"U#GA[=.%7!0$3 B45BF$[M"F6+\H <!
ML"E4\+H>%:BZC9PYZGNK$VTN6(\=XV[@[D(1]!_7M]M3YP WU"%M-0\1\.1'
M(<[HA]Y$+P%3N>;P]]0[.L%X'(_&@#:/8GQ>20_NS.##$8+^*S">>B5"O-$.
MQ^TGO-:A%01<;YBA%G@$!^+PJ+BI!-JE-+197%8W#?.Z4>O5IB56HE<]-ZOH
M#Q .OJ4/"FJ> QPW)XL $!J_';_R4KD&<,)R?R)1.9\T@9]8IT<E.%"$;P*B
M5>E6*#!76R2Z30Z'KG ,%\LUI:O(5<9]7L/Y<*CZAV6D]95QI!DB!"L\'^MC
MM 0 <W5/SA UXLW2;$;2TF/ YV T,81&@]\]JL= K4/4MD;GI:-H@6%=>KXK
M]]WG_U:]DS<[$P>=2X$7C?R-XZXG[*Q?G0A@-TA4Z;B+1["'?;OAB%4G$^PB
MC8O!>TH'W0".L3J!"X#"/8]# B^OK_FRWOC/:TZIZ8O@#$U?!;"^Y F;R/J*
M-SG[ILZS/+-P(\\/"L+OHO,  %USJ\,*P"#-BGF&A<"H>S(FG,B#V=,QW&$=
M\E%7WO/#G2,GS@?]ONN^F:(&CL"HY*?P&'S9_)U+3HOG#I,C-L"WX9H&XY$/
M@U?(+EQ\.9B:6;_@GT-@>C^SX1A8P_;G+^3=X-^$O2D<*(,\SS!E!9.<AIDI
MF2Y*@*RGQ\.\$($>0H?HL^Q[/MR%PPT+S4K6?>14=W1D4*K-P&\3[7:05EW\
M6;*((SSG* G\6FMWPKF&\SL\GSO^O\V%+V[#$*YQP=PP#AQ=%P>^-C!*V1IQ
MHTOL<=9$1I=&1K],F0?8K@")D<\@[*(*EZ]-O/.\R@[\"H;'1S Z/L'_7\&8
M^-S;_;8OO__YO=N^^,0[O0_'WWO_[G;VOI[/&R6=O>YQ^]AV.SOP_]ZVZ/P)
M]X&A\KWW]:*S8]@^K/W[MZ]@Y/PK[1SO!YW3 R5,8C@+20Q6(A'.I23A:4*<
M# 2 G <F9O/Q3C : ?X!!WN6B2"*=)2F(A"2&[!N(\/GXYU?QKT><EU@:#54
MM*:X:%7(N$4T]/K%S"[><J!#9X/ 2B%"%R8)9SIEE =.)J&D#TZ-8,5D^6XZ
M1XGGQ;^OF1IWMP]DZN*(*4-<&DDBTI02375" AO'DL=![)B=1ZC@41!:AG%[
M*P 5B>8N,K%+F+(1QRDDL]1XC>O^N3ME/7GYD-C0@?HQC:G6<T#P^VGVV,=^
MX>CQZ0CWIK_+=8#>M4&/?"ZK]&N5=-;R^>-9;Y7DN]:1^HFFO,/8-D(?K4OO
M[QT,K==%O36%VI.:,C_02N%!8"?GK2(@ASHR?(]Q%UMI6U^WOFQ-5/P_M[?_
MGNCWB-O)8[,^Z&%C,_5!? #,MFA /OGK/D_#[%_(_P.T3%-DM_TB83U=;V""
M\FL'WD:I@GVPK$I-S:8$4T:F,7X]1',3MYR6%GW7@0J<3N!4?UL!^>P6(,Z/
M!N,N!@;A?<H6H=?^<16^G@#B^@?APLLL2]!N7>DZ\)[N"NCSMM=V'T1/%Z (
MZOT(5>T*NO\7MHD9!)/7>W1]<68\+!P(^++W9X4&C8_M9:"\PP-^J656?'G_
M;H)4^*J-5E[I?2J<3S-78W7%]/W5C15D[T;&/F&B8!<%,/QV+-HO0[ ,BK2#
MS .N564.H&O&^T/,O.GJ-U\X0FHO!E,YSVRFP"3+[V?5%:'6CE=^BZ5L YU[
MPJRBDWK21!-S(X; <%1YP*;'W:$EWU<EN$P]_6ZK]:XT'%6O6-.$NF[#6(;.
M=!403YIYOP&^"P]CY2RJ?%+G3@TK'!;+6+3-9A2MJVRU)DO^<AD27IXE_^@)
M[TL5Y&L5WCE]B@FN:4IE3*T36H2*A49H2P,9ABRET<8E[[E6#WOIFM<B][J#
MBG5I'LFZ0>GZM))[U*^*[)(R<CY)62X$UJ1<8'.9&E8Z 7,PQ8"AHXJL"OFE
M"ID^(Q"6Z2R%2[YDW8.3K%^JT=-HTR8L+?6)(*@J*8L8ZQ5A@%)BE@)JT <%
MKX_TT$5V#AS;AQOJ-TR<_6568*JR679>";;"J^OE7!FYJ#0_[_/TD:1\*LR+
ML D*!^*\2[*"_<S^2XD'NA:&MN SY7."+#SM)X('78H5&I?!"C P.,7<P%;E
M,YW7&-/!8(1:XPP6"Y  ;$I >5FZ%!=7:=>H'-<H8+I%C%CTLM$$"I=L_G*(
M>B=_2;4%9#WAH9)<X2OSJR_R-G^Z>22!C-:N#%:5>G*A0@&]>($-'U0O*GRN
MI9^^^G+V[=>Z6Q_6D?$U=[OI>^!*/738OSZ'Q47GTX$ O+/4"8)#:XBP$24Z
M=IP(ET8FX:'@(7ME#@@@"Z3["6&\.GEW4G.\3,R/5<R82J?'V-F4I97F=5[/
M;\#L _7#M8[']K#DO*Z">Y&OG.?C7C&6MXAYJS3U 4K/E=",Q>AZ;V(KP?4.
MG]+-BN"=#\D/@96#>E@\$;D7!OXW+Q/&6ZW6+C)Y$'.' Q_L5#[IM[9L]U-U
MQWZ-:(M-5ER/D!HTG#$YO>XH*;W$/BMALLUJ"0"+<J$H5 >'?6][;!8)HT2K
MO$PXA=6KXIM+0ZG5'OT7W<6\:-S2_.)1PSC"4/[0+]L7#10%$#[(WF_]!.DP
M&%?!M%Z1G)J#*/ )^C-IZ@ ?6,4"[I8FM@Q*5T@.)CA& Z?IKB8;FG$/F_N;
M*K&B)ML*E:0P'8\JG0B%#Q 4 GM"4I@A,BXHQI3I7"W$GZL13 &H*<V4M%8*
M1W34H&!4)RBTJYADL=M\,!X:!.\?SJAQ/A&9TTAXYD..Z*+I^TQ[GR)3HQDP
MQL=>D2JVACDC-@,JQYV@M/0:A7_CR#L9)K=>8Q&_;"Y];2#F=3%MH-13Y\EU
M-M6@#'F7SI5EO,CZ4>B%<9&=E:E=+<P&L/61*Y@Z5A'AS"N6/M/7N.E"OT4?
M98M5Y^+F70\J6V7647CS[/0K(N\/JU?"SM#U4TA03"9_!YI^-L+?7I^2>=X^
M/9"")URD%+1*'A$14TEB$SC"4N.T#70:R565S"<_D2OS*^>ED1<T,P2"!^.^
M*PZ>!\^::"-E#JD_\0/@.'D!JQF599KP>I2YM);EB!G=/A2!BN1P)L3P;G>G
M7046BE3&=_[F]V?.C+U]NXMYL&Y8*7?YTJA)S8I&ZW_>U5#I'2?CX<D@+[6*
M;G=@BO6!7*]4A&]'Z&DO=,>*Y\Z_;.HN@+=ZGP/02IE5"MM!%3%SI[EWT4RO
MK;LG+EGC?:8V/@/Z^E"##884"Y'BU;I)$C#H59.$QQHY%D&)V1-J/ OWB9 >
MMJ H^X\OS[Y&XZ4*XH ^[^ ;4&]GU?"3KC*E'K[P &\X'<&6JG?_ UHB6E3I
MS,ZRT7A28;N)%<!>")]O%JF9I8O0VT>U;8!R[VV=XB5%!9M;_N"MUH[S<9"\
M=>2Z9810J_Z/0E,M4Y!GWP*WCX?>H87ICYDMW)=>[[7EP\#(J@/B2.5>TYY:
M'=8O"TRRO#!-< '5S==#WD.TAK+)AN&LCD_F$I/1VAK:99GY,SI*.8NN]06=
MBJ_L-.UYVZLBXGP*LJM#@3,@FP;B2W/=@J5;N&++='(\E2-$NJD"D5^ W"[<
M$"LSMUJ?:];Q#5Y>TR2!7G:G3+P\OV7M^T*NZ;1>^U+[&L#X,S.+Q<;W0W+7
M0O*5$5^K=7EUXBIU9)$.A4J#*$FC2"@1JEB[6(<RHCR,.:CV=Z\C^WN(RL+H
M_.\NYFKV+1:3>9+IN#4J,GQL*V#G\&QW^\"DD:/4!"1.A20B 0M*IW%"*$U9
MXG1L&,,)VUOL\K+"2TH*3DJH%_Z]"N08A!H55K&77/5$)+QP!<JAU'(621D'
MJ<)0<H*5AW$@G0RM#NS-* ?HWR#UG,+)SUV_(9V;D8YL'QX8%08V#2P1D; X
MGI(1);D@*1.@W+,H"9)HXRT@TRW2CB> K%\5^&]5W*2JER\Y2E$TGZS&46P:
M,TV9-3I00M( 1Z58QB(7I5+HH)R(1AFG#4>Y7[+X@7X%;8SBL>4D3<(4R<(0
M8.L)B:-06R.TL]0A1[F\!'6.H_S/(_ 2+EWH0JF$E;'0+%1AE&@3<*>D-$G!
M2ZZEF8:7W(IH9.?T@ =.I()Q$ME 8+=[2Q*I.=&2B3BQP.*-O#$ON9DB%KT$
M+:QNKMF!*^RUP6G?IR641<"I,E4 I<H-@!>/4PQQ#-UFZP3VI&#/AV">*@P!
MX6\8<E*'Z./ R 86 0\Q'%<TQB[/*&"A:M'ERVVKW_/QR4DW*WTN?9^XZ0W%
MX?BP5HLW:W2C<8N9M[[5MC*5J5U& [/"W!P=94-+L/PM*]S52_;ARET46R@W
M4-@*U?*+K.,3S'DL5UPW([SYNFPKOHO7[!XV2[NVK&N>*Q2V@U8^F.9C#-!R
M<3Z<5B1@S$( .,I@Z5[/O6TT[HY4O\CVP$3-W$>MO(.L=%KE;@X^9:06+_6P
MS'P<JP(8WH4E@2-WN*S"KAZS>EC'/!R%6M7*<- ?8)3.FXA-#8OWUM/VIX,D
M<6%LC214*@4,4@NB:>R(="8(0]!T7+20<ZD#*@*1RD@&$:AD::P"'BB>*)NX
M@+KHIM[]E]!5Z+-#U^%,4'*&U%Z7\;Y;ZTQ%XTK)1B[UH6QN4 /4%V \5H%*
MT_IC #]:OVQ\V/[RQP8V:<R!U)9?^O4$&:1_,*$,[MG^\K7Z:^/7S=;'OAGT
M7&M/G<&V?MD;G !GB43PZ^^M+UD/6&YZ7OGB:X]'5EJ_L4J!S(M;LC)4H&;O
MR(H[1OY5JN@D6*F8N)-I2.&G+Y.!&T!:%JEV/OW#CLN&DUUWAJZP,CVP?$5>
M[1F-&* E.ULW,'0]7]:.WM$R;1'=LU4&1N& *BMTZD4[V('NRSN$R>;<GI&O
M5SLV9:HT4)KOFMB=M$]P*B^<N]@I;18@JI6B(_@(FT\"5%J_P&?PP*RKAOCW
MKX5#/BL@57CD==4DI0 F1DVR;I6'41;H%$DCR@Y\A1&^KXO^(%KD?PQR+,3O
M.H1564=0=):8-%KQCD;$X2^X0[B3^3N+#55? NG O9CV@>_Q>\\Q*%.D8$[R
M'"^M#UK4EHK$R8)PJF=ZX$_H%7?F4S_53(P=4 "2M'*#-X40#\*IHC4JA%@.
MQ^<I 9976]RV2N-:3>/MM9GPLZ?S-.MV9W3I*KFOJ!0L3][L*2T/XO5O6G(:
MEWQRNZ80(KAS4XAUHIY+M"G>](18:LM\4-G0=Z6;=KY?EU8007O2GV[_K,/V
MS]M[;0GO$/O'G\Z^_XG#G; _7?NT<_%#M/?LC\ZW?3YON'P_?L^_'W\\:U_\
MX)V=HZRS\^'']S\_9& $G;8OMOGNWB$\&]9];-/V\<>@O7U@4YHF26*(E6"S
MB#!6!+A"2J0VV@@&UHN0\X9+($R06"H4XTHHI6+.N&5PX+1D<9*H><,%P=[R
M<&^U0>\!J)<Z_<I]'ZY]\\NW#>ILN%= ,Y^HKE-^>DF*+BB.OJK(Y_(662_3
M8J0R9[N6CSV7)K!5^/T_3)^0^3Z_J'>C<HQ)-T-7UAU5!D*9XN"5UM-I&3?&
MQ0NM-/<-A_K%DGTG,Y7Y+WS9+>;TJLD>"NT>_6?6#8O^O%5E+K:-/L7BGS++
MVFO'H*VKHM*]4+<WZ]OW7>R+J\M4\=Z4/(L%3PO/K<,.>;Y0?*)M+TG67GAU
MN>=QU?T^*WK#U[9;VQVL$_N\.4< 6\/Z6H_@;PRK^XYC+L>!7UE^5'9:KB54
M^3@]UFRAZ5/8%],U%D58:'*=C&%EXWR:#U F6&%*F!L=#6S9L<][L3Q0O'4R
M6<_O-YL\(Q+/V&=X?<1>PC'\"UV2Q7&@Q0]OI[(WQ1^[&M,=O#.Q!'9E[/TS
M'HQ\EWS,A6CAO"-? NALT?$\0\ 5-1#%"8;/Z@?8&[?>]BUH[88I:J\#$ZSX
MT9I!Q<>J -,;JB4V)J4*Q5D>GP#ASV(FK5G=]6RX!01L+KEQBL7+GU+>/ELU
M43RZ<"+T!M9U2\8T/9Z^BUWVS]C5IT&@6V3&]BUVZ1N\U2FQC"YX)H7,HICH
M,%/B6;N^O!!+07T>)CQ-H;_=X+>;I5/;K]*' 'U.8+WK9MH=G.:5;]^44F#2
MF+/*:/)M$TN943([=#D<SG+FP<*!FHJIK!SZV?+Q%)!F/]$/@PY]  FZ<XH.
M',-I2*#*.?(II<T1JATAOH29?>TO0G]"M1B"*2K*]#EPJM&HBTT%L::B))]I
M1]7*'UA(Q-(Q-9]%6L9ZBMZZIS,R]I6E<*&FMU0#*$-1964@ZE]%#J"/N)T!
MM[DHH%I65BTBSW.7K+]PY7@)HD\Q_WJ9"E#64U?58;5ZPD5MM,;Z-B>2<+%Q
M[I+<W]J')^K<+ZS,$AZB<WNF9-%W#CWS=5YUP-G"10'[S,IY,,#M,(WY"!OZ
MP-5EOYZ"-0#/JBAWAJ],FI.6_.]>&W$_ VJ<Z<.]C"QGNSA/^M5<D:D-).(Y
M3XLB+8$"F^&(CZ(BL/ZLLO!PZ7,*45%*X$K]'B[DF4Z"".4+P>B8M&DJ4UMQ
M=ZOUV->,\R"E-#*:"RI%XBPU.I2IBX1+T_O(C6P/^NZ\&#'R 4AA7;OK/X'W
MXOW%[J<#ZW08"4%)+,.$" 6&DY8R)"K5)I812UQB-]ZR.-H*KIZ[L%("6^3"
MR)DD98H*:CF\3*J462&,X"85]Y# UJ#]4K0'G<,#IN+$LB F4@82T!Y8$EON
M"&-2"\821BUFQ?+XJKQ85,$1S!772!'0,UU(5A\3 -=>EB()@@0#65[TW*AE
M\@T=VOPU.+1%X]!>WN08\Y^*40O=LMK!%SNLHW][DIC3[>WN?:3?>VTXWM]_
M[.Y\/L(DF_;%AQ[.5VGO?;UH?_OWC^_?WB^P"DS@@6?V]B^V+SJ]3Z(#ZVWO
M',+UW[/=;Y_..GOM,WAW=W\/6,7%1WF0A#;!*!<)E0Z(,!$GL0H9B500QLI%
MVJIDH16:362B8A=:D"RIC1-'(^DBQ[1,$0WSWFW4,,I0+RH05=^_V3*>CR/7
MNXW#^_K%S$VEE90:$1@71(&(F53,AHPGJ6#&2!I%+SN+Z.]Z'O+[F3SDQZQE
MOS23^!6?Q8L#26/N7$0)G,*(",T,:&U. '%(:IAV\,="$_'KK*IU(]BK3:B_
MKTB3GS%"BGS4+IBB:-S\XOUV@S&\V^:_7N-YGTD>F0-/^6>9AE)FK(R\35U!
MS,=5B!]:<9*[WZM?WM@L/^FJ\]^SOM^7O^G-3YR0BP. BY?":\JDC239BHJY
MP_]G-(3_;?7\,J=CJ\AQ^&UD%[^,^%8HD\N_O_+F*[],MN(HO.6]P1:]ZDO)
M^2WOO6;%$6<WO/<W#^D"VH VI)'_;P,.U&IGH49#J,?,H[@@G3E5IZ9>#@MR
M+RBK6O.2U537(V6RD[/)_25IXD>K+[@D^KLLN<X]IN<[6:+^W9A-S'*7&^YJ
MXVW5169RVB\'9H/:YX7:26HO&(<SZ&V.\(O",ZJ'S?%]@6BER2K']C80_0]C
MG$O3ZY".&M==P+=4<7UH^+65.0(=<CBG!L^?E(>'7DE_I<[KYWV=C%H^.;55
M[6H!NNL%R_]\6*AY$KH+V H:++34-0+;P\]1YJLX^ZL#47<5_#D<Y/G$S\^?
MI\/@:+]WUMWM?;W8W_O$OO<^9)V]#T<8'_B^\Z^CW3\_L<[%U_/V!0Y1_E>O
M\VW_M+H'WC7^SKZ&W_<Z1YV=[[W];Q]I&Y[9V3GZT>Z]A_OW>6?OXT4'W]?;
MI]^/_TC;67#VU][[4?M+<'J@6)A:G1H21(DE L=)Z5A;P@Q-:42IC4*S\3;9
MY%PL1 @*S_VS.%GKQY&6 ^\F:L]J7'LU1:<1)HTP60-AXF0<,!5295PH4B5U
MJ *>N-@EH:-A$ET2.6Z$R5,(DXN),#':*L5D2G"V#1'<< (D"<*$Q8%44<2%
M2KTPH8OAYD:8W*\P>0AC*_7_O4ACZR_L8W\TP.X[/3]6>[::?EX\L_L&Y%6D
M>0TPGS.C?P2K88+9CS7$-HQ^949_7K,:) NQBP<C81(+(A(AB%96D#2QRFA*
M X9Y1703T/@(C/YVIVE=.=$=#(.;\>>[>4 ;SO=L5-R&\]T7YYNJN!K[NFH1
MDR@4E @1122.&"=AP+AF:8"-]AK.M]9:[ L.&?P]'IJCR2RG\<B/$$I'IVKH
M'DJ57<W*>L$,_1%4V7?JQ.?X73C[KL3OEQ*]#5M?E:UWWM44VB1PD8R$(CR4
MH- J PJM<Y2DTE"><AL:D,/ UGFR?IZ+=6=*Z^GI;OC?\U-H&_YWO_ROYKD5
M5,E41$0SQ3#_/R0Z593$C*>2I@Z^%Y[_!7'#_QY<K7T%EOUJ\;^7PR4?04N\
MM*JBX9$K\\@O-1U1)U):D0K"BA$C1I$DI0D!_FC#& M=D@1X)-U,XFCM;/^7
M%MYJ&.<K8YR/H%XVC/,^&>=4N016F2@-VB1704@$TXPD7 #C3-,D"F6BI**>
M<<;Q^CE-7QKC;#RJ*^8%Y/GOV$5GW!MW?2M>BWT;35;4'OL6.[T![//"?]!X
M66\#Y%_62X'>GF)[IX9L^+WK\!<0#=LUG%\J-AJ)L8K$F,E*#D$T"*%(:"1(
M#!ZCQ+"<T%3&-J1Q&H=LXVV\&46+[MA?&T]$XXE]W3SR$73EAD<^#8^<:M6A
ME#2Q5A$;84LOP11F(BB2Q)9K$5AJ(XH\,@@6O1$-CWQJE?FVJ;1TB\EGH#9?
MT<'C84VYVY:<E%^6;^/PO1V,L>'':ZQ)N4<+^<9P75.QNUZ6R8U&KS:2] :2
MM)[-;$*7*I.&)*7:$9'R@,2AX234D91!P@(CQ,9;OLFH?%[NJ14/W_IQM?5T
M_#<2JY%8+T)B/65,I9%8*TNL6D0E"F(G+"-4:@FV7V*(YIH2T$ "D%DJD;&7
M6''T&%7[C<2ZWGS\S7<"O&RLYNH]\3<N'_)XZX>M:SO(NH/)CSGMYZYUJO*5
MFI$'2H919%,1I(E(;!"'UB;PKXF9C(+ E>U*Q4R[TEMV):\O>'U:D#]V+],]
M,'FT%#16@A$;<U\1'I.$.TNXX"H*N-#2IAMO@ZU%-G7[KO.WZ4O;(/KVB.X<
M;P>=BS;VI0=)]Y[CL$07!8EFE#BP?8G07 +:(TT,"*9$49ZFBB/:%Y-))VC'
MF4W8WM5/>2MG19]A(_K1$8Y8QL[SRSK+U[O';_HJ&%7.=%Z%AF2@T(5J@B!*
M1!CI)$IB)V7$. ?^$<=(0S0IF07\TM#0/=-0Y].!<EK'00R:311R(A@#UN$H
MD%0:,8LZJF+NGEF'#D'B)/"6)#;"I4HSF4BJ-'*0)#)AB7;:H/V!T+[KT1[!
M49, 84Z)"$)&=(#-L 53J364I4K=/^NXU>")2F=NQIY?JKK%:SSV_$Y*]M(A
M!/<V5("*=6C2ONI4@5T_./+=>#C$"85_32>./>9,@2_FR-EQU^VFV\7HL]HZ
M]M &>[VS!=Z+ QYR2>,T(2),%1%Q9$@LHH"X6 L7)HFVL7S9LP4*(C4ED=8G
MQC[D9(%'&2402W[+40)T*TINVC]_M2^#K8A'#S5+X(HEWWZ6@%_R3><J-)W(
M7U3+ZF:8P(M%;3-,X'7@N1DF\$+1^@C#!%YP?\N_U?D0%$OO#?%^"E!SRU#*
M0I?+]<AO:-(77GD3Z$?(IWO?.^D.SIW[7)R(FJN@]&*\C!2%XVZW<_$CV+_X
M?N13$78^L<[>H>SL=8[WC\WY?N_3:>?B0[=]L7TVGZ*P^^TKW]W[#.MXCZD(
M06=GG^[N_*!MULDZ%__*ON]L\_8W>.?.A]G! H'C++$V)8(E(1%&1R2Q240D
MI6D0"6-"XS!%@<MGEE2W[IR^R9EK9$HC4YXNXZV1*?<L4Z9I;Y$(!95*D,BG
M%:0L)1K$#-&&:N=X:)6(-]Z*S9@^1I>JURU3FCX"J]E?PT'J\APH475;\*2?
MF5DTO)I*V+4Q(1:J73&46$?B!]<P]%LQ]-DY I%,(HU)@0H8NE IB4TH"9="
M!A%E*HFCC;?1H]3=O/@RUJ;4_^4QN-OKLPV#>S@&-]580?28P*6.<$$%$3IV
M)-%2$RJ,Y G7T@]* :)J&-QZJJ0O."3@,V&:"5?/1 7UV/H"2QN>-RZ%.S'H
MF<;_D31<1MR1B$E*A)62Q-A*!3[7.I9"1$9LO TCOG8.A75G+^OIAV[XVYIJ
MH U_NT?^-E5  QUK(;0A5"K@;S*@))%,$["I90CX8)3SC;></<98DQ?/W];)
M)_I,&D5=FH[]L)9/TW1CO08LOZ*F&X^0UN(/52-%[R9%9T8_!*$4,5<DX1S]
MU$Z1F%)&9*Q8&CF7R"#$P&,D'L-.>+ISMWX,;3W]W(VP:H35BQ!6CY OTPBK
M>Q%64Y-/"6LY3078> *'LUM.="H2XIS1BL8V,LILO)6;4JQ?U.'5":L;-(>Z
MLOG I1T!+NL,59RE*%;2F31,>"2DTS%5SJ9PI)DTH8[,@0@WKBF;)TE-"'H!
MLD[%OY=4J,M)7X?U7>6L4-Z2!50?MFC^O1KVX9WYWV[XY4@-UZ9&OI-5O/<C
MQ_O:>Y_..^R]V 4^NH_/86T.3S^'S\_:?[X'7GQT-%\CWSXVN,:SS@X\<^]0
M=':^'\/??/_"7'P__@B?OS^%SR]V__R0[NYMGQT$$?!/F<0D"D1(1!I8DB2A
M)G&0Q(F*F58Z*<0DG$AGMU'(Q<:*0*O0&PII*F-!@T!2(V.I@.VF\S7U'3=J
M_37(\Q9 O+4[!(2KX7G+PW[Q_%_;=^+:M]^F^<7S*NO_0^5P+OH UJQO!CW7
M^J4+X/VU=0+P'53PS1&^K2QO@=PQY3@??=X"V&1XY);<#M]B)X#BW<X2!6)+
M';H6:#182SI(YQZ>MP;C43Y2??\\.Q[B#WP"K",;V*T"Q7EKC#/:LSZ\&CN_
MV/J;EZSX=##NXN6F.[;./\[?E_UT+9"MSHR6+>1D, (,9ZK;/8<MYV/?<V!\
M,NC[![@S-S19[O#.? 0GO34X08*:V<!6ZW\'IPZVO+G\:?.OQ+7V!Z/)[HHA
M]!X2M7TB9)?M4N6XLFQ8[:G8M<8./J.,3'9LQP[;>>$F_).&SJ!>8.O07K%I
M&%Y8] #"WU ?=:"^NN6KGA"1^V>LNK@4/:&]V8NV%H[NH_0]F6?F_FAL]^U.
ML9NU:H+R! S^_("'DJ9&2Q*G44R$C1R)PS0E4NM(.4! & 4ONPE*YXICB(TU
MK0--L@?W63R511^4?+8+RB:P$.- !Y^>"=6#'8ZNZH_R:-U00/YM!65KJ)7;
MH0BV%8A;=SRY\DO0Y^@#M4/A\95?W[H=2K/DF:8S+'RH);.;WOP,.E8DS[2U
M0?P$K0WVO++2+I24]ZBD>--]A5XT%6\$]<)=TVEBA4L;.GI>=/0%5-VGI*)G
MP):>LN/*709WKQVM/467G0<#X-,$8=9I+14FKT5H<VSNMXM1PRI? <Z?):ML
M".)9MS)[HE+ZQX"?]Z"J$5SQ\&D_EQ+>W4_1TQ3>-I!I(/.\(;-.59[Q,S T
M*E__DW5Y?$U9AG<I<5F[/,%?5DD4-(9:@P7N7(D@B>) ASP089(*KA+'KANO
MA@<8( ._K9 Z"*3]T0?-,95B;1(&;QG3+!,&W\O]O4YO]UOGJ+,'SSO^)#L7
M7;CG*^\<?_[Q?>\K:^]LGW=V]N5\PF![KWL$SY7[[#UM']NLL_.#[WY[S[_O
M&=;Y\W.WL[=_VM[Y&'2.N_4N+.?MX[8X8#*) BH4$<I1(E@DL"<+_"-H:J-0
M!UII4%W#318OEHK]NBY':/VXR[U6P=ZAQ'3](+-6:UGN &M$9",B[T]$WG6H
M8",B'UM$7LR(R"1TL8ZD)B G4VQ6)C%MR!(N@T [;A*-'8VIW(SI8F)](R(;
M$=F(R$9$-B+R(6<W-R+RJ:S(TX. .4[!.B1)BKT\96S!>$P9$92R,'*&.24W
MWHID,Y:T$8^->&S$8R,>&_&XDGB\ZWSR1CP^E05Y>L!Y;"33@H3::!"/TA)E
M3$",T<()R6C@PHVW/-P,H\5NUXUX?*YMN)Y!/L6.ZP]Z6?_Q,RINTI'D]4;(
M&^@TT'D:Z#09%JLQT&_SU>%7U(0W_;;OM6-1 > Y-3E0,HPBFXH@341B@SBT
M-H%_3<PD"%1W@UR$&VO'%>ZW"]1W?%^ W=077N].T3Y7@]VHT2NHT;5.?.?M
MXT_T(.6,1H$)B1:@0 NA'%&QP?KM-(BX"0V81Z!*)YL)7?0T-6UM&W?3BW4W
M-=+D_J7)/83M&VFR5M+D8D::2,%XRCD(DC!.B*#.$)4F,4E"*R(;)H%-8B]-
MXJAIDMY(DT::--+D#M+D'B+<C319*VDRC8"G*8^5CACA"?PC++4D3L XX4R8
MA#D32^Y*N^0Q.J\VDJ21)(TD>;&2Y!Z"P8TD62M),@T6:\IYQ&U$ AJ'1#AA
MB$X$)V'(PH 'C >Q+6R2</TFW:\[OVPBQO=54CKM_?BD@>,GC[P]]?L;T#2@
M>2K0/%VP>"D8GT.\N.A5CJVF+V\P_62)I%<.V6C23*^;7'(-W-;4\K@R";7J
M(WZ_4796RT6]>AC%959%T%@5UUL5,W7^7T\/+ M#*R-)9( A#Q%%1"MA"8NY
M5")P+*5FXVVP%8;KE(2ZRN%:/Z[4N*Z>L>NJ$;R-X%TOP7O'A(1&\#Z2X+V8
M$;Q1+ -+%24ZBD#P!A@<BA)-$FT2Z>(T8K% P;MD*%\C>!O!VPC>1O V@O=I
M!>\=<S<:P?O(%N_I09**(.*"$@D((T([1U1D-.':138.TH RNO&6;K&U*KEL
MA&XC=!NAVPC=1NC>/<VE$;J/;.VBBUDQ)6T(IBV8NZ L,9)8%A.:R-@Z:2@'
MZ(*EFZQ5(]D7)W1O,%G^L2;2;O='636_]XLSXV$VRES^_LS/,[8?AH/>.S\I
MV(^T7AQ@^XJ'U08'E(>&)J$D,8XD%PGZC9CC)!!)FB32QHPM3!=_\=.^]W""
M]3_C["=PZ/YHH=X:9U"7T[(7IFS/S7'6SJAQ[FXT>;H84ET<M7(F;O''+UF_
M^&4R'??YS\"56XRQ!YF!&VQ%-'FH@;+B0::S-DNN?RGY;>^]=LF,W\\,W-LH
M# \_9&VYPC _@VH-C/1F[&HSOO<^<A4;.GHQXWL;CGI/;L_'/PEW';NU/F=D
MK69I-@[H5S=S^!D>F&;@\%T0_CQQOD9,\N8 ; CB%0P<?JZAVR^C@?G1&IR@
M@SIOC0:MD_'0'*E\H=?C0U6^+X+W!L&,Y>1[9:3C!O2]=F'%%?MY"1TED>*,
MZ5#P6":.6B9%(*,DB)44]]D=\HZ!C^T>['[T0LKH_]WK['WN[>[]\:.S]_&L
ML_>)?]^S1[M[_S[>_?;Q;']O7W[_]E[N7QSR^4ADY]L^[?P)Z_OS$VT?OZ>=
M'=N%]TK8B]P__G#4.>YV]_>ZQ[L[-FUG]8(7<WX012Z482!)(E-#!""8)*$P
M1 &*39*(2"?!QMMX,WR4[EY/<8S7E:?>(5%H-3 ^.VFS5FMYV(XN]W0@7KM0
M2ZW3PH8R33#(G!@%@BMVG-(T5EQ$_#Z;5#9"[0F$VL6,4 ML(IAEBJ1I&A#!
MN"(QLXJX0*@HE0FE+MEX&VW21VD/\^AG>%WY]KU*M/OWL*P'JVZX=>: 3UJN
MHB",N5 NB*G5%/@W@#=0L=;WV02RX=9/:(*<'H1 MRF+@7X4=P0L#D&4 T.$
M&YND04@E8+\Q/QIFW3#K=676AJ<JYB:(K0H$353,XB1($V,MBV,5\/OLL]@P
MZR=4K4\/M)6 WL"1.(TH$58YHH5(" \5306/4A'&STZM?JG,^@;Y[?@WGN6L
M/_8GQN?A%OMZZ]-K%I-TBP,3Q4HZDX8)CX1T.J;*V31TE$D3ZL@<B&2C=M.:
MY$I'RW.EPZW6 R?Z T_J9:.>ZX_R[;Y]YP%^Z/H&6-=.EION(!^O3Q+_[I>*
M*;T_:_?^=?S]SP\9/"O;W_LDVL?=H_;QMOB^]U6VV;^S[SMM>-_W[D(2/ZQA
MO]?YL?_M7UF'_>NHLW-XOOOM_7E[YZC;V?MQ\?W;OWZT+[YW.[U_IYWC[:!S
MT3YK7_Q@F/S?WCY@0>RTB2)"M02=$*0)B75("7>!U4JE .6@$$) N,YNH^1@
MPFH31R""I!64,Q4R%<@@E3$%&K7Q? E #2>^T]P,5A8/2OT8S!V: EW7OW]V
MO9$6!NC%I#+E(M4B"8T$LF*&,JZLI)<7*6#YP;I5(_@7_YZ-@..:FYRYOQR&
M!FLXN+0:H+YS'BZOS=BXFF4M*_2(KGS2D[.J*\HZ4,%1_?.6LH,3K-G8_O*N
M%0NVV?(PS<L2#2S'^)<""AV>M^AF"Q6OK=;?PVPPQ-J.;&!;RNM">>M(P:58
M$**=Z\-3$13P6#P3$XK%@*YVK:$[&0Q'1<F(,@9DINH;USK-1D=8'U(M[;__
M(V8T>@./SO+18(BBV%\^]B<,M$D0M>6R@ZW6!UA2UY.#&@X5G,#B3/KD WC5
MB5\SO!]?X/>,1VZ03O?M13(9I 3+5%2>NY%??/',;J9TULU&Y[XXQ3IX: _@
M:EL:OK4M>!0^]P2T6JR3^:FZ8X</AVNRWKA7/N1$G1>+&H!JX6\8NI[*4+4L
MK\#'^K<N T/6-T._*X #*!K#P2G>.%0C-UU%UB]T8-R<^JFRKJ]W43DN9@&/
M2 ;+=MW-!U59#S*U\VKY@+=J!SUEG5^H.RNO&X.L JP"&58P@T? M4!!>?DT
MOUR$C]*PZ G/_ T0 R1B7)[[J#\^UE]VA+J5.L]AI:ZOX(.L=S($V-66H,_K
MH,*-*G@[;,-M(G6='F7FJ)6/X9^9>PLDPA\520Y./3*+I^$#!L--?]7/S)TB
M&>=+@##_<E@WWE*OB!HM!?%6<<@ >">NCY#*8<-F<-CWT$/4 ><8*G\?'E_$
M;U8C&[S/C": 1JH!& V0, 9P+-5H2E%FD(]:I[#\_UQA_OE=!SO*%4RQW6K!
M'B3O8+D3NRI\U2K,5][^=) :D=)(&4)!323"R90DJ1,DXD'"7"K ;$JQL<9B
M%TG@/=VN9P- EJL@_ZZ3<QKDWPKY[;UMVCD]<$Q(KL*$2,YPMDVH2:*B@,@T
M#&2J0\45Z'1\:]&+.4%X.BBXQ,@7S"#Z\^RLU2M*'AR6/+2PW*$P]7B TH#!
MOR"[3@J)WSW?7)EJ[CJ]KZ&:>V 9^Z>=3P<B#2C8 1%Q/+1$F" D<<P9B5@:
M<@IVA;/\GEG&74>D-,B_#^2?M0\/J(Q98!))1,0B(ABC@/PD(+&E.E:68S'[
M->QC!;9!DUFV42DA1N5'H.UFH \=@GX+&@CRHWG59*I3/Q_]Y.]2]VMHKJ Y
M"307<*IXE#H2<Y404$DTB15Z<X'M*Q4DTD6^^==B[Z]GJ*.\>@* :^GN]@$
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MK,I=.YKG1PLA#-"T>2C>7*KLN/&\X;B*^%HM<_ JWO!717++>G"\.H7GXJ,
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MD2J@VR*:6A#6M:#S,S94%]9B<,X9$%+W?!YXUD_<FQONX6>BI8,*0;6G7C:
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M##"68_HX[LJFP):X5N?@#V1B])?G^V[*RJII@9W8L^N 7P?N1\>S\',YLHU
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MM82,T<1 2,*1(A_C"8MSD+-B@0EH)W0<U]LXWVCICK;I&%B_C_>7F'[H&R6
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M*DTI38J$@"'.XUB0.,TDYVFB9&K037*7OXWR*/Y<A)U69_T;-?L EEMU4->
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M-M%< X]R[;JBD?HM.FX+N!S4@/&IQLH2NM&Y&Y_::>V#]_'\M62$O3&8QF_
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M9A^]/_BS_&!$+=P"ZV:,HG>I +R+@82LH?/GH.4X!L.7?0''_A[ V%6SV(^
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M:X/?B].0:R(DSX(BB5E ,OBG8#(/8J&HSF*1DB+>>S)7?N[3@*,&QE[%)8_
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MJ7$G.P)&,5>SB?X+5E$]7/IY?PC^B8QDED0T('F:!20D).#@E@0%D1GC!4_
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M&,\.&$_,HQ2 L0> \:,%&/H7W]9-Q?&Q#I 2RH:I>;*K:;X<VI;FJCXQ=14
MPU$7;#\+P!" \<0<-@$8>P 8WYM4;4)]"FOKRB0T5+ N=$-V0XW(#HA+$#HA
MU6R'@<7\X28!%@(LGI@/(\!B#\#B1ZLE <$VM+JL.0 1!@E#V?%U5=:IK2J6
MJ9H>55:R+$0+E[5D\C+*O\DA[EI'B$,T+Z0,.'E;X9AY2FYM1W(/(*[3$1?D
MC(_ &&<57PB 6QO@QC/Q%D/7;$P#D4/-\&0C< )PGVPB@U(+J&L[@>J;1^^5
MOK$A@^@Y*NH+0'@I$14!"!L A.EX"M5M'8!=DSU'#P 0*'A'@::"Q^0 )X26
M0EQS<?J' (07 0B=CI@(0-B@A7#WQ=4-T[=\6$DM<&7#<ZCL63J175U5=-4!
MJ5#]Q1FJ @Q>!!AT.B(BP&"#UL'=%\=23#<@5+8,=!4L+P0;(=!DHJH*L8BM
M.K:].,]O^^&0EW R)8ANHX F@32.:!QTY'3*WI'SN<,A[<3D'S1+ Y(/GB4.
M?%*QBT"]=5'OXL-,D,11==WS30/C(QH>2K%DSS=LV0V<P L\1R6^CR5]'$W5
MWHF=HY<)%4\/E BHV$>HF Z?Z'ZHARIU9<?1P6,"?I ]7?5D4U>(HWC$(+HA
MH.*%0\730R@"*O81*B:!%=.WJ *6I$RH"3!!P)=R5?CD69I) @N00E,$3+QP
MF'AZ<$7 Q#["Q"3DHFA@/BJ^)VNAXH,U8818\,V1J6VHCD,44S')JC A3J$\
M+NP21R&57D6)-*8DRU^+8RA/@KZ%=;D>%65I81O,S'\;E!FNT$)X\QZ&-V\=
M>+NFV5 58/8PF%W-1%)LQR.FHU!9#11--GS?E!V#$-FR?:Q*&E*'V$?OK;Y2
M@UG%+\NK4XCMI+T5^T=%3(38[X783T=%-$H0V@-9 P%'L??!CM$L.0AM13=M
MW7&I)<3^A8C]HZ(?0NSW0NPG$0['=53'-(GLTQ!<%P  V3,\_--6--]6'<-6
MA,B_$)%_5"1#B/Q>B/PD6J$%JLJ.AUF&X\F&2O$8N6L"TUFVKJFF[P?JPR(O
MCH>L)79_5H5TI;J0;JL\[Z2<L#@M\M@F9/=4L?],,X8LFSTSHFTL0%N5(?\5
M&2(_2V"Z41K4_'+,V87]> +,TJ!A$ZY5!/X]C'^S]4MTU;=#)S3D4$4,=(D&
M9H\>RJ'IJ%0)+.[IV'US_OR\V-1Y.1CQQ,,B B/V"R.FHR&V;?LZM8"O?-\
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MUNX.K/P![_K;ET[Q<]5=*TI&99%+093[9<XZ WLP($X@+[VOO.<=Z]%U0Q-
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M=).$MAL$=J#J=F J5)TYH\/Q==N)3P]B;1.P:<5J,$RSW_5;G@UMU<E)/L4
MK"6.;(2N)AMJ2&3'-D,9I"7P;$VW+,O#; #-V$@6I#!7A;EZ8.;J1LQ46=]-
MV*0)=$X?>-0%C*X"HWH#H[KNA [U;5E5?0)8ZF&/5ZK(IJZK6NA3U;?-H_>J
MV@--*JS6+5NM7:HCYNR!><A./M/E]=J?&'*?)]U]S'C84?4G9LP\;WA]^KB\
MB&BLHQS:V3*:Z2D6L3TYT$)+-J@5RJX2V+)N&HH=.&% G "40\]6G9YK*L^@
M'QXGDEW%KR<$+IZC*HN S\T&@I\]ZS!_2EJ1B H_ 4,G46$7&UL0C<@6EIC%
MI9<)H89,%=?W+:I;KHD8JO8=6^#G8>&G>/[S/[]+IYGVP86J47YK3M1Z'OV^
M60&ONNQ%86+.69Z7-#AAV3A<S3.+(&^GA34\(+3\.EJ^W<U3IY;F^+8EJU:@
MR8894MGS3$TVB>H'CJ?A7@5H>:WG+*A.-'<L]_GEK:OPU/&M78&-!^XAU= H
MG*0MP.?$25(5+_!=0F2=.@8O;^E0XLB4^G:HT,#VM9 Y2?9\W85=;T(("-V:
MDR">OYWGBWVF]43H8YJ%-!([38?H)#UQJZEBC3*C8K_I,6; 5.L^S=)\4Z.&
MK+B&*AL![C<Y1)5=U3(-1PT#J@1'[S6EYUKSFTT;]:)$G%3L,W5C[0[!BUH
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M>)"KR"@IVI9=3C&DS2)GS*L[C0G?0,+-<_I/B9<V1PNJXTW,2\A@?#P>R!O
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M@>=D$2TP,#*'(0PUC ??Y/KZLH9VG.$]1#[^][]<PWH'[U!I @^>_/K1I'K
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M)G:K;T";88>C_ S>P!W-JFA6"G?GG.41['%1E+ZJU,N .P22;O?-GZ4Z^-#
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M/VFQ_*,Z^!T$1\[()/(,:+.<"_U/=LLV =APE)][*[=WY?;-]'ANWZK'Z^&
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M$8C0 !@.;F!BQL+6XXI%.14FQ/4Q)\]+*ZCN 7$Q^?LF\N=^@;<"_F1/!)W
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MH#OZ'LRDK9RTN8DV3YY@;&/$HCGL^W145:L )Z?2* 4",== ;,#6*&@NIPG
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ML]W"<[PQUQPIR0)DX0#4A%^D6:U@V0Q1[< 2<3\"IG>39DQ?D#A._=H%0*6
MT<'DAOL(%-0"5T&56F$2B[X&*O/)B_6E:\:E2 28#!,#D"TVR!P)^.0Y/8&Q
M8?%NV;T)$CYF<ZA! +Y.1ZS>&( ',.D8[QE2RA<&?V*3K74C=^BE3XN?&.=I
M106FY3(* TK_E,#!,&Y>P'.!?GECU4Q&X($<AFDYHQ]A;A2^7#5*FT78(J)
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M%;>%1,(UZ8G&J<KP4$C<16@_2:$E\^>89<Q]^)C\IV^MYC"!P,7\XF=IN>N
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M#C)'/_QZR9*[)4)>W(8.B\_/\$)(;EQ*P\$_[*B/U2EII[6@=7B;MM(,S1D
M:DH$@1_$<VQ)8L2/8EY0Z\M! S8M*I2JP$W)F\/\)+!9,@Q!I>QD.WW]Q6(-
MIU9Q:R!GQ.I=;*(6X.%]<T6X^S['8_+\#[._YME-_Q2L%=^KQA\V?GU9)'P%
M,&#@YV&RN3A95[M\/32.%B4UG.NH3227Q_EF73%W:FL]LA#I[$TO(=QK]L/U
MX*BH77:DC'T _$AF[KL7.,PPHL 06T_PAVB'Q:(,.=;9T)^%V2S[HN0Y(5TW
M/S8%$=?-35[9_=/PG<\WOO8<X5[;V) VO>T+UT+J@9:KMY#>H82K=DH:Y5HG
M-Q@MNO'Q[YF8V7JMN?5BV1:H;53-C$ #:3H[/?6>F[!6M*ERA?.18PLRM$.+
MT:C;4W"!,SA]R3M<A(A4)[D4?\=;!7+UB^W;EVQP/>#RSV*'COA=4@F8[2I]
ME[]$30Y\.YDU@R&\&CINO8.I;&8L&3;,]"\X>CWX>J;IY;GRP71 V]6K#[0^
M9DG@[IBK1J:Y6U.&BQ(BDF9G,]#[?XT*:)V<@D3YW*GV4'UQWT2P9@%5)4R:
M3Z%[ZXHLS&1YII2'/[VQ=KFL[T)<'-[&OI4_LR_:CNQX6_KW4>V;CV0FZ]AD
MUBGXW1/B!^S^,-_+J*AN T*N(\<1#!R, ,@9JI/2 E.DI+I()3XWM9#I\6PF
MY[KHVKK4[<G9*:3$<+K7#<W4!#9O1U#77W[QGYP)*1_@5W&E#37<\'NHB*J8
M0H$1WX!T%Q686"9T8*5[6@O>:GR0FF3BPLKDUXLWZFO EWY#V/6D$VNGX1FR
MYI_9]8W\5#E5CB!U2T5F#'KAI;97NC>BHS[#1_PD,ZL"7KH+^=HZJ[#<@PC@
M,:GD[#?U@4G+,U,P<M S 6UF#X@>G9G(8Z"$P@GICD\$]<C>&LM1].PGXC2X
MMM&6Y> ?'0'"V8>&XIEM!W>Z%'[D4\! L;GQ)+1'SH Q\\S(M)0)VSL.^B'7
M@Y7@5DU3X<V9E3C^MKGTQOF2WO?P:]_VW.24XRVO03-SKBR*W7'G-N.&3-BD
MIXJQ*O5XX>J/@38>HFA8)6>)E6#_O<;UBSVHG,[A"S8.=T>%5$3#U(1];DW:
M_];G#<RY9$0<F+\]7.2^Z(:Z:6F B5^+WK:DSK1YV_:[O35B<5:SB8B? ^C^
M9=YRE< MO?N2"(WJ!G0I$J"MNMZU,J> W&V!/XBC$)-EP5%:64(44;SZ7."%
M6\$:HHOL83A/U$\BCK5*O"/M*H2+RF52]D5I3K96NX37!?Z=U"?AI.-2Z6PR
M*9+RNS7U8"QYS.F(6RNG^<>D)M2\\38THL[LH/Z8!AFL'79UF,\O3U[(279B
M(.!B6.LUST%\I#02WW_6H-!"MJ%'4.*5T#)0G<Q[ZDK/*MSW4Y.K0TKE5&.[
M,A TS%7=2&SCRL61T%L"_VA#1@V>MV6)%6U\FIL8"_#!V%AF.K(2<[P/8 2.
M)TL8QM)\5$WJ+/YEH%>38E4Z65A7V9.F</DV+^<EFET41*$0.L55DJQB+ O7
M</W8QG6O0"X7"-PS)(;J=QIMCJ7()=?X::_59EET+O EZD<O65HT3'13L&#F
M E"[X [4FD3-N4[*\^<--X-XKG"BY4%B%!Q*19:1%5\64YFQR=+XA#(XE?6I
M '8U9E ]&L2^X"6.X"5>7/ 2_RJ\Q(^#L(/'1IBO#*(6Z+@,4L]>I7,NR[H8
MBE8*!=G=ZP(-EU*J>QLJ+"> N.9!,\[<-OSM!\5^HVH97S%H+%3#R-94%%T\
M;>OP0B[J^'K3X,P8/F+*("'0/%M8PT],P]LWDSI]*L054U=)_IE]K:B@1\(P
M4LMLF!\)GG2PE*S./PT,Y^Q1G?6FOO[JM]\\^S0F?WRJ[:'J5V4HX/Z_;LEC
M-D))IF^& P=RT;:#;8VQ^;&HI$@M44E'K<RHDEQ+YILFWQW)&(+!E,GI]493
M"K;0A_#=C9F-^@'!7"*3_Z=A# 19$$VD^Y %OQ),<&:*+6$$<3EWJ]]W)OU#
M81%'$_LMN;O;$,-;419G,LD8EP:C=Q6A4PXKR 8W2."JQS0O:E=)UDMR7;+M
M> .'>G.U^!/X6!2U&=R=H6+B##E/ I&:QPB #Y.3T$D1_2[D2%J#Z5CLIHXE
M9319,MX9C,#0%-B_#1Q6RIG!M#GPZ/)=5-"OV"D\@1C[!X.%R]F(X1MKYRTL
MP=VOA]#*C\$2^61F446+P +X*?.^G,6X;WD[@^;>%'1Y29$&F$259/[P';%U
M1)HH%S@H.=W<U9HC8X[=/$9".-1&A[YN+6,TF^(<,-]0 ^RX:"BT1<H8VG\$
M%,@YV.JQ%JV^#L=VQ,-/8&^1\%&(S836"93UU>*=^Z;KS)%>"Y;5%.P!*7E6
MB/Z:T!0QKBQL,A=*-),0RUDGM#<3R*\Q.^;>8^38TZS<)6470SCN0/=,PCWO
MVXG)*ZKW-4(3AK)&@*;NYU]G"G_BM\,C^H"(\Q0;R&#@$@2EW4[FOE?Y/C?H
MY0 XH\JT5;XLYSHQS)PK1ZA:&Y3"B(K/FH(L_81L=V-?/-K>L[O=?R;F/()D
M&LF4!(OI4#UK5WE)P40';M)L+VWFO<83HBCR58 _K")NC*G&#/1DVW@8F'ZR
M<Y/(Z^ZC>URP,&#T/L*YAB^1274WUQE8 JVJ85/#:LO N:'([O(/"59X3ERU
M^PP'_&'3;I$V[!RECH0L@<7/)64-C*MB-VC%,_*%$V*C!+#']ENJ?8H*;"T0
MV9[( X]E4STPYB,!#_>ZZ";@./"#@!,*4/@%K[E6H9<R<SI[>Z.]2;7QKUD;
MCY,^=L<V<WGG^8B4,W;2=,M]^*%FT#;)+Y+H#T9RG78*_=R4Q/>""4K9=B:O
MA<PUD9NR.HS+X_X;RVMVM-2#8C1<E$*Z=@T#N??4JPY,#5-5_'W*=6G_N/+>
MW?[$=_811J/K>LC.R)!%Q4H+H]-W/UU+0[%JA9?-,!@*RRBG?B>I[CQ&-6T?
MQ4E.U_;/,L*J<\[LV(**7<*19?6+:X66D^AB/'5R R0$VFDRHDUH^C _#E(0
M*U2'K#T3_#QCX1&0_(14"7+#RQ^3$VK,M+6N'Z^)D+ ):B(J 1#+(W$8-L4M
M"J&,0"RM]$&\1KPEW1)(MZ% C_?[+>A#/;D3FM*$(M8?@'09N/%F.6!"A.>]
MG/^-5UX62M*C0V?&X&G-H-*C;MJ!.9 4' B^I7$#L_E.0(;Q)OH:!EBHEKD9
MB?]QM'_U!LP#QDR1B.@FQ=4AKE[.5,-OZ %$"1ISYVWH.L'I%VP3I?-1MM_)
M"=!K(6!!*.FI?!&K9@("GSA&3B3,\"!'>\E(VB6:JMBFG;,Z&(<DAH6^4GC3
MDE0431B_0V<KV7@Z$SO^A9;[B!;:YVQV8""-]C_C?<E;BC@RK7)"XTDC,T"?
ME:SI55VZC6S^J(,L&/4[LJ:JH-A%;EM"[;[BE:L RK3H1;GX(J'_LQ%MQY2J
MX)K?K6R&(M!-:@B)04=?'\MS3&-XDC1("RYX39DN!$\[IU.T*":&&>/1MDP#
M5_0.IRJK ZNLU1LE63&8(T+]@?HD>>^KQ;6NOC_V@[-BHR;GEN+5]%]]F]3C
MLY )@LBE22@(J6>7U09\E6]4>(\J(OTUYFY,OM$?(Z_D(?>RU6+:A$G8_5>P
M#4[\M.(XJ7#YRORS664T88@EL<*ALK*X@[<+4-25='S47;AHK9_P!>WR.+3+
MEY\PVN7)V67OMV;;1J@Y&ST3XLVVS$H 8K,F0W*Y+&ZQ9!96'O4:V6'<Y^'
M*I;^$PP0CC.R$F4-68:;HBU=ZYLDC.XZ9=GA2QJ*8S6>%<QSND$[7/B.6=8C
MADN)'$20CG'R]G!G4*I:^U38?3'L#XAFK*A4O*#X5ER&#?;S+3IM7:*83 I
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M'1?P\F/ RU]]PN#EDSY^2<72U>+/#B_' .2(X60T4F%@(W;21Z0#BBP5)+'
M<Z?@C;E!?*44VX".W.7!U#>>O(G",U/H5@!]' \RO"@,AY<\R"XCX>=CE)86
MMB$Z+&TPQDTZJ&$0U7Q(3V-11#:UD;+BZ4AK#JP;H><M X51A^6L1E:?=U)7
MXHL@!\2J<;7/[SIAHXWK_ 0/7M5$C-TPV@W5\H0P9E(Y=QA+)65!/6Z26B,8
M"X:!OK44U548[4A"V9LUQBF&+V-U#"+X&6:-:!'$_3E^^FQ87W:L>(E!D\-J
MN4QQS7*;T144BX1FZ@'U8:YZD"PXFLSP$9IMFR[AB]Q10];:(7B:^&2FE(15
M:1^.[]"9U7"_WVJA0SM7),B<JA&5#]X*T7T8*8+P)H]*^94!T-%/9),/$ .K
M0=PNRF155YYQ :>%1@F,=79ZB N -%3PH!::L;0'_+XM#,:5<[J<5/-)YVF3
MKY)='#4EHNXR@[VZ4^I)H2,97AF)=2QW7QJ6%S0G\?)@1H=GEU=TSNNF7&,Q
M$M^0'P(V'U]1/"XU&QSU&%K#0P8I4SX4]W6Z$!01IA\#5E#F*VQ8FF]"=V#U
M@"I**CG [&/G&8DG0K<%_Q,?M4;@8"MLX1/55MFP8K):1_5H+"_BF=\66BE>
MW(9(><?-NO9<J7&>MV]"($>E5R6RX7Z$)*&;#!?4CJY"#N/Q9J;X>3",5DH9
M+Y0EG%GRR'H]?RDX@Y0=D3BJ3 XHCJH:]UV01'3K$:.OU X127[L(2/*,Y+^
MTEED!@MY.I,(QD<8.^S/@8YR9BSW21481SWH<]7<@R(/KP+ *4;]8>7/3.O6
MV2VAU/&,%;25QS44.A2[[J\6KQU]ASX$CS*&0R[P_]..HJ<5)C?(@Q1<*"I;
M1-XU%)EM#Y/PK+[8^^).&,645&>);EZ'XV N9[^7_IZ8_R5J5VL5YE(W$\21
M@ROKDMX[;4FCD)K@]&XYR@>.$CIA8&N@J6B-<1'9K-SK:;?<S-4+3W %*;FE
M2I6.XEIJ3!,B7F3KM&5KDE0J)I7,K*0V,21PR.L#7A8%=57&W*W\C38]O,C%
M*<N%(["^'7"$"B.U&'/J.Y.YAHV,U*!B?X9CGV+ >4/T[$SZEV,*10VD6A'\
M?::NA0$67)GB@P02'[[C<)UF!0E5QB3<K6LC-=>A8Y(B:=3J?FCGPPI%1E%V
M%JWW*=-SK\&G;K#+%>60I.]4S'V"2'@''JWFVWRU*KC>?_"X ;,B/D,?WD:V
M5::?G/ KM$<=+?H1>KUT>;-DZ?L*BZ;K'2H_#?W,DGH+^< 4'X0]+G9A'<4D
MN+.@I,3$62<_9\@S%:E&8AB ]RLV\2[8HVD.D;Q6W!K*#$C"PD)7 VG%7F9Q
M+[(QKQV+%-, 4$/#PY"UD@GT4KK*F=@!1Q>P27#><2RT+2R?PD(@H9&KQ2LA
M?YC;A^'F,M\&!AN&GPBO=+[:%L$L<R&A4@]PA7VB<VJ.DK;@UB!MTL7^S *J
M/TZ<I4A)=1?8"5]SK#I\B.<"/.\1PID4Y.A(M'5=D6ZC$FSI2GB&I)6XU$*
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M/#+>NX+M9XZ/G.ANA"TD@M-?'I^^8>H+[$<S$'J%?+4]8ALXY#%8#KEWQ8[
M&!O)2Q%:K0B48HA!0=J&<)$82"%+1A\\W@)%%CW@%/%#TVZW-WFS+N5T(L4M
MW;[$D8?6?,UDS]GL<U..OPM&Z+2#"9HIQZKB'1EY@AM.:"LOG"%/9L.Q;*EH
MK&3:.S+1NKYL\FEO,EYZZR:_8^S;X'XR1ZVZL+2<^D93B(,)1CF=@'?^S>4,
M/X&MI98K6G6WD5Z(J+<MJY5W5!9WV>I3WVION2,BD3*5.2*<N6$#-V1Q" 6R
MQ%E_7[KNG/KNEW4K*IP8R&5/.3'D^9N]MYC2^AVSU\\NC/)S4.H+6"<*!<^&
M*PI#*1F!-[D_96G<G&G$Q557XZ<3OT?GV(A>D$JWL&XL@I+02 )N6B1@:A8H
M!I%%F.,+ODAYXF&%4(MRT$-92TL=E]B)J#'*H#''73)/):4V-IN))U%>S3&L
M,Y</A?K<:^8[[D;(368Z#+;W,9 A+RC5Y2[.AP%++"=!ZH.CL2JK:9V,D&4I
M40GU4%S/[1-5DW ?(Q]!2WD.A,APJWL><RN1REMF2W7UXY!)?#+B4VWPE*Z>
M$*Q7BQ_AGE^M\E;8F)'5]Z_]^H;SP8YY#^\%;K8"UP#V.&(; =-!/3)4&+.'
M(]C=YHCD=>7O"RS/EXQ(BVGAHP'C^?#P1!R/8U)8)L!M$J@E#]YH[9:C>=2\
M!:'/>+J"2.C&O2Q&C\/<UF7R@(CQQW.*U4)"P#MFP;<BM\>J0DFR>$WXXA/2
MA#.)@+=%^P&;MAG0""LTOZ/ZZR B^9[RG&\DS_G8.NI/8BT>44?=H)P0_MIG
M>SEX;!62([Y4OITQ7I[^3E7J/C2$7&C!;&NY>KW@HC8%)&">6$IH=B%TCC,(
MQ3I?$RC-^#Z8Q<9G@"G].[J:SN^>%THVTHU$[A2M)7Q=%O2.S"7I/CA(H,ST
M=<B4]FI20&)!'Z4K2K3<76'X#"EZ9MAK3W:9IE,8P8O^.U4Y=]16I6"MZL $
ML:KZBHXTS++0.X:_D0KFQN?[DD8)L3Q;D]U43<E=Z^B%ZG*A=)&#)P_)'R?/
M RQRS?NC'(((5Y:W85]&BS)@69$DW7+Y<M,.&-+AJBH1?72S33BR.8M%C.R4
M_<EOFB!(*K=P@VU49D4BHVGW2%FCG97AW3=%LV/D4SZI" BK(8+%US&WGXM(
M%D[^<(<AO[D,7]B7BN-$6ZF&<],..6F(P(G >:^O$P >]=#$N7K&9H=@431J
M/T++)NVFN$"Q6J.CF9%Y4E=DFF#=+%\9*.5_?/D&41*\+-3'2>I\N=F>(C/J
MQI!B#CHQ7+5.>@4)" ?.6^X&($XU_BTM+\RBT(X^L+Q]DQOR39!@XY@F=Z^1
M%CQ4OTBF*%+^C$^+%]AU'9BWI!$NIUYQ6ZV3$$UT\Z0C9$^3>ZF-ZM'/JB&0
MS60**N203[+FI/[MY.)2:;^JM;+M#M=7CLT:Q1]M/GI=7<*14,6(PKTRQ6D_
M+U=ZT?DFFX/9"/<L6_"*^$HL>Z6.:ZE;@V1&14(.=<\;W>\)4D3U6D1]"E-;
MW"#%Z=1L#YFVB!U_I"0T:'.C\3FDZQJ^ */3M&0,MV4 X4JZL4[M!]RNTEA*
M- 6-I#8V_Z]QV*W^^'KP !19%!8Z,5/0,G^BQWL$QRKDHXO/>JR*)5WF!SFW
M(P)XY8T[._M"^IS5"Z/A58HWOI(>?O5[7/\ 5PB[:!@-5%MW=4-%GG2QR?E"
MD0EEZ?S08C-YX8HYE :*\@9+0(G5%F^CA+ZFYWN0;5#JCN(-T$Q:&$WIIQG(
MH<C>6B2/Z)S@N;OTUDZH\IBECE2VXX,:%X=[Y6G AU#=B#,?6[H,#)6Y:(<W
M%CR).;]I"1]6TGUH9A(UD63!FH.%<Y]SGSF;QK='Y)-W010^!E'X^PNB\)^S
MLG(3HGV*;) C/_/:=UF.9Y]D6>R2XQU%9KOIQ68W?C#X9MC ;Z1M]A2+]R0[
M_9G=5R-+9$YQH:Y%94@+"]J]/@1U>;DJES8(K=HUV;E6#(P,MJT8*M1<<N!D
MD=$U\]3,X=[4L;S;!E+S1",H?3AA1\%:3V+GQ4XY :U%4LV!Q>JFIJ)XE5#\
MEF][HUAS,LWGEN-QMR:W7C2: BJXF[M&M:MF%8+B^N5RI#IJ_IAI7AF<RY[.
MZJ!5(ZD+0&-)V%E(CIMZ5[21N95B_=%FS-=TQ\JJ^=5AMS/SQS2M0FKXL';<
MS1XOM7;&S.5S2RRJZT 4+'R"\9HD6SM7JN7I^UA>:,H"I2DTQQ)@D^<_H6Z6
M)AIC0'^LHSI&<3SJ]:BLN5B$@*_+-B&",0R2R=%IS4&XV-2PY[#^)NJ],Z.T
M9,=9#J(%0[U?2:4IX8:H?:W_C#<^.098L^66M$P9]0;]S: SIQ#N83CF["Z-
MM[,-5(US>;J5ZN2A0-=:W4^/:? ! DS48-O%7CHR8OJ3O5S9XX,FYMJ4]SGN
MN_: =,-J?Z&/:*B:1%=!\VPXGLE6RQ'1N6=A-(@YW0&[DL\YR7P3\'[:;QFE
M;97FZP(O/W024C^EYJXWU/5-B\#2XY F>JW_95K_Y;BQ<3XA?+ DZ[XA)HB$
M;5,59!N&#^, :*38QYOZ&4/X);M1A9NZ*S1FMZY7/:XDS6OB"HC?'CRHKK2U
MBO.H< T[7,8LDENN4.,.-(*4F0DG4M(P*)>X88_EU,.^.QP&YS9#Z*5A:G6R
M\U(SW!BR3>C*G/A^F[GQCLI2[(/$IIJKXH_,3%W^8?!:4\K-\["RX5??57K\
M-' 92FMC/?=8/;@?\T IMX,'QHB[6D+: <GK!R)0\0ZS2LG #CTN%/I2/D7D
MC$I\"Y<!& CBTHI3)ZCK7;=7N\@UFB<7^IE=WS]+(J:J!XTBL9O32HN&(O&W
MM\1'5!G<'<HR7MZ<GR@],AXC/,T1MC.7SQLPD'_,1#!&3,,.NQ6HT4@0$NXT
M=03!@I6R4U%X"D$_(!)_N <$<W863$P#HTJKM628+CY-U6@FW>TQ-@];?<AO
M*)5%K<_IOUI8;,*8:,=45/\(Q"V6O761=R+I,ZN)+![9H)^)[:;#IG<6.!81
M6\]#$B;F'JQI.TY;)LUG3:<<Y@^0G^ZQ,X.&\;!I-D<]=5DQQ0-F!(FLLSPH
M]YN\3_2^-78^D>,FH+,D$EL??M6DFU7TI<I&S4?!DQUBZBX=0C-OFKT:!HRY
MMA7>?VZ?AUT')ZZ)H3^73=2G5X^I2\^..+%P*N\XL\3.Z]FI@A\VOU*U"H:V
M/7)\I[0^V1'3W>51_#,T2<!!(<+=@MV9+#T3O_*,^_FX4\TPE007;(V\WCF/
MH 6I#L_ZO909N#/E\XG>2)-UY(@&W&N%$&:W7;_FG N)^Z]*-V/>=-PAC5W%
M^8N;"XP']EP2.8KQ!7&@_+MXHYM#?S,6#:5OT.%A\G+M^HE?KT(S-$2'X=@!
M'6#C :4SDWWD/-5:\+MOJCU]L+Q-?*3Z">.A8R7_(')6YGV%Z<^-H#O<4T=*
M4>JCFQ _R;D+%6&;*VL4>M&=_WS=>?142<61-ZGB9E)!/-7!;PK26T0[3@R4
M3;_GA??$=^VA14)]B4_#-9O#0_!:+5I0D9P.8"6A1&=4FYZ* :.+-8&*P>&A
MW!RS;"X"]:\1J.'=*5<)ZQ_42M)=,%$3/HJ(+ 1A1:WFMC"XY4@2C73<E!>"
MUK8S+!_E:?#NK&Z(K.N/K]]DEN*8SH-$ (?AY>Z[B 8]FC17Q4W[A"(;$?E5
MC<T?UP[=U";]&Q\#_Z.P8=MK>*Y(((D8QX-7;A_US@/0K8>(RJ[B=BKREG!;
MXV3DI&XY.M-9U")RM!TLUT6PL+DG3:.G)AY0NS>V#H<QRW8$)G_!:QS!:_SA
M@M?XYZQL%]N_'XT\+"9,P=GKM&^I@HPC'O+ECXA_S#Q^QE%)XFK9?;-Y@%\>
MV6MB$W'J(O; 3%;=#.<445MM*/Z.RH;;!4G0,9G0^"7][XE%;[J32_Q2VCJ"
M>)VX"!@^_&O?'#@MD7?;E  IB=P;_>$,0=Z_P.8A*K)9A2QPD)H!K@FDN*!$
M>@1=X)H6G;3@,YSV,*IO7H\6UN#K.'')DGTRRB.W82/T@TZ,AIN^+ :7Y'UX
M2.9;TJ:^>9+]F%NJ.?SD%'0RYI0\BC&Y<]FJ\-TWO>5BK-I50$<4*_=2#]!Q
M3J+5@)&/IBL$Z^!\A#2BX3H1E,4'%E',#R]K@AD5+??@0_!# F4:LERYP$42
MDFC%9B&M09E0Z<AQT#G+FO,_$8YS-[O@F8?2N/2Q\G*+H[ZE01*AII1S8!7V
MJXPX"H!H7WB=;_*H/9B23;K*,WFKJ\6[& M"TC=:T)BJM]+/B5?-!J$'!V86
MJUI4JYIOSI*]6KR7422<Y.>)H=_Q2_%>DVA3Z8 YDA8.D&MAJB)'W(IQ0$)R
M]V/]>*P$[-^F-Q_F*KZX>AJ>XMMZM0V9@N'KG4:F4L0'UC.G@?=]@^7NX>_]
M+E]F7HBFDAR:JWA#K?Y>#/.(Q-7LQF/2X#;"^9*D!]=@+ELX/TSWG(KA8&Z<
M#$G\(G@9>NMAN-BK2_%/AF_RT$#"DY$.O(I7VQ)4P[=%S?B>Q;M7UN@E?A[[
MO;1'7<[$7CMNM"[>O/V_7WSQU<P.QID];.L(S=RL^?N<"NB"3T^,95*>?VYP
M@ND4O:RC] /Z$ Z+)K\SFN<6R5,-,9Y>-5+#I%E-5 3*NC),$?K'&('G@(@E
M!09(I>%@,GIC@#&;]MD]LSC@L,Q^<B^I]BQ9/K.<]>/4!YVT<2CDF- ;'-M<
MP_UNP8<+U4WD7B'(7%+&8'OLU44Z86&@!_?PELI]D4$WZ70CUFU:5HUD&!2M
M%'03"5EF<4ZQ9[F/'S8-Q 8#2:4D5A9JVSLM5([O2+%4?\$(E:XO*,>':5^\
M6.V:O!N-?&?N#+GD1&YP,"O>:$6DX8,S;_1ETF+9Z^J@)\GG"MCYY97"Q]1@
M(#/L?SUYP/3?Q/4C9\V=5:^5/0GPHH<YEV)_\OB<,643LZ XBC*-( ^_-/<3
M"#M[$@7Z*L<=L\A$I'(AWF+4,9-+/LTU W;EFKB](^..<_%D-4&>JRJ4G*'T
MA6@% T_O)Z+!K1%'G QZ#:]*IT(\2'H&XWNL!J6DOQY//#H\A/+0 QB=TX3>
MP'D"4[5':>'KQS4*>- M_(288GZ -RD1$XHQDC<-.BW=D6+%4[BJ'E>8D*;)
MQ\P"W$L'Q)"K74F?V<+M=>$X)\!^[V3,,=5<'U?M8D067(]R=E8&U0_PBHD)
M0-8VJZIJN+:"S\0;BX'9G?(*U-2T=6&M>L@-K$:-KV:"!FR"N >9@$P!B1 *
M"F+%(9^_2RU8M4&#%<4$ TB4"$Q*O..[^0*+X^_)=95"[D9H'2[V8Y$EN>:E
M@!?XCNV$@,8,*=YPPZVE)!_FI9@O _RA&2XTNEHN]@#!K&ST,<SE-5&O@1PI
M55J6U:[@_#C",6K#9TV)6YMZ-OWR67QS-R6;2(&6@!I0O-G22$@+&W@!)+))
M)QJ<_E:B6TDI;(,"J?61Z-45;=N'M3W+^*$&-IB[SITHSE6>4:""!YC^(:HH
M+)==$_>>CX7!]0;R0CEQ86NS6I#;$$TC?@+[2_"*%F,EU-H##])LB2]B0E6(
M16"3:I.,9+FB('52/DJ[I]6JNDUK/:R"Q+>^S%,*&&,M#V!#B$:'D'PQ0O6&
M6C8&7,$Y!<_[+X8/4_"1_1# P]APU<*C&>A.5"^/(OGLM6"O;5C(X/A7])30
M148G1WJSD3%:K06,+8@1D3C/'T/=< F'A&2:Q0I+6]9:*R(%RW!>RH(U]2LD
MCRFB2B);4$XL=DZQ:1R9-]?FDEHR,U['R]E/TGN9U6XT%$CKZN=#C4#Q19?G
M< ?KOI,;<X'+D-KYV$4TEL]<+=Y,+&%R]37!=*?032(I%OO6A)'>XU#/_X"4
MQ=T6WA@3]G*P-D1P1YD<*GC#PBQLZJ(,)E/[!ZYA[IY"%YN?D$X8%,'[)L=V
M%<V'Q8^H L/B,_R61 1_>O?F_8\6#-3X 0[8B!=DB1/<8')Q<E25]!2>&0)D
M"7R&2F_?+W66E*TN6KZ_@BU82UJ8&AVB]N2)@I)$G42>$RP-,G3>7, CCP./
M?'T!C_QS5A8N)PHJR!T81?MJ\1(.)6<XA.AC)N3$G&>H7UGK"CG.JG[&_<GA
M"QP31X!H*Q6&#.G4 A+].[9<FM;M B.;L(98X1!BI&7*6U([=.9OB4""NX)&
M0QI#16**2(\G?_3]@^]WVAJ,QPA.U:S7455Z[(U(@44*>&'[J$H+3*D+-I6A
MH^45\+9KB2 WEQY3I 51L3%SKM*7D283X]H>GVC-]]NPL"X1<D6Y9UB$*ZG7
MGNF8Z:E8C &AKZ*KJEE.)J2&I=$H._[2K[%JK0&-I*.&X/O8A=W@GC27#)N,
MN^'89NV50C61'-[],1?P(A3DU,':+LMZ]4$SY\ZZG?:ZZ6'4JTQ\&-U^RYW+
MZ=GI2SZK-\]VV*RAB?/E'5)(A "'MF''=5HKOM>'SM$-TB&2B#9J\G)TH$(V
MY\;81>A*ZIH:@]K$YK*;MXH'1OO@F1$ E;<,>- W4)O%_5[[ G.+,3*<P9#9
M!?CK&B?0M^%8Z-I94Y+$F=($MNRKR056\B*%MXTC)&ZUU'DM0WK$&-#0-UUJ
M$?&^1Z\7'K:AOJ_I]P?! BPD(ZP31XCO>V<Q0:??+C&290VY72P<?K4P^\K;
MF&#B6H9C?;5X3;N!0_;.6-4X11=;$.:VAFI!26@?)L=;BKH%5$1W8/]<UL3
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M5DW(.PD3X87.9#4K:6MY5M@"[7.BM;F24,-_+JH<GZU!O#&%"F*O83.JF>;
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MI#U&4=^JLL$%>KDVVV==62#.0Y.'IAXG+$< ,Q_ ];[L@=:'Z@$]?-!8!RG
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M'8HXA\7XDI@W;[5'X[+B7%KYR $FXHT2('S<1YW%$&;PXIK;E3N6HGI#K,I
M&*@M*3,>G*OD30ACULVK%.<!7[GIG>=Z+@8.X" ; *:-\I,:#"!L7A9U+<)<
M#B;%S)4'Y0G!^E,GA2]I!$<?#EJA:AGYE\AE&P2F>91I%CZ<?B\8C1$%KD?#
MD:>94WL(BT2 4D;]RIIB5"'5P,7V&01$-U^Y;0A>ENFQCNRYH-UAAHK8 L)B
M4_/]UDGHJ_):!C!,"4%B VUB&"AIO5M:)^*_-?3J"F?W:J7S!HB[-$8HA<DI
MP!(\@9L!8)4_G\:DL-6!SA,TAXIQAZ0&PL :-U9[K#GD-U8?B438V:GBYQA
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M-G!O+LX FCTR!ZKIG=8+E!75B1&$$UPO 09=3_U82WU;4#96NG^#4%CUQ%M
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M-8'3A)M:&R@"C5*=^L57,2,5Z67Z7)D%]656QM.$-O$:JEOO*S-?/,"(%!R
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M8X (:X0WEL3/7?"DX9_1CB.#MB$A#0'ZJ;,*L((J\+']X'V6GU='&@*'332
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M2TI_8IO391H:+/H+\26M1?;P?7IKK"\Q"N9S=Q'E<_6"D]]VYP*27T(?>&#
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M4^.NXC4$50?='<P>3ZZ$H\X$(J(PM)@I'*W[]96U3(7DLN<\9FY:6>/)G3E
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MJQUGKP_9M!!&RV (I$B)3,80YR(G4FBNHW8TIR;AJUH3V/ON]GXX3LY*&M<
MN1,81$/0MRI2=.4RNW*$E>9M^$* I&U*#M5 ?_APX5'8>^>^^,$UWZ(9R]+Z
M?I?WG,[B+%*:'%,"3I(JK<TL?H>S@9)'6KK.X)Q2FRKN5:=QJ'2'1T'C(S+@
ML>0V[#GQ7[^M?\#\C(L9&X(-D7"K2Z4L;4CPW!$38F9,.>%"DZN+#>=TM+I2
M1V1JW;6_&F-:%*-9B^RM/X/EZ5L??"WS*QX">*3J5H^%$;V8NJ<ZCT$[M)$R
M!>&(4U03"<$32RTE7%'05GCEXP$7TM9T>ZA>UE-EVS9:;%' ^>Q\U'V#FXU)
M+L_^F<#57QKB(P,B=;E!C983R5)[RI)R$)N48-N(Z+%X5;LJ;[60<Q7)'RSK
MXFPXKT;GQZ7#:ZGW >-=*^'<\[0ZISV]L*Z>W5"K4^:6>N]E-MX*J:6FP0EP
M^),;]$.]JURGJP_=*W_B@8=6E7(OY"O"!LX4"R)'205Z^"PP8R(5S$GKLXXP
MV&H.M;C\!OP4WOK)9-Y1<8]R0=L.T93U/6:U^BHHIYV)/#'OI'<Q4,Y]<(9Z
MX4$;>L^KL'ZP_;:H-S"= LR?_!M,XV1XOA3/I:\?2A5#CAX^.BGHX4,D7CM'
M)%51X)K)J6A2^N<!7/ONS._0$?1%LO,17G33V4 HRWV,F21:*D+;7 H')T&
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M3K_Z42D1^?$42I?L.']!YH$\S;.-6AJ23=EW.4^D]'8G-OO ) A(M,EYZB9
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MA[P^]^-O-R8BN;8JZ$QR-JQ4114D6*V)07JC(1F]C_W2BFJB>HY4.I".:N<
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ME]BD9PDG1Z@KN>R")>*E=24ERW'#N: ]2^$\,-"35W!-0=9^>S]>G)^/OJT
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M=&3*K1_T8YS2C&B6I >@AC*Q!PM7AOO!K%JZJ%WU=3W"A2N"&*]*3S+^.SK
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M41)E-CIX4*#;Y/Y4GTKKZJJ/AL^/A W'KNEZ_P4#II5/7GJ27+E4IIPBEK)
M*&=HSH!4.O0I[/HTJQ0\%H;TJG*PC:8>PSWT'G ?[>6-XU8YV$K3^UY(WT%-
MCX!=BG/A=/(DZN+V>VV)]UZC^\64Y-EY3^'9LFJG*@>')-4VVCE\E0.1;)8T
M",*5=NBUIT"<B"7_UVOMC/'2R!;<>>I5#K;2ZG95#K912<5; !OO.8<(-FHE
M"# 7B=2T- >T:&YJ:V3F ,$]J[*-C\P0JJ*7HY5][ /RD5P?/UK9QZT4N5,Q
MOUVT<+2RCU))#\(EHC.4#G.1$9<T)Z+<*V AX1+;9TMZ"E39MNQC>Z9L(_S:
M=566UTLOC7$#1@/'S2^P>7:V(TZ&2 )SH&7D.JJ>Z5<W'_M82S]N)?>NBM!J
M5TBZW>EK$?W\X^.'X>?3V:75Y&BTDHI(:. :31N#LV3EI12:1LZ,2KY?F^:'
MQWI^BJXKWNHO[QIX_QQUP8]N032!4JN\*.C**:$W)%#K"23C%$,+.K-^]9'Z
MC?==L&!/,;>XE7<1IL,T])-O-VYTS7<PQSS52B62@Z(%&!#K+,4-+7FFC'9)
M-BD$NQ'1=^Y=U-58@X*R-R\RX_OS+M^8]_)EZH.P973U88C'":A6TND]-\LK
M*J3MO?)-2"-:2!Y0I4FZTG>#*A("KL-***FXHDK+)D4^CT69!Z*E1V/,-GIH
MP)3WD^$7/X/W(Q]O1N*RC='I)$@*I2^R H^H?.F1$Z+B'#)PW8(=Z^$</BA:
M6W%==:E7CG^N[7D7T&@2BEN"#K8CQ7(CCC-/F+,A2>XB==7J/#Z&=I^/S$*I
MHI>*U[?O;^34!]3WUBYT*T7U:AJYBY0/URXT*IW0U2:V=#^4D#,)R2?DO'"X
M9>IH1!\7YS&J?MMVH?4UOXUP#Q'B6(G 9!^"Q2_$Y803=CH2S[TBG&NN$Q7<
M\'Z-)1];@*N21K8,:&TCSD.$,]=$6CQ <E(%8JE21(;HB"]V<LC!^22396SW
MD.:Q UH'TOJ>8JU]4E7LE\7RQ7"ADM$0'1).TEM+O$2;)7%C0Q:,)UZO\//E
MJ#_,O1TU4+'@R16(RS:W/6!4/\6^'O_P=MR.&EC5X1[B:_%27QZ210W:<H4"
M+_7< S/$^J2)4-J8E)/AO$]9P<>AQ7M,LKI*W$9JE97W.TKJ[.+LL@L, P\R
M:**%0:- )$F"9V@C,&FETEFDT"?=L9?Z;HU\X,.D767?U1!<Y<#*[_[K#2 1
M/&<B T["X[[ '*!9AW0,"J1T1CF=JV5XW!KY"6IP9\%M? ?K%F(O14!/NQ$.
M,'WYWQ?#V;?;X_>LL'[W*35*IS^ ;:4FNK"AY/V"% :%:57P4FO*%:Z0(3%)
M!_>CW%=N^Q2HW_BP)E+L4V#> PO9.I-!"\F#1+E&$Q-ES'BEZ3IAKL&\@TQ_
M]5,HU?3.<8.<^Q@["_3NDVI)\P&,*Z)440=&58[&@K0^VP!9)@8YLL2"YX.'
MT=:0X]RDWYV>FY[73*;K\*Y(UCD--OK@G4DRLQPLSRHFEIWC0CB]0;)WD=>0
M[W4=M=?CW$W.YK]<O!/UA'[?(,TTT7MF*^KA+D3O0@C62>F#<1#P52B-*E3@
MCID-ZKEON/V."5^BX+MO ,M8R(;AKZJ^O,L?(':?Q\/_!VE1J6S>SN[-U45.
M9S/3@ELB(T6CP*-K;+.3A)4W72NO9)MDF,KSV/N<?OWXUY&%7[]=?V1YP_KD
M+S])EY7MKS6^J'%_<C$[[28%[@!%R9P2B7#<RTMY<HH6DW!$:Q/1(,.]?C7C
ML-(!?[LY'?X<^)B\OY-,\$C(TJ+_QKY3NS,AGHU*I65B8J6C&Q>9.%\B $%F
MRZRDK%%Z2^V9_.#\\8A1^QAMZ=)>UH]=8)MU 9:M23Z^NRS7/HCX-EKF%?&T
M=)CP ,0)9%QT@*9OCI[+?A5Y^H_Y?3*MI6):Y!<7:.'A%R*LOA OOYX/ET=/
MB]*QD6ON9:F,G4HM#>\2\48$@KZJ$DXJ*F*;CB"U9O!]\O6X1&B1YEQIB?^"
M7DYQ3U]UDW_BOYT-;,H0:#($J(Y$2J/P32U?O%22I;()-"D.T&I"/_A^=)I4
M3*;;>UZ+^H33^22FKR]?9L\ F."2)%&JJC(:B+-1D\QIII1R97R[5;W:-'Y0
M_4B4J)A)L/=LYE_^$^VPX?CS8BILH%QP$I0JW8U3R8LN18-U(#1[!Y9QZ7*3
M9L<U)_&#W$>A0\4^+[5>U'<7L^G,CQ/.:+%+#50*GDJ:2%+HHDI#T3L5-I#
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M3NGL%6[[:/L5L_("G_?MUH<'TN VD:DE4:62?X=3L!0,*7T,L@43*6MB@E?
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MJL":Y.,=GB&],C8/2Y!MA-\D7_,+C"^@W*$<3HN08#)]/8$1;GZ7-C.5T98
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M29)*AFGJ=VZ[@IKQ'>%*9N!"P[4Q;ZK2K?;BP4I'@O6+O<&6BY>F+/+]E]>
MX,1/&UTC/3=U-9!$>M9G&U$8/JJVLZ#AQ-YB-+P O5@>GA;[J-T3 -20:O$:
M<@;5FP%P.U2L(8;LJ'G5-S5?;]/;/ZNE^?R>;0.Q3WPV?:S\QIA$>::D[:NH
M$X@QH9#$>0JC-->QCJ5*$J?P'Z]9QV:VU43?&?79%+]XV=(-%AO"[P KVV9Z
M:E$G23CJR]#X]JT9&VBW=45V2 :?=J"];X?67POZ0!54WSE-/*QF\\'B2(=Y
MO=RU6NF]E.;#*U[;CV#Y8Z)S&RAMDRLX)A!39HR_2"F8Y3PR(^@X$<2O7NG^
M!&/3016-H";2G(HJ,GV+EAZ@V*Y40F#3L_[PA:5#[=+3O%]=O?1@V('KEYYF
MZKB"Z9GGNM[,&?OE[?>7:16F]H:M5#Q!,M5,:@UC1,PI#L<9I"R/H(Y$*C5-
M143\O$$G)AG;8JXL>[4A$DA#I>]UVPDL7:_4KD.H]VLS"\Z6/O"F#9P.%V+G
MN0][Z75BGH$OMLYS>GQYU?)LM]5N6],9!;+Q^D9*F\."@BBBS'IK%*0DIY!A
MR;E..!+<*ZM\?_BQK?"*NL[)X ?8N:WK[HCTO4D[@^&]FD_S''(='\PPZ H^
MS=WAVCWS5(=8R@<EUZ)JFE7?$4W_VSHCS(I1Q>K->EF5P3,358]530J,L?]J
M/9W)U:(PA)2:9*?7U@1I1C%.$$Q(1"$FDD(N(@VS2+ HITQ'A/K&7/9!J-."
M&3XV<\.J]=**+;-@6G,+UG,C7L M9W"U@):W^E+[.B]O?Y]$NSZ[K82'\GOL
M2'6'0=!P""H6P2Z/==>;TDW\:D_<E<VTP^JM)>P1?7IK20\4I7HSB?M%M/8I
MC=;(UUXF'BY"MD_<]B)I>YVH>TG(_WO-EH:$V8\'];)8KB9<TD1JAF$N,G.L
MCW@$.=$,LA0E*DTS+C*G8WW+'&.S^3>U$C=T@HI0_Z*1AVA>]M,%P*CG+<\?
MGDYE)<\ $*#"Y.'(@Q>;/,/:J;J3YQ[M&&NZ>'Z>KJK227-I"V$;):/F8JJ*
M"<DQ83S.H,YX"C&F.:0)X>9P3SE.X@R12'I%F)Z?:VP+?H?4LMR&V"46_/1Q
ML5(@\^RPT :UFQL@$( ]:X-#[/;H#!@S>AF,H)&B+=,-&Q]ZF>^CJ%"'5[J&
MJA=/]G_64?&-S529^VD,E*GMU&U_8>;;_\'.DQ/"-<KR+(%9)#7$/*>0ID;?
MI 3%.).8Y"R>O)16SI>5T7J.:N8:FGS6T2%E/2XI0^0=$.9/H+:TEJMKN>&D
M_/T=X.IQ.B^OV\UI9/6DRFXPOO'OUT@UCC.5T"2&FB0,8L0B2)!(;$XN2I5(
M!9>-5-_.Y2AEVM U#HDJ\\-:EA5Y0TK3&/0HQ[8V4"X36^LAL=5BA3$"8J'R
MU%H%:K)M5#\>26YIZD^*5?J)^*/(TM'*&$I"?=LA)>#V3[!#H(U'VLBD_*65
MT^'/=EX(F>42 -BPV2_7$#1P5DP [(ZS94(,>FVIMCK(:I(2GJ#,Z%>%TASB
M-%.0QTD*<X8Y1S2)4N'40._L#.,[9.T6HEI61':M\M6@Z' !<2TVO9^?=F%Y
M" -+UPIG'>"Y21FS2S!=4:7L  +W4F3-BS>J-W9 ]_FB8H</=B_.<!C1WB0=
M?EV\4E5-("6K8%(S[B?];EH(-K-9TY,\%HP+EL.8$P1Q'L>01#2",4,,YSIG
M.L7^E1HZT^/SO0]6MB$"/V7@V9S>GWR;>UXG&S>S<3"\>U:_%1\G:CML4I]7
M"W/(!@T_38"[O:DWEGW%4UGO(6RIAZNQ#5WWH3M!@Q>!N!J[4Q4AKA^TFZ(]
MZ&+Y<6T+!W_292^$3^M5L3('&D/3*U9,A3%@WTQG:_/TA"8H5A%1$-G>4ACQ
M%'*928BY1 *1*(Z04UC]=62,S08MR2W VG8;,>M:+)Y?#)F 6ZK+DZ&LZ 9S
MM0*S15'88SLH[%MEJ^7R;[[JN+,$F<0T$E!QSB%.(@I)K@4DL5:<4,$$DWY[
M9/\R'&9S;/B K.YE;-;3=,Z6/VKY@,66F<'%YK9]]B^*GO?-HW[2%0MV3ZP7
MV0X;=^#59H75K(3;+:^#,N0VV9&20??'Z] ZW!BO'*V#+V5_$RZ^K'D9(?E@
M3Z"SPI9$7NBFP?,D$SQ5MEX2S7!D4U+,,2,3%&8)PQQSK2AUZJWH/?/H]KTU
MAT5-,%A6%-^5I9+*8-2::@^O@Y<8')PT?8';LQ8\.#483!O*P4.#\M<:Y=<]
MH^SA\^D+[8%\04%1]W,5=4&NU87D->!PKJ4N?.ZYG#H-T.V$](7-E-ES5@OQ
MS\_+J5"?U;+<@"91S%,>BQB:LY#M?QEGD)!$0*05SD4<9;'$/F>@<Q.-3MN7
MYQ6C[PNQG+X<]CAYL:0?G&ND=1 N=TX[GK;R61&X6<,A@.U9TUL22^/6$GD'
M2C)M4'=E[8:S9B]!$=)>/3O7H!;I)8X/;<Z+SW<M3/!N.JLMV$G.N<XUTC!+
M8^N?QAFD:93!..$QX3*.6>*4XWAJ\+%IBSKSWA)8'^)\:Q'L ->^WJ^%H^<U
M[H%$A_(#QRQ?77I@9\B!RPX<,W-<<N#$,QTW>+N\7]F^K[N=87>Z!+_ZL7VD
M]LO>_\Z6LOSC[ZI85<5,I@L93W0<X12E"<0\QF9ITQRR5$@H--<9L660I%<A
MI)#$C4TUU-35L4NEI6##"WT]:4'EYVA1W$@J?5LA.]VR=QG;:YG-?X"37;4M
M9W?5?T CV<_M46G^YDL/N <U>4+2-ZR9U .R1Z95'W-<T_SA0]5P:'..^3"=
MJ_<K]5Q,,$YRG45&C>?$J/&($,A8JB%".,-)FBNLG5Q[CO.-33-76:,[E(+?
M+*V@)-:S1L4EJ-T# @(!.,"5OVWG4%_T>X/8L77#16C"=VHX/^4-&C-<Y/]T
M'X;+KW6L:L.6-FVB:(Z/!W<4FY(M2,J,2:MCB%$O.&4I9-S8BSI6282ES%/F
ME1;G.._8%$Y#]M;G<>)2KWN9'$=AN*FB'B#N^^09"EW_NCM^6 4MR.,X];"5
M>OSP."KAX_EZ-]UUX%P_U_EALVQ(E"9,4@2QP!+BF$20)0Q!HC5)9")BIIB/
M#O.<?VRZ[.#^R$]5^6+OIK)Z1'3P*]"6'C)WNP&3X%=F'NRKH%A'1$,J.%\2
M!E5T'?$Y5'A=A^E:ZWPW/:?N8#&A44Y4Q 7$3-G"9!F"-,D5Y"+&YE=$RMBK
M-];)6<:FQ!X.<PU%1:=OR?)3@+KIK*MAZEDS'63Y;1K0A*P\WH) V$KCIR8:
MN+)X"Z_'E<3;'N[2''HJU+Q0]\TU]M>R0WHDHXS%A$.!; 'Q/$T@1;8?54XI
M%8)($J?.\5TGIQC;JJ^)!!LJP6\EG8[GK18LV]=\&(3Z=NST!HY/#^9K01JJ
MV;(W6)X=E=MP:&^=?/+- 7LDMU&^WPRY]<E^$^N^_KZP1G0Q233C24(RH_^D
M,8$BH2%CD=&$*>-IC"57 O632]>0X/-U#Y8^%_>3,[>!W=TKWA>4 [C)_3+C
M#!/EP2Y@$86N^-TB^VU#PR@3W@X1ZIKC=C3.P#$=G\I;@.+=8JG5U!XVB_=U
M:<R)0EA*E%$C2($@3G $*28:<AGS/%-$:95Z%*CND52G93Y\B>J:X#M;IM:2
MK&3W]*D^!.RF<V\EKS],",A&S#N<VO:%HPD&N2R(4<2$M)#YQP@-N8QSL @1
MAZEZMI?-)Z,JTRW'"4_2",,D1M@Z#1-($!>09X0AI87&3/=D,6^(&*7-[-DU
MM@/T@:WF3G".SVZV;-S,<C["\":V\Y:*<5K/1RAUMI^/1^I8C'7]O)Z9N;ZI
MMUHKL?JD/ZK?[X6P'=YL&-YR.A?3EYEJ].PG?5\W$)E$68Q$DJ80<1O8$J,$
M,LUC&Q)-$AW1W/R_5ZGGSJ2,S;^ZY00P^;_715E&URY8)D3U*V-.2:6G8KHZ
MV94%>O?>OD*.;MIT&.GTK%5W!%-Q8?$V?( M(V##R=:8+:52<Q.PM./5B :M
MZ]B=FF&+.EZ-VE%%Q^M'[-XHHXIDJ 9^9WY63!CEN4[2&-(D3B'6,H-,:F-F
M9AC%B(@TYTXE'5MG&9O&W'2#J",[ZG57TNK?+^,8U'8=%PRJGM57)Y0ZM<TX
MBT* QAG'8P_>.N,L>Z>:9YQ_N,,5]&?S+3P9HXY5-?5M-,N:S;:-L=^LU73^
M]6FZE&49O5@(R>,HARG%#&*,.*1*9!!%)%%Y(@7#VJ62=H>YO53$ '6SW4^6
M78!VN+CN#[Z>U49#^*:S1DTZV-)^9^/JK,%3TM]>B?!JK#WNP?O#?* +\L#8
M^]V>=T.O]5K=<\CA[MN[\;IW$=]Q"+]=H%BN)I^7"]NUS396^:*6WZ9"%6\6
MMNCC!#'!6)Y8:T\K<Y)&L<TKCF&2,$8TUEKF3@476V<9F_%7$UHND9I2\%M%
MJF/033NH[;H]&%1]:_$N*#GK"R<46LZ;YOV=LZ;YUZ$%V#[!('K"B<=&([@]
MW/':6CPIN2X+D)R\YBC+DM1W'7]GLW5U/5(4Z^?J9V6$T%?U??7*L/7/B:2<
MR31-8"H3HS1TIJ#1(1RRB(HDD:DDRBF L1_RQJ9MWK'I$EBRRTH\-1O@KTLV
M;RLH.80<'2^F;R:=ON^D:\8VU3]/WSN7_&UOGS<L@AT>ZRA$8-D$)9\!<T+Z
M$4#0N^BP% Y[#=T+ND<WT/W,$FX[.',Q7IR[&:\BC!.:Q2@AVFP"*8(8X0QR
M$B50)&G$8AEK)KWJ&02C;&R;P#E=<RX6IF@-AO&+$ \O]NX;1^_"O-&>T9,<
M@^P55V'>]S;1C;B;[Q!78>JR.5PWP94)VN_G8O&L/BR*8A()0@AB*;1%(R 6
M*(&$2@9)1C-,18Q2+'Q:*YZ88VR.7TL3L)\!6%3$FOVW8[;U#I!N.O-*>'K6
M?MO@H(H\\),E\'R(;??TYV/V>TEQWIGF-FG,QWR>354^\6B E,3/BY7Y<\IF
MM3+1B^6]>)JJ;^5O%WJ^F/_MSU_^;+LSJZ4PS]E"IL6O4_/':C&W#=BC*,ZE
MUC E$MGK8Z,@B&(PEAH9]4"P2)V*CO9"W=C,P"9];;>P<<,B>*E- \,D8%LN
MK:EA^ 264=O[I>84%)95\+SA]8ITP:L_ H?;K%N*MF>U>)24> <VW&T,/BO5
M^S-2W3()2B[!KZ.0ZA7YHT-*]U:IIT-(^;KLU5!2\$I\O7K2V^7,AL*K-=TV
MV"3=C/SFTG'OFO']_)U9)ZNGZKJ<8:D0)9#EUK/#4VI,?LY@3M.$2"%9S)5?
MHL'%.7V6^V!Y!<C/Z+\,K-L1("A80T5ZG(@NJ @.W&32&9R0QX7+DPYZ>'#&
MX/ HX?YB-]5ROXD]MQE3!T&MB[GYJZB<&/??I\4DRW6$B>8PT[;-5189A8.%
MA$10JA/$F?"K?^0U^]@.!CO$ES;$48SX+@/@-\N"I_?73SANJJHWR'M66T'1
M]M9AG5 +J<_\"!A4MW7"YE#/=1NDXUV:.7:4@WW85)Y60F199"/HM8$?<X8@
M52B&$LN,8*X1DK'7I=C1%&/37AL*KZCG?0)(QVNFJ^#I^[[(#QG_^YZSS >]
MN#F>9=@;F+-<'EVEG'^R:^W&;VJ^5N\,34V,YC^FJZ?71L$LS/GL[7<Q6]MF
MH?=%80M_RZ_L^T1GC/!4IY )F1K+ABC(5":@0#3+DCB1L5N!MRMH&)N&^&KO
M;<"R8L2WV*._!-PT1\^X]JQ::NJKFZJ&?O"[80 T'-R!#0^@80(8+D+6DNP,
M8=A*D_YD#%R'LC-.QU4JNP_5X<*HO&[FAU?2']7*C/OE:;%<:3:;F4G-7.8G
MK]1<Z>GJ_MG:6Z\6BW\JN5I4-U?FM\;Z^C8MRESNG.8L002*F"J(%4HAD4K"
M6-$HRW.N&7;*Y>Z/Q+%I4,,.6+'OH&@8 C^IDJ7RI[QBZF? 2X9L[O>TNJ*U
MOWUIF+H#K&3;XU:A'_D[7!C=7*I]FX9GPH?N@!6U(1I\V8JZXK/\Z:M&U!6O
MX-5&XO6EO'UHP_#-)>UQB71SB0]TDW1CR?O=*?4JE-:+I7YF'NYVJ5?D]JZ8
M^IVIV\')ICV460]OIH68+0I;/&O37D)J0:C,,$P%SB FG$(6:0XQ)6F:L9Q&
MRBEHQ&6RL6WD._D@.]1V;D+4BK/;.2@4>CUOF-V!\S[6N" 2\OS2.M^@!Q47
MS@]/)$[OW*;@ZMOO]@Z]V-;M*QT1[\VQ:3HOIJ*D>L(B%&<V_S7)"8(XYAQ2
MI@0D"E%%<XYED@S27->#Z+%IM0UUX%N3ZK:H<Z-4S8YOLML0HG=T,8],H#<Z
MF70IUKIA?5O=Z@YL/Y:2]?'4;O41U)B*N3K1_8>J[NHCB=#E7KWF[MC'\_EE
MMOBA5)WF?9KBK:U>.?NVOWG[W?Y533*1IBK.$8QCV^8SE@QRE68P9RCG&962
MTL@O5"L,8>.+Y_JZ=9)5'G.QJ]A41;9G^\\P,G3;@H:7RX";S&;SV"Y1NW.4
M)-_MNCX"=A -BF?0!J-A*!NV_VA0-(_:DX8=_38GD4_K5;%B<WLS\P\U?7RR
M?56-ZF./JMEN/B\-<Q,=Y0E6(H<JYK:X!I&0FR,(3 G')")Y)KA?2O4P=(_M
M/-+0"EA%[.84 EXLN66'"+F8S=BR "]J676+&+A9A.LGP:G&5.<8JE0PB!'%
MD&<,P31/(A+S)$$DFKR4ELJ7%5NN_K ?QB$/-_L\[L!BRYVQ&QZG\WGY-V9&
M^8-]/6E,D(JEL1%39+T;60:IHAH215.&19YEJOEZWL[E'_S;:3@8R9>CZ@_H
M#_C9#.,9Z>%#^ ,Y1W:XOP.;#ZL&8.,Z 24$XW&2>,IL3'X25]+_4*X23WF$
M]I;X3M\Q;<TLPH]F69;9"32*DB0A.92$"8A5FD+.\]P8REF:$IGH5$H?&WEW
M\+$9LI8V8(GKE/6Q!YN;2N\*1L]ZUQD'_YRR$PP'31_;'7_83+$3G!TEA9UZ
MYNK\KZ^+>RFG5C_8/->I?#]_S5ZF*S8[K6UVRY\]J/]:3XOIJCGN5R[8!R46
MC_-RQ(DQ6'.4YAIF..?FB(P9Y%1J6W\L2E4>R3CSNJ\;B.ZQ:99="V77&]HY
MKZQ7H;LIKQ&*LF>]>/_Y_>N[T];FKC>UXLQ>O8FE;?)4YKV]7A0KL,-6+SEN
M0\BAI^RX7DF_55[=$/)HR<@;9/IKZV+>SU=3.9VM;9.>+TJLEV9X552A]4HV
M#N9U%2CZ2;]E2^L>*@Q!)1=5E42%""8D0Y!DMCAFEF>0J5S"/.(LPR)."&'=
MBF.&(&]TN]%.9<5=_L"60=!PV.2\;'BT+S5<VBB#2A]>6R8SR%?@Z$>YF6S[
M=I?<0*Q75,T,B7X_I3.#4'BC^IDAT3U?1#/H+.';^U;MG6RYC5_9RA+W8Q.N
MRR@U^#(,\S0B$$=$0A:A#(HTB6B&TC3#7@>;;F2,;F=8<VC^-RO-U@>;GC$+
MU_&W11INFKM_C'O6T!<[_]XU[=\L(Z#AI)>XZ^O '*H%< LEHVD#?!DMGU;
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M=2[/?RNGCC,R+3X=]S$Z1RP+9>,12Y_1M/AG=0%K_S:)$(UC23*($JP@MN5
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M$" A#$$2YYG:<B8ISHQVFEZEG-N>TL&Q\KBS'Y=/@.WQSPO-Z_PC!?P= 'F
MW,\9D$M!7^@8R /6UT^"? PVP+M9-Z-Y(#]%PPDY9&%&(00A#=5;@808X)AG
M((ZS*.$,DY!"8__CZ=WGQN9-IZ1*0#MBO@R>@6=M#"2>B= U&A8^HS&H3.35
ML4+'SM=R3?M>;\C91=/Y*Z[)>^11N/JE$8E-]';0/#T-FO_T5!V;?]IMRZUZ
M@2M[_3_%\MOWK>#W:IM-OHDOXI$L=5W33FKJ@R@>XP6"0J*48) P91S#!"6
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M8>$13_,X:542USK,JV2)IQFRKF?B2XX!YOL^(%64'Y9K\7XK'LM%2&F8"$9
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M7AS-PT%T:2D.D&)2,W(X2J<VYH@[#6/!!W79)WG?G.(W4?NZ RU*& (HAS&
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MKXEB!(O3BBC](TY;#\5(^[-J*&97#2.5MD?SCJRN5@)"(E'_0R%@F#, $4.
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MX\"T8U=#='KY]=8]IF-80VV..-;TFJ&5_]^O%6E5B:#B#=F2]I SI81%1&)
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M7@W'^2RDE?TN$(WT@12B.HE]JA6PB#.WF8]^KO>)LO=#V2[ ]P> 6\&#=PW
MG[T";!'4[PGHB0+\W0%N%^P_ +7>P'^;^TV7!#! RZ.$@"'7#RXE5S?!$/R-
M>"H$6U9CJI]7HAI\S>\?-\5V^<^ZQ=?54K X3[)<X@R$J0[82?69-PDER*%0
M^Q%"4)B(Q5I\TR,9.B\=B6:T^G"]^KH"^EM\NB[]O^NJY:U^ >\H6-?#[&AF
M7='.S8P:>E&GG*7)JN;M)Z:KDV[LT&A5U][LZ'4W665@UX [+M'G1K:IB_HY
M1?1"&4"W]_?D<"JO[4:J_SRH494T6BI=Z>?-YI$LUXLT2P@C(@<<QAF ))>
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M+7Q$S=G?MR?4W)>G681/S RT4#\>E3I\LT-D5X2VG@2&J)%,ET"P6IC%&.&
M,0D!DBTSRS.N37,Q)F%*T-IL0J]G<52T&#1-*M0QB6V86<B!V,QV(0VL:,O@
M0R*G:9B4M:AM\/7XM7'P7C]E'<:#],U\^OAN^,;\L.='/K[[#U!+ P04
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M8#Q:??)%6"SG/BY'+E GP ().@<B::3$!R>)IY$)2:GU@3]DO9"]0+I7"EE
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M\M4"_&(!&#UJ2% J9)DL^51K0XDC#<F*&2^I$D!_F-GY\3+#EN4U@Z^>]=&
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M59'8DYX: .*#<:HCBX0'E1S:<8NB<C03'[TB%JFW-G+(IE8?ZCLJ&NF^TP^
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MQZ6-7"1-S&H@++!,K"WB Y!26L>DKU+1>R"=K>:7^\GPU51:JY@<\8 V/6!
M3ET91&M2N9L)EG@6(H=LC5257E ?6V]9L7"CHOX[U5X>HHP&$GZ[!;:G<>7N
M]%#,-.> UMSF53U]1KN.;@91W@;C/("25<K-3R=]6%LX.%;KJ;E54[F=9A)@
M SH?%J,ND= ;MH:$F WQ()-,U#$;JR1ENA W;"YP<'">HJJFX7>7<HK40@BT
M](X4Z-XD(PD*3Y L(\HR!\?JO-/I0-NP6<$VP'><HIK&WKW44Y >F 1*1&9
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MRP2",Q6<X4ZD;<@!#H],F_6T+=(?,RKMH>\>8?/Q<K5<A5F>SKY,N.12,6-
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M\1%YN\?R0Z5K/"FS)R?K#TU-J2%'5\O&@._GBZL?U;_')])()HLI()UF=7J
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MG]NJ?,KI-68R/I-WN8RK0=RCC?GI[+,PG1?0_A!NC8.F# 8:?NN?'\1_7KG
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M;#V]N25(OFEX:T,&+X &V;6\6U[@4O:T4@365OW<$Q3?V%7<]S ;+@IJ)/
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M0(L[IPW@=(^[<A07?+X@DK&28XY)0T*'^5,[G?MY'J=233FT3D;*>W;Z@".
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M)0+H9:E6*B@*T&O'5N/W=T&0.TT/;1BE"Z#1$;3JK8SA2I M)#N1!>)Z*OM
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M82TR,#(P,#8S,"YX<V102P$"% ,4    " #X@P912]B\J4 >   4/0$ %0
M            @ &=9 ( <')T82TR,#(P,#8S,%]C86PN>&UL4$L! A0#%
M  @ ^(,&48)ZK%Y:00  O*$" !4              ( !$(," '!R=&$M,C R
M,# V,S!?9&5F+GAM;%!+ 0(4 Q0    ( /B#!E%X%]]$)<(  +E$"  5
M          "  9W$ @!P<G1A+3(P,C P-C,P7VQA8BYX;6Q02P$"% ,4
M" #X@P91.G$W<)UK  !JW 0 %0              @ 'UA@, <')T82TR,#(P
M,#8S,%]P<F4N>&UL4$L! A0#%     @ ^(,&4:B\P)?!!   M1<  !H
M         ( !Q?(# '!R=&$R,#(P<3(Q,"UQ>&5X,3 R9FDN:'1M4$L! A0#
M%     @ ^(,&4>KQ2SPS&@  _PT! !H              ( !OO<# '!R=&$R
M,#(P<3(Q,"UQ>&5X,3 S,C N:'1M4$L! A0#%     @ ^8,&41*E4HO("
M!C4  !@              ( !*1($ '!R=&$R,#(P<3(Q,"UQ>&5X,S$Q+FAT
M;5!+ 0(4 Q0    ( /F#!E&+M*EBO0@  !LU   8              "  2<;
M! !P<G1A,C R,'$R,3 M<7AE>#,Q,BYH=&U02P$"% ,4    " #Y@P91'YQF
M8Q\'   3-   &               @ $:) 0 <')T83(P,C!Q,C$P+7%X97@S
<,C$N:'1M4$L%!@     +  L [ (  &\K!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
